

# Secukinumab/PsA CAIN457F2366

AMNOG Dossier Main Analysis

Date: 22.08.2020

Document Status: Final

Author: Monika Schwager, Winicker Norimed GmbH

## Table of Contents

Tables.....	38
Patient Disposition and Baseline Characteristics .....	38
1.1 Patient Disposition and Compliance (RAN, FAS).....	38
1.2 Length of Treatment Phase (FAS).....	40
1.3 Characterization of Study Population, Demographic Characteristics (FAS).....	41
1.4 PsA Disease History and Baseline Characteristics (FAS).....	43
1.5 Concomitant Medication (FAS) .....	44
1.6 Definition of Subpopulation (FAS).....	45
1.7 Number of Subjects in Subgroups (FAS).....	46
Efficacy Analysis .....	48
2.1 All-Cause Mortality (FAS).....	48
3.0 BSA (Percent) - Return Rates (FAS) .....	49
3.1 BSA (Percent) - Change from Baseline (FAS).....	50
3.2 BSA (Percent) - Change from Baseline by Age (FAS).....	51
3.3 BSA (Percent) - Change from Baseline by Gender (FAS).....	52
3.4 BSA (Percent) - Change from Baseline by Disease Severity (FAS).....	53
3.5 BSA (Percent) - Change from Baseline by Moderate/Severe PSO D (FAS) .....	54
3.6 BSA (Percent) - Change from Baseline by Lymphocyte Count at BL (FAS).....	55
3.7 BSA (Percent) - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	56
3.8 BSA (Percent) - Change from Baseline by HLA-DQA1*05 (FAS).....	57
3.9 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	58
3.10 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	59
3.11 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	60
3.12 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	61
3.13 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	62
3.14 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	63
3.15 BSA (Percent) - Change from Baseline by Lead Candidate Allele Score (FAS).....	64
3.16 BSA (Percent) - Change from Baseline by Linkage Variant rs10891185 (FAS).....	65
3.17 BSA (Percent) - Change from Baseline by Linkage Variant rs12065362 (FAS).....	66
3.18 BSA (Percent) - Change from Baseline by Linkage Variant rs11721988 (FAS).....	67
3.19 BSA (Percent) - Change from Baseline by Linkage Variant rs7787032 (FAS).....	68
4.0 C-Reactive Protein (hsCRP) (mg/L) - Return Rates (FAS).....	69
4.1 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline (FAS).....	70
4.2 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Age (FAS) .....	71
4.3 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Gender (FAS).....	72
4.4 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Disease Severity (FAS).....	73
4.5 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Moderate/Severe PSO D (FAS) .....	74
4.6 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lymphocyte Count at BL (FAS).....	75

4.7 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	76
4.8 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by HLA-DQA1*05 (FAS).....	77
4.9 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	78
4.10 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	79
4.11 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	80
4.12 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	81
4.13 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	82
4.14 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	83
4.15 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Allele Score (FAS)	84
4.16 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Linkage Variant rs10891185 (FAS)	85
4.17 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Linkage Variant rs12065362 (FAS)	86
4.18 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Linkage Variant rs11721988 (FAS)	87
4.19 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Linkage Variant rs7787032 (FAS)..	88
5.0 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Return Rates (FAS) .....	89
5.1 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline (FAS) .....	90
5.2 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Age (FAS).....	91
5.3 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Gender (FAS) .....	92
5.4 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Disease Severity (FAS)....	93
5.5 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Moderate/Severe PSO D (FAS).....	94
5.6 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lymphocyte Count at BL (FAS).....	95
5.7 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Enthesitis at BL According to LEI (FAS) .....	96
5.8 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by HLA-DQA1*05 (FAS) ....	97
5.9 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	98
5.10 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	99
5.11 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	100
5.12 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	101
5.13 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	102
5.14 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	103
5.15 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Allele Score (FAS).....	104

5.16 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Linkage Variant rs10891185 (FAS).....	105
5.17 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Linkage Variant rs12065362 (FAS).....	106
5.18 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Linkage Variant rs11721988 (FAS).....	107
5.19 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Linkage Variant rs7787032 (FAS).....	108
6.0 HAQ-DI - Return Rates (FAS).....	109
6.1 HAQ-DI - Change from Baseline (FAS).....	110
6.2 HAQ-DI - Change from Baseline by Age (FAS) .....	111
6.3 HAQ-DI - Change from Baseline by Gender (FAS) .....	113
6.4 HAQ-DI - Change from Baseline by Disease Severity (FAS) .....	115
6.5 HAQ-DI - Change from Baseline by Moderate/Severe PSO D (FAS) .....	117
6.6 HAQ-DI - Change from Baseline by Lymphocyte Count at BL (FAS) .....	119
6.7 HAQ-DI - Change from Baseline by Enthesitis at BL According to LEI (FAS) .....	121
6.8 HAQ-DI - Change from Baseline by HLA-DQA1*05 (FAS).....	123
6.9 HAQ-DI - Change from Baseline by Lead Candidate Variant rs10555659 (FAS) .....	125
6.10 HAQ-DI - Change from Baseline by Lead Candidate Variant rs111937633 (FAS) .....	127
6.11 HAQ-DI - Change from Baseline by Lead Candidate Variant rs11726476 (FAS) .....	129
6.12 HAQ-DI - Change from Baseline by Lead Candidate Variant rs10609046 (FAS) .....	131
6.13 HAQ-DI - Change from Baseline by Lead Candidate Variant rs8007401 (FAS) .....	133
6.14 HAQ-DI - Change from Baseline by Lead Candidate Variant rs7349145 (FAS) .....	135
6.15 HAQ-DI - Change from Baseline by Lead Candidate Allele Score (FAS) .....	137
6.16 HAQ-DI - Change from Baseline by Linkage Variant rs10891185 (FAS) .....	139
6.17 HAQ-DI - Change from Baseline by Linkage Variant rs12065362 (FAS) .....	141
6.18 HAQ-DI - Change from Baseline by Linkage Variant rs11721988 (FAS) .....	143
6.19 HAQ-DI - Change from Baseline by Linkage Variant rs7787032 (FAS) .....	145
7.1 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) (FAS) .....	147
7.2 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Age (FAS).....	148
7.3 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Gender (FAS).....	149
7.4 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Disease Severity (FAS).....	150
7.5 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Moderate/Severe PSO D (FAS) .....	151
7.6 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lymphocyte Count at BL (FAS).....	152
7.7 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Enthesitis at BL According to LEI (FAS) .....	153
7.8 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by HLA-DQA1*05 (FAS) .....	154
7.9 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Variant rs10555659 (FAS) .....	155
7.10 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Variant rs111937633 (FAS).....	156
7.11 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Variant rs11726476 (FAS) .....	157

7.12 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Variant rs10609046 (FAS)	158
7.13 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Variant rs8007401 (FAS)	159
7.14 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Variant rs7349145 (FAS)	160
7.15 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Allele Score (FAS).....	161
7.16 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Linkage Variant rs10891185 (FAS).....	162
7.17 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Linkage Variant rs12065362 (FAS).....	163
7.18 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Linkage Variant rs11721988 (FAS).....	164
7.19 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Linkage Variant rs7787032 (FAS).....	165
8.0 LDI Leeds Dactylitis Index - Return Rates (FAS)	166
8.1 LDI Leeds Dactylitis Index - Change from Baseline (FAS)	167
8.2 LDI Leeds Dactylitis Index - Change from Baseline by Age (FAS)	168
8.3 LDI Leeds Dactylitis Index - Change from Baseline by Gender (FAS)	169
8.4 LDI Leeds Dactylitis Index - Change from Baseline by Disease Severity (FAS)	170
8.5 LDI Leeds Dactylitis Index - Change from Baseline by Moderate/Severe PSO D (FAS)	171
8.6 LDI Leeds Dactylitis Index - Change from Baseline by Lymphocyte Count at BL (FAS)	172
8.7 LDI Leeds Dactylitis Index - Change from Baseline by Enthesitis at BL According to LEI (FAS)	173
8.8 LDI Leeds Dactylitis Index - Change from Baseline by HLA-DQA1*05 (FAS)	174
8.9 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)	175
8.10 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)	176
8.11 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)	177
8.12 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)	178
8.13 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)	179
8.14 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)	180
8.15 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Allele Score (FAS)	181
8.16 LDI Leeds Dactylitis Index - Change from Baseline by Linkage Variant rs10891185 (FAS)	182
8.17 LDI Leeds Dactylitis Index - Change from Baseline by Linkage Variant rs12065362 (FAS)	183
8.18 LDI Leeds Dactylitis Index - Change from Baseline by Linkage Variant rs11721988 (FAS)	184
8.19 LDI Leeds Dactylitis Index - Change from Baseline by Linkage Variant rs7787032 (FAS)	185
9.0 LDI Dactylitis Count - Return Rates (FAS)	186
9.1 LDI Dactylitis Count - Change from Baseline (FAS)	187
9.2 LDI Dactylitis Count - Change from Baseline by Age (FAS)	188
9.3 LDI Dactylitis Count - Change from Baseline by Gender (FAS)	189
9.4 LDI Dactylitis Count - Change from Baseline by Disease Severity (FAS)	190
9.5 LDI Dactylitis Count - Change from Baseline by Moderate/Severe PSO D (FAS)	191
9.6 LDI Dactylitis Count - Change from Baseline by Lymphocyte Count at BL (FAS)	192
9.7 LDI Dactylitis Count - Change from Baseline by Enthesitis at BL According to LEI (FAS)	193
9.8 LDI Dactylitis Count - Change from Baseline by HLA-DQA1*05 (FAS)	194
9.9 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)	195

9.10 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	196
9.11 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	197
9.12 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	198
9.13 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	199
9.14 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	200
9.15 LDI Dactylitis Count - Change from Baseline by Lead Candidate Allele Score (FAS) .....	201
9.16 LDI Dactylitis Count - Change from Baseline by Linkage Variant rs10891185 (FAS).....	202
9.17 LDI Dactylitis Count - Change from Baseline by Linkage Variant rs12065362 (FAS).....	203
9.18 LDI Dactylitis Count - Change from Baseline by Linkage Variant rs11721988 (FAS).....	204
9.19 LDI Dactylitis Count - Change from Baseline by Linkage Variant rs7787032 (FAS).....	205
10.1 LDI Presence of Dactylitis (FAS) .....	206
10.2 LDI Presence of Dactylitis by Age (FAS).....	207
10.3 LDI Presence of Dactylitis by Gender (FAS).....	208
10.4 LDI Presence of Dactylitis by Disease Severity (FAS).....	209
10.5 LDI Presence of Dactylitis by Moderate/Severe PSO D (FAS) .....	210
10.6 LDI Presence of Dactylitis by Lymphocyte Count at BL (FAS).....	211
10.7 LDI Presence of Dactylitis by Enthesitis at BL According to LEI (FAS).....	212
10.8 LDI Presence of Dactylitis by HLA-DQA1*05 (FAS) .....	213
10.9 LDI Presence of Dactylitis by Lead Candidate Variant rs10555659 (FAS).....	214
10.10 LDI Presence of Dactylitis by Lead Candidate Variant rs111937633 (FAS).....	215
10.11 LDI Presence of Dactylitis by Lead Candidate Variant rs11726476 (FAS).....	216
10.12 LDI Presence of Dactylitis by Lead Candidate Variant rs10609046 (FAS).....	217
10.13 LDI Presence of Dactylitis by Lead Candidate Variant rs8007401 (FAS).....	218
10.14 LDI Presence of Dactylitis by Lead Candidate Variant rs7349145 (FAS).....	219
10.15 LDI Presence of Dactylitis by Lead Candidate Allele Score (FAS) .....	220
10.16 LDI Presence of Dactylitis by Linkage Variant rs10891185 (FAS).....	221
10.17 LDI Presence of Dactylitis by Linkage Variant rs12065362 (FAS).....	222
10.18 LDI Presence of Dactylitis by Linkage Variant rs11721988 (FAS).....	223
10.19 LDI Presence of Dactylitis by Linkage Variant rs7787032 (FAS).....	224
11.0 LEI Leeds Enthesitis Index - Return Rates (FAS) .....	225
11.1 LEI Leeds Enthesitis Index - Change from Baseline (FAS).....	226
11.2 LEI Leeds Enthesitis Index - Change from Baseline by Age (FAS) .....	227
11.3 LEI Leeds Enthesitis Index - Change from Baseline by Gender (FAS).....	228
11.4 LEI Leeds Enthesitis Index - Change from Baseline by Disease Severity (FAS).....	229
11.5 LEI Leeds Enthesitis Index - Change from Baseline by Moderate/Severe PSO D (FAS) .....	230
11.6 LEI Leeds Enthesitis Index - Change from Baseline by Lymphocyte Count at BL (FAS).....	231
11.7 LEI Leeds Enthesitis Index - Change from Baseline by Enthesitis at BL According to LEI (FAS) ...	232
11.8 LEI Leeds Enthesitis Index - Change from Baseline by HLA-DQA1*05 (FAS).....	233
11.9 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)	234
11.10 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs111937633 (FAS) .....	235

11.11 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)	236
11.12 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)	237
11.13 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)	238
11.14 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)	239
11.15 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Allele Score (FAS)	240
11.16 LEI Leeds Enthesitis Index - Change from Baseline by Linkage Variant rs10891185 (FAS)	241
11.17 LEI Leeds Enthesitis Index - Change from Baseline by Linkage Variant rs12065362 (FAS)	242
11.18 LEI Leeds Enthesitis Index - Change from Baseline by Linkage Variant rs11721988 (FAS)	243
11.19 LEI Leeds Enthesitis Index - Change from Baseline by Linkage Variant rs7787032 (FAS)	244
12.1 LEI Presence of Enthesitis (FAS)	245
12.2 LEI Presence of Enthesitis by Age (FAS)	246
12.3 LEI Presence of Enthesitis by Gender (FAS)	247
12.4 LEI Presence of Enthesitis by Disease Severity (FAS)	248
12.5 LEI Presence of Enthesitis by Moderate/Severe PSO D (FAS)	249
12.6 LEI Presence of Enthesitis by Lymphocyte Count at BL (FAS)	250
12.7 LEI Presence of Enthesitis by Enthesitis at BL According to LEI (FAS)	251
12.8 LEI Presence of Enthesitis by HLA-DQA1*05 (FAS)	252
12.9 LEI Presence of Enthesitis by Lead Candidate Variant rs10555659 (FAS)	253
12.10 LEI Presence of Enthesitis by Lead Candidate Variant rs111937633 (FAS)	254
12.11 LEI Presence of Enthesitis by Lead Candidate Variant rs11726476 (FAS)	255
12.12 LEI Presence of Enthesitis by Lead Candidate Variant rs10609046 (FAS)	256
12.13 LEI Presence of Enthesitis by Lead Candidate Variant rs8007401 (FAS)	257
12.14 LEI Presence of Enthesitis by Lead Candidate Variant rs7349145 (FAS)	258
12.15 LEI Presence of Enthesitis by Lead Candidate Allele Score (FAS)	259
12.16 LEI Presence of Enthesitis by Linkage Variant rs10891185 (FAS)	260
12.17 LEI Presence of Enthesitis by Linkage Variant rs12065362 (FAS)	261
12.18 LEI Presence of Enthesitis by Linkage Variant rs11721988 (FAS)	262
12.19 LEI Presence of Enthesitis by Linkage Variant rs7787032 (FAS)	263
13.0 PASI Score - Return Rates (FAS)	264
13.1 PASI Score - Change from Baseline (FAS)	265
13.2 PASI Score - Change from Baseline by Age (FAS)	266
13.3 PASI Score - Change from Baseline by Gender (FAS)	267
13.4 PASI Score - Change from Baseline by Disease Severity (FAS)	268
13.5 PASI Score - Change from Baseline by Moderate/Severe PSO D (FAS)	269
13.6 PASI Score - Change from Baseline by Lymphocyte Count at BL (FAS)	270
13.7 PASI Score - Change from Baseline by Enthesitis at BL According to LEI (FAS)	271
13.8 PASI Score - Change from Baseline by HLA-DQA1*05 (FAS)	272
13.9 PASI Score - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)	273
13.10 PASI Score - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)	274

13.11 PASI Score - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	275
13.12 PASI Score - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	276
13.13 PASI Score - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	277
13.14 PASI Score - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	278
13.15 PASI Score - Change from Baseline by Lead Candidate Allele Score (FAS).....	279
13.16 PASI Score - Change from Baseline by Linkage Variant rs10891185 (FAS).....	280
13.17 PASI Score - Change from Baseline by Linkage Variant rs12065362 (FAS).....	281
13.18 PASI Score - Change from Baseline by Linkage Variant rs11721988 (FAS).....	282
13.19 PASI Score - Change from Baseline by Linkage Variant rs7787032 (FAS).....	283
14.1 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 (FAS) .....	284
14.2 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Age (FAS).....	285
14.3 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Gender (FAS).....	287
14.4 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Disease Severity (FAS).....	289
14.5 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Moderate/Severe PSO D (FAS) .....	291
14.6 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lymphocyte Count at BL (FAS).....	293
14.7 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Entesitis at BL According to LEI (FAS) .....	295
14.8 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by HLA-DQA1*05 (FAS) .....	297
14.9 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs10555659 (FAS) .....	299
14.10 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs111937633 (FAS).....	301
14.11 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs11726476 (FAS).....	303
14.12 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs10609046 (FAS).....	305
14.13 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs8007401 (FAS) .....	307
14.14 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs7349145 (FAS) .....	309
14.15 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Allele Score (FAS) ..	311
14.16 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Linkage Variant rs10891185 (FAS)...	313
14.17 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Linkage Variant rs12065362 (FAS)...	315
14.18 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Linkage Variant rs11721988 (FAS)...	317
14.19 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Linkage Variant rs7787032 (FAS).....	319
15.0 Patient's Assessment of PsA Pain (VAS) - Return Rates (FAS) .....	321
15.1 Patient's Assessment of PsA Pain (VAS) - Change from Baseline (FAS) .....	322
15.2 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Age (FAS).....	323
15.3 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Gender (FAS).....	325
15.4 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Disease Severity (FAS).....	327
15.5 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Moderate/Severe PSO D (FAS) .....	329
15.6 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lymphocyte Count at BL (FAS) .....	331



15.7 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	333
15.8 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by HLA-DQA1*05 (FAS) .....	335
15.9 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	337
15.10 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	339
15.11 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	341
15.12 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	343
15.13 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	345
15.14 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	347
15.15 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Allele Score (FAS).....	349
15.16 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Linkage Variant rs10891185 (FAS).....	351
15.17 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Linkage Variant rs12065362 (FAS).....	353
15.18 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Linkage Variant rs11721988 (FAS).....	355
15.19 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Linkage Variant rs7787032 (FAS).....	357
16.0 Patient's Global Assessment of PsA Disease Activity (VAS) - Return Rates (FAS) .....	359
16.1 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline (FAS) .....	360
16.2 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Age (FAS)	361
16.3 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Gender (FAS) .....	363
16.4 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Disease Severity (FAS) .....	365
16.5 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Moderate/Severe PSO D (FAS) .....	367
16.6 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lymphocyte Count at BL (FAS) .....	369
16.7 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	371
16.8 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by HLA-DQA1*05 (FAS) .....	373
16.9 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	375
16.10 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	377
16.11 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	379
16.12 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	381

16.13 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	383
16.14 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	385
16.15 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Allele Score (FAS).....	387
16.16 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs10891185 (FAS).....	389
16.17 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs12065362 (FAS).....	391
16.18 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs11721988 (FAS).....	393
16.19 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs7787032 (FAS).....	395
17.0 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Return Rates (FAS).....	397
17.1 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline (FAS).....	398
17.2 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Age (FAS).....	399
17.3 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Gender (FAS).....	401
17.4 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Disease Severity (FAS).....	403
17.5 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Moderate/Severe PSO D (FAS).....	405
17.6 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lymphocyte Count at BL (FAS).....	407
17.7 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	409
17.8 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by HLA-DQA1*05 (FAS).....	411
17.9 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	413
17.10 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	415
17.11 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	417
17.12 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	419
17.13 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	421
17.14 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	423
17.15 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Allele Score (FAS).....	425
17.16 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Linkage Variant rs10891185 (FAS).....	427
17.17 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Linkage Variant rs12065362 (FAS).....	429

17.18 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Linkage Variant rs11721988 (FAS).....	431
17.19 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Linkage Variant rs7787032 (FAS).....	433
18.0 Physician's Global Assessment of PsA Disease Activity (VAS) - Return Rates (FAS).....	435
18.1 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline (FAS).....	436
18.2 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Age (FAS).....	437
18.3 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Gender (FAS).....	438
18.4 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Disease Severity (FAS).....	439
18.5 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Moderate/Severe PSO D (FAS).....	440
18.6 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lymphocyte Count at BL (FAS).....	441
18.7 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Entesitis at BL According to LEI (FAS).....	442
18.8 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by HLA-DQA1*05 (FAS).....	443
18.9 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	444
18.10 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	445
18.11 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	446
18.12 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	447
18.13 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	448
18.14 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	449
18.15 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Allele Score (FAS).....	450
18.16 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs10891185 (FAS).....	451
18.17 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs12065362 (FAS).....	452
18.18 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs11721988 (FAS).....	453
18.19 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs7787032 (FAS).....	454
19.0 SJC28 - Return Rates (FAS).....	455
19.1 SJC28 - Change from Baseline (FAS).....	456
19.2 SJC28 - Change from Baseline by Age (FAS).....	457
19.3 SJC28 - Change from Baseline by Gender (FAS).....	458
19.4 SJC28 - Change from Baseline by Disease Severity (FAS).....	459
19.5 SJC28 - Change from Baseline by Moderate/Severe PSO D (FAS).....	460

19.6 SJC28 - Change from Baseline by Lymphocyte Count at BL (FAS).....	461
19.7 SJC28 - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	462
19.8 SJC28 - Change from Baseline by HLA-DQA1*05 (FAS) .....	463
19.9 SJC28 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	464
19.10 SJC28 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	465
19.11 SJC28 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	466
19.12 SJC28 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	467
19.13 SJC28 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	468
19.14 SJC28 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	469
19.15 SJC28 - Change from Baseline by Lead Candidate Allele Score (FAS).....	470
19.16 SJC28 - Change from Baseline by Linkage Variant rs10891185 (FAS).....	471
19.17 SJC28 - Change from Baseline by Linkage Variant rs12065362 (FAS).....	472
19.18 SJC28 - Change from Baseline by Linkage Variant rs11721988 (FAS).....	473
19.19 SJC28 - Change from Baseline by Linkage Variant rs7787032 (FAS).....	474
20.0 SJC66 - Return Rates (FAS) .....	475
20.1 SJC66 - Change from Baseline (FAS) .....	476
20.2 SJC66 - Change from Baseline by Age (FAS).....	477
20.3 SJC66 - Change from Baseline by Gender (FAS).....	478
20.4 SJC66 - Change from Baseline by Disease Severity (FAS).....	479
20.5 SJC66 - Change from Baseline by Moderate/Severe PSO D (FAS) .....	480
20.6 SJC66 - Change from Baseline by Lymphocyte Count at BL (FAS).....	481
20.7 SJC66 - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	482
20.8 SJC66 - Change from Baseline by HLA-DQA1*05 (FAS) .....	483
20.9 SJC66 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	484
20.10 SJC66 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	485
20.11 SJC66 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	486
20.12 SJC66 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	487
20.13 SJC66 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	488
20.14 SJC66 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	489
20.15 SJC66 - Change from Baseline by Lead Candidate Allele Score (FAS).....	490
20.16 SJC66 - Change from Baseline by Linkage Variant rs10891185 (FAS).....	491
20.17 SJC66 - Change from Baseline by Linkage Variant rs12065362 (FAS).....	492
20.18 SJC66 - Change from Baseline by Linkage Variant rs11721988 (FAS).....	493
20.19 SJC66 - Change from Baseline by Linkage Variant rs7787032 (FAS).....	494
21.0 SJC76 - Return Rates (FAS) .....	495
21.1 SJC76 - Change from Baseline (FAS) .....	496
21.2 SJC76 - Change from Baseline by Age (FAS).....	497
21.3 SJC76 - Change from Baseline by Gender (FAS).....	498
21.4 SJC76 - Change from Baseline by Disease Severity (FAS).....	499
21.5 SJC76 - Change from Baseline by Moderate/Severe PSO D (FAS) .....	500
21.6 SJC76 - Change from Baseline by Lymphocyte Count at BL (FAS).....	501

21.7 SJC76 - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	502
21.8 SJC76 - Change from Baseline by HLA-DQA1*05 (FAS) .....	503
21.9 SJC76 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	504
21.10 SJC76 - Change from Baseline by Lead Candidate Variant rs11937633 (FAS).....	505
21.11 SJC76 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	506
21.12 SJC76 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	507
21.13 SJC76 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	508
21.14 SJC76 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	509
21.15 SJC76 - Change from Baseline by Lead Candidate Allele Score (FAS).....	510
21.16 SJC76 - Change from Baseline by Linkage Variant rs10891185 (FAS).....	511
21.17 SJC76 - Change from Baseline by Linkage Variant rs12065362 (FAS).....	512
21.18 SJC76 - Change from Baseline by Linkage Variant rs11721988 (FAS).....	513
21.19 SJC76 - Change from Baseline by Linkage Variant rs7787032 (FAS).....	514
22.0 SPARCC Enthesitis Index - Return Rates (FAS).....	515
22.1 SPARCC Enthesitis Index - Change from Baseline (FAS).....	516
22.2 SPARCC Enthesitis Index - Change from Baseline by Age (FAS) .....	517
22.3 SPARCC Enthesitis Index - Change from Baseline by Gender (FAS) .....	518
22.4 SPARCC Enthesitis Index - Change from Baseline by Disease Severity (FAS) .....	519
22.5 SPARCC Enthesitis Index - Change from Baseline by Moderate/Severe PSO D (FAS).....	520
22.6 SPARCC Enthesitis Index - Change from Baseline by Lymphocyte Count at BL (FAS) .....	521
22.7 SPARCC Enthesitis Index - Change from Baseline by Enthesitis at BL According to LEI (FAS) ....	522
22.8 SPARCC Enthesitis Index - Change from Baseline by HLA-DQA1*05 (FAS).....	523
22.9 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs10555659 (FAS) .	524
22.10 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs11937633 (FAS) .....	525
22.11 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)	526
22.12 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)	527
22.13 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs8007401 (FAS) .	528
22.14 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs7349145 (FAS) .	529
22.15 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Allele Score (FAS) .....	530
22.16 SPARCC Enthesitis Index - Change from Baseline by Linkage Variant rs10891185 (FAS) .....	531
22.17 SPARCC Enthesitis Index - Change from Baseline by Linkage Variant rs12065362 (FAS) .....	532
22.18 SPARCC Enthesitis Index - Change from Baseline by Linkage Variant rs11721988 (FAS) .....	533
22.19 SPARCC Enthesitis Index - Change from Baseline by Linkage Variant rs7787032 (FAS) .....	534
23.1 SPARCC Resolution of Enthesitis (FAS) .....	535
23.2 SPARCC Resolution of Enthesitis by Age (FAS).....	536
23.3 SPARCC Resolution of Enthesitis by Gender (FAS).....	537
23.4 SPARCC Resolution of Enthesitis by Disease Severity (FAS).....	538
23.5 SPARCC Resolution of Enthesitis by Moderate/Severe PSO D (FAS) .....	539
23.6 SPARCC Resolution of Enthesitis by Lymphocyte Count at BL (FAS).....	540
23.7 SPARCC Resolution of Enthesitis by Enthesitis at BL According to LEI (FAS).....	541

23.8 SPARCC Resolution of Enthesitis by HLA-DQA1*05 (FAS) .....	542
23.9 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs10555659 (FAS).....	543
23.10 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs111937633 (FAS).....	544
23.11 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs11726476 (FAS).....	545
23.12 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs10609046 (FAS).....	546
23.13 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs8007401 (FAS).....	547
23.14 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs7349145 (FAS).....	548
23.15 SPARCC Resolution of Enthesitis by Lead Candidate Allele Score (FAS).....	549
23.16 SPARCC Resolution of Enthesitis by Linkage Variant rs10891185 (FAS).....	550
23.17 SPARCC Resolution of Enthesitis by Linkage Variant rs12065362 (FAS).....	551
23.18 SPARCC Resolution of Enthesitis by Linkage Variant rs11721988 (FAS).....	552
23.19 SPARCC Resolution of Enthesitis by Linkage Variant rs7787032 (FAS).....	553
24.0 TJC28 - Return Rates (FAS) .....	554
24.1 TJC28 - Change from Baseline (FAS) .....	555
24.2 TJC28 - Change from Baseline by Age (FAS).....	556
24.3 TJC28 - Change from Baseline by Gender (FAS).....	557
24.4 TJC28 - Change from Baseline by Disease Severity (FAS).....	558
24.5 TJC28 - Change from Baseline by Moderate/Severe PSO D (FAS) .....	559
24.6 TJC28 - Change from Baseline by Lymphocyte Count at BL (FAS).....	560
24.7 TJC28 - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	561
24.8 TJC28 - Change from Baseline by HLA-DQA1*05 (FAS) .....	562
24.9 TJC28 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	563
24.10 TJC28 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	564
24.11 TJC28 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	565
24.12 TJC28 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	566
24.13 TJC28 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	567
24.14 TJC28 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	568
24.15 TJC28 - Change from Baseline by Lead Candidate Allele Score (FAS).....	569
24.16 TJC28 - Change from Baseline by Linkage Variant rs10891185 (FAS).....	570
24.17 TJC28 - Change from Baseline by Linkage Variant rs12065362 (FAS).....	571
24.18 TJC28 - Change from Baseline by Linkage Variant rs11721988 (FAS).....	572
24.19 TJC28 - Change from Baseline by Linkage Variant rs7787032 (FAS).....	573
25.0 TJC68 - Return Rates (FAS) .....	574
25.1 TJC68 - Change from Baseline (FAS) .....	575
25.2 TJC68 - Change from Baseline by Age (FAS).....	576
25.3 TJC68 - Change from Baseline by Gender (FAS).....	577
25.4 TJC68 - Change from Baseline by Disease Severity (FAS).....	578
25.5 TJC68 - Change from Baseline by Moderate/Severe PSO D (FAS) .....	579
25.6 TJC68 - Change from Baseline by Lymphocyte Count at BL (FAS).....	580
25.7 TJC68 - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	581
25.8 TJC68 - Change from Baseline by HLA-DQA1*05 (FAS) .....	582

25.9 TJC68 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	583
25.10 TJC68 - Change from Baseline by Lead Candidate Variant rs11937633 (FAS).....	584
25.11 TJC68 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	585
25.12 TJC68 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	586
25.13 TJC68 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	587
25.14 TJC68 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	588
25.15 TJC68 - Change from Baseline by Lead Candidate Allele Score (FAS).....	589
25.16 TJC68 - Change from Baseline by Linkage Variant rs10891185 (FAS).....	590
25.17 TJC68 - Change from Baseline by Linkage Variant rs12065362 (FAS).....	591
25.18 TJC68 - Change from Baseline by Linkage Variant rs11721988 (FAS).....	592
25.19 TJC68 - Change from Baseline by Linkage Variant rs7787032 (FAS).....	593
26.0 TJC78 - Return Rates (FAS) .....	594
26.1 TJC78 - Change from Baseline (FAS) .....	595
26.2 TJC78 - Change from Baseline by Age (FAS).....	596
26.3 TJC78 - Change from Baseline by Gender (FAS).....	597
26.4 TJC78 - Change from Baseline by Disease Severity (FAS).....	598
26.5 TJC78 - Change from Baseline by Moderate/Severe PSO D (FAS) .....	599
26.6 TJC78 - Change from Baseline by Lymphocyte Count at BL (FAS).....	600
26.7 TJC78 - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	601
26.8 TJC78 - Change from Baseline by HLA-DQA1*05 (FAS) .....	602
26.9 TJC78 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	603
26.10 TJC78 - Change from Baseline by Lead Candidate Variant rs11937633 (FAS).....	604
26.11 TJC78 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	605
26.12 TJC78 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	606
26.13 TJC78 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	607
26.14 TJC78 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	608
26.15 TJC78 - Change from Baseline by Lead Candidate Allele Score (FAS).....	609
26.16 TJC78 - Change from Baseline by Linkage Variant rs10891185 (FAS).....	610
26.17 TJC78 - Change from Baseline by Linkage Variant rs12065362 (FAS).....	611
26.18 TJC78 - Change from Baseline by Linkage Variant rs11721988 (FAS).....	612
26.19 TJC78 - Change from Baseline by Linkage Variant rs7787032 (FAS).....	613
27.1 ACR Response ACR20 / ACR50 / ACR70 (FAS).....	614
27.2 ACR Response ACR20 / ACR50 / ACR70 by Age (FAS) .....	615
27.3 ACR Response ACR20 / ACR50 / ACR70 by Gender (FAS) .....	616
27.4 ACR Response ACR20 / ACR50 / ACR70 by Disease Severity (FAS) .....	617
27.5 ACR Response ACR20 / ACR50 / ACR70 by Moderate/Severe PSO D (FAS) .....	618
27.6 ACR Response ACR20 / ACR50 / ACR70 by Lymphocyte Count at BL (FAS).....	620
27.7 ACR Response ACR20 / ACR50 / ACR70 by Enthesitis at BL According to LEI (FAS) .....	621
27.8 ACR Response ACR20 / ACR50 / ACR70 by HLA-DQA1*05 (FAS).....	622
27.9 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs10555659 (FAS) .....	623
27.10 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs11937633 (FAS) .....	624

27.11 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs11726476 (FAS) .....	625
27.12 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs10609046 (FAS) .....	626
27.13 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs8007401 (FAS) .....	627
27.14 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs7349145 (FAS) .....	629
27.15 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Allele Score (FAS) .....	630
27.16 ACR Response ACR20 / ACR50 / ACR70 by Linkage Variant rs10891185 (FAS) .....	631
27.17 ACR Response ACR20 / ACR50 / ACR70 by Linkage Variant rs12065362 (FAS) .....	632
27.18 ACR Response ACR20 / ACR50 / ACR70 by Linkage Variant rs11721988 (FAS) .....	633
27.19 ACR Response ACR20 / ACR50 / ACR70 by Linkage Variant rs7787032 (FAS) .....	634
28.0 DAPSA - Return Rates (FAS) .....	635
28.1 DAPSA - Change from Baseline (FAS) .....	636
28.2 DAPSA - Change from Baseline by Age (FAS) .....	637
28.3 DAPSA - Change from Baseline by Gender (FAS) .....	638
28.4 DAPSA - Change from Baseline by Disease Severity (FAS) .....	639
28.5 DAPSA - Change from Baseline by Moderate/Severe PSO D (FAS) .....	640
28.6 DAPSA - Change from Baseline by Lymphocyte Count at BL (FAS) .....	641
28.7 DAPSA - Change from Baseline by Enthesitis at BL According to LEI (FAS) .....	642
28.8 DAPSA - Change from Baseline by HLA-DQA1*05 (FAS) .....	643
28.9 DAPSA - Change from Baseline by Lead Candidate Variant rs10555659 (FAS) .....	644
28.10 DAPSA - Change from Baseline by Lead Candidate Variant rs111937633 (FAS) .....	645
28.11 DAPSA - Change from Baseline by Lead Candidate Variant rs11726476 (FAS) .....	646
28.12 DAPSA - Change from Baseline by Lead Candidate Variant rs10609046 (FAS) .....	647
28.13 DAPSA - Change from Baseline by Lead Candidate Variant rs8007401 (FAS) .....	648
28.14 DAPSA - Change from Baseline by Lead Candidate Variant rs7349145 (FAS) .....	649
28.15 DAPSA - Change from Baseline by Lead Candidate Allele Score (FAS) .....	650
28.16 DAPSA - Change from Baseline by Linkage Variant rs10891185 (FAS) .....	651
28.17 DAPSA - Change from Baseline by Linkage Variant rs12065362 (FAS) .....	652
28.18 DAPSA - Change from Baseline by Linkage Variant rs11721988 (FAS) .....	653
28.19 DAPSA - Change from Baseline by Linkage Variant rs7787032 (FAS) .....	654
29.1 DAPSA Low Disease Activity / Remission (FAS) .....	655
29.2 DAPSA Low Disease Activity / Remission by Age (FAS) .....	656
29.3 DAPSA Low Disease Activity / Remission by Gender (FAS) .....	657
29.4 DAPSA Low Disease Activity / Remission by Disease Severity (FAS) .....	658
29.5 DAPSA Low Disease Activity / Remission by Moderate/Severe PSO D (FAS) .....	659
29.6 DAPSA Low Disease Activity / Remission by Lymphocyte Count at BL (FAS) .....	660
29.7 DAPSA Low Disease Activity / Remission by Enthesitis at BL According to LEI (FAS) .....	661
29.8 DAPSA Low Disease Activity / Remission by HLA-DQA1*05 (FAS) .....	662
29.9 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs10555659 (FAS) .....	663
29.10 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs111937633 (FAS) .....	664
29.11 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs11726476 (FAS) .....	665
29.12 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs10609046 (FAS) .....	666



29.13 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs8007401 (FAS).....	667
29.14 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs7349145 (FAS).....	668
29.15 DAPSA Low Disease Activity / Remission by Lead Candidate Allele Score (FAS) .....	669
29.16 DAPSA Low Disease Activity / Remission by Linkage Variant rs10891185 (FAS).....	670
29.17 DAPSA Low Disease Activity / Remission by Linkage Variant rs12065362 (FAS).....	671
29.18 DAPSA Low Disease Activity / Remission by Linkage Variant rs11721988 (FAS).....	672
29.19 DAPSA Low Disease Activity / Remission by Linkage Variant rs7787032 (FAS).....	673
30.0 DAS28 - Return Rates (FAS).....	674
30.1 DAS28 - Change from Baseline (FAS).....	675
30.2 DAS28 - Change from Baseline by Age (FAS) .....	676
30.3 DAS28 - Change from Baseline by Gender (FAS) .....	677
30.4 DAS28 - Change from Baseline by Disease Severity (FAS) .....	678
30.5 DAS28 - Change from Baseline by Moderate/Severe PSO D (FAS).....	679
30.6 DAS28 - Change from Baseline by Lymphocyte Count at BL (FAS) .....	680
30.7 DAS28 - Change from Baseline by Enthesitis at BL According to LEI (FAS) .....	681
30.8 DAS28 - Change from Baseline by HLA-DQA1*05 (FAS).....	682
30.9 DAS28 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS) .....	683
30.10 DAS28 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS) .....	684
30.11 DAS28 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS) .....	685
30.12 DAS28 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS) .....	686
30.13 DAS28 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS) .....	687
30.14 DAS28 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS) .....	688
30.15 DAS28 - Change from Baseline by Lead Candidate Allele Score (FAS) .....	689
30.16 DAS28 - Change from Baseline by Linkage Variant rs10891185 (FAS) .....	690
30.17 DAS28 - Change from Baseline by Linkage Variant rs12065362 (FAS) .....	691
30.18 DAS28 - Change from Baseline by Linkage Variant rs11721988 (FAS) .....	692
30.19 DAS28 - Change from Baseline by Linkage Variant rs7787032 (FAS) .....	693
31.1 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response (FAS).....	694
31.2 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Age (FAS)	695
31.3 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Gender (FAS)	697
31.4 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Disease Severity (FAS) .....	699
31.5 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Moderate/Severe PSO D (FAS) .....	701
31.6 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lymphocyte Count at BL (FAS).....	703
31.7 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Enthesitis at BL According to LEI (FAS).....	705
31.8 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by HLA-DQA1*05 (FAS).....	707
31.9 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs10555659 (FAS).....	709

31.10 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs111937633 (FAS).....	711
31.11 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs11726476 (FAS).....	713
31.12 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs10609046 (FAS).....	715
31.13 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs8007401 (FAS).....	717
31.14 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs7349145 (FAS).....	719
31.15 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Allele Score (FAS).....	721
31.16 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Linkage Variant rs10891185 (FAS).....	723
31.17 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Linkage Variant rs12065362 (FAS).....	725
31.18 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Linkage Variant rs11721988 (FAS).....	727
31.19 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Linkage Variant rs7787032 (FAS).....	729
32.0 mCPDAI - Return Rates (FAS).....	731
32.1 mCPDAI - Change from Baseline (FAS).....	732
32.2 mCPDAI - Change from Baseline by Age (FAS) .....	733
32.3 mCPDAI - Change from Baseline by Gender (FAS) .....	734
32.4 mCPDAI - Change from Baseline by Disease Severity (FAS) .....	735
32.5 mCPDAI - Change from Baseline by Moderate/Severe PSO D (FAS).....	736
32.6 mCPDAI - Change from Baseline by Lymphocyte Count at BL (FAS) .....	737
32.7 mCPDAI - Change from Baseline by Enthesitis at BL According to LEI (FAS) .....	738
32.8 mCPDAI - Change from Baseline by HLA-DQA1*05 (FAS).....	739
32.9 mCPDAI - Change from Baseline by Lead Candidate Variant rs10555659 (FAS) .....	740
32.10 mCPDAI - Change from Baseline by Lead Candidate Variant rs111937633 (FAS) .....	741
32.11 mCPDAI - Change from Baseline by Lead Candidate Variant rs11726476 (FAS) .....	742
32.12 mCPDAI - Change from Baseline by Lead Candidate Variant rs10609046 (FAS) .....	743
32.13 mCPDAI - Change from Baseline by Lead Candidate Variant rs8007401 (FAS) .....	744
32.14 mCPDAI - Change from Baseline by Lead Candidate Variant rs7349145 (FAS) .....	745
32.15 mCPDAI - Change from Baseline by Lead Candidate Allele Score (FAS) .....	746
32.16 mCPDAI - Change from Baseline by Linkage Variant rs10891185 (FAS) .....	747
32.17 mCPDAI - Change from Baseline by Linkage Variant rs12065362 (FAS) .....	748
32.18 mCPDAI - Change from Baseline by Linkage Variant rs11721988 (FAS) .....	749
32.19 mCPDAI - Change from Baseline by Linkage Variant rs7787032 (FAS) .....	750
33.1 mCPDAI Low Disease Activity (FAS).....	751
33.2 mCPDAI Low Disease Activity by Age (FAS) .....	752
33.3 mCPDAI Low Disease Activity by Gender (FAS) .....	753
33.4 mCPDAI Low Disease Activity by Disease Severity (FAS).....	754

33.5 mCPDAI Low Disease Activity by Moderate/Severe PSO D (FAS).....	755
33.6 mCPDAI Low Disease Activity by Lymphocyte Count at BL (FAS) .....	756
33.7 mCPDAI Low Disease Activity by Enthesitis at BL According to LEI (FAS).....	757
33.8 mCPDAI Low Disease Activity by HLA-DQA1*05 (FAS) .....	758
33.9 mCPDAI Low Disease Activity by Lead Candidate Variant rs10555659 (FAS) .....	759
33.10 mCPDAI Low Disease Activity by Lead Candidate Variant rs111937633 (FAS) .....	760
33.11 mCPDAI Low Disease Activity by Lead Candidate Variant rs11726476 (FAS) .....	761
33.12 mCPDAI Low Disease Activity by Lead Candidate Variant rs10609046 (FAS) .....	762
33.13 mCPDAI Low Disease Activity by Lead Candidate Variant rs8007401 (FAS) .....	763
33.14 mCPDAI Low Disease Activity by Lead Candidate Variant rs7349145 (FAS) .....	764
33.15 mCPDAI Low Disease Activity by Lead Candidate Allele Score (FAS) .....	765
33.16 mCPDAI Low Disease Activity by Linkage Variant rs10891185 (FAS) .....	766
33.17 mCPDAI Low Disease Activity by Linkage Variant rs12065362 (FAS) .....	767
33.18 mCPDAI Low Disease Activity by Linkage Variant rs11721988 (FAS) .....	768
33.19 mCPDAI Low Disease Activity by Linkage Variant rs7787032 (FAS) .....	769
34.1 MDA Minimal Disease Activity / Very Low Disease Activity (FAS).....	770
34.2 MDA Minimal Disease Activity / Very Low Disease Activity by Age (FAS) .....	771
34.3 MDA Minimal Disease Activity / Very Low Disease Activity by Gender (FAS) .....	772
34.4 MDA Minimal Disease Activity / Very Low Disease Activity by Disease Severity (FAS) .....	773
34.5 MDA Minimal Disease Activity / Very Low Disease Activity by Moderate/Severe PSO D (FAS)...	774
34.6 MDA Minimal Disease Activity / Very Low Disease Activity by Lymphocyte Count at BL (FAS) .	775
34.7 MDA Minimal Disease Activity / Very Low Disease Activity by Enthesitis at BL According to LEI (FAS).....	776
34.8 MDA Minimal Disease Activity / Very Low Disease Activity by HLA-DQA1*05 (FAS).....	777
34.9 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs10555659 (FAS).....	778
34.10 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs111937633 (FAS).....	779
34.11 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs11726476 (FAS).....	780
34.12 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs10609046 (FAS).....	781
34.13 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs8007401 (FAS).....	782
34.14 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs7349145 (FAS).....	783
34.15 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Allele Score (FAS) .....	784
34.16 MDA Minimal Disease Activity / Very Low Disease Activity by Linkage Variant rs10891185 (FAS) .....	785
34.17 MDA Minimal Disease Activity / Very Low Disease Activity by Linkage Variant rs12065362 (FAS) .....	786
34.18 MDA Minimal Disease Activity / Very Low Disease Activity by Linkage Variant rs11721988 (FAS) .....	787

34.19 MDA Minimal Disease Activity / Very Low Disease Activity by Linkage Variant rs7787032 (FAS)	788
35.0 PASDAS - Return Rates (FAS)	789
35.1 PASDAS - Change from Baseline (FAS)	790
35.2 PASDAS - Change from Baseline by Age (FAS)	791
35.3 PASDAS - Change from Baseline by Gender (FAS)	792
35.4 PASDAS - Change from Baseline by Disease Severity (FAS)	793
35.5 PASDAS - Change from Baseline by Moderate/Severe PSO D (FAS)	794
35.6 PASDAS - Change from Baseline by Lymphocyte Count at BL (FAS)	795
35.7 PASDAS - Change from Baseline by Enthesitis at BL According to LEI (FAS)	796
35.8 PASDAS - Change from Baseline by HLA-DQA1*05 (FAS)	797
35.9 PASDAS - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)	798
35.10 PASDAS - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)	799
35.11 PASDAS - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)	800
35.12 PASDAS - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)	801
35.13 PASDAS - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)	802
35.14 PASDAS - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)	803
35.15 PASDAS - Change from Baseline by Lead Candidate Allele Score (FAS)	804
35.16 PASDAS - Change from Baseline by Linkage Variant rs10891185 (FAS)	805
35.17 PASDAS - Change from Baseline by Linkage Variant rs12065362 (FAS)	806
35.18 PASDAS - Change from Baseline by Linkage Variant rs11721988 (FAS)	807
35.19 PASDAS - Change from Baseline by Linkage Variant rs7787032 (FAS)	808
36.1 PASDAS Good Response / Moderate-to-Good Response (FAS)	809
36.2 PASDAS Good Response / Moderate-to-Good Response by Age (FAS)	810
36.3 PASDAS Good Response / Moderate-to-Good Response by Gender (FAS)	811
36.4 PASDAS Good Response / Moderate-to-Good Response by Disease Severity (FAS)	812
36.5 PASDAS Good Response / Moderate-to-Good Response by Moderate/Severe PSO D (FAS)	813
36.6 PASDAS Good Response / Moderate-to-Good Response by Lymphocyte Count at BL (FAS)	814
36.7 PASDAS Good Response / Moderate-to-Good Response by Enthesitis at BL According to LEI (FAS)	815
36.8 PASDAS Good Response / Moderate-to-Good Response by HLA-DQA1*05 (FAS)	816
36.9 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs10555659 (FAS)	817
36.10 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs111937633 (FAS)	818
36.11 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs11726476 (FAS)	819
36.12 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs10609046 (FAS)	820
36.13 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs8007401 (FAS)	821
36.14 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs7349145 (FAS)	822

36.15 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Allele Score (FAS)..	823
36.16 PASDAS Good Response / Moderate-to-Good Response by Linkage Variant rs10891185 (FAS)..	824
36.17 PASDAS Good Response / Moderate-to-Good Response by Linkage Variant rs12065362 (FAS)..	825
36.18 PASDAS Good Response / Moderate-to-Good Response by Linkage Variant rs11721988 (FAS)..	826
36.19 PASDAS Good Response / Moderate-to-Good Response by Linkage Variant rs7787032 (FAS)....	827
37.1 PsARC Response (FAS).....	828
37.2 PsARC Response by Age (FAS).....	829
37.3 PsARC Response by Gender (FAS).....	830
37.4 PsARC Response by Disease Severity (FAS).....	831
37.5 PsARC Response by Moderate/Severe PSO D (FAS) .....	832
37.6 PsARC Response by Lymphocyte Count at BL (FAS).....	833
37.7 PsARC Response by Enthesitis at BL According to LEI (FAS).....	834
37.8 PsARC Response by HLA-DQA1*05 (FAS).....	835
37.9 PsARC Response by Lead Candidate Variant rs10555659 (FAS).....	836
37.10 PsARC Response by Lead Candidate Variant rs111937633 (FAS).....	837
37.11 PsARC Response by Lead Candidate Variant rs11726476 (FAS).....	838
37.12 PsARC Response by Lead Candidate Variant rs10609046 (FAS).....	839
37.13 PsARC Response by Lead Candidate Variant rs8007401 (FAS).....	840
37.14 PsARC Response by Lead Candidate Variant rs7349145 (FAS).....	841
37.15 PsARC Response by Lead Candidate Allele Score (FAS).....	842
37.16 PsARC Response by Linkage Variant rs10891185 (FAS).....	843
37.17 PsARC Response by Linkage Variant rs12065362 (FAS).....	844
37.18 PsARC Response by Linkage Variant rs11721988 (FAS).....	845
37.19 PsARC Response by Linkage Variant rs7787032 (FAS).....	846
38.0 DLQI - Return Rates (FAS) .....	847
38.1 DLQI - Change from Baseline (FAS) .....	848
38.2 DLQI - Change from Baseline by Age (FAS).....	849
38.3 DLQI - Change from Baseline by Gender (FAS).....	850
38.4 DLQI - Change from Baseline by Disease Severity (FAS).....	851
38.5 DLQI - Change from Baseline by Moderate/Severe PSO D (FAS).....	852
38.6 DLQI - Change from Baseline by Lymphocyte Count at BL (FAS).....	853
38.7 DLQI - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	854
38.8 DLQI - Change from Baseline by HLA-DQA1*05 (FAS) .....	855
38.9 DLQI - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	856
38.10 DLQI - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	857
38.11 DLQI - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	858
38.12 DLQI - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	859
38.13 DLQI - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	860
38.14 DLQI - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	861
38.15 DLQI - Change from Baseline by Lead Candidate Allele Score (FAS).....	862
38.16 DLQI - Change from Baseline by Linkage Variant rs10891185 (FAS).....	863

38.17 DLQI - Change from Baseline by Linkage Variant rs12065362 (FAS).....	864
38.18 DLQI - Change from Baseline by Linkage Variant rs11721988 (FAS).....	865
38.19 DLQI - Change from Baseline by Linkage Variant rs7787032 (FAS).....	866
39.1 DLQI 0/1 (FAS).....	867
39.2 DLQI 0/1 by Age (FAS).....	868
39.3 DLQI 0/1 by Gender (FAS) .....	869
39.4 DLQI 0/1 by Disease Severity (FAS).....	870
39.5 DLQI 0/1 by Moderate/Severe PSO D (FAS).....	871
39.6 DLQI 0/1 by Lymphocyte Count at BL (FAS) .....	872
39.7 DLQI 0/1 by Enthesitis at BL According to LEI (FAS).....	873
39.8 DLQI 0/1 by HLA-DQA1*05 (FAS) .....	874
39.9 DLQI 0/1 by Lead Candidate Variant rs10555659 (FAS) .....	875
39.10 DLQI 0/1 by Lead Candidate Variant rs111937633 (FAS).....	876
39.11 DLQI 0/1 by Lead Candidate Variant rs11726476 (FAS).....	877
39.12 DLQI 0/1 by Lead Candidate Variant rs10609046 (FAS).....	878
39.13 DLQI 0/1 by Lead Candidate Variant rs8007401 (FAS) .....	879
39.14 DLQI 0/1 by Lead Candidate Variant rs7349145 (FAS) .....	880
39.15 DLQI 0/1 by Lead Candidate Allele Score (FAS) .....	881
39.16 DLQI 0/1 by Linkage Variant rs10891185 (FAS).....	882
39.17 DLQI 0/1 by Linkage Variant rs12065362 (FAS).....	883
39.18 DLQI 0/1 by Linkage Variant rs11721988 (FAS).....	884
39.19 DLQI 0/1 by Linkage Variant rs7787032 (FAS) .....	885
40.0 EQ-5D VAS Score - Return Rates (FAS) .....	886
40.1 EQ-5D VAS Score - Change from Baseline (FAS) .....	887
40.2 EQ-5D VAS Score - Change from Baseline by Age (FAS).....	888
40.3 EQ-5D VAS Score - Change from Baseline by Gender (FAS).....	889
40.4 EQ-5D VAS Score - Change from Baseline by Disease Severity (FAS).....	890
40.5 EQ-5D VAS Score - Change from Baseline by Moderate/Severe PSO D (FAS) .....	891
40.6 EQ-5D VAS Score - Change from Baseline by Lymphocyte Count at BL (FAS).....	892
40.7 EQ-5D VAS Score - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	893
40.8 EQ-5D VAS Score - Change from Baseline by HLA-DQA1*05 (FAS) .....	894
40.9 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	895
40.10 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	896
40.11 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	897
40.12 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	898
40.13 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	899
40.14 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	900
40.15 EQ-5D VAS Score - Change from Baseline by Lead Candidate Allele Score (FAS).....	901
40.16 EQ-5D VAS Score - Change from Baseline by Linkage Variant rs10891185 (FAS).....	902
40.17 EQ-5D VAS Score - Change from Baseline by Linkage Variant rs12065362 (FAS).....	903
40.18 EQ-5D VAS Score - Change from Baseline by Linkage Variant rs11721988 (FAS).....	904

40.19 EQ-5D VAS Score - Change from Baseline by Linkage Variant rs7787032 (FAS).....	905
41.0 FACIT Fatigue - Return Rates (FAS) .....	906
41.1 FACIT Fatigue - Change from Baseline (FAS) .....	907
41.2 FACIT Fatigue - Change from Baseline by Age (FAS).....	908
41.3 FACIT Fatigue - Change from Baseline by Gender (FAS).....	909
41.4 FACIT Fatigue - Change from Baseline by Disease Severity (FAS).....	910
41.5 FACIT Fatigue - Change from Baseline by Moderate/Severe PSO D (FAS) .....	911
41.6 FACIT Fatigue - Change from Baseline by Lymphocyte Count at BL (FAS).....	912
41.7 FACIT Fatigue - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	913
41.8 FACIT Fatigue - Change from Baseline by HLA-DQA1*05 (FAS).....	914
41.9 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	915
41.10 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	916
41.11 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	917
41.12 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	918
41.13 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	919
41.14 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	920
41.15 FACIT Fatigue - Change from Baseline by Lead Candidate Allele Score (FAS).....	921
41.16 FACIT Fatigue - Change from Baseline by Linkage Variant rs10891185 (FAS).....	922
41.17 FACIT Fatigue - Change from Baseline by Linkage Variant rs12065362 (FAS).....	923
41.18 FACIT Fatigue - Change from Baseline by Linkage Variant rs11721988 (FAS).....	924
41.19 FACIT Fatigue - Change from Baseline by Linkage Variant rs7787032 (FAS).....	925
42.1 FACIT 4-Point Response (FAS) .....	926
42.2 FACIT 4-Point Response by Age (FAS).....	927
42.3 FACIT 4-Point Response by Gender (FAS).....	928
42.4 FACIT 4-Point Response by Disease Severity (FAS).....	929
42.5 FACIT 4-Point Response by Moderate/Severe PSO D (FAS) .....	930
42.6 FACIT 4-Point Response by Lymphocyte Count at BL (FAS).....	931
42.7 FACIT 4-Point Response by Enthesitis at BL According to LEI (FAS).....	932
42.8 FACIT 4-Point Response by HLA-DQA1*05 (FAS) .....	933
42.9 FACIT 4-Point Response by Lead Candidate Variant rs10555659 (FAS).....	934
42.10 FACIT 4-Point Response by Lead Candidate Variant rs111937633 (FAS).....	935
42.11 FACIT 4-Point Response by Lead Candidate Variant rs11726476 (FAS).....	936
42.12 FACIT 4-Point Response by Lead Candidate Variant rs10609046 (FAS).....	937
42.13 FACIT 4-Point Response by Lead Candidate Variant rs8007401 (FAS).....	938
42.14 FACIT 4-Point Response by Lead Candidate Variant rs7349145 (FAS).....	939
42.15 FACIT 4-Point Response by Lead Candidate Allele Score (FAS).....	940
42.16 FACIT 4-Point Response by Linkage Variant rs10891185 (FAS).....	941
42.17 FACIT 4-Point Response by Linkage Variant rs12065362 (FAS).....	942
42.18 FACIT 4-Point Response by Linkage Variant rs11721988 (FAS).....	943
42.19 FACIT 4-Point Response by Linkage Variant rs7787032 (FAS).....	944
43.0 SF-36 Bodily Pain - Return Rates (FAS) .....	945

43.1 SF-36 Bodily Pain - Change from Baseline (FAS) .....	946
43.2 SF-36 Bodily Pain - Change from Baseline by Age (FAS).....	947
43.3 SF-36 Bodily Pain - Change from Baseline by Gender (FAS).....	948
43.4 SF-36 Bodily Pain - Change from Baseline by Disease Severity (FAS).....	949
43.5 SF-36 Bodily Pain - Change from Baseline by Moderate/Severe PSO D (FAS) .....	950
43.6 SF-36 Bodily Pain - Change from Baseline by Lymphocyte Count at BL (FAS).....	951
43.7 SF-36 Bodily Pain - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	952
43.8 SF-36 Bodily Pain - Change from Baseline by HLA-DQA1*05 (FAS) .....	953
43.9 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	954
43.10 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	955
43.11 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	956
43.12 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	957
43.13 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	958
43.14 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	959
43.15 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Allele Score (FAS).....	960
43.16 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs10891185 (FAS).....	961
43.17 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs12065362 (FAS).....	962
43.18 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs11721988 (FAS).....	963
43.19 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs7787032 (FAS).....	964
44.0 SF-36 General Health - Return Rates (FAS) .....	965
44.1 SF-36 General Health - Change from Baseline (FAS) .....	966
44.2 SF-36 General Health - Change from Baseline by Age (FAS) .....	967
44.3 SF-36 General Health - Change from Baseline by Gender (FAS) .....	968
44.4 SF-36 General Health - Change from Baseline by Disease Severity (FAS).....	969
44.5 SF-36 General Health - Change from Baseline by Moderate/Severe PSO D (FAS).....	970
44.6 SF-36 General Health - Change from Baseline by Lymphocyte Count at BL (FAS) .....	971
44.7 SF-36 General Health - Change from Baseline by Enthesitis at BL According to LEI (FAS) .....	972
44.8 SF-36 General Health - Change from Baseline by HLA-DQA1*05 (FAS) .....	973
44.9 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS) .....	974
44.10 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS) ....	975
44.11 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS) .....	976
44.12 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS) .....	977
44.13 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS) .....	978
44.14 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS) .....	979
44.15 SF-36 General Health - Change from Baseline by Lead Candidate Allele Score (FAS) .....	980
44.16 SF-36 General Health - Change from Baseline by Linkage Variant rs10891185 (FAS) .....	981
44.17 SF-36 General Health - Change from Baseline by Linkage Variant rs12065362 (FAS) .....	982
44.18 SF-36 General Health - Change from Baseline by Linkage Variant rs11721988 (FAS) .....	983
44.19 SF-36 General Health - Change from Baseline by Linkage Variant rs7787032 (FAS) .....	984
45.0 SF-36 Mental Health - Return Rates (FAS) .....	985
45.1 SF-36 Mental Health - Change from Baseline (FAS) .....	986



45.2 SF-36 Mental Health - Change from Baseline by Age (FAS).....	987
45.3 SF-36 Mental Health - Change from Baseline by Gender (FAS).....	988
45.4 SF-36 Mental Health - Change from Baseline by Disease Severity (FAS).....	989
45.5 SF-36 Mental Health - Change from Baseline by Moderate/Severe PSO D (FAS).....	990
45.6 SF-36 Mental Health - Change from Baseline by Lymphocyte Count at BL (FAS).....	991
45.7 SF-36 Mental Health - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	992
45.8 SF-36 Mental Health - Change from Baseline by HLA-DQA1*05 (FAS).....	993
45.9 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	994
45.10 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	995
45.11 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	996
45.12 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	997
45.13 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	998
45.14 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	999
45.15 SF-36 Mental Health - Change from Baseline by Lead Candidate Allele Score (FAS).....	1000
45.16 SF-36 Mental Health - Change from Baseline by Linkage Variant rs10891185 (FAS).....	1001
45.17 SF-36 Mental Health - Change from Baseline by Linkage Variant rs12065362 (FAS).....	1002
45.18 SF-36 Mental Health - Change from Baseline by Linkage Variant rs11721988 (FAS).....	1003
45.19 SF-36 Mental Health - Change from Baseline by Linkage Variant rs7787032 (FAS).....	1004
46.0 SF-36 Physical Functioning - Return Rates (FAS).....	1005
46.1 SF-36 Physical Functioning - Change from Baseline (FAS).....	1006
46.2 SF-36 Physical Functioning - Change from Baseline by Age (FAS).....	1007
46.3 SF-36 Physical Functioning - Change from Baseline by Gender (FAS).....	1008
46.4 SF-36 Physical Functioning - Change from Baseline by Disease Severity (FAS).....	1009
46.5 SF-36 Physical Functioning - Change from Baseline by Moderate/Severe PSO D (FAS).....	1010
46.6 SF-36 Physical Functioning - Change from Baseline by Lymphocyte Count at BL (FAS).....	1011
46.7 SF-36 Physical Functioning - Change from Baseline by Enthesitis at BL According to LEI (FAS)	1012
46.8 SF-36 Physical Functioning - Change from Baseline by HLA-DQA1*05 (FAS).....	1013
46.9 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs10555659 (FAS) .....	1014
46.10 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs111937633 (FAS) .....	1015
46.11 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs11726476 (FAS) .....	1016
46.12 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs10609046 (FAS) .....	1017
46.13 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs8007401 (FAS) .....	1018
46.14 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs7349145 (FAS) .....	1019
46.15 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Allele Score (FAS).....	1020
46.16 SF-36 Physical Functioning - Change from Baseline by Linkage Variant rs10891185 (FAS).....	1021
46.17 SF-36 Physical Functioning - Change from Baseline by Linkage Variant rs12065362 (FAS).....	1022
46.18 SF-36 Physical Functioning - Change from Baseline by Linkage Variant rs11721988 (FAS).....	1023

46.19 SF-36 Physical Functioning - Change from Baseline by Linkage Variant rs7787032 (FAS).....	1024
47.0 SF-36 Role Emotional - Return Rates (FAS).....	1025
47.1 SF-36 Role Emotional - Change from Baseline (FAS).....	1026
47.2 SF-36 Role Emotional - Change from Baseline by Age (FAS).....	1027
47.3 SF-36 Role Emotional - Change from Baseline by Gender (FAS).....	1028
47.4 SF-36 Role Emotional - Change from Baseline by Disease Severity (FAS).....	1029
47.5 SF-36 Role Emotional - Change from Baseline by Moderate/Severe PSO D (FAS).....	1030
47.6 SF-36 Role Emotional - Change from Baseline by Lymphocyte Count at BL (FAS).....	1031
47.7 SF-36 Role Emotional - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	1032
47.8 SF-36 Role Emotional - Change from Baseline by HLA-DQA1*05 (FAS).....	1033
47.9 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	1034
47.10 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)..	1035
47.11 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)....	1036
47.12 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)....	1037
47.13 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	1038
47.14 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	1039
47.15 SF-36 Role Emotional - Change from Baseline by Lead Candidate Allele Score (FAS).....	1040
47.16 SF-36 Role Emotional - Change from Baseline by Linkage Variant rs10891185 (FAS).....	1041
47.17 SF-36 Role Emotional - Change from Baseline by Linkage Variant rs12065362 (FAS).....	1042
47.18 SF-36 Role Emotional - Change from Baseline by Linkage Variant rs11721988 (FAS).....	1043
47.19 SF-36 Role Emotional - Change from Baseline by Linkage Variant rs7787032 (FAS).....	1044
48.0 SF-36 Role Physical - Return Rates (FAS).....	1045
48.1 SF-36 Role Physical - Change from Baseline (FAS).....	1046
48.2 SF-36 Role Physical - Change from Baseline by Age (FAS).....	1047
48.3 SF-36 Role Physical - Change from Baseline by Gender (FAS).....	1048
48.4 SF-36 Role Physical - Change from Baseline by Disease Severity (FAS).....	1049
48.5 SF-36 Role Physical - Change from Baseline by Moderate/Severe PSO D (FAS).....	1050
48.6 SF-36 Role Physical - Change from Baseline by Lymphocyte Count at BL (FAS).....	1051
48.7 SF-36 Role Physical - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	1052
48.8 SF-36 Role Physical - Change from Baseline by HLA-DQA1*05 (FAS).....	1053
48.9 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	1054
48.10 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	1055
48.11 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	1056
48.12 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	1057
48.13 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	1058
48.14 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	1059
48.15 SF-36 Role Physical - Change from Baseline by Lead Candidate Allele Score (FAS).....	1060
48.16 SF-36 Role Physical - Change from Baseline by Linkage Variant rs10891185 (FAS).....	1061
48.17 SF-36 Role Physical - Change from Baseline by Linkage Variant rs12065362 (FAS).....	1062
48.18 SF-36 Role Physical - Change from Baseline by Linkage Variant rs11721988 (FAS).....	1063
48.19 SF-36 Role Physical - Change from Baseline by Linkage Variant rs7787032 (FAS).....	1064

49.0 SF-36 Social Functioning - Return Rates (FAS).....	1065
49.1 SF-36 Social Functioning - Change from Baseline (FAS).....	1066
49.2 SF-36 Social Functioning - Change from Baseline by Age (FAS) .....	1067
49.3 SF-36 Social Functioning - Change from Baseline by Gender (FAS) .....	1068
49.4 SF-36 Social Functioning - Change from Baseline by Disease Severity (FAS).....	1069
49.5 SF-36 Social Functioning - Change from Baseline by Moderate/Severe PSO D (FAS).....	1070
49.6 SF-36 Social Functioning - Change from Baseline by Lymphocyte Count at BL (FAS) .....	1071
49.7 SF-36 Social Functioning - Change from Baseline by Enthesitis at BL According to LEI (FAS)....	1072
49.8 SF-36 Social Functioning - Change from Baseline by HLA-DQA1*05 (FAS).....	1073
49.9 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)	1074
49.10 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs111937633 (FAS) .....	1075
49.11 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)	1076
49.12 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)	1077
49.13 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)	1078
49.14 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)	1079
49.15 SF-36 Social Functioning - Change from Baseline by Lead Candidate Allele Score (FAS) .....	1080
49.16 SF-36 Social Functioning - Change from Baseline by Linkage Variant rs10891185 (FAS) .....	1081
49.17 SF-36 Social Functioning - Change from Baseline by Linkage Variant rs12065362 (FAS) .....	1082
49.18 SF-36 Social Functioning - Change from Baseline by Linkage Variant rs11721988 (FAS) .....	1083
49.19 SF-36 Social Functioning - Change from Baseline by Linkage Variant rs7787032 (FAS).....	1084
50.0 SF-36 Vitality - Return Rates (FAS).....	1085
50.1 SF-36 Vitality - Change from Baseline (FAS).....	1086
50.2 SF-36 Vitality - Change from Baseline by Age (FAS) .....	1087
50.3 SF-36 Vitality - Change from Baseline by Gender (FAS) .....	1088
50.4 SF-36 Vitality - Change from Baseline by Disease Severity (FAS) .....	1089
50.5 SF-36 Vitality - Change from Baseline by Moderate/Severe PSO D (FAS).....	1090
50.6 SF-36 Vitality - Change from Baseline by Lymphocyte Count at BL (FAS) .....	1091
50.7 SF-36 Vitality - Change from Baseline by Enthesitis at BL According to LEI (FAS) .....	1092
50.8 SF-36 Vitality - Change from Baseline by HLA-DQA1*05 (FAS).....	1093
50.9 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs10555659 (FAS) .....	1094
50.10 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs111937633 (FAS) .....	1095
50.11 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs11726476 (FAS) .....	1096
50.12 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs10609046 (FAS) .....	1097
50.13 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs8007401 (FAS) .....	1098
50.14 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs7349145 (FAS) .....	1099
50.15 SF-36 Vitality - Change from Baseline by Lead Candidate Allele Score (FAS) .....	1100
50.16 SF-36 Vitality - Change from Baseline by Linkage Variant rs10891185 (FAS) .....	1101
50.17 SF-36 Vitality - Change from Baseline by Linkage Variant rs12065362 (FAS) .....	1102
50.18 SF-36 Vitality - Change from Baseline by Linkage Variant rs11721988 (FAS) .....	1103
50.19 SF-36 Vitality - Change from Baseline by Linkage Variant rs7787032 (FAS) .....	1104

51.0 SF-36 MCS - Return Rates (FAS).....	1105
51.1 SF-36 MCS - Change from Baseline (FAS).....	1106
51.2 SF-36 MCS - Change from Baseline by Age (FAS) .....	1107
51.3 SF-36 MCS - Change from Baseline by Gender (FAS) .....	1108
51.4 SF-36 MCS - Change from Baseline by Disease Severity (FAS) .....	1109
51.5 SF-36 MCS - Change from Baseline by Moderate/Severe PSO D (FAS).....	1110
51.6 SF-36 MCS - Change from Baseline by Lymphocyte Count at BL (FAS) .....	1111
51.7 SF-36 MCS - Change from Baseline by Enthesitis at BL According to LEI (FAS) .....	1112
51.8 SF-36 MCS - Change from Baseline by HLA-DQA1*05 (FAS).....	1113
51.9 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs10555659 (FAS) .....	1114
51.10 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs111937633 (FAS) .....	1115
51.11 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs11726476 (FAS) .....	1116
51.12 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs10609046 (FAS) .....	1117
51.13 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs8007401 (FAS) .....	1118
51.14 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs7349145 (FAS) .....	1119
51.15 SF-36 MCS - Change from Baseline by Lead Candidate Allele Score (FAS) .....	1120
51.16 SF-36 MCS - Change from Baseline by Linkage Variant rs10891185 (FAS) .....	1121
51.17 SF-36 MCS - Change from Baseline by Linkage Variant rs12065362 (FAS) .....	1122
51.18 SF-36 MCS - Change from Baseline by Linkage Variant rs11721988 (FAS) .....	1123
51.19 SF-36 MCS - Change from Baseline by Linkage Variant rs7787032 (FAS) .....	1124
52.1 SF-36 MCS 2.5-Point Response / 5-Point Response (FAS).....	1125
52.2 SF-36 MCS 2.5-Point Response / 5-Point Response by Age (FAS) .....	1126
52.3 SF-36 MCS 2.5-Point Response / 5-Point Response by Gender (FAS) .....	1127
52.4 SF-36 MCS 2.5-Point Response / 5-Point Response by Disease Severity (FAS) .....	1128
52.5 SF-36 MCS 2.5-Point Response / 5-Point Response by Moderate/Severe PSO D (FAS).....	1129
52.6 SF-36 MCS 2.5-Point Response / 5-Point Response by Lymphocyte Count at BL (FAS) .....	1130
52.7 SF-36 MCS 2.5-Point Response / 5-Point Response by Enthesitis at BL According to LEI (FAS) .	1131
52.8 SF-36 MCS 2.5-Point Response / 5-Point Response by HLA-DQA1*05 (FAS).....	1132
52.9 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs10555659 (FAS) .....	1133
52.10 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs111937633 (FAS) .....	1134
52.11 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs11726476 (FAS) .....	1135
52.12 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs10609046 (FAS) .....	1136
52.13 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs8007401 (FAS) .....	1137
52.14 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs7349145 (FAS) .....	1138
52.15 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Allele Score (FAS) .....	1139
52.16 SF-36 MCS 2.5-Point Response / 5-Point Response by Linkage Variant rs10891185 (FAS) .....	1140
52.17 SF-36 MCS 2.5-Point Response / 5-Point Response by Linkage Variant rs12065362 (FAS) .....	1141

52.18 SF-36 MCS 2.5-Point Response / 5-Point Response by Linkage Variant rs11721988 (FAS) .....	1142
52.19 SF-36 MCS 2.5-Point Response / 5-Point Response by Linkage Variant rs7787032 (FAS) .....	1143
53.0 SF-36 PCS - Return Rates (FAS) .....	1144
53.1 SF-36 PCS - Change from Baseline (FAS) .....	1145
53.2 SF-36 PCS - Change from Baseline by Age (FAS) .....	1146
53.3 SF-36 PCS - Change from Baseline by Gender (FAS) .....	1147
53.4 SF-36 PCS - Change from Baseline by Disease Severity (FAS).....	1148
53.5 SF-36 PCS - Change from Baseline by Moderate/Severe PSO D (FAS).....	1149
53.6 SF-36 PCS - Change from Baseline by Lymphocyte Count at BL (FAS) .....	1150
53.7 SF-36 PCS - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	1151
53.8 SF-36 PCS - Change from Baseline by HLA-DQA1*05 (FAS) .....	1152
53.9 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs10555659 (FAS) .....	1153
53.10 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	1154
53.11 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	1155
53.12 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	1156
53.13 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs8007401 (FAS) .....	1157
53.14 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs7349145 (FAS) .....	1158
53.15 SF-36 PCS - Change from Baseline by Lead Candidate Allele Score (FAS) .....	1159
53.16 SF-36 PCS - Change from Baseline by Linkage Variant rs10891185 (FAS).....	1160
53.17 SF-36 PCS - Change from Baseline by Linkage Variant rs12065362 (FAS).....	1161
53.18 SF-36 PCS - Change from Baseline by Linkage Variant rs11721988 (FAS).....	1162
53.19 SF-36 PCS - Change from Baseline by Linkage Variant rs7787032 (FAS).....	1163
54.1 SF-36 PCS 2.5-Point Response / 5-Point Response (FAS) .....	1164
54.2 SF-36 PCS 2.5-Point Response / 5-Point Response by Age (FAS) .....	1165
54.3 SF-36 PCS 2.5-Point Response / 5-Point Response by Gender (FAS) .....	1166
54.4 SF-36 PCS 2.5-Point Response / 5-Point Response by Disease Severity (FAS).....	1167
54.5 SF-36 PCS 2.5-Point Response / 5-Point Response by Moderate/Severe PSO D (FAS).....	1168
54.6 SF-36 PCS 2.5-Point Response / 5-Point Response by Lymphocyte Count at BL (FAS) .....	1169
54.7 SF-36 PCS 2.5-Point Response / 5-Point Response by Enthesitis at BL According to LEI (FAS)...	1170
54.8 SF-36 PCS 2.5-Point Response / 5-Point Response by HLA-DQA1*05 (FAS) .....	1171
54.9 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs10555659 (FAS)	1172
54.10 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs111937633 (FAS) .....	1173
54.11 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs11726476 (FAS) .....	1174
54.12 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs10609046 (FAS) .....	1175
54.13 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs8007401 (FAS)	1176
54.14 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs7349145 (FAS)	1177
54.15 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Allele Score (FAS) .....	1178
54.16 SF-36 PCS 2.5-Point Response / 5-Point Response by Linkage Variant rs10891185 (FAS) .....	1179
54.17 SF-36 PCS 2.5-Point Response / 5-Point Response by Linkage Variant rs12065362 (FAS) .....	1180

54.18 SF-36 PCS 2.5-Point Response / 5-Point Response by Linkage Variant rs11721988 (FAS) .....	1181
54.19 SF-36 PCS 2.5-Point Response / 5-Point Response by Linkage Variant rs7787032 (FAS).....	1182
55.0 WPAI-GH Percent Work Time Missed due to Health - Return Rates (FAS) .....	1183
55.1 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline (FAS).....	1184
55.2 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Age (FAS).....	1185
55.3 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Gender (FAS)...	1186
55.4 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Disease Severity (FAS).....	1187
55.5 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Moderate/Severe PSO D (FAS) .....	1188
55.6 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lymphocyte Count at BL (FAS) .....	1189
55.7 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	1190
55.8 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by HLA-DQA1*05 (FAS).....	1191
55.9 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	1192
55.10 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	1193
55.11 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	1194
55.12 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	1195
55.13 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	1196
55.14 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	1197
55.15 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Allele Score (FAS).....	1198
55.16 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Linkage Variant rs10891185 (FAS).....	1199
55.17 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Linkage Variant rs12065362 (FAS).....	1200
55.18 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Linkage Variant rs11721988 (FAS).....	1201
55.19 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Linkage Variant rs7787032 (FAS).....	1202
56.0 WPAI-GH Percent Impairment while Working due to Health - Return Rates (FAS).....	1203
56.1 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline (FAS).....	1204
56.2 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Age (FAS) .....	1205
56.3 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Gender (FAS).....	1206
56.4 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Disease Severity (FAS) .....	1207
56.5 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Moderate/Severe PSO D (FAS) .....	1208

56.6 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lymphocyte Count at BL (FAS).....	1209
56.7 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	1210
56.8 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by HLA-DQA1*05 (FAS).....	1211
56.9 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	1212
56.10 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	1213
56.11 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	1214
56.12 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	1215
56.13 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	1216
56.14 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	1217
56.15 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Allele Score (FAS).....	1218
56.16 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Linkage Variant rs10891185 (FAS).....	1219
56.17 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Linkage Variant rs12065362 (FAS).....	1220
56.18 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Linkage Variant rs11721988 (FAS).....	1221
56.19 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Linkage Variant rs7787032 (FAS).....	1222
57.0 WPAI-GH Percent Overall Work Impairment due to Health - Return Rates (FAS).....	1223
57.1 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline (FAS).....	1224
57.2 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Age (FAS).....	1225
57.3 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Gender (FAS).....	1226
57.4 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Disease Severity (FAS).....	1227
57.5 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Moderate/Severe PSO D (FAS).....	1228
57.6 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lymphocyte Count at BL (FAS).....	1229
57.7 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	1230
57.8 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by HLA-DQA1*05 (FAS).....	1231
57.9 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	1232
57.10 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	1233

57.11 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	1234
57.12 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	1235
57.13 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	1236
57.14 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	1237
57.15 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Allele Score (FAS).....	1238
57.16 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Linkage Variant rs10891185 (FAS).....	1239
57.17 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Linkage Variant rs12065362 (FAS).....	1240
57.18 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Linkage Variant rs11721988 (FAS).....	1241
57.19 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Linkage Variant rs7787032 (FAS).....	1242
58.0 WPAI-GH Percent Activity Impairment due to Health - Return Rates (FAS).....	1243
58.1 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline (FAS).....	1244
58.2 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Age (FAS).....	1245
58.3 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Gender (FAS).....	1246
58.4 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Disease Severity (FAS).....	1247
58.5 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Moderate/Severe PSO D (FAS).....	1248
58.6 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lymphocyte Count at BL (FAS).....	1249
58.7 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	1250
58.8 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by HLA-DQA1*05 (FAS).....	1251
58.9 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS).....	1252
58.10 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS).....	1253
58.11 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).....	1254
58.12 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).....	1255
58.13 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS).....	1256
58.14 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS).....	1257
58.15 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Allele Score (FAS).....	1258
58.16 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Linkage Variant rs10891185 (FAS).....	1259



58.17 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Linkage Variant rs12065362 (FAS).....	1260
58.18 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Linkage Variant rs11721988 (FAS).....	1261
58.19 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Linkage Variant rs7787032 (FAS).....	1262
59.0 Tender Dactylitis Count - Return Rates (FAS) .....	1263
59.1 Tender Dactylitis Count - Change from Baseline (FAS) .....	1264
59.2 Tender Dactylitis Count - Change from Baseline by Age (FAS).....	1265
59.3 Tender Dactylitis Count - Change from Baseline by Gender (FAS).....	1266
59.4 Tender Dactylitis Count - Change from Baseline by Disease Severity (FAS).....	1267
59.5 Tender Dactylitis Count - Change from Baseline by Moderate/Severe PSO D (FAS) .....	1268
59.6 Tender Dactylitis Count - Change from Baseline by Lymphocyte Count at BL (FAS).....	1269
59.7 Tender Dactylitis Count - Change from Baseline by Enthesitis at BL According to LEI (FAS).....	1270
59.8 Tender Dactylitis Count - Change from Baseline by HLA-DQA1*05 (FAS).....	1271
59.9 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)...	1272
59.10 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)	1273
59.11 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs11726476 (FAS).	1274
59.12 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs10609046 (FAS).	1275
59.13 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)...	1276
59.14 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)...	1277
59.15 Tender Dactylitis Count - Change from Baseline by Lead Candidate Allele Score (FAS).....	1278
59.16 Tender Dactylitis Count - Change from Baseline by Linkage Variant rs10891185 (FAS).....	1279
59.17 Tender Dactylitis Count - Change from Baseline by Linkage Variant rs12065362 (FAS).....	1280
59.18 Tender Dactylitis Count - Change from Baseline by Linkage Variant rs11721988 (FAS).....	1281
59.19 Tender Dactylitis Count - Change from Baseline by Linkage Variant rs7787032 (FAS).....	1282
Safety Analysis .....	1283
S.1.1 Adverse Events, Binary Analysis (SAF).....	1283
S.1.2 Adverse Events by SOC, PT and Severity, Binary Analysis (SAF) .....	1286
S.1.3 Serious Adverse Events by SOC, PT and Severity, Binary Analysis (SAF).....	1289
S.1.4 Any Adverse Event Leading to Study Discontinuation by SOC and PT, Frequencies (SAF) .....	1290
S.1.5 Any Adverse Event Leading to Study Drug Discontinuation by SOC and PT, Frequencies (SAF)	1291
S.1.6 Adverse Events of Special Interest by Severity, Binary Analysis (SAF).....	1292
S.2.1 Adverse Events, Binary Analysis by Age (SAF) .....	1295
S.2.2 Adverse Events by SOC and PT, Binary Analysis by Age (SAF) .....	1297
S.2.3 Serious Adverse Events by SOC and PT, Binary Analysis by Age (SAF) .....	1298
S.2.4 Severe Adverse Events by SOC and PT, Binary Analysis by Age (SAF) .....	1299
S.2.5 Adverse Events of Special Interest, Binary Analysis by Age (SAF) .....	1300
S.3.1 Adverse Events, Binary Analysis by Gender (SAF) .....	1302
S.3.2 Adverse Events by SOC and PT, Binary Analysis by Gender (SAF) .....	1304
S.3.3 Serious Adverse Events by SOC and PT, Binary Analysis by Gender (SAF) .....	1305
S.3.4 Severe Adverse Events by SOC and PT, Binary Analysis by Gender (SAF) .....	1306

S.3.5 Adverse Events of Special Interest, Binary Analysis by Gender (SAF) .....	1307
S.4.1 Adverse Events, Binary Analysis by Disease Severity (SAF) .....	1309
S.4.2 Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF) .....	1311
S.4.3 Serious Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF) .....	1312
S.4.4 Severe Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF) .....	1313
S.4.5 Adverse Events of Special Interest, Binary Analysis by Disease Severity (SAF) .....	1314
S.5.1 Adverse Events, Binary Analysis by Moderate/Severe PSO D (SAF).....	1317
S.5.2 Adverse Events by SOC and PT, Binary Analysis by Moderate/Severe PSO D (SAF).....	1319
S.5.3 Serious Adverse Events by SOC and PT, Binary Analysis by Moderate/Severe PSO D (SAF).....	1320
S.5.4 Severe Adverse Events by SOC and PT, Binary Analysis by Moderate/Severe PSO D (SAF).....	1321
S.5.5 Adverse Events of Special Interest, Binary Analysis by Moderate/Severe PSO D (SAF).....	1322
S.6.1 Adverse Events, Binary Analysis by Lymphocyte Count at BL (SAF) .....	1325
S.6.2 Adverse Events by SOC and PT, Binary Analysis by Lymphocyte Count at BL (SAF).....	1327
S.6.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lymphocyte Count at BL (SAF) ....	1328
S.6.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lymphocyte Count at BL (SAF) .....	1329
S.6.5 Adverse Events of Special Interest, Binary Analysis by Lymphocyte Count at BL (SAF) .....	1330
S.7.1 Adverse Events, Binary Analysis by Enthesitis at BL According to LEI (SAF) .....	1332
S.7.2 Adverse Events by SOC and PT, Binary Analysis by Enthesitis at BL According to LEI (SAF) ...	1334
S.7.3 Serious Adverse Events by SOC and PT, Binary Analysis by Enthesitis at BL According to LEI (SAF).....	1335
S.7.4 Severe Adverse Events by SOC and PT, Binary Analysis by Enthesitis at BL According to LEI (SAF) .....	1336
S.7.5 Adverse Events of Special Interest, Binary Analysis by Enthesitis at BL According to LEI (SAF)	1337
S.8.1 Adverse Events, Binary Analysis by HLA-DQA1*05 (SAF).....	1339
S.8.2 Adverse Events by SOC and PT, Binary Analysis by HLA-DQA1*05 (SAF).....	1341
S.8.3 Serious Adverse Events by SOC and PT, Binary Analysis by HLA-DQA1*05 (SAF).....	1342
S.8.4 Severe Adverse Events by SOC and PT, Binary Analysis by HLA-DQA1*05 (SAF).....	1343
S.8.5 Adverse Events of Special Interest, Binary Analysis by HLA-DQA1*05 (SAF).....	1344
S.9.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs10555659 (SAF) .....	1346
S.9.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10555659 (SAF)	1348
S.9.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10555659 (SAF).....	1349
S.9.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10555659 (SAF).....	1350
S.9.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs10555659 (SAF) .....	1351
S.10.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs111937633 (SAF) .....	1353
S.10.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs111937633 (SAF) .....	1355
S.10.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs111937633 (SAF).....	1356
S.10.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs111937633 (SAF).....	1357

S.10.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs111937633 (SAF)	1358
S.11.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)	1360
S.11.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)	1362
S.11.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)	1363
S.11.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)	1364
S.11.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)	1365
S.12.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)	1367
S.12.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)	1369
S.12.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)	1370
S.12.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)	1371
S.12.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)	1372
S.13.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)	1374
S.13.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)	1376
S.13.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)	1377
S.13.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)	1378
S.13.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)	1379
S.14.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)	1381
S.14.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)	1383
S.14.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)	1384
S.14.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)	1385
S.14.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)	1386
S.15.1 Adverse Events, Binary Analysis by Lead Candidate Allele Score (SAF)	1388
S.15.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Allele Score (SAF)	1390
S.15.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Allele Score (SAF)	1391
S.15.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Allele Score (SAF)	1392
S.15.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Allele Score (SAF)	1393
S.16.1 Adverse Events, Binary Analysis by Linkage Variant rs10891185 (SAF)	1395
S.16.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs10891185 (SAF)	1397
S.16.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs10891185 (SAF)	1398

S.16.4 Severe Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs10891185 (SAF)	1399
S.16.5 Adverse Events of Special Interest, Binary Analysis by Linkage Variant rs10891185 (SAF)	1400
S.17.1 Adverse Events, Binary Analysis by Linkage Variant rs12065362 (SAF)	1402
S.17.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs12065362 (SAF)	1404
S.17.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs12065362 (SAF)	1405
S.17.4 Severe Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs12065362 (SAF)	1406
S.17.5 Adverse Events of Special Interest, Binary Analysis by Linkage Variant rs12065362 (SAF)	1407
S.18.1 Adverse Events, Binary Analysis by Linkage Variant rs11721988 (SAF)	1409
S.18.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs11721988 (SAF)	1411
S.18.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs11721988 (SAF)	1412
S.18.4 Severe Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs11721988 (SAF)	1413
S.18.5 Adverse Events of Special Interest, Binary Analysis by Linkage Variant rs11721988 (SAF)	1414
S.19.1 Adverse Events, Binary Analysis by Linkage Variant rs7787032 (SAF)	1416
S.19.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs7787032 (SAF)	1418
S.19.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs7787032 (SAF)	1419
S.19.4 Severe Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs7787032 (SAF)	1420
S.19.5 Adverse Events of Special Interest, Binary Analysis by Linkage Variant rs7787032 (SAF)	1421
Figures	1423
Efficacy Analysis	1423
6.1 HAQ-DI - Boxplot (FAS)	1423
15.1 Patient's Assessment of PsA Pain (VAS) - Boxplot (FAS)	1424
16.1 Patient's Global Assessment of PsA Disease Activity (VAS) - Boxplot (FAS)	1425
17.1 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Boxplot (FAS)	1426
38.1 DLQI - Boxplot (FAS)	1427
40.1 EQ-5D VAS Score - Boxplot (FAS)	1428
41.1 FACIT Fatigue - Boxplot (FAS)	1429
41.13 FACIT Fatigue - Boxplot by Lead Candidate Variant rs8007401 (FAS)	1430
43.1 SF-36 Bodily Pain - Boxplot (FAS)	1432
43.19 SF-36 Bodily Pain - Boxplot by Linkage Variant rs7787032 (FAS)	1433
44.1 SF-36 General Health - Boxplot (FAS)	1435
45.1 SF-36 Mental Health - Boxplot (FAS)	1436
46.1 SF-36 Physical Functioning - Boxplot (FAS)	1437
47.1 SF-36 Role Emotional - Boxplot (FAS)	1438
47.13 SF-36 Role Emotional - Boxplot by Lead Candidate Variant rs8007401 (FAS)	1439
48.1 SF-36 Role Physical - Boxplot (FAS)	1441
49.1 SF-36 Social Functioning - Boxplot (FAS)	1442
49.7 SF-36 Social Functioning - Boxplot by Enthesitis at BL According to LEI (FAS)	1443

50.1 SF-36 Vitality - Boxplot (FAS).....	1445
50.13 SF-36 Vitality - Boxplot by Lead Candidate Variant rs8007401 (FAS) .....	1446
51.1 SF-36 MCS - Boxplot (FAS) .....	1448
51.13 SF-36 MCS - Boxplot by Lead Candidate Variant rs8007401 (FAS).....	1449
53.1 SF-36 PCS - Boxplot (FAS).....	1451
55.1 WPAI-GH Percent Work Time Missed due to Health - Boxplot (FAS) .....	1452
56.1 WPAI-GH Percent Impairment while Working due to Health - Boxplot (FAS).....	1453
57.1 WPAI-GH Percent Overall Work Impairment due to Health - Boxplot (FAS).....	1454
58.1 WPAI-GH Percent Activity Impairment due to Health - Boxplot (FAS).....	1455
58.13 WPAI-GH Percent Activity Impairment due to Health - Boxplot by Lead Candidate Variant rs8007401 (FAS).....	1456

## Tables

### Patient Disposition and Baseline Characteristics

#### 1.1 Patient Disposition and Compliance (RAN, FAS)

Disposition/Reason	Treatment Groups		
	SEC (N=110) n (%)	ADA (N=101) n (%)	Total (N=211) n (%)
<b>Randomized (RAN)</b>	<b>110 (100.0)</b>	<b>101 (100.0)</b>	<b>211 (100.0)</b>
<b>Full Analysis Set (FAS)</b>	<b>110 (100.0)</b>	<b>101 (100.0)</b>	<b>211 (100.0)</b>
<b>Study discontinuation (RAN)</b>	<b>6 (5.5)</b>	<b>17 (16.8)</b>	<b>23 (10.9)</b>
<b><u>Reasons for study discontinuation during Treatment Period</u></b>			
Adverse event	0 (0.0)	2 (2.0)	2 (0.9)
Death	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	1 (0.9)	5 (5.0)	6 (2.8)
No longer requires treatment	0 (0.0)	0 (0.0)	0 (0.0)
New therapy for study indication	0 (0.0)	0 (0.0)	0 (0.0)
Non-compliance with study treatment	0 (0.0)	0 (0.0)	0 (0.0)
Pregnancy	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)
Study terminated by sponsor	0 (0.0)	0 (0.0)	0 (0.0)
Lost to follow-up	1 (0.9)	3 (3.0)	4 (1.9)
Technical problems	0 (0.0)	0 (0.0)	0 (0.0)
Physician decision	1 (0.9)	0 (0.0)	1 (0.5)
Subject/guardian decision	3 (2.7)	7 (6.9)	10 (4.7)
<b><u>Study drug</u></b>			
Received study drug	110 (100.0)	101 (100.0)	211 (100.0)
Did not receive study drug	0 (0.0)	0 (0.0)	0 (0.0)
Completed treatment period on double-blind study drug	104 (94.5)	83 (82.2)	187 (88.6)
Prematurely discontinued double-blind study drug during treatment period	6 (5.5)	18 (17.8)	24 (11.4)
<b><u>Primary reason for premature discontinuation of double-blind study drug</u></b>			
Adverse event	0 (0.0)	2 (2.0)	2 (0.9)
Death	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	1 (0.9)	7 (6.9)	8 (3.8)
No longer requires treatment	0 (0.0)	0 (0.0)	0 (0.0)
New therapy for study indication	0 (0.0)	0 (0.0)	0 (0.0)

Disposition/Reason	Treatment Groups		
	SEC (N=110) n (%)	ADA (N=101) n (%)	Total (N=211) n (%)
Non-compliance with study treatment	0 (0.0)	0 (0.0)	0 (0.0)
Pregnancy	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)
Study terminated by sponsor	0 (0.0)	0 (0.0)	0 (0.0)
Lost to follow-up	0 (0.0)	3 (3.0)	3 (1.4)
Technical problems	0 (0.0)	0 (0.0)	0 (0.0)
Physician decision	1 (0.9)	0 (0.0)	1 (0.5)
Subject/guardian decision	4 (3.6)	6 (5.9)	10 (4.7)
<b>Subjects who received rescue medication before week 52</b>	<b>8 (7.3)</b>	<b>5 (5.0)</b>	<b>13 (6.2)</b>
Patients who received cDMARDs (e.g. MTX) including apremilast	2 (1.8)	3 (3.0)	5 (2.4)
<b>Subject with at least one protocol deviation</b>	<b>32 (29.1)</b>	<b>35 (34.7)</b>	<b>67 (31.8)</b>
Key procedures not performed	0 (0.0)	0 (0.0)	0 (0.0)
Other deviation	19 (17.3)	19 (18.8)	38 (18.0)
Prohibited concomitant medication	10 (9.1)	20 (19.8)	30 (14.2)
Selection criteria not met	6 (5.5)	10 (9.9)	16 (7.6)
Subject not withdrawn as per protocol	0 (0.0)	0 (0.0)	0 (0.0)
Treatment deviation	1 (0.9)	0 (0.0)	1 (0.5)

## 1.2 Length of Treatment Phase (FAS)

Treatment phase (FAS)	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
Mean ± SD (in days)	372.7 ± 34.8	346.0 ± 88.0	359.9 ± 67.0
Median (in days)	375.0	370.0	373.0
Range (in days)	155 - 454	18 - 457	18 - 457



### 1.3 Characterization of Study Population, Demographic Characteristics (FAS)

Patient characteristics	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Age (years)</b>			
Mean ± SD	48.9 ± 12.2	46.9 ± 12.3	47.9 ± 12.2
Median	51.0	49.0	50.0
Range	21.0 - 73.0	18.0 - 72.0	18.0 - 73.0
<b>Age group (years), n (%)</b>			
< 65	103 (93.6)	94 (93.1)	197 (93.4)
65 - 74	7 (6.4)	7 (6.9)	14 (6.6)
<b>Sex, n (%)</b>			
Male	66 (60.0)	57 (56.4)	123 (58.3)
Female	44 (40.0)	44 (43.6)	88 (41.7)
<b>Weight (kg)</b>			
Mean ± SD	87.3 ± 20.4	85.9 ± 16.6	86.6 ± 18.6
Median	87.0	85.2	86.0
Range	51.0 - 153.0	45.0 - 122.9	45.0 - 153.0
<b>Height (cm)</b>			
Mean ± SD	171.8 ± 9.3	170.5 ± 9.1	171.2 ± 9.2
Median	173.0	171.0	172.0
Range	150.0 - 190.0	152.0 - 196.0	150.0 - 196.0
<b>BMI (kg/m<sup>2</sup>)</b>			
Mean ± SD	29.5 ± 6.1	29.6 ± 5.6	29.5 ± 5.8
Median	29.6	29.1	29.2
Range	18.9 - 51.4	18.0 - 45.5	18.0 - 51.4
<b>Current smoker</b>	<b>29 (26.4)</b>	<b>25 (24.8)</b>	<b>54 (25.6)</b>
<b>Race, n (%)</b>			
Asian	2 (1.8)	7 (6.9)	9 (4.3)
American Indian or Alaska Native	0 (0.0)	1 (1.0)	1 (0.5)
Black or African American	0 (0.0)	2 (2.0)	2 (0.9)
White	108 (98.2)	90 (89.1)	198 (93.8)
Other	0 (0.0)	1 (1.0)	1 (0.5)
<b>Ethnicity, n (%)</b>			
Hispanic or Latino	6 (5.5)	5 (5.0)	11 (5.2)
Not Hispanic or Latino	99 (90.0)	91 (90.1)	190 (90.0)
Not reported	4 (3.6)	3 (3.0)	7 (3.3)
Unknown	1 (0.9)	2 (2.0)	3 (1.4)
<b>Region, n (%)</b>			

<b>Treatment Groups</b>			
<b>Patient characteristics</b>	<b>SEC (N=110)</b>	<b>ADA (N=101)</b>	<b>Total (N=211)</b>
America	0 (0.0)	5 (5.0)	5 (2.4)
Asia	4 (3.6)	8 (7.9)	12 (5.7)
Australia	1 (0.9)	3 (3.0)	4 (1.9)
Europe	105 (95.5)	85 (84.2)	190 (90.0)

## 1.4 PsA Disease History and Baseline Characteristics (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Time since first PsA diagnosis (years)</b>			
Mean ± SD	6.1 ± 8.9	6.7 ± 8.4	6.4 ± 8.7
Median	2.8	3.6	2.8
Range	-0.1 - 50.9	-0.0 - 35.1	-0.1 - 50.9
<b>CASPAR score at baseline, n (%)</b>			
3	20 (18.2)	16 (15.8)	36 (17.1)
4	47 (42.7)	46 (45.5)	93 (44.1)
5	35 (31.8)	27 (26.7)	62 (29.4)
6	8 (7.3)	12 (11.9)	20 (9.5)
<b>Enthesitis at baseline, n (%)</b>	<b>59 (53.6)</b>	<b>69 (68.3)</b>	<b>128 (60.7)</b>
<b>Dactylitis at baseline, n (%)</b>	<b>35 (31.8)</b>	<b>33 (32.7)</b>	<b>68 (32.2)</b>
<b>Concomitant medication, n (%)</b>			
Corticosteroid use at baseline	8 (7.3)	5 (5.0)	13 (6.2)
Methotrexate use at baseline	0 (0.0)	0 (0.0)	0 (0.0)
Sulfasalazine use at baseline	0 (0.0)	0 (0.0)	0 (0.0)
<b>Prior Medication, n (%)</b>			
Patients without prior cDMARD treatment*	3 (2.7)	5 (5.0)	8 (3.8)
DMARDs documented as prior treatments**	107 (97.3)	96 (95.0)	203 (96.2)
Discontinued due to lack of tolerability	41 (37.3)	42 (41.6)	83 (39.3)
Discontinued due to lack of efficacy	66 (60.0)	62 (61.4)	128 (60.7)
MTX documented as prior treatments**	92 (83.6)	87 (86.1)	179 (84.8)
Discontinued due to lack of tolerability	32 (29.1)	37 (36.6)	69 (32.7)
Discontinued due to lack of efficacy	54 (49.1)	52 (51.5)	106 (50.2)
TNFalpha-Antagonists documented as prior treatments**	0 (0.0)	0 (0.0)	0 (0.0)
Discontinued due to lack of tolerability	0 (0.0)	0 (0.0)	0 (0.0)
Discontinued due to lack of efficacy	0 (0.0)	0 (0.0)	0 (0.0)
* Based on documented protocol deviations from inclusion criterion 9 and documented prior treatments			
** Based on documented prior treatments			
Medications classified as cDMARDs: AZATHIOPRINE, CHLOROQUINE, CICLOSPORIN, GOLD PREPARATIONS, HYDROXYCHLOROQUINE, LEFLUNOMIDE, MESALAZINE, METHOTREXATE, SODIUM AUROTHIOMALATE, SULFASALAZINE, TRUXOFOL			
Medications classified as bDMARDs: DENOSUMAB, INFlixIMAB, TOCILIZUMAB			
Medications classified as DMARDs: cDMARDs, bDMARDs, APREMILAST, TOFACITINIB			

## 1.5 Concomitant Medication (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
DMARDs, n (%)	2 (1.8)	3 (3.0)	5 (2.4)
Median; range of application time (weeks)	3.1; 0.1 - 6.1	0.1; 0.1 - 5.7	0.1; 0.1 - 6.1
cDMARDs, n (%)	2 (1.8)	3 (3.0)	5 (2.4)
Median; range of application time (weeks)	3.1; 0.1 - 6.1	0.1; 0.1 - 5.7	0.1; 0.1 - 6.1
Methotrexate, n (%)	2 (1.8)	2 (2.0)	4 (1.9)
Median; range of application time (weeks)	3.1; 0.1 - 6.1	2.9; 0.1 - 5.7	2.9; 0.1 - 6.1
bDMARDs, n (%)	0 (0.0)	0 (0.0)	0 (0.0)
Median; range of application time (weeks)	-; - - -	-; - - -	-; - - -
NSAIDs, n (%)	80 (72.7)	67 (66.3)	147 (69.7)
Median; range of application time (weeks)	53.1; 5.4 - 64.9	52.1; 2.6 - 65.3	53.0; 2.6 - 65.3
Psoriasis medication, n (%)	6 (5.5)	7 (6.9)	13 (6.2)
Median; range of application time (weeks)	20.3; 0.1 - 53.9	17.7; 0.1 - 56.1	17.7; 0.1 - 56.1
Intraarticular corticosteroids, n (%)	1 (0.9)	1 (1.0)	2 (0.9)
Median; range of application time (weeks)	4.1; 4.1 - 4.1	19.1; 19.1 - 19.1	11.6; 4.1 - 19.1
Systemic corticosteroids, n (%)	9 (8.2)	11 (10.9)	20 (9.5)
Median; range of application time (weeks)	53.1; 17.4 - 56.1	48.4; 3.1 - 65.1	52.1; 3.1 - 65.1
Patients who experienced any dose change of systemic corticosteroids during study period, n (%)	3 (2.7)	6 (5.9)	9 (4.3)
<p>Medications classified as cDMARDs: AZATHIOPRINE, CHLOROQUINE, CICLOSPORIN, GOLD PREPARATIONS, HYDROXYCHLOROQUINE, LEFLUNOMIDE, MESALAZINE, METHOTREXATE, SODIUM AUROTHIOMALATE, SULFASALAZINE, TRUXOFOL</p> <p>Medications classified as bDMARDs: DENOSUMAB, INFLIXIMAB, TOCILIZUMAB</p> <p>Medications classified as DMARDs: cDMARDs, bDMARDs, APREMILAST, TOFACITINIB</p> <p>Medication classified as Psoriasis medication: Acitretin, Alpicort A, Apremilast, Belosalic, Betadermic, Betamethason, Betzee S, Calpsor C, Ciclosporin, Clobetasol, Clobetasonbutyrat, Clotrason, Daivobet, Desonid, Desoximetason, Dexamethason, Diflucortolonvalerat, Dimethylfumarat, Diprosopan, Dithranol, Fluocinolonacetamid, Fluticasonpropionat, Hydrocortison, Methotrexat, Methylprednisolonaceponat, Mometason, Phototherapie, Prdenicarbat, Propysalic NF, Travocort, Triamcinolon, Truxofol, Ulobetasol, Velosalic, Xamiol</p>			

## 1.6 Definition of Subpopulation (FAS)

		Treatment Groups		
BSA	PASI	SEC (N=426)	ADA (N=427)	Total (N=853)
<b><u>Patients with Moderate / Severe Psoriasis</u></b>				
≤ 10%	< 10	315	324	639
≤ 10%	≥ 10	8	7	15
> 10%	< 10	23	32	55
> 10%	≥ 10	79	62	141
<b>BSA &gt; 10% and/or PASI ≥ 10</b>	<b>PASI ≥ 10</b>	<b>110</b>	<b>101</b>	<b>211</b>
The table is based on the total population (N in the column headers refers to the total population).				

## 1.7 Number of Subjects in Subgroups (FAS)

Subgrouping Factor	Subgroup	Treatment Groups		
		SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Age</b>	< 65 years	103	94	197
	>= 65 years	7	7	14
<b>Gender</b>	Male	66	57	123
	Female	44	44	88
<b>Disease Severity</b>	PASDAS <= 3.2	0	0	0
	3.2 < PASDAS < 5.4	24	21	45
	PASDAS >= 5.4	86	80	166
<b>Disease Severity</b>	PASDAS < 5.4	24	21	45
	PASDAS >= 5.4	86	80	166
<b>Region</b>	America	0	5	5
	Asia	4	8	12
	Australia	1	3	4
	Europe	105	85	190
<b>Moderate/Severe PSO Def. 1</b>	No	0	0	0
	Yes	110	101	211
<b>Moderate/Severe PSO Def. 2</b>	No	42	51	93
	Yes	68	50	118
<b>Lymphocyte Count at BL</b>	<= Median	72	49	121
	> Median	38	52	90
<b>Enthesitis at BL According to LEI</b>	No	51	32	83
	Yes	59	69	128
<b>HLA-DQA1*05</b>	Non-carrier	51	41	92
	Carrier	34	26	60
	Missing	25	34	59
<b>Lead Candidate Variant rs10555659</b>	Non-carrier	45	27	72
	Carrier	38	30	68
	Missing	27	44	71
<b>Lead Candidate Variant rs111937633</b>	Non-carrier	30	33	63
	Carrier	51	34	85
	Missing	29	34	63
<b>Lead Candidate Variant rs11726476</b>	Non-carrier	43	43	86
	Carrier	42	24	66
	Missing	25	34	59
<b>Lead Candidate Variant rs10609046</b>	Non-carrier	62	47	109

Subgrouping Factor	Subgroup	Treatment Groups		
		SEC (N=110)	ADA (N=101)	Total (N=211)
	Carrier	20	18	38
	Missing	28	36	64
<b>Lead Candidate Variant rs8007401</b>	Non-carrier	63	51	114
	Carrier	19	12	31
	Missing	28	38	66
<b>Lead Candidate Variant rs7349145</b>	Non-carrier	71	53	124
	Carrier	13	10	23
	Missing	26	38	64
<b>Lead Candidate Allele Score</b>	Low score	22	26	48
	High score	63	41	104
	Missing	25	34	59
<b>Linkage Variant rs10891185</b>	Non-carrier	51	35	86
	Carrier	34	32	66
	Missing	25	34	59
<b>Linkage Variant rs12065362</b>	Non-carrier	30	31	61
	Carrier	55	36	91
	Missing	25	34	59
<b>Linkage Variant rs11721988</b>	Non-carrier	43	43	86
	Carrier	42	24	66
	Missing	25	34	59
<b>Linkage Variant rs7787032</b>	Non-carrier	65	49	114
	Carrier	18	18	36
	Missing	27	34	61
<b>Presence of Antibodies</b>	Not present	109	92	201
	Present	0	4	4
	Missing	1	5	6

Efficacy and safety subgroup analysis is displayed for all subgrouping factors with at least 10 patients in each subgroup.

## Efficacy Analysis

### 2.1 All-Cause Mortality (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
All-cause Mortality Week 52, N' n (%)	110 0 (0.0)	101 0 (0.0)	N.E.	N.E.	N.E.
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR (with Wald CI) from logistic regression model with predictors treatment and weight, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) without adjustment.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					



### 3.0 BSA (Percent) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	110 (100.0)	98 (97.0)	208 (98.6)
Week 4 Returns	110 (100.0)	97 (96.0)	207 (98.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	95 (94.1)	201 (95.3)
Week 16 Returns	108 (98.2)	93 (92.1)	201 (95.3)
Week 24 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	104 (94.5)	85 (84.2)	189 (89.6)

### 3.1 BSA (Percent) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	24.45 (15.66)	24.19 (16.28)		
Week 52 Mean (SD)	2.53 (4.99)	5.53 (8.81)		
Week 52 Adjusted Mean Change (SE)	-21.70 (0.59)	-18.28 (0.64)	-3.42 [-5.15; -1.69]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

### 3.2 BSA (Percent) - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.078</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	24.94 (16.04)	24.49 (16.53)		
Week 52 Mean (SD)	2.53 (5.07)	5.94 (9.07)		
Week 52 Adjusted Mean Change (SE)	-21.90 (0.61)	-17.97 (0.66)	-3.93 [-5.71; -2.16]	<.001
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	17.29 (4.03)	20.14 (12.65)		
Week 52 Mean (SD)	2.60 (3.13)	1.00 (2.24)		
Week 52 Adjusted Mean Change (SE)	-18.45 (2.50)	-22.26 (2.30)	3.81 [-2.88; 10.49]	0.263
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.3 BSA (Percent) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.566</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	26.73 (17.80)	26.60 (17.90)		
Week 52 Mean (SD)	2.71 (5.70)	5.94 (9.31)		
Week 52 Adjusted Mean Change (SE)	-22.21 (0.78)	-18.74 (0.86)	-3.47 [-5.74; -1.20]	0.003
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	21.05 (11.08)	21.07 (13.47)		
Week 52 Mean (SD)	2.24 (3.67)	4.97 (8.17)		
Week 52 Adjusted Mean Change (SE)	-20.92 (0.96)	-17.63 (0.99)	-3.30 [-6.00; -0.59]	0.017
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.4 BSA (Percent) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.568</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	19.63 (13.61)	21.71 (11.84)		
Week 52 Mean (SD)	2.22 (5.58)	4.65 (8.16)		
Week 52 Adjusted Mean Change (SE)	-21.06 (1.28)	-19.01 (1.43)	-2.05 [-5.84; 1.73]	0.287
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	25.80 (16.00)	24.84 (17.26)		
Week 52 Mean (SD)	2.62 (4.84)	5.75 (9.01)		
Week 52 Adjusted Mean Change (SE)	-21.88 (0.68)	-18.09 (0.72)	-3.79 [-5.75; -1.84]	<.001
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.5 BSA (Percent) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.034</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	14.26 (5.62)	14.10 (4.93)		
Week 52 Mean (SD)	1.00 (1.70)	2.70 (4.46)		
Week 52 Adjusted Mean Change (SE)	-20.93 (1.02)	-18.71 (0.99)	-2.22 [-4.86; 0.42]	0.099
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	30.75 (16.56)	34.48 (17.38)		
Week 52 Mean (SD)	3.45 (6.00)	8.04 (10.81)		
Week 52 Adjusted Mean Change (SE)	-22.18 (0.79)	-17.81 (0.96)	-4.37 [-6.70; -2.04]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment            x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters,            subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.6 BSA (Percent) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.772</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	26.88 (17.71)	21.45 (13.02)		
Week 52 Mean (SD)	2.64 (5.28)	3.50 (6.08)		
Week 52 Adjusted Mean Change (SE)	-22.07 (0.73)	-19.35 (0.94)	-2.71 [-5.07; -0.36]	0.024
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	19.87 (9.35)	26.77 (18.61)		
Week 52 Mean (SD)	2.29 (4.39)	7.17 (10.29)		
Week 52 Adjusted Mean Change (SE)	-21.00 (1.03)	-17.37 (0.88)	-3.63 [-6.31; -0.96]	0.008
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.7 BSA (Percent) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.856</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	22.06 (13.79)	23.41 (13.12)		
Week 52 Mean (SD)	2.04 (4.85)	6.25 (10.07)		
Week 52 Adjusted Mean Change (SE)	-21.72 (0.88)	-17.74 (1.14)	-3.98 [-6.81; -1.15]	0.006
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	26.53 (16.95)	24.55 (17.63)		
Week 52 Mean (SD)	2.95 (5.11)	5.18 (8.20)		
Week 52 Adjusted Mean Change (SE)	-21.69 (0.82)	-18.55 (0.79)	-3.14 [-5.37; -0.90]	0.006
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 3.8 BSA (Percent) - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.866</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	22.82 (15.07)	21.90 (16.59)		
Week 52 Mean (SD)	2.45 (4.43)	5.14 (10.54)		
Week 52 Adjusted Mean Change (SE)	-21.12 (0.89)	-18.43 (1.01)	-2.69 [-5.36; -0.02]	0.048
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	27.15 (16.18)	23.15 (16.33)		
Week 52 Mean (SD)	2.13 (3.94)	3.27 (5.20)		
Week 52 Adjusted Mean Change (SE)	-22.03 (1.11)	-18.61 (1.30)	-3.41 [-6.81; -0.02]	0.049
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.9 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.697</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	24.51 (13.25)	21.33 (12.07)		
Week 52 Mean (SD)	1.81 (3.92)	3.29 (9.38)		
Week 52 Adjusted Mean Change (SE)	-21.43 (0.89)	-18.56 (1.22)	-2.87 [-5.87; 0.13]	0.061
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	23.39 (17.34)	21.33 (15.42)		
Week 52 Mean (SD)	2.80 (4.52)	5.18 (7.02)		
Week 52 Adjusted Mean Change (SE)	-20.06 (0.98)	-17.22 (1.10)	-2.84 [-5.76; 0.07]	0.056
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.10 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.609</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	21.53 (14.25)	25.03 (16.77)		
Week 52 Mean (SD)	2.76 (4.80)	4.54 (9.94)		
Week 52 Adjusted Mean Change (SE)	-20.85 (1.16)	-18.34 (1.17)	-2.51 [-5.78; 0.75]	0.130
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	27.02 (16.46)	19.82 (15.81)		
Week 52 Mean (SD)	2.04 (3.91)	4.36 (8.18)		
Week 52 Adjusted Mean Change (SE)	-22.46 (0.89)	-18.90 (1.10)	-3.55 [-6.37; -0.74]	0.014
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.11 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.677</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	22.02 (12.24)	25.12 (18.41)		
Week 52 Mean (SD)	1.18 (2.36)	4.67 (8.50)		
Week 52 Adjusted Mean Change (SE)	-22.01 (0.98)	-18.97 (0.98)	-3.04 [-5.79; -0.29]	0.030
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	27.14 (18.16)	17.50 (10.57)		
Week 52 Mean (SD)	3.41 (5.23)	4.00 (9.89)		
Week 52 Adjusted Mean Change (SE)	-20.97 (0.98)	-17.60 (1.37)	-3.37 [-6.73; -0.02]	0.049
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.12 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.398</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	24.21 (14.50)	25.77 (18.14)		
Week 52 Mean (SD)	3.03 (4.75)	5.60 (10.35)		
Week 52 Adjusted Mean Change (SE)	-20.53 (0.81)	-17.91 (0.96)	-2.61 [-5.10; -0.13]	0.039
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	23.50 (16.66)	14.56 (6.06)		
Week 52 Mean (SD)	0.53 (0.84)	1.94 (3.99)		
Week 52 Adjusted Mean Change (SE)	-23.03 (1.43)	-19.38 (1.53)	-3.65 [-7.80; 0.50]	0.084
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.13 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.243</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	24.17 (15.89)	24.51 (17.91)		
Week 52 Mean (SD)	2.40 (4.43)	5.45 (10.05)		
Week 52 Adjusted Mean Change (SE)	-21.45 (0.82)	-17.92 (0.93)	-3.53 [-5.97; -1.09]	0.005
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	26.32 (15.68)	14.42 (5.12)		
Week 52 Mean (SD)	2.37 (3.93)	1.83 (2.76)		
Week 52 Adjusted Mean Change (SE)	-21.89 (1.46)	-20.49 (1.87)	-1.40 [-6.11; 3.31]	0.558
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.14 BSA (Percent) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.830</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	25.18 (16.45)	20.91 (12.95)		
Week 52 Mean (SD)	2.55 (4.30)	4.13 (8.10)		
Week 52 Adjusted Mean Change (SE)	-21.15 (0.75)	-18.25 (0.89)	-2.90 [-5.22; -0.58]	0.015
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	22.46 (9.32)	24.10 (24.11)		
Week 52 Mean (SD)	1.38 (3.95)	6.70 (13.22)		
Week 52 Adjusted Mean Change (SE)	-21.76 (1.73)	-16.89 (1.97)	-4.87 [-10.05; 0.30]	0.065
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.15 BSA (Percent) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.242</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	20.23 (9.70)	29.00 (17.14)		
Week 52 Mean (SD)	2.68 (5.22)	4.00 (9.51)		
Week 52 Adjusted Mean Change (SE)	-19.94 (1.39)	-19.64 (1.34)	-0.30 [-4.13; 3.54]	0.879
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	26.06 (16.96)	18.20 (14.58)		
Week 52 Mean (SD)	2.21 (3.90)	4.67 (8.72)		
Week 52 Adjusted Mean Change (SE)	-21.99 (0.80)	-17.81 (1.01)	-4.18 [-6.74; -1.61]	0.002
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 3.16 BSA (Percent) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.538</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	26.57 (15.32)	21.86 (16.35)		
Week 52 Mean (SD)	2.06 (3.98)	3.90 (10.75)		
Week 52 Adjusted Mean Change (SE)	-22.26 (0.89)	-18.80 (1.12)	-3.47 [-6.30; -0.63]	0.017
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	21.53 (15.69)	22.97 (16.65)		
Week 52 Mean (SD)	2.74 (4.61)	4.97 (6.85)		
Week 52 Adjusted Mean Change (SE)	-20.31 (1.10)	-18.22 (1.13)	-2.08 [-5.20; 1.03]	0.187
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.17 BSA (Percent) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.694</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	21.53 (14.25)	24.77 (17.01)		
Week 52 Mean (SD)	2.76 (4.80)	4.67 (10.31)		
Week 52 Adjusted Mean Change (SE)	-20.73 (1.17)	-17.88 (1.22)	-2.84 [-6.18; 0.49]	0.094
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	26.20 (16.14)	20.33 (15.76)		
Week 52 Mean (SD)	2.08 (3.88)	4.29 (7.98)		
Week 52 Adjusted Mean Change (SE)	-21.90 (0.87)	-18.95 (1.07)	-2.95 [-5.69; -0.22]	0.034
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.18 BSA (Percent) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.677</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	22.02 (12.24)	25.12 (18.41)		
Week 52 Mean (SD)	1.18 (2.36)	4.67 (8.50)		
Week 52 Adjusted Mean Change (SE)	-22.01 (0.98)	-18.97 (0.98)	-3.04 [-5.79; -0.29]	0.030
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	27.14 (18.16)	17.50 (10.57)		
Week 52 Mean (SD)	3.41 (5.23)	4.00 (9.89)		
Week 52 Adjusted Mean Change (SE)	-20.97 (0.98)	-17.60 (1.37)	-3.37 [-6.73; -0.02]	0.049
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 3.19 BSA (Percent) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.523</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	24.88 (15.34)	25.55 (17.79)		
Week 52 Mean (SD)	2.89 (4.68)	5.67 (10.22)		
Week 52 Adjusted Mean Change (SE)	-20.98 (0.79)	-17.95 (0.94)	-3.03 [-5.45; -0.60]	0.015
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	23.83 (17.34)	13.78 (6.35)		
Week 52 Mean (SD)	0.47 (0.80)	1.41 (2.67)		
Week 52 Adjusted Mean Change (SE)	-23.32 (1.51)	-20.15 (1.54)	-3.17 [-7.44; 1.10]	0.144
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.0 C-Reactive Protein (hsCRP) (mg/L) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	108 (98.2)	98 (97.0)	206 (97.6)
Week 4 Returns	108 (98.2)	97 (96.0)	205 (97.2)
Week 8 Returns	107 (97.3)	96 (95.0)	203 (96.2)
Week 12 Returns	108 (98.2)	98 (97.0)	206 (97.6)
Week 16 Returns	107 (97.3)	93 (92.1)	200 (94.8)
Week 20 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	102 (92.7)	86 (85.1)	188 (89.1)
Week 32 Returns	102 (92.7)	82 (81.2)	184 (87.2)
Week 36 Returns	102 (92.7)	83 (82.2)	185 (87.7)
Week 40 Returns	104 (94.5)	82 (81.2)	186 (88.2)
Week 44 Returns	105 (95.5)	83 (82.2)	188 (89.1)
Week 48 Returns	99 (90.0)	80 (79.2)	179 (84.8)
Week 52 Returns	104 (94.5)	83 (82.2)	187 (88.6)

#### 4.1 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	10.33 (20.25)	13.08 (25.22)		
Week 52 Mean (SD)	5.13 (9.37)	3.76 (4.85)		
Week 52 Adjusted Mean Change (SE)	-5.16 (0.78)	-6.05 (0.86)	0.89 [-1.39; 3.18]	0.443
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

#### 4.2 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.087</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	10.60 (20.84)	12.81 (24.05)		
Week 52 Mean (SD)	4.71 (7.97)	3.98 (5.01)		
Week 52 Adjusted Mean Change (SE)	-5.75 (0.79)	-5.65 (0.88)	-0.10 [-2.44; 2.24]	0.933
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	6.37 (7.08)	16.66 (40.24)		
Week 52 Mean (SD)	11.98 (22.74)	1.34 (0.53)		
Week 52 Adjusted Mean Change (SE)	4.61 (3.16)	-10.81 (3.00)	15.42 [6.82; 24.02]	<.001
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.3 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.027</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	8.66 (10.66)	11.42 (12.87)		
Week 52 Mean (SD)	4.72 (9.97)	2.94 (2.96)		
Week 52 Adjusted Mean Change (SE)	-5.41 (0.99)	-7.90 (1.12)	2.49 [-0.47; 5.44]	0.098
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	12.85 (29.28)	15.23 (35.42)		
Week 52 Mean (SD)	5.75 (8.46)	4.83 (6.44)		
Week 52 Adjusted Mean Change (SE)	-4.83 (1.23)	-3.66 (1.29)	-1.17 [-4.68; 2.33]	0.511
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



#### 4.4 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.199</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	4.05 (4.17)	4.27 (7.53)		
Week 52 Mean (SD)	4.84 (11.82)	2.80 (4.32)		
Week 52 Adjusted Mean Change (SE)	-3.42 (1.69)	-5.87 (1.95)	2.44 [-2.61; 7.49]	0.341
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	12.09 (22.52)	15.39 (27.65)		
Week 52 Mean (SD)	5.21 (8.64)	3.99 (4.97)		
Week 52 Adjusted Mean Change (SE)	-5.64 (0.89)	-6.05 (0.97)	0.41 [-2.17; 3.00]	0.754
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.5 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.623</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	7.91 (11.03)	11.73 (19.87)		
Week 52 Mean (SD)	5.54 (10.53)	4.61 (6.02)		
Week 52 Adjusted Mean Change (SE)	-3.90 (1.28)	-5.42 (1.24)	1.51 [-2.00; 5.02]	0.397
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	11.83 (24.22)	14.46 (29.85)		
Week 52 Mean (SD)	4.88 (8.68)	3.00 (3.40)		
Week 52 Adjusted Mean Change (SE)	-5.91 (0.99)	-6.58 (1.19)	0.67 [-2.40; 3.73]	0.668
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.6 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.070</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	11.49 (24.26)	16.12 (33.26)		
Week 52 Mean (SD)	3.99 (6.72)	3.57 (5.86)		
Week 52 Adjusted Mean Change (SE)	-6.70 (0.93)	-6.16 (1.25)	-0.54 [-3.62; 2.53]	0.729
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	8.15 (8.46)	10.21 (13.73)		
Week 52 Mean (SD)	7.47 (13.10)	3.90 (3.96)		
Week 52 Adjusted Mean Change (SE)	-2.13 (1.32)	-5.98 (1.13)	3.85 [0.43; 7.28]	0.028
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.7 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.547</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	7.59 (8.17)	12.55 (22.42)		
Week 52 Mean (SD)	4.29 (8.62)	5.20 (7.01)		
Week 52 Adjusted Mean Change (SE)	-5.43 (1.15)	-5.72 (1.49)	0.30 [-3.42; 4.01]	0.876
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	12.71 (26.48)	13.32 (26.57)		
Week 52 Mean (SD)	5.84 (9.99)	3.03 (3.08)		
Week 52 Adjusted Mean Change (SE)	-4.93 (1.07)	-6.27 (1.05)	1.34 [-1.61; 4.29]	0.373
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.8 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.974</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	9.20 (11.08)	9.21 (12.60)		
Week 52 Mean (SD)	5.31 (9.25)	4.59 (6.33)		
Week 52 Adjusted Mean Change (SE)	-5.38 (1.00)	-6.70 (1.15)	1.32 [-1.69; 4.32]	0.388
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	13.55 (32.88)	16.43 (24.96)		
Week 52 Mean (SD)	4.76 (8.11)	3.54 (3.79)		
Week 52 Adjusted Mean Change (SE)	-6.45 (1.23)	-7.93 (1.46)	1.49 [-2.29; 5.26]	0.437
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.9 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.223</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	9.95 (16.30)	13.67 (23.94)		
Week 52 Mean (SD)	4.12 (7.60)	3.10 (3.16)		
Week 52 Adjusted Mean Change (SE)	-7.28 (1.08)	-8.08 (1.50)	0.81 [-2.85; 4.47]	0.663
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	12.59 (28.57)	11.68 (14.02)		
Week 52 Mean (SD)	6.45 (10.23)	5.15 (6.64)		
Week 52 Adjusted Mean Change (SE)	-4.61 (1.19)	-7.06 (1.35)	2.45 [-1.11; 6.00]	0.176
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.10 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.778</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	15.73 (31.70)	14.93 (23.30)		
Week 52 Mean (SD)	7.70 (12.68)	3.33 (3.21)		
Week 52 Adjusted Mean Change (SE)	-4.33 (1.24)	-8.27 (1.28)	3.95 [0.43; 7.46]	0.028
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	8.04 (15.31)	9.19 (12.09)		
Week 52 Mean (SD)	3.64 (4.99)	4.90 (6.79)		
Week 52 Adjusted Mean Change (SE)	-7.24 (0.96)	-6.18 (1.19)	-1.07 [-4.07; 1.94]	0.485
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.11 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.827</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	10.05 (16.46)	10.31 (13.81)		
Week 52 Mean (SD)	2.98 (2.98)	4.96 (6.37)		
Week 52 Adjusted Mean Change (SE)	-7.29 (1.07)	-6.47 (1.08)	-0.82 [-3.83; 2.18]	0.590
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	11.86 (27.39)	15.07 (25.01)		
Week 52 Mean (SD)	7.16 (11.67)	2.75 (2.84)		
Week 52 Adjusted Mean Change (SE)	-4.42 (1.06)	-8.57 (1.48)	4.15 [0.55; 7.75]	0.024
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



#### 4.12 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.176</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	8.71 (14.69)	10.90 (19.92)		
Week 52 Mean (SD)	4.91 (7.83)	3.74 (4.38)		
Week 52 Adjusted Mean Change (SE)	-5.67 (0.93)	-7.24 (1.12)	1.57 [-1.31; 4.45]	0.282
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	17.44 (37.98)	15.97 (15.31)		
Week 52 Mean (SD)	6.10 (11.83)	5.35 (7.60)		
Week 52 Adjusted Mean Change (SE)	-5.88 (1.63)	-7.07 (1.72)	1.19 [-3.47; 5.86]	0.614
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.13 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.869</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	13.18 (25.62)	14.76 (20.45)		
Week 52 Mean (SD)	5.54 (9.92)	4.80 (6.06)		
Week 52 Adjusted Mean Change (SE)	-5.94 (0.92)	-7.40 (1.07)	1.46 [-1.32; 4.24]	0.301
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	3.99 (3.45)	4.01 (4.23)		
Week 52 Mean (SD)	3.13 (3.29)	2.83 (3.01)		
Week 52 Adjusted Mean Change (SE)	-7.04 (1.67)	-7.15 (2.06)	0.11 [-5.08; 5.31]	0.965
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.14 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.790</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	9.80 (21.50)	11.96 (19.32)		
Week 52 Mean (SD)	5.66 (9.55)	4.26 (5.56)		
Week 52 Adjusted Mean Change (SE)	-4.97 (0.84)	-6.93 (0.99)	1.95 [-0.61; 4.52]	0.135
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	16.67 (27.80)	13.11 (18.71)		
Week 52 Mean (SD)	2.44 (1.77)	2.33 (2.27)		
Week 52 Adjusted Mean Change (SE)	-9.52 (1.90)	-9.52 (2.32)	0.00 [-5.93; 5.94]	0.999
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.15 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.347</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	11.55 (10.30)	15.11 (25.06)		
Week 52 Mean (SD)	6.55 (11.15)	3.97 (4.48)		
Week 52 Adjusted Mean Change (SE)	-3.18 (1.56)	-7.61 (1.51)	4.43 [0.13; 8.72]	0.043
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	10.73 (25.39)	10.05 (12.90)		
Week 52 Mean (SD)	4.64 (7.93)	4.30 (6.00)		
Week 52 Adjusted Mean Change (SE)	-6.65 (0.89)	-6.90 (1.13)	0.25 [-2.58; 3.09]	0.861
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error  Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un)  Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

#### 4.16 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.149</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	12.43 (27.37)	13.53 (22.38)		
Week 52 Mean (SD)	4.79 (9.15)	2.98 (2.94)		
Week 52 Adjusted Mean Change (SE)	-6.85 (0.98)	-7.91 (1.27)	1.06 [-2.12; 4.24]	0.510
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	8.72 (11.65)	10.36 (13.39)		
Week 52 Mean (SD)	5.60 (8.23)	5.34 (6.98)		
Week 52 Adjusted Mean Change (SE)	-4.21 (1.24)	-6.35 (1.27)	2.14 [-1.37; 5.65]	0.230
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.17 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.836</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	15.73 (31.70)	15.75 (23.83)		
Week 52 Mean (SD)	7.70 (12.68)	3.50 (3.29)		
Week 52 Adjusted Mean Change (SE)	-4.34 (1.27)	-8.32 (1.36)	3.98 [0.31; 7.65]	0.034
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	8.33 (14.90)	8.80 (11.85)		
Week 52 Mean (SD)	3.59 (4.91)	4.68 (6.64)		
Week 52 Adjusted Mean Change (SE)	-6.68 (0.96)	-6.30 (1.18)	-0.38 [-3.37; 2.62]	0.803
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.18 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.827</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	10.05 (16.46)	10.31 (13.81)		
Week 52 Mean (SD)	2.98 (2.98)	4.96 (6.37)		
Week 52 Adjusted Mean Change (SE)	-7.29 (1.07)	-6.47 (1.08)	-0.82 [-3.83; 2.18]	0.590
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	11.86 (27.39)	15.07 (25.01)		
Week 52 Mean (SD)	7.16 (11.67)	2.75 (2.84)		
Week 52 Adjusted Mean Change (SE)	-4.42 (1.06)	-8.57 (1.48)	4.15 [0.55; 7.75]	0.024
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 4.19 C-Reactive Protein (hsCRP) (mg/L) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.681</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	9.03 (14.65)	10.64 (19.55)		
Week 52 Mean (SD)	4.78 (7.65)	3.76 (4.33)		
Week 52 Adjusted Mean Change (SE)	-5.77 (0.90)	-7.14 (1.08)	1.37 [-1.41; 4.15]	0.331
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	17.53 (40.14)	15.76 (15.46)		
Week 52 Mean (SD)	6.64 (12.43)	5.18 (7.59)		
Week 52 Adjusted Mean Change (SE)	-5.31 (1.71)	-7.06 (1.70)	1.75 [-2.99; 6.49]	0.468
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 5.0 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	109 (99.1)	100 (99.0)	209 (99.1)
Week 4 Returns	109 (99.1)	99 (98.0)	208 (98.6)
Week 8 Returns	110 (100.0)	98 (97.0)	208 (98.6)
Week 12 Returns	107 (97.3)	98 (97.0)	205 (97.2)
Week 16 Returns	108 (98.2)	95 (94.1)	203 (96.2)
Week 20 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	102 (92.7)	84 (83.2)	186 (88.2)
Week 32 Returns	102 (92.7)	82 (81.2)	184 (87.2)
Week 36 Returns	102 (92.7)	84 (83.2)	186 (88.2)
Week 40 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 44 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 48 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 52 Returns	104 (94.5)	83 (82.2)	187 (88.6)

### 5.1 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	24.07 (18.65)	26.45 (19.62)		
Week 52 Mean (SD)	12.99 (11.57)	12.98 (12.13)		
Week 52 Adjusted Mean Change (SE)	-10.94 (1.18)	-11.19 (1.27)	0.25 [-3.17; 3.67]	0.885
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 5.2 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.240</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	23.43 (17.94)	25.56 (18.06)		
Week 52 Mean (SD)	12.92 (11.56)	12.49 (11.74)		
Week 52 Adjusted Mean Change (SE)	-11.25 (1.22)	-11.25 (1.32)	-0.01 [-3.55; 3.54]	0.998
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	33.57 (27.02)	38.29 (34.44)		
Week 52 Mean (SD)	14.17 (12.75)	18.29 (15.81)		
Week 52 Adjusted Mean Change (SE)	-6.48 (4.74)	-10.84 (4.67)	4.36 [-8.70; 17.42]	0.511
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.3 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.530</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	20.76 (18.02)	22.72 (15.90)		
Week 52 Mean (SD)	8.81 (7.98)	9.23 (8.62)		
Week 52 Adjusted Mean Change (SE)	-14.16 (1.46)	-15.13 (1.60)	0.97 [-3.27; 5.21]	0.653
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	29.05 (18.66)	31.27 (22.88)		
Week 52 Mean (SD)	19.41 (13.27)	17.86 (14.27)		
Week 52 Adjusted Mean Change (SE)	-6.27 (1.79)	-5.89 (1.85)	-0.38 [-5.41; 4.65]	0.882
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.4 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.227</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	13.08 (9.99)	14.71 (14.92)		
Week 52 Mean (SD)	11.83 (12.29)	13.56 (15.55)		
Week 52 Adjusted Mean Change (SE)	-8.15 (2.60)	-7.68 (2.85)	-0.46 [-7.94; 7.01]	0.903
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	27.14 (19.37)	29.53 (19.61)		
Week 52 Mean (SD)	13.32 (11.42)	12.84 (11.30)		
Week 52 Adjusted Mean Change (SE)	-11.67 (1.34)	-11.96 (1.44)	0.29 [-3.57; 4.15]	0.882
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.5 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.659</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	23.83 (18.50)	28.33 (19.53)		
Week 52 Mean (SD)	14.56 (12.23)	14.33 (14.26)		
Week 52 Adjusted Mean Change (SE)	-9.88 (1.92)	-10.70 (1.83)	0.82 [-4.41; 6.06]	0.757
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	24.22 (18.87)	24.52 (19.72)		
Week 52 Mean (SD)	12.05 (11.14)	11.77 (9.87)		
Week 52 Adjusted Mean Change (SE)	-11.58 (1.50)	-11.75 (1.79)	0.18 [-4.44; 4.79]	0.939
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 5.6 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.187</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	21.44 (19.03)	27.10 (22.48)		
Week 52 Mean (SD)	9.30 (7.05)	11.03 (11.24)		
Week 52 Adjusted Mean Change (SE)	-13.94 (1.40)	-11.75 (1.78)	-2.20 [-6.68; 2.29]	0.335
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	29.05 (17.05)	25.83 (16.68)		
Week 52 Mean (SD)	20.59 (15.02)	14.47 (12.68)		
Week 52 Adjusted Mean Change (SE)	-5.22 (1.95)	-10.56 (1.68)	5.34 [0.26; 10.42]	0.039
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.7 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.883</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	21.24 (18.80)	26.84 (20.68)		
Week 52 Mean (SD)	11.88 (9.70)	14.82 (15.36)		
Week 52 Adjusted Mean Change (SE)	-11.77 (1.74)	-10.16 (2.25)	-1.61 [-7.22; 4.01]	0.574
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	26.53 (18.32)	26.26 (19.26)		
Week 52 Mean (SD)	13.95 (12.97)	12.04 (10.13)		
Week 52 Adjusted Mean Change (SE)	-10.18 (1.62)	-11.76 (1.55)	1.58 [-2.83; 6.00]	0.481
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 5.8 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.522</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	25.29 (20.72)	20.73 (15.81)		
Week 52 Mean (SD)	12.98 (11.17)	13.26 (13.13)		
Week 52 Adjusted Mean Change (SE)	-11.14 (1.66)	-11.11 (1.90)	-0.03 [-5.02; 4.97]	0.991
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	23.79 (17.57)	30.81 (22.67)		
Week 52 Mean (SD)	11.45 (7.35)	11.73 (14.02)		
Week 52 Adjusted Mean Change (SE)	-11.32 (2.05)	-12.66 (2.43)	1.35 [-4.94; 7.63]	0.672
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.9 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.599</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	22.84 (18.81)	22.30 (19.14)		
Week 52 Mean (SD)	11.40 (11.30)	10.24 (7.21)		
Week 52 Adjusted Mean Change (SE)	-13.06 (1.75)	-13.70 (2.39)	0.64 [-5.22; 6.50]	0.829
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	27.50 (20.38)	27.93 (19.29)		
Week 52 Mean (SD)	13.41 (7.11)	14.96 (17.13)		
Week 52 Adjusted Mean Change (SE)	-9.93 (1.93)	-10.00 (2.18)	0.07 [-5.67; 5.80]	0.982
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.10 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.069</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	24.60 (17.46)	24.70 (23.12)		
Week 52 Mean (SD)	15.69 (12.42)	10.65 (9.16)		
Week 52 Adjusted Mean Change (SE)	-8.66 (2.03)	-12.42 (2.05)	3.76 [-1.94; 9.46]	0.194
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	23.96 (19.79)	24.59 (14.92)		
Week 52 Mean (SD)	10.31 (7.13)	14.35 (16.05)		
Week 52 Adjusted Mean Change (SE)	-13.84 (1.56)	-10.66 (1.93)	-3.18 [-8.08; 1.72]	0.202
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.11 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.135</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	25.58 (19.53)	23.88 (17.97)		
Week 52 Mean (SD)	12.54 (11.12)	12.68 (12.25)		
Week 52 Adjusted Mean Change (SE)	-10.36 (1.83)	-12.01 (1.84)	1.65 [-3.48; 6.78]	0.527
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	23.79 (19.52)	26.00 (21.69)		
Week 52 Mean (SD)	12.23 (8.51)	12.65 (15.58)		
Week 52 Adjusted Mean Change (SE)	-12.04 (1.83)	-11.08 (2.53)	-0.95 [-7.12; 5.22]	0.761
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 5.12 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.195</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	24.89 (21.19)	24.83 (21.09)		
Week 52 Mean (SD)	12.61 (10.57)	14.16 (15.24)		
Week 52 Adjusted Mean Change (SE)	-10.73 (1.53)	-10.51 (1.82)	-0.22 [-4.92; 4.47]	0.925
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	23.20 (14.68)	24.33 (14.67)		
Week 52 Mean (SD)	12.58 (7.88)	10.24 (8.36)		
Week 52 Adjusted Mean Change (SE)	-11.07 (2.69)	-13.70 (2.84)	2.63 [-5.11; 10.37]	0.503
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.13 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.439</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	26.78 (21.28)	24.61 (20.00)		
Week 52 Mean (SD)	12.33 (10.63)	13.26 (14.13)		
Week 52 Adjusted Mean Change (SE)	-11.32 (1.46)	-11.03 (1.66)	-0.29 [-4.65; 4.07]	0.896
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	16.21 (9.60)	24.33 (16.10)		
Week 52 Mean (SD)	10.50 (4.83)	9.08 (7.33)		
Week 52 Adjusted Mean Change (SE)	-11.23 (2.66)	-15.14 (3.30)	3.91 [-4.48; 12.29]	0.358
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.14 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.346</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	23.82 (16.94)	23.62 (20.25)		
Week 52 Mean (SD)	13.08 (9.90)	12.57 (13.33)		
Week 52 Adjusted Mean Change (SE)	-9.58 (1.38)	-10.90 (1.63)	1.33 [-2.89; 5.55]	0.536
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	23.69 (22.15)	28.30 (15.78)		
Week 52 Mean (SD)	9.54 (9.35)	12.75 (13.90)		
Week 52 Adjusted Mean Change (SE)	-14.41 (3.17)	-12.55 (3.73)	-1.86 [-11.54; 7.83]	0.705
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.15 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.099</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	26.59 (20.65)	25.04 (24.25)		
Week 52 Mean (SD)	17.11 (14.72)	12.85 (10.07)		
Week 52 Adjusted Mean Change (SE)	-4.45 (2.52)	-11.58 (2.41)	7.13 [0.23; 14.03]	0.043
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	24.03 (19.11)	24.39 (15.61)		
Week 52 Mean (SD)	10.88 (7.22)	12.57 (14.99)		
Week 52 Adjusted Mean Change (SE)	-13.44 (1.46)	-11.74 (1.83)	-1.70 [-6.33; 2.93]	0.468
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 5.16 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.854</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	22.53 (18.60)	23.17 (19.73)		
Week 52 Mean (SD)	11.49 (11.08)	9.04 (6.86)		
Week 52 Adjusted Mean Change (SE)	-12.71 (1.63)	-15.18 (2.05)	2.47 [-2.70; 7.64]	0.346
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	27.94 (20.46)	26.25 (18.89)		
Week 52 Mean (SD)	13.83 (7.27)	16.17 (16.93)		
Week 52 Adjusted Mean Change (SE)	-8.97 (2.02)	-8.16 (2.07)	-0.81 [-6.53; 4.90]	0.779
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.17 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.228</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	24.60 (17.46)	25.68 (23.54)		
Week 52 Mean (SD)	15.69 (12.42)	10.96 (9.48)		
Week 52 Adjusted Mean Change (SE)	-8.77 (2.15)	-12.27 (2.24)	3.51 [-2.63; 9.64]	0.260
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	24.75 (20.57)	23.75 (14.91)		
Week 52 Mean (SD)	10.46 (7.43)	13.91 (15.65)		
Week 52 Adjusted Mean Change (SE)	-12.59 (1.60)	-11.05 (1.98)	-1.54 [-6.57; 3.49]	0.545
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.18 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.135</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	25.58 (19.53)	23.88 (17.97)		
Week 52 Mean (SD)	12.54 (11.12)	12.68 (12.25)		
Week 52 Adjusted Mean Change (SE)	-10.36 (1.83)	-12.01 (1.84)	1.65 [-3.48; 6.78]	0.527
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	23.79 (19.52)	26.00 (21.69)		
Week 52 Mean (SD)	12.23 (8.51)	12.65 (15.58)		
Week 52 Adjusted Mean Change (SE)	-12.04 (1.83)	-11.08 (2.53)	-0.95 [-7.12; 5.22]	0.761
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 5.19 Erythrocyte Sedimentation Rate (ESR) (mm/h) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.067</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	24.85 (20.79)	24.55 (20.75)		
Week 52 Mean (SD)	12.27 (10.43)	14.35 (15.12)		
Week 52 Adjusted Mean Change (SE)	-11.02 (1.49)	-10.19 (1.76)	-0.83 [-5.39; 3.73]	0.719
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	22.89 (14.72)	24.89 (14.93)		
Week 52 Mean (SD)	12.94 (8.27)	8.71 (6.74)		
Week 52 Adjusted Mean Change (SE)	-10.58 (2.82)	-15.25 (2.83)	4.67 [-3.23; 12.57]	0.244
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 6.0 HAQ-DI - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	110 (100.0)	100 (99.0)	210 (99.5)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	108 (98.2)	95 (94.1)	203 (96.2)
Week 20 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	102 (92.7)	86 (85.1)	188 (89.1)
Week 32 Returns	102 (92.7)	81 (80.2)	183 (86.7)
Week 36 Returns	102 (92.7)	84 (83.2)	186 (88.2)
Week 40 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 44 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 48 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 52 Returns	104 (94.5)	80 (79.2)	184 (87.2)

## 6.1 HAQ-DI - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	1.26 (0.63)	1.32 (0.69)		
Week 52 Mean (SD)	0.66 (0.61)	0.70 (0.59)		
Week 2 Adjusted Mean Change (SE)	-0.20 (0.03)	-0.21 (0.04)		
Week 4 Adjusted Mean Change (SE)	-0.33 (0.04)	-0.28 (0.04)		
Week 8 Adjusted Mean Change (SE)	-0.40 (0.04)	-0.33 (0.04)		
Week 12 Adjusted Mean Change (SE)	-0.48 (0.05)	-0.38 (0.05)		
Week 16 Adjusted Mean Change (SE)	-0.47 (0.05)	-0.41 (0.05)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.05)	-0.42 (0.05)		
Week 24 Adjusted Mean Change (SE)	-0.51 (0.05)	-0.44 (0.05)		
Week 28 Adjusted Mean Change (SE)	-0.56 (0.05)	-0.45 (0.05)		
Week 32 Adjusted Mean Change (SE)	-0.57 (0.05)	-0.45 (0.05)		
Week 36 Adjusted Mean Change (SE)	-0.58 (0.05)	-0.49 (0.05)		
Week 40 Adjusted Mean Change (SE)	-0.57 (0.05)	-0.50 (0.05)		
Week 44 Adjusted Mean Change (SE)	-0.60 (0.05)	-0.57 (0.05)		
Week 48 Adjusted Mean Change (SE)	-0.61 (0.05)	-0.57 (0.05)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.05)	-0.56 (0.05)	-0.05 [-0.19; 0.09]	0.517
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 6.2 HAQ-DI - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.207</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	1.26 (0.62)	1.32 (0.67)		
Week 52 Mean (SD)	0.65 (0.60)	0.68 (0.59)		
Week 2 Adjusted Mean Change (SE)	-0.21 (0.03)	-0.24 (0.04)		
Week 4 Adjusted Mean Change (SE)	-0.34 (0.04)	-0.29 (0.04)		
Week 8 Adjusted Mean Change (SE)	-0.40 (0.04)	-0.34 (0.04)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.05)	-0.40 (0.05)		
Week 16 Adjusted Mean Change (SE)	-0.48 (0.05)	-0.44 (0.05)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.05)	-0.45 (0.05)		
Week 24 Adjusted Mean Change (SE)	-0.51 (0.05)	-0.46 (0.05)		
Week 28 Adjusted Mean Change (SE)	-0.57 (0.05)	-0.48 (0.05)		
Week 32 Adjusted Mean Change (SE)	-0.58 (0.05)	-0.49 (0.05)		
Week 36 Adjusted Mean Change (SE)	-0.59 (0.05)	-0.52 (0.05)		
Week 40 Adjusted Mean Change (SE)	-0.58 (0.05)	-0.54 (0.05)		
Week 44 Adjusted Mean Change (SE)	-0.61 (0.05)	-0.61 (0.06)		
Week 48 Adjusted Mean Change (SE)	-0.62 (0.05)	-0.60 (0.05)		
Week 52 Adjusted Mean Change (SE)	-0.62 (0.05)	-0.59 (0.05)	-0.03 [-0.17; 0.12]	0.706
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	1.21 (0.68)	1.30 (0.91)		
Week 52 Mean (SD)	0.79 (0.82)	0.98 (0.53)		
Week 2 Adjusted Mean Change (SE)	-0.02 (0.13)	0.10 (0.13)		
Week 4 Adjusted Mean Change (SE)	-0.25 (0.16)	-0.06 (0.15)		
Week 8 Adjusted Mean Change (SE)	-0.33 (0.16)	-0.11 (0.16)		
Week 12 Adjusted Mean Change (SE)	-0.41 (0.18)	-0.06 (0.18)		
Week 16 Adjusted Mean Change (SE)	-0.40 (0.18)	0.05 (0.18)		
Week 20 Adjusted Mean Change (SE)	-0.51 (0.18)	-0.04 (0.19)		
Week 24 Adjusted Mean Change (SE)	-0.46 (0.19)	-0.09 (0.19)		
Week 28 Adjusted Mean Change (SE)	-0.43 (0.19)	-0.09 (0.19)		
Week 32 Adjusted Mean Change (SE)	-0.41 (0.19)	0.01 (0.19)		
Week 36 Adjusted Mean Change (SE)	-0.48 (0.19)	-0.11 (0.18)		
Week 40 Adjusted Mean Change (SE)	-0.39 (0.18)	-0.09 (0.18)		
Week 44 Adjusted Mean Change (SE)	-0.51 (0.20)	-0.08 (0.19)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.50 (0.19)	-0.18 (0.19)		
Week 52 Adjusted Mean Change (SE)	-0.42 (0.19)	-0.16 (0.19)	-0.26 [-0.79; 0.28]	0.341
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 6.3 HAQ-DI - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.239</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	1.12 (0.60)	1.08 (0.67)		
Week 52 Mean (SD)	0.52 (0.59)	0.50 (0.53)		
Week 2 Adjusted Mean Change (SE)	-0.26 (0.04)	-0.23 (0.05)		
Week 4 Adjusted Mean Change (SE)	-0.40 (0.05)	-0.36 (0.05)		
Week 8 Adjusted Mean Change (SE)	-0.47 (0.05)	-0.42 (0.06)		
Week 12 Adjusted Mean Change (SE)	-0.53 (0.06)	-0.50 (0.06)		
Week 16 Adjusted Mean Change (SE)	-0.54 (0.06)	-0.52 (0.06)		
Week 20 Adjusted Mean Change (SE)	-0.56 (0.06)	-0.55 (0.06)		
Week 24 Adjusted Mean Change (SE)	-0.60 (0.06)	-0.56 (0.07)		
Week 28 Adjusted Mean Change (SE)	-0.60 (0.06)	-0.58 (0.07)		
Week 32 Adjusted Mean Change (SE)	-0.62 (0.06)	-0.61 (0.07)		
Week 36 Adjusted Mean Change (SE)	-0.61 (0.06)	-0.64 (0.07)		
Week 40 Adjusted Mean Change (SE)	-0.60 (0.06)	-0.66 (0.07)		
Week 44 Adjusted Mean Change (SE)	-0.67 (0.06)	-0.72 (0.07)		
Week 48 Adjusted Mean Change (SE)	-0.69 (0.06)	-0.70 (0.07)		
Week 52 Adjusted Mean Change (SE)	-0.67 (0.06)	-0.67 (0.07)	0.00 [-0.18; 0.18]	0.963
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	1.48 (0.60)	1.62 (0.59)		
Week 52 Mean (SD)	0.88 (0.58)	0.97 (0.55)		
Week 2 Adjusted Mean Change (SE)	-0.11 (0.06)	-0.19 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.23 (0.06)	-0.17 (0.06)		
Week 8 Adjusted Mean Change (SE)	-0.30 (0.07)	-0.20 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.41 (0.07)	-0.22 (0.08)		
Week 16 Adjusted Mean Change (SE)	-0.39 (0.07)	-0.26 (0.07)		
Week 20 Adjusted Mean Change (SE)	-0.38 (0.07)	-0.25 (0.08)		
Week 24 Adjusted Mean Change (SE)	-0.38 (0.08)	-0.27 (0.08)		
Week 28 Adjusted Mean Change (SE)	-0.52 (0.08)	-0.27 (0.08)		
Week 32 Adjusted Mean Change (SE)	-0.49 (0.08)	-0.24 (0.08)		
Week 36 Adjusted Mean Change (SE)	-0.55 (0.07)	-0.30 (0.08)		
Week 40 Adjusted Mean Change (SE)	-0.52 (0.07)	-0.29 (0.08)		
Week 44 Adjusted Mean Change (SE)	-0.50 (0.08)	-0.37 (0.08)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.51 (0.08)	-0.40 (0.08)		
Week 52 Adjusted Mean Change (SE)	-0.51 (0.08)	-0.40 (0.08)	-0.11 [-0.32; 0.11]	0.324
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 6.4 HAQ-DI - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.951</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	0.83 (0.51)	0.58 (0.55)		
Week 52 Mean (SD)	0.38 (0.47)	0.46 (0.42)		
Week 2 Adjusted Mean Change (SE)	-0.28 (0.07)	-0.31 (0.08)		
Week 4 Adjusted Mean Change (SE)	-0.44 (0.09)	-0.37 (0.10)		
Week 8 Adjusted Mean Change (SE)	-0.38 (0.09)	-0.39 (0.10)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.10)	-0.49 (0.11)		
Week 16 Adjusted Mean Change (SE)	-0.57 (0.10)	-0.47 (0.11)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.11)	-0.52 (0.12)		
Week 24 Adjusted Mean Change (SE)	-0.53 (0.11)	-0.46 (0.12)		
Week 28 Adjusted Mean Change (SE)	-0.62 (0.11)	-0.62 (0.12)		
Week 32 Adjusted Mean Change (SE)	-0.62 (0.11)	-0.54 (0.12)		
Week 36 Adjusted Mean Change (SE)	-0.64 (0.10)	-0.58 (0.12)		
Week 40 Adjusted Mean Change (SE)	-0.60 (0.10)	-0.56 (0.12)		
Week 44 Adjusted Mean Change (SE)	-0.66 (0.11)	-0.50 (0.13)		
Week 48 Adjusted Mean Change (SE)	-0.66 (0.11)	-0.52 (0.12)		
Week 52 Adjusted Mean Change (SE)	-0.67 (0.11)	-0.51 (0.12)	-0.16 [-0.47; 0.15]	0.309
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	1.38 (0.60)	1.51 (0.58)		
Week 52 Mean (SD)	0.74 (0.62)	0.76 (0.61)		
Week 2 Adjusted Mean Change (SE)	-0.17 (0.04)	-0.19 (0.04)		
Week 4 Adjusted Mean Change (SE)	-0.31 (0.04)	-0.25 (0.05)		
Week 8 Adjusted Mean Change (SE)	-0.40 (0.05)	-0.31 (0.05)		
Week 12 Adjusted Mean Change (SE)	-0.48 (0.05)	-0.35 (0.06)		
Week 16 Adjusted Mean Change (SE)	-0.45 (0.05)	-0.39 (0.06)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.05)	-0.39 (0.06)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.05)	-0.43 (0.06)		
Week 28 Adjusted Mean Change (SE)	-0.55 (0.05)	-0.40 (0.06)		
Week 32 Adjusted Mean Change (SE)	-0.55 (0.05)	-0.43 (0.06)		
Week 36 Adjusted Mean Change (SE)	-0.57 (0.05)	-0.47 (0.06)		
Week 40 Adjusted Mean Change (SE)	-0.56 (0.05)	-0.49 (0.06)		
Week 44 Adjusted Mean Change (SE)	-0.58 (0.06)	-0.58 (0.06)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.60 (0.05)	-0.58 (0.06)		
Week 52 Adjusted Mean Change (SE)	-0.59 (0.06)	-0.57 (0.06)	-0.02 [-0.18; 0.14]	0.842
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 6.5 HAQ-DI - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.398</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	1.30 (0.65)	1.37 (0.70)		
Week 52 Mean (SD)	0.71 (0.60)	0.74 (0.61)		
Week 2 Adjusted Mean Change (SE)	-0.25 (0.05)	-0.21 (0.05)		
Week 4 Adjusted Mean Change (SE)	-0.43 (0.06)	-0.29 (0.06)		
Week 8 Adjusted Mean Change (SE)	-0.48 (0.07)	-0.31 (0.06)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.08)	-0.36 (0.07)		
Week 16 Adjusted Mean Change (SE)	-0.51 (0.07)	-0.41 (0.07)		
Week 20 Adjusted Mean Change (SE)	-0.47 (0.08)	-0.41 (0.07)		
Week 24 Adjusted Mean Change (SE)	-0.53 (0.08)	-0.42 (0.07)		
Week 28 Adjusted Mean Change (SE)	-0.63 (0.08)	-0.46 (0.07)		
Week 32 Adjusted Mean Change (SE)	-0.60 (0.08)	-0.44 (0.07)		
Week 36 Adjusted Mean Change (SE)	-0.65 (0.08)	-0.44 (0.07)		
Week 40 Adjusted Mean Change (SE)	-0.60 (0.08)	-0.46 (0.07)		
Week 44 Adjusted Mean Change (SE)	-0.61 (0.08)	-0.48 (0.08)		
Week 48 Adjusted Mean Change (SE)	-0.62 (0.08)	-0.52 (0.07)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.08)	-0.54 (0.08)	-0.06 [-0.28; 0.16]	0.588
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	1.24 (0.62)	1.27 (0.68)		
Week 52 Mean (SD)	0.63 (0.61)	0.67 (0.57)		
Week 2 Adjusted Mean Change (SE)	-0.16 (0.04)	-0.21 (0.05)		
Week 4 Adjusted Mean Change (SE)	-0.28 (0.05)	-0.27 (0.06)		
Week 8 Adjusted Mean Change (SE)	-0.35 (0.05)	-0.34 (0.06)		
Week 12 Adjusted Mean Change (SE)	-0.48 (0.06)	-0.40 (0.07)		
Week 16 Adjusted Mean Change (SE)	-0.45 (0.06)	-0.41 (0.07)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.06)	-0.43 (0.07)		
Week 24 Adjusted Mean Change (SE)	-0.49 (0.06)	-0.45 (0.07)		
Week 28 Adjusted Mean Change (SE)	-0.52 (0.06)	-0.44 (0.07)		
Week 32 Adjusted Mean Change (SE)	-0.55 (0.06)	-0.46 (0.07)		
Week 36 Adjusted Mean Change (SE)	-0.54 (0.06)	-0.54 (0.07)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 40 Adjusted Mean Change (SE)	-0.54 (0.06)	-0.54 (0.07)		
Week 44 Adjusted Mean Change (SE)	-0.60 (0.06)	-0.64 (0.08)		
Week 48 Adjusted Mean Change (SE)	-0.61 (0.06)	-0.62 (0.07)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.06)	-0.58 (0.07)	-0.03 [-0.22; 0.16]	0.768
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 6.6 HAQ-DI - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.082</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	1.23 (0.56)	1.26 (0.71)		
Week 52 Mean (SD)	0.58 (0.58)	0.68 (0.58)		
Week 2 Adjusted Mean Change (SE)	-0.24 (0.04)	-0.24 (0.05)		
Week 4 Adjusted Mean Change (SE)	-0.39 (0.05)	-0.29 (0.06)		
Week 8 Adjusted Mean Change (SE)	-0.44 (0.05)	-0.38 (0.06)		
Week 12 Adjusted Mean Change (SE)	-0.53 (0.06)	-0.43 (0.07)		
Week 16 Adjusted Mean Change (SE)	-0.53 (0.06)	-0.40 (0.07)		
Week 20 Adjusted Mean Change (SE)	-0.55 (0.06)	-0.46 (0.07)		
Week 24 Adjusted Mean Change (SE)	-0.56 (0.06)	-0.43 (0.07)		
Week 28 Adjusted Mean Change (SE)	-0.63 (0.06)	-0.46 (0.07)		
Week 32 Adjusted Mean Change (SE)	-0.64 (0.06)	-0.42 (0.07)		
Week 36 Adjusted Mean Change (SE)	-0.63 (0.06)	-0.48 (0.07)		
Week 40 Adjusted Mean Change (SE)	-0.65 (0.06)	-0.46 (0.07)		
Week 44 Adjusted Mean Change (SE)	-0.69 (0.06)	-0.48 (0.08)		
Week 48 Adjusted Mean Change (SE)	-0.70 (0.06)	-0.51 (0.07)		
Week 52 Adjusted Mean Change (SE)	-0.67 (0.06)	-0.45 (0.08)	-0.22 [-0.41; -0.03]	0.027
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	1.32 (0.74)	1.38 (0.66)		
Week 52 Mean (SD)	0.82 (0.65)	0.71 (0.60)		
Week 2 Adjusted Mean Change (SE)	-0.12 (0.06)	-0.19 (0.05)		
Week 4 Adjusted Mean Change (SE)	-0.22 (0.07)	-0.26 (0.06)		
Week 8 Adjusted Mean Change (SE)	-0.33 (0.07)	-0.27 (0.06)		
Week 12 Adjusted Mean Change (SE)	-0.39 (0.08)	-0.33 (0.07)		
Week 16 Adjusted Mean Change (SE)	-0.36 (0.08)	-0.41 (0.07)		
Week 20 Adjusted Mean Change (SE)	-0.37 (0.08)	-0.38 (0.07)		
Week 24 Adjusted Mean Change (SE)	-0.41 (0.08)	-0.44 (0.07)		
Week 28 Adjusted Mean Change (SE)	-0.42 (0.08)	-0.44 (0.07)		
Week 32 Adjusted Mean Change (SE)	-0.42 (0.08)	-0.48 (0.07)		
Week 36 Adjusted Mean Change (SE)	-0.48 (0.08)	-0.51 (0.07)		
Week 40 Adjusted Mean Change (SE)	-0.41 (0.08)	-0.54 (0.07)		
Week 44 Adjusted Mean Change (SE)	-0.43 (0.08)	-0.64 (0.07)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.45 (0.08)	-0.62 (0.07)		
Week 52 Adjusted Mean Change (SE)	-0.48 (0.08)	-0.64 (0.07)	0.16 [-0.05; 0.38]	0.142
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 6.7 HAQ-DI - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.636</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	1.20 (0.68)	1.26 (0.75)		
Week 52 Mean (SD)	0.57 (0.59)	0.63 (0.59)		
Week 2 Adjusted Mean Change (SE)	-0.21 (0.05)	-0.29 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.35 (0.06)	-0.36 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.37 (0.06)	-0.44 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.53 (0.07)	-0.51 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.47 (0.07)	-0.53 (0.09)		
Week 20 Adjusted Mean Change (SE)	-0.52 (0.07)	-0.53 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.53 (0.07)	-0.47 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.58 (0.07)	-0.52 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.60 (0.07)	-0.47 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.61 (0.07)	-0.55 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.59 (0.07)	-0.54 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.62 (0.07)	-0.55 (0.09)		
Week 48 Adjusted Mean Change (SE)	-0.64 (0.07)	-0.58 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.65 (0.07)	-0.60 (0.09)	-0.05 [-0.28; 0.18]	0.655
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	1.31 (0.57)	1.35 (0.66)		
Week 52 Mean (SD)	0.73 (0.62)	0.73 (0.59)		
Week 2 Adjusted Mean Change (SE)	-0.19 (0.05)	-0.18 (0.04)		
Week 4 Adjusted Mean Change (SE)	-0.32 (0.05)	-0.24 (0.05)		
Week 8 Adjusted Mean Change (SE)	-0.43 (0.06)	-0.27 (0.05)		
Week 12 Adjusted Mean Change (SE)	-0.44 (0.06)	-0.32 (0.06)		
Week 16 Adjusted Mean Change (SE)	-0.48 (0.06)	-0.35 (0.06)		
Week 20 Adjusted Mean Change (SE)	-0.46 (0.06)	-0.37 (0.06)		
Week 24 Adjusted Mean Change (SE)	-0.49 (0.07)	-0.42 (0.06)		
Week 28 Adjusted Mean Change (SE)	-0.55 (0.07)	-0.42 (0.06)		
Week 32 Adjusted Mean Change (SE)	-0.54 (0.07)	-0.44 (0.06)		
Week 36 Adjusted Mean Change (SE)	-0.56 (0.06)	-0.47 (0.06)		
Week 40 Adjusted Mean Change (SE)	-0.55 (0.06)	-0.49 (0.06)		
Week 44 Adjusted Mean Change (SE)	-0.59 (0.07)	-0.57 (0.07)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.59 (0.07)	-0.57 (0.06)		
Week 52 Adjusted Mean Change (SE)	-0.56 (0.07)	-0.54 (0.06)	-0.02 [-0.21; 0.16]	0.794
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 6.8 HAQ-DI - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.746</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	1.36 (0.62)	1.21 (0.70)		
Week 52 Mean (SD)	0.74 (0.65)	0.65 (0.56)		
Week 2 Adjusted Mean Change (SE)	-0.22 (0.05)	-0.25 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.33 (0.06)	-0.40 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.41 (0.06)	-0.41 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.47 (0.07)	-0.47 (0.08)		
Week 16 Adjusted Mean Change (SE)	-0.49 (0.07)	-0.46 (0.08)		
Week 20 Adjusted Mean Change (SE)	-0.55 (0.07)	-0.51 (0.08)		
Week 24 Adjusted Mean Change (SE)	-0.56 (0.07)	-0.53 (0.08)		
Week 28 Adjusted Mean Change (SE)	-0.59 (0.07)	-0.51 (0.08)		
Week 32 Adjusted Mean Change (SE)	-0.58 (0.07)	-0.48 (0.08)		
Week 36 Adjusted Mean Change (SE)	-0.63 (0.07)	-0.57 (0.08)		
Week 40 Adjusted Mean Change (SE)	-0.61 (0.07)	-0.55 (0.08)		
Week 44 Adjusted Mean Change (SE)	-0.61 (0.07)	-0.64 (0.08)		
Week 48 Adjusted Mean Change (SE)	-0.61 (0.07)	-0.58 (0.08)		
Week 52 Adjusted Mean Change (SE)	-0.57 (0.07)	-0.63 (0.08)	0.05 [-0.16; 0.26]	0.627
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	1.16 (0.59)	1.38 (0.76)		
Week 52 Mean (SD)	0.58 (0.51)	0.69 (0.64)		
Week 2 Adjusted Mean Change (SE)	-0.16 (0.06)	-0.20 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.33 (0.07)	-0.27 (0.09)		
Week 8 Adjusted Mean Change (SE)	-0.34 (0.07)	-0.23 (0.09)		
Week 12 Adjusted Mean Change (SE)	-0.53 (0.09)	-0.32 (0.10)		
Week 16 Adjusted Mean Change (SE)	-0.43 (0.08)	-0.40 (0.10)		
Week 20 Adjusted Mean Change (SE)	-0.41 (0.08)	-0.42 (0.10)		
Week 24 Adjusted Mean Change (SE)	-0.41 (0.09)	-0.39 (0.10)		
Week 28 Adjusted Mean Change (SE)	-0.51 (0.09)	-0.46 (0.10)		
Week 32 Adjusted Mean Change (SE)	-0.54 (0.09)	-0.47 (0.10)		
Week 36 Adjusted Mean Change (SE)	-0.49 (0.09)	-0.51 (0.10)		
Week 40 Adjusted Mean Change (SE)	-0.52 (0.08)	-0.45 (0.10)		
Week 44 Adjusted Mean Change (SE)	-0.60 (0.09)	-0.49 (0.11)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.65 (0.09)	-0.50 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.61 (0.09)	-0.49 (0.10)	-0.12 [-0.38; 0.15]	0.394
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 6.9 HAQ-DI - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.827</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	1.25 (0.63)	1.29 (0.72)		
Week 52 Mean (SD)	0.68 (0.62)	0.70 (0.51)		
Week 2 Adjusted Mean Change (SE)	-0.19 (0.06)	-0.12 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.31 (0.07)	-0.21 (0.08)		
Week 8 Adjusted Mean Change (SE)	-0.38 (0.07)	-0.26 (0.09)		
Week 12 Adjusted Mean Change (SE)	-0.51 (0.08)	-0.40 (0.10)		
Week 16 Adjusted Mean Change (SE)	-0.48 (0.07)	-0.37 (0.10)		
Week 20 Adjusted Mean Change (SE)	-0.52 (0.07)	-0.42 (0.10)		
Week 24 Adjusted Mean Change (SE)	-0.48 (0.08)	-0.44 (0.10)		
Week 28 Adjusted Mean Change (SE)	-0.51 (0.08)	-0.48 (0.10)		
Week 32 Adjusted Mean Change (SE)	-0.53 (0.08)	-0.46 (0.11)		
Week 36 Adjusted Mean Change (SE)	-0.51 (0.08)	-0.50 (0.10)		
Week 40 Adjusted Mean Change (SE)	-0.55 (0.08)	-0.49 (0.10)		
Week 44 Adjusted Mean Change (SE)	-0.61 (0.08)	-0.60 (0.11)		
Week 48 Adjusted Mean Change (SE)	-0.63 (0.08)	-0.50 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.57 (0.08)	-0.55 (0.11)	-0.02 [-0.28; 0.24]	0.880
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	1.31 (0.59)	1.27 (0.72)		
Week 52 Mean (SD)	0.66 (0.59)	0.63 (0.64)		
Week 2 Adjusted Mean Change (SE)	-0.21 (0.06)	-0.31 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.36 (0.07)	-0.44 (0.08)		
Week 8 Adjusted Mean Change (SE)	-0.40 (0.07)	-0.37 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.08)	-0.39 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.47 (0.08)	-0.51 (0.09)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.08)	-0.54 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.54 (0.08)	-0.49 (0.10)		
Week 28 Adjusted Mean Change (SE)	-0.63 (0.08)	-0.48 (0.10)		
Week 32 Adjusted Mean Change (SE)	-0.62 (0.09)	-0.46 (0.10)		
Week 36 Adjusted Mean Change (SE)	-0.66 (0.08)	-0.57 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.63 (0.08)	-0.52 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.63 (0.09)	-0.60 (0.10)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.64 (0.08)	-0.58 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.62 (0.09)	-0.62 (0.10)	0.00 [-0.25; 0.26]	0.981
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 6.10 HAQ-DI - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.521</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	1.38 (0.60)	1.28 (0.81)		
Week 52 Mean (SD)	0.73 (0.64)	0.64 (0.62)		
Week 2 Adjusted Mean Change (SE)	-0.23 (0.07)	-0.18 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.34 (0.08)	-0.26 (0.08)		
Week 8 Adjusted Mean Change (SE)	-0.39 (0.08)	-0.34 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.09)	-0.44 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.46 (0.09)	-0.39 (0.09)		
Week 20 Adjusted Mean Change (SE)	-0.48 (0.09)	-0.41 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.09)	-0.41 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.61 (0.09)	-0.41 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.57 (0.09)	-0.39 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.59 (0.09)	-0.53 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.57 (0.09)	-0.45 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.58 (0.10)	-0.56 (0.10)		
Week 48 Adjusted Mean Change (SE)	-0.59 (0.09)	-0.54 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.59 (0.09)	-0.56 (0.09)	-0.03 [-0.29; 0.23]	0.817
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	1.26 (0.59)	1.26 (0.65)		
Week 52 Mean (SD)	0.67 (0.58)	0.69 (0.57)		
Week 2 Adjusted Mean Change (SE)	-0.16 (0.05)	-0.28 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.32 (0.06)	-0.44 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.37 (0.06)	-0.35 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.51 (0.07)	-0.40 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.47 (0.07)	-0.48 (0.08)		
Week 20 Adjusted Mean Change (SE)	-0.50 (0.07)	-0.54 (0.08)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.07)	-0.55 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.55 (0.07)	-0.57 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.57 (0.07)	-0.56 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.57 (0.07)	-0.58 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.59 (0.07)	-0.58 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.63 (0.07)	-0.62 (0.09)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.65 (0.07)	-0.57 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.59 (0.07)	-0.60 (0.09)	0.02 [-0.21; 0.24]	0.893
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 6.11 HAQ-DI - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.753</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	1.30 (0.61)	1.24 (0.70)		
Week 52 Mean (SD)	0.69 (0.64)	0.73 (0.60)		
Week 2 Adjusted Mean Change (SE)	-0.18 (0.06)	-0.23 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.36 (0.07)	-0.38 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.44 (0.07)	-0.38 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.54 (0.08)	-0.44 (0.08)		
Week 16 Adjusted Mean Change (SE)	-0.51 (0.07)	-0.42 (0.07)		
Week 20 Adjusted Mean Change (SE)	-0.56 (0.07)	-0.52 (0.07)		
Week 24 Adjusted Mean Change (SE)	-0.53 (0.08)	-0.48 (0.08)		
Week 28 Adjusted Mean Change (SE)	-0.58 (0.08)	-0.47 (0.08)		
Week 32 Adjusted Mean Change (SE)	-0.61 (0.08)	-0.47 (0.08)		
Week 36 Adjusted Mean Change (SE)	-0.58 (0.08)	-0.56 (0.08)		
Week 40 Adjusted Mean Change (SE)	-0.59 (0.08)	-0.51 (0.08)		
Week 44 Adjusted Mean Change (SE)	-0.65 (0.08)	-0.57 (0.08)		
Week 48 Adjusted Mean Change (SE)	-0.67 (0.08)	-0.53 (0.08)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.08)	-0.58 (0.08)	-0.02 [-0.24; 0.20]	0.851
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	1.25 (0.62)	1.32 (0.78)		
Week 52 Mean (SD)	0.67 (0.57)	0.55 (0.55)		
Week 2 Adjusted Mean Change (SE)	-0.21 (0.06)	-0.22 (0.08)		
Week 4 Adjusted Mean Change (SE)	-0.30 (0.07)	-0.29 (0.09)		
Week 8 Adjusted Mean Change (SE)	-0.32 (0.07)	-0.26 (0.09)		
Week 12 Adjusted Mean Change (SE)	-0.45 (0.08)	-0.37 (0.10)		
Week 16 Adjusted Mean Change (SE)	-0.42 (0.07)	-0.46 (0.10)		
Week 20 Adjusted Mean Change (SE)	-0.43 (0.07)	-0.39 (0.10)		
Week 24 Adjusted Mean Change (SE)	-0.46 (0.08)	-0.47 (0.11)		
Week 28 Adjusted Mean Change (SE)	-0.54 (0.08)	-0.53 (0.11)		
Week 32 Adjusted Mean Change (SE)	-0.52 (0.08)	-0.49 (0.11)		
Week 36 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.51 (0.11)		
Week 40 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.51 (0.10)		
Week 44 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.60 (0.11)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.57 (0.08)	-0.57 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.57 (0.08)	-0.56 (0.11)	-0.01 [-0.27; 0.26]	0.951
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 6.12 HAQ-DI - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.395</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	1.29 (0.60)	1.25 (0.75)		
Week 52 Mean (SD)	0.71 (0.60)	0.65 (0.55)		
Week 2 Adjusted Mean Change (SE)	-0.22 (0.04)	-0.22 (0.05)		
Week 4 Adjusted Mean Change (SE)	-0.31 (0.05)	-0.30 (0.06)		
Week 8 Adjusted Mean Change (SE)	-0.36 (0.05)	-0.31 (0.06)		
Week 12 Adjusted Mean Change (SE)	-0.47 (0.06)	-0.39 (0.07)		
Week 16 Adjusted Mean Change (SE)	-0.45 (0.06)	-0.41 (0.07)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.06)	-0.43 (0.07)		
Week 24 Adjusted Mean Change (SE)	-0.51 (0.06)	-0.46 (0.07)		
Week 28 Adjusted Mean Change (SE)	-0.52 (0.06)	-0.47 (0.07)		
Week 32 Adjusted Mean Change (SE)	-0.56 (0.06)	-0.48 (0.07)		
Week 36 Adjusted Mean Change (SE)	-0.56 (0.06)	-0.55 (0.07)		
Week 40 Adjusted Mean Change (SE)	-0.58 (0.06)	-0.51 (0.07)		
Week 44 Adjusted Mean Change (SE)	-0.57 (0.07)	-0.59 (0.08)		
Week 48 Adjusted Mean Change (SE)	-0.60 (0.06)	-0.52 (0.07)		
Week 52 Adjusted Mean Change (SE)	-0.56 (0.06)	-0.57 (0.08)	0.01 [-0.19; 0.20]	0.940
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	1.21 (0.67)	1.24 (0.67)		
Week 52 Mean (SD)	0.56 (0.64)	0.56 (0.53)		
Week 2 Adjusted Mean Change (SE)	-0.11 (0.08)	-0.30 (0.08)		
Week 4 Adjusted Mean Change (SE)	-0.31 (0.09)	-0.55 (0.09)		
Week 8 Adjusted Mean Change (SE)	-0.35 (0.10)	-0.46 (0.10)		
Week 12 Adjusted Mean Change (SE)	-0.45 (0.11)	-0.60 (0.11)		
Week 16 Adjusted Mean Change (SE)	-0.50 (0.11)	-0.51 (0.11)		
Week 20 Adjusted Mean Change (SE)	-0.51 (0.11)	-0.64 (0.11)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.11)	-0.61 (0.11)		
Week 28 Adjusted Mean Change (SE)	-0.63 (0.11)	-0.65 (0.11)		
Week 32 Adjusted Mean Change (SE)	-0.54 (0.11)	-0.57 (0.12)		
Week 36 Adjusted Mean Change (SE)	-0.61 (0.11)	-0.64 (0.11)		
Week 40 Adjusted Mean Change (SE)	-0.54 (0.11)	-0.62 (0.11)		
Week 44 Adjusted Mean Change (SE)	-0.61 (0.12)	-0.65 (0.12)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.59 (0.11)	-0.69 (0.12)		
Week 52 Adjusted Mean Change (SE)	-0.63 (0.11)	-0.66 (0.12)	0.03 [-0.29; 0.36]	0.848
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 6.13 HAQ-DI - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.240</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	1.26 (0.59)	1.21 (0.78)		
Week 52 Mean (SD)	0.70 (0.62)	0.59 (0.56)		
Week 2 Adjusted Mean Change (SE)	-0.17 (0.05)	-0.24 (0.05)		
Week 4 Adjusted Mean Change (SE)	-0.27 (0.05)	-0.42 (0.06)		
Week 8 Adjusted Mean Change (SE)	-0.38 (0.05)	-0.41 (0.06)		
Week 12 Adjusted Mean Change (SE)	-0.48 (0.06)	-0.49 (0.07)		
Week 16 Adjusted Mean Change (SE)	-0.43 (0.06)	-0.49 (0.07)		
Week 20 Adjusted Mean Change (SE)	-0.48 (0.06)	-0.51 (0.07)		
Week 24 Adjusted Mean Change (SE)	-0.47 (0.06)	-0.49 (0.07)		
Week 28 Adjusted Mean Change (SE)	-0.50 (0.06)	-0.52 (0.07)		
Week 32 Adjusted Mean Change (SE)	-0.51 (0.06)	-0.54 (0.07)		
Week 36 Adjusted Mean Change (SE)	-0.52 (0.06)	-0.62 (0.07)		
Week 40 Adjusted Mean Change (SE)	-0.53 (0.06)	-0.55 (0.07)		
Week 44 Adjusted Mean Change (SE)	-0.55 (0.07)	-0.63 (0.07)		
Week 48 Adjusted Mean Change (SE)	-0.60 (0.06)	-0.59 (0.07)		
Week 52 Adjusted Mean Change (SE)	-0.57 (0.06)	-0.61 (0.07)	0.03 [-0.16; 0.23]	0.729
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	1.22 (0.64)	1.53 (0.46)		
Week 52 Mean (SD)	0.62 (0.54)	0.84 (0.65)		
Week 2 Adjusted Mean Change (SE)	-0.23 (0.09)	-0.21 (0.11)		
Week 4 Adjusted Mean Change (SE)	-0.45 (0.09)	-0.14 (0.12)		
Week 8 Adjusted Mean Change (SE)	-0.32 (0.10)	-0.09 (0.12)		
Week 12 Adjusted Mean Change (SE)	-0.46 (0.11)	-0.21 (0.14)		
Week 16 Adjusted Mean Change (SE)	-0.48 (0.11)	-0.37 (0.14)		
Week 20 Adjusted Mean Change (SE)	-0.42 (0.11)	-0.37 (0.14)		
Week 24 Adjusted Mean Change (SE)	-0.49 (0.11)	-0.49 (0.15)		
Week 28 Adjusted Mean Change (SE)	-0.63 (0.11)	-0.44 (0.15)		
Week 32 Adjusted Mean Change (SE)	-0.62 (0.11)	-0.39 (0.15)		
Week 36 Adjusted Mean Change (SE)	-0.63 (0.11)	-0.39 (0.14)		
Week 40 Adjusted Mean Change (SE)	-0.61 (0.11)	-0.48 (0.14)		
Week 44 Adjusted Mean Change (SE)	-0.71 (0.12)	-0.50 (0.15)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.62 (0.11)	-0.43 (0.14)		
Week 52 Adjusted Mean Change (SE)	-0.54 (0.12)	-0.54 (0.15)	-0.00 [-0.37; 0.37]	0.984
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 6.14 HAQ-DI - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.823</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	1.27 (0.62)	1.32 (0.74)		
Week 52 Mean (SD)	0.66 (0.59)	0.67 (0.61)		
Week 2 Adjusted Mean Change (SE)	-0.19 (0.04)	-0.23 (0.05)		
Week 4 Adjusted Mean Change (SE)	-0.34 (0.05)	-0.35 (0.06)		
Week 8 Adjusted Mean Change (SE)	-0.40 (0.05)	-0.31 (0.06)		
Week 12 Adjusted Mean Change (SE)	-0.48 (0.06)	-0.42 (0.07)		
Week 16 Adjusted Mean Change (SE)	-0.46 (0.06)	-0.43 (0.07)		
Week 20 Adjusted Mean Change (SE)	-0.48 (0.06)	-0.48 (0.07)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.06)	-0.50 (0.07)		
Week 28 Adjusted Mean Change (SE)	-0.56 (0.06)	-0.49 (0.07)		
Week 32 Adjusted Mean Change (SE)	-0.57 (0.06)	-0.48 (0.07)		
Week 36 Adjusted Mean Change (SE)	-0.57 (0.06)	-0.55 (0.07)		
Week 40 Adjusted Mean Change (SE)	-0.58 (0.06)	-0.51 (0.07)		
Week 44 Adjusted Mean Change (SE)	-0.60 (0.06)	-0.59 (0.07)		
Week 48 Adjusted Mean Change (SE)	-0.63 (0.06)	-0.55 (0.07)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.06)	-0.59 (0.07)	-0.01 [-0.20; 0.17]	0.903
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	1.30 (0.60)	1.05 (0.68)		
Week 52 Mean (SD)	0.81 (0.70)	0.73 (0.46)		
Week 2 Adjusted Mean Change (SE)	-0.17 (0.10)	-0.19 (0.12)		
Week 4 Adjusted Mean Change (SE)	-0.28 (0.12)	-0.29 (0.14)		
Week 8 Adjusted Mean Change (SE)	-0.26 (0.12)	-0.33 (0.14)		
Week 12 Adjusted Mean Change (SE)	-0.51 (0.14)	-0.27 (0.16)		
Week 16 Adjusted Mean Change (SE)	-0.47 (0.13)	-0.36 (0.15)		
Week 20 Adjusted Mean Change (SE)	-0.53 (0.13)	-0.40 (0.15)		
Week 24 Adjusted Mean Change (SE)	-0.45 (0.14)	-0.31 (0.16)		
Week 28 Adjusted Mean Change (SE)	-0.54 (0.14)	-0.43 (0.16)		
Week 32 Adjusted Mean Change (SE)	-0.51 (0.14)	-0.38 (0.16)		
Week 36 Adjusted Mean Change (SE)	-0.57 (0.14)	-0.45 (0.16)		
Week 40 Adjusted Mean Change (SE)	-0.54 (0.14)	-0.46 (0.16)		
Week 44 Adjusted Mean Change (SE)	-0.59 (0.15)	-0.54 (0.17)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.54 (0.14)	-0.49 (0.16)		
Week 52 Adjusted Mean Change (SE)	-0.46 (0.14)	-0.45 (0.16)	-0.01 [-0.43; 0.41]	0.962
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 6.15 HAQ-DI - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.544</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	1.25 (0.78)	1.30 (0.84)		
Week 52 Mean (SD)	0.68 (0.72)	0.78 (0.64)		
Week 2 Adjusted Mean Change (SE)	-0.25 (0.08)	-0.13 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.31 (0.09)	-0.24 (0.08)		
Week 8 Adjusted Mean Change (SE)	-0.39 (0.09)	-0.34 (0.09)		
Week 12 Adjusted Mean Change (SE)	-0.51 (0.11)	-0.44 (0.10)		
Week 16 Adjusted Mean Change (SE)	-0.44 (0.10)	-0.33 (0.10)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.10)	-0.40 (0.10)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.11)	-0.39 (0.10)		
Week 28 Adjusted Mean Change (SE)	-0.51 (0.11)	-0.39 (0.10)		
Week 32 Adjusted Mean Change (SE)	-0.54 (0.11)	-0.42 (0.10)		
Week 36 Adjusted Mean Change (SE)	-0.54 (0.11)	-0.53 (0.10)		
Week 40 Adjusted Mean Change (SE)	-0.55 (0.11)	-0.41 (0.10)		
Week 44 Adjusted Mean Change (SE)	-0.52 (0.11)	-0.49 (0.11)		
Week 48 Adjusted Mean Change (SE)	-0.56 (0.11)	-0.43 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.57 (0.11)	-0.51 (0.11)	-0.05 [-0.35; 0.25]	0.735
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	1.29 (0.55)	1.25 (0.66)		
Week 52 Mean (SD)	0.68 (0.57)	0.61 (0.56)		
Week 2 Adjusted Mean Change (SE)	-0.17 (0.05)	-0.29 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.34 (0.05)	-0.42 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.38 (0.06)	-0.34 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.06)	-0.40 (0.08)		
Week 16 Adjusted Mean Change (SE)	-0.48 (0.06)	-0.50 (0.08)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.06)	-0.52 (0.08)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.06)	-0.53 (0.08)		
Week 28 Adjusted Mean Change (SE)	-0.58 (0.06)	-0.55 (0.08)		
Week 32 Adjusted Mean Change (SE)	-0.57 (0.06)	-0.51 (0.08)		
Week 36 Adjusted Mean Change (SE)	-0.58 (0.06)	-0.56 (0.08)		
Week 40 Adjusted Mean Change (SE)	-0.58 (0.06)	-0.57 (0.08)		
Week 44 Adjusted Mean Change (SE)	-0.63 (0.07)	-0.64 (0.08)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.64 (0.06)	-0.61 (0.08)		
Week 52 Adjusted Mean Change (SE)	-0.59 (0.06)	-0.62 (0.08)	0.02 [-0.18; 0.22]	0.825
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 6.16 HAQ-DI - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.964</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	1.23 (0.61)	1.29 (0.74)		
Week 52 Mean (SD)	0.68 (0.61)	0.69 (0.52)		
Week 2 Adjusted Mean Change (SE)	-0.19 (0.05)	-0.16 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.32 (0.06)	-0.28 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.37 (0.06)	-0.32 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.07)	-0.43 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.47 (0.07)	-0.39 (0.08)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.07)	-0.43 (0.08)		
Week 24 Adjusted Mean Change (SE)	-0.48 (0.07)	-0.47 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.52 (0.07)	-0.49 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.53 (0.07)	-0.48 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.52 (0.07)	-0.52 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.54 (0.07)	-0.51 (0.08)		
Week 44 Adjusted Mean Change (SE)	-0.60 (0.07)	-0.60 (0.09)		
Week 48 Adjusted Mean Change (SE)	-0.61 (0.07)	-0.54 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.56 (0.07)	-0.55 (0.09)	-0.01 [-0.23; 0.22]	0.953
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	1.35 (0.61)	1.25 (0.72)		
Week 52 Mean (SD)	0.67 (0.60)	0.65 (0.65)		
Week 2 Adjusted Mean Change (SE)	-0.20 (0.06)	-0.31 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.35 (0.07)	-0.43 (0.08)		
Week 8 Adjusted Mean Change (SE)	-0.40 (0.08)	-0.37 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.09)	-0.40 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.47 (0.08)	-0.49 (0.09)		
Week 20 Adjusted Mean Change (SE)	-0.50 (0.08)	-0.52 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.53 (0.09)	-0.49 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.63 (0.09)	-0.49 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.61 (0.09)	-0.47 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.65 (0.09)	-0.57 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.62 (0.08)	-0.51 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.62 (0.09)	-0.57 (0.09)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.63 (0.09)	-0.55 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.63 (0.09)	-0.60 (0.09)	-0.03 [-0.28; 0.22]	0.819
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 6.17 HAQ-DI - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.856</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	1.38 (0.60)	1.33 (0.80)		
Week 52 Mean (SD)	0.73 (0.64)	0.60 (0.64)		
Week 2 Adjusted Mean Change (SE)	-0.23 (0.07)	-0.27 (0.07)		
Week 4 Adjusted Mean Change (SE)	-0.34 (0.08)	-0.33 (0.08)		
Week 8 Adjusted Mean Change (SE)	-0.39 (0.08)	-0.41 (0.08)		
Week 12 Adjusted Mean Change (SE)	-0.48 (0.09)	-0.49 (0.09)		
Week 16 Adjusted Mean Change (SE)	-0.46 (0.09)	-0.45 (0.09)		
Week 20 Adjusted Mean Change (SE)	-0.48 (0.09)	-0.49 (0.09)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.09)	-0.48 (0.09)		
Week 28 Adjusted Mean Change (SE)	-0.60 (0.09)	-0.46 (0.09)		
Week 32 Adjusted Mean Change (SE)	-0.57 (0.09)	-0.43 (0.10)		
Week 36 Adjusted Mean Change (SE)	-0.59 (0.09)	-0.57 (0.09)		
Week 40 Adjusted Mean Change (SE)	-0.56 (0.09)	-0.48 (0.09)		
Week 44 Adjusted Mean Change (SE)	-0.58 (0.10)	-0.59 (0.10)		
Week 48 Adjusted Mean Change (SE)	-0.58 (0.09)	-0.58 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.59 (0.09)	-0.60 (0.10)	0.01 [-0.25; 0.27]	0.939
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	1.22 (0.62)	1.23 (0.66)		
Week 52 Mean (SD)	0.65 (0.58)	0.71 (0.56)		
Week 2 Adjusted Mean Change (SE)	-0.17 (0.05)	-0.20 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.33 (0.06)	-0.37 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.37 (0.06)	-0.29 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.50 (0.07)	-0.35 (0.08)		
Week 16 Adjusted Mean Change (SE)	-0.47 (0.07)	-0.42 (0.08)		
Week 20 Adjusted Mean Change (SE)	-0.50 (0.07)	-0.46 (0.08)		
Week 24 Adjusted Mean Change (SE)	-0.50 (0.07)	-0.47 (0.08)		
Week 28 Adjusted Mean Change (SE)	-0.54 (0.07)	-0.50 (0.08)		
Week 32 Adjusted Mean Change (SE)	-0.56 (0.07)	-0.51 (0.09)		
Week 36 Adjusted Mean Change (SE)	-0.56 (0.07)	-0.53 (0.08)		
Week 40 Adjusted Mean Change (SE)	-0.58 (0.07)	-0.53 (0.08)		
Week 44 Adjusted Mean Change (SE)	-0.62 (0.07)	-0.57 (0.09)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.64 (0.07)	-0.52 (0.08)		
Week 52 Adjusted Mean Change (SE)	-0.59 (0.07)	-0.56 (0.08)	-0.03 [-0.24; 0.19]	0.793
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 6.18 HAQ-DI - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.753</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	1.30 (0.61)	1.24 (0.70)		
Week 52 Mean (SD)	0.69 (0.64)	0.73 (0.60)		
Week 2 Adjusted Mean Change (SE)	-0.18 (0.06)	-0.23 (0.06)		
Week 4 Adjusted Mean Change (SE)	-0.36 (0.07)	-0.38 (0.07)		
Week 8 Adjusted Mean Change (SE)	-0.44 (0.07)	-0.38 (0.07)		
Week 12 Adjusted Mean Change (SE)	-0.54 (0.08)	-0.44 (0.08)		
Week 16 Adjusted Mean Change (SE)	-0.51 (0.07)	-0.42 (0.07)		
Week 20 Adjusted Mean Change (SE)	-0.56 (0.07)	-0.52 (0.07)		
Week 24 Adjusted Mean Change (SE)	-0.53 (0.08)	-0.48 (0.08)		
Week 28 Adjusted Mean Change (SE)	-0.58 (0.08)	-0.47 (0.08)		
Week 32 Adjusted Mean Change (SE)	-0.61 (0.08)	-0.47 (0.08)		
Week 36 Adjusted Mean Change (SE)	-0.58 (0.08)	-0.56 (0.08)		
Week 40 Adjusted Mean Change (SE)	-0.59 (0.08)	-0.51 (0.08)		
Week 44 Adjusted Mean Change (SE)	-0.65 (0.08)	-0.57 (0.08)		
Week 48 Adjusted Mean Change (SE)	-0.67 (0.08)	-0.53 (0.08)		
Week 52 Adjusted Mean Change (SE)	-0.60 (0.08)	-0.58 (0.08)	-0.02 [-0.24; 0.20]	0.851
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	1.25 (0.62)	1.32 (0.78)		
Week 52 Mean (SD)	0.67 (0.57)	0.55 (0.55)		
Week 2 Adjusted Mean Change (SE)	-0.21 (0.06)	-0.22 (0.08)		
Week 4 Adjusted Mean Change (SE)	-0.30 (0.07)	-0.29 (0.09)		
Week 8 Adjusted Mean Change (SE)	-0.32 (0.07)	-0.26 (0.09)		
Week 12 Adjusted Mean Change (SE)	-0.45 (0.08)	-0.37 (0.10)		
Week 16 Adjusted Mean Change (SE)	-0.42 (0.07)	-0.46 (0.10)		
Week 20 Adjusted Mean Change (SE)	-0.43 (0.07)	-0.39 (0.10)		
Week 24 Adjusted Mean Change (SE)	-0.46 (0.08)	-0.47 (0.11)		
Week 28 Adjusted Mean Change (SE)	-0.54 (0.08)	-0.53 (0.11)		
Week 32 Adjusted Mean Change (SE)	-0.52 (0.08)	-0.49 (0.11)		
Week 36 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.51 (0.11)		
Week 40 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.51 (0.10)		
Week 44 Adjusted Mean Change (SE)	-0.56 (0.08)	-0.60 (0.11)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.57 (0.08)	-0.57 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.57 (0.08)	-0.56 (0.11)	-0.01 [-0.27; 0.26]	0.951
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 6.19 HAQ-DI - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.594</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	1.27 (0.61)	1.28 (0.75)		
Week 52 Mean (SD)	0.70 (0.60)	0.69 (0.57)		
Week 2 Adjusted Mean Change (SE)	-0.20 (0.04)	-0.21 (0.05)		
Week 4 Adjusted Mean Change (SE)	-0.31 (0.05)	-0.30 (0.06)		
Week 8 Adjusted Mean Change (SE)	-0.37 (0.05)	-0.31 (0.06)		
Week 12 Adjusted Mean Change (SE)	-0.49 (0.06)	-0.38 (0.07)		
Week 16 Adjusted Mean Change (SE)	-0.44 (0.06)	-0.41 (0.07)		
Week 20 Adjusted Mean Change (SE)	-0.49 (0.06)	-0.42 (0.07)		
Week 24 Adjusted Mean Change (SE)	-0.49 (0.06)	-0.44 (0.07)		
Week 28 Adjusted Mean Change (SE)	-0.52 (0.06)	-0.44 (0.07)		
Week 32 Adjusted Mean Change (SE)	-0.55 (0.06)	-0.45 (0.07)		
Week 36 Adjusted Mean Change (SE)	-0.54 (0.06)	-0.53 (0.07)		
Week 40 Adjusted Mean Change (SE)	-0.57 (0.06)	-0.48 (0.07)		
Week 44 Adjusted Mean Change (SE)	-0.58 (0.07)	-0.57 (0.08)		
Week 48 Adjusted Mean Change (SE)	-0.61 (0.06)	-0.50 (0.07)		
Week 52 Adjusted Mean Change (SE)	-0.56 (0.06)	-0.56 (0.08)	-0.00 [-0.20; 0.19]	0.971
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	1.24 (0.65)	1.25 (0.68)		
Week 52 Mean (SD)	0.57 (0.66)	0.63 (0.64)		
Week 2 Adjusted Mean Change (SE)	-0.13 (0.09)	-0.26 (0.09)		
Week 4 Adjusted Mean Change (SE)	-0.33 (0.10)	-0.49 (0.10)		
Week 8 Adjusted Mean Change (SE)	-0.32 (0.10)	-0.42 (0.10)		
Week 12 Adjusted Mean Change (SE)	-0.41 (0.12)	-0.50 (0.12)		
Week 16 Adjusted Mean Change (SE)	-0.51 (0.11)	-0.48 (0.11)		
Week 20 Adjusted Mean Change (SE)	-0.51 (0.12)	-0.59 (0.12)		
Week 24 Adjusted Mean Change (SE)	-0.51 (0.12)	-0.55 (0.12)		
Week 28 Adjusted Mean Change (SE)	-0.66 (0.12)	-0.61 (0.12)		
Week 32 Adjusted Mean Change (SE)	-0.54 (0.12)	-0.54 (0.12)		
Week 36 Adjusted Mean Change (SE)	-0.65 (0.12)	-0.57 (0.12)		
Week 40 Adjusted Mean Change (SE)	-0.56 (0.12)	-0.59 (0.12)		
Week 44 Adjusted Mean Change (SE)	-0.63 (0.12)	-0.62 (0.13)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-0.60 (0.12)	-0.65 (0.12)		
Week 52 Adjusted Mean Change (SE)	-0.64 (0.12)	-0.61 (0.12)	-0.04 [-0.37; 0.30]	0.838
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 7.1 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N' n (%)	104 67.60 (61.45)	80 62.99 (62.37)	0.99 [0.55; 1.76] 0.961	0.99 [0.79; 1.23] 0.896	-0.009 [-0.144; 0.126] 0.894
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR from logistic regression model with predictors treatment and weight.  RR and RD calculated directly without adjustment.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

## 7.2 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.303				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N' n (%)	98 63.67 (61.82)	74 60.99 (64.88)	0.90 [0.49; 1.65] 0.738	0.95 [0.77; 1.19] 0.665	-0.031 [-0.169; 0.108] 0.664
<b><math>\geq 65</math> years (N)</b>	<b>7</b>	<b>7</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N' n (%)	6 3.93 (56.14)	6 2.00 (28.57)	3.08 [0.32; 29.42] 0.329	1.96 [0.51; 7.57] 0.329	0.276 [-0.226; 0.777] 0.281
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.3 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.849				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N' n (%)	63 40.62 (61.55)	46 35.92 (63.02)	1.03 [0.48; 2.20] 0.943	0.98 [0.74; 1.29] 0.870	-0.015 [-0.189; 0.160] 0.869
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N' n (%)	41 26.98 (61.32)	34 27.07 (61.52)	0.92 [0.37; 2.27] 0.849	1.00 [0.71; 1.41] 0.987	-0.002 [-0.214; 0.210] 0.985
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

#### 7.4 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.003				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N' n (%)	23 14.28 (59.50)	16 5.00 (23.81)	5.81 [1.52; 22.23] 0.010	2.50 [1.08; 5.76] 0.032	0.357 [0.087; 0.627] 0.010
<b>PASDAS <math>\geq 5.4</math> (N)</b>	<b>86</b>	<b>80</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N' n (%)	81 53.32 (62.00)	64 57.99 (72.49)	0.61 [0.31; 1.22] 0.160	0.86 [0.69; 1.07] 0.165	-0.105 [-0.251; 0.042] 0.161
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.5 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.742				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N' n (%)	39 27.05 (64.40)	37 31.00 (60.78)	1.10 [0.45; 2.69] 0.828	1.06 [0.76; 1.47] 0.728	0.036 [-0.169; 0.242] 0.730
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N' n (%)	65 40.55 (59.63)	43 31.99 (63.98)	0.90 [0.41; 1.97] 0.799	0.93 [0.70; 1.25] 0.636	-0.043 [-0.223; 0.136] 0.636
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

## 7.6 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.558				
<b><math>\leq</math> Median (N)</b>	<b>72</b>	<b>49</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>1</sup> n (%)	70 43.70 (60.69)	34 28.09 (57.33)	1.20 [0.55; 2.61] 0.653	1.06 [0.77; 1.46] 0.721	0.034 [-0.153; 0.220] 0.723
<b><math>&gt;</math> Median (N)</b>	<b>38</b>	<b>52</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>1</sup> n (%)	34 23.90 (62.89)	46 34.90 (67.12)	0.83 [0.34; 2.07] 0.697	0.94 [0.68; 1.29] 0.689	-0.042 [-0.247; 0.163] 0.687
<p>N<sup>1</sup>: Number of patients with available response value  N-N<sup>1</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					



### 7.7 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.624				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>1</sup> n (%)	48 31.69 (62.14)	25 21.29 (66.53)	0.80 [0.30; 2.09] 0.644	0.93 [0.67; 1.31] 0.691	-0.044 [-0.260; 0.172] 0.690
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>1</sup> n (%)	56 35.91 (60.86)	55 41.70 (60.43)	1.08 [0.51; 2.27] 0.839	1.01 [0.76; 1.34] 0.961	0.004 [-0.170; 0.179] 0.961
<p>N<sup>1</sup>: Number of patients with available response value  N-N<sup>1</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.8 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.473				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N' n (%)	48 34.20 (67.06)	34 26.07 (63.59)	1.20 [0.50; 2.92] 0.681	1.05 [0.78; 1.43] 0.731	0.035 [-0.163; 0.232] 0.730
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N' n (%)	31 18.40 (54.12)	21 16.12 (62.00)	0.72 [0.24; 2.17] 0.555	0.87 [0.56; 1.37] 0.557	-0.079 [-0.340; 0.183] 0.555
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.9 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.658				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>1</sup> n (%)	43 28.47 (63.27)	19 18.88 (69.93)	0.79 [0.27; 2.35] 0.675	0.91 [0.64; 1.28] 0.573	-0.067 [-0.298; 0.165] 0.572
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>1</sup> n (%)	34 23.13 (60.87)	27 17.31 (57.70)	1.11 [0.40; 3.03] 0.842	1.06 [0.70; 1.58] 0.796	0.032 [-0.207; 0.270] 0.795
<p>N<sup>1</sup>: Number of patients with available response value  N-N<sup>1</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.10 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.445				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	29 20.70 (69.00)	24 20.19 (61.18)	1.42 [0.47; 4.25] 0.535	1.13 [0.78; 1.64] 0.528	0.078 [-0.164; 0.320] 0.527
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	48 29.69 (58.22)	31 22.00 (64.71)	0.81 [0.32; 2.03] 0.654	0.90 [0.64; 1.27] 0.544	-0.065 [-0.276; 0.146] 0.547
<p>N<sup>a</sup>: Number of patients with available response value  N-N<sup>a</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.11 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.802				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	39 26.91 (62.58)	37 26.24 (61.02)	1.03 [0.42; 2.53] 0.955	1.03 [0.73; 1.44] 0.884	0.016 [-0.193; 0.224] 0.883
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	40 25.69 (61.17)	18 15.95 (66.46)	0.85 [0.28; 2.60] 0.782	0.92 [0.63; 1.36] 0.679	-0.053 [-0.302; 0.196] 0.677
<p>N<sup>a</sup>: Number of patients with available response value  N-N<sup>a</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.12 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.037				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	57 39.90 (64.35)	36 27.61 (58.74)	1.42 [0.63; 3.23] 0.401	1.10 [0.80; 1.49] 0.563	0.056 [-0.132; 0.244] 0.559
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	19 10.70 (53.50)	17 14.58 (81.00)	0.21 [0.04; 1.03] 0.054	0.66 [0.41; 1.07] 0.089	-0.275 [-0.567; 0.017] 0.065
<p>N<sup>a</sup>: Number of patients with available response value  N-N<sup>a</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.13 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.161				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	58 39.68 (62.98)	40 32.12 (62.98)	0.99 [0.45; 2.20] 0.982	1.00 [0.75; 1.34] 0.999	0.000 [-0.183; 0.183] 1.000
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	18 9.92 (52.21)	12 10.00 (83.33)	0.24 [0.04; 1.47] 0.123	0.63 [0.38; 1.04] 0.068	-0.311 [-0.621; -0.002] 0.049
<p>N<sup>a</sup>: Number of patients with available response value  N-N<sup>a</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.14 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.317				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	65 44.60 (62.82)	44 35.61 (67.19)	0.87 [0.40; 1.90] 0.723	0.93 [0.72; 1.22] 0.620	-0.044 [-0.217; 0.129] 0.621
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	13 7.00 (53.85)	8 3.00 (30.00)	2.31 [0.40; 13.31] 0.348	1.79 [0.61; 5.24] 0.285	0.238 [-0.154; 0.631] 0.234
<p>N<sup>a</sup>: Number of patients with available response value  N-N<sup>a</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) HAQ-DI Response (<math>\geq 0.3</math>), all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					



### 7.15 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.860				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	19 13.91 (63.23)	18 15.54 (59.77)	1.06 [0.31; 3.67] 0.925	1.06 [0.66; 1.69] 0.814	0.035 [-0.252; 0.322] 0.813
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	60 38.69 (61.41)	37 26.65 (65.00)	0.93 [0.40; 2.16] 0.861	0.94 [0.70; 1.28] 0.713	-0.036 [-0.227; 0.156] 0.714
<p>N<sup>a</sup>: Number of patients with available response value  N-N<sup>a</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.16 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.483				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	49 30.47 (59.75)	26 23.88 (68.23)	0.76 [0.29; 1.98] 0.579	0.88 [0.63; 1.22] 0.429	-0.085 [-0.295; 0.125] 0.429
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	30 22.13 (65.09)	29 18.31 (57.22)	1.26 [0.45; 3.52] 0.657	1.14 [0.77; 1.69] 0.522	0.079 [-0.160; 0.317] 0.518
<p>N<sup>a</sup>: Number of patients with available response value  N-N<sup>a</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.17 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.741				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	29 20.70 (69.00)	22 20.19 (65.13)	1.18 [0.38; 3.65] 0.775	1.06 [0.74; 1.53] 0.754	0.039 [-0.205; 0.282] 0.756
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	50 31.90 (58.00)	33 22.00 (61.11)	0.93 [0.38; 2.23] 0.864	0.95 [0.67; 1.34] 0.767	-0.031 [-0.239; 0.176] 0.769
<p>N<sup>a</sup>: Number of patients with available response value  N-N<sup>a</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.18 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.802				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	39 26.91 (62.58)	37 26.24 (61.02)	1.03 [0.42; 2.53] 0.955	1.03 [0.73; 1.44] 0.884	0.016 [-0.193; 0.224] 0.883
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	40 25.69 (61.17)	18 15.95 (66.46)	0.85 [0.28; 2.60] 0.782	0.92 [0.63; 1.36] 0.679	-0.053 [-0.302; 0.196] 0.677
<p>N<sup>a</sup>: Number of patients with available response value  N-N<sup>a</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

### 7.19 HAQ-DI Response ( $\geq 0.3$ ) / HAQ-DI Response ( $\geq 0.35$ ) by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
HAQ-DI Response ( $\geq 0.3$ ) Week 52	p=0.102				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	60 40.90 (62.92)	38 28.61 (58.39)	1.32 [0.60; 2.91] 0.497	1.08 [0.79; 1.47] 0.633	0.045 [-0.140; 0.230] 0.631
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
HAQ-DI Response ( $\geq 0.3$ ) Week 52, N <sup>a</sup> n (%)	17 9.70 (53.89)	17 13.58 (75.44)	0.32 [0.07; 1.42] 0.134	0.71 [0.43; 1.20] 0.201	-0.216 [-0.528; 0.097] 0.176
<p>N<sup>a</sup>: Number of patients with available response value  N-N<sup>a</sup> is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>Note: HAQ-DI Response (<math>\geq 0.3</math>) is identical to HAQ-DI Response (<math>\geq 0.35</math>) as HAQ-DI can take only a limited number of values.</p>					

## 8.0 LDI Leeds Dactylitis Index - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	109 (99.1)	100 (99.0)	209 (99.1)
Week 4 Returns	110 (100.0)	98 (97.0)	208 (98.6)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	107 (97.3)	98 (97.0)	205 (97.2)
Week 16 Returns	109 (99.1)	94 (93.1)	203 (96.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	102 (92.7)	86 (85.1)	188 (89.1)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	85 (84.2)	190 (90.0)

### 8.1 LDI Leeds Dactylitis Index - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	17.64 (49.52)	19.62 (58.36)		
Week 52 Mean (SD)	-0.45 (6.91)	0.21 (1.94)		
Week 52 Adjusted Mean Change (SE)	-19.72 (0.51)	-18.88 (0.56)	-0.85 [-2.34; 0.65]	0.267
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 8.2 LDI Leeds Dactylitis Index - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.902</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	18.14 (50.72)	20.40 (60.13)		
Week 52 Mean (SD)	0.21 (2.08)	0.23 (2.02)		
Week 52 Adjusted Mean Change (SE)	-19.07 (0.49)	-18.85 (0.54)	-0.22 [-1.67; 1.22]	0.761
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	10.39 (27.48)	9.14 (24.19)		
Week 52 Mean (SD)	-11.25 (27.56)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-30.24 (1.97)	-19.35 (1.86)	-10.89 [-16.23; -5.54]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 8.3 LDI Leeds Dactylitis Index - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.925</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	17.74 (54.19)	12.30 (33.52)		
Week 52 Mean (SD)	0.32 (2.59)	0.36 (2.55)		
Week 52 Adjusted Mean Change (SE)	-18.97 (0.66)	-18.88 (0.74)	-0.09 [-2.03; 1.85]	0.924
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	17.50 (42.17)	29.11 (79.34)		
Week 52 Mean (SD)	-1.65 (10.54)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-20.85 (0.81)	-18.86 (0.86)	-1.99 [-4.32; 0.34]	0.094
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.4 LDI Leeds Dactylitis Index - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.595</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	0.85 (4.16)	1.86 (5.88)		
Week 52 Mean (SD)	0.90 (4.32)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-18.49 (1.10)	-18.56 (1.24)	0.07 [-3.18; 3.33]	0.964
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	22.33 (55.12)	24.29 (64.78)		
Week 52 Mean (SD)	-0.82 (7.46)	0.26 (2.17)		
Week 52 Adjusted Mean Change (SE)	-20.07 (0.58)	-18.97 (0.63)	-1.10 [-2.78; 0.59]	0.200
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.5 LDI Leeds Dactylitis Index - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.540</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	8.90 (21.28)	23.81 (60.89)		
Week 52 Mean (SD)	0.53 (3.32)	0.45 (2.82)		
Week 52 Adjusted Mean Change (SE)	-18.83 (0.83)	-18.51 (0.80)	-0.32 [-2.60; 1.97]	0.786
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	23.04 (60.29)	15.35 (55.95)		
Week 52 Mean (SD)	-1.02 (8.31)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-20.26 (0.65)	-19.27 (0.78)	-0.99 [-2.99; 1.01]	0.330
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.6 LDI Leeds Dactylitis Index - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.683</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	20.89 (58.14)	18.71 (55.28)		
Week 52 Mean (SD)	0.30 (2.48)	0.47 (2.90)		
Week 52 Adjusted Mean Change (SE)	-18.97 (0.62)	-18.47 (0.81)	-0.50 [-2.52; 1.52]	0.625
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	11.49 (26.05)	20.49 (61.65)		
Week 52 Mean (SD)	-1.93 (11.41)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-21.19 (0.87)	-19.17 (0.76)	-2.02 [-4.30; 0.27]	0.083
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.7 LDI Leeds Dactylitis Index - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.719</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	9.91 (24.09)	25.31 (71.05)		
Week 52 Mean (SD)	0.42 (2.96)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-18.92 (0.75)	-18.81 (0.98)	-0.11 [-2.55; 2.32]	0.928
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	24.33 (63.33)	16.99 (51.82)		
Week 52 Mean (SD)	-1.21 (9.02)	0.31 (2.37)		
Week 52 Adjusted Mean Change (SE)	-20.42 (0.70)	-18.92 (0.68)	-1.50 [-3.43; 0.43]	0.126
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.8 LDI Leeds Dactylitis Index - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.575</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	14.39 (29.43)	17.31 (59.57)		
Week 52 Mean (SD)	0.42 (2.96)	0.48 (2.94)		
Week 52 Adjusted Mean Change (SE)	-14.55 (0.33)	-14.34 (0.38)	-0.21 [-1.21; 0.78]	0.670
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	11.77 (35.75)	14.77 (36.31)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-15.00 (0.41)	-14.99 (0.49)	-0.00 [-1.28; 1.27]	0.994
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.9 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.415</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	15.55 (29.31)	16.28 (63.64)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-15.79 (0.28)	-15.61 (0.40)	-0.19 [-1.16; 0.78]	0.702
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	11.43 (35.68)	19.50 (47.87)		
Week 52 Mean (SD)	0.59 (3.50)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-15.22 (0.31)	-15.79 (0.35)	0.57 [-0.36; 1.51]	0.229
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.10 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.136</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	18.59 (43.18)	9.94 (32.24)		
Week 52 Mean (SD)	0.71 (3.85)	0.69 (3.50)		
Week 52 Adjusted Mean Change (SE)	-14.24 (0.44)	-14.11 (0.45)	-0.13 [-1.37; 1.11]	0.836
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	10.25 (23.69)	22.51 (64.93)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-14.96 (0.33)	-14.92 (0.41)	-0.05 [-1.09; 1.00]	0.932
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 8.11 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.298</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	9.45 (22.16)	7.47 (27.87)		
Week 52 Mean (SD)	0.53 (3.32)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-14.45 (0.37)	-14.85 (0.37)	0.39 [-0.63; 1.41]	0.449
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	17.33 (39.41)	32.18 (76.04)		
Week 52 Mean (SD)	0.00 (0.00)	0.89 (3.99)		
Week 52 Adjusted Mean Change (SE)	-14.99 (0.36)	-14.04 (0.52)	-0.95 [-2.19; 0.30]	0.136
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.12 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.073</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	12.77 (26.84)	18.98 (59.29)		
Week 52 Mean (SD)	0.36 (2.72)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-15.04 (0.31)	-15.20 (0.37)	0.17 [-0.79; 1.12]	0.729
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	16.18 (46.51)	11.20 (26.56)		
Week 52 Mean (SD)	0.00 (0.00)	1.05 (4.33)		
Week 52 Adjusted Mean Change (SE)	-15.29 (0.55)	-14.32 (0.57)	-0.97 [-2.54; 0.59]	0.222
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.13 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.640</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	15.12 (34.58)	14.25 (38.53)		
Week 52 Mean (SD)	0.00 (0.00)	0.41 (2.69)		
Week 52 Adjusted Mean Change (SE)	-15.53 (0.31)	-15.02 (0.35)	-0.51 [-1.43; 0.42]	0.279
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	9.56 (24.14)	28.95 (94.31)		
Week 52 Mean (SD)	1.09 (4.76)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-14.43 (0.55)	-15.43 (0.69)	1.01 [-0.74; 2.75]	0.255
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.14 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.592</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	11.38 (31.30)	17.19 (57.28)		
Week 52 Mean (SD)	0.31 (2.55)	0.39 (2.63)		
Week 52 Adjusted Mean Change (SE)	-14.52 (0.29)	-14.29 (0.35)	-0.23 [-1.13; 0.66]	0.603
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	25.11 (35.11)	8.51 (15.55)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-14.73 (0.66)	-14.85 (0.75)	0.12 [-1.87; 2.10]	0.907
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.15 LDI Leeds Dactylitis Index - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.028</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	11.95 (27.62)	11.54 (36.19)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-14.98 (0.52)	-14.74 (0.51)	-0.25 [-1.69; 1.20]	0.734
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	13.83 (33.49)	19.35 (59.43)		
Week 52 Mean (SD)	0.34 (2.65)	0.46 (2.86)		
Week 52 Adjusted Mean Change (SE)	-14.65 (0.30)	-14.50 (0.37)	-0.15 [-1.09; 0.80]	0.758
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.16 LDI Leeds Dactylitis Index - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.686</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	17.53 (37.61)	14.53 (56.26)		
Week 52 Mean (SD)	0.42 (2.96)	0.62 (3.32)		
Week 52 Adjusted Mean Change (SE)	-14.57 (0.33)	-14.19 (0.42)	-0.38 [-1.44; 0.68]	0.479
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	7.06 (19.59)	18.28 (46.55)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-14.97 (0.41)	-14.98 (0.42)	0.01 [-1.16; 1.18]	0.986
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.17 LDI Leeds Dactylitis Index - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.140</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	18.59 (43.18)	10.58 (33.19)		
Week 52 Mean (SD)	0.71 (3.85)	0.74 (3.65)		
Week 52 Adjusted Mean Change (SE)	-14.27 (0.43)	-14.08 (0.46)	-0.19 [-1.43; 1.06]	0.769
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	10.48 (23.68)	21.26 (63.26)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-14.98 (0.32)	-14.95 (0.39)	-0.03 [-1.04; 0.97]	0.946
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 8.18 LDI Leeds Dactylitis Index - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.298</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	9.45 (22.16)	7.47 (27.87)		
Week 52 Mean (SD)	0.53 (3.32)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-14.45 (0.37)	-14.85 (0.37)	0.39 [-0.63; 1.41]	0.449
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	17.33 (39.41)	32.18 (76.04)		
Week 52 Mean (SD)	0.00 (0.00)	0.89 (3.99)		
Week 52 Adjusted Mean Change (SE)	-14.99 (0.36)	-14.04 (0.52)	-0.95 [-2.19; 0.30]	0.136
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 8.19 LDI Leeds Dactylitis Index - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.065</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	12.47 (26.31)	18.20 (58.16)		
Week 52 Mean (SD)	0.34 (2.65)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-14.88 (0.30)	-15.05 (0.36)	0.18 [-0.74; 1.10]	0.703
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	17.98 (48.82)	11.20 (26.56)		
Week 52 Mean (SD)	0.00 (0.00)	1.05 (4.33)		
Week 52 Adjusted Mean Change (SE)	-15.12 (0.57)	-14.14 (0.56)	-0.97 [-2.55; 0.61]	0.226
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 9.0 LDI Dactylitis Count - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	109 (99.1)	100 (99.0)	209 (99.1)
Week 4 Returns	110 (100.0)	98 (97.0)	208 (98.6)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	107 (97.3)	98 (97.0)	205 (97.2)
Week 16 Returns	109 (99.1)	94 (93.1)	203 (96.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	102 (92.7)	86 (85.1)	188 (89.1)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	85 (84.2)	190 (90.0)

### 9.1 LDI Dactylitis Count - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	1.42 (2.95)	1.33 (2.87)		
Week 52 Mean (SD)	0.22 (1.33)	0.06 (0.32)		
Week 52 Adjusted Mean Change (SE)	-1.21 (0.08)	-1.34 (0.09)	0.13 [-0.11; 0.37]	0.300
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 9.2 LDI Dactylitis Count - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.002</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	1.29 (2.40)	1.35 (2.93)		
Week 52 Mean (SD)	0.11 (0.67)	0.06 (0.34)		
Week 52 Adjusted Mean Change (SE)	-1.30 (0.08)	-1.34 (0.09)	0.04 [-0.20; 0.28]	0.732
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	3.29 (7.45)	1.00 (1.91)		
Week 52 Mean (SD)	2.00 (4.90)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	0.07 (0.32)	-1.35 (0.32)	1.41 [0.53; 2.30]	0.002
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.3 LDI Dactylitis Count - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.746</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	1.20 (2.24)	1.54 (3.08)		
Week 52 Mean (SD)	0.17 (0.83)	0.10 (0.42)		
Week 52 Adjusted Mean Change (SE)	-1.23 (0.11)	-1.35 (0.12)	0.12 [-0.19; 0.44]	0.452
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	1.75 (3.77)	1.05 (2.57)		
Week 52 Mean (SD)	0.29 (1.87)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.19 (0.13)	-1.33 (0.14)	0.15 [-0.23; 0.52]	0.448
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.4 LDI Dactylitis Count - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.948</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	0.17 (0.64)	0.48 (1.03)		
Week 52 Mean (SD)	0.04 (0.21)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.18 (0.18)	-1.19 (0.20)	0.00 [-0.52; 0.53]	0.989
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	1.77 (3.23)	1.55 (3.15)		
Week 52 Mean (SD)	0.27 (1.50)	0.07 (0.36)		
Week 52 Adjusted Mean Change (SE)	-1.22 (0.09)	-1.38 (0.10)	0.16 [-0.11; 0.43]	0.244
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.5 LDI Dactylitis Count - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.513</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	0.74 (1.27)	1.61 (3.41)		
Week 52 Mean (SD)	0.03 (0.16)	0.08 (0.35)		
Week 52 Adjusted Mean Change (SE)	-1.28 (0.14)	-1.36 (0.13)	0.08 [-0.29; 0.44]	0.679
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	1.84 (3.56)	1.04 (2.18)		
Week 52 Mean (SD)	0.33 (1.67)	0.04 (0.30)		
Week 52 Adjusted Mean Change (SE)	-1.17 (0.11)	-1.31 (0.13)	0.14 [-0.18; 0.47]	0.387
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 9.6 LDI Dactylitis Count - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.113</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	1.39 (2.47)	1.41 (2.96)		
Week 52 Mean (SD)	0.13 (0.76)	0.13 (0.47)		
Week 52 Adjusted Mean Change (SE)	-1.29 (0.10)	-1.29 (0.13)	-0.00 [-0.32; 0.32]	0.991
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	1.47 (3.73)	1.25 (2.81)		
Week 52 Mean (SD)	0.40 (2.05)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.05 (0.14)	-1.39 (0.12)	0.34 [-0.04; 0.71]	0.076
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 9.7 LDI Dactylitis Count - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.447</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	0.84 (1.78)	1.16 (2.33)		
Week 52 Mean (SD)	0.06 (0.32)	0.14 (0.52)		
Week 52 Adjusted Mean Change (SE)	-1.27 (0.12)	-1.23 (0.16)	-0.05 [-0.44; 0.35]	0.817
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	1.92 (3.61)	1.41 (3.10)		
Week 52 Mean (SD)	0.36 (1.79)	0.02 (0.13)		
Week 52 Adjusted Mean Change (SE)	-1.16 (0.11)	-1.39 (0.11)	0.23 [-0.08; 0.54]	0.145
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.8 LDI Dactylitis Count - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.743</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	1.37 (2.41)	1.54 (3.55)		
Week 52 Mean (SD)	0.18 (0.91)	0.03 (0.16)		
Week 52 Adjusted Mean Change (SE)	-1.11 (0.08)	-1.26 (0.09)	0.15 [-0.09; 0.38]	0.222
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	1.00 (2.12)	0.96 (1.54)		
Week 52 Mean (SD)	0.06 (0.36)	0.09 (0.43)		
Week 52 Adjusted Mean Change (SE)	-1.22 (0.10)	-1.21 (0.12)	-0.01 [-0.31; 0.29]	0.935
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.9 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.118</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	1.47 (2.43)	1.22 (2.82)		
Week 52 Mean (SD)	0.23 (1.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.13 (0.09)	-1.31 (0.12)	0.18 [-0.11; 0.47]	0.232
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	1.00 (2.17)	1.60 (3.42)		
Week 52 Mean (SD)	0.03 (0.17)	0.07 (0.38)		
Week 52 Adjusted Mean Change (SE)	-1.30 (0.10)	-1.30 (0.11)	-0.00 [-0.29; 0.29]	0.999
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.10 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.706</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	1.40 (2.37)	0.79 (1.47)		
Week 52 Mean (SD)	0.10 (0.41)	0.12 (0.43)		
Week 52 Adjusted Mean Change (SE)	-1.18 (0.10)	-1.15 (0.10)	-0.04 [-0.32; 0.25]	0.801
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	1.10 (2.23)	1.82 (3.82)		
Week 52 Mean (SD)	0.12 (0.86)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.15 (0.08)	-1.30 (0.10)	0.15 [-0.10; 0.39]	0.241
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.11 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.815</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	1.07 (2.23)	0.72 (1.75)		
Week 52 Mean (SD)	0.08 (0.35)	0.05 (0.32)		
Week 52 Adjusted Mean Change (SE)	-1.20 (0.09)	-1.20 (0.09)	-0.00 [-0.24; 0.24]	0.999
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	1.38 (2.37)	2.38 (4.16)		
Week 52 Mean (SD)	0.20 (0.98)	0.05 (0.22)		
Week 52 Adjusted Mean Change (SE)	-1.11 (0.09)	-1.31 (0.12)	0.20 [-0.09; 0.50]	0.178
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.12 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.372</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	1.24 (2.27)	1.26 (2.52)		
Week 52 Mean (SD)	0.12 (0.80)	0.05 (0.32)		
Week 52 Adjusted Mean Change (SE)	-1.18 (0.07)	-1.24 (0.08)	0.05 [-0.17; 0.27]	0.629
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	1.05 (2.28)	1.61 (3.99)		
Week 52 Mean (SD)	0.11 (0.46)	0.06 (0.24)		
Week 52 Adjusted Mean Change (SE)	-1.16 (0.13)	-1.25 (0.13)	0.10 [-0.27; 0.46]	0.607
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.13 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.686</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	1.24 (2.22)	1.37 (2.91)		
Week 52 Mean (SD)	0.17 (0.86)	0.07 (0.33)		
Week 52 Adjusted Mean Change (SE)	-1.14 (0.07)	-1.24 (0.08)	0.11 [-0.11; 0.33]	0.345
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	1.05 (2.46)	1.33 (3.55)		
Week 52 Mean (SD)	0.05 (0.23)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.23 (0.13)	-1.27 (0.17)	0.05 [-0.37; 0.47]	0.820
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.14 LDI Dactylitis Count - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.704</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	1.11 (2.29)	1.28 (3.16)		
Week 52 Mean (SD)	0.17 (0.81)	0.02 (0.15)		
Week 52 Adjusted Mean Change (SE)	-1.10 (0.07)	-1.22 (0.08)	0.12 [-0.08; 0.33]	0.233
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	1.77 (2.39)	1.10 (1.66)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.26 (0.15)	-1.25 (0.18)	-0.01 [-0.47; 0.45]	0.967
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 9.15 LDI Dactylitis Count - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.562</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	1.45 (2.40)	1.08 (2.15)		
Week 52 Mean (SD)	0.21 (0.63)	0.10 (0.45)		
Week 52 Adjusted Mean Change (SE)	-1.11 (0.12)	-1.20 (0.12)	0.09 [-0.25; 0.43]	0.598
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	1.14 (2.26)	1.46 (3.35)		
Week 52 Mean (SD)	0.11 (0.78)	0.03 (0.16)		
Week 52 Adjusted Mean Change (SE)	-1.17 (0.07)	-1.27 (0.09)	0.10 [-0.13; 0.32]	0.399
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.16 LDI Dactylitis Count - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.216</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	1.47 (2.49)	1.14 (2.56)		
Week 52 Mean (SD)	0.22 (0.94)	0.03 (0.19)		
Week 52 Adjusted Mean Change (SE)	-1.09 (0.08)	-1.23 (0.10)	0.14 [-0.11; 0.39]	0.281
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	0.85 (1.92)	1.50 (3.33)		
Week 52 Mean (SD)	0.00 (0.00)	0.07 (0.37)		
Week 52 Adjusted Mean Change (SE)	-1.26 (0.10)	-1.25 (0.10)	-0.01 [-0.29; 0.27]	0.943
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.17 LDI Dactylitis Count - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.589</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	1.40 (2.37)	0.68 (1.30)		
Week 52 Mean (SD)	0.10 (0.41)	0.13 (0.45)		
Week 52 Adjusted Mean Change (SE)	-1.20 (0.10)	-1.14 (0.11)	-0.05 [-0.35; 0.24]	0.727
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	1.13 (2.26)	1.86 (3.76)		
Week 52 Mean (SD)	0.16 (0.88)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.13 (0.08)	-1.32 (0.09)	0.19 [-0.06; 0.43]	0.132
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.18 LDI Dactylitis Count - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.815</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	1.07 (2.23)	0.72 (1.75)		
Week 52 Mean (SD)	0.08 (0.35)	0.05 (0.32)		
Week 52 Adjusted Mean Change (SE)	-1.20 (0.09)	-1.20 (0.09)	-0.00 [-0.24; 0.24]	0.999
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	1.38 (2.37)	2.38 (4.16)		
Week 52 Mean (SD)	0.20 (0.98)	0.05 (0.22)		
Week 52 Adjusted Mean Change (SE)	-1.11 (0.09)	-1.31 (0.12)	0.20 [-0.09; 0.50]	0.178
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 9.19 LDI Dactylitis Count - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.320</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	1.31 (2.30)	1.20 (2.48)		
Week 52 Mean (SD)	0.15 (0.81)	0.05 (0.31)		
Week 52 Adjusted Mean Change (SE)	-1.17 (0.07)	-1.25 (0.08)	0.08 [-0.14; 0.30]	0.486
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	1.06 (2.39)	1.61 (3.99)		
Week 52 Mean (SD)	0.12 (0.49)	0.06 (0.24)		
Week 52 Adjusted Mean Change (SE)	-1.16 (0.14)	-1.27 (0.14)	0.11 [-0.27; 0.49]	0.572
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 10.1 LDI Presence of Dactylitis (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
LDI Presence of Dactylitis Week 52, N' n (%)	105 5.14 (4.67)	85 4.78 (4.73)	0.91 [0.22; 3.76] 0.901	1.02 [0.27; 3.88] 0.980	-0.001 [-0.063; 0.062] 0.985
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR from logistic regression model with predictors treatment and weight.  RR and RD calculated directly without adjustment.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 10.2 LDI Presence of Dactylitis by Age (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

### 10.3 LDI Presence of Dactylitis by Gender (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---



## 10.4 LDI Presence of Dactylitis by Disease Severity (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---

## 10.5 LDI Presence of Dactylitis by Moderate/Severe PSO D (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

## 10.6 LDI Presence of Dactylitis by Lymphocyte Count at BL (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---

## 10.7 LDI Presence of Dactylitis by Enthesitis at BL According to LEI (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---

## 10.8 LDI Presence of Dactylitis by HLA-DQA1\*05 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---

## 10.9 LDI Presence of Dactylitis by Lead Candidate Variant rs10555659 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---

### 10.10 LDI Presence of Dactylitis by Lead Candidate Variant rs111937633 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---

### 10.11 LDI Presence of Dactylitis by Lead Candidate Variant rs11726476 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---



### 10.12 LDI Presence of Dactylitis by Lead Candidate Variant rs10609046 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---

### 10.13 LDI Presence of Dactylitis by Lead Candidate Variant rs8007401 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---

### 10.14 LDI Presence of Dactylitis by Lead Candidate Variant rs7349145 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---

### 10.15 LDI Presence of Dactylitis by Lead Candidate Allele Score (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

### 10.16 LDI Presence of Dactylitis by Linkage Variant rs10891185 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---

### 10.17 LDI Presence of Dactylitis by Linkage Variant rs12065362 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---

### 10.18 LDI Presence of Dactylitis by Linkage Variant rs11721988 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---

### 10.19 LDI Presence of Dactylitis by Linkage Variant rs7787032 (FAS)

Table is not displayed as no parameter fulfills the condition for subgroup analysis.
--

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.
---



### 11.0 LEI Leads Enthesitis Index - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	109 (99.1)	100 (99.0)	209 (99.1)
Week 4 Returns	110 (100.0)	98 (97.0)	208 (98.6)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	107 (97.3)	98 (97.0)	205 (97.2)
Week 16 Returns	109 (99.1)	94 (93.1)	203 (96.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	102 (92.7)	86 (85.1)	188 (89.1)
Week 40 Returns	106 (96.4)	83 (82.2)	189 (89.6)
Week 52 Returns	105 (95.5)	85 (84.2)	190 (90.0)

### 11.1 LEI Leads Enthesitis Index - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	1.31 (1.49)	2.00 (1.93)		
Week 52 Mean (SD)	0.43 (0.96)	0.45 (1.07)		
Week 52 Adjusted Mean Change (SE)	-1.14 (0.09)	-1.21 (0.10)	0.07 [-0.21; 0.35]	0.620
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 11.2 LEI Leeds Enthesitis Index - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.440</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	1.30 (1.51)	2.04 (1.96)		
Week 52 Mean (SD)	0.45 (0.98)	0.49 (1.11)		
Week 52 Adjusted Mean Change (SE)	-1.13 (0.10)	-1.18 (0.11)	0.05 [-0.24; 0.34]	0.727
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	1.43 (1.40)	1.43 (1.62)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-1.42 (0.38)	-1.59 (0.37)	0.17 [-0.87; 1.22]	0.742
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.3 LEI Leeds Enthesitis Index - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.641</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	1.14 (1.41)	1.86 (1.76)		
Week 52 Mean (SD)	0.34 (0.78)	0.35 (0.78)		
Week 52 Adjusted Mean Change (SE)	-1.22 (0.12)	-1.33 (0.14)	0.11 [-0.26; 0.47]	0.564
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	1.57 (1.59)	2.18 (2.15)		
Week 52 Mean (SD)	0.56 (1.18)	0.58 (1.38)		
Week 52 Adjusted Mean Change (SE)	-1.03 (0.15)	-1.05 (0.16)	0.02 [-0.41; 0.45]	0.924
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.4 LEI Leeds Enthesitis Index - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.810</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	0.46 (0.83)	0.71 (1.10)		
Week 52 Mean (SD)	0.04 (0.21)	0.24 (0.56)		
Week 52 Adjusted Mean Change (SE)	-1.40 (0.21)	-1.19 (0.23)	-0.21 [-0.81; 0.39]	0.489
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	1.55 (1.55)	2.34 (1.97)		
Week 52 Mean (SD)	0.54 (1.06)	0.50 (1.17)		
Week 52 Adjusted Mean Change (SE)	-1.08 (0.11)	-1.22 (0.12)	0.14 [-0.18; 0.45]	0.382
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.5 LEI Leeds Enthesitis Index - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.490</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	1.00 (1.33)	1.94 (1.94)		
Week 52 Mean (SD)	0.31 (0.69)	0.43 (1.17)		
Week 52 Adjusted Mean Change (SE)	-1.20 (0.16)	-1.15 (0.15)	-0.04 [-0.47; 0.38]	0.838
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	1.50 (1.57)	2.06 (1.94)		
Week 52 Mean (SD)	0.50 (1.08)	0.47 (0.99)		
Week 52 Adjusted Mean Change (SE)	-1.11 (0.12)	-1.28 (0.14)	0.17 [-0.20; 0.54]	0.379
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.6 LEI Leeds Enthesitis Index - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.711</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	1.32 (1.47)	1.35 (1.58)		
Week 52 Mean (SD)	0.30 (0.64)	0.29 (0.80)		
Week 52 Adjusted Mean Change (SE)	-1.27 (0.12)	-1.19 (0.15)	-0.09 [-0.46; 0.29]	0.649
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	1.29 (1.56)	2.62 (2.05)		
Week 52 Mean (SD)	0.69 (1.37)	0.57 (1.25)		
Week 52 Adjusted Mean Change (SE)	-0.88 (0.16)	-1.24 (0.15)	0.35 [-0.08; 0.79]	0.111
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.7 LEI Leads Enthesitis Index - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.539</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Mean (SD)	0.24 (0.75)	0.18 (0.48)		
Week 52 Adjusted Mean Change (SE)	-1.00 (0.17)	-1.07 (0.21)	0.07 [-0.37; 0.52]	0.750
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	2.44 (1.18)	2.93 (1.66)		
Week 52 Mean (SD)	0.59 (1.09)	0.58 (1.25)		
Week 52 Adjusted Mean Change (SE)	-1.24 (0.14)	-1.31 (0.15)	0.07 [-0.29; 0.43]	0.707
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 11.8 LEI Leeds Enthesitis Index - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.928</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	1.45 (1.58)	2.12 (2.09)		
Week 52 Mean (SD)	0.59 (1.21)	0.30 (1.05)		
Week 52 Adjusted Mean Change (SE)	-0.97 (0.13)	-1.35 (0.16)	0.38 [-0.03; 0.79]	0.066
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	1.03 (1.29)	1.65 (1.90)		
Week 52 Mean (SD)	0.29 (0.64)	0.45 (0.86)		
Week 52 Adjusted Mean Change (SE)	-1.17 (0.17)	-1.13 (0.20)	-0.04 [-0.56; 0.47]	0.865
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.9 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.278</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	1.40 (1.50)	1.96 (2.16)		
Week 52 Mean (SD)	0.47 (1.03)	0.43 (1.33)		
Week 52 Adjusted Mean Change (SE)	-1.07 (0.15)	-1.16 (0.21)	0.09 [-0.41; 0.60]	0.721
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	1.11 (1.47)	1.93 (1.95)		
Week 52 Mean (SD)	0.49 (1.07)	0.43 (0.84)		
Week 52 Adjusted Mean Change (SE)	-0.96 (0.16)	-1.21 (0.18)	0.26 [-0.24; 0.75]	0.304
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.10 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.581</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	1.47 (1.63)	2.00 (2.24)		
Week 52 Mean (SD)	0.55 (1.15)	0.54 (1.30)		
Week 52 Adjusted Mean Change (SE)	-1.04 (0.18)	-1.09 (0.18)	0.06 [-0.45; 0.56]	0.823
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	1.18 (1.41)	1.88 (1.81)		
Week 52 Mean (SD)	0.45 (0.98)	0.21 (0.60)		
Week 52 Adjusted Mean Change (SE)	-1.07 (0.14)	-1.43 (0.17)	0.36 [-0.07; 0.78]	0.103
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.11 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.308</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	1.35 (1.53)	2.05 (2.02)		
Week 52 Mean (SD)	0.46 (1.07)	0.33 (0.74)		
Week 52 Adjusted Mean Change (SE)	-1.06 (0.15)	-1.32 (0.15)	0.26 [-0.16; 0.69]	0.224
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	1.21 (1.44)	1.75 (2.03)		
Week 52 Mean (SD)	0.49 (1.00)	0.40 (1.35)		
Week 52 Adjusted Mean Change (SE)	-1.04 (0.15)	-1.19 (0.21)	0.14 [-0.36; 0.65]	0.577
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.12 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.884</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	1.31 (1.46)	2.02 (1.99)		
Week 52 Mean (SD)	0.43 (0.96)	0.40 (1.08)		
Week 52 Adjusted Mean Change (SE)	-1.11 (0.12)	-1.22 (0.15)	0.11 [-0.27; 0.49]	0.567
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	1.25 (1.65)	1.67 (2.03)		
Week 52 Mean (SD)	0.53 (1.26)	0.12 (0.33)		
Week 52 Adjusted Mean Change (SE)	-0.97 (0.22)	-1.49 (0.23)	0.52 [-0.10; 1.14]	0.097
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.13 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.204</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	1.29 (1.46)	1.69 (1.87)		
Week 52 Mean (SD)	0.48 (1.05)	0.23 (0.57)		
Week 52 Adjusted Mean Change (SE)	-1.07 (0.13)	-1.37 (0.14)	0.30 [-0.08; 0.68]	0.116
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	1.32 (1.63)	3.25 (2.42)		
Week 52 Mean (SD)	0.53 (1.07)	0.92 (1.83)		
Week 52 Adjusted Mean Change (SE)	-1.02 (0.22)	-0.92 (0.29)	-0.10 [-0.83; 0.63]	0.790
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.14 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.367</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	1.39 (1.50)	2.02 (2.18)		
Week 52 Mean (SD)	0.52 (1.10)	0.39 (1.06)		
Week 52 Adjusted Mean Change (SE)	-1.05 (0.12)	-1.27 (0.14)	0.21 [-0.15; 0.57]	0.246
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	0.77 (1.30)	1.90 (1.10)		
Week 52 Mean (SD)	0.31 (0.63)	0.10 (0.32)		
Week 52 Adjusted Mean Change (SE)	-1.11 (0.27)	-1.58 (0.30)	0.47 [-0.32; 1.27]	0.242
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.15 LEI Leeds Enthesitis Index - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.508</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	1.45 (1.44)	1.92 (2.06)		
Week 52 Mean (SD)	0.53 (0.90)	0.40 (0.75)		
Week 52 Adjusted Mean Change (SE)	-0.99 (0.21)	-1.22 (0.21)	0.23 [-0.36; 0.82]	0.442
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	1.22 (1.50)	1.95 (2.01)		
Week 52 Mean (SD)	0.46 (1.07)	0.33 (1.08)		
Week 52 Adjusted Mean Change (SE)	-1.06 (0.12)	-1.30 (0.15)	0.24 [-0.15; 0.63]	0.232
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 11.16 LEI Leeds Enthesitis Index - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.462</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	1.37 (1.50)	1.83 (2.01)		
Week 52 Mean (SD)	0.43 (0.98)	0.31 (1.14)		
Week 52 Adjusted Mean Change (SE)	-1.14 (0.14)	-1.26 (0.17)	0.13 [-0.31; 0.56]	0.564
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	1.15 (1.46)	2.06 (2.05)		
Week 52 Mean (SD)	0.55 (1.12)	0.40 (0.81)		
Week 52 Adjusted Mean Change (SE)	-0.91 (0.17)	-1.29 (0.17)	0.38 [-0.10; 0.86]	0.123
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.17 LEI Leeds Enthesitis Index - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.442</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	1.47 (1.63)	2.03 (2.30)		
Week 52 Mean (SD)	0.55 (1.15)	0.58 (1.35)		
Week 52 Adjusted Mean Change (SE)	-1.03 (0.18)	-1.05 (0.19)	0.02 [-0.49; 0.53]	0.924
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	1.18 (1.39)	1.86 (1.76)		
Week 52 Mean (SD)	0.43 (0.96)	0.20 (0.58)		
Week 52 Adjusted Mean Change (SE)	-1.06 (0.13)	-1.43 (0.16)	0.37 [-0.04; 0.78]	0.080
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.18 LEI Leeds Enthesitis Index - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.308</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	1.35 (1.53)	2.05 (2.02)		
Week 52 Mean (SD)	0.46 (1.07)	0.33 (0.74)		
Week 52 Adjusted Mean Change (SE)	-1.06 (0.15)	-1.32 (0.15)	0.26 [-0.16; 0.69]	0.224
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	1.21 (1.44)	1.75 (2.03)		
Week 52 Mean (SD)	0.49 (1.00)	0.40 (1.35)		
Week 52 Adjusted Mean Change (SE)	-1.04 (0.15)	-1.19 (0.21)	0.14 [-0.36; 0.65]	0.577
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 11.19 LEI Leeds Enthesitis Index - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.716</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	1.31 (1.44)	1.94 (1.99)		
Week 52 Mean (SD)	0.43 (0.94)	0.40 (1.06)		
Week 52 Adjusted Mean Change (SE)	-1.10 (0.11)	-1.17 (0.13)	0.07 [-0.28; 0.42]	0.685
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	0.94 (1.26)	1.94 (2.13)		
Week 52 Mean (SD)	0.29 (0.69)	0.24 (0.75)		
Week 52 Adjusted Mean Change (SE)	-1.13 (0.22)	-1.39 (0.21)	0.26 [-0.35; 0.86]	0.403
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 12.1 LEI Presence of Enthesitis (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
LEI Presence of Enthesitis Week 52, N' n (%)	105 24.72 (22.47)	85 26.01 (25.75)	0.80 [0.41; 1.57] 0.514	0.87 [0.53; 1.45] 0.602	-0.033 [-0.155; 0.089] 0.598
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR from logistic regression model with predictors treatment and weight.  RR and RD calculated directly without adjustment.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 12.2 LEI Presence of Enthesitis by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	N.E.				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	99 23.97 (23.27)	78 26.01 (27.67)	0.75 [0.38; 1.49] 0.414	0.84 [0.51; 1.40] 0.505	-0.044 [-0.173; 0.085] 0.502
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	6 0.75 (10.71)	7 0.00 (0.00)	N.E.	N.E.	N.E.
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 12.3 LEI Presence of Enthesitis by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.603				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	64 13.99 (21.20)	49 14.39 (25.25)	0.69 [0.28; 1.70] 0.419	0.84 [0.43; 1.65] 0.615	-0.040 [-0.197; 0.116] 0.611
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	41 10.73 (24.39)	36 11.62 (26.41)	0.99 [0.35; 2.82] 0.992	0.93 [0.43; 1.99] 0.846	-0.020 [-0.213; 0.173] 0.837
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 12.4 LEI Presence of Enthesitis by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.118				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	23 1.25 (5.21)	17 4.68 (22.29)	0.14 [0.01; 1.53] 0.107	0.23 [0.03; 1.88] 0.169	-0.171 [-0.393; 0.051] 0.131
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	82 23.47 (27.29)	68 21.33 (26.66)	1.03 [0.50; 2.14] 0.937	1.03 [0.61; 1.73] 0.925	0.006 [-0.135; 0.147] 0.930
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



## 12.5 LEI Presence of Enthesitis by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.653				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	39 7.73 (18.40)	40 13.63 (26.73)	0.65 [0.22; 1.93] 0.440	0.69 [0.30; 1.60] 0.385	-0.083 [-0.265; 0.098] 0.369
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	66 16.99 (24.99)	45 12.38 (24.76)	0.90 [0.37; 2.20] 0.818	1.01 [0.52; 1.95] 0.972	0.002 [-0.161; 0.165] 0.978
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 12.6 LEI Presence of Enthesitis by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.888				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	70 14.99 (20.82)	38 11.60 (23.67)	0.80 [0.31; 2.08] 0.646	0.89 [0.43; 1.84] 0.747	-0.029 [-0.193; 0.135] 0.733
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	35 9.73 (25.61)	47 14.41 (27.71)	0.88 [0.32; 2.41] 0.808	0.92 [0.44; 1.92] 0.830	-0.021 [-0.214; 0.172] 0.830
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 12.7 LEI Presence of Enthesitis by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.772				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	49 6.48 (12.71)	28 5.28 (16.50)	0.76 [0.20; 2.94] 0.689	0.78 [0.25; 2.44] 0.669	-0.038 [-0.207; 0.131] 0.660
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	56 18.24 (30.92)	57 20.73 (30.04)	0.96 [0.43; 2.16] 0.919	1.03 [0.59; 1.79] 0.914	0.009 [-0.159; 0.176] 0.919
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 12.8 LEI Presence of Enthesitis by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.230				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	49 13.49 (26.45)	37 7.02 (17.12)	1.72 [0.56; 5.24] 0.343	1.56 [0.65; 3.75] 0.322	0.093 [-0.083; 0.269] 0.299
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	31 7.23 (21.26)	22 7.67 (29.50)	0.61 [0.17; 2.19] 0.451	0.72 [0.29; 1.83] 0.492	-0.082 [-0.317; 0.153] 0.492
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 12.9 LEI Presence of Enthesitis by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.884				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	43 10.48 (23.29)	21 6.89 (25.52)	0.81 [0.24; 2.78] 0.741	0.92 [0.37; 2.29] 0.863	-0.022 [-0.244; 0.200] 0.844
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	35 9.24 (24.32)	28 7.80 (26.00)	0.92 [0.28; 3.00] 0.892	0.94 [0.39; 2.23] 0.880	-0.017 [-0.235; 0.201] 0.879
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 12.10 LEI Presence of Enthesitis by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.625				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	29 8.24 (27.47)	26 9.45 (28.64)	0.95 [0.28; 3.18] 0.936	0.97 [0.41; 2.26] 0.938	-0.012 [-0.248; 0.225] 0.923
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	49 11.48 (22.51)	33 5.24 (15.41)	1.45 [0.44; 4.73] 0.539	1.46 [0.56; 3.82] 0.436	0.071 [-0.099; 0.241] 0.414
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 12.11 LEI Presence of Enthesitis by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.720				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	39 9.48 (22.05)	39 9.84 (22.88)	0.97 [0.32; 2.95] 0.964	0.96 [0.42; 2.23] 0.932	-0.008 [-0.196; 0.179] 0.930
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	41 11.24 (26.76)	20 4.85 (20.21)	1.34 [0.35; 5.11] 0.668	1.35 [0.48; 3.80] 0.572	0.066 [-0.158; 0.289] 0.565
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 12.12 LEI Presence of Enthesitis by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.366				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	58 14.48 (23.35)	40 11.36 (24.17)	0.84 [0.31; 2.27] 0.729	0.97 [0.47; 2.02] 0.936	-0.008 [-0.182; 0.165] 0.927
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	19 4.24 (21.20)	17 2.33 (12.94)	2.23 [0.35; 14.29] 0.396	1.66 [0.36; 7.72] 0.517	0.083 [-0.161; 0.326] 0.506
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 12.13 LEI Presence of Enthesitis by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.352				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	58 15.72 (24.95)	44 10.20 (20.00)	1.36 [0.51; 3.60] 0.541	1.25 [0.59; 2.66] 0.554	0.050 [-0.114; 0.213] 0.552
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	19 5.00 (26.32)	12 4.00 (33.33)	0.54 [0.10; 2.85] 0.471	0.79 [0.26; 2.37] 0.673	-0.070 [-0.402; 0.262] 0.679
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) LEI Presence of Enthesitis, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

## 12.14 LEI Presence of Enthesitis by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.386				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	66 17.72 (24.96)	46 12.36 (23.32)	1.02 [0.41; 2.56] 0.968	1.07 [0.54; 2.13] 0.837	0.016 [-0.146; 0.179] 0.844
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	13 3.00 (23.08)	10 1.00 (10.00)	3.24 [0.28; 37.52] 0.346	2.31 [0.28; 18.99] 0.437	0.131 [-0.164; 0.426] 0.385
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) LEI Presence of Enthesitis, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

## 12.15 LEI Presence of Enthesitis by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.962				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	19 7.24 (32.91)	20 7.87 (30.27)	1.27 [0.32; 4.96] 0.735	1.09 [0.44; 2.73] 0.851	0.026 [-0.260; 0.312] 0.856
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	61 13.48 (21.40)	39 6.82 (16.63)	1.21 [0.41; 3.55] 0.724	1.29 [0.55; 3.05] 0.561	0.048 [-0.109; 0.204] 0.551
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 12.16 LEI Presence of Enthesitis by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.765				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	49 11.48 (22.51)	29 6.89 (19.69)	1.02 [0.31; 3.33] 0.974	1.16 [0.46; 2.89] 0.755	0.028 [-0.158; 0.215] 0.767
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	31 9.24 (27.18)	30 7.80 (24.38)	1.32 [0.40; 4.30] 0.648	1.12 [0.47; 2.65] 0.805	0.028 [-0.193; 0.249] 0.804
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 12.17 LEI Presence of Enthesitis by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.481				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	29 8.24 (27.47)	24 9.45 (30.48)	0.88 [0.26; 2.95] 0.830	0.91 [0.39; 2.12] 0.823	-0.030 [-0.274; 0.213] 0.808
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	51 12.48 (22.69)	35 5.24 (14.56)	1.60 [0.50; 5.17] 0.430	1.56 [0.60; 4.06] 0.362	0.081 [-0.083; 0.246] 0.333
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 12.18 LEI Presence of Enthesitis by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.720				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	39 9.48 (22.05)	39 9.84 (22.88)	0.97 [0.32; 2.95] 0.964	0.96 [0.42; 2.23] 0.932	-0.008 [-0.196; 0.179] 0.930
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	41 11.24 (26.76)	20 4.85 (20.21)	1.34 [0.35; 5.11] 0.668	1.35 [0.48; 3.80] 0.572	0.066 [-0.158; 0.289] 0.565
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 12.19 LEI Presence of Enthesitis by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
LEI Presence of Enthesitis Week 52	p=0.480				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	61 15.48 (23.82)	42 12.36 (25.22)	0.81 [0.31; 2.13] 0.676	0.95 [0.47; 1.90] 0.880	-0.014 [-0.185; 0.157] 0.872
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
LEI Presence of Enthesitis Week 52, N' n (%)	17 3.24 (18.00)	17 2.33 (12.94)	1.79 [0.26; 12.53] 0.558	1.41 [0.28; 7.14] 0.681	0.051 [-0.192; 0.293] 0.683
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 13.0 PASI Score - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	110 (100.0)	98 (97.0)	208 (98.6)
Week 4 Returns	110 (100.0)	97 (96.0)	207 (98.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	95 (94.1)	201 (95.3)
Week 16 Returns	108 (98.2)	93 (92.1)	201 (95.3)
Week 24 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	104 (94.5)	85 (84.2)	189 (89.6)



### 13.1 PASI Score - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	16.15 (9.58)	14.98 (8.87)		
Week 52 Mean (SD)	1.50 (2.79)	3.13 (4.55)		
Week 52 Adjusted Mean Change (SE)	-14.10 (0.35)	-12.14 (0.38)	-1.96 [-2.97; -0.95]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

### 13.2 PASI Score - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.051</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	16.32 (9.83)	15.17 (9.09)		
Week 52 Mean (SD)	1.51 (2.84)	3.37 (4.67)		
Week 52 Adjusted Mean Change (SE)	-14.22 (0.35)	-11.94 (0.39)	-2.28 [-3.31; -1.24]	<.001
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	13.64 (4.02)	12.36 (4.63)		
Week 52 Mean (SD)	1.36 (1.56)	0.51 (0.91)		
Week 52 Adjusted Mean Change (SE)	-12.24 (1.43)	-14.69 (1.34)	2.45 [-1.41; 6.30]	0.212
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.3 PASI Score - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.530</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	17.35 (10.01)	16.49 (8.38)		
Week 52 Mean (SD)	1.46 (2.49)	3.35 (4.32)		
Week 52 Adjusted Mean Change (SE)	-14.39 (0.45)	-12.31 (0.50)	-2.09 [-3.41; -0.77]	0.002
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	14.36 (8.69)	13.02 (9.19)		
Week 52 Mean (SD)	1.56 (3.22)	2.84 (4.89)		
Week 52 Adjusted Mean Change (SE)	-13.65 (0.56)	-11.88 (0.58)	-1.76 [-3.34; -0.19]	0.029
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.4 PASI Score - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.762</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	12.72 (5.03)	13.49 (6.94)		
Week 52 Mean (SD)	1.41 (2.12)	2.45 (3.38)		
Week 52 Adjusted Mean Change (SE)	-13.99 (0.75)	-12.68 (0.84)	-1.31 [-3.51; 0.90]	0.245
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	17.11 (10.32)	15.37 (9.30)		
Week 52 Mean (SD)	1.53 (2.96)	3.30 (4.80)		
Week 52 Adjusted Mean Change (SE)	-14.13 (0.39)	-12.01 (0.42)	-2.12 [-3.26; -0.98]	<.001
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.5 PASI Score - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.091</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	8.70 (2.62)	8.68 (2.54)		
Week 52 Mean (SD)	0.68 (1.00)	1.72 (2.58)		
Week 52 Adjusted Mean Change (SE)	-14.26 (0.61)	-12.94 (0.59)	-1.32 [-2.85; 0.20]	0.089
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	20.75 (9.42)	21.40 (8.39)		
Week 52 Mean (SD)	2.00 (3.36)	4.39 (5.49)		
Week 52 Adjusted Mean Change (SE)	-13.96 (0.47)	-11.42 (0.56)	-2.54 [-3.88; -1.20]	<.001
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.6 PASI Score - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.977</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	17.62 (10.56)	13.86 (7.36)		
Week 52 Mean (SD)	1.53 (2.72)	2.28 (3.14)		
Week 52 Adjusted Mean Change (SE)	-14.19 (0.43)	-12.64 (0.55)	-1.55 [-2.93; -0.17]	0.028
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	13.37 (6.66)	16.03 (10.04)		
Week 52 Mean (SD)	1.45 (2.97)	3.82 (5.36)		
Week 52 Adjusted Mean Change (SE)	-13.91 (0.60)	-11.72 (0.51)	-2.19 [-3.74; -0.64]	0.006
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.7 PASI Score - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.802</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	13.76 (6.30)	14.30 (7.88)		
Week 52 Mean (SD)	1.00 (1.80)	3.33 (5.49)		
Week 52 Adjusted Mean Change (SE)	-14.39 (0.51)	-12.10 (0.66)	-2.29 [-3.94; -0.65]	0.007
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	18.22 (11.35)	15.29 (9.32)		
Week 52 Mean (SD)	1.94 (3.37)	3.03 (4.05)		
Week 52 Adjusted Mean Change (SE)	-13.83 (0.48)	-12.16 (0.46)	-1.67 [-2.98; -0.36]	0.013
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.8 PASI Score - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.357</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	14.88 (8.97)	13.90 (8.90)		
Week 52 Mean (SD)	1.46 (2.95)	2.44 (5.01)		
Week 52 Adjusted Mean Change (SE)	-13.83 (0.53)	-12.77 (0.60)	-1.06 [-2.63; 0.52]	0.186
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	17.58 (10.88)	14.55 (9.57)		
Week 52 Mean (SD)	1.35 (2.59)	2.98 (3.74)		
Week 52 Adjusted Mean Change (SE)	-13.92 (0.66)	-11.56 (0.77)	-2.36 [-4.36; -0.35]	0.022
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 13.9 PASI Score - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.620</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	16.30 (8.61)	13.15 (7.39)		
Week 52 Mean (SD)	1.38 (3.04)	2.25 (5.81)		
Week 52 Adjusted Mean Change (SE)	-13.63 (0.57)	-11.82 (0.78)	-1.82 [-3.73; 0.10]	0.063
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	14.49 (9.99)	13.81 (8.15)		
Week 52 Mean (SD)	1.40 (2.56)	3.35 (3.86)		
Week 52 Adjusted Mean Change (SE)	-13.08 (0.62)	-11.23 (0.70)	-1.85 [-3.70; 0.01]	0.051
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.10 PASI Score - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.873</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	13.48 (6.70)	16.01 (8.82)		
Week 52 Mean (SD)	1.40 (2.97)	2.85 (5.50)		
Week 52 Adjusted Mean Change (SE)	-13.86 (0.67)	-12.06 (0.68)	-1.80 [-3.69; 0.10]	0.063
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	17.69 (11.21)	12.34 (9.14)		
Week 52 Mean (SD)	1.39 (2.76)	2.47 (3.72)		
Week 52 Adjusted Mean Change (SE)	-14.22 (0.52)	-12.64 (0.63)	-1.58 [-3.21; 0.06]	0.059
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.11 PASI Score - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.444</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	15.16 (7.77)	16.04 (10.30)		
Week 52 Mean (SD)	0.90 (2.48)	2.43 (3.13)		
Week 52 Adjusted Mean Change (SE)	-14.09 (0.58)	-12.80 (0.58)	-1.29 [-2.91; 0.32]	0.116
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	16.78 (11.56)	10.75 (5.02)		
Week 52 Mean (SD)	1.91 (3.02)	3.04 (6.59)		
Week 52 Adjusted Mean Change (SE)	-13.64 (0.58)	-11.35 (0.81)	-2.29 [-4.27; -0.31]	0.024
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.12 PASI Score - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.979</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	15.67 (8.39)	15.60 (10.10)		
Week 52 Mean (SD)	1.83 (3.19)	3.29 (5.20)		
Week 52 Adjusted Mean Change (SE)	-13.18 (0.47)	-11.60 (0.56)	-1.58 [-3.03; -0.14]	0.032
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	15.02 (11.28)	10.43 (4.91)		
Week 52 Mean (SD)	0.35 (0.47)	0.96 (1.75)		
Week 52 Adjusted Mean Change (SE)	-14.68 (0.83)	-13.53 (0.89)	-1.14 [-3.56; 1.27]	0.350
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.13 PASI Score - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.071</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	16.05 (9.54)	15.59 (9.78)		
Week 52 Mean (SD)	1.34 (2.69)	3.09 (5.05)		
Week 52 Adjusted Mean Change (SE)	-14.03 (0.49)	-12.11 (0.55)	-1.92 [-3.37; -0.46]	0.010
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	16.08 (11.31)	9.07 (3.41)		
Week 52 Mean (SD)	1.78 (3.34)	1.64 (2.43)		
Week 52 Adjusted Mean Change (SE)	-13.74 (0.87)	-13.24 (1.11)	-0.51 [-3.30; 2.28]	0.719
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.14 PASI Score - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.858</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	16.28 (10.35)	13.52 (7.45)		
Week 52 Mean (SD)	1.50 (2.77)	2.64 (4.80)		
Week 52 Adjusted Mean Change (SE)	-13.54 (0.46)	-11.92 (0.54)	-1.62 [-3.02; -0.22]	0.024
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	14.62 (6.55)	12.69 (8.29)		
Week 52 Mean (SD)	1.11 (3.14)	2.85 (4.23)		
Week 52 Adjusted Mean Change (SE)	-13.82 (1.04)	-11.98 (1.19)	-1.85 [-4.96; 1.27]	0.244
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.15 PASI Score - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.798</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	14.29 (6.30)	18.80 (11.06)		
Week 52 Mean (SD)	1.74 (3.58)	2.97 (5.89)		
Week 52 Adjusted Mean Change (SE)	-12.98 (0.83)	-12.09 (0.81)	-0.89 [-3.17; 1.40]	0.446
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	16.54 (10.74)	11.20 (6.11)		
Week 52 Mean (SD)	1.32 (2.54)	2.47 (3.77)		
Week 52 Adjusted Mean Change (SE)	-14.14 (0.47)	-12.42 (0.61)	-1.72 [-3.26; -0.19]	0.028
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.16 PASI Score - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.462</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	17.05 (9.30)	13.26 (7.63)		
Week 52 Mean (SD)	1.37 (2.89)	2.04 (5.25)		
Week 52 Adjusted Mean Change (SE)	-14.20 (0.53)	-12.67 (0.66)	-1.53 [-3.22; 0.15]	0.074
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	14.32 (10.45)	15.12 (10.52)		
Week 52 Mean (SD)	1.50 (2.70)	3.22 (3.76)		
Week 52 Adjusted Mean Change (SE)	-13.36 (0.65)	-11.96 (0.67)	-1.40 [-3.24; 0.44]	0.135
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 13.17 PASI Score - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.941</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	13.48 (6.70)	16.13 (9.04)		
Week 52 Mean (SD)	1.40 (2.97)	3.03 (5.69)		
Week 52 Adjusted Mean Change (SE)	-13.84 (0.69)	-11.77 (0.73)	-2.08 [-4.07; -0.09]	0.041
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	17.31 (10.96)	12.45 (8.94)		
Week 52 Mean (SD)	1.43 (2.73)	2.37 (3.64)		
Week 52 Adjusted Mean Change (SE)	-13.87 (0.52)	-12.74 (0.63)	-1.13 [-2.77; 0.51]	0.174
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.18 PASI Score - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.444</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	15.16 (7.77)	16.04 (10.30)		
Week 52 Mean (SD)	0.90 (2.48)	2.43 (3.13)		
Week 52 Adjusted Mean Change (SE)	-14.09 (0.58)	-12.80 (0.58)	-1.29 [-2.91; 0.32]	0.116
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	16.78 (11.56)	10.75 (5.02)		
Week 52 Mean (SD)	1.91 (3.02)	3.04 (6.59)		
Week 52 Adjusted Mean Change (SE)	-13.64 (0.58)	-11.35 (0.81)	-2.29 [-4.27; -0.31]	0.024
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 13.19 PASI Score - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.868</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	16.21 (9.41)	15.66 (9.89)		
Week 52 Mean (SD)	1.75 (3.13)	3.26 (5.11)		
Week 52 Adjusted Mean Change (SE)	-13.52 (0.47)	-11.84 (0.56)	-1.68 [-3.11; -0.24]	0.022
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	15.15 (11.76)	10.05 (4.62)		
Week 52 Mean (SD)	0.32 (0.45)	1.10 (2.17)		
Week 52 Adjusted Mean Change (SE)	-14.95 (0.89)	-13.65 (0.91)	-1.30 [-3.82; 1.21]	0.308
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 14.1 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI75 Response Week 52, N' n (%)	104 98.43 (89.48)	85 67.38 (66.71)	4.95 [2.23; 10.95] <.001	1.34 [1.14; 1.57] <.001	0.228 [0.114; 0.341] <.001
PASI90 Response Week 52, N' n (%)	104 77.97 (70.88)	85 45.88 (45.43)	3.11 [1.72; 5.61] <.001	1.56 [1.21; 2.01] <.001	0.255 [0.123; 0.386] <.001
PASI100 Response Week 52, N' n (%)	104 43.79 (39.81)	85 24.51 (24.27)	2.16 [1.17; 3.99] 0.014	1.64 [1.08; 2.50] 0.021	0.155 [0.030; 0.281] 0.015
PASI Absolute ≤ 3 Week 52, N' n (%)	104 92.50 (84.09)	85 64.73 (64.09)	3.38 [1.67; 6.85] <.001	1.31 [1.10; 1.56] 0.002	0.200 [0.079; 0.321] 0.001
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>OR from logistic regression model with predictors treatment and weight. RR and RD calculated directly without adjustment.</p> <p>All results are combined over MI: n and % are averages of all imputations. Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 14.2 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	N.E.				
PASI90 Response Week 52	p=0.034				
PASI100 Response Week 52	p=0.007				
PASI Absolute ≤ 3 Week 52	N.E.				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
PASI75 Response Week 52, N' n (%)	99 92.38 (89.69)	78 60.38 (64.23)	5.88 [2.56; 13.53] <.001	1.40 [1.17; 1.66] <.001	0.255 [0.136; 0.373] <.001
PASI90 Response Week 52, N' n (%)	99 74.00 (71.84)	78 39.88 (42.43)	3.73 [2.01; 6.93] <.001	1.69 [1.29; 2.23] <.001	0.294 [0.159; 0.430] <.001
PASI100 Response Week 52, N' n (%)	99 42.74 (41.50)	78 19.51 (20.76)	2.90 [1.50; 5.60] 0.002	2.00 [1.26; 3.18] 0.003	0.207 [0.080; 0.335] 0.001
PASI Absolute ≤ 3 Week 52, N' n (%)	99 87.46 (84.91)	78 57.73 (61.41)	4.23 [2.00; 8.95] <.001	1.38 [1.15; 1.67] <.001	0.235 [0.110; 0.360] <.001
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
PASI75 Response Week 52, N' n (%)	5 6.05 (86.43)	7 7.00 (100.00)	N.E.	0.86 [0.63; 1.16] 0.318	-0.143 [-0.402; 0.116] 0.280
PASI90 Response Week 52, N' n (%)	5 3.97 (56.71)	7 6.00 (85.71)	0.20 [0.01; 2.77] 0.230	0.66 [0.32; 1.36] 0.261	-0.290 [-0.742; 0.162] 0.208
PASI100 Response Week 52, N' n (%)	5 1.05 (15.00)	7 5.00 (71.43)	0.06 [<0.01; 0.89] 0.041	0.21 [0.03; 1.35] 0.099	-0.564 [-0.995; -0.134] 0.010
PASI Absolute ≤ 3 Week 52, N' n (%)	5 5.04 (72.00)	7 7.00 (100.00)	N.E.	0.72 [0.45; 1.15] 0.168	-0.280 [-0.617; 0.057] 0.103

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) PASI75 Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>				

### 14.3 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.560				
PASI90 Response Week 52	p=0.874				
PASI100 Response Week 52	p=0.358				
PASI Absolute ≤ 3 Week 52	p=0.774				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
PASI75 Response Week 52, N' n (%)	63 60.05 (90.98)	49 39.72 (69.68)	6.13 [2.02; 18.63] 0.001	1.31 [1.07; 1.59] 0.007	0.213 [0.070; 0.356] 0.004
PASI90 Response Week 52, N' n (%)	63 47.92 (72.61)	49 27.93 (49.00)	3.23 [1.47; 7.13] 0.004	1.48 [1.09; 2.02] 0.013	0.236 [0.064; 0.408] 0.007
PASI100 Response Week 52, N' n (%)	63 26.36 (39.94)	49 12.34 (21.65)	2.79 [1.21; 6.41] 0.016	1.85 [1.03; 3.31] 0.039	0.183 [0.022; 0.344] 0.026
PASI Absolute ≤ 3 Week 52, N' n (%)	63 54.04 (81.88)	49 36.98 (64.88)	3.09 [1.26; 7.55] 0.013	1.26 [1.00; 1.59] 0.046	0.170 [0.011; 0.329] 0.036
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
PASI75 Response Week 52, N' n (%)	41 38.38 (87.23)	36 27.66 (62.86)	3.80 [1.19; 12.09] 0.024	1.39 [1.06; 1.82] 0.016	0.244 [0.061; 0.426] 0.009
PASI90 Response Week 52, N' n (%)	41 30.05 (68.30)	36 17.95 (40.80)	2.94 [1.19; 7.26] 0.020	1.68 [1.10; 2.55] 0.016	0.275 [0.071; 0.479] 0.008
PASI100 Response Week 52, N' n (%)	41 17.43 (39.61)	36 12.17 (27.66)	1.55 [0.62; 3.92] 0.350	1.43 [0.78; 2.63] 0.246	0.120 [-0.078; 0.317] 0.236
PASI Absolute ≤ 3 Week 52, N' n (%)	41 38.46 (87.41)	36 27.75 (63.07)	3.83 [1.20; 12.24] 0.024	1.39 [1.06; 1.81] 0.017	0.243 [0.061; 0.426] 0.009

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value            N-N' is the number of values with MI.            n (%): Number and percentage of patients with event            CI: Confidence Interval            MI: Multiple Imputation            N.E.: Not estimable            OR: Odds Ratio            RR: Relative Risk            RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.            RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:            n and % are averages of all imputations.            P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.            OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.            RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				



### 14.4 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.722				
PASI90 Response Week 52	p=0.091				
PASI100 Response Week 52	p=0.825				
PASI Absolute ≤ 3 Week 52	p=0.777				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
PASI75 Response Week 52, N' n (%)	23 20.20 (84.17)	17 13.74 (65.43)	3.94 [0.83; 18.71] 0.085	1.29 [0.89; 1.87] 0.183	0.187 [-0.073; 0.447] 0.158
PASI90 Response Week 52, N' n (%)	23 14.03 (58.46)	17 12.04 (57.33)	1.22 [0.36; 4.17] 0.755	1.02 [0.61; 1.69] 0.938	0.011 [-0.282; 0.304] 0.940
PASI100 Response Week 52, N' n (%)	23 8.00 (33.33)	17 4.19 (19.95)	2.50 [0.60; 10.38] 0.206	1.68 [0.59; 4.77] 0.332	0.134 [-0.123; 0.391] 0.308
PASI Absolute ≤ 3 Week 52, N' n (%)	23 19.68 (82.00)	17 14.53 (69.19)	2.77 [0.59; 12.94] 0.196	1.19 [0.83; 1.70] 0.353	0.128 [-0.134; 0.390] 0.338
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
PASI75 Response Week 52, N' n (%)	81 78.23 (90.97)	68 53.64 (67.05)	5.46 [2.16; 13.78] <.001	1.36 [1.14; 1.62] <.001	0.239 [0.114; 0.364] <.001
PASI90 Response Week 52, N' n (%)	81 63.94 (74.35)	68 33.84 (42.30)	4.06 [2.07; 7.99] <.001	1.76 [1.31; 2.36] <.001	0.320 [0.175; 0.466] <.001
PASI100 Response Week 52, N' n (%)	81 35.79 (41.62)	68 20.32 (25.40)	2.09 [1.06; 4.13] 0.033	1.64 [1.04; 2.59] 0.034	0.162 [0.019; 0.305] 0.026
PASI Absolute ≤ 3 Week 52, N' n (%)	81 72.82 (84.67)	68 50.20 (62.75)	3.55 [1.61; 7.80] 0.002	1.35 [1.11; 1.65] 0.003	0.219 [0.084; 0.354] 0.001

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 14.5 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.710				
PASI90 Response Week 52	p=0.566				
PASI100 Response Week 52	p=0.236				
PASI Absolute ≤ 3 Week 52	p=0.604				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
PASI75 Response Week 52, N' n (%)	39 37.38 (89.00)	40 33.70 (66.08)	4.12 [1.21; 14.08] 0.024	1.35 [1.06; 1.72] 0.016	0.229 [0.056; 0.402] 0.009
PASI90 Response Week 52, N' n (%)	39 29.01 (69.07)	40 23.28 (45.65)	2.54 [1.05; 6.16] 0.040	1.51 [1.04; 2.20] 0.029	0.234 [0.034; 0.434] 0.022
PASI100 Response Week 52, N' n (%)	39 17.31 (41.21)	40 15.18 (29.76)	1.51 [0.62; 3.67] 0.361	1.38 [0.79; 2.43] 0.255	0.114 [-0.082; 0.311] 0.254
PASI Absolute ≤ 3 Week 52, N' n (%)	39 39.46 (93.95)	40 37.12 (72.78)	6.00 [1.21; 29.74] 0.028	1.29 [1.05; 1.58] 0.014	0.212 [0.056; 0.367] 0.008
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
PASI75 Response Week 52, N' n (%)	65 61.05 (89.78)	45 33.68 (67.36)	5.61 [1.96; 16.07] 0.001	1.33 [1.08; 1.65] 0.008	0.224 [0.073; 0.376] 0.004
PASI90 Response Week 52, N' n (%)	65 48.96 (72.00)	45 22.60 (45.20)	3.60 [1.62; 8.04] 0.002	1.59 [1.13; 2.25] 0.008	0.268 [0.091; 0.445] 0.003
PASI100 Response Week 52, N' n (%)	65 26.48 (38.94)	45 9.33 (18.66)	3.26 [1.33; 7.99] 0.010	2.09 [1.08; 4.05] 0.029	0.203 [0.042; 0.363] 0.013
PASI Absolute ≤ 3 Week 52, N' n (%)	65 53.04 (78.00)	45 27.61 (55.22)	3.72 [1.57; 8.80] 0.003	1.41 [1.06; 1.88] 0.018	0.228 [0.056; 0.400] 0.010

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 14.6 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.529				
PASI90 Response Week 52	p=0.961				
PASI100 Response Week 52	p=0.713				
PASI Absolute ≤ 3 Week 52	p=0.328				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
PASI75 Response Week 52, N' n (%)	70 64.05 (88.96)	38 35.17 (71.78)	3.77 [1.33; 10.73] 0.013	1.24 [1.01; 1.52] 0.041	0.172 [0.018; 0.326] 0.029
PASI90 Response Week 52, N' n (%)	70 50.95 (70.76)	38 22.65 (46.22)	3.05 [1.38; 6.75] 0.006	1.53 [1.08; 2.17] 0.016	0.245 [0.066; 0.425] 0.007
PASI100 Response Week 52, N' n (%)	70 30.31 (42.10)	38 12.36 (25.22)	2.32 [1.01; 5.30] 0.047	1.67 [0.95; 2.93] 0.074	0.169 [-0.000; 0.338] 0.050
PASI Absolute ≤ 3 Week 52, N' n (%)	70 59.04 (82.00)	38 33.25 (67.86)	2.48 [0.99; 6.22] 0.052	1.21 [0.96; 1.53] 0.110	0.141 [-0.024; 0.307] 0.094
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
PASI75 Response Week 52, N' n (%)	34 34.38 (90.47)	47 32.21 (61.94)	6.45 [1.74; 23.98] 0.005	1.46 [1.14; 1.87] 0.002	0.285 [0.118; 0.453] <.001
PASI90 Response Week 52, N' n (%)	34 27.02 (71.11)	47 23.23 (44.67)	3.14 [1.26; 7.83] 0.014	1.59 [1.10; 2.31] 0.014	0.264 [0.064; 0.465] 0.010
PASI100 Response Week 52, N' n (%)	34 13.48 (35.47)	47 12.15 (23.37)	1.83 [0.71; 4.73] 0.212	1.52 [0.78; 2.94] 0.216	0.121 [-0.072; 0.314] 0.219
PASI Absolute ≤ 3 Week 52, N' n (%)	34 33.46 (88.05)	47 31.48 (60.54)	5.26 [1.57; 17.61] 0.007	1.46 [1.12; 1.89] 0.005	0.275 [0.100; 0.450] 0.002

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 14.7 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.832				
PASI90 Response Week 52	p=0.194				
PASI100 Response Week 52	p=0.039				
PASI Absolute ≤ 3 Week 52	p=0.549				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
PASI75 Response Week 52, N' n (%)	48 46.18 (90.55)	28 22.41 (70.03)	4.31 [1.17; 15.80] 0.028	1.29 [1.00; 1.68] 0.050	0.205 [0.018; 0.393] 0.032
PASI90 Response Week 52, N' n (%)	48 37.95 (74.41)	28 11.53 (36.03)	5.24 [1.96; 14.03] <.001	2.07 [1.26; 3.40] 0.004	0.384 [0.176; 0.592] <.001
PASI100 Response Week 52, N' n (%)	48 25.36 (49.73)	28 5.12 (16.00)	5.24 [1.71; 16.12] 0.004	3.11 [1.33; 7.29] 0.009	0.337 [0.148; 0.526] <.001
PASI Absolute ≤ 3 Week 52, N' n (%)	48 44.78 (87.80)	28 20.29 (63.41)	4.36 [1.34; 14.26] 0.015	1.39 [1.03; 1.87] 0.032	0.244 [0.045; 0.443] 0.016
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
PASI75 Response Week 52, N' n (%)	56 52.25 (88.56)	57 44.97 (65.17)	5.14 [1.87; 14.16] 0.002	1.36 [1.11; 1.67] 0.003	0.234 [0.090; 0.377] 0.001
PASI90 Response Week 52, N' n (%)	56 40.02 (67.83)	57 34.35 (49.78)	2.32 [1.10; 4.89] 0.028	1.36 [1.01; 1.84] 0.044	0.180 [0.010; 0.351] 0.038
PASI100 Response Week 52, N' n (%)	56 18.43 (31.24)	57 19.39 (28.10)	1.24 [0.57; 2.72] 0.590	1.11 [0.65; 1.91] 0.701	0.031 [-0.129; 0.192] 0.702
PASI Absolute ≤ 3 Week 52, N' n (%)	56 47.72 (80.88)	57 44.44 (64.41)	2.79 [1.16; 6.72] 0.022	1.26 [1.00; 1.57] 0.045	0.165 [0.008; 0.321] 0.039

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				



### 14.8 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.205				
PASI90 Response Week 52	p=0.383				
PASI100 Response Week 52	p=0.317				
PASI Absolute ≤ 3 Week 52	p=0.220				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
PASI75 Response Week 52, N' n (%)	49 45.38 (88.98)	37 32.99 (80.46)	2.14 [0.62; 7.45] 0.230	1.11 [0.92; 1.33] 0.289	0.085 [-0.069; 0.240] 0.280
PASI90 Response Week 52, N' n (%)	49 36.06 (70.71)	37 23.18 (56.54)	1.93 [0.80; 4.70] 0.145	1.25 [0.90; 1.73] 0.178	0.142 [-0.057; 0.341] 0.163
PASI100 Response Week 52, N' n (%)	49 21.00 (41.18)	37 14.24 (34.73)	1.35 [0.56; 3.22] 0.502	1.19 [0.69; 2.03] 0.533	0.064 [-0.136; 0.264] 0.528
PASI Absolute ≤ 3 Week 52, N' n (%)	49 43.46 (85.22)	37 33.10 (80.73)	1.50 [0.46; 4.82] 0.501	1.06 [0.87; 1.28] 0.587	0.045 [-0.116; 0.205] 0.584
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
PASI75 Response Week 52, N' n (%)	31 31.05 (91.32)	22 16.04 (61.69)	7.62 [1.65; 35.26] 0.009	1.48 [1.06; 2.07] 0.021	0.296 [0.079; 0.514] 0.008
PASI90 Response Week 52, N' n (%)	31 24.94 (73.35)	22 11.46 (44.08)	3.65 [1.19; 11.13] 0.023	1.67 [1.02; 2.71] 0.040	0.293 [0.048; 0.538] 0.019
PASI100 Response Week 52, N' n (%)	31 15.74 (46.29)	22 6.12 (23.54)	2.83 [0.88; 9.11] 0.080	1.97 [0.89; 4.35] 0.095	0.228 [-0.011; 0.466] 0.061
PASI Absolute ≤ 3 Week 52, N' n (%)	31 28.04 (82.47)	22 14.34 (55.15)	4.37 [1.24; 15.39] 0.022	1.50 [1.01; 2.22] 0.045	0.273 [0.036; 0.511] 0.024

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 14.9 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.285				
PASI90 Response Week 52	p=0.849				
PASI100 Response Week 52	p=0.403				
PASI Absolute ≤ 3 Week 52	p=0.678				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
PASI75 Response Week 52, N' n (%)	43 43.00 (95.56)	21 20.39 (75.52)	8.34 [1.46; 47.71] 0.017	1.27 [1.00; 1.61] 0.054	0.200 [0.016; 0.384] 0.033
PASI90 Response Week 52, N' n (%)	43 35.94 (79.87)	21 15.41 (57.07)	3.30 [1.10; 9.89] 0.033	1.40 [0.97; 2.03] 0.073	0.228 [0.002; 0.453] 0.048
PASI100 Response Week 52, N' n (%)	43 19.74 (43.87)	21 10.31 (38.19)	1.36 [0.50; 3.76] 0.548	1.15 [0.63; 2.09] 0.647	0.057 [-0.182; 0.296] 0.641
PASI Absolute ≤ 3 Week 52, N' n (%)	43 39.00 (86.67)	21 20.53 (76.04)	2.39 [0.62; 9.13] 0.203	1.14 [0.88; 1.48] 0.315	0.106 [-0.094; 0.307] 0.299
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
PASI75 Response Week 52, N' n (%)	35 31.43 (82.71)	28 19.64 (65.47)	2.64 [0.79; 8.77] 0.113	1.26 [0.93; 1.72] 0.133	0.172 [-0.041; 0.386] 0.114
PASI90 Response Week 52, N' n (%)	35 24.06 (63.32)	28 11.23 (37.43)	2.86 [1.04; 7.87] 0.042	1.69 [1.00; 2.87] 0.051	0.259 [0.026; 0.492] 0.030
PASI100 Response Week 52, N' n (%)	35 17.00 (44.74)	28 7.05 (23.50)	2.56 [0.88; 7.49] 0.086	1.90 [0.91; 3.99] 0.087	0.212 [-0.007; 0.432] 0.058
PASI Absolute ≤ 3 Week 52, N' n (%)	35 31.50 (82.89)	28 17.91 (59.70)	3.48 [1.06; 11.48] 0.040	1.39 [1.00; 1.94] 0.054	0.232 [0.015; 0.448] 0.036

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 14.10 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.789				
PASI90 Response Week 52	p=0.805				
PASI100 Response Week 52	p=0.863				
PASI Absolute ≤ 3 Week 52	p=0.837				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
PASI75 Response Week 52, N' n (%)	29 28.00 (93.33)	26 24.04 (72.85)	5.94 [1.06; 33.22] 0.042	1.28 [1.00; 1.64] 0.048	0.205 [0.017; 0.392] 0.032
PASI90 Response Week 52, N' n (%)	29 21.99 (73.30)	26 15.74 (47.70)	3.09 [1.04; 9.24] 0.043	1.54 [1.00; 2.36] 0.048	0.256 [0.020; 0.492] 0.034
PASI100 Response Week 52, N' n (%)	29 13.43 (44.77)	26 9.17 (27.79)	2.10 [0.71; 6.23] 0.180	1.61 [0.81; 3.21] 0.174	0.170 [-0.068; 0.408] 0.162
PASI Absolute ≤ 3 Week 52, N' n (%)	29 26.00 (86.67)	26 22.48 (68.12)	3.39 [0.85; 13.50] 0.083	1.27 [0.96; 1.70] 0.099	0.185 [-0.024; 0.394] 0.082
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
PASI75 Response Week 52, N' n (%)	49 46.18 (90.55)	33 24.99 (73.50)	4.44 [1.20; 16.41] 0.025	1.23 [0.99; 1.54] 0.065	0.170 [0.001; 0.340] 0.049
PASI90 Response Week 52, N' n (%)	49 37.98 (74.47)	33 18.90 (55.59)	2.58 [1.00; 6.67] 0.051	1.34 [0.95; 1.89] 0.094	0.189 [-0.018; 0.395] 0.073
PASI100 Response Week 52, N' n (%)	49 23.31 (45.71)	33 11.19 (32.91)	1.85 [0.73; 4.69] 0.193	1.39 [0.78; 2.46] 0.260	0.128 [-0.083; 0.339] 0.235
PASI Absolute ≤ 3 Week 52, N' n (%)	49 43.78 (85.84)	33 24.96 (73.41)	2.81 [0.87; 9.09] 0.084	1.17 [0.93; 1.48] 0.187	0.124 [-0.054; 0.302] 0.171

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 14.11 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.987				
PASI90 Response Week 52	p=0.315				
PASI100 Response Week 52	p=0.775				
PASI Absolute ≤ 3 Week 52	p=0.043				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
PASI75 Response Week 52, N' n (%)	39 38.43 (89.37)	39 30.75 (71.51)	3.56 [1.00; 12.63] 0.050	1.25 [1.00; 1.56] 0.048	0.179 [0.011; 0.346] 0.037
PASI90 Response Week 52, N' n (%)	39 34.05 (79.19)	39 22.01 (51.19)	3.64 [1.38; 9.59] 0.009	1.55 [1.11; 2.16] 0.010	0.280 [0.086; 0.474] 0.005
PASI100 Response Week 52, N' n (%)	39 18.43 (42.86)	39 13.19 (30.67)	1.61 [0.65; 4.02] 0.303	1.40 [0.79; 2.48] 0.252	0.122 [-0.082; 0.326] 0.242
PASI Absolute ≤ 3 Week 52, N' n (%)	39 39.50 (91.86)	39 28.31 (65.84)	6.60 [1.62; 26.96] 0.009	1.40 [1.10; 1.77] 0.006	0.260 [0.092; 0.428] 0.002
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
PASI75 Response Week 52, N' n (%)	41 38.00 (90.48)	20 18.28 (76.17)	3.50 [0.80; 15.29] 0.096	1.19 [0.92; 1.54] 0.190	0.143 [-0.059; 0.345] 0.165
PASI90 Response Week 52, N' n (%)	41 26.95 (64.17)	20 12.63 (52.63)	1.75 [0.61; 5.02] 0.301	1.22 [0.78; 1.92] 0.388	0.115 [-0.136; 0.367] 0.369
PASI100 Response Week 52, N' n (%)	41 18.31 (43.60)	20 7.17 (29.87)	1.99 [0.66; 5.98] 0.221	1.46 [0.72; 2.98] 0.298	0.137 [-0.103; 0.377] 0.262
PASI Absolute ≤ 3 Week 52, N' n (%)	41 32.00 (76.19)	20 19.13 (79.71)	0.92 [0.24; 3.47] 0.902	0.96 [0.73; 1.26] 0.753	-0.035 [-0.250; 0.180] 0.749

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				



### 14.12 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	N.E.				
PASI90 Response Week 52	p=0.252				
PASI100 Response Week 52	p=0.116				
PASI Absolute ≤ 3 Week 52	N.E.				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
PASI75 Response Week 52, N' n (%)	58 53.43 (86.18)	40 32.96 (70.13)	3.21 [1.13; 9.13] 0.029	1.23 [0.98; 1.54] 0.068	0.160 [-0.003; 0.324] 0.054
PASI90 Response Week 52, N' n (%)	58 39.01 (62.92)	40 21.64 (46.04)	2.14 [0.96; 4.74] 0.062	1.37 [0.94; 1.98] 0.099	0.169 [-0.021; 0.358] 0.081
PASI100 Response Week 52, N' n (%)	58 25.31 (40.82)	40 10.36 (22.04)	2.70 [1.11; 6.56] 0.028	1.85 [0.99; 3.47] 0.054	0.188 [0.015; 0.361] 0.033
PASI Absolute ≤ 3 Week 52, N' n (%)	58 48.50 (78.23)	40 31.11 (66.19)	2.20 [0.87; 5.57] 0.095	1.18 [0.92; 1.52] 0.190	0.120 [-0.054; 0.295] 0.177
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
PASI75 Response Week 52, N' n (%)	19 20.00 (100.00)	17 15.07 (83.72)	N.E.	1.19 [0.97; 1.47] 0.091	0.163 [-0.010; 0.335] 0.065
PASI90 Response Week 52, N' n (%)	19 18.99 (94.95)	17 12.00 (66.67)	8.63 [0.91; 81.50] 0.060	1.42 [1.01; 2.01] 0.043	0.283 [0.045; 0.521] 0.020
PASI100 Response Week 52, N' n (%)	19 9.43 (47.15)	17 9.00 (50.00)	0.74 [0.20; 2.81] 0.663	0.94 [0.48; 1.83] 0.859	-0.028 [-0.350; 0.293] 0.862
PASI Absolute ≤ 3 Week 52, N' n (%)	19 20.00 (100.00)	17 15.33 (85.17)	N.E.	1.17 [0.96; 1.44] 0.119	0.148 [-0.023; 0.320] 0.090

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 14.13 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.334				
PASI90 Response Week 52	p=0.949				
PASI100 Response Week 52	p=0.223				
PASI Absolute ≤ 3 Week 52	p=0.922				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
PASI75 Response Week 52, N' n (%)	58 57.43 (91.16)	44 35.59 (69.78)	4.70 [1.54; 14.36] 0.007	1.31 [1.07; 1.60] 0.010	0.214 [0.064; 0.363] 0.005
PASI90 Response Week 52, N' n (%)	58 46.00 (73.02)	44 25.44 (49.88)	2.77 [1.24; 6.17] 0.013	1.46 [1.06; 2.01] 0.019	0.231 [0.053; 0.409] 0.011
PASI100 Response Week 52, N' n (%)	58 26.74 (42.44)	44 12.31 (24.14)	2.33 [1.01; 5.38] 0.047	1.76 [0.99; 3.13] 0.054	0.183 [0.011; 0.355] 0.037
PASI Absolute ≤ 3 Week 52, N' n (%)	58 52.50 (83.33)	44 34.59 (67.82)	2.47 [0.96; 6.32] 0.059	1.23 [0.98; 1.54] 0.075	0.155 [-0.008; 0.318] 0.062
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
PASI75 Response Week 52, N' n (%)	19 16.00 (84.21)	12 10.00 (83.33)	1.50 [0.19; 11.72] 0.700	1.01 [0.73; 1.39] 0.949	0.009 [-0.258; 0.276] 0.949
PASI90 Response Week 52, N' n (%)	19 13.00 (68.42)	12 6.00 (50.00)	2.61 [0.56; 12.15] 0.220	1.37 [0.72; 2.60] 0.339	0.184 [-0.168; 0.536] 0.305
PASI100 Response Week 52, N' n (%)	19 8.00 (42.11)	12 6.00 (50.00)	0.81 [0.18; 3.56] 0.778	0.84 [0.39; 1.82] 0.663	-0.079 [-0.439; 0.281] 0.667
PASI Absolute ≤ 3 Week 52, N' n (%)	19 16.00 (84.21)	12 9.00 (75.00)	2.74 [0.40; 18.91] 0.305	1.12 [0.77; 1.64] 0.551	0.092 [-0.203; 0.387] 0.540

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value            N-N' is the number of values with MI.            n (%): Number and percentage of patients with event            CI: Confidence Interval            MI: Multiple Imputation            N.E.: Not estimable            OR: Odds Ratio            RR: Relative Risk            RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.            RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:            n and % are averages of all imputations.            P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.            OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.            RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) PASI75 Response, PASI90 Response, PASI100 Response, PASI Absolute &lt;= 3, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>				

### 14.14 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.914				
PASI90 Response Week 52	p=0.796				
PASI100 Response Week 52	p=0.830				
PASI Absolute ≤ 3 Week 52	p=0.613				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
PASI75 Response Week 52, N' n (%)	66 63.43 (89.34)	46 38.96 (73.51)	3.61 [1.25; 10.42] 0.018	1.22 [1.01; 1.47] 0.043	0.158 [0.013; 0.303] 0.032
PASI90 Response Week 52, N' n (%)	66 49.00 (69.01)	46 26.64 (50.26)	2.39 [1.11; 5.14] 0.026	1.37 [1.00; 1.88] 0.049	0.187 [0.012; 0.363] 0.036
PASI100 Response Week 52, N' n (%)	66 26.74 (37.66)	46 15.36 (28.98)	1.55 [0.71; 3.42] 0.274	1.30 [0.77; 2.20] 0.328	0.087 [-0.082; 0.256] 0.313
PASI Absolute ≤ 3 Week 52, N' n (%)	66 58.50 (82.39)	46 38.11 (71.91)	2.12 [0.84; 5.33] 0.112	1.15 [0.93; 1.41] 0.194	0.105 [-0.049; 0.259] 0.183
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
PASI75 Response Week 52, N' n (%)	13 12.00 (92.31)	10 7.00 (70.00)	4.19 [0.36; 49.12] 0.254	1.32 [0.85; 2.04] 0.213	0.223 [-0.096; 0.542] 0.170
PASI90 Response Week 52, N' n (%)	13 11.00 (84.62)	10 6.00 (60.00)	3.16 [0.44; 22.83] 0.254	1.41 [0.81; 2.46] 0.226	0.246 [-0.115; 0.608] 0.182
PASI100 Response Week 52, N' n (%)	13 9.00 (69.23)	10 5.00 (50.00)	1.91 [0.34; 10.72] 0.461	1.38 [0.68; 2.84] 0.374	0.192 [-0.206; 0.591] 0.345
PASI Absolute ≤ 3 Week 52, N' n (%)	13 12.00 (92.31)	10 7.00 (70.00)	4.18 [0.36; 48.95] 0.255	1.32 [0.85; 2.04] 0.213	0.223 [-0.096; 0.542] 0.170

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) PASI75 Response, PASI90 Response, PASI100 Response, PASI Absolute &lt;= 3, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>				

### 14.15 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.421				
PASI90 Response Week 52	p=0.355				
PASI100 Response Week 52	p=0.399				
PASI Absolute ≤ 3 Week 52	p=0.388				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
PASI75 Response Week 52, N' n (%)	19 19.25 (87.50)	20 19.52 (75.08)	2.10 [0.38; 11.48] 0.394	1.17 [0.87; 1.56] 0.300	0.124 [-0.105; 0.353] 0.288
PASI90 Response Week 52, N' n (%)	19 14.02 (63.73)	20 13.44 (51.69)	1.52 [0.46; 5.06] 0.494	1.23 [0.75; 2.03] 0.408	0.120 [-0.163; 0.403] 0.405
PASI100 Response Week 52, N' n (%)	19 9.43 (42.86)	20 5.31 (20.42)	2.77 [0.73; 10.46] 0.134	2.11 [0.83; 5.33] 0.116	0.224 [-0.041; 0.490] 0.097
PASI Absolute ≤ 3 Week 52, N' n (%)	19 16.72 (76.00)	20 17.26 (66.38)	1.42 [0.36; 5.57] 0.618	1.15 [0.79; 1.67] 0.479	0.096 [-0.168; 0.360] 0.476
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
PASI75 Response Week 52, N' n (%)	61 57.18 (90.76)	39 29.51 (71.98)	4.99 [1.50; 16.53] 0.009	1.26 [1.02; 1.56] 0.030	0.188 [0.031; 0.345] 0.019
PASI90 Response Week 52, N' n (%)	61 46.98 (74.57)	39 21.20 (51.71)	3.07 [1.30; 7.29] 0.011	1.44 [1.04; 2.01] 0.030	0.229 [0.041; 0.417] 0.017
PASI100 Response Week 52, N' n (%)	61 27.31 (43.35)	39 15.05 (36.71)	1.41 [0.62; 3.21] 0.413	1.18 [0.72; 1.93] 0.509	0.066 [-0.126; 0.259] 0.499
PASI Absolute ≤ 3 Week 52, N' n (%)	61 54.78 (86.95)	39 30.18 (73.61)	3.09 [1.03; 9.25] 0.044	1.18 [0.96; 1.46] 0.122	0.133 [-0.028; 0.295] 0.106

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value            N-N' is the number of values with MI.            n (%): Number and percentage of patients with event            CI: Confidence Interval            MI: Multiple Imputation            N.E.: Not estimable            OR: Odds Ratio            RR: Relative Risk            RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.            RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:            n and % are averages of all imputations.            P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.            OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.            RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				



**14.16 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Linkage Variant rs10891185 (FAS)**

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.290				
PASI90 Response Week 52	p=0.474				
PASI100 Response Week 52	p=0.392				
PASI Absolute ≤ 3 Week 52	p=0.987				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
PASI75 Response Week 52, N' n (%)	49 48.00 (94.12)	29 27.39 (78.26)	6.40 [1.36; 30.21] 0.019	1.20 [0.99; 1.47] 0.067	0.159 [-0.000; 0.317] 0.050
PASI90 Response Week 52, N' n (%)	49 40.94 (80.27)	29 21.41 (61.17)	3.11 [1.12; 8.65] 0.030	1.31 [0.97; 1.78] 0.079	0.191 [-0.007; 0.389] 0.059
PASI100 Response Week 52, N' n (%)	49 21.74 (42.63)	29 13.31 (38.03)	1.35 [0.54; 3.38] 0.521	1.12 [0.65; 1.92] 0.678	0.046 [-0.168; 0.260] 0.674
PASI Absolute ≤ 3 Week 52, N' n (%)	49 44.00 (86.27)	29 27.53 (78.66)	2.26 [0.64; 7.96] 0.204	1.10 [0.88; 1.36] 0.397	0.076 [-0.097; 0.249] 0.389
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
PASI75 Response Week 52, N' n (%)	31 28.43 (83.62)	30 21.64 (67.63)	2.18 [0.63; 7.52] 0.219	1.24 [0.93; 1.65] 0.151	0.160 [-0.050; 0.370] 0.135
PASI90 Response Week 52, N' n (%)	31 20.06 (59.00)	30 13.23 (41.34)	1.83 [0.67; 5.01] 0.238	1.43 [0.86; 2.36] 0.166	0.177 [-0.063; 0.416] 0.148
PASI100 Response Week 52, N' n (%)	31 15.00 (44.12)	30 7.05 (22.03)	2.52 [0.85; 7.52] 0.097	2.00 [0.94; 4.27] 0.072	0.221 [0.000; 0.441] 0.050
PASI Absolute ≤ 3 Week 52, N' n (%)	31 27.50 (80.88)	30 19.91 (62.22)	2.29 [0.71; 7.43] 0.166	1.30 [0.94; 1.79] 0.110	0.187 [-0.032; 0.405] 0.094

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

**14.17 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Linkage Variant rs12065362 (FAS)**

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.469				
PASI90 Response Week 52	p=0.391				
PASI100 Response Week 52	p=0.582				
PASI Absolute ≤ 3 Week 52	p=0.462				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
PASI75 Response Week 52, N' n (%)	29 28.00 (93.33)	24 22.04 (71.10)	6.19 [1.12; 34.23] 0.037	1.31 [1.01; 1.71] 0.042	0.222 [0.027; 0.418] 0.026
PASI90 Response Week 52, N' n (%)	29 21.99 (73.30)	24 13.74 (44.32)	3.52 [1.16; 10.66] 0.026	1.66 [1.04; 2.63] 0.032	0.290 [0.050; 0.530] 0.018
PASI100 Response Week 52, N' n (%)	29 13.43 (44.77)	24 8.17 (26.35)	2.25 [0.74; 6.84] 0.153	1.70 [0.83; 3.49] 0.149	0.184 [-0.055; 0.424] 0.132
PASI Absolute ≤ 3 Week 52, N' n (%)	29 26.00 (86.67)	24 20.48 (66.06)	3.59 [0.91; 14.15] 0.068	1.31 [0.97; 1.78] 0.081	0.206 [-0.010; 0.422] 0.062
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
PASI75 Response Week 52, N' n (%)	51 48.43 (88.05)	35 26.99 (74.97)	2.89 [0.89; 9.38] 0.076	1.17 [0.95; 1.45] 0.140	0.131 [-0.036; 0.297] 0.124
PASI90 Response Week 52, N' n (%)	51 39.01 (70.93)	35 20.90 (58.06)	1.88 [0.77; 4.64] 0.168	1.22 [0.88; 1.69] 0.230	0.129 [-0.073; 0.331] 0.212
PASI100 Response Week 52, N' n (%)	51 23.31 (42.38)	35 12.19 (33.86)	1.51 [0.62; 3.69] 0.369	1.25 [0.72; 2.18] 0.429	0.085 [-0.119; 0.290] 0.414
PASI Absolute ≤ 3 Week 52, N' n (%)	51 45.50 (82.73)	35 26.96 (74.89)	1.87 [0.63; 5.53] 0.258	1.10 [0.88; 1.39] 0.390	0.078 [-0.097; 0.254] 0.380

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

**14.18 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Linkage Variant rs11721988 (FAS)**

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	p=0.987				
PASI90 Response Week 52	p=0.315				
PASI100 Response Week 52	p=0.775				
PASI Absolute ≤ 3 Week 52	p=0.043				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
PASI75 Response Week 52, N' n (%)	39 38.43 (89.37)	39 30.75 (71.51)	3.56 [1.00; 12.63] 0.050	1.25 [1.00; 1.56] 0.048	0.179 [0.011; 0.346] 0.037
PASI90 Response Week 52, N' n (%)	39 34.05 (79.19)	39 22.01 (51.19)	3.64 [1.38; 9.59] 0.009	1.55 [1.11; 2.16] 0.010	0.280 [0.086; 0.474] 0.005
PASI100 Response Week 52, N' n (%)	39 18.43 (42.86)	39 13.19 (30.67)	1.61 [0.65; 4.02] 0.303	1.40 [0.79; 2.48] 0.252	0.122 [-0.082; 0.326] 0.242
PASI Absolute ≤ 3 Week 52, N' n (%)	39 39.50 (91.86)	39 28.31 (65.84)	6.60 [1.62; 26.96] 0.009	1.40 [1.10; 1.77] 0.006	0.260 [0.092; 0.428] 0.002
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
PASI75 Response Week 52, N' n (%)	41 38.00 (90.48)	20 18.28 (76.17)	3.50 [0.80; 15.29] 0.096	1.19 [0.92; 1.54] 0.190	0.143 [-0.059; 0.345] 0.165
PASI90 Response Week 52, N' n (%)	41 26.95 (64.17)	20 12.63 (52.63)	1.75 [0.61; 5.02] 0.301	1.22 [0.78; 1.92] 0.388	0.115 [-0.136; 0.367] 0.369
PASI100 Response Week 52, N' n (%)	41 18.31 (43.60)	20 7.17 (29.87)	1.99 [0.66; 5.98] 0.221	1.46 [0.72; 2.98] 0.298	0.137 [-0.103; 0.377] 0.262
PASI Absolute ≤ 3 Week 52, N' n (%)	41 32.00 (76.19)	20 19.13 (79.71)	0.92 [0.24; 3.47] 0.902	0.96 [0.73; 1.26] 0.753	-0.035 [-0.250; 0.180] 0.749

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 14.19 PASI Response PASI75 / PASI90 / PASI100 / PASI ≤ 3 by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASI75 Response Week 52	N.E.				
PASI90 Response Week 52	p=0.313				
PASI100 Response Week 52	p=0.127				
PASI Absolute ≤ 3 Week 52	N.E.				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
PASI75 Response Week 52, N' n (%)	61 56.43 (86.82)	42 33.96 (69.31)	3.53 [1.26; 9.89] 0.017	1.25 [1.01; 1.56] 0.044	0.175 [0.015; 0.335] 0.032
PASI90 Response Week 52, N' n (%)	61 42.01 (64.63)	42 22.64 (46.20)	2.28 [1.04; 4.99] 0.039	1.40 [0.98; 2.00] 0.066	0.184 [-0.000; 0.369] 0.051
PASI100 Response Week 52, N' n (%)	61 27.31 (42.02)	42 11.36 (23.18)	2.62 [1.12; 6.17] 0.027	1.81 [1.00; 3.29] 0.050	0.188 [0.018; 0.359] 0.031
PASI Absolute ≤ 3 Week 52, N' n (%)	61 51.50 (79.23)	42 32.11 (65.53)	2.40 [0.96; 5.99] 0.060	1.21 [0.95; 1.55] 0.129	0.137 [-0.033; 0.307] 0.115
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
PASI75 Response Week 52, N' n (%)	17 18.00 (100.00)	17 15.07 (83.72)	N.E.	1.19 [0.97; 1.47] 0.091	0.163 [-0.010; 0.335] 0.065
PASI90 Response Week 52, N' n (%)	17 16.99 (94.39)	17 12.00 (66.67)	7.79 [0.82; 74.08] 0.074	1.42 [1.00; 2.00] 0.049	0.277 [0.035; 0.520] 0.025
PASI100 Response Week 52, N' n (%)	17 8.43 (46.83)	17 9.00 (50.00)	0.75 [0.19; 2.92] 0.673	0.94 [0.47; 1.86] 0.848	-0.032 [-0.362; 0.299] 0.851
PASI Absolute ≤ 3 Week 52, N' n (%)	17 18.00 (100.00)	17 15.33 (85.17)	N.E.	1.17 [0.96; 1.44] 0.119	0.148 [-0.023; 0.320] 0.090

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				



### 15.0 Patient's Assessment of PsA Pain (VAS) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	110 (100.0)	100 (99.0)	210 (99.5)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	108 (98.2)	95 (94.1)	203 (96.2)
Week 20 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	102 (92.7)	86 (85.1)	188 (89.1)
Week 32 Returns	102 (92.7)	81 (80.2)	183 (86.7)
Week 36 Returns	102 (92.7)	84 (83.2)	186 (88.2)
Week 40 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 44 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 48 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 52 Returns	104 (94.5)	80 (79.2)	184 (87.2)

### 15.1 Patient's Assessment of PsA Pain (VAS) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	57.89 (25.01)	59.71 (24.00)		
Week 52 Mean (SD)	26.17 (22.68)	27.06 (22.73)		
Week 2 Adjusted Mean Change (SE)	-11.54 (1.84)	-10.65 (1.94)		
Week 4 Adjusted Mean Change (SE)	-20.77 (1.96)	-16.07 (2.06)		
Week 8 Adjusted Mean Change (SE)	-22.29 (1.99)	-20.63 (2.10)		
Week 12 Adjusted Mean Change (SE)	-26.22 (2.13)	-21.40 (2.24)		
Week 16 Adjusted Mean Change (SE)	-27.10 (2.07)	-23.58 (2.19)		
Week 20 Adjusted Mean Change (SE)	-26.29 (2.22)	-23.24 (2.38)		
Week 24 Adjusted Mean Change (SE)	-27.51 (2.13)	-22.89 (2.28)		
Week 28 Adjusted Mean Change (SE)	-28.59 (1.98)	-23.49 (2.12)		
Week 32 Adjusted Mean Change (SE)	-28.74 (2.04)	-28.92 (2.22)		
Week 36 Adjusted Mean Change (SE)	-30.98 (1.94)	-28.58 (2.10)		
Week 40 Adjusted Mean Change (SE)	-30.20 (2.05)	-28.13 (2.23)		
Week 44 Adjusted Mean Change (SE)	-31.23 (2.07)	-28.79 (2.24)		
Week 48 Adjusted Mean Change (SE)	-30.02 (2.07)	-29.68 (2.25)		
Week 52 Adjusted Mean Change (SE)	-31.64 (2.07)	-30.32 (2.27)	-1.32 [-7.37; 4.73]	0.667
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 15.2 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.576</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	57.85 (24.66)	60.00 (23.84)		
Week 52 Mean (SD)	26.36 (22.78)	26.84 (23.08)		
Week 2 Adjusted Mean Change (SE)	-11.17 (1.90)	-11.37 (2.01)		
Week 4 Adjusted Mean Change (SE)	-20.15 (2.02)	-15.77 (2.14)		
Week 8 Adjusted Mean Change (SE)	-21.88 (2.06)	-20.94 (2.18)		
Week 12 Adjusted Mean Change (SE)	-26.10 (2.22)	-21.58 (2.33)		
Week 16 Adjusted Mean Change (SE)	-26.85 (2.14)	-23.79 (2.28)		
Week 20 Adjusted Mean Change (SE)	-26.43 (2.31)	-23.12 (2.48)		
Week 24 Adjusted Mean Change (SE)	-27.43 (2.21)	-22.86 (2.37)		
Week 28 Adjusted Mean Change (SE)	-28.36 (2.06)	-23.37 (2.22)		
Week 32 Adjusted Mean Change (SE)	-28.48 (2.12)	-28.39 (2.33)		
Week 36 Adjusted Mean Change (SE)	-30.84 (2.00)	-29.52 (2.19)		
Week 40 Adjusted Mean Change (SE)	-30.29 (2.13)	-28.45 (2.33)		
Week 44 Adjusted Mean Change (SE)	-31.03 (2.14)	-28.72 (2.35)		
Week 48 Adjusted Mean Change (SE)	-29.74 (2.15)	-29.53 (2.36)		
Week 52 Adjusted Mean Change (SE)	-31.42 (2.14)	-30.59 (2.37)	-0.83 [-7.13; 5.47]	0.796
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	58.43 (31.97)	55.86 (27.76)		
Week 52 Mean (SD)	23.17 (22.60)	29.83 (19.49)		
Week 2 Adjusted Mean Change (SE)	-17.00 (7.31)	-1.20 (7.30)		
Week 4 Adjusted Mean Change (SE)	-29.86 (7.77)	-19.96 (7.77)		
Week 8 Adjusted Mean Change (SE)	-28.29 (7.92)	-16.45 (7.91)		
Week 12 Adjusted Mean Change (SE)	-28.00 (8.43)	-19.08 (8.43)		
Week 16 Adjusted Mean Change (SE)	-30.95 (8.46)	-21.03 (8.20)		
Week 20 Adjusted Mean Change (SE)	-24.43 (8.81)	-25.06 (9.09)		
Week 24 Adjusted Mean Change (SE)	-28.72 (8.41)	-23.39 (8.65)		
Week 28 Adjusted Mean Change (SE)	-31.86 (7.76)	-24.53 (7.76)		
Week 32 Adjusted Mean Change (SE)	-32.43 (8.01)	-33.67 (8.01)		
Week 36 Adjusted Mean Change (SE)	-33.00 (7.98)	-18.32 (7.58)		
Week 40 Adjusted Mean Change (SE)	-29.00 (8.08)	-24.27 (8.07)		
Week 44 Adjusted Mean Change (SE)	-34.23 (8.35)	-29.23 (8.14)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-34.45 (8.34)	-30.81 (8.12)		
Week 52 Adjusted Mean Change (SE)	-35.25 (8.35)	-26.94 (8.29)	-8.31 [-31.49; 14.88]	0.481
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.3 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.776</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	54.89 (24.78)	56.72 (22.44)		
Week 52 Mean (SD)	21.95 (21.07)	22.80 (22.38)		
Week 2 Adjusted Mean Change (SE)	-14.08 (2.42)	-11.69 (2.59)		
Week 4 Adjusted Mean Change (SE)	-23.06 (2.56)	-16.92 (2.74)		
Week 8 Adjusted Mean Change (SE)	-27.27 (2.56)	-23.26 (2.74)		
Week 12 Adjusted Mean Change (SE)	-29.94 (2.75)	-25.45 (2.92)		
Week 16 Adjusted Mean Change (SE)	-29.85 (2.68)	-26.69 (2.87)		
Week 20 Adjusted Mean Change (SE)	-31.10 (2.86)	-25.21 (3.09)		
Week 24 Adjusted Mean Change (SE)	-31.65 (2.69)	-28.87 (2.92)		
Week 28 Adjusted Mean Change (SE)	-30.98 (2.53)	-27.33 (2.76)		
Week 32 Adjusted Mean Change (SE)	-32.71 (2.63)	-31.93 (2.91)		
Week 36 Adjusted Mean Change (SE)	-33.10 (2.53)	-31.76 (2.76)		
Week 40 Adjusted Mean Change (SE)	-34.00 (2.62)	-32.61 (2.89)		
Week 44 Adjusted Mean Change (SE)	-35.37 (2.64)	-31.40 (2.90)		
Week 48 Adjusted Mean Change (SE)	-34.34 (2.64)	-33.34 (2.89)		
Week 52 Adjusted Mean Change (SE)	-35.29 (2.64)	-34.70 (2.94)	-0.58 [-8.34; 7.17]	0.882
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	62.39 (24.94)	63.59 (25.61)		
Week 52 Mean (SD)	32.66 (23.77)	32.82 (22.24)		
Week 2 Adjusted Mean Change (SE)	-7.82 (2.97)	-9.21 (2.94)		
Week 4 Adjusted Mean Change (SE)	-17.41 (3.13)	-14.90 (3.13)		
Week 8 Adjusted Mean Change (SE)	-14.92 (3.14)	-17.08 (3.14)		
Week 12 Adjusted Mean Change (SE)	-20.77 (3.35)	-16.00 (3.36)		
Week 16 Adjusted Mean Change (SE)	-23.03 (3.26)	-19.39 (3.32)		
Week 20 Adjusted Mean Change (SE)	-19.09 (3.54)	-20.85 (3.66)		
Week 24 Adjusted Mean Change (SE)	-21.38 (3.35)	-14.68 (3.41)		
Week 28 Adjusted Mean Change (SE)	-25.28 (3.18)	-18.28 (3.25)		
Week 32 Adjusted Mean Change (SE)	-22.78 (3.25)	-24.84 (3.38)		
Week 36 Adjusted Mean Change (SE)	-27.83 (3.11)	-24.29 (3.22)		
Week 40 Adjusted Mean Change (SE)	-24.58 (3.23)	-22.10 (3.36)		
Week 44 Adjusted Mean Change (SE)	-24.99 (3.28)	-25.43 (3.43)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 48 Adjusted Mean Change (SE)	-23.58 (3.26)	-24.72 (3.42)		
Week 52 Adjusted Mean Change (SE)	-26.23 (3.26)	-24.43 (3.42)	-1.81 [-11.06; 7.45]	0.701
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.4 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.983</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	43.00 (22.09)	32.71 (24.10)		
Week 52 Mean (SD)	18.48 (19.19)	17.00 (21.16)		
Week 2 Adjusted Mean Change (SE)	-10.84 (4.06)	-17.09 (4.51)		
Week 4 Adjusted Mean Change (SE)	-20.74 (4.33)	-18.38 (4.81)		
Week 8 Adjusted Mean Change (SE)	-20.84 (4.39)	-25.70 (4.88)		
Week 12 Adjusted Mean Change (SE)	-26.06 (4.77)	-19.80 (5.21)		
Week 16 Adjusted Mean Change (SE)	-29.83 (4.55)	-20.17 (5.05)		
Week 20 Adjusted Mean Change (SE)	-27.32 (5.01)	-19.36 (5.60)		
Week 24 Adjusted Mean Change (SE)	-27.41 (4.77)	-23.34 (5.34)		
Week 28 Adjusted Mean Change (SE)	-33.40 (4.37)	-27.32 (4.97)		
Week 32 Adjusted Mean Change (SE)	-31.84 (4.53)	-31.29 (5.21)		
Week 36 Adjusted Mean Change (SE)	-31.26 (4.28)	-34.57 (4.94)		
Week 40 Adjusted Mean Change (SE)	-32.23 (4.57)	-29.45 (5.33)		
Week 44 Adjusted Mean Change (SE)	-34.70 (4.55)	-27.21 (5.26)		
Week 48 Adjusted Mean Change (SE)	-29.81 (4.63)	-27.17 (5.36)		
Week 52 Adjusted Mean Change (SE)	-35.76 (4.56)	-33.36 (5.34)	-2.40 [-15.74; 10.94]	0.723
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	62.05 (24.28)	66.80 (18.37)		
Week 52 Mean (SD)	28.36 (23.21)	29.58 (22.57)		
Week 2 Adjusted Mean Change (SE)	-11.76 (2.09)	-8.89 (2.23)		
Week 4 Adjusted Mean Change (SE)	-20.78 (2.24)	-15.45 (2.39)		
Week 8 Adjusted Mean Change (SE)	-22.71 (2.27)	-19.24 (2.43)		
Week 12 Adjusted Mean Change (SE)	-26.21 (2.43)	-21.88 (2.60)		
Week 16 Adjusted Mean Change (SE)	-26.31 (2.36)	-24.59 (2.54)		
Week 20 Adjusted Mean Change (SE)	-26.00 (2.52)	-24.28 (2.74)		
Week 24 Adjusted Mean Change (SE)	-27.51 (2.43)	-22.78 (2.64)		
Week 28 Adjusted Mean Change (SE)	-27.32 (2.24)	-22.45 (2.45)		
Week 32 Adjusted Mean Change (SE)	-27.91 (2.32)	-28.31 (2.57)		
Week 36 Adjusted Mean Change (SE)	-30.95 (2.21)	-26.97 (2.42)		
Week 40 Adjusted Mean Change (SE)	-29.64 (2.34)	-27.81 (2.56)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-30.24 (2.35)	-29.27 (2.58)		
Week 48 Adjusted Mean Change (SE)	-30.00 (2.36)	-30.26 (2.60)		
Week 52 Adjusted Mean Change (SE)	-30.54 (2.35)	-29.56 (2.60)	-0.98 [-7.82; 5.87]	0.779
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 15.5 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.703</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	56.88 (23.09)	61.33 (24.21)		
Week 52 Mean (SD)	26.44 (19.20)	24.95 (20.08)		
Week 2 Adjusted Mean Change (SE)	-14.30 (2.95)	-15.22 (2.68)		
Week 4 Adjusted Mean Change (SE)	-24.95 (3.15)	-19.44 (2.87)		
Week 8 Adjusted Mean Change (SE)	-21.87 (3.24)	-22.12 (2.96)		
Week 12 Adjusted Mean Change (SE)	-25.39 (3.46)	-23.23 (3.15)		
Week 16 Adjusted Mean Change (SE)	-27.88 (3.35)	-21.83 (3.09)		
Week 20 Adjusted Mean Change (SE)	-25.10 (3.65)	-24.53 (3.39)		
Week 24 Adjusted Mean Change (SE)	-28.20 (3.48)	-22.85 (3.26)		
Week 28 Adjusted Mean Change (SE)	-29.96 (3.23)	-24.47 (3.04)		
Week 32 Adjusted Mean Change (SE)	-29.50 (3.31)	-30.30 (3.15)		
Week 36 Adjusted Mean Change (SE)	-32.16 (3.18)	-28.93 (3.02)		
Week 40 Adjusted Mean Change (SE)	-28.08 (3.34)	-26.95 (3.20)		
Week 44 Adjusted Mean Change (SE)	-32.31 (3.38)	-29.26 (3.24)		
Week 48 Adjusted Mean Change (SE)	-27.65 (3.36)	-31.12 (3.22)		
Week 52 Adjusted Mean Change (SE)	-31.53 (3.38)	-32.84 (3.27)	1.31 [-7.98; 10.60]	0.782
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	58.51 (26.27)	58.06 (23.91)		
Week 52 Mean (SD)	26.02 (24.67)	28.88 (24.88)		
Week 2 Adjusted Mean Change (SE)	-9.83 (2.32)	-5.91 (2.73)		
Week 4 Adjusted Mean Change (SE)	-18.18 (2.47)	-12.60 (2.91)		
Week 8 Adjusted Mean Change (SE)	-22.54 (2.55)	-19.06 (3.00)		
Week 12 Adjusted Mean Change (SE)	-26.74 (2.73)	-19.48 (3.20)		
Week 16 Adjusted Mean Change (SE)	-26.61 (2.65)	-25.33 (3.13)		
Week 20 Adjusted Mean Change (SE)	-26.95 (2.82)	-21.92 (3.37)		
Week 24 Adjusted Mean Change (SE)	-27.09 (2.72)	-22.85 (3.22)		
Week 28 Adjusted Mean Change (SE)	-27.78 (2.52)	-22.54 (2.99)		
Week 32 Adjusted Mean Change (SE)	-28.27 (2.61)	-27.49 (3.16)		
Week 36 Adjusted Mean Change (SE)	-30.27 (2.48)	-28.10 (2.96)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 40 Adjusted Mean Change (SE)	-31.51 (2.62)	-29.06 (3.13)		
Week 44 Adjusted Mean Change (SE)	-30.55 (2.64)	-28.22 (3.16)		
Week 48 Adjusted Mean Change (SE)	-31.52 (2.63)	-28.24 (3.15)		
Week 52 Adjusted Mean Change (SE)	-31.68 (2.63)	-27.93 (3.17)	-3.74 [-11.87; 4.38]	0.364
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit</p> <p>Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.6 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.868</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	56.51 (24.93)	57.88 (26.30)		
Week 52 Mean (SD)	24.39 (22.28)	24.35 (22.48)		
Week 2 Adjusted Mean Change (SE)	-12.30 (2.28)	-12.77 (2.77)		
Week 4 Adjusted Mean Change (SE)	-20.22 (2.43)	-17.10 (2.95)		
Week 8 Adjusted Mean Change (SE)	-23.07 (2.47)	-22.00 (2.99)		
Week 12 Adjusted Mean Change (SE)	-26.95 (2.66)	-23.52 (3.18)		
Week 16 Adjusted Mean Change (SE)	-28.78 (2.57)	-24.97 (3.13)		
Week 20 Adjusted Mean Change (SE)	-26.98 (2.74)	-26.73 (3.41)		
Week 24 Adjusted Mean Change (SE)	-28.98 (2.60)	-27.55 (3.24)		
Week 28 Adjusted Mean Change (SE)	-29.36 (2.43)	-22.86 (3.06)		
Week 32 Adjusted Mean Change (SE)	-29.18 (2.53)	-27.76 (3.26)		
Week 36 Adjusted Mean Change (SE)	-31.63 (2.41)	-29.01 (3.08)		
Week 40 Adjusted Mean Change (SE)	-32.15 (2.55)	-26.87 (3.27)		
Week 44 Adjusted Mean Change (SE)	-33.08 (2.55)	-28.54 (3.26)		
Week 48 Adjusted Mean Change (SE)	-31.08 (2.57)	-30.48 (3.31)		
Week 52 Adjusted Mean Change (SE)	-33.36 (2.55)	-30.87 (3.36)	-2.49 [-10.79; 5.81]	0.555
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	60.50 (25.27)	61.44 (21.73)		
Week 52 Mean (SD)	29.85 (23.37)	29.07 (22.96)		
Week 2 Adjusted Mean Change (SE)	-10.10 (3.14)	-8.61 (2.72)		
Week 4 Adjusted Mean Change (SE)	-21.81 (3.35)	-15.10 (2.91)		
Week 8 Adjusted Mean Change (SE)	-20.82 (3.40)	-19.30 (2.96)		
Week 12 Adjusted Mean Change (SE)	-24.79 (3.61)	-19.34 (3.16)		
Week 16 Adjusted Mean Change (SE)	-23.99 (3.51)	-22.22 (3.07)		
Week 20 Adjusted Mean Change (SE)	-25.05 (3.80)	-19.94 (3.32)		
Week 24 Adjusted Mean Change (SE)	-24.72 (3.62)	-18.43 (3.16)		
Week 28 Adjusted Mean Change (SE)	-27.17 (3.48)	-24.03 (2.97)		
Week 32 Adjusted Mean Change (SE)	-27.88 (3.51)	-29.81 (3.08)		
Week 36 Adjusted Mean Change (SE)	-29.70 (3.34)	-28.04 (2.92)		
Week 40 Adjusted Mean Change (SE)	-26.40 (3.54)	-28.83 (3.09)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-27.61 (3.56)	-28.81 (3.12)		
Week 48 Adjusted Mean Change (SE)	-27.88 (3.56)	-28.82 (3.11)		
Week 52 Adjusted Mean Change (SE)	-28.26 (3.58)	-29.74 (3.11)	1.47 [-7.86; 10.80]	0.756
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.7 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.657</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	56.59 (26.15)	53.03 (30.29)		
Week 52 Mean (SD)	23.50 (22.00)	21.16 (24.43)		
Week 2 Adjusted Mean Change (SE)	-11.95 (2.68)	-18.23 (3.39)		
Week 4 Adjusted Mean Change (SE)	-20.54 (2.89)	-18.47 (3.70)		
Week 8 Adjusted Mean Change (SE)	-21.65 (2.92)	-26.05 (3.75)		
Week 12 Adjusted Mean Change (SE)	-28.41 (3.15)	-23.11 (4.03)		
Week 16 Adjusted Mean Change (SE)	-27.78 (3.03)	-27.31 (3.92)		
Week 20 Adjusted Mean Change (SE)	-25.21 (3.28)	-25.05 (4.25)		
Week 24 Adjusted Mean Change (SE)	-29.52 (3.12)	-24.98 (4.04)		
Week 28 Adjusted Mean Change (SE)	-28.61 (2.89)	-27.58 (3.77)		
Week 32 Adjusted Mean Change (SE)	-30.34 (2.99)	-28.32 (3.95)		
Week 36 Adjusted Mean Change (SE)	-32.02 (2.84)	-29.66 (3.72)		
Week 40 Adjusted Mean Change (SE)	-30.44 (3.01)	-29.03 (3.94)		
Week 44 Adjusted Mean Change (SE)	-32.85 (3.04)	-28.46 (3.99)		
Week 48 Adjusted Mean Change (SE)	-29.80 (3.06)	-29.52 (3.99)		
Week 52 Adjusted Mean Change (SE)	-33.49 (3.04)	-32.92 (4.04)	-0.57 [-10.50; 9.37]	0.911
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	59.02 (24.14)	62.81 (19.94)		
Week 52 Mean (SD)	28.46 (23.19)	29.75 (21.61)		
Week 2 Adjusted Mean Change (SE)	-11.21 (2.49)	-7.05 (2.33)		
Week 4 Adjusted Mean Change (SE)	-20.97 (2.68)	-14.90 (2.51)		
Week 8 Adjusted Mean Change (SE)	-22.86 (2.71)	-18.07 (2.54)		
Week 12 Adjusted Mean Change (SE)	-24.43 (2.90)	-20.55 (2.71)		
Week 16 Adjusted Mean Change (SE)	-26.51 (2.83)	-21.82 (2.66)		
Week 20 Adjusted Mean Change (SE)	-27.19 (3.04)	-22.39 (2.91)		
Week 24 Adjusted Mean Change (SE)	-25.77 (2.92)	-21.89 (2.79)		
Week 28 Adjusted Mean Change (SE)	-28.60 (2.71)	-21.51 (2.60)		
Week 32 Adjusted Mean Change (SE)	-27.25 (2.81)	-29.20 (2.72)		
Week 36 Adjusted Mean Change (SE)	-30.04 (2.68)	-28.13 (2.58)		
Week 40 Adjusted Mean Change (SE)	-30.00 (2.82)	-27.73 (2.74)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-29.83 (2.83)	-29.01 (2.75)		
Week 48 Adjusted Mean Change (SE)	-30.17 (2.85)	-29.83 (2.77)		
Week 52 Adjusted Mean Change (SE)	-30.09 (2.83)	-29.18 (2.77)	-0.91 [-8.71; 6.89]	0.818
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.8 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.354</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	62.51 (22.61)	56.61 (24.07)		
Week 52 Mean (SD)	26.38 (22.04)	24.18 (19.76)		
Week 2 Adjusted Mean Change (SE)	-13.48 (2.69)	-11.11 (2.99)		
Week 4 Adjusted Mean Change (SE)	-22.67 (2.78)	-21.55 (3.08)		
Week 8 Adjusted Mean Change (SE)	-24.06 (2.93)	-23.74 (3.25)		
Week 12 Adjusted Mean Change (SE)	-28.54 (3.07)	-24.86 (3.42)		
Week 16 Adjusted Mean Change (SE)	-28.69 (3.02)	-27.62 (3.37)		
Week 20 Adjusted Mean Change (SE)	-29.99 (3.32)	-25.36 (3.77)		
Week 24 Adjusted Mean Change (SE)	-31.40 (3.22)	-23.67 (3.63)		
Week 28 Adjusted Mean Change (SE)	-32.43 (2.87)	-23.74 (3.24)		
Week 32 Adjusted Mean Change (SE)	-30.81 (2.93)	-29.75 (3.33)		
Week 36 Adjusted Mean Change (SE)	-34.24 (2.80)	-29.74 (3.14)		
Week 40 Adjusted Mean Change (SE)	-33.11 (3.01)	-28.41 (3.39)		
Week 44 Adjusted Mean Change (SE)	-33.59 (3.11)	-29.90 (3.52)		
Week 48 Adjusted Mean Change (SE)	-31.94 (3.12)	-30.49 (3.51)		
Week 52 Adjusted Mean Change (SE)	-32.26 (3.08)	-31.46 (3.51)	-0.80 [-10.04; 8.43]	0.864
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	52.62 (26.31)	57.96 (26.51)		
Week 52 Mean (SD)	26.94 (24.92)	26.19 (25.63)		
Week 2 Adjusted Mean Change (SE)	-10.49 (3.29)	-9.68 (3.75)		
Week 4 Adjusted Mean Change (SE)	-15.42 (3.40)	-11.06 (3.91)		
Week 8 Adjusted Mean Change (SE)	-16.98 (3.58)	-15.95 (4.14)		
Week 12 Adjusted Mean Change (SE)	-22.65 (3.80)	-19.15 (4.34)		
Week 16 Adjusted Mean Change (SE)	-23.09 (3.70)	-24.80 (4.29)		
Week 20 Adjusted Mean Change (SE)	-18.75 (4.08)	-25.72 (4.73)		
Week 24 Adjusted Mean Change (SE)	-22.05 (3.93)	-24.32 (4.62)		
Week 28 Adjusted Mean Change (SE)	-19.64 (3.55)	-27.90 (4.18)		
Week 32 Adjusted Mean Change (SE)	-25.33 (3.66)	-29.57 (4.26)		
Week 36 Adjusted Mean Change (SE)	-24.46 (3.45)	-26.50 (4.07)		
Week 40 Adjusted Mean Change (SE)	-25.16 (3.71)	-30.87 (4.39)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-26.41 (3.85)	-27.56 (4.55)		
Week 48 Adjusted Mean Change (SE)	-25.76 (3.91)	-27.65 (4.62)		
Week 52 Adjusted Mean Change (SE)	-28.36 (3.82)	-29.86 (4.50)	1.51 [-10.12; 13.14]	0.798
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 15.9 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.267</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	59.71 (23.53)	64.15 (20.97)		
Week 52 Mean (SD)	26.16 (22.76)	30.74 (23.56)		
Week 2 Adjusted Mean Change (SE)	-13.64 (2.88)	-5.75 (3.74)		
Week 4 Adjusted Mean Change (SE)	-21.01 (3.06)	-14.00 (4.01)		
Week 8 Adjusted Mean Change (SE)	-22.20 (3.18)	-16.67 (4.18)		
Week 12 Adjusted Mean Change (SE)	-28.11 (3.29)	-24.24 (4.33)		
Week 16 Adjusted Mean Change (SE)	-27.00 (3.16)	-22.27 (4.18)		
Week 20 Adjusted Mean Change (SE)	-27.50 (3.63)	-21.28 (4.93)		
Week 24 Adjusted Mean Change (SE)	-29.22 (3.43)	-23.42 (4.67)		
Week 28 Adjusted Mean Change (SE)	-29.23 (3.13)	-27.67 (4.30)		
Week 32 Adjusted Mean Change (SE)	-29.01 (3.17)	-29.96 (4.35)		
Week 36 Adjusted Mean Change (SE)	-31.28 (3.04)	-26.00 (4.17)		
Week 40 Adjusted Mean Change (SE)	-31.79 (3.26)	-26.06 (4.47)		
Week 44 Adjusted Mean Change (SE)	-34.17 (3.31)	-25.26 (4.60)		
Week 48 Adjusted Mean Change (SE)	-31.67 (3.41)	-26.49 (4.67)		
Week 52 Adjusted Mean Change (SE)	-31.77 (3.33)	-26.80 (4.67)	-4.97 [-16.31; 6.36]	0.387
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	58.21 (25.02)	51.87 (25.85)		
Week 52 Mean (SD)	26.91 (23.38)	23.07 (21.73)		
Week 2 Adjusted Mean Change (SE)	-10.84 (3.13)	-14.81 (3.55)		
Week 4 Adjusted Mean Change (SE)	-18.77 (3.32)	-19.81 (3.77)		
Week 8 Adjusted Mean Change (SE)	-21.32 (3.46)	-23.99 (3.92)		
Week 12 Adjusted Mean Change (SE)	-25.51 (3.61)	-22.08 (4.08)		
Week 16 Adjusted Mean Change (SE)	-27.29 (3.44)	-29.91 (3.94)		
Week 20 Adjusted Mean Change (SE)	-24.05 (3.98)	-31.57 (4.56)		
Week 24 Adjusted Mean Change (SE)	-27.53 (3.73)	-25.15 (4.31)		
Week 28 Adjusted Mean Change (SE)	-26.15 (3.46)	-25.10 (3.95)		
Week 32 Adjusted Mean Change (SE)	-29.15 (3.47)	-28.97 (3.99)		
Week 36 Adjusted Mean Change (SE)	-30.95 (3.30)	-30.89 (3.77)		
Week 40 Adjusted Mean Change (SE)	-29.31 (3.54)	-31.40 (4.10)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-28.02 (3.62)	-31.58 (4.15)		
Week 48 Adjusted Mean Change (SE)	-28.04 (3.71)	-29.62 (4.26)		
Week 52 Adjusted Mean Change (SE)	-30.59 (3.66)	-32.48 (4.17)	1.90 [-9.08; 12.87]	0.733
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.10 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.442</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	64.03 (22.14)	61.76 (27.35)		
Week 52 Mean (SD)	29.52 (22.11)	26.92 (25.25)		
Week 2 Adjusted Mean Change (SE)	-14.79 (3.48)	-8.12 (3.31)		
Week 4 Adjusted Mean Change (SE)	-23.05 (3.68)	-18.94 (3.53)		
Week 8 Adjusted Mean Change (SE)	-15.19 (3.83)	-24.38 (3.68)		
Week 12 Adjusted Mean Change (SE)	-24.39 (4.02)	-27.67 (3.90)		
Week 16 Adjusted Mean Change (SE)	-25.18 (3.96)	-27.77 (3.86)		
Week 20 Adjusted Mean Change (SE)	-24.46 (4.47)	-24.37 (4.40)		
Week 24 Adjusted Mean Change (SE)	-26.49 (4.29)	-26.69 (4.24)		
Week 28 Adjusted Mean Change (SE)	-26.35 (3.93)	-27.84 (3.88)		
Week 32 Adjusted Mean Change (SE)	-25.92 (3.88)	-32.59 (3.87)		
Week 36 Adjusted Mean Change (SE)	-28.99 (3.74)	-30.52 (3.74)		
Week 40 Adjusted Mean Change (SE)	-29.46 (3.98)	-31.56 (3.99)		
Week 44 Adjusted Mean Change (SE)	-26.76 (4.10)	-29.64 (4.15)		
Week 48 Adjusted Mean Change (SE)	-28.33 (4.14)	-30.35 (4.17)		
Week 52 Adjusted Mean Change (SE)	-29.69 (4.06)	-28.33 (4.14)	-1.36 [-12.78; 10.07]	0.815
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	56.47 (24.79)	52.65 (21.65)		
Week 52 Mean (SD)	25.58 (23.85)	23.42 (19.35)		
Week 2 Adjusted Mean Change (SE)	-11.44 (2.65)	-13.17 (3.27)		
Week 4 Adjusted Mean Change (SE)	-18.11 (2.81)	-16.56 (3.46)		
Week 8 Adjusted Mean Change (SE)	-23.99 (2.92)	-17.81 (3.60)		
Week 12 Adjusted Mean Change (SE)	-27.60 (3.09)	-18.55 (3.78)		
Week 16 Adjusted Mean Change (SE)	-27.15 (3.03)	-25.72 (3.74)		
Week 20 Adjusted Mean Change (SE)	-26.41 (3.39)	-26.94 (4.22)		
Week 24 Adjusted Mean Change (SE)	-28.42 (3.23)	-21.77 (4.04)		
Week 28 Adjusted Mean Change (SE)	-28.47 (2.93)	-23.37 (3.67)		
Week 32 Adjusted Mean Change (SE)	-30.30 (2.95)	-27.42 (3.67)		
Week 36 Adjusted Mean Change (SE)	-31.05 (2.84)	-27.10 (3.51)		
Week 40 Adjusted Mean Change (SE)	-30.52 (3.02)	-27.60 (3.76)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-32.99 (3.12)	-28.78 (3.87)		
Week 48 Adjusted Mean Change (SE)	-29.98 (3.16)	-28.81 (3.90)		
Week 52 Adjusted Mean Change (SE)	-31.19 (3.10)	-32.98 (3.84)	1.79 [-7.95; 11.53]	0.717
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.11 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.731</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	57.72 (23.65)	52.86 (25.41)		
Week 52 Mean (SD)	26.41 (23.53)	25.54 (23.10)		
Week 2 Adjusted Mean Change (SE)	-12.06 (2.93)	-10.61 (2.94)		
Week 4 Adjusted Mean Change (SE)	-19.76 (3.07)	-19.25 (3.09)		
Week 8 Adjusted Mean Change (SE)	-21.24 (3.23)	-20.56 (3.24)		
Week 12 Adjusted Mean Change (SE)	-25.57 (3.35)	-20.25 (3.36)		
Week 16 Adjusted Mean Change (SE)	-25.47 (3.30)	-26.50 (3.32)		
Week 20 Adjusted Mean Change (SE)	-26.47 (3.60)	-22.11 (3.67)		
Week 24 Adjusted Mean Change (SE)	-28.27 (3.50)	-21.15 (3.54)		
Week 28 Adjusted Mean Change (SE)	-27.57 (3.19)	-23.10 (3.25)		
Week 32 Adjusted Mean Change (SE)	-30.12 (3.23)	-29.36 (3.29)		
Week 36 Adjusted Mean Change (SE)	-29.68 (3.12)	-29.27 (3.13)		
Week 40 Adjusted Mean Change (SE)	-29.75 (3.31)	-29.57 (3.36)		
Week 44 Adjusted Mean Change (SE)	-32.35 (3.43)	-29.48 (3.47)		
Week 48 Adjusted Mean Change (SE)	-29.15 (3.45)	-29.12 (3.49)		
Week 52 Adjusted Mean Change (SE)	-30.82 (3.39)	-31.46 (3.43)	0.64 [-8.89; 10.17]	0.895
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	59.40 (25.59)	64.79 (22.33)		
Week 52 Mean (SD)	26.78 (22.88)	23.72 (20.02)		
Week 2 Adjusted Mean Change (SE)	-12.49 (2.97)	-10.45 (3.94)		
Week 4 Adjusted Mean Change (SE)	-19.74 (3.12)	-14.46 (4.19)		
Week 8 Adjusted Mean Change (SE)	-21.20 (3.27)	-21.22 (4.41)		
Week 12 Adjusted Mean Change (SE)	-26.78 (3.40)	-27.17 (4.57)		
Week 16 Adjusted Mean Change (SE)	-27.35 (3.32)	-26.57 (4.52)		
Week 20 Adjusted Mean Change (SE)	-24.51 (3.67)	-32.11 (5.02)		
Week 24 Adjusted Mean Change (SE)	-27.05 (3.51)	-29.39 (4.91)		
Week 28 Adjusted Mean Change (SE)	-27.27 (3.23)	-29.25 (4.44)		
Week 32 Adjusted Mean Change (SE)	-27.04 (3.23)	-30.07 (4.45)		
Week 36 Adjusted Mean Change (SE)	-30.90 (3.11)	-27.08 (4.35)		
Week 40 Adjusted Mean Change (SE)	-30.08 (3.33)	-28.66 (4.66)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-29.08 (3.42)	-28.15 (4.81)		
Week 48 Adjusted Mean Change (SE)	-29.68 (3.43)	-29.93 (4.77)		
Week 52 Adjusted Mean Change (SE)	-30.47 (3.39)	-29.62 (4.78)	-0.85 [-12.41; 10.72]	0.885
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.12 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.097</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	59.58 (23.99)	53.68 (24.78)		
Week 52 Mean (SD)	27.65 (23.04)	25.36 (20.18)		
Week 2 Adjusted Mean Change (SE)	-11.52 (2.40)	-11.52 (2.75)		
Week 4 Adjusted Mean Change (SE)	-20.59 (2.53)	-18.93 (2.92)		
Week 8 Adjusted Mean Change (SE)	-22.46 (2.64)	-19.11 (3.06)		
Week 12 Adjusted Mean Change (SE)	-26.35 (2.74)	-21.17 (3.15)		
Week 16 Adjusted Mean Change (SE)	-26.04 (2.69)	-25.17 (3.13)		
Week 20 Adjusted Mean Change (SE)	-26.41 (2.88)	-21.86 (3.40)		
Week 24 Adjusted Mean Change (SE)	-29.07 (2.84)	-20.66 (3.37)		
Week 28 Adjusted Mean Change (SE)	-27.26 (2.59)	-23.77 (3.04)		
Week 32 Adjusted Mean Change (SE)	-28.54 (2.64)	-30.41 (3.10)		
Week 36 Adjusted Mean Change (SE)	-30.93 (2.48)	-27.30 (2.92)		
Week 40 Adjusted Mean Change (SE)	-30.15 (2.60)	-26.68 (3.09)		
Week 44 Adjusted Mean Change (SE)	-29.34 (2.76)	-26.03 (3.29)		
Week 48 Adjusted Mean Change (SE)	-28.23 (2.76)	-27.25 (3.27)		
Week 52 Adjusted Mean Change (SE)	-30.32 (2.67)	-28.79 (3.21)	-1.53 [-9.81; 6.76]	0.716
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	55.95 (28.08)	63.00 (23.63)		
Week 52 Mean (SD)	22.42 (23.39)	17.35 (16.43)		
Week 2 Adjusted Mean Change (SE)	-11.10 (4.24)	-10.54 (4.45)		
Week 4 Adjusted Mean Change (SE)	-14.92 (4.46)	-17.03 (4.68)		
Week 8 Adjusted Mean Change (SE)	-15.53 (4.66)	-27.91 (4.90)		
Week 12 Adjusted Mean Change (SE)	-22.67 (4.79)	-30.66 (5.10)		
Week 16 Adjusted Mean Change (SE)	-26.29 (4.72)	-33.55 (5.01)		
Week 20 Adjusted Mean Change (SE)	-22.15 (5.10)	-38.80 (5.37)		
Week 24 Adjusted Mean Change (SE)	-24.52 (5.04)	-35.15 (5.31)		
Week 28 Adjusted Mean Change (SE)	-27.46 (4.60)	-32.87 (4.92)		
Week 32 Adjusted Mean Change (SE)	-28.44 (4.64)	-31.04 (4.94)		
Week 36 Adjusted Mean Change (SE)	-30.58 (4.38)	-35.09 (4.67)		
Week 40 Adjusted Mean Change (SE)	-30.74 (4.64)	-39.88 (4.88)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-32.44 (4.88)	-39.75 (5.14)		
Week 48 Adjusted Mean Change (SE)	-30.78 (4.84)	-39.73 (5.13)		
Week 52 Adjusted Mean Change (SE)	-32.14 (4.71)	-40.84 (4.95)	8.70 [-4.82; 22.21]	0.206
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 15.13 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.788</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	59.27 (24.08)	56.67 (27.24)		
Week 52 Mean (SD)	27.38 (24.49)	23.10 (21.29)		
Week 2 Adjusted Mean Change (SE)	-11.84 (2.42)	-11.28 (2.69)		
Week 4 Adjusted Mean Change (SE)	-20.05 (2.53)	-18.25 (2.82)		
Week 8 Adjusted Mean Change (SE)	-22.26 (2.64)	-24.44 (2.95)		
Week 12 Adjusted Mean Change (SE)	-28.08 (2.71)	-25.86 (3.04)		
Week 16 Adjusted Mean Change (SE)	-27.90 (2.61)	-31.05 (2.94)		
Week 20 Adjusted Mean Change (SE)	-25.73 (3.00)	-28.27 (3.39)		
Week 24 Adjusted Mean Change (SE)	-28.37 (2.91)	-25.44 (3.30)		
Week 28 Adjusted Mean Change (SE)	-26.46 (2.63)	-26.39 (2.98)		
Week 32 Adjusted Mean Change (SE)	-28.96 (2.67)	-31.60 (3.01)		
Week 36 Adjusted Mean Change (SE)	-30.80 (2.52)	-30.70 (2.87)		
Week 40 Adjusted Mean Change (SE)	-31.60 (2.68)	-30.80 (3.06)		
Week 44 Adjusted Mean Change (SE)	-30.55 (2.77)	-30.68 (3.16)		
Week 48 Adjusted Mean Change (SE)	-30.53 (2.84)	-30.62 (3.22)		
Week 52 Adjusted Mean Change (SE)	-30.70 (2.77)	-32.56 (3.20)	1.87 [-6.50; 10.23]	0.660
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	54.32 (27.05)	61.50 (15.81)		
Week 52 Mean (SD)	25.28 (19.79)	30.67 (24.42)		
Week 2 Adjusted Mean Change (SE)	-12.16 (4.41)	-9.84 (5.58)		
Week 4 Adjusted Mean Change (SE)	-14.95 (4.60)	-14.40 (5.81)		
Week 8 Adjusted Mean Change (SE)	-17.26 (4.80)	-11.21 (6.06)		
Week 12 Adjusted Mean Change (SE)	-17.91 (4.92)	-18.77 (6.21)		
Week 16 Adjusted Mean Change (SE)	-19.66 (4.71)	-16.87 (5.96)		
Week 20 Adjusted Mean Change (SE)	-22.24 (5.48)	-19.80 (6.96)		
Week 24 Adjusted Mean Change (SE)	-23.39 (5.23)	-22.82 (6.61)		
Week 28 Adjusted Mean Change (SE)	-29.56 (4.74)	-26.53 (6.15)		
Week 32 Adjusted Mean Change (SE)	-25.47 (4.76)	-25.74 (6.37)		
Week 36 Adjusted Mean Change (SE)	-25.60 (4.58)	-23.69 (5.77)		
Week 40 Adjusted Mean Change (SE)	-24.07 (4.81)	-28.86 (6.07)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-31.15 (4.96)	-24.10 (6.34)		
Week 48 Adjusted Mean Change (SE)	-25.01 (5.07)	-25.73 (6.51)		
Week 52 Adjusted Mean Change (SE)	-28.43 (4.99)	-27.02 (6.25)	-1.42 [-17.23; 14.40]	0.860
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.14 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.892</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	57.45 (25.77)	58.98 (25.75)		
Week 52 Mean (SD)	25.55 (22.90)	25.61 (23.21)		
Week 2 Adjusted Mean Change (SE)	-13.14 (2.28)	-9.35 (2.63)		
Week 4 Adjusted Mean Change (SE)	-19.84 (2.37)	-16.96 (2.76)		
Week 8 Adjusted Mean Change (SE)	-21.89 (2.51)	-21.46 (2.93)		
Week 12 Adjusted Mean Change (SE)	-25.94 (2.57)	-24.74 (3.00)		
Week 16 Adjusted Mean Change (SE)	-26.71 (2.49)	-26.29 (2.93)		
Week 20 Adjusted Mean Change (SE)	-25.42 (2.87)	-25.14 (3.38)		
Week 24 Adjusted Mean Change (SE)	-26.85 (2.71)	-23.31 (3.21)		
Week 28 Adjusted Mean Change (SE)	-27.03 (2.47)	-26.01 (2.94)		
Week 32 Adjusted Mean Change (SE)	-28.14 (2.51)	-28.58 (2.98)		
Week 36 Adjusted Mean Change (SE)	-29.81 (2.42)	-27.77 (2.87)		
Week 40 Adjusted Mean Change (SE)	-29.97 (2.57)	-29.15 (3.06)		
Week 44 Adjusted Mean Change (SE)	-30.56 (2.67)	-27.72 (3.17)		
Week 48 Adjusted Mean Change (SE)	-30.40 (2.67)	-27.92 (3.17)		
Week 52 Adjusted Mean Change (SE)	-31.22 (2.63)	-30.39 (3.13)	-0.83 [-8.92; 7.26]	0.839
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	64.92 (16.54)	43.80 (17.90)		
Week 52 Mean (SD)	33.38 (23.81)	24.00 (16.66)		
Week 2 Adjusted Mean Change (SE)	-7.10 (5.35)	-12.79 (6.12)		
Week 4 Adjusted Mean Change (SE)	-17.70 (5.56)	-19.69 (6.37)		
Week 8 Adjusted Mean Change (SE)	-16.31 (5.90)	-13.01 (6.76)		
Week 12 Adjusted Mean Change (SE)	-25.20 (6.10)	-12.56 (6.89)		
Week 16 Adjusted Mean Change (SE)	-22.33 (5.82)	-17.75 (6.67)		
Week 20 Adjusted Mean Change (SE)	-23.00 (6.67)	-23.63 (7.80)		
Week 24 Adjusted Mean Change (SE)	-29.45 (6.30)	-25.26 (7.36)		
Week 28 Adjusted Mean Change (SE)	-27.48 (5.68)	-21.44 (6.51)		
Week 32 Adjusted Mean Change (SE)	-28.17 (5.77)	-28.47 (6.61)		
Week 36 Adjusted Mean Change (SE)	-30.61 (5.58)	-28.53 (6.40)		
Week 40 Adjusted Mean Change (SE)	-27.22 (5.95)	-27.08 (6.89)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-28.77 (6.16)	-31.44 (7.16)		
Week 48 Adjusted Mean Change (SE)	-22.24 (6.19)	-32.60 (7.03)		
Week 52 Adjusted Mean Change (SE)	-25.60 (6.06)	-29.45 (7.14)	3.85 [-14.79; 22.49]	0.684
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.15 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.497</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	62.09 (25.41)	61.12 (27.42)		
Week 52 Mean (SD)	27.68 (23.69)	32.72 (23.65)		
Week 2 Adjusted Mean Change (SE)	-15.33 (4.05)	-6.01 (3.73)		
Week 4 Adjusted Mean Change (SE)	-23.02 (4.30)	-16.54 (4.01)		
Week 8 Adjusted Mean Change (SE)	-20.46 (4.51)	-20.35 (4.22)		
Week 12 Adjusted Mean Change (SE)	-28.25 (4.69)	-24.13 (4.39)		
Week 16 Adjusted Mean Change (SE)	-24.56 (4.62)	-25.83 (4.37)		
Week 20 Adjusted Mean Change (SE)	-26.23 (5.12)	-21.24 (4.85)		
Week 24 Adjusted Mean Change (SE)	-29.81 (5.02)	-19.64 (4.71)		
Week 28 Adjusted Mean Change (SE)	-25.88 (4.54)	-24.42 (4.34)		
Week 32 Adjusted Mean Change (SE)	-26.66 (4.61)	-31.00 (4.37)		
Week 36 Adjusted Mean Change (SE)	-28.89 (4.41)	-26.26 (4.18)		
Week 40 Adjusted Mean Change (SE)	-31.26 (4.66)	-24.38 (4.46)		
Week 44 Adjusted Mean Change (SE)	-26.13 (4.83)	-24.08 (4.64)		
Week 48 Adjusted Mean Change (SE)	-28.68 (4.93)	-25.41 (4.67)		
Week 52 Adjusted Mean Change (SE)	-30.15 (4.77)	-25.17 (4.62)	-4.98 [-18.08; 8.12]	0.454
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	57.32 (24.25)	54.61 (23.09)		
Week 52 Mean (SD)	26.25 (23.05)	21.16 (20.38)		
Week 2 Adjusted Mean Change (SE)	-11.20 (2.39)	-13.44 (2.97)		
Week 4 Adjusted Mean Change (SE)	-18.62 (2.54)	-18.28 (3.16)		
Week 8 Adjusted Mean Change (SE)	-21.48 (2.66)	-21.13 (3.31)		
Week 12 Adjusted Mean Change (SE)	-25.38 (2.78)	-21.81 (3.45)		
Week 16 Adjusted Mean Change (SE)	-27.05 (2.71)	-27.00 (3.38)		
Week 20 Adjusted Mean Change (SE)	-25.25 (3.00)	-28.30 (3.80)		
Week 24 Adjusted Mean Change (SE)	-26.97 (2.85)	-26.49 (3.62)		
Week 28 Adjusted Mean Change (SE)	-27.81 (2.65)	-25.76 (3.34)		
Week 32 Adjusted Mean Change (SE)	-29.14 (2.64)	-28.92 (3.34)		
Week 36 Adjusted Mean Change (SE)	-30.76 (2.53)	-29.90 (3.19)		
Week 40 Adjusted Mean Change (SE)	-29.45 (2.68)	-32.16 (3.39)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-32.06 (2.76)	-31.87 (3.48)		
Week 48 Adjusted Mean Change (SE)	-29.67 (2.78)	-31.79 (3.51)		
Week 52 Adjusted Mean Change (SE)	-30.78 (2.73)	-34.01 (3.44)	3.23 [-5.45; 11.91]	0.463
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.16 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.543</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	57.51 (24.62)	62.97 (21.72)		
Week 52 Mean (SD)	25.96 (22.40)	26.92 (22.80)		
Week 2 Adjusted Mean Change (SE)	-13.48 (2.66)	-6.64 (3.22)		
Week 4 Adjusted Mean Change (SE)	-19.93 (2.82)	-15.14 (3.45)		
Week 8 Adjusted Mean Change (SE)	-21.18 (2.97)	-19.74 (3.63)		
Week 12 Adjusted Mean Change (SE)	-27.23 (3.07)	-25.68 (3.75)		
Week 16 Adjusted Mean Change (SE)	-25.94 (3.00)	-23.49 (3.68)		
Week 20 Adjusted Mean Change (SE)	-25.92 (3.34)	-21.79 (4.18)		
Week 24 Adjusted Mean Change (SE)	-29.09 (3.23)	-25.48 (4.05)		
Week 28 Adjusted Mean Change (SE)	-28.31 (2.93)	-27.27 (3.71)		
Week 32 Adjusted Mean Change (SE)	-28.04 (2.95)	-30.18 (3.70)		
Week 36 Adjusted Mean Change (SE)	-31.20 (2.83)	-27.62 (3.56)		
Week 40 Adjusted Mean Change (SE)	-31.37 (3.01)	-29.39 (3.80)		
Week 44 Adjusted Mean Change (SE)	-32.36 (3.10)	-27.90 (3.94)		
Week 48 Adjusted Mean Change (SE)	-31.88 (3.11)	-30.62 (3.92)		
Week 52 Adjusted Mean Change (SE)	-31.33 (3.06)	-30.01 (3.93)	-1.32 [-11.20; 8.55]	0.791
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	60.12 (24.60)	50.75 (26.79)		
Week 52 Mean (SD)	27.63 (24.44)	23.17 (21.45)		
Week 2 Adjusted Mean Change (SE)	-10.43 (3.26)	-14.84 (3.38)		
Week 4 Adjusted Mean Change (SE)	-19.49 (3.46)	-20.24 (3.58)		
Week 8 Adjusted Mean Change (SE)	-21.28 (3.64)	-21.97 (3.77)		
Week 12 Adjusted Mean Change (SE)	-24.47 (3.78)	-19.44 (3.91)		
Week 16 Adjusted Mean Change (SE)	-27.17 (3.69)	-29.89 (3.85)		
Week 20 Adjusted Mean Change (SE)	-24.74 (4.14)	-29.84 (4.32)		
Week 24 Adjusted Mean Change (SE)	-25.42 (3.97)	-22.26 (4.17)		
Week 28 Adjusted Mean Change (SE)	-25.86 (3.68)	-23.05 (3.81)		
Week 32 Adjusted Mean Change (SE)	-29.34 (3.64)	-29.11 (3.83)		
Week 36 Adjusted Mean Change (SE)	-28.98 (3.48)	-29.59 (3.64)		
Week 40 Adjusted Mean Change (SE)	-27.70 (3.71)	-29.22 (3.90)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-28.05 (3.83)	-30.23 (4.00)		
Week 48 Adjusted Mean Change (SE)	-25.72 (3.83)	-28.27 (4.00)		
Week 52 Adjusted Mean Change (SE)	-29.69 (3.81)	-31.68 (3.95)	1.99 [-8.88; 12.87]	0.718
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 15.17 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.287</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	64.03 (22.14)	61.42 (28.20)		
Week 52 Mean (SD)	29.52 (22.11)	26.32 (26.24)		
Week 2 Adjusted Mean Change (SE)	-14.57 (3.51)	-9.32 (3.44)		
Week 4 Adjusted Mean Change (SE)	-22.87 (3.69)	-19.63 (3.65)		
Week 8 Adjusted Mean Change (SE)	-15.03 (3.80)	-25.34 (3.77)		
Week 12 Adjusted Mean Change (SE)	-24.20 (3.98)	-28.38 (3.98)		
Week 16 Adjusted Mean Change (SE)	-25.05 (3.92)	-29.84 (3.95)		
Week 20 Adjusted Mean Change (SE)	-24.37 (4.43)	-26.56 (4.51)		
Week 24 Adjusted Mean Change (SE)	-26.32 (4.24)	-27.65 (4.34)		
Week 28 Adjusted Mean Change (SE)	-26.17 (3.88)	-29.12 (3.97)		
Week 32 Adjusted Mean Change (SE)	-25.69 (3.85)	-30.87 (3.98)		
Week 36 Adjusted Mean Change (SE)	-28.76 (3.70)	-31.02 (3.84)		
Week 40 Adjusted Mean Change (SE)	-29.21 (3.94)	-31.81 (4.10)		
Week 44 Adjusted Mean Change (SE)	-26.53 (4.06)	-30.44 (4.24)		
Week 48 Adjusted Mean Change (SE)	-28.12 (4.10)	-29.78 (4.29)		
Week 52 Adjusted Mean Change (SE)	-29.48 (4.03)	-28.05 (4.25)	-1.43 [-12.97; 10.11]	0.807
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	55.56 (25.38)	53.44 (21.29)		
Week 52 Mean (SD)	24.90 (23.64)	24.03 (18.99)		
Week 2 Adjusted Mean Change (SE)	-11.03 (2.58)	-11.61 (3.20)		
Week 4 Adjusted Mean Change (SE)	-18.09 (2.71)	-15.86 (3.36)		
Week 8 Adjusted Mean Change (SE)	-24.59 (2.79)	-17.02 (3.46)		
Week 12 Adjusted Mean Change (SE)	-27.25 (2.94)	-18.04 (3.62)		
Week 16 Adjusted Mean Change (SE)	-27.19 (2.90)	-23.75 (3.59)		
Week 20 Adjusted Mean Change (SE)	-26.16 (3.25)	-24.59 (4.05)		
Week 24 Adjusted Mean Change (SE)	-28.37 (3.09)	-20.87 (3.86)		
Week 28 Adjusted Mean Change (SE)	-28.08 (2.80)	-22.21 (3.50)		
Week 32 Adjusted Mean Change (SE)	-30.10 (2.83)	-28.56 (3.53)		
Week 36 Adjusted Mean Change (SE)	-31.16 (2.73)	-26.55 (3.36)		
Week 40 Adjusted Mean Change (SE)	-30.31 (2.90)	-27.18 (3.61)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-32.99 (3.00)	-27.73 (3.72)		
Week 48 Adjusted Mean Change (SE)	-30.06 (3.04)	-28.88 (3.75)		
Week 52 Adjusted Mean Change (SE)	-31.29 (2.99)	-32.41 (3.69)	1.12 [-8.24; 10.48]	0.814
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.18 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.731</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	57.72 (23.65)	52.86 (25.41)		
Week 52 Mean (SD)	26.41 (23.53)	25.54 (23.10)		
Week 2 Adjusted Mean Change (SE)	-12.06 (2.93)	-10.61 (2.94)		
Week 4 Adjusted Mean Change (SE)	-19.76 (3.07)	-19.25 (3.09)		
Week 8 Adjusted Mean Change (SE)	-21.24 (3.23)	-20.56 (3.24)		
Week 12 Adjusted Mean Change (SE)	-25.57 (3.35)	-20.25 (3.36)		
Week 16 Adjusted Mean Change (SE)	-25.47 (3.30)	-26.50 (3.32)		
Week 20 Adjusted Mean Change (SE)	-26.47 (3.60)	-22.11 (3.67)		
Week 24 Adjusted Mean Change (SE)	-28.27 (3.50)	-21.15 (3.54)		
Week 28 Adjusted Mean Change (SE)	-27.57 (3.19)	-23.10 (3.25)		
Week 32 Adjusted Mean Change (SE)	-30.12 (3.23)	-29.36 (3.29)		
Week 36 Adjusted Mean Change (SE)	-29.68 (3.12)	-29.27 (3.13)		
Week 40 Adjusted Mean Change (SE)	-29.75 (3.31)	-29.57 (3.36)		
Week 44 Adjusted Mean Change (SE)	-32.35 (3.43)	-29.48 (3.47)		
Week 48 Adjusted Mean Change (SE)	-29.15 (3.45)	-29.12 (3.49)		
Week 52 Adjusted Mean Change (SE)	-30.82 (3.39)	-31.46 (3.43)	0.64 [-8.89; 10.17]	0.895
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	59.40 (25.59)	64.79 (22.33)		
Week 52 Mean (SD)	26.78 (22.88)	23.72 (20.02)		
Week 2 Adjusted Mean Change (SE)	-12.49 (2.97)	-10.45 (3.94)		
Week 4 Adjusted Mean Change (SE)	-19.74 (3.12)	-14.46 (4.19)		
Week 8 Adjusted Mean Change (SE)	-21.20 (3.27)	-21.22 (4.41)		
Week 12 Adjusted Mean Change (SE)	-26.78 (3.40)	-27.17 (4.57)		
Week 16 Adjusted Mean Change (SE)	-27.35 (3.32)	-26.57 (4.52)		
Week 20 Adjusted Mean Change (SE)	-24.51 (3.67)	-32.11 (5.02)		
Week 24 Adjusted Mean Change (SE)	-27.05 (3.51)	-29.39 (4.91)		
Week 28 Adjusted Mean Change (SE)	-27.27 (3.23)	-29.25 (4.44)		
Week 32 Adjusted Mean Change (SE)	-27.04 (3.23)	-30.07 (4.45)		
Week 36 Adjusted Mean Change (SE)	-30.90 (3.11)	-27.08 (4.35)		
Week 40 Adjusted Mean Change (SE)	-30.08 (3.33)	-28.66 (4.66)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-29.08 (3.42)	-28.15 (4.81)		
Week 48 Adjusted Mean Change (SE)	-29.68 (3.43)	-29.93 (4.77)		
Week 52 Adjusted Mean Change (SE)	-30.47 (3.39)	-29.62 (4.78)	-0.85 [-12.41; 10.72]	0.885
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 15.19 Patient's Assessment of PsA Pain (VAS) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.068</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	59.51 (23.42)	53.96 (25.41)		
Week 52 Mean (SD)	26.97 (22.95)	27.87 (22.54)		
Week 2 Adjusted Mean Change (SE)	-12.16 (2.38)	-10.45 (2.74)		
Week 4 Adjusted Mean Change (SE)	-21.21 (2.49)	-18.25 (2.89)		
Week 8 Adjusted Mean Change (SE)	-23.08 (2.62)	-18.79 (3.04)		
Week 12 Adjusted Mean Change (SE)	-27.26 (2.74)	-20.27 (3.17)		
Week 16 Adjusted Mean Change (SE)	-26.47 (2.68)	-24.37 (3.12)		
Week 20 Adjusted Mean Change (SE)	-27.43 (2.89)	-21.23 (3.41)		
Week 24 Adjusted Mean Change (SE)	-29.09 (2.79)	-19.08 (3.31)		
Week 28 Adjusted Mean Change (SE)	-27.49 (2.61)	-22.48 (3.08)		
Week 32 Adjusted Mean Change (SE)	-28.73 (2.64)	-28.93 (3.12)		
Week 36 Adjusted Mean Change (SE)	-30.67 (2.52)	-26.54 (2.97)		
Week 40 Adjusted Mean Change (SE)	-30.36 (2.63)	-25.53 (3.13)		
Week 44 Adjusted Mean Change (SE)	-30.30 (2.74)	-25.09 (3.27)		
Week 48 Adjusted Mean Change (SE)	-29.35 (2.78)	-25.95 (3.29)		
Week 52 Adjusted Mean Change (SE)	-30.98 (2.67)	-26.51 (3.21)	-4.47 [-12.73; 3.79]	0.287
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	53.50 (27.76)	65.78 (21.63)		
Week 52 Mean (SD)	22.65 (23.71)	18.41 (19.73)		
Week 2 Adjusted Mean Change (SE)	-10.25 (4.54)	-10.28 (4.54)		
Week 4 Adjusted Mean Change (SE)	-12.04 (4.75)	-15.22 (4.75)		
Week 8 Adjusted Mean Change (SE)	-14.34 (4.99)	-25.50 (4.99)		
Week 12 Adjusted Mean Change (SE)	-20.80 (5.19)	-28.47 (5.19)		
Week 16 Adjusted Mean Change (SE)	-24.18 (5.08)	-31.68 (5.13)		
Week 20 Adjusted Mean Change (SE)	-21.07 (5.52)	-36.16 (5.54)		
Week 24 Adjusted Mean Change (SE)	-24.53 (5.35)	-35.93 (5.36)		
Week 28 Adjusted Mean Change (SE)	-26.00 (5.02)	-31.85 (5.10)		
Week 32 Adjusted Mean Change (SE)	-26.23 (5.05)	-30.38 (5.16)		
Week 36 Adjusted Mean Change (SE)	-29.46 (4.82)	-32.93 (4.88)		
Week 40 Adjusted Mean Change (SE)	-29.63 (5.08)	-38.32 (5.08)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-31.52 (5.24)	-38.51 (5.29)		
Week 48 Adjusted Mean Change (SE)	-29.45 (5.28)	-38.13 (5.35)		
Week 52 Adjusted Mean Change (SE)	-30.95 (5.09)	-41.13 (5.09)	10.18 [-4.11; 24.47]	0.161
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 16.0 Patient's Global Assessment of PsA Disease Activity (VAS) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	110 (100.0)	100 (99.0)	210 (99.5)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	108 (98.2)	95 (94.1)	203 (96.2)
Week 20 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	102 (92.7)	86 (85.1)	188 (89.1)
Week 32 Returns	102 (92.7)	81 (80.2)	183 (86.7)
Week 36 Returns	102 (92.7)	84 (83.2)	186 (88.2)
Week 40 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 44 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 48 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 52 Returns	104 (94.5)	80 (79.2)	184 (87.2)

### 16.1 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	63.93 (21.29)	64.11 (20.56)		
Week 52 Mean (SD)	29.38 (21.99)	28.03 (23.01)		
Week 2 Adjusted Mean Change (SE)	-16.21 (1.76)	-14.44 (1.85)		
Week 4 Adjusted Mean Change (SE)	-23.02 (1.88)	-18.92 (1.97)		
Week 8 Adjusted Mean Change (SE)	-26.42 (1.94)	-23.15 (2.04)		
Week 12 Adjusted Mean Change (SE)	-27.81 (2.05)	-26.06 (2.15)		
Week 16 Adjusted Mean Change (SE)	-29.29 (1.93)	-25.50 (2.04)		
Week 20 Adjusted Mean Change (SE)	-29.38 (2.06)	-27.21 (2.20)		
Week 24 Adjusted Mean Change (SE)	-28.09 (2.14)	-24.93 (2.29)		
Week 28 Adjusted Mean Change (SE)	-28.88 (2.04)	-28.80 (2.20)		
Week 32 Adjusted Mean Change (SE)	-32.60 (2.03)	-27.81 (2.20)		
Week 36 Adjusted Mean Change (SE)	-34.35 (1.98)	-30.47 (2.14)		
Week 40 Adjusted Mean Change (SE)	-33.82 (2.04)	-30.69 (2.21)		
Week 44 Adjusted Mean Change (SE)	-34.29 (2.08)	-32.59 (2.26)		
Week 48 Adjusted Mean Change (SE)	-33.67 (2.10)	-33.86 (2.28)		
Week 52 Adjusted Mean Change (SE)	-34.21 (2.16)	-33.58 (2.37)	-0.63 [-6.96; 5.69]	0.843
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				



## 16.2 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.785</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	64.28 (21.02)	64.33 (20.48)		
Week 52 Mean (SD)	29.71 (22.18)	27.95 (23.19)		
Week 2 Adjusted Mean Change (SE)	-16.23 (1.83)	-14.27 (1.92)		
Week 4 Adjusted Mean Change (SE)	-22.95 (1.95)	-18.93 (2.06)		
Week 8 Adjusted Mean Change (SE)	-26.09 (2.01)	-23.13 (2.13)		
Week 12 Adjusted Mean Change (SE)	-28.00 (2.13)	-26.04 (2.24)		
Week 16 Adjusted Mean Change (SE)	-28.97 (2.00)	-25.25 (2.12)		
Week 20 Adjusted Mean Change (SE)	-29.28 (2.14)	-27.00 (2.30)		
Week 24 Adjusted Mean Change (SE)	-27.89 (2.23)	-24.89 (2.38)		
Week 28 Adjusted Mean Change (SE)	-28.39 (2.12)	-29.06 (2.29)		
Week 32 Adjusted Mean Change (SE)	-32.37 (2.11)	-27.55 (2.30)		
Week 36 Adjusted Mean Change (SE)	-34.30 (2.05)	-30.79 (2.23)		
Week 40 Adjusted Mean Change (SE)	-34.19 (2.11)	-30.87 (2.31)		
Week 44 Adjusted Mean Change (SE)	-34.06 (2.16)	-32.97 (2.36)		
Week 48 Adjusted Mean Change (SE)	-33.27 (2.17)	-33.94 (2.39)		
Week 52 Adjusted Mean Change (SE)	-34.01 (2.25)	-33.46 (2.48)	-0.55 [-7.14; 6.04]	0.870
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	58.71 (26.21)	61.14 (23.12)		
Week 52 Mean (SD)	23.83 (19.51)	29.00 (22.60)		
Week 2 Adjusted Mean Change (SE)	-15.93 (7.02)	-16.80 (7.01)		
Week 4 Adjusted Mean Change (SE)	-24.01 (7.49)	-18.84 (7.48)		
Week 8 Adjusted Mean Change (SE)	-31.28 (7.74)	-23.44 (7.73)		
Week 12 Adjusted Mean Change (SE)	-25.36 (8.12)	-26.41 (8.11)		
Week 16 Adjusted Mean Change (SE)	-34.37 (7.84)	-28.58 (7.66)		
Week 20 Adjusted Mean Change (SE)	-30.84 (8.18)	-30.04 (8.40)		
Week 24 Adjusted Mean Change (SE)	-31.10 (8.50)	-25.32 (8.70)		
Week 28 Adjusted Mean Change (SE)	-35.80 (8.02)	-26.13 (8.00)		
Week 32 Adjusted Mean Change (SE)	-35.88 (8.00)	-30.31 (7.99)		
Week 36 Adjusted Mean Change (SE)	-35.99 (8.14)	-26.88 (7.78)		
Week 40 Adjusted Mean Change (SE)	-28.98 (8.04)	-29.01 (8.03)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-38.13 (8.41)	-28.61 (8.19)		
Week 48 Adjusted Mean Change (SE)	-40.16 (8.45)	-33.00 (8.19)		
Week 52 Adjusted Mean Change (SE)	-37.63 (8.77)	-35.29 (8.72)	-2.34 [-26.70; 22.02]	0.850
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.3 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.760</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	61.17 (19.17)	61.89 (22.11)		
Week 52 Mean (SD)	26.05 (21.04)	23.35 (21.17)		
Week 2 Adjusted Mean Change (SE)	-16.95 (2.31)	-16.87 (2.48)		
Week 4 Adjusted Mean Change (SE)	-25.77 (2.44)	-21.49 (2.62)		
Week 8 Adjusted Mean Change (SE)	-30.32 (2.52)	-25.14 (2.70)		
Week 12 Adjusted Mean Change (SE)	-31.67 (2.65)	-29.35 (2.82)		
Week 16 Adjusted Mean Change (SE)	-34.24 (2.46)	-28.97 (2.64)		
Week 20 Adjusted Mean Change (SE)	-35.07 (2.63)	-29.75 (2.84)		
Week 24 Adjusted Mean Change (SE)	-33.55 (2.71)	-28.87 (2.94)		
Week 28 Adjusted Mean Change (SE)	-32.74 (2.58)	-33.42 (2.83)		
Week 32 Adjusted Mean Change (SE)	-34.24 (2.60)	-32.86 (2.87)		
Week 36 Adjusted Mean Change (SE)	-37.11 (2.57)	-32.78 (2.82)		
Week 40 Adjusted Mean Change (SE)	-37.71 (2.61)	-34.80 (2.87)		
Week 44 Adjusted Mean Change (SE)	-38.02 (2.67)	-35.98 (2.93)		
Week 48 Adjusted Mean Change (SE)	-38.51 (2.67)	-36.48 (2.93)		
Week 52 Adjusted Mean Change (SE)	-37.91 (2.76)	-38.23 (3.07)	0.32 [-7.79; 8.43]	0.938
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	68.07 (23.75)	66.98 (18.22)		
Week 52 Mean (SD)	34.49 (22.70)	34.35 (24.16)		
Week 2 Adjusted Mean Change (SE)	-15.16 (2.84)	-11.28 (2.80)		
Week 4 Adjusted Mean Change (SE)	-18.97 (2.99)	-15.55 (2.98)		
Week 8 Adjusted Mean Change (SE)	-20.66 (3.09)	-20.52 (3.08)		
Week 12 Adjusted Mean Change (SE)	-22.12 (3.23)	-21.73 (3.23)		
Week 16 Adjusted Mean Change (SE)	-21.95 (3.00)	-20.89 (3.03)		
Week 20 Adjusted Mean Change (SE)	-20.77 (3.25)	-24.05 (3.34)		
Week 24 Adjusted Mean Change (SE)	-19.92 (3.36)	-19.71 (3.41)		
Week 28 Adjusted Mean Change (SE)	-23.00 (3.25)	-22.63 (3.32)		
Week 32 Adjusted Mean Change (SE)	-30.35 (3.23)	-20.97 (3.33)		
Week 36 Adjusted Mean Change (SE)	-30.25 (3.17)	-27.37 (3.28)		
Week 40 Adjusted Mean Change (SE)	-28.10 (3.21)	-25.24 (3.33)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-28.82 (3.32)	-28.05 (3.46)		
Week 48 Adjusted Mean Change (SE)	-26.52 (3.30)	-30.58 (3.48)		
Week 52 Adjusted Mean Change (SE)	-28.73 (3.42)	-27.40 (3.57)	-1.33 [-11.01; 8.36]	0.787
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.4 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.500</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	44.63 (15.23)	42.38 (24.14)		
Week 52 Mean (SD)	24.09 (18.87)	20.75 (24.37)		
Week 2 Adjusted Mean Change (SE)	-18.36 (3.98)	-23.24 (4.29)		
Week 4 Adjusted Mean Change (SE)	-25.77 (4.24)	-28.79 (4.57)		
Week 8 Adjusted Mean Change (SE)	-27.25 (4.37)	-34.07 (4.71)		
Week 12 Adjusted Mean Change (SE)	-28.02 (4.73)	-30.35 (5.01)		
Week 16 Adjusted Mean Change (SE)	-32.09 (4.38)	-33.13 (4.71)		
Week 20 Adjusted Mean Change (SE)	-32.50 (4.78)	-29.81 (5.18)		
Week 24 Adjusted Mean Change (SE)	-26.59 (4.95)	-28.53 (5.34)		
Week 28 Adjusted Mean Change (SE)	-30.19 (4.65)	-35.30 (5.17)		
Week 32 Adjusted Mean Change (SE)	-35.55 (4.63)	-34.66 (5.15)		
Week 36 Adjusted Mean Change (SE)	-36.19 (4.51)	-34.30 (5.04)		
Week 40 Adjusted Mean Change (SE)	-38.98 (4.65)	-36.26 (5.25)		
Week 44 Adjusted Mean Change (SE)	-38.89 (4.74)	-31.76 (5.30)		
Week 48 Adjusted Mean Change (SE)	-39.70 (4.79)	-37.82 (5.41)		
Week 52 Adjusted Mean Change (SE)	-38.11 (4.94)	-38.22 (5.57)	0.11 [-13.73; 13.95]	0.988
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	69.31 (19.59)	69.81 (15.14)		
Week 52 Mean (SD)	30.88 (22.69)	29.84 (22.48)		
Week 2 Adjusted Mean Change (SE)	-15.61 (2.01)	-12.10 (2.10)		
Week 4 Adjusted Mean Change (SE)	-22.25 (2.14)	-16.28 (2.25)		
Week 8 Adjusted Mean Change (SE)	-26.19 (2.21)	-20.22 (2.32)		
Week 12 Adjusted Mean Change (SE)	-27.73 (2.36)	-24.94 (2.48)		
Week 16 Adjusted Mean Change (SE)	-28.50 (2.21)	-23.44 (2.34)		
Week 20 Adjusted Mean Change (SE)	-28.59 (2.36)	-26.47 (2.52)		
Week 24 Adjusted Mean Change (SE)	-28.42 (2.47)	-23.96 (2.63)		
Week 28 Adjusted Mean Change (SE)	-28.53 (2.34)	-27.10 (2.52)		
Week 32 Adjusted Mean Change (SE)	-31.79 (2.33)	-26.00 (2.52)		
Week 36 Adjusted Mean Change (SE)	-33.85 (2.28)	-29.44 (2.45)		
Week 40 Adjusted Mean Change (SE)	-32.41 (2.33)	-29.29 (2.51)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-33.00 (2.39)	-32.78 (2.58)		
Week 48 Adjusted Mean Change (SE)	-32.05 (2.40)	-32.89 (2.60)		
Week 52 Adjusted Mean Change (SE)	-33.15 (2.49)	-32.35 (2.71)	-0.79 [-7.92; 6.33]	0.826
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.5 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.388</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	60.02 (21.21)	63.98 (20.02)		
Week 52 Mean (SD)	29.64 (19.60)	25.54 (19.07)		
Week 2 Adjusted Mean Change (SE)	-17.61 (2.83)	-18.91 (2.56)		
Week 4 Adjusted Mean Change (SE)	-23.83 (3.03)	-23.05 (2.76)		
Week 8 Adjusted Mean Change (SE)	-26.71 (3.15)	-26.70 (2.86)		
Week 12 Adjusted Mean Change (SE)	-26.03 (3.34)	-25.56 (3.03)		
Week 16 Adjusted Mean Change (SE)	-27.15 (3.14)	-25.44 (2.88)		
Week 20 Adjusted Mean Change (SE)	-26.91 (3.38)	-29.46 (3.12)		
Week 24 Adjusted Mean Change (SE)	-25.47 (3.50)	-25.51 (3.25)		
Week 28 Adjusted Mean Change (SE)	-25.61 (3.34)	-27.51 (3.14)		
Week 32 Adjusted Mean Change (SE)	-31.64 (3.31)	-27.55 (3.13)		
Week 36 Adjusted Mean Change (SE)	-33.22 (3.25)	-30.14 (3.07)		
Week 40 Adjusted Mean Change (SE)	-32.24 (3.34)	-31.13 (3.18)		
Week 44 Adjusted Mean Change (SE)	-33.72 (3.43)	-32.00 (3.26)		
Week 48 Adjusted Mean Change (SE)	-29.49 (3.40)	-32.76 (3.25)		
Week 52 Adjusted Mean Change (SE)	-33.58 (3.55)	-34.93 (3.42)	1.35 [-8.39; 11.08]	0.785
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	66.34 (21.13)	64.24 (21.31)		
Week 52 Mean (SD)	29.22 (23.46)	30.16 (25.96)		
Week 2 Adjusted Mean Change (SE)	-15.34 (2.22)	-9.79 (2.61)		
Week 4 Adjusted Mean Change (SE)	-22.52 (2.38)	-14.64 (2.80)		
Week 8 Adjusted Mean Change (SE)	-26.25 (2.47)	-19.47 (2.90)		
Week 12 Adjusted Mean Change (SE)	-28.89 (2.63)	-26.56 (3.08)		
Week 16 Adjusted Mean Change (SE)	-30.63 (2.48)	-25.56 (2.91)		
Week 20 Adjusted Mean Change (SE)	-30.83 (2.62)	-24.95 (3.11)		
Week 24 Adjusted Mean Change (SE)	-29.70 (2.74)	-24.32 (3.23)		
Week 28 Adjusted Mean Change (SE)	-30.82 (2.60)	-30.00 (3.09)		
Week 32 Adjusted Mean Change (SE)	-33.17 (2.61)	-28.00 (3.13)		
Week 36 Adjusted Mean Change (SE)	-35.07 (2.53)	-30.71 (3.02)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 40 Adjusted Mean Change (SE)	-34.83 (2.61)	-30.16 (3.11)		
Week 44 Adjusted Mean Change (SE)	-34.66 (2.67)	-32.95 (3.19)		
Week 48 Adjusted Mean Change (SE)	-36.36 (2.67)	-34.78 (3.19)		
Week 52 Adjusted Mean Change (SE)	-34.62 (2.77)	-32.40 (3.32)	-2.22 [-10.75; 6.30]	0.608
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit</p> <p>Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 16.6 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.351</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	64.50 (21.24)	61.37 (22.28)		
Week 52 Mean (SD)	27.70 (21.39)	24.03 (20.92)		
Week 2 Adjusted Mean Change (SE)	-19.53 (2.15)	-15.07 (2.61)		
Week 4 Adjusted Mean Change (SE)	-25.03 (2.32)	-19.54 (2.82)		
Week 8 Adjusted Mean Change (SE)	-27.66 (2.40)	-25.22 (2.92)		
Week 12 Adjusted Mean Change (SE)	-28.39 (2.55)	-26.24 (3.07)		
Week 16 Adjusted Mean Change (SE)	-31.39 (2.38)	-27.87 (2.91)		
Week 20 Adjusted Mean Change (SE)	-31.21 (2.53)	-30.08 (3.16)		
Week 24 Adjusted Mean Change (SE)	-31.80 (2.62)	-25.98 (3.25)		
Week 28 Adjusted Mean Change (SE)	-31.04 (2.49)	-30.52 (3.16)		
Week 32 Adjusted Mean Change (SE)	-35.55 (2.49)	-29.55 (3.19)		
Week 36 Adjusted Mean Change (SE)	-35.43 (2.45)	-27.49 (3.12)		
Week 40 Adjusted Mean Change (SE)	-35.82 (2.52)	-29.78 (3.24)		
Week 44 Adjusted Mean Change (SE)	-36.31 (2.57)	-32.76 (3.28)		
Week 48 Adjusted Mean Change (SE)	-35.53 (2.60)	-33.27 (3.36)		
Week 52 Adjusted Mean Change (SE)	-36.24 (2.66)	-35.58 (3.48)	-0.66 [-9.30; 7.98]	0.881
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	62.84 (21.63)	66.69 (18.65)		
Week 52 Mean (SD)	32.82 (23.14)	30.98 (24.23)		
Week 2 Adjusted Mean Change (SE)	-9.91 (2.96)	-13.84 (2.56)		
Week 4 Adjusted Mean Change (SE)	-19.22 (3.19)	-18.32 (2.78)		
Week 8 Adjusted Mean Change (SE)	-24.09 (3.31)	-21.12 (2.88)		
Week 12 Adjusted Mean Change (SE)	-26.63 (3.48)	-25.89 (3.04)		
Week 16 Adjusted Mean Change (SE)	-25.35 (3.26)	-23.21 (2.85)		
Week 20 Adjusted Mean Change (SE)	-25.86 (3.51)	-24.50 (3.07)		
Week 24 Adjusted Mean Change (SE)	-21.01 (3.63)	-23.86 (3.17)		
Week 28 Adjusted Mean Change (SE)	-24.83 (3.55)	-27.13 (3.06)		
Week 32 Adjusted Mean Change (SE)	-26.94 (3.46)	-26.20 (3.04)		
Week 36 Adjusted Mean Change (SE)	-32.26 (3.40)	-32.71 (2.97)		
Week 40 Adjusted Mean Change (SE)	-29.99 (3.49)	-31.18 (3.06)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-30.37 (3.58)	-32.21 (3.14)		
Week 48 Adjusted Mean Change (SE)	-30.07 (3.59)	-34.10 (3.14)		
Week 52 Adjusted Mean Change (SE)	-30.25 (3.73)	-31.95 (3.25)	1.70 [-8.06; 11.46]	0.731
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.7 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.771</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	64.35 (23.48)	60.69 (24.65)		
Week 52 Mean (SD)	25.10 (20.02)	23.12 (23.77)		
Week 2 Adjusted Mean Change (SE)	-16.53 (2.58)	-18.63 (3.27)		
Week 4 Adjusted Mean Change (SE)	-24.07 (2.76)	-22.19 (3.53)		
Week 8 Adjusted Mean Change (SE)	-24.96 (2.85)	-27.75 (3.64)		
Week 12 Adjusted Mean Change (SE)	-30.17 (3.02)	-30.08 (3.85)		
Week 16 Adjusted Mean Change (SE)	-30.65 (2.81)	-31.13 (3.62)		
Week 20 Adjusted Mean Change (SE)	-30.63 (3.04)	-29.85 (3.92)		
Week 24 Adjusted Mean Change (SE)	-29.46 (3.14)	-26.52 (4.05)		
Week 28 Adjusted Mean Change (SE)	-30.38 (2.98)	-32.11 (3.89)		
Week 32 Adjusted Mean Change (SE)	-34.87 (2.95)	-32.05 (3.90)		
Week 36 Adjusted Mean Change (SE)	-35.66 (2.89)	-33.32 (3.78)		
Week 40 Adjusted Mean Change (SE)	-35.70 (2.99)	-31.67 (3.90)		
Week 44 Adjusted Mean Change (SE)	-36.27 (3.06)	-31.72 (4.00)		
Week 48 Adjusted Mean Change (SE)	-36.27 (3.08)	-34.73 (4.02)		
Week 52 Adjusted Mean Change (SE)	-38.47 (3.14)	-38.14 (4.17)	-0.33 [-10.63; 9.97]	0.950
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	63.56 (19.39)	65.70 (18.35)		
Week 52 Mean (SD)	33.04 (23.10)	30.25 (22.52)		
Week 2 Adjusted Mean Change (SE)	-15.93 (2.40)	-12.47 (2.24)		
Week 4 Adjusted Mean Change (SE)	-22.11 (2.57)	-17.39 (2.39)		
Week 8 Adjusted Mean Change (SE)	-27.69 (2.65)	-21.01 (2.47)		
Week 12 Adjusted Mean Change (SE)	-25.82 (2.78)	-24.18 (2.59)		
Week 16 Adjusted Mean Change (SE)	-28.09 (2.63)	-22.91 (2.46)		
Week 20 Adjusted Mean Change (SE)	-28.28 (2.82)	-26.01 (2.68)		
Week 24 Adjusted Mean Change (SE)	-26.91 (2.94)	-24.26 (2.79)		
Week 28 Adjusted Mean Change (SE)	-27.55 (2.80)	-27.29 (2.67)		
Week 32 Adjusted Mean Change (SE)	-30.56 (2.78)	-25.90 (2.67)		
Week 36 Adjusted Mean Change (SE)	-33.23 (2.72)	-29.15 (2.61)		
Week 40 Adjusted Mean Change (SE)	-32.20 (2.79)	-30.34 (2.70)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-32.56 (2.85)	-33.12 (2.75)		
Week 48 Adjusted Mean Change (SE)	-31.42 (2.87)	-33.58 (2.78)		
Week 52 Adjusted Mean Change (SE)	-30.59 (2.93)	-31.62 (2.85)	1.03 [-7.03; 9.10]	0.801
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.8 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.953</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	65.35 (21.16)	61.78 (20.70)		
Week 52 Mean (SD)	29.48 (22.55)	25.50 (18.05)		
Week 2 Adjusted Mean Change (SE)	-14.24 (2.39)	-16.12 (2.67)		
Week 4 Adjusted Mean Change (SE)	-22.92 (2.83)	-22.40 (3.16)		
Week 8 Adjusted Mean Change (SE)	-26.47 (2.96)	-25.03 (3.30)		
Week 12 Adjusted Mean Change (SE)	-28.38 (2.99)	-30.62 (3.36)		
Week 16 Adjusted Mean Change (SE)	-28.61 (2.86)	-28.04 (3.20)		
Week 20 Adjusted Mean Change (SE)	-31.37 (3.05)	-28.05 (3.47)		
Week 24 Adjusted Mean Change (SE)	-29.92 (3.16)	-27.98 (3.57)		
Week 28 Adjusted Mean Change (SE)	-29.52 (2.97)	-30.32 (3.37)		
Week 32 Adjusted Mean Change (SE)	-33.55 (2.91)	-29.67 (3.31)		
Week 36 Adjusted Mean Change (SE)	-35.66 (2.99)	-33.62 (3.37)		
Week 40 Adjusted Mean Change (SE)	-34.01 (3.02)	-32.22 (3.42)		
Week 44 Adjusted Mean Change (SE)	-33.93 (3.17)	-35.20 (3.60)		
Week 48 Adjusted Mean Change (SE)	-30.24 (3.20)	-34.74 (3.62)		
Week 52 Adjusted Mean Change (SE)	-34.37 (3.22)	-36.24 (3.69)	1.87 [-7.82; 11.56]	0.703
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	63.71 (22.51)	64.35 (22.70)		
Week 52 Mean (SD)	30.00 (23.24)	31.05 (30.11)		
Week 2 Adjusted Mean Change (SE)	-17.73 (2.93)	-13.09 (3.35)		
Week 4 Adjusted Mean Change (SE)	-20.98 (3.46)	-15.94 (4.00)		
Week 8 Adjusted Mean Change (SE)	-23.45 (3.62)	-24.41 (4.20)		
Week 12 Adjusted Mean Change (SE)	-25.17 (3.71)	-22.67 (4.26)		
Week 16 Adjusted Mean Change (SE)	-24.60 (3.50)	-26.87 (4.08)		
Week 20 Adjusted Mean Change (SE)	-26.95 (3.75)	-30.82 (4.37)		
Week 24 Adjusted Mean Change (SE)	-25.20 (3.87)	-25.30 (4.55)		
Week 28 Adjusted Mean Change (SE)	-26.11 (3.66)	-31.73 (4.34)		
Week 32 Adjusted Mean Change (SE)	-32.93 (3.61)	-28.64 (4.24)		
Week 36 Adjusted Mean Change (SE)	-30.27 (3.68)	-30.63 (4.36)		
Week 40 Adjusted Mean Change (SE)	-33.50 (3.72)	-30.60 (4.42)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-32.66 (3.91)	-32.98 (4.64)		
Week 48 Adjusted Mean Change (SE)	-36.08 (4.02)	-35.48 (4.80)		
Week 52 Adjusted Mean Change (SE)	-32.79 (3.97)	-31.63 (4.72)	-1.15 [-13.34; 11.03]	0.852
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.9 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.103</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	64.22 (21.51)	63.96 (19.83)		
Week 52 Mean (SD)	29.40 (23.00)	31.95 (26.02)		
Week 2 Adjusted Mean Change (SE)	-15.01 (2.50)	-9.06 (3.23)		
Week 4 Adjusted Mean Change (SE)	-23.79 (2.97)	-16.31 (3.88)		
Week 8 Adjusted Mean Change (SE)	-24.85 (3.14)	-18.63 (4.12)		
Week 12 Adjusted Mean Change (SE)	-28.24 (3.18)	-22.52 (4.18)		
Week 16 Adjusted Mean Change (SE)	-27.39 (2.98)	-21.51 (3.92)		
Week 20 Adjusted Mean Change (SE)	-32.14 (3.25)	-24.12 (4.39)		
Week 24 Adjusted Mean Change (SE)	-28.50 (3.31)	-19.98 (4.43)		
Week 28 Adjusted Mean Change (SE)	-29.69 (3.14)	-31.04 (4.29)		
Week 32 Adjusted Mean Change (SE)	-32.81 (3.12)	-25.39 (4.23)		
Week 36 Adjusted Mean Change (SE)	-34.10 (3.20)	-27.99 (4.35)		
Week 40 Adjusted Mean Change (SE)	-34.99 (3.20)	-25.40 (4.34)		
Week 44 Adjusted Mean Change (SE)	-34.64 (3.39)	-30.66 (4.66)		
Week 48 Adjusted Mean Change (SE)	-34.20 (3.49)	-30.79 (4.77)		
Week 52 Adjusted Mean Change (SE)	-33.51 (3.50)	-30.94 (4.86)	-2.57 [-14.42; 9.28]	0.669
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	63.71 (21.43)	62.17 (21.43)		
Week 52 Mean (SD)	29.76 (22.24)	26.07 (22.69)		
Week 2 Adjusted Mean Change (SE)	-14.71 (2.72)	-19.23 (3.07)		
Week 4 Adjusted Mean Change (SE)	-18.97 (3.23)	-23.02 (3.63)		
Week 8 Adjusted Mean Change (SE)	-25.04 (3.42)	-27.26 (3.85)		
Week 12 Adjusted Mean Change (SE)	-25.22 (3.50)	-30.34 (3.93)		
Week 16 Adjusted Mean Change (SE)	-26.24 (3.25)	-32.11 (3.68)		
Week 20 Adjusted Mean Change (SE)	-26.66 (3.57)	-33.13 (4.05)		
Week 24 Adjusted Mean Change (SE)	-27.10 (3.59)	-31.98 (4.10)		
Week 28 Adjusted Mean Change (SE)	-25.49 (3.46)	-30.98 (3.94)		
Week 32 Adjusted Mean Change (SE)	-33.37 (3.41)	-30.53 (3.88)		
Week 36 Adjusted Mean Change (SE)	-32.58 (3.48)	-33.86 (3.94)		
Week 40 Adjusted Mean Change (SE)	-32.01 (3.48)	-33.77 (3.98)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-31.69 (3.70)	-36.75 (4.21)		
Week 48 Adjusted Mean Change (SE)	-29.61 (3.80)	-36.87 (4.33)		
Week 52 Adjusted Mean Change (SE)	-33.53 (3.84)	-35.83 (4.35)	2.30 [-9.18; 13.78]	0.692
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 16.10 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.291</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	64.50 (24.47)	65.24 (23.14)		
Week 52 Mean (SD)	33.79 (22.09)	28.50 (25.90)		
Week 2 Adjusted Mean Change (SE)	-17.17 (3.12)	-12.83 (2.97)		
Week 4 Adjusted Mean Change (SE)	-19.72 (3.71)	-20.42 (3.57)		
Week 8 Adjusted Mean Change (SE)	-18.49 (3.80)	-24.03 (3.67)		
Week 12 Adjusted Mean Change (SE)	-23.13 (3.88)	-29.96 (3.77)		
Week 16 Adjusted Mean Change (SE)	-21.80 (3.64)	-27.52 (3.54)		
Week 20 Adjusted Mean Change (SE)	-26.70 (3.96)	-28.10 (3.92)		
Week 24 Adjusted Mean Change (SE)	-23.27 (4.12)	-26.21 (4.05)		
Week 28 Adjusted Mean Change (SE)	-24.34 (3.90)	-34.03 (3.88)		
Week 32 Adjusted Mean Change (SE)	-27.64 (3.79)	-29.15 (3.77)		
Week 36 Adjusted Mean Change (SE)	-30.86 (3.92)	-31.87 (3.93)		
Week 40 Adjusted Mean Change (SE)	-30.23 (3.94)	-29.30 (3.95)		
Week 44 Adjusted Mean Change (SE)	-28.49 (4.12)	-35.79 (4.17)		
Week 48 Adjusted Mean Change (SE)	-25.15 (4.17)	-35.88 (4.25)		
Week 52 Adjusted Mean Change (SE)	-29.95 (4.21)	-33.17 (4.30)	3.21 [-8.69; 15.12]	0.594
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	66.33 (19.35)	60.38 (19.53)		
Week 52 Mean (SD)	28.00 (23.05)	26.94 (21.46)		
Week 2 Adjusted Mean Change (SE)	-15.17 (2.39)	-17.35 (2.94)		
Week 4 Adjusted Mean Change (SE)	-23.50 (2.85)	-19.93 (3.50)		
Week 8 Adjusted Mean Change (SE)	-28.28 (2.92)	-26.07 (3.59)		
Week 12 Adjusted Mean Change (SE)	-30.89 (3.00)	-25.83 (3.66)		
Week 16 Adjusted Mean Change (SE)	-30.41 (2.80)	-28.13 (3.45)		
Week 20 Adjusted Mean Change (SE)	-31.76 (3.04)	-30.60 (3.76)		
Week 24 Adjusted Mean Change (SE)	-31.06 (3.14)	-28.13 (3.89)		
Week 28 Adjusted Mean Change (SE)	-30.76 (2.94)	-28.51 (3.67)		
Week 32 Adjusted Mean Change (SE)	-36.82 (2.90)	-29.78 (3.60)		
Week 36 Adjusted Mean Change (SE)	-35.32 (3.00)	-33.37 (3.69)		
Week 40 Adjusted Mean Change (SE)	-36.25 (3.02)	-34.14 (3.74)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-36.44 (3.16)	-33.82 (3.91)		
Week 48 Adjusted Mean Change (SE)	-36.40 (3.22)	-34.81 (3.96)		
Week 52 Adjusted Mean Change (SE)	-36.20 (3.23)	-35.99 (4.00)	-0.21 [-10.41; 9.99]	0.968
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.11 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.732</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	65.21 (19.02)	62.16 (21.50)		
Week 52 Mean (SD)	30.31 (23.54)	29.38 (25.50)		
Week 2 Adjusted Mean Change (SE)	-16.45 (2.61)	-15.67 (2.61)		
Week 4 Adjusted Mean Change (SE)	-21.33 (3.07)	-22.82 (3.07)		
Week 8 Adjusted Mean Change (SE)	-25.30 (3.22)	-25.25 (3.22)		
Week 12 Adjusted Mean Change (SE)	-27.45 (3.31)	-27.59 (3.31)		
Week 16 Adjusted Mean Change (SE)	-23.60 (3.10)	-27.44 (3.10)		
Week 20 Adjusted Mean Change (SE)	-30.88 (3.31)	-27.50 (3.35)		
Week 24 Adjusted Mean Change (SE)	-27.12 (3.47)	-28.21 (3.48)		
Week 28 Adjusted Mean Change (SE)	-27.38 (3.26)	-29.56 (3.31)		
Week 32 Adjusted Mean Change (SE)	-33.74 (3.21)	-28.83 (3.24)		
Week 36 Adjusted Mean Change (SE)	-32.42 (3.30)	-34.22 (3.30)		
Week 40 Adjusted Mean Change (SE)	-33.41 (3.30)	-33.29 (3.33)		
Week 44 Adjusted Mean Change (SE)	-33.41 (3.50)	-34.83 (3.51)		
Week 48 Adjusted Mean Change (SE)	-33.30 (3.59)	-36.58 (3.62)		
Week 52 Adjusted Mean Change (SE)	-33.29 (3.55)	-33.92 (3.59)	0.62 [-9.35; 10.60]	0.902
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	64.17 (24.17)	63.88 (21.53)		
Week 52 Mean (SD)	29.08 (22.08)	24.00 (18.02)		
Week 2 Adjusted Mean Change (SE)	-14.81 (2.65)	-13.63 (3.49)		
Week 4 Adjusted Mean Change (SE)	-22.98 (3.11)	-14.60 (4.16)		
Week 8 Adjusted Mean Change (SE)	-25.21 (3.26)	-23.95 (4.38)		
Week 12 Adjusted Mean Change (SE)	-26.75 (3.35)	-27.55 (4.48)		
Week 16 Adjusted Mean Change (SE)	-30.30 (3.12)	-27.84 (4.22)		
Week 20 Adjusted Mean Change (SE)	-28.32 (3.36)	-32.29 (4.57)		
Week 24 Adjusted Mean Change (SE)	-28.96 (3.49)	-24.50 (4.79)		
Week 28 Adjusted Mean Change (SE)	-29.06 (3.28)	-33.07 (4.51)		
Week 32 Adjusted Mean Change (SE)	-32.80 (3.21)	-30.08 (4.40)		
Week 36 Adjusted Mean Change (SE)	-34.52 (3.30)	-29.00 (4.58)		
Week 40 Adjusted Mean Change (SE)	-34.17 (3.33)	-28.32 (4.62)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-33.38 (3.49)	-33.47 (4.87)		
Week 48 Adjusted Mean Change (SE)	-31.35 (3.57)	-32.08 (4.94)		
Week 52 Adjusted Mean Change (SE)	-34.10 (3.55)	-35.61 (4.99)	1.51 [-10.60; 13.61]	0.806
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.12 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.704</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	65.98 (20.93)	61.49 (22.18)		
Week 52 Mean (SD)	31.26 (22.24)	28.97 (22.97)		
Week 2 Adjusted Mean Change (SE)	-14.56 (2.13)	-14.95 (2.43)		
Week 4 Adjusted Mean Change (SE)	-20.38 (2.53)	-23.25 (2.91)		
Week 8 Adjusted Mean Change (SE)	-24.60 (2.68)	-24.29 (3.09)		
Week 12 Adjusted Mean Change (SE)	-24.32 (2.67)	-28.03 (3.07)		
Week 16 Adjusted Mean Change (SE)	-24.57 (2.56)	-26.24 (2.95)		
Week 20 Adjusted Mean Change (SE)	-28.53 (2.75)	-27.02 (3.22)		
Week 24 Adjusted Mean Change (SE)	-28.44 (2.87)	-26.40 (3.35)		
Week 28 Adjusted Mean Change (SE)	-27.94 (2.65)	-30.26 (3.11)		
Week 32 Adjusted Mean Change (SE)	-31.55 (2.58)	-28.89 (3.02)		
Week 36 Adjusted Mean Change (SE)	-32.45 (2.60)	-33.04 (3.04)		
Week 40 Adjusted Mean Change (SE)	-32.97 (2.64)	-31.41 (3.12)		
Week 44 Adjusted Mean Change (SE)	-31.56 (2.85)	-31.24 (3.36)		
Week 48 Adjusted Mean Change (SE)	-29.90 (2.93)	-33.17 (3.44)		
Week 52 Adjusted Mean Change (SE)	-32.40 (2.81)	-32.42 (3.36)	0.01 [-8.68; 8.70]	0.998
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	60.45 (23.59)	63.22 (18.69)		
Week 52 Mean (SD)	22.89 (22.60)	18.35 (14.52)		
Week 2 Adjusted Mean Change (SE)	-14.75 (3.76)	-16.68 (3.92)		
Week 4 Adjusted Mean Change (SE)	-22.81 (4.46)	-13.92 (4.66)		
Week 8 Adjusted Mean Change (SE)	-23.86 (4.73)	-28.40 (4.94)		
Week 12 Adjusted Mean Change (SE)	-30.54 (4.68)	-30.07 (4.95)		
Week 16 Adjusted Mean Change (SE)	-31.60 (4.49)	-33.41 (4.72)		
Week 20 Adjusted Mean Change (SE)	-30.94 (4.85)	-36.40 (5.10)		
Week 24 Adjusted Mean Change (SE)	-26.57 (5.07)	-30.87 (5.31)		
Week 28 Adjusted Mean Change (SE)	-27.26 (4.71)	-36.46 (4.98)		
Week 32 Adjusted Mean Change (SE)	-36.43 (4.56)	-34.22 (4.81)		
Week 36 Adjusted Mean Change (SE)	-37.17 (4.58)	-36.41 (4.86)		
Week 40 Adjusted Mean Change (SE)	-35.46 (4.71)	-37.05 (4.94)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-35.95 (5.02)	-45.02 (5.27)		
Week 48 Adjusted Mean Change (SE)	-35.96 (5.09)	-43.86 (5.40)		
Week 52 Adjusted Mean Change (SE)	-38.15 (4.96)	-44.42 (5.20)	6.27 [-7.92; 20.47]	0.384
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.13 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.359</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	65.02 (20.81)	62.41 (23.50)		
Week 52 Mean (SD)	30.34 (24.51)	26.08 (22.00)		
Week 2 Adjusted Mean Change (SE)	-13.91 (2.13)	-15.27 (2.36)		
Week 4 Adjusted Mean Change (SE)	-22.66 (2.55)	-22.33 (2.85)		
Week 8 Adjusted Mean Change (SE)	-25.98 (2.65)	-27.11 (2.97)		
Week 12 Adjusted Mean Change (SE)	-27.82 (2.68)	-30.99 (3.01)		
Week 16 Adjusted Mean Change (SE)	-27.48 (2.56)	-30.22 (2.88)		
Week 20 Adjusted Mean Change (SE)	-29.98 (2.76)	-30.90 (3.12)		
Week 24 Adjusted Mean Change (SE)	-28.13 (2.87)	-27.86 (3.24)		
Week 28 Adjusted Mean Change (SE)	-27.78 (2.66)	-32.66 (3.02)		
Week 32 Adjusted Mean Change (SE)	-32.74 (2.64)	-31.08 (2.99)		
Week 36 Adjusted Mean Change (SE)	-33.53 (2.71)	-34.18 (3.09)		
Week 40 Adjusted Mean Change (SE)	-34.05 (2.74)	-32.90 (3.13)		
Week 44 Adjusted Mean Change (SE)	-32.47 (2.86)	-35.93 (3.26)		
Week 48 Adjusted Mean Change (SE)	-32.07 (2.94)	-36.53 (3.33)		
Week 52 Adjusted Mean Change (SE)	-33.53 (2.93)	-36.02 (3.38)	2.48 [-6.36; 11.32]	0.580
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	62.95 (24.63)	65.42 (12.58)		
Week 52 Mean (SD)	28.50 (17.15)	34.58 (28.38)		
Week 2 Adjusted Mean Change (SE)	-19.71 (3.87)	-13.12 (4.89)		
Week 4 Adjusted Mean Change (SE)	-20.04 (4.64)	-12.17 (5.86)		
Week 8 Adjusted Mean Change (SE)	-21.59 (4.83)	-17.48 (6.10)		
Week 12 Adjusted Mean Change (SE)	-23.45 (4.87)	-16.86 (6.15)		
Week 16 Adjusted Mean Change (SE)	-26.13 (4.65)	-19.63 (5.87)		
Week 20 Adjusted Mean Change (SE)	-27.50 (5.04)	-24.85 (6.39)		
Week 24 Adjusted Mean Change (SE)	-26.17 (5.18)	-24.73 (6.53)		
Week 28 Adjusted Mean Change (SE)	-31.64 (4.80)	-26.68 (6.18)		
Week 32 Adjusted Mean Change (SE)	-33.07 (4.74)	-24.15 (6.22)		
Week 36 Adjusted Mean Change (SE)	-30.60 (4.93)	-28.02 (6.20)		
Week 40 Adjusted Mean Change (SE)	-30.98 (4.93)	-28.61 (6.22)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-36.33 (5.14)	-31.77 (6.55)		
Week 48 Adjusted Mean Change (SE)	-34.14 (5.24)	-30.17 (6.78)		
Week 52 Adjusted Mean Change (SE)	-33.15 (5.28)	-28.24 (6.62)	-4.91 [-21.64; 11.82]	0.563
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 16.14 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.535</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	63.65 (23.16)	64.02 (21.06)		
Week 52 Mean (SD)	30.46 (23.06)	27.66 (23.66)		
Week 2 Adjusted Mean Change (SE)	-16.37 (2.04)	-13.18 (2.35)		
Week 4 Adjusted Mean Change (SE)	-23.01 (2.35)	-19.29 (2.74)		
Week 8 Adjusted Mean Change (SE)	-26.39 (2.51)	-24.11 (2.92)		
Week 12 Adjusted Mean Change (SE)	-27.66 (2.56)	-27.33 (2.99)		
Week 16 Adjusted Mean Change (SE)	-28.03 (2.42)	-27.26 (2.83)		
Week 20 Adjusted Mean Change (SE)	-30.43 (2.61)	-29.58 (3.08)		
Week 24 Adjusted Mean Change (SE)	-27.96 (2.67)	-26.64 (3.15)		
Week 28 Adjusted Mean Change (SE)	-28.53 (2.52)	-31.44 (2.99)		
Week 32 Adjusted Mean Change (SE)	-33.48 (2.49)	-29.45 (2.95)		
Week 36 Adjusted Mean Change (SE)	-33.49 (2.56)	-31.77 (3.03)		
Week 40 Adjusted Mean Change (SE)	-33.96 (2.57)	-29.87 (3.05)		
Week 44 Adjusted Mean Change (SE)	-33.74 (2.71)	-34.16 (3.22)		
Week 48 Adjusted Mean Change (SE)	-32.83 (2.79)	-34.16 (3.33)		
Week 52 Adjusted Mean Change (SE)	-32.88 (2.76)	-35.05 (3.29)	2.17 [-6.32; 10.66]	0.614
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	70.77 (9.31)	57.90 (21.95)		
Week 52 Mean (SD)	27.77 (21.04)	28.13 (22.03)		
Week 2 Adjusted Mean Change (SE)	-11.87 (4.78)	-22.60 (5.44)		
Week 4 Adjusted Mean Change (SE)	-17.98 (5.52)	-23.12 (6.28)		
Week 8 Adjusted Mean Change (SE)	-18.54 (5.89)	-26.86 (6.69)		
Week 12 Adjusted Mean Change (SE)	-24.20 (6.09)	-23.41 (6.82)		
Week 16 Adjusted Mean Change (SE)	-21.25 (5.67)	-28.79 (6.44)		
Week 20 Adjusted Mean Change (SE)	-25.14 (6.09)	-24.81 (7.04)		
Week 24 Adjusted Mean Change (SE)	-26.94 (6.24)	-29.92 (7.19)		
Week 28 Adjusted Mean Change (SE)	-25.19 (5.81)	-29.28 (6.60)		
Week 32 Adjusted Mean Change (SE)	-31.01 (5.78)	-27.49 (6.57)		
Week 36 Adjusted Mean Change (SE)	-33.22 (5.93)	-32.80 (6.74)		
Week 40 Adjusted Mean Change (SE)	-31.81 (5.97)	-36.69 (6.85)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-30.38 (6.28)	-36.41 (7.23)		
Week 48 Adjusted Mean Change (SE)	-28.37 (6.48)	-39.42 (7.27)		
Week 52 Adjusted Mean Change (SE)	-36.36 (6.38)	-32.89 (7.47)	-3.47 [-22.96; 16.02]	0.726
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.15 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.634</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	63.14 (25.19)	65.73 (24.21)		
Week 52 Mean (SD)	35.42 (26.39)	34.56 (27.96)		
Week 2 Adjusted Mean Change (SE)	-14.16 (3.64)	-12.26 (3.36)		
Week 4 Adjusted Mean Change (SE)	-19.66 (4.32)	-22.02 (4.03)		
Week 8 Adjusted Mean Change (SE)	-21.53 (4.48)	-22.85 (4.20)		
Week 12 Adjusted Mean Change (SE)	-20.45 (4.55)	-28.60 (4.27)		
Week 16 Adjusted Mean Change (SE)	-21.37 (4.33)	-25.45 (4.08)		
Week 20 Adjusted Mean Change (SE)	-27.23 (4.67)	-27.17 (4.43)		
Week 24 Adjusted Mean Change (SE)	-27.88 (4.88)	-23.74 (4.59)		
Week 28 Adjusted Mean Change (SE)	-22.12 (4.59)	-30.74 (4.39)		
Week 32 Adjusted Mean Change (SE)	-27.79 (4.50)	-27.09 (4.27)		
Week 36 Adjusted Mean Change (SE)	-28.33 (4.64)	-32.47 (4.42)		
Week 40 Adjusted Mean Change (SE)	-31.23 (4.65)	-29.03 (4.45)		
Week 44 Adjusted Mean Change (SE)	-25.66 (4.87)	-29.52 (4.68)		
Week 48 Adjusted Mean Change (SE)	-27.33 (5.13)	-31.65 (4.87)		
Week 52 Adjusted Mean Change (SE)	-26.76 (4.98)	-29.29 (4.83)	2.53 [-11.18; 16.25]	0.716
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	65.24 (20.39)	60.90 (19.43)		
Week 52 Mean (SD)	27.87 (21.29)	24.24 (20.21)		
Week 2 Adjusted Mean Change (SE)	-16.15 (2.15)	-16.65 (2.68)		
Week 4 Adjusted Mean Change (SE)	-23.02 (2.55)	-18.70 (3.18)		
Week 8 Adjusted Mean Change (SE)	-26.56 (2.65)	-26.00 (3.30)		
Week 12 Adjusted Mean Change (SE)	-29.46 (2.71)	-26.89 (3.37)		
Week 16 Adjusted Mean Change (SE)	-28.95 (2.55)	-28.88 (3.18)		
Week 20 Adjusted Mean Change (SE)	-30.52 (2.75)	-30.40 (3.47)		
Week 24 Adjusted Mean Change (SE)	-28.29 (2.82)	-28.91 (3.55)		
Week 28 Adjusted Mean Change (SE)	-30.24 (2.67)	-30.82 (3.37)		
Week 32 Adjusted Mean Change (SE)	-35.13 (2.60)	-30.54 (3.28)		
Week 36 Adjusted Mean Change (SE)	-35.26 (2.68)	-32.46 (3.37)		
Week 40 Adjusted Mean Change (SE)	-34.69 (2.70)	-33.09 (3.40)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-35.93 (2.81)	-37.05 (3.53)		
Week 48 Adjusted Mean Change (SE)	-33.96 (2.89)	-36.91 (3.64)		
Week 52 Adjusted Mean Change (SE)	-36.04 (2.86)	-37.16 (3.61)	1.13 [-7.99; 10.25]	0.807
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.16 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.211</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	64.06 (21.40)	64.71 (18.68)		
Week 52 Mean (SD)	29.49 (22.67)	28.50 (23.97)		
Week 2 Adjusted Mean Change (SE)	-16.26 (2.37)	-10.68 (2.86)		
Week 4 Adjusted Mean Change (SE)	-24.03 (2.82)	-16.32 (3.43)		
Week 8 Adjusted Mean Change (SE)	-25.47 (2.96)	-23.01 (3.61)		
Week 12 Adjusted Mean Change (SE)	-29.22 (3.01)	-24.88 (3.67)		
Week 16 Adjusted Mean Change (SE)	-27.63 (2.85)	-24.89 (3.48)		
Week 20 Adjusted Mean Change (SE)	-31.67 (3.05)	-26.16 (3.79)		
Week 24 Adjusted Mean Change (SE)	-28.76 (3.16)	-23.93 (3.91)		
Week 28 Adjusted Mean Change (SE)	-29.77 (2.98)	-31.59 (3.74)		
Week 32 Adjusted Mean Change (SE)	-32.41 (2.92)	-28.35 (3.63)		
Week 36 Adjusted Mean Change (SE)	-34.64 (3.00)	-30.80 (3.75)		
Week 40 Adjusted Mean Change (SE)	-35.55 (3.01)	-29.47 (3.76)		
Week 44 Adjusted Mean Change (SE)	-33.86 (3.18)	-33.48 (4.01)		
Week 48 Adjusted Mean Change (SE)	-35.68 (3.21)	-33.78 (4.04)		
Week 52 Adjusted Mean Change (SE)	-34.07 (3.23)	-33.66 (4.13)	-0.41 [-10.78; 9.97]	0.938
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	65.65 (22.16)	60.66 (24.08)		
Week 52 Mean (SD)	30.00 (23.08)	26.83 (23.06)		
Week 2 Adjusted Mean Change (SE)	-14.71 (2.91)	-19.60 (2.99)		
Week 4 Adjusted Mean Change (SE)	-19.32 (3.45)	-23.88 (3.56)		
Week 8 Adjusted Mean Change (SE)	-24.95 (3.63)	-26.74 (3.74)		
Week 12 Adjusted Mean Change (SE)	-23.91 (3.70)	-30.48 (3.82)		
Week 16 Adjusted Mean Change (SE)	-26.10 (3.50)	-30.51 (3.62)		
Week 20 Adjusted Mean Change (SE)	-26.55 (3.77)	-32.55 (3.91)		
Week 24 Adjusted Mean Change (SE)	-26.88 (3.88)	-30.24 (4.04)		
Week 28 Adjusted Mean Change (SE)	-25.35 (3.72)	-29.93 (3.85)		
Week 32 Adjusted Mean Change (SE)	-34.70 (3.60)	-30.26 (3.75)		
Week 36 Adjusted Mean Change (SE)	-31.72 (3.69)	-34.30 (3.82)		
Week 40 Adjusted Mean Change (SE)	-31.08 (3.70)	-33.90 (3.85)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-32.79 (3.93)	-35.41 (4.07)		
Week 48 Adjusted Mean Change (SE)	-27.28 (3.96)	-36.24 (4.11)		
Week 52 Adjusted Mean Change (SE)	-33.34 (4.01)	-35.42 (4.14)	2.08 [-9.34; 13.50]	0.720
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.17 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.148</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	64.50 (24.47)	65.84 (21.66)		
Week 52 Mean (SD)	33.79 (22.09)	27.27 (26.24)		
Week 2 Adjusted Mean Change (SE)	-16.98 (3.12)	-12.81 (3.07)		
Week 4 Adjusted Mean Change (SE)	-19.51 (3.70)	-20.82 (3.68)		
Week 8 Adjusted Mean Change (SE)	-18.24 (3.79)	-25.61 (3.78)		
Week 12 Adjusted Mean Change (SE)	-22.86 (3.90)	-31.01 (3.92)		
Week 16 Adjusted Mean Change (SE)	-21.54 (3.68)	-29.05 (3.70)		
Week 20 Adjusted Mean Change (SE)	-26.47 (3.99)	-30.43 (4.09)		
Week 24 Adjusted Mean Change (SE)	-23.06 (4.13)	-27.88 (4.20)		
Week 28 Adjusted Mean Change (SE)	-24.07 (3.88)	-35.04 (4.01)		
Week 32 Adjusted Mean Change (SE)	-27.40 (3.77)	-30.64 (3.89)		
Week 36 Adjusted Mean Change (SE)	-30.58 (3.92)	-31.98 (4.07)		
Week 40 Adjusted Mean Change (SE)	-29.99 (3.93)	-29.54 (4.08)		
Week 44 Adjusted Mean Change (SE)	-28.23 (4.09)	-36.49 (4.27)		
Week 48 Adjusted Mean Change (SE)	-24.88 (4.14)	-36.24 (4.39)		
Week 52 Adjusted Mean Change (SE)	-29.67 (4.20)	-33.52 (4.45)	3.85 [-8.24; 15.94]	0.530
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	64.80 (20.09)	60.14 (21.05)		
Week 52 Mean (SD)	27.30 (22.89)	27.85 (21.52)		
Week 2 Adjusted Mean Change (SE)	-14.90 (2.30)	-16.79 (2.86)		
Week 4 Adjusted Mean Change (SE)	-23.59 (2.73)	-19.24 (3.39)		
Week 8 Adjusted Mean Change (SE)	-29.09 (2.80)	-24.12 (3.47)		
Week 12 Adjusted Mean Change (SE)	-29.47 (2.90)	-24.76 (3.57)		
Week 16 Adjusted Mean Change (SE)	-30.01 (2.73)	-26.37 (3.38)		
Week 20 Adjusted Mean Change (SE)	-31.39 (2.95)	-28.16 (3.68)		
Week 24 Adjusted Mean Change (SE)	-30.70 (3.03)	-26.18 (3.78)		
Week 28 Adjusted Mean Change (SE)	-30.47 (2.83)	-27.55 (3.54)		
Week 32 Adjusted Mean Change (SE)	-36.50 (2.78)	-28.10 (3.47)		
Week 36 Adjusted Mean Change (SE)	-35.00 (2.90)	-32.62 (3.58)		
Week 40 Adjusted Mean Change (SE)	-35.81 (2.91)	-33.00 (3.62)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-36.21 (3.04)	-32.63 (3.78)		
Week 48 Adjusted Mean Change (SE)	-36.47 (3.10)	-33.91 (3.82)		
Week 52 Adjusted Mean Change (SE)	-35.88 (3.13)	-34.86 (3.87)	-1.02 [-10.87; 8.83]	0.839
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 16.18 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.732</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	65.21 (19.02)	62.16 (21.50)		
Week 52 Mean (SD)	30.31 (23.54)	29.38 (25.50)		
Week 2 Adjusted Mean Change (SE)	-16.45 (2.61)	-15.67 (2.61)		
Week 4 Adjusted Mean Change (SE)	-21.33 (3.07)	-22.82 (3.07)		
Week 8 Adjusted Mean Change (SE)	-25.30 (3.22)	-25.25 (3.22)		
Week 12 Adjusted Mean Change (SE)	-27.45 (3.31)	-27.59 (3.31)		
Week 16 Adjusted Mean Change (SE)	-23.60 (3.10)	-27.44 (3.10)		
Week 20 Adjusted Mean Change (SE)	-30.88 (3.31)	-27.50 (3.35)		
Week 24 Adjusted Mean Change (SE)	-27.12 (3.47)	-28.21 (3.48)		
Week 28 Adjusted Mean Change (SE)	-27.38 (3.26)	-29.56 (3.31)		
Week 32 Adjusted Mean Change (SE)	-33.74 (3.21)	-28.83 (3.24)		
Week 36 Adjusted Mean Change (SE)	-32.42 (3.30)	-34.22 (3.30)		
Week 40 Adjusted Mean Change (SE)	-33.41 (3.30)	-33.29 (3.33)		
Week 44 Adjusted Mean Change (SE)	-33.41 (3.50)	-34.83 (3.51)		
Week 48 Adjusted Mean Change (SE)	-33.30 (3.59)	-36.58 (3.62)		
Week 52 Adjusted Mean Change (SE)	-33.29 (3.55)	-33.92 (3.59)	0.62 [-9.35; 10.60]	0.902
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	64.17 (24.17)	63.88 (21.53)		
Week 52 Mean (SD)	29.08 (22.08)	24.00 (18.02)		
Week 2 Adjusted Mean Change (SE)	-14.81 (2.65)	-13.63 (3.49)		
Week 4 Adjusted Mean Change (SE)	-22.98 (3.11)	-14.60 (4.16)		
Week 8 Adjusted Mean Change (SE)	-25.21 (3.26)	-23.95 (4.38)		
Week 12 Adjusted Mean Change (SE)	-26.75 (3.35)	-27.55 (4.48)		
Week 16 Adjusted Mean Change (SE)	-30.30 (3.12)	-27.84 (4.22)		
Week 20 Adjusted Mean Change (SE)	-28.32 (3.36)	-32.29 (4.57)		
Week 24 Adjusted Mean Change (SE)	-28.96 (3.49)	-24.50 (4.79)		
Week 28 Adjusted Mean Change (SE)	-29.06 (3.28)	-33.07 (4.51)		
Week 32 Adjusted Mean Change (SE)	-32.80 (3.21)	-30.08 (4.40)		
Week 36 Adjusted Mean Change (SE)	-34.52 (3.30)	-29.00 (4.58)		
Week 40 Adjusted Mean Change (SE)	-34.17 (3.33)	-28.32 (4.62)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-33.38 (3.49)	-33.47 (4.87)		
Week 48 Adjusted Mean Change (SE)	-31.35 (3.57)	-32.08 (4.94)		
Week 52 Adjusted Mean Change (SE)	-34.10 (3.55)	-35.61 (4.99)	1.51 [-10.60; 13.61]	0.806
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 16.19 Patient's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.622</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	65.38 (21.16)	62.29 (22.27)		
Week 52 Mean (SD)	30.92 (22.50)	31.11 (24.27)		
Week 2 Adjusted Mean Change (SE)	-14.71 (2.07)	-14.31 (2.38)		
Week 4 Adjusted Mean Change (SE)	-21.23 (2.47)	-21.88 (2.86)		
Week 8 Adjusted Mean Change (SE)	-25.19 (2.62)	-23.60 (3.03)		
Week 12 Adjusted Mean Change (SE)	-25.64 (2.69)	-27.26 (3.11)		
Week 16 Adjusted Mean Change (SE)	-25.03 (2.53)	-25.75 (2.94)		
Week 20 Adjusted Mean Change (SE)	-29.40 (2.67)	-25.58 (3.13)		
Week 24 Adjusted Mean Change (SE)	-28.65 (2.80)	-25.06 (3.29)		
Week 28 Adjusted Mean Change (SE)	-28.32 (2.65)	-29.25 (3.13)		
Week 32 Adjusted Mean Change (SE)	-31.75 (2.60)	-27.64 (3.05)		
Week 36 Adjusted Mean Change (SE)	-32.30 (2.70)	-32.18 (3.17)		
Week 40 Adjusted Mean Change (SE)	-33.07 (2.69)	-29.69 (3.19)		
Week 44 Adjusted Mean Change (SE)	-32.42 (2.80)	-30.66 (3.32)		
Week 48 Adjusted Mean Change (SE)	-30.93 (2.92)	-32.45 (3.43)		
Week 52 Adjusted Mean Change (SE)	-32.80 (2.84)	-30.64 (3.40)	-2.15 [-10.92; 6.61]	0.628
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	60.17 (23.53)	64.11 (19.20)		
Week 52 Mean (SD)	23.06 (23.05)	19.82 (19.35)		
Week 2 Adjusted Mean Change (SE)	-14.16 (3.96)	-15.86 (3.92)		
Week 4 Adjusted Mean Change (SE)	-20.57 (4.71)	-13.94 (4.68)		
Week 8 Adjusted Mean Change (SE)	-21.75 (4.98)	-26.99 (4.95)		
Week 12 Adjusted Mean Change (SE)	-28.42 (5.09)	-27.31 (5.06)		
Week 16 Adjusted Mean Change (SE)	-31.17 (4.81)	-31.69 (4.80)		
Week 20 Adjusted Mean Change (SE)	-31.95 (5.10)	-37.60 (5.08)		
Week 24 Adjusted Mean Change (SE)	-27.70 (5.36)	-31.01 (5.33)		
Week 28 Adjusted Mean Change (SE)	-25.90 (5.12)	-34.38 (5.14)		
Week 32 Adjusted Mean Change (SE)	-35.54 (4.96)	-33.08 (5.01)		
Week 36 Adjusted Mean Change (SE)	-36.28 (5.15)	-31.89 (5.18)		
Week 40 Adjusted Mean Change (SE)	-34.88 (5.19)	-35.83 (5.16)		

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
Week 44 Adjusted Mean Change (SE)	-35.66 (5.35)	-43.33 (5.36)		
Week 48 Adjusted Mean Change (SE)	-35.80 (5.50)	-41.10 (5.60)		
Week 52 Adjusted Mean Change (SE)	-37.70 (5.42)	-43.20 (5.39)	5.50 [-9.62; 20.63]	0.473
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 17.0 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	110 (100.0)	100 (99.0)	210 (99.5)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

### 17.1 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	70.65 (19.23)	69.18 (19.53)		
Week 52 Mean (SD)	31.33 (23.09)	30.16 (24.11)		
Week 2 Adjusted Mean Change (SE)	-19.42 (1.72)	-16.14 (1.81)		
Week 4 Adjusted Mean Change (SE)	-27.42 (1.92)	-23.15 (2.02)		
Week 8 Adjusted Mean Change (SE)	-32.14 (2.01)	-25.99 (2.11)		
Week 12 Adjusted Mean Change (SE)	-33.32 (2.05)	-29.06 (2.15)		
Week 16 Adjusted Mean Change (SE)	-34.48 (2.01)	-29.77 (2.12)		
Week 24 Adjusted Mean Change (SE)	-34.04 (2.05)	-30.64 (2.20)		
Week 32 Adjusted Mean Change (SE)	-36.44 (1.99)	-33.23 (2.14)		
Week 40 Adjusted Mean Change (SE)	-38.57 (2.07)	-35.67 (2.25)		
Week 52 Adjusted Mean Change (SE)	-38.70 (2.25)	-38.14 (2.47)	-0.56 [-7.16; 6.03]	0.866
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 17.2 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.469</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	70.58 (19.53)	69.95 (18.90)		
Week 52 Mean (SD)	31.55 (23.38)	29.70 (23.66)		
Week 2 Adjusted Mean Change (SE)	-19.12 (1.79)	-16.16 (1.88)		
Week 4 Adjusted Mean Change (SE)	-27.04 (1.99)	-23.00 (2.10)		
Week 8 Adjusted Mean Change (SE)	-31.89 (2.08)	-26.53 (2.20)		
Week 12 Adjusted Mean Change (SE)	-32.97 (2.13)	-29.12 (2.24)		
Week 16 Adjusted Mean Change (SE)	-34.26 (2.08)	-30.09 (2.21)		
Week 24 Adjusted Mean Change (SE)	-33.77 (2.13)	-30.93 (2.29)		
Week 32 Adjusted Mean Change (SE)	-36.09 (2.06)	-33.28 (2.23)		
Week 40 Adjusted Mean Change (SE)	-38.61 (2.15)	-35.78 (2.35)		
Week 52 Adjusted Mean Change (SE)	-38.53 (2.33)	-38.69 (2.57)	0.16 [-6.67; 6.99]	0.964
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	71.57 (15.33)	58.86 (26.30)		
Week 52 Mean (SD)	27.83 (19.08)	36.00 (31.30)		
Week 2 Adjusted Mean Change (SE)	-23.81 (6.85)	-15.98 (6.88)		
Week 4 Adjusted Mean Change (SE)	-32.99 (7.65)	-25.18 (7.68)		
Week 8 Adjusted Mean Change (SE)	-35.73 (7.98)	-18.85 (8.02)		
Week 12 Adjusted Mean Change (SE)	-38.36 (8.12)	-28.33 (8.16)		
Week 16 Adjusted Mean Change (SE)	-37.57 (8.19)	-25.58 (8.03)		
Week 24 Adjusted Mean Change (SE)	-37.91 (8.10)	-26.92 (8.14)		
Week 32 Adjusted Mean Change (SE)	-41.39 (7.82)	-32.11 (7.85)		
Week 40 Adjusted Mean Change (SE)	-38.16 (8.15)	-34.00 (8.19)		
Week 52 Adjusted Mean Change (SE)	-41.26 (9.11)	-30.92 (9.18)	-10.34 [-35.82; 15.14]	0.425

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			



### 17.3 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.783</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	69.20 (16.87)	67.75 (18.00)		
Week 52 Mean (SD)	28.55 (22.74)	27.63 (24.21)		
Week 2 Adjusted Mean Change (SE)	-22.02 (2.25)	-18.21 (2.42)		
Week 4 Adjusted Mean Change (SE)	-32.81 (2.43)	-27.26 (2.61)		
Week 8 Adjusted Mean Change (SE)	-36.10 (2.58)	-29.63 (2.78)		
Week 12 Adjusted Mean Change (SE)	-37.55 (2.63)	-31.83 (2.81)		
Week 16 Adjusted Mean Change (SE)	-39.57 (2.51)	-35.35 (2.69)		
Week 24 Adjusted Mean Change (SE)	-39.02 (2.57)	-34.15 (2.81)		
Week 32 Adjusted Mean Change (SE)	-39.20 (2.56)	-36.21 (2.81)		
Week 40 Adjusted Mean Change (SE)	-41.75 (2.63)	-40.78 (2.91)		
Week 52 Adjusted Mean Change (SE)	-42.14 (2.87)	-41.74 (3.20)	-0.40 [-8.84; 8.04]	0.926
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	72.82 (22.34)	71.02 (21.43)		
Week 52 Mean (SD)	35.68 (23.25)	33.74 (23.87)		
Week 2 Adjusted Mean Change (SE)	-15.59 (2.77)	-13.43 (2.73)		
Week 4 Adjusted Mean Change (SE)	-19.39 (2.99)	-17.81 (2.97)		
Week 8 Adjusted Mean Change (SE)	-26.26 (3.17)	-21.23 (3.16)		
Week 12 Adjusted Mean Change (SE)	-27.05 (3.22)	-25.51 (3.21)		
Week 16 Adjusted Mean Change (SE)	-26.91 (3.08)	-22.23 (3.11)		
Week 24 Adjusted Mean Change (SE)	-26.49 (3.22)	-26.12 (3.29)		
Week 32 Adjusted Mean Change (SE)	-32.42 (3.18)	-29.29 (3.22)		
Week 40 Adjusted Mean Change (SE)	-33.85 (3.26)	-28.80 (3.39)		
Week 52 Adjusted Mean Change (SE)	-33.58 (3.57)	-33.39 (3.74)	-0.18 [-10.32; 9.96]	0.972

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 17.4 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.276</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	55.25 (17.26)	49.29 (22.16)		
Week 52 Mean (SD)	27.30 (21.25)	24.29 (25.46)		
Week 2 Adjusted Mean Change (SE)	-25.80 (3.78)	-25.92 (4.15)		
Week 4 Adjusted Mean Change (SE)	-29.98 (4.27)	-31.53 (4.69)		
Week 8 Adjusted Mean Change (SE)	-30.70 (4.45)	-35.63 (4.89)		
Week 12 Adjusted Mean Change (SE)	-35.16 (4.62)	-35.21 (5.01)		
Week 16 Adjusted Mean Change (SE)	-37.56 (4.46)	-38.50 (4.90)		
Week 24 Adjusted Mean Change (SE)	-34.62 (4.62)	-35.90 (5.11)		
Week 32 Adjusted Mean Change (SE)	-41.19 (4.44)	-39.87 (5.00)		
Week 40 Adjusted Mean Change (SE)	-42.88 (4.64)	-44.54 (5.24)		
Week 52 Adjusted Mean Change (SE)	-39.93 (5.05)	-42.84 (5.76)	2.92 [-11.47; 17.31]	0.690
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	74.94 (17.55)	74.40 (15.03)		
Week 52 Mean (SD)	32.46 (23.58)	31.69 (23.71)		
Week 2 Adjusted Mean Change (SE)	-17.55 (1.94)	-13.65 (2.02)		
Week 4 Adjusted Mean Change (SE)	-26.64 (2.20)	-20.99 (2.29)		
Week 8 Adjusted Mean Change (SE)	-32.49 (2.29)	-23.47 (2.39)		
Week 12 Adjusted Mean Change (SE)	-32.73 (2.35)	-27.49 (2.45)		
Week 16 Adjusted Mean Change (SE)	-33.55 (2.30)	-27.50 (2.41)		
Week 24 Adjusted Mean Change (SE)	-33.83 (2.35)	-29.28 (2.51)		
Week 32 Adjusted Mean Change (SE)	-35.12 (2.27)	-31.57 (2.41)		
Week 40 Adjusted Mean Change (SE)	-37.34 (2.35)	-33.45 (2.54)		
Week 52 Adjusted Mean Change (SE)	-38.32 (2.59)	-36.91 (2.81)	-1.41 [-8.84; 6.02]	0.709

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 17.5 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.362</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	64.29 (18.99)	68.25 (18.64)		
Week 52 Mean (SD)	32.10 (21.60)	27.71 (21.57)		
Week 2 Adjusted Mean Change (SE)	-19.37 (2.82)	-18.46 (2.53)		
Week 4 Adjusted Mean Change (SE)	-27.20 (3.15)	-25.59 (2.84)		
Week 8 Adjusted Mean Change (SE)	-30.91 (3.28)	-28.78 (2.97)		
Week 12 Adjusted Mean Change (SE)	-30.29 (3.35)	-28.62 (3.02)		
Week 16 Adjusted Mean Change (SE)	-32.59 (3.29)	-28.53 (3.00)		
Week 24 Adjusted Mean Change (SE)	-30.54 (3.34)	-33.26 (3.08)		
Week 32 Adjusted Mean Change (SE)	-36.10 (3.26)	-34.03 (3.02)		
Week 40 Adjusted Mean Change (SE)	-38.52 (3.41)	-34.60 (3.25)		
Week 52 Adjusted Mean Change (SE)	-36.75 (3.72)	-39.06 (3.55)	2.31 [-7.81; 12.42]	0.654
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	74.57 (18.44)	70.12 (20.55)		
Week 52 Mean (SD)	30.88 (24.08)	32.27 (26.17)		
Week 2 Adjusted Mean Change (SE)	-19.45 (2.22)	-13.73 (2.58)		
Week 4 Adjusted Mean Change (SE)	-27.56 (2.47)	-20.64 (2.89)		
Week 8 Adjusted Mean Change (SE)	-32.90 (2.58)	-23.10 (3.01)		
Week 12 Adjusted Mean Change (SE)	-35.23 (2.64)	-29.46 (3.07)		
Week 16 Adjusted Mean Change (SE)	-35.66 (2.59)	-30.96 (3.03)		
Week 24 Adjusted Mean Change (SE)	-36.17 (2.61)	-27.95 (3.10)		
Week 32 Adjusted Mean Change (SE)	-36.68 (2.56)	-32.39 (3.03)		
Week 40 Adjusted Mean Change (SE)	-38.62 (2.67)	-36.40 (3.16)		
Week 52 Adjusted Mean Change (SE)	-39.91 (2.89)	-37.09 (3.45)	-2.81 [-11.68; 6.05]	0.532

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 17.6 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.314</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	72.11 (19.40)	67.92 (21.66)		
Week 52 Mean (SD)	28.21 (21.12)	28.44 (23.25)		
Week 2 Adjusted Mean Change (SE)	-22.51 (2.11)	-16.13 (2.56)		
Week 4 Adjusted Mean Change (SE)	-30.53 (2.36)	-24.97 (2.86)		
Week 8 Adjusted Mean Change (SE)	-33.30 (2.49)	-28.39 (3.01)		
Week 12 Adjusted Mean Change (SE)	-34.66 (2.56)	-29.44 (3.07)		
Week 16 Adjusted Mean Change (SE)	-36.58 (2.47)	-33.11 (3.01)		
Week 24 Adjusted Mean Change (SE)	-37.43 (2.49)	-33.19 (3.12)		
Week 32 Adjusted Mean Change (SE)	-38.81 (2.45)	-34.43 (3.08)		
Week 40 Adjusted Mean Change (SE)	-41.05 (2.55)	-35.26 (3.28)		
Week 52 Adjusted Mean Change (SE)	-42.19 (2.75)	-38.22 (3.61)	-3.97 [-12.93; 4.99]	0.383
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	67.87 (18.84)	70.37 (17.42)		
Week 52 Mean (SD)	37.57 (25.80)	31.50 (24.94)		
Week 2 Adjusted Mean Change (SE)	-13.59 (2.90)	-16.13 (2.50)		
Week 4 Adjusted Mean Change (SE)	-21.56 (3.24)	-21.36 (2.81)		
Week 8 Adjusted Mean Change (SE)	-29.94 (3.42)	-23.64 (2.97)		
Week 12 Adjusted Mean Change (SE)	-30.72 (3.48)	-28.71 (3.03)		
Week 16 Adjusted Mean Change (SE)	-30.52 (3.39)	-26.53 (2.96)		
Week 24 Adjusted Mean Change (SE)	-27.36 (3.49)	-28.19 (3.02)		
Week 32 Adjusted Mean Change (SE)	-31.84 (3.40)	-32.04 (2.95)		
Week 40 Adjusted Mean Change (SE)	-33.78 (3.54)	-35.74 (3.09)		
Week 52 Adjusted Mean Change (SE)	-31.88 (3.85)	-37.84 (3.35)	5.96 [-4.11; 16.03]	0.245

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			



### 17.7 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.448</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	69.92 (20.30)	66.63 (24.68)		
Week 52 Mean (SD)	28.65 (23.60)	26.84 (27.20)		
Week 2 Adjusted Mean Change (SE)	-20.06 (2.51)	-22.30 (3.17)		
Week 4 Adjusted Mean Change (SE)	-26.75 (2.82)	-27.40 (3.60)		
Week 8 Adjusted Mean Change (SE)	-30.19 (2.94)	-30.73 (3.77)		
Week 12 Adjusted Mean Change (SE)	-35.54 (3.02)	-32.73 (3.86)		
Week 16 Adjusted Mean Change (SE)	-34.77 (2.94)	-35.34 (3.79)		
Week 24 Adjusted Mean Change (SE)	-35.78 (3.01)	-30.98 (3.90)		
Week 32 Adjusted Mean Change (SE)	-38.32 (2.91)	-37.31 (3.77)		
Week 40 Adjusted Mean Change (SE)	-40.09 (3.03)	-38.16 (3.96)		
Week 52 Adjusted Mean Change (SE)	-41.77 (3.29)	-40.61 (4.40)	-1.17 [-12.00; 9.67]	0.832
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	71.27 (18.41)	70.36 (16.71)		
Week 52 Mean (SD)	33.68 (22.59)	31.61 (22.74)		
Week 2 Adjusted Mean Change (SE)	-18.86 (2.33)	-13.26 (2.17)		
Week 4 Adjusted Mean Change (SE)	-28.00 (2.62)	-21.15 (2.44)		
Week 8 Adjusted Mean Change (SE)	-33.81 (2.74)	-23.78 (2.55)		
Week 12 Adjusted Mean Change (SE)	-31.46 (2.79)	-27.31 (2.59)		
Week 16 Adjusted Mean Change (SE)	-34.23 (2.74)	-27.20 (2.56)		
Week 24 Adjusted Mean Change (SE)	-32.51 (2.81)	-30.51 (2.67)		
Week 32 Adjusted Mean Change (SE)	-34.79 (2.71)	-31.36 (2.58)		
Week 40 Adjusted Mean Change (SE)	-37.22 (2.83)	-34.56 (2.74)		
Week 52 Adjusted Mean Change (SE)	-36.00 (3.08)	-37.06 (2.98)	1.06 [-7.39; 9.50]	0.806

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 17.8 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.750</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	73.63 (18.30)	66.44 (19.84)		
Week 52 Mean (SD)	31.12 (23.93)	27.75 (20.89)		
Week 2 Adjusted Mean Change (SE)	-19.21 (2.49)	-17.79 (2.78)		
Week 4 Adjusted Mean Change (SE)	-28.12 (2.85)	-27.84 (3.17)		
Week 8 Adjusted Mean Change (SE)	-34.12 (3.07)	-29.06 (3.42)		
Week 12 Adjusted Mean Change (SE)	-33.02 (3.04)	-33.48 (3.40)		
Week 16 Adjusted Mean Change (SE)	-36.61 (2.99)	-31.11 (3.35)		
Week 24 Adjusted Mean Change (SE)	-35.95 (3.10)	-31.58 (3.51)		
Week 32 Adjusted Mean Change (SE)	-37.05 (2.96)	-34.15 (3.35)		
Week 40 Adjusted Mean Change (SE)	-39.65 (3.14)	-37.41 (3.56)		
Week 52 Adjusted Mean Change (SE)	-39.45 (3.40)	-40.01 (3.86)	0.56 [-9.65; 10.76]	0.914
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	69.12 (21.79)	68.77 (22.46)		
Week 52 Mean (SD)	32.06 (23.13)	35.57 (31.00)		
Week 2 Adjusted Mean Change (SE)	-18.61 (3.04)	-9.14 (3.47)		
Week 4 Adjusted Mean Change (SE)	-24.10 (3.47)	-17.04 (4.01)		
Week 8 Adjusted Mean Change (SE)	-27.33 (3.74)	-24.08 (4.34)		
Week 12 Adjusted Mean Change (SE)	-32.49 (3.74)	-26.19 (4.31)		
Week 16 Adjusted Mean Change (SE)	-27.34 (3.65)	-29.45 (4.22)		
Week 24 Adjusted Mean Change (SE)	-31.73 (3.80)	-29.36 (4.46)		
Week 32 Adjusted Mean Change (SE)	-36.58 (3.67)	-34.14 (4.25)		
Week 40 Adjusted Mean Change (SE)	-38.11 (3.86)	-33.71 (4.60)		
Week 52 Adjusted Mean Change (SE)	-36.85 (4.19)	-32.63 (4.97)	-4.22 [-17.06; 8.62]	0.517

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 17.9 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.105</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	73.18 (19.87)	67.41 (18.17)		
Week 52 Mean (SD)	31.28 (23.32)	33.79 (28.51)		
Week 2 Adjusted Mean Change (SE)	-19.94 (2.53)	-9.13 (3.25)		
Week 4 Adjusted Mean Change (SE)	-27.52 (3.02)	-18.40 (3.93)		
Week 8 Adjusted Mean Change (SE)	-31.08 (3.33)	-23.19 (4.35)		
Week 12 Adjusted Mean Change (SE)	-35.13 (3.26)	-28.86 (4.25)		
Week 16 Adjusted Mean Change (SE)	-34.05 (3.18)	-25.94 (4.17)		
Week 24 Adjusted Mean Change (SE)	-35.45 (3.26)	-25.56 (4.37)		
Week 32 Adjusted Mean Change (SE)	-37.66 (3.19)	-32.30 (4.26)		
Week 40 Adjusted Mean Change (SE)	-41.37 (3.27)	-27.51 (4.43)		
Week 52 Adjusted Mean Change (SE)	-38.45 (3.71)	-34.50 (5.16)	-3.94 [-16.54; 8.66]	0.537
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	68.76 (19.08)	67.50 (21.56)		
Week 52 Mean (SD)	31.51 (23.53)	30.64 (25.21)		
Week 2 Adjusted Mean Change (SE)	-16.58 (2.73)	-19.55 (3.08)		
Week 4 Adjusted Mean Change (SE)	-23.90 (3.27)	-28.25 (3.69)		
Week 8 Adjusted Mean Change (SE)	-30.93 (3.61)	-28.58 (4.07)		
Week 12 Adjusted Mean Change (SE)	-29.39 (3.55)	-30.36 (3.99)		
Week 16 Adjusted Mean Change (SE)	-31.41 (3.45)	-32.89 (3.89)		
Week 24 Adjusted Mean Change (SE)	-32.52 (3.54)	-33.49 (4.05)		
Week 32 Adjusted Mean Change (SE)	-35.30 (3.48)	-33.81 (3.92)		
Week 40 Adjusted Mean Change (SE)	-35.90 (3.53)	-41.75 (4.07)		
Week 52 Adjusted Mean Change (SE)	-37.91 (4.04)	-37.16 (4.57)	-0.74 [-12.80; 11.31]	0.903

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 17.10 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.147</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	66.77 (23.62)	71.18 (20.74)		
Week 52 Mean (SD)	35.41 (23.95)	30.71 (26.72)		
Week 2 Adjusted Mean Change (SE)	-17.78 (3.28)	-13.00 (3.12)		
Week 4 Adjusted Mean Change (SE)	-23.03 (3.75)	-24.36 (3.60)		
Week 8 Adjusted Mean Change (SE)	-24.93 (3.99)	-30.06 (3.84)		
Week 12 Adjusted Mean Change (SE)	-27.04 (3.86)	-33.09 (3.73)		
Week 16 Adjusted Mean Change (SE)	-28.46 (3.85)	-32.10 (3.72)		
Week 24 Adjusted Mean Change (SE)	-27.36 (4.01)	-29.65 (3.98)		
Week 32 Adjusted Mean Change (SE)	-29.16 (3.77)	-34.17 (3.72)		
Week 40 Adjusted Mean Change (SE)	-34.68 (4.10)	-33.67 (4.09)		
Week 52 Adjusted Mean Change (SE)	-33.06 (4.42)	-35.93 (4.53)	2.87 [-9.66; 15.41]	0.651
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	75.04 (16.93)	63.62 (20.39)		
Week 52 Mean (SD)	29.69 (23.33)	30.58 (24.29)		
Week 2 Adjusted Mean Change (SE)	-18.82 (2.54)	-15.81 (3.11)		
Week 4 Adjusted Mean Change (SE)	-27.68 (2.91)	-22.96 (3.56)		
Week 8 Adjusted Mean Change (SE)	-34.64 (3.09)	-24.20 (3.78)		
Week 12 Adjusted Mean Change (SE)	-36.68 (3.00)	-28.11 (3.66)		
Week 16 Adjusted Mean Change (SE)	-35.77 (2.98)	-28.76 (3.66)		
Week 24 Adjusted Mean Change (SE)	-38.03 (3.06)	-31.34 (3.78)		
Week 32 Adjusted Mean Change (SE)	-41.44 (2.92)	-33.80 (3.58)		
Week 40 Adjusted Mean Change (SE)	-41.91 (3.15)	-37.70 (3.91)		
Week 52 Adjusted Mean Change (SE)	-41.84 (3.41)	-37.99 (4.18)	-3.85 [-14.64; 6.94]	0.482

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			



### 17.11 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.355</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	73.70 (19.50)	66.40 (22.40)		
Week 52 Mean (SD)	31.56 (24.68)	30.10 (25.26)		
Week 2 Adjusted Mean Change (SE)	-18.33 (2.73)	-17.08 (2.72)		
Week 4 Adjusted Mean Change (SE)	-27.37 (3.13)	-26.59 (3.13)		
Week 8 Adjusted Mean Change (SE)	-31.18 (3.35)	-30.10 (3.34)		
Week 12 Adjusted Mean Change (SE)	-32.41 (3.35)	-31.41 (3.34)		
Week 16 Adjusted Mean Change (SE)	-30.22 (3.29)	-30.72 (3.28)		
Week 24 Adjusted Mean Change (SE)	-34.10 (3.41)	-31.64 (3.43)		
Week 32 Adjusted Mean Change (SE)	-39.08 (3.24)	-35.09 (3.24)		
Week 40 Adjusted Mean Change (SE)	-38.86 (3.44)	-38.66 (3.47)		
Week 52 Adjusted Mean Change (SE)	-38.13 (3.76)	-39.40 (3.76)	1.27 [-9.28; 11.82]	0.812
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	69.90 (20.09)	69.04 (17.76)		
Week 52 Mean (SD)	31.41 (22.59)	31.78 (25.47)		
Week 2 Adjusted Mean Change (SE)	-19.62 (2.75)	-9.71 (3.63)		
Week 4 Adjusted Mean Change (SE)	-25.61 (3.16)	-18.43 (4.22)		
Week 8 Adjusted Mean Change (SE)	-31.58 (3.38)	-21.79 (4.53)		
Week 12 Adjusted Mean Change (SE)	-33.07 (3.37)	-29.30 (4.51)		
Week 16 Adjusted Mean Change (SE)	-35.61 (3.31)	-30.29 (4.46)		
Week 24 Adjusted Mean Change (SE)	-34.46 (3.40)	-29.05 (4.67)		
Week 32 Adjusted Mean Change (SE)	-34.67 (3.22)	-32.39 (4.40)		
Week 40 Adjusted Mean Change (SE)	-39.18 (3.43)	-30.81 (4.79)		
Week 52 Adjusted Mean Change (SE)	-38.70 (3.73)	-33.13 (5.27)	-5.57 [-18.33; 7.19]	0.390

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 17.12 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.696</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	73.37 (17.88)	66.13 (21.84)		
Week 52 Mean (SD)	33.36 (22.83)	33.13 (24.43)		
Week 2 Adjusted Mean Change (SE)	-17.43 (2.31)	-14.81 (2.62)		
Week 4 Adjusted Mean Change (SE)	-25.62 (2.61)	-25.72 (2.99)		
Week 8 Adjusted Mean Change (SE)	-30.32 (2.82)	-26.37 (3.24)		
Week 12 Adjusted Mean Change (SE)	-28.73 (2.67)	-30.52 (3.06)		
Week 16 Adjusted Mean Change (SE)	-29.97 (2.69)	-27.84 (3.09)		
Week 24 Adjusted Mean Change (SE)	-33.98 (2.78)	-28.92 (3.25)		
Week 32 Adjusted Mean Change (SE)	-34.68 (2.66)	-33.22 (3.09)		
Week 40 Adjusted Mean Change (SE)	-37.23 (2.75)	-34.19 (3.23)		
Week 52 Adjusted Mean Change (SE)	-36.74 (2.96)	-33.97 (3.51)	-2.77 [-11.91; 6.37]	0.550
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	66.10 (24.40)	67.11 (16.33)		
Week 52 Mean (SD)	24.37 (24.23)	17.94 (13.58)		
Week 2 Adjusted Mean Change (SE)	-20.70 (4.05)	-14.99 (4.22)		
Week 4 Adjusted Mean Change (SE)	-23.62 (4.59)	-19.45 (4.79)		
Week 8 Adjusted Mean Change (SE)	-30.23 (4.95)	-30.89 (5.17)		
Week 12 Adjusted Mean Change (SE)	-38.21 (4.67)	-35.10 (4.92)		
Week 16 Adjusted Mean Change (SE)	-38.34 (4.71)	-39.50 (4.96)		
Week 24 Adjusted Mean Change (SE)	-33.36 (4.96)	-38.41 (5.20)		
Week 32 Adjusted Mean Change (SE)	-40.09 (4.68)	-39.03 (4.93)		
Week 40 Adjusted Mean Change (SE)	-42.42 (4.86)	-45.35 (5.12)		
Week 52 Adjusted Mean Change (SE)	-42.65 (5.20)	-50.50 (5.44)	7.85 [-7.00; 22.70]	0.298

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 17.13 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.528</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	72.30 (19.10)	67.63 (21.20)		
Week 52 Mean (SD)	32.14 (25.23)	30.36 (24.96)		
Week 2 Adjusted Mean Change (SE)	-18.15 (2.23)	-15.25 (2.49)		
Week 4 Adjusted Mean Change (SE)	-27.44 (2.60)	-27.03 (2.91)		
Week 8 Adjusted Mean Change (SE)	-33.20 (2.69)	-30.94 (3.02)		
Week 12 Adjusted Mean Change (SE)	-33.90 (2.73)	-34.19 (3.07)		
Week 16 Adjusted Mean Change (SE)	-34.26 (2.65)	-34.85 (2.98)		
Week 24 Adjusted Mean Change (SE)	-34.83 (2.82)	-31.88 (3.21)		
Week 32 Adjusted Mean Change (SE)	-35.76 (2.68)	-35.72 (3.03)		
Week 40 Adjusted Mean Change (SE)	-39.36 (2.86)	-38.11 (3.27)		
Week 52 Adjusted Mean Change (SE)	-38.25 (3.09)	-38.31 (3.54)	0.06 [-9.25; 9.37]	0.990
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	70.53 (22.75)	72.25 (13.48)		
Week 52 Mean (SD)	31.16 (18.91)	33.00 (27.04)		
Week 2 Adjusted Mean Change (SE)	-21.77 (4.06)	-15.48 (5.14)		
Week 4 Adjusted Mean Change (SE)	-24.50 (4.72)	-14.88 (5.97)		
Week 8 Adjusted Mean Change (SE)	-27.81 (4.90)	-21.96 (6.19)		
Week 12 Adjusted Mean Change (SE)	-30.34 (4.95)	-25.70 (6.25)		
Week 16 Adjusted Mean Change (SE)	-30.39 (4.80)	-24.14 (6.07)		
Week 24 Adjusted Mean Change (SE)	-33.02 (5.07)	-30.52 (6.41)		
Week 32 Adjusted Mean Change (SE)	-39.55 (4.81)	-33.89 (6.16)		
Week 40 Adjusted Mean Change (SE)	-38.97 (5.14)	-32.22 (6.57)		
Week 52 Adjusted Mean Change (SE)	-39.18 (5.51)	-37.01 (6.96)	-2.17 [-19.70; 15.36]	0.807

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 17.14 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.783</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	70.42 (20.60)	69.11 (19.90)		
Week 52 Mean (SD)	32.45 (23.75)	30.95 (26.40)		
Week 2 Adjusted Mean Change (SE)	-19.33 (2.14)	-13.33 (2.48)		
Week 4 Adjusted Mean Change (SE)	-27.72 (2.42)	-23.63 (2.81)		
Week 8 Adjusted Mean Change (SE)	-32.38 (2.62)	-27.32 (3.05)		
Week 12 Adjusted Mean Change (SE)	-33.18 (2.57)	-30.58 (3.00)		
Week 16 Adjusted Mean Change (SE)	-33.58 (2.55)	-31.34 (2.98)		
Week 24 Adjusted Mean Change (SE)	-34.01 (2.60)	-29.91 (3.08)		
Week 32 Adjusted Mean Change (SE)	-36.76 (2.53)	-33.32 (2.97)		
Week 40 Adjusted Mean Change (SE)	-38.67 (2.67)	-34.46 (3.19)		
Week 52 Adjusted Mean Change (SE)	-37.26 (2.90)	-37.18 (3.46)	-0.07 [-9.01; 8.86]	0.987
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	79.77 (13.39)	59.30 (26.45)		
Week 52 Mean (SD)	28.77 (22.18)	31.50 (22.20)		
Week 2 Adjusted Mean Change (SE)	-16.52 (5.06)	-15.99 (5.75)		
Week 4 Adjusted Mean Change (SE)	-19.57 (5.71)	-23.85 (6.50)		
Week 8 Adjusted Mean Change (SE)	-25.58 (6.18)	-23.79 (7.03)		
Week 12 Adjusted Mean Change (SE)	-30.16 (6.15)	-25.14 (6.91)		
Week 16 Adjusted Mean Change (SE)	-28.99 (6.02)	-24.85 (6.85)		
Week 24 Adjusted Mean Change (SE)	-33.66 (6.10)	-34.56 (6.94)		
Week 32 Adjusted Mean Change (SE)	-35.92 (5.91)	-34.52 (6.72)		
Week 40 Adjusted Mean Change (SE)	-39.45 (6.25)	-41.67 (7.11)		
Week 52 Adjusted Mean Change (SE)	-42.77 (6.75)	-36.48 (7.68)	-6.29 [-26.71; 14.14]	0.544

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			



### 17.15 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.518</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	71.77 (20.67)	71.27 (21.74)		
Week 52 Mean (SD)	36.79 (27.13)	35.78 (29.15)		
Week 2 Adjusted Mean Change (SE)	-17.13 (3.81)	-11.83 (3.51)		
Week 4 Adjusted Mean Change (SE)	-26.82 (4.39)	-25.38 (4.08)		
Week 8 Adjusted Mean Change (SE)	-26.25 (4.66)	-28.48 (4.36)		
Week 12 Adjusted Mean Change (SE)	-27.70 (4.60)	-34.11 (4.30)		
Week 16 Adjusted Mean Change (SE)	-26.77 (4.57)	-29.97 (4.28)		
Week 24 Adjusted Mean Change (SE)	-33.17 (4.77)	-28.11 (4.52)		
Week 32 Adjusted Mean Change (SE)	-29.44 (4.51)	-33.29 (4.26)		
Week 40 Adjusted Mean Change (SE)	-35.17 (4.82)	-30.75 (4.59)		
Week 52 Adjusted Mean Change (SE)	-31.15 (5.27)	-33.23 (5.13)	2.08 [-12.45; 16.61]	0.778
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	71.84 (19.61)	64.85 (19.98)		
Week 52 Mean (SD)	29.84 (22.21)	28.26 (23.04)		
Week 2 Adjusted Mean Change (SE)	-19.61 (2.25)	-16.10 (2.82)		
Week 4 Adjusted Mean Change (SE)	-26.41 (2.60)	-22.69 (3.25)		
Week 8 Adjusted Mean Change (SE)	-33.19 (2.76)	-26.35 (3.45)		
Week 12 Adjusted Mean Change (SE)	-34.51 (2.73)	-28.45 (3.42)		
Week 16 Adjusted Mean Change (SE)	-35.05 (2.69)	-30.86 (3.37)		
Week 24 Adjusted Mean Change (SE)	-34.70 (2.77)	-32.21 (3.50)		
Week 32 Adjusted Mean Change (SE)	-39.28 (2.63)	-34.62 (3.31)		
Week 40 Adjusted Mean Change (SE)	-40.32 (2.78)	-39.04 (3.54)		
Week 52 Adjusted Mean Change (SE)	-40.84 (3.02)	-39.35 (3.81)	-1.49 [-11.13; 8.15]	0.760

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 17.16 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.204</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	72.94 (19.61)	68.46 (18.22)		
Week 52 Mean (SD)	31.10 (23.08)	30.67 (26.04)		
Week 2 Adjusted Mean Change (SE)	-21.84 (2.47)	-9.93 (2.96)		
Week 4 Adjusted Mean Change (SE)	-28.42 (2.86)	-19.14 (3.47)		
Week 8 Adjusted Mean Change (SE)	-31.53 (3.10)	-26.42 (3.76)		
Week 12 Adjusted Mean Change (SE)	-34.95 (3.05)	-30.31 (3.70)		
Week 16 Adjusted Mean Change (SE)	-33.94 (3.02)	-29.10 (3.68)		
Week 24 Adjusted Mean Change (SE)	-35.30 (3.09)	-29.57 (3.84)		
Week 32 Adjusted Mean Change (SE)	-37.21 (2.97)	-34.49 (3.65)		
Week 40 Adjusted Mean Change (SE)	-41.39 (3.10)	-31.77 (3.85)		
Week 52 Adjusted Mean Change (SE)	-39.19 (3.41)	-37.49 (4.33)	-1.70 [-12.61; 9.20]	0.758
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	70.15 (20.18)	66.13 (23.46)		
Week 52 Mean (SD)	32.10 (24.48)	30.60 (24.69)		
Week 2 Adjusted Mean Change (SE)	-14.71 (3.01)	-19.31 (3.10)		
Week 4 Adjusted Mean Change (SE)	-23.65 (3.49)	-28.61 (3.60)		
Week 8 Adjusted Mean Change (SE)	-31.19 (3.78)	-27.98 (3.91)		
Week 12 Adjusted Mean Change (SE)	-29.43 (3.73)	-30.95 (3.86)		
Week 16 Adjusted Mean Change (SE)	-31.42 (3.70)	-32.05 (3.82)		
Week 24 Adjusted Mean Change (SE)	-32.77 (3.81)	-31.95 (3.97)		
Week 32 Adjusted Mean Change (SE)	-36.19 (3.65)	-33.76 (3.78)		
Week 40 Adjusted Mean Change (SE)	-35.50 (3.78)	-40.74 (3.98)		
Week 52 Adjusted Mean Change (SE)	-37.40 (4.20)	-37.23 (4.33)	-0.17 [-12.10; 11.77]	0.978

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 17.17 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.062</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	66.77 (23.62)	71.32 (20.71)		
Week 52 Mean (SD)	35.41 (23.95)	28.50 (25.42)		
Week 2 Adjusted Mean Change (SE)	-17.79 (3.28)	-14.36 (3.22)		
Week 4 Adjusted Mean Change (SE)	-23.07 (3.75)	-24.74 (3.72)		
Week 8 Adjusted Mean Change (SE)	-24.94 (3.93)	-31.93 (3.91)		
Week 12 Adjusted Mean Change (SE)	-27.11 (3.91)	-34.54 (3.91)		
Week 16 Adjusted Mean Change (SE)	-28.52 (3.88)	-34.06 (3.88)		
Week 24 Adjusted Mean Change (SE)	-27.40 (4.01)	-31.47 (4.12)		
Week 32 Adjusted Mean Change (SE)	-29.20 (3.77)	-35.67 (3.85)		
Week 40 Adjusted Mean Change (SE)	-34.74 (4.10)	-34.52 (4.24)		
Week 52 Adjusted Mean Change (SE)	-33.11 (4.41)	-37.40 (4.69)	4.29 [-8.46; 17.05]	0.507
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	74.58 (16.92)	63.92 (20.46)		
Week 52 Mean (SD)	29.25 (23.14)	31.97 (25.19)		
Week 2 Adjusted Mean Change (SE)	-19.65 (2.44)	-14.46 (3.02)		
Week 4 Adjusted Mean Change (SE)	-28.44 (2.79)	-22.72 (3.46)		
Week 8 Adjusted Mean Change (SE)	-35.04 (2.93)	-22.94 (3.63)		
Week 12 Adjusted Mean Change (SE)	-35.93 (2.92)	-27.24 (3.60)		
Week 16 Adjusted Mean Change (SE)	-35.41 (2.90)	-27.39 (3.59)		
Week 24 Adjusted Mean Change (SE)	-38.02 (2.96)	-29.79 (3.67)		
Week 32 Adjusted Mean Change (SE)	-41.10 (2.82)	-32.60 (3.48)		
Week 40 Adjusted Mean Change (SE)	-41.34 (3.05)	-36.75 (3.79)		
Week 52 Adjusted Mean Change (SE)	-41.36 (3.31)	-36.68 (4.05)	-4.68 [-15.12; 5.76]	0.377

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 17.18 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.355</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	73.70 (19.50)	66.40 (22.40)		
Week 52 Mean (SD)	31.56 (24.68)	30.10 (25.26)		
Week 2 Adjusted Mean Change (SE)	-18.33 (2.73)	-17.08 (2.72)		
Week 4 Adjusted Mean Change (SE)	-27.37 (3.13)	-26.59 (3.13)		
Week 8 Adjusted Mean Change (SE)	-31.18 (3.35)	-30.10 (3.34)		
Week 12 Adjusted Mean Change (SE)	-32.41 (3.35)	-31.41 (3.34)		
Week 16 Adjusted Mean Change (SE)	-30.22 (3.29)	-30.72 (3.28)		
Week 24 Adjusted Mean Change (SE)	-34.10 (3.41)	-31.64 (3.43)		
Week 32 Adjusted Mean Change (SE)	-39.08 (3.24)	-35.09 (3.24)		
Week 40 Adjusted Mean Change (SE)	-38.86 (3.44)	-38.66 (3.47)		
Week 52 Adjusted Mean Change (SE)	-38.13 (3.76)	-39.40 (3.76)	1.27 [-9.28; 11.82]	0.812
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	69.90 (20.09)	69.04 (17.76)		
Week 52 Mean (SD)	31.41 (22.59)	31.78 (25.47)		
Week 2 Adjusted Mean Change (SE)	-19.62 (2.75)	-9.71 (3.63)		
Week 4 Adjusted Mean Change (SE)	-25.61 (3.16)	-18.43 (4.22)		
Week 8 Adjusted Mean Change (SE)	-31.58 (3.38)	-21.79 (4.53)		
Week 12 Adjusted Mean Change (SE)	-33.07 (3.37)	-29.30 (4.51)		
Week 16 Adjusted Mean Change (SE)	-35.61 (3.31)	-30.29 (4.46)		
Week 24 Adjusted Mean Change (SE)	-34.46 (3.40)	-29.05 (4.67)		
Week 32 Adjusted Mean Change (SE)	-34.67 (3.22)	-32.39 (4.40)		
Week 40 Adjusted Mean Change (SE)	-39.18 (3.43)	-30.81 (4.79)		
Week 52 Adjusted Mean Change (SE)	-38.70 (3.73)	-33.13 (5.27)	-5.57 [-18.33; 7.19]	0.390

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			



### 17.19 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.597</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	73.00 (18.04)	67.20 (22.08)		
Week 52 Mean (SD)	32.82 (23.08)	35.00 (25.49)		
Week 2 Adjusted Mean Change (SE)	-17.98 (2.25)	-14.15 (2.57)		
Week 4 Adjusted Mean Change (SE)	-26.97 (2.56)	-24.93 (2.95)		
Week 8 Adjusted Mean Change (SE)	-31.30 (2.74)	-25.61 (3.16)		
Week 12 Adjusted Mean Change (SE)	-30.63 (2.72)	-29.41 (3.13)		
Week 16 Adjusted Mean Change (SE)	-30.86 (2.65)	-27.21 (3.06)		
Week 24 Adjusted Mean Change (SE)	-34.54 (2.76)	-28.48 (3.25)		
Week 32 Adjusted Mean Change (SE)	-35.37 (2.64)	-32.60 (3.07)		
Week 40 Adjusted Mean Change (SE)	-37.85 (2.80)	-33.63 (3.30)		
Week 52 Adjusted Mean Change (SE)	-37.65 (3.00)	-32.47 (3.56)	-5.18 [-14.41; 4.05]	0.269
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	65.89 (25.20)	67.72 (17.22)		
Week 52 Mean (SD)	24.53 (24.80)	20.35 (21.51)		
Week 2 Adjusted Mean Change (SE)	-20.57 (4.27)	-14.65 (4.23)		
Week 4 Adjusted Mean Change (SE)	-22.80 (4.86)	-19.66 (4.82)		
Week 8 Adjusted Mean Change (SE)	-28.15 (5.20)	-30.33 (5.16)		
Week 12 Adjusted Mean Change (SE)	-36.75 (5.13)	-33.14 (5.10)		
Week 16 Adjusted Mean Change (SE)	-37.20 (5.03)	-38.75 (5.03)		
Week 24 Adjusted Mean Change (SE)	-33.60 (5.34)	-35.89 (5.25)		
Week 32 Adjusted Mean Change (SE)	-38.95 (5.02)	-37.50 (5.02)		
Week 40 Adjusted Mean Change (SE)	-42.13 (5.36)	-41.47 (5.41)		
Week 52 Adjusted Mean Change (SE)	-42.26 (5.71)	-48.36 (5.67)	6.11 [-9.77; 21.98]	0.448

Treatment Groups		Comparison	
SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<p>N: Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>			

### 18.0 Physician's Global Assessment of PsA Disease Activity (VAS) - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 4 Returns	110 (100.0)	97 (96.0)	207 (98.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	97 (96.0)	203 (96.2)
Week 16 Returns	107 (97.3)	92 (91.1)	199 (94.3)
Week 20 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 24 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 28 Returns	101 (91.8)	83 (82.2)	184 (87.2)
Week 32 Returns	101 (91.8)	79 (78.2)	180 (85.3)
Week 36 Returns	101 (91.8)	83 (82.2)	184 (87.2)
Week 40 Returns	104 (94.5)	81 (80.2)	185 (87.7)
Week 44 Returns	102 (92.7)	83 (82.2)	185 (87.7)
Week 48 Returns	99 (90.0)	81 (80.2)	180 (85.3)
Week 52 Returns	103 (93.6)	83 (82.2)	186 (88.2)

### 18.1 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	64.78 (15.08)	64.68 (13.90)		
Week 52 Mean (SD)	15.38 (15.05)	17.72 (15.32)		
Week 52 Adjusted Mean Change (SE)	-49.08 (1.47)	-46.47 (1.61)	-2.61 [-6.92; 1.70]	0.233
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 18.2 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.597</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	64.13 (15.09)	64.40 (14.02)		
Week 52 Mean (SD)	15.40 (15.31)	18.32 (15.62)		
Week 52 Adjusted Mean Change (SE)	-48.93 (1.52)	-45.83 (1.68)	-3.10 [-7.58; 1.37]	0.173
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	74.43 (12.05)	68.43 (12.34)		
Week 52 Mean (SD)	15.00 (9.72)	11.29 (10.21)		
Week 52 Adjusted Mean Change (SE)	-51.99 (6.21)	-53.58 (5.76)	1.59 [-15.06; 18.24]	0.851
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.3 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.573</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	62.03 (14.80)	63.49 (14.70)		
Week 52 Mean (SD)	11.98 (10.99)	16.13 (15.72)		
Week 52 Adjusted Mean Change (SE)	-52.71 (1.87)	-48.73 (2.07)	-3.99 [-9.47; 1.49]	0.153
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	68.91 (14.69)	66.23 (12.77)		
Week 52 Mean (SD)	20.51 (18.67)	19.81 (14.74)		
Week 52 Adjusted Mean Change (SE)	-43.58 (2.33)	-43.51 (2.40)	-0.07 [-6.60; 6.46]	0.983
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.4 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.517</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	53.29 (15.19)	54.62 (16.45)		
Week 52 Mean (SD)	11.74 (10.86)	15.75 (15.44)		
Week 52 Adjusted Mean Change (SE)	-51.80 (3.29)	-47.14 (3.67)	-4.66 [-14.15; 4.82]	0.334
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	67.99 (13.47)	67.33 (11.92)		
Week 52 Mean (SD)	16.43 (15.96)	18.19 (15.37)		
Week 52 Adjusted Mean Change (SE)	-48.31 (1.69)	-46.23 (1.81)	-2.07 [-6.93; 2.78]	0.401
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.5 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.710</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	62.57 (15.84)	61.33 (13.22)		
Week 52 Mean (SD)	15.92 (12.81)	16.36 (14.23)		
Week 52 Adjusted Mean Change (SE)	-48.33 (2.42)	-46.58 (2.34)	-1.74 [-8.36; 4.87]	0.603
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	66.15 (14.54)	68.10 (13.86)		
Week 52 Mean (SD)	15.05 (16.35)	18.93 (16.29)		
Week 52 Adjusted Mean Change (SE)	-49.51 (1.88)	-46.40 (2.27)	-3.11 [-8.91; 2.69]	0.292
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 18.6 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.597</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	64.15 (15.57)	65.80 (13.83)		
Week 52 Mean (SD)	13.70 (13.73)	15.06 (13.46)		
Week 52 Adjusted Mean Change (SE)	-51.10 (1.78)	-48.87 (2.36)	-2.22 [-8.05; 3.61]	0.453
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	65.97 (14.22)	63.63 (14.01)		
Week 52 Mean (SD)	18.94 (17.22)	19.77 (16.46)		
Week 52 Adjusted Mean Change (SE)	-45.12 (2.52)	-44.42 (2.17)	-0.70 [-7.27; 5.87]	0.834
N': Number of patients in the analysis CI: Confidence interval MMRM: Mixed effects repeated measures model N.E.: Not estimable SD: Standard deviation SE: Standard error  Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects: treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit Covariance structure: unstructured (un)  Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.				

### 18.7 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.690</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	63.57 (14.32)	63.31 (16.24)		
Week 52 Mean (SD)	14.38 (15.38)	15.82 (17.22)		
Week 52 Adjusted Mean Change (SE)	-49.43 (2.18)	-48.21 (2.83)	-1.22 [-8.26; 5.83]	0.734
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	65.83 (15.75)	65.32 (12.75)		
Week 52 Mean (SD)	16.21 (14.85)	18.69 (14.33)		
Week 52 Adjusted Mean Change (SE)	-48.80 (2.02)	-45.67 (1.97)	-3.12 [-8.70; 2.45]	0.271
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.8 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.962</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	64.00 (13.79)	66.00 (12.93)		
Week 52 Mean (SD)	15.60 (16.69)	15.80 (12.22)		
Week 52 Adjusted Mean Change (SE)	-48.15 (2.19)	-49.34 (2.50)	1.19 [-5.39; 7.76]	0.722
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	65.85 (14.38)	63.27 (12.50)		
Week 52 Mean (SD)	15.58 (15.27)	17.77 (17.07)		
Week 52 Adjusted Mean Change (SE)	-50.25 (2.71)	-45.57 (3.21)	-4.68 [-12.98; 3.63]	0.268
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.9 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.321</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	64.27 (13.18)	60.96 (11.80)		
Week 52 Mean (SD)	11.91 (10.45)	13.24 (11.29)		
Week 52 Adjusted Mean Change (SE)	-52.55 (2.31)	-48.78 (3.20)	-3.78 [-11.60; 4.04]	0.341
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	64.53 (14.95)	66.47 (11.91)		
Week 52 Mean (SD)	19.32 (19.92)	19.52 (17.24)		
Week 52 Adjusted Mean Change (SE)	-44.03 (2.55)	-45.16 (2.88)	1.13 [-6.48; 8.73]	0.770
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.10 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.480</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	67.30 (14.10)	68.24 (11.85)		
Week 52 Mean (SD)	16.69 (13.66)	16.69 (13.79)		
Week 52 Adjusted Mean Change (SE)	-48.83 (2.88)	-46.81 (2.94)	-2.02 [-10.10; 6.06]	0.622
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	63.22 (14.21)	61.74 (12.93)		
Week 52 Mean (SD)	15.56 (17.49)	16.45 (14.71)		
Week 52 Adjusted Mean Change (SE)	-48.42 (2.21)	-48.70 (2.73)	0.27 [-6.64; 7.19]	0.938
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.11 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.887</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	62.05 (14.96)	64.91 (13.38)		
Week 52 Mean (SD)	11.21 (10.64)	17.38 (15.25)		
Week 52 Adjusted Mean Change (SE)	-53.16 (2.38)	-47.79 (2.38)	-5.37 [-12.02; 1.29]	0.113
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	67.50 (12.46)	65.00 (11.79)		
Week 52 Mean (SD)	19.88 (19.15)	15.05 (12.13)		
Week 52 Adjusted Mean Change (SE)	-44.83 (2.37)	-48.22 (3.27)	3.39 [-4.60; 11.38]	0.403
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.12 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.866</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	65.48 (12.96)	66.13 (13.23)		
Week 52 Mean (SD)	17.11 (17.17)	17.24 (13.46)		
Week 52 Adjusted Mean Change (SE)	-47.96 (1.96)	-47.71 (2.33)	-0.25 [-6.27; 5.78]	0.936
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	64.90 (16.27)	61.94 (11.95)		
Week 52 Mean (SD)	12.16 (13.06)	13.35 (11.19)		
Week 52 Adjusted Mean Change (SE)	-52.52 (3.45)	-50.71 (3.62)	-1.82 [-11.70; 8.06]	0.717
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.13 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.345</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	65.57 (12.70)	65.04 (12.42)		
Week 52 Mean (SD)	15.47 (16.44)	15.07 (13.17)		
Week 52 Adjusted Mean Change (SE)	-49.82 (1.96)	-49.75 (2.24)	-0.07 [-5.95; 5.80]	0.980
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	62.00 (16.00)	61.83 (12.39)		
Week 52 Mean (SD)	17.89 (15.64)	21.83 (17.33)		
Week 52 Adjusted Mean Change (SE)	-44.16 (3.51)	-41.30 (4.40)	-2.86 [-13.95; 8.22]	0.610
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 18.14 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.726</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	64.11 (14.29)	65.42 (12.30)		
Week 52 Mean (SD)	16.08 (15.96)	17.74 (15.03)		
Week 52 Adjusted Mean Change (SE)	-48.47 (1.87)	-46.49 (2.21)	-1.98 [-7.71; 3.75]	0.496
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	69.15 (11.76)	62.70 (14.02)		
Week 52 Mean (SD)	14.23 (17.22)	13.13 (9.54)		
Week 52 Adjusted Mean Change (SE)	-50.71 (4.30)	-54.24 (5.05)	3.53 [-9.61; 16.67]	0.596
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.15 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.914</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	65.59 (10.35)	66.73 (13.50)		
Week 52 Mean (SD)	12.42 (13.56)	15.00 (10.60)		
Week 52 Adjusted Mean Change (SE)	-52.42 (3.42)	-49.21 (3.28)	-3.21 [-12.58; 6.16]	0.500
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	64.44 (15.10)	63.80 (12.27)		
Week 52 Mean (SD)	16.60 (16.74)	17.41 (15.84)		
Week 52 Adjusted Mean Change (SE)	-47.78 (1.95)	-47.03 (2.46)	-0.75 [-6.96; 5.47]	0.812
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.16 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.582</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	64.45 (13.17)	62.40 (12.30)		
Week 52 Mean (SD)	12.29 (10.40)	13.36 (10.57)		
Week 52 Adjusted Mean Change (SE)	-53.07 (2.11)	-50.04 (2.68)	-3.03 [-9.78; 3.72]	0.376
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	65.18 (15.29)	67.72 (12.82)		
Week 52 Mean (SD)	21.00 (21.56)	19.66 (16.54)		
Week 52 Adjusted Mean Change (SE)	-42.57 (2.63)	-45.87 (2.71)	3.30 [-4.15; 10.76]	0.383
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.17 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.486</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	67.30 (14.10)	68.29 (12.20)		
Week 52 Mean (SD)	16.69 (13.66)	17.33 (14.13)		
Week 52 Adjusted Mean Change (SE)	-48.87 (2.87)	-45.95 (3.04)	-2.91 [-11.13; 5.30]	0.484
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	63.35 (13.83)	62.06 (12.65)		
Week 52 Mean (SD)	14.96 (17.38)	16.00 (14.39)		
Week 52 Adjusted Mean Change (SE)	-48.99 (2.14)	-49.19 (2.64)	0.21 [-6.50; 6.91]	0.951
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.18 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.887</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	62.05 (14.96)	64.91 (13.38)		
Week 52 Mean (SD)	11.21 (10.64)	17.38 (15.25)		
Week 52 Adjusted Mean Change (SE)	-53.16 (2.38)	-47.79 (2.38)	-5.37 [-12.02; 1.29]	0.113
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	67.50 (12.46)	65.00 (11.79)		
Week 52 Mean (SD)	19.88 (19.15)	15.05 (12.13)		
Week 52 Adjusted Mean Change (SE)	-44.83 (2.37)	-48.22 (3.27)	3.39 [-4.60; 11.38]	0.403
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 18.19 Physician's Global Assessment of PsA Disease Activity (VAS) - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.625</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	65.00 (12.88)	66.18 (12.99)		
Week 52 Mean (SD)	16.70 (16.83)	17.55 (14.22)		
Week 52 Adjusted Mean Change (SE)	-48.06 (1.95)	-47.24 (2.33)	-0.82 [-6.83; 5.19]	0.787
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	64.56 (16.66)	61.56 (11.72)		
Week 52 Mean (SD)	11.71 (13.49)	14.24 (14.20)		
Week 52 Adjusted Mean Change (SE)	-52.77 (3.72)	-49.58 (3.71)	-3.19 [-13.56; 7.19]	0.545
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 19.0 SJC28 - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	109 (99.1)	100 (99.0)	209 (99.1)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	108 (98.2)	93 (92.1)	201 (95.3)
Week 20 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	100 (90.9)	84 (83.2)	184 (87.2)
Week 32 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 36 Returns	100 (90.9)	83 (82.2)	183 (86.7)
Week 40 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 44 Returns	102 (92.7)	82 (81.2)	184 (87.2)
Week 48 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 52 Returns	104 (94.5)	83 (82.2)	187 (88.6)

### 19.1 SJC28 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	5.38 (3.91)	5.54 (4.53)		
Week 52 Mean (SD)	0.49 (1.14)	0.80 (1.71)		
Week 52 Adjusted Mean Change (SE)	-4.98 (0.13)	-4.72 (0.15)	-0.27 [-0.66; 0.12]	0.171
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				



## 19.2 SJC28 - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.204</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	5.16 (3.48)	5.64 (4.63)		
Week 52 Mean (SD)	0.44 (1.07)	0.84 (1.77)		
Week 52 Adjusted Mean Change (SE)	-5.01 (0.14)	-4.68 (0.15)	-0.32 [-0.73; 0.08]	0.114
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	8.71 (7.65)	4.29 (2.93)		
Week 52 Mean (SD)	1.33 (1.97)	0.29 (0.76)		
Week 52 Adjusted Mean Change (SE)	-4.64 (0.54)	-5.08 (0.51)	0.44 [-1.04; 1.92]	0.558
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.3 SJC28 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.842</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	5.20 (3.54)	4.81 (4.19)		
Week 52 Mean (SD)	0.35 (0.83)	0.55 (1.49)		
Week 52 Adjusted Mean Change (SE)	-5.13 (0.17)	-4.90 (0.19)	-0.24 [-0.74; 0.27]	0.356
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	5.66 (4.45)	6.50 (4.82)		
Week 52 Mean (SD)	0.71 (1.49)	1.11 (1.94)		
Week 52 Adjusted Mean Change (SE)	-4.76 (0.21)	-4.46 (0.22)	-0.30 [-0.90; 0.30]	0.321
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.4 SJC28 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.465</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	4.54 (2.70)	3.81 (3.49)		
Week 52 Mean (SD)	0.39 (0.84)	0.19 (0.54)		
Week 52 Adjusted Mean Change (SE)	-5.05 (0.28)	-5.01 (0.33)	-0.03 [-0.89; 0.82]	0.937
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	5.62 (4.17)	6.00 (4.68)		
Week 52 Mean (SD)	0.52 (1.22)	0.94 (1.86)		
Week 52 Adjusted Mean Change (SE)	-4.97 (0.15)	-4.64 (0.16)	-0.33 [-0.76; 0.11]	0.140
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.5 SJC28 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.737</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	5.05 (3.37)	6.78 (5.38)		
Week 52 Mean (SD)	0.41 (0.82)	0.87 (1.88)		
Week 52 Adjusted Mean Change (SE)	-5.01 (0.22)	-4.84 (0.22)	-0.17 [-0.78; 0.43]	0.573
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	5.59 (4.22)	4.28 (3.02)		
Week 52 Mean (SD)	0.54 (1.30)	0.73 (1.56)		
Week 52 Adjusted Mean Change (SE)	-4.97 (0.17)	-4.62 (0.20)	-0.35 [-0.87; 0.17]	0.185
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment            x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters,            subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 19.6 SJC28 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.260</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	5.38 (3.72)	4.04 (3.58)		
Week 52 Mean (SD)	0.51 (1.00)	0.56 (1.48)		
Week 52 Adjusted Mean Change (SE)	-4.98 (0.16)	-4.78 (0.22)	-0.20 [-0.73; 0.34]	0.471
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	5.39 (4.30)	6.96 (4.90)		
Week 52 Mean (SD)	0.44 (1.40)	0.98 (1.86)		
Week 52 Adjusted Mean Change (SE)	-5.00 (0.23)	-4.66 (0.20)	-0.34 [-0.94; 0.26]	0.263
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.7 SJC28 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.618</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	4.37 (3.39)	3.53 (3.38)		
Week 52 Mean (SD)	0.40 (0.98)	0.46 (1.10)		
Week 52 Adjusted Mean Change (SE)	-4.91 (0.20)	-4.86 (0.26)	-0.05 [-0.68; 0.58]	0.883
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	6.25 (4.15)	6.48 (4.71)		
Week 52 Mean (SD)	0.57 (1.26)	0.96 (1.93)		
Week 52 Adjusted Mean Change (SE)	-5.05 (0.18)	-4.64 (0.18)	-0.41 [-0.91; 0.09]	0.109
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.8 SJC28 - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.910</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	4.71 (2.94)	5.71 (4.64)		
Week 52 Mean (SD)	0.46 (1.17)	0.54 (1.24)		
Week 52 Adjusted Mean Change (SE)	-4.64 (0.17)	-4.70 (0.20)	0.06 [-0.47; 0.58]	0.831
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	5.50 (3.85)	4.88 (3.79)		
Week 52 Mean (SD)	0.48 (1.06)	0.86 (1.75)		
Week 52 Adjusted Mean Change (SE)	-4.76 (0.21)	-4.31 (0.25)	-0.45 [-1.10; 0.21]	0.181
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.9 SJC28 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.465</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	5.93 (3.75)	5.56 (4.09)		
Week 52 Mean (SD)	0.35 (0.75)	0.33 (0.73)		
Week 52 Adjusted Mean Change (SE)	-5.00 (0.19)	-4.89 (0.26)	-0.11 [-0.75; 0.53]	0.740
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	4.05 (2.51)	5.37 (4.03)		
Week 52 Mean (SD)	0.65 (1.47)	1.00 (1.90)		
Week 52 Adjusted Mean Change (SE)	-4.42 (0.21)	-4.32 (0.23)	-0.10 [-0.72; 0.53]	0.762
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 19.10 SJC28 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.938</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	4.97 (3.17)	4.79 (3.56)		
Week 52 Mean (SD)	0.48 (1.06)	0.81 (1.55)		
Week 52 Adjusted Mean Change (SE)	-4.74 (0.23)	-4.34 (0.23)	-0.40 [-1.04; 0.24]	0.223
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	5.22 (3.49)	5.97 (4.93)		
Week 52 Mean (SD)	0.48 (1.18)	0.55 (1.39)		
Week 52 Adjusted Mean Change (SE)	-4.70 (0.17)	-4.82 (0.22)	0.11 [-0.44; 0.66]	0.687
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.11 SJC28 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.036</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	4.74 (3.23)	5.14 (4.52)		
Week 52 Mean (SD)	0.26 (0.64)	0.92 (1.74)		
Week 52 Adjusted Mean Change (SE)	-4.90 (0.19)	-4.28 (0.19)	-0.62 [-1.14; -0.10]	0.021
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	5.31 (3.45)	5.83 (3.97)		
Week 52 Mean (SD)	0.68 (1.42)	0.20 (0.41)		
Week 52 Adjusted Mean Change (SE)	-4.49 (0.18)	-5.11 (0.26)	0.62 [-0.01; 1.25]	0.054
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.12 SJC28 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.444</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	4.90 (3.36)	5.40 (3.99)		
Week 52 Mean (SD)	0.44 (1.13)	0.63 (1.32)		
Week 52 Adjusted Mean Change (SE)	-4.67 (0.14)	-4.53 (0.17)	-0.13 [-0.58; 0.32]	0.564
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	5.20 (3.40)	5.00 (4.79)		
Week 52 Mean (SD)	0.42 (1.02)	0.41 (0.87)		
Week 52 Adjusted Mean Change (SE)	-4.76 (0.25)	-4.71 (0.27)	-0.04 [-0.77; 0.68]	0.903
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.13 SJC28 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.460</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	5.13 (3.44)	4.41 (2.99)		
Week 52 Mean (SD)	0.50 (1.26)	0.33 (0.85)		
Week 52 Adjusted Mean Change (SE)	-4.76 (0.16)	-4.81 (0.18)	0.05 [-0.42; 0.53]	0.821
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	4.79 (3.05)	10.25 (6.20)		
Week 52 Mean (SD)	0.33 (0.49)	2.00 (2.37)		
Week 52 Adjusted Mean Change (SE)	-4.76 (0.28)	-3.65 (0.38)	-1.11 [-2.06; -0.17]	0.022
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.14 SJC28 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.861</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	5.11 (3.27)	5.38 (4.49)		
Week 52 Mean (SD)	0.52 (1.21)	0.67 (1.51)		
Week 52 Adjusted Mean Change (SE)	-4.65 (0.15)	-4.53 (0.17)	-0.12 [-0.57; 0.32]	0.584
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	4.69 (3.88)	5.60 (3.27)		
Week 52 Mean (SD)	0.23 (0.44)	0.25 (0.71)		
Week 52 Adjusted Mean Change (SE)	-4.92 (0.33)	-5.02 (0.40)	0.10 [-0.93; 1.13]	0.843
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.15 SJC28 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.616</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	4.86 (3.00)	4.46 (3.15)		
Week 52 Mean (SD)	0.37 (0.96)	0.70 (1.22)		
Week 52 Adjusted Mean Change (SE)	-4.83 (0.27)	-4.31 (0.26)	-0.52 [-1.27; 0.24]	0.177
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	5.08 (3.47)	5.98 (4.86)		
Week 52 Mean (SD)	0.50 (1.17)	0.65 (1.58)		
Week 52 Adjusted Mean Change (SE)	-4.65 (0.15)	-4.69 (0.20)	0.04 [-0.45; 0.54]	0.864
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.16 SJC28 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.190</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	5.65 (3.67)	5.09 (3.77)		
Week 52 Mean (SD)	0.33 (0.72)	0.25 (0.65)		
Week 52 Adjusted Mean Change (SE)	-4.92 (0.17)	-4.87 (0.22)	-0.06 [-0.60; 0.49]	0.834
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	4.09 (2.53)	5.72 (4.89)		
Week 52 Mean (SD)	0.70 (1.56)	1.07 (1.87)		
Week 52 Adjusted Mean Change (SE)	-4.32 (0.21)	-4.25 (0.22)	-0.07 [-0.68; 0.54]	0.819
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.17 SJC28 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.777</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	4.97 (3.17)	4.65 (3.63)		
Week 52 Mean (SD)	0.48 (1.06)	0.88 (1.60)		
Week 52 Adjusted Mean Change (SE)	-4.70 (0.22)	-4.22 (0.24)	-0.48 [-1.13; 0.17]	0.146
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	5.05 (3.45)	6.03 (4.79)		
Week 52 Mean (SD)	0.46 (1.16)	0.52 (1.35)		
Week 52 Adjusted Mean Change (SE)	-4.67 (0.17)	-4.81 (0.21)	0.14 [-0.39; 0.67]	0.605
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 19.18 SJC28 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.036</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	4.74 (3.23)	5.14 (4.52)		
Week 52 Mean (SD)	0.26 (0.64)	0.92 (1.74)		
Week 52 Adjusted Mean Change (SE)	-4.90 (0.19)	-4.28 (0.19)	-0.62 [-1.14; -0.10]	0.021
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	5.31 (3.45)	5.83 (3.97)		
Week 52 Mean (SD)	0.68 (1.42)	0.20 (0.41)		
Week 52 Adjusted Mean Change (SE)	-4.49 (0.18)	-5.11 (0.26)	0.62 [-0.01; 1.25]	0.054
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 19.19 SJC28 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.358</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	4.97 (3.34)	5.29 (3.95)		
Week 52 Mean (SD)	0.47 (1.16)	0.65 (1.31)		
Week 52 Adjusted Mean Change (SE)	-4.69 (0.15)	-4.57 (0.19)	-0.11 [-0.59; 0.37]	0.638
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	5.28 (3.54)	5.67 (5.30)		
Week 52 Mean (SD)	0.47 (1.07)	0.71 (1.79)		
Week 52 Adjusted Mean Change (SE)	-4.78 (0.29)	-4.57 (0.29)	-0.22 [-1.04; 0.60]	0.601
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.0 SJC66 - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	109 (99.1)	100 (99.0)	209 (99.1)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	108 (98.2)	93 (92.1)	201 (95.3)
Week 20 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	100 (90.9)	84 (83.2)	184 (87.2)
Week 32 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 36 Returns	100 (90.9)	83 (82.2)	183 (86.7)
Week 40 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 44 Returns	102 (92.7)	82 (81.2)	184 (87.2)
Week 48 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 52 Returns	104 (94.5)	83 (82.2)	187 (88.6)

## 20.1 SJC66 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	8.75 (6.17)	9.87 (7.46)		
Week 52 Mean (SD)	0.93 (2.18)	1.34 (2.80)		
Week 52 Adjusted Mean Change (SE)	-8.23 (0.22)	-8.01 (0.24)	-0.22 [-0.88; 0.44]	0.508
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 20.2 SJC66 - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.536</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	8.34 (4.88)	10.07 (7.67)		
Week 52 Mean (SD)	0.86 (2.04)	1.43 (2.90)		
Week 52 Adjusted Mean Change (SE)	-8.23 (0.23)	-7.95 (0.26)	-0.28 [-0.97; 0.40]	0.416
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	14.86 (15.48)	7.14 (2.61)		
Week 52 Mean (SD)	2.17 (3.92)	0.29 (0.76)		
Week 52 Adjusted Mean Change (SE)	-8.14 (0.93)	-8.65 (0.87)	0.51 [-2.02; 3.03]	0.694
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.3 SJC66 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.700</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	8.33 (5.25)	9.16 (6.77)		
Week 52 Mean (SD)	0.67 (1.89)	1.02 (2.45)		
Week 52 Adjusted Mean Change (SE)	-8.48 (0.29)	-8.24 (0.32)	-0.24 [-1.09; 0.61]	0.579
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	9.39 (7.36)	10.80 (8.26)		
Week 52 Mean (SD)	1.34 (2.54)	1.75 (3.19)		
Week 52 Adjusted Mean Change (SE)	-7.85 (0.36)	-7.67 (0.38)	-0.18 [-1.20; 0.83]	0.722
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.4 SJC66 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.209</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	6.75 (4.13)	7.14 (4.45)		
Week 52 Mean (SD)	0.48 (1.04)	0.31 (0.70)		
Week 52 Adjusted Mean Change (SE)	-8.52 (0.48)	-8.34 (0.55)	-0.18 [-1.62; 1.26]	0.810
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	9.31 (6.54)	10.59 (7.94)		
Week 52 Mean (SD)	1.06 (2.40)	1.58 (3.06)		
Week 52 Adjusted Mean Change (SE)	-8.15 (0.25)	-7.91 (0.28)	-0.23 [-0.97; 0.51]	0.538
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.5 SJC66 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.780</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	8.31 (4.89)	11.53 (8.99)		
Week 52 Mean (SD)	0.72 (1.32)	1.54 (3.19)		
Week 52 Adjusted Mean Change (SE)	-8.35 (0.37)	-8.04 (0.36)	-0.31 [-1.33; 0.72]	0.556
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	9.03 (6.86)	8.18 (5.04)		
Week 52 Mean (SD)	1.06 (2.57)	1.16 (2.43)		
Week 52 Adjusted Mean Change (SE)	-8.15 (0.28)	-7.97 (0.34)	-0.18 [-1.06; 0.70]	0.688
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 20.6 SJC66 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.678</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	8.53 (5.24)	8.31 (5.96)		
Week 52 Mean (SD)	0.89 (2.03)	0.83 (1.86)		
Week 52 Adjusted Mean Change (SE)	-8.28 (0.27)	-8.29 (0.36)	0.01 [-0.89; 0.90]	0.987
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	9.18 (7.69)	11.35 (8.44)		
Week 52 Mean (SD)	1.03 (2.50)	1.72 (3.32)		
Week 52 Adjusted Mean Change (SE)	-8.13 (0.39)	-7.74 (0.34)	-0.38 [-1.39; 0.62]	0.453
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.7 SJC66 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.377</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	7.80 (5.02)	7.56 (5.29)		
Week 52 Mean (SD)	0.54 (1.32)	0.75 (1.71)		
Week 52 Adjusted Mean Change (SE)	-8.36 (0.33)	-8.38 (0.43)	0.03 [-1.04; 1.09]	0.959
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	9.58 (6.95)	10.94 (8.09)		
Week 52 Mean (SD)	1.27 (2.68)	1.64 (3.19)		
Week 52 Adjusted Mean Change (SE)	-8.12 (0.31)	-7.82 (0.30)	-0.30 [-1.15; 0.55]	0.486
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.8 SJC66 - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.745</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	7.67 (4.07)	10.56 (8.81)		
Week 52 Mean (SD)	1.08 (2.51)	0.97 (2.09)		
Week 52 Adjusted Mean Change (SE)	-7.58 (0.34)	-8.19 (0.39)	0.60 [-0.42; 1.62]	0.245
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	8.82 (5.75)	9.69 (6.59)		
Week 52 Mean (SD)	0.74 (1.61)	1.95 (3.75)		
Week 52 Adjusted Mean Change (SE)	-8.26 (0.41)	-7.17 (0.49)	-1.09 [-2.36; 0.18]	0.092
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.9 SJC66 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.934</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	9.16 (5.91)	10.04 (6.82)		
Week 52 Mean (SD)	0.88 (2.22)	0.76 (1.81)		
Week 52 Adjusted Mean Change (SE)	-8.23 (0.38)	-8.17 (0.52)	-0.06 [-1.33; 1.21]	0.925
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	7.03 (2.89)	10.77 (7.67)		
Week 52 Mean (SD)	1.06 (2.26)	1.93 (3.63)		
Week 52 Adjusted Mean Change (SE)	-7.51 (0.42)	-7.54 (0.47)	0.03 [-1.24; 1.30]	0.962
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.10 SJC66 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.397</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	8.17 (4.01)	9.61 (6.63)		
Week 52 Mean (SD)	0.76 (1.33)	1.65 (2.64)		
Week 52 Adjusted Mean Change (SE)	-8.25 (0.44)	-7.37 (0.45)	-0.88 [-2.11; 0.36]	0.164
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	8.49 (5.24)	10.82 (9.17)		
Week 52 Mean (SD)	1.02 (2.59)	1.10 (3.05)		
Week 52 Adjusted Mean Change (SE)	-7.85 (0.34)	-8.39 (0.42)	0.54 [-0.53; 1.62]	0.318
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.11 SJC66 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.114</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	7.35 (4.03)	9.26 (8.02)		
Week 52 Mean (SD)	0.51 (1.21)	1.70 (3.26)		
Week 52 Adjusted Mean Change (SE)	-8.23 (0.37)	-7.32 (0.37)	-0.91 [-1.94; 0.13]	0.085
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	8.93 (5.44)	11.96 (7.79)		
Week 52 Mean (SD)	1.38 (2.80)	0.70 (1.78)		
Week 52 Adjusted Mean Change (SE)	-7.48 (0.36)	-8.77 (0.52)	1.29 [0.04; 2.55]	0.044
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.12 SJC66 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.215</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	8.03 (5.07)	10.21 (7.04)		
Week 52 Mean (SD)	0.93 (2.40)	1.34 (2.46)		
Week 52 Adjusted Mean Change (SE)	-7.81 (0.27)	-7.67 (0.32)	-0.14 [-0.98; 0.69]	0.735
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	7.80 (3.71)	10.06 (10.36)		
Week 52 Mean (SD)	0.74 (1.33)	0.65 (1.50)		
Week 52 Adjusted Mean Change (SE)	-8.04 (0.47)	-8.43 (0.50)	0.39 [-0.96; 1.75]	0.567
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 20.13 SJC66 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.244</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	8.41 (5.24)	8.98 (6.21)		
Week 52 Mean (SD)	1.03 (2.46)	0.69 (1.70)		
Week 52 Adjusted Mean Change (SE)	-8.02 (0.30)	-8.30 (0.35)	0.27 [-0.64; 1.19]	0.555
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	7.26 (3.49)	17.08 (11.83)		
Week 52 Mean (SD)	0.72 (1.27)	4.00 (4.57)		
Week 52 Adjusted Mean Change (SE)	-7.85 (0.55)	-6.05 (0.73)	-1.80 [-3.64; 0.04]	0.056
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 20.14 SJC66 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.844</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	8.00 (4.90)	10.57 (8.47)		
Week 52 Mean (SD)	1.08 (2.39)	1.30 (2.86)		
Week 52 Adjusted Mean Change (SE)	-7.69 (0.29)	-7.80 (0.34)	0.11 [-0.79; 1.01]	0.804
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	8.92 (4.61)	8.70 (4.69)		
Week 52 Mean (SD)	0.38 (0.65)	0.88 (2.47)		
Week 52 Adjusted Mean Change (SE)	-8.57 (0.66)	-8.18 (0.78)	-0.39 [-2.41; 1.62]	0.700
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.15 SJC66 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.424</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	7.45 (4.34)	9.04 (6.12)		
Week 52 Mean (SD)	0.89 (1.56)	1.40 (2.33)		
Week 52 Adjusted Mean Change (SE)	-7.93 (0.53)	-7.33 (0.51)	-0.59 [-2.05; 0.86]	0.421
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	8.37 (4.98)	10.98 (8.96)		
Week 52 Mean (SD)	0.97 (2.37)	1.32 (3.14)		
Week 52 Adjusted Mean Change (SE)	-7.82 (0.30)	-8.07 (0.39)	0.25 [-0.74; 1.23]	0.622
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.16 SJC66 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.558</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	8.73 (5.70)	9.14 (6.35)		
Week 52 Mean (SD)	0.80 (2.09)	0.57 (1.60)		
Week 52 Adjusted Mean Change (SE)	-8.19 (0.34)	-8.17 (0.43)	-0.03 [-1.11; 1.05]	0.961
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	7.24 (2.90)	11.41 (9.41)		
Week 52 Mean (SD)	1.20 (2.37)	2.10 (3.56)		
Week 52 Adjusted Mean Change (SE)	-7.33 (0.42)	-7.40 (0.44)	0.06 [-1.16; 1.28]	0.919
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.17 SJC66 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.219</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	8.17 (4.01)	9.58 (6.85)		
Week 52 Mean (SD)	0.76 (1.33)	1.79 (2.70)		
Week 52 Adjusted Mean Change (SE)	-8.15 (0.44)	-7.14 (0.46)	-1.02 [-2.27; 0.24]	0.113
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	8.11 (5.24)	10.78 (8.90)		
Week 52 Mean (SD)	1.06 (2.57)	1.03 (2.96)		
Week 52 Adjusted Mean Change (SE)	-7.68 (0.33)	-8.33 (0.41)	0.65 [-0.39; 1.69]	0.219
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.18 SJC66 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.114</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	7.35 (4.03)	9.26 (8.02)		
Week 52 Mean (SD)	0.51 (1.21)	1.70 (3.26)		
Week 52 Adjusted Mean Change (SE)	-8.23 (0.37)	-7.32 (0.37)	-0.91 [-1.94; 0.13]	0.085
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	8.93 (5.44)	11.96 (7.79)		
Week 52 Mean (SD)	1.38 (2.80)	0.70 (1.78)		
Week 52 Adjusted Mean Change (SE)	-7.48 (0.36)	-8.77 (0.52)	1.29 [0.04; 2.55]	0.044
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 20.19 SJC66 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.215</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	8.22 (5.14)	9.98 (6.98)		
Week 52 Mean (SD)	0.93 (2.36)	1.33 (2.41)		
Week 52 Adjusted Mean Change (SE)	-7.90 (0.30)	-7.79 (0.36)	-0.12 [-1.05; 0.81]	0.801
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	8.06 (3.83)	10.89 (10.44)		
Week 52 Mean (SD)	0.76 (1.39)	1.41 (3.79)		
Week 52 Adjusted Mean Change (SE)	-8.16 (0.57)	-7.94 (0.57)	-0.21 [-1.82; 1.39]	0.792
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.0 SJC76 - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	109 (99.1)	100 (99.0)	209 (99.1)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	108 (98.2)	93 (92.1)	201 (95.3)
Week 20 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	100 (90.9)	84 (83.2)	184 (87.2)
Week 32 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 36 Returns	100 (90.9)	83 (82.2)	183 (86.7)
Week 40 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 44 Returns	102 (92.7)	82 (81.2)	184 (87.2)
Week 48 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 52 Returns	104 (94.5)	83 (82.2)	187 (88.6)

## 21.1 SJC76 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	9.27 (6.53)	10.69 (8.16)		
Week 52 Mean (SD)	0.99 (2.38)	1.39 (2.89)		
Week 52 Adjusted Mean Change (SE)	-8.77 (0.24)	-8.60 (0.26)	-0.17 [-0.87; 0.52]	0.621
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				



## 21.2 SJC76 - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.559</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	8.84 (5.22)	10.96 (8.37)		
Week 52 Mean (SD)	0.91 (2.22)	1.49 (3.00)		
Week 52 Adjusted Mean Change (SE)	-8.79 (0.25)	-8.55 (0.27)	-0.24 [-0.97; 0.49]	0.514
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	15.57 (16.20)	7.14 (2.61)		
Week 52 Mean (SD)	2.33 (4.32)	0.29 (0.76)		
Week 52 Adjusted Mean Change (SE)	-8.56 (0.98)	-9.19 (0.93)	0.63 [-2.05; 3.31]	0.643
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 21.3 SJC76 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.578</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	8.76 (5.61)	10.16 (7.89)		
Week 52 Mean (SD)	0.73 (2.17)	1.02 (2.45)		
Week 52 Adjusted Mean Change (SE)	-9.01 (0.31)	-8.91 (0.34)	-0.10 [-1.01; 0.81]	0.830
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	10.05 (7.72)	11.39 (8.54)		
Week 52 Mean (SD)	1.39 (2.65)	1.86 (3.36)		
Week 52 Adjusted Mean Change (SE)	-8.42 (0.38)	-8.15 (0.40)	-0.27 [-1.35; 0.81]	0.622
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.4 SJC76 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.292</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	7.08 (4.37)	7.57 (4.47)		
Week 52 Mean (SD)	0.48 (1.04)	0.31 (0.70)		
Week 52 Adjusted Mean Change (SE)	-9.13 (0.51)	-8.94 (0.59)	-0.19 [-1.72; 1.33]	0.803
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	9.88 (6.91)	11.51 (8.71)		
Week 52 Mean (SD)	1.14 (2.63)	1.64 (3.15)		
Week 52 Adjusted Mean Change (SE)	-8.68 (0.27)	-8.51 (0.29)	-0.17 [-0.96; 0.62]	0.671
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.5 SJC76 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.632</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	8.90 (5.45)	12.31 (9.67)		
Week 52 Mean (SD)	0.74 (1.39)	1.59 (3.35)		
Week 52 Adjusted Mean Change (SE)	-8.95 (0.39)	-8.59 (0.38)	-0.36 [-1.45; 0.72]	0.512
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	9.50 (7.15)	9.04 (5.90)		
Week 52 Mean (SD)	1.14 (2.82)	1.20 (2.45)		
Week 52 Adjusted Mean Change (SE)	-8.67 (0.30)	-8.60 (0.36)	-0.06 [-1.00; 0.87]	0.895
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.6 SJC76 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.829</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	9.08 (5.73)	9.24 (6.95)		
Week 52 Mean (SD)	0.93 (2.23)	0.83 (1.86)		
Week 52 Adjusted Mean Change (SE)	-8.86 (0.29)	-8.96 (0.38)	0.10 [-0.85; 1.04]	0.841
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	9.63 (7.91)	12.06 (9.01)		
Week 52 Mean (SD)	1.12 (2.71)	1.81 (3.44)		
Week 52 Adjusted Mean Change (SE)	-8.61 (0.41)	-8.26 (0.36)	-0.35 [-1.42; 0.72]	0.520
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.7 SJC76 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.487</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	8.43 (5.60)	8.50 (6.18)		
Week 52 Mean (SD)	0.54 (1.32)	0.82 (1.76)		
Week 52 Adjusted Mean Change (SE)	-8.97 (0.35)	-8.99 (0.46)	0.02 [-1.11; 1.15]	0.975
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	10.00 (7.21)	11.71 (8.79)		
Week 52 Mean (SD)	1.38 (2.97)	1.67 (3.30)		
Week 52 Adjusted Mean Change (SE)	-8.61 (0.32)	-8.41 (0.32)	-0.20 [-1.10; 0.70]	0.660
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.8 SJC76 - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.849</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	8.24 (4.41)	11.37 (9.67)		
Week 52 Mean (SD)	1.19 (2.80)	1.06 (2.20)		
Week 52 Adjusted Mean Change (SE)	-8.12 (0.37)	-8.77 (0.42)	0.65 [-0.45; 1.76]	0.246
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	9.38 (6.31)	10.77 (7.39)		
Week 52 Mean (SD)	0.74 (1.61)	2.00 (3.92)		
Week 52 Adjusted Mean Change (SE)	-8.91 (0.45)	-7.84 (0.53)	-1.07 [-2.45; 0.31]	0.127
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.9 SJC76 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.958</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	9.89 (6.41)	10.67 (7.14)		
Week 52 Mean (SD)	1.00 (2.59)	0.86 (1.88)		
Week 52 Adjusted Mean Change (SE)	-8.82 (0.41)	-8.69 (0.57)	-0.13 [-1.51; 1.25]	0.854
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	7.42 (3.12)	12.03 (9.25)		
Week 52 Mean (SD)	1.06 (2.26)	2.00 (3.81)		
Week 52 Adjusted Mean Change (SE)	-8.13 (0.46)	-8.20 (0.52)	0.07 [-1.32; 1.46]	0.920
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 21.10 SJC76 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.379</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	8.73 (4.29)	10.39 (7.19)		
Week 52 Mean (SD)	0.79 (1.42)	1.77 (2.72)		
Week 52 Adjusted Mean Change (SE)	-8.87 (0.47)	-7.92 (0.48)	-0.95 [-2.28; 0.37]	0.157
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	9.04 (5.80)	11.85 (10.19)		
Week 52 Mean (SD)	1.06 (2.79)	1.13 (3.20)		
Week 52 Adjusted Mean Change (SE)	-8.43 (0.36)	-9.07 (0.45)	0.65 [-0.51; 1.80]	0.269
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.11 SJC76 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.115</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	7.81 (4.28)	10.07 (8.69)		
Week 52 Mean (SD)	0.56 (1.39)	1.76 (3.42)		
Week 52 Adjusted Mean Change (SE)	-8.83 (0.40)	-7.97 (0.40)	-0.86 [-1.99; 0.27]	0.135
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	9.60 (6.00)	13.04 (8.87)		
Week 52 Mean (SD)	1.45 (3.05)	0.80 (1.85)		
Week 52 Adjusted Mean Change (SE)	-8.04 (0.40)	-9.31 (0.56)	1.28 [-0.09; 2.65]	0.067
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.12 SJC76 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.298</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	8.56 (5.63)	11.17 (7.86)		
Week 52 Mean (SD)	0.98 (2.61)	1.42 (2.53)		
Week 52 Adjusted Mean Change (SE)	-8.42 (0.29)	-8.30 (0.34)	-0.11 [-1.01; 0.78]	0.803
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	8.50 (3.66)	10.94 (11.31)		
Week 52 Mean (SD)	0.84 (1.64)	0.65 (1.50)		
Week 52 Adjusted Mean Change (SE)	-8.62 (0.50)	-9.13 (0.53)	0.51 [-0.94; 1.96]	0.490
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 21.13 SJC76 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.130</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	9.00 (5.69)	9.98 (7.44)		
Week 52 Mean (SD)	1.12 (2.71)	0.74 (1.74)		
Week 52 Adjusted Mean Change (SE)	-8.61 (0.33)	-8.96 (0.38)	0.35 [-0.65; 1.36]	0.485
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	7.68 (3.87)	17.83 (12.14)		
Week 52 Mean (SD)	0.72 (1.27)	4.17 (4.84)		
Week 52 Adjusted Mean Change (SE)	-8.36 (0.60)	-6.49 (0.79)	-1.87 [-3.88; 0.13]	0.067
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.14 SJC76 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.970</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	8.61 (5.34)	11.36 (9.27)		
Week 52 Mean (SD)	1.15 (2.62)	1.39 (3.01)		
Week 52 Adjusted Mean Change (SE)	-8.23 (0.31)	-8.32 (0.37)	0.08 [-0.89; 1.05]	0.867
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	9.31 (5.09)	9.70 (5.68)		
Week 52 Mean (SD)	0.38 (0.65)	0.88 (2.47)		
Week 52 Adjusted Mean Change (SE)	-9.16 (0.71)	-8.96 (0.84)	-0.20 [-2.38; 1.98]	0.855
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.15 SJC76 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.477</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	8.23 (4.68)	9.85 (6.87)		
Week 52 Mean (SD)	1.05 (1.93)	1.50 (2.35)		
Week 52 Adjusted Mean Change (SE)	-8.48 (0.57)	-7.89 (0.55)	-0.59 [-2.16; 0.97]	0.457
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	8.86 (5.46)	11.95 (9.83)		
Week 52 Mean (SD)	1.00 (2.55)	1.38 (3.30)		
Week 52 Adjusted Mean Change (SE)	-8.41 (0.33)	-8.72 (0.42)	0.31 [-0.76; 1.37]	0.568
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.16 SJC76 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.603</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	9.39 (6.20)	9.74 (6.71)		
Week 52 Mean (SD)	0.90 (2.44)	0.64 (1.66)		
Week 52 Adjusted Mean Change (SE)	-8.77 (0.37)	-8.74 (0.46)	-0.02 [-1.19; 1.15]	0.968
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	7.65 (3.16)	12.66 (10.54)		
Week 52 Mean (SD)	1.20 (2.37)	2.17 (3.73)		
Week 52 Adjusted Mean Change (SE)	-7.93 (0.46)	-8.04 (0.48)	0.11 [-1.22; 1.45]	0.865
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.17 SJC76 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.227</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	8.73 (4.29)	10.42 (7.42)		
Week 52 Mean (SD)	0.79 (1.42)	1.92 (2.78)		
Week 52 Adjusted Mean Change (SE)	-8.78 (0.47)	-7.67 (0.50)	-1.10 [-2.46; 0.25]	0.110
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	8.67 (5.74)	11.75 (9.90)		
Week 52 Mean (SD)	1.14 (2.83)	1.06 (3.11)		
Week 52 Adjusted Mean Change (SE)	-8.24 (0.35)	-9.01 (0.44)	0.78 [-0.35; 1.90]	0.175
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 21.18 SJC76 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.115</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	7.81 (4.28)	10.07 (8.69)		
Week 52 Mean (SD)	0.56 (1.39)	1.76 (3.42)		
Week 52 Adjusted Mean Change (SE)	-8.83 (0.40)	-7.97 (0.40)	-0.86 [-1.99; 0.27]	0.135
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	9.60 (6.00)	13.04 (8.87)		
Week 52 Mean (SD)	1.45 (3.05)	0.80 (1.85)		
Week 52 Adjusted Mean Change (SE)	-8.04 (0.40)	-9.31 (0.56)	1.28 [-0.09; 2.65]	0.067
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 21.19 SJC76 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.318</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	8.74 (5.68)	10.90 (7.81)		
Week 52 Mean (SD)	0.98 (2.56)	1.40 (2.48)		
Week 52 Adjusted Mean Change (SE)	-8.49 (0.33)	-8.41 (0.39)	-0.09 [-1.10; 0.92]	0.866
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	8.83 (3.71)	11.78 (11.32)		
Week 52 Mean (SD)	0.88 (1.73)	1.47 (4.02)		
Week 52 Adjusted Mean Change (SE)	-8.74 (0.62)	-8.57 (0.62)	-0.17 [-1.91; 1.57]	0.847
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.0 SPARCC Enthesitis Index - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	110 (100.0)	100 (99.0)	210 (99.5)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	107 (97.3)	98 (97.0)	205 (97.2)
Week 16 Returns	109 (99.1)	95 (94.1)	204 (96.7)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	85 (84.2)	190 (90.0)

## 22.1 SPARCC Enthesitis Index - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	3.33 (3.47)	4.53 (4.38)		
Week 52 Mean (SD)	0.89 (2.12)	0.96 (2.32)		
Week 52 Adjusted Mean Change (SE)	-2.91 (0.19)	-3.01 (0.21)	0.10 [-0.46; 0.67]	0.721
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 22.2 SPARCC Enthesitis Index - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.925</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	3.36 (3.54)	4.62 (4.37)		
Week 52 Mean (SD)	0.93 (2.18)	1.00 (2.40)		
Week 52 Adjusted Mean Change (SE)	-2.89 (0.20)	-2.99 (0.22)	0.10 [-0.49; 0.69]	0.739
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	2.86 (2.27)	3.43 (4.79)		
Week 52 Mean (SD)	0.17 (0.41)	0.57 (1.13)		
Week 52 Adjusted Mean Change (SE)	-3.16 (0.78)	-3.19 (0.75)	0.03 [-2.11; 2.17]	0.977
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.3 SPARCC Enthesitis Index - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.355</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	2.70 (2.92)	4.07 (3.90)		
Week 52 Mean (SD)	0.50 (1.38)	0.61 (1.71)		
Week 52 Adjusted Mean Change (SE)	-3.22 (0.25)	-3.36 (0.27)	0.14 [-0.59; 0.87]	0.700
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	4.27 (4.01)	5.14 (4.92)		
Week 52 Mean (SD)	1.49 (2.85)	1.44 (2.92)		
Week 52 Adjusted Mean Change (SE)	-2.47 (0.30)	-2.53 (0.32)	0.06 [-0.80; 0.92]	0.889
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.4 SPARCC Enthesitis Index - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.698</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	1.63 (2.10)	1.71 (1.90)		
Week 52 Mean (SD)	0.61 (1.41)	0.35 (1.00)		
Week 52 Adjusted Mean Change (SE)	-2.78 (0.42)	-2.98 (0.47)	0.19 [-1.03; 1.42]	0.756
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	3.80 (3.63)	5.28 (4.55)		
Week 52 Mean (SD)	0.96 (2.28)	1.12 (2.53)		
Week 52 Adjusted Mean Change (SE)	-2.94 (0.22)	-3.03 (0.24)	0.08 [-0.56; 0.72]	0.795
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.5 SPARCC Enthesitis Index - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.356</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	2.86 (2.77)	4.59 (4.36)		
Week 52 Mean (SD)	0.74 (1.52)	1.03 (2.61)		
Week 52 Adjusted Mean Change (SE)	-2.93 (0.32)	-2.86 (0.30)	-0.06 [-0.93; 0.80]	0.887
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	3.62 (3.82)	4.48 (4.45)		
Week 52 Mean (SD)	0.97 (2.42)	0.91 (2.07)		
Week 52 Adjusted Mean Change (SE)	-2.90 (0.24)	-3.18 (0.29)	0.28 [-0.48; 1.03]	0.471
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 22.6 SPARCC Enthesitis Index - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.691</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	3.43 (3.22)	3.65 (3.84)		
Week 52 Mean (SD)	0.70 (1.57)	0.61 (1.39)		
Week 52 Adjusted Mean Change (SE)	-3.10 (0.24)	-2.98 (0.31)	-0.12 [-0.88; 0.64]	0.758
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	3.13 (3.93)	5.37 (4.72)		
Week 52 Mean (SD)	1.26 (2.92)	1.26 (2.85)		
Week 52 Adjusted Mean Change (SE)	-2.53 (0.33)	-3.01 (0.29)	0.49 [-0.39; 1.36]	0.271
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.7 SPARCC Enthesitis Index - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.459</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	0.94 (1.73)	1.34 (1.96)		
Week 52 Mean (SD)	0.47 (1.53)	0.29 (0.71)		
Week 52 Adjusted Mean Change (SE)	-2.60 (0.31)	-2.89 (0.38)	0.29 [-0.62; 1.20]	0.535
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	5.39 (3.27)	6.01 (4.41)		
Week 52 Mean (SD)	1.25 (2.49)	1.30 (2.74)		
Week 52 Adjusted Mean Change (SE)	-3.15 (0.27)	-3.10 (0.27)	-0.05 [-0.77; 0.67]	0.894
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.8 SPARCC Enthesitis Index - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.695</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	3.84 (3.76)	5.05 (4.78)		
Week 52 Mean (SD)	1.51 (2.89)	0.89 (2.27)		
Week 52 Adjusted Mean Change (SE)	-2.46 (0.29)	-3.36 (0.33)	0.90 [0.03; 1.77]	0.042
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	2.65 (3.02)	3.69 (4.38)		
Week 52 Mean (SD)	0.42 (0.89)	0.86 (2.36)		
Week 52 Adjusted Mean Change (SE)	-3.21 (0.36)	-3.02 (0.42)	-0.20 [-1.29; 0.90]	0.722
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.9 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.363</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	3.53 (3.71)	4.37 (4.95)		
Week 52 Mean (SD)	0.88 (2.11)	0.81 (2.38)		
Week 52 Adjusted Mean Change (SE)	-2.98 (0.32)	-3.15 (0.44)	0.18 [-0.90; 1.25]	0.747
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	3.13 (3.38)	4.67 (4.92)		
Week 52 Mean (SD)	1.37 (2.73)	1.14 (2.58)		
Week 52 Adjusted Mean Change (SE)	-2.38 (0.35)	-3.03 (0.40)	0.66 [-0.40; 1.71]	0.219
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.10 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.535</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	4.07 (3.82)	5.12 (5.57)		
Week 52 Mean (SD)	1.21 (2.57)	1.31 (2.62)		
Week 52 Adjusted Mean Change (SE)	-2.87 (0.38)	-3.02 (0.39)	0.15 [-0.93; 1.24]	0.779
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	3.04 (3.38)	3.94 (3.52)		
Week 52 Mean (SD)	1.06 (2.32)	0.55 (1.95)		
Week 52 Adjusted Mean Change (SE)	-2.73 (0.30)	-3.41 (0.36)	0.67 [-0.25; 1.59]	0.150
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.11 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.467</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	3.37 (3.55)	4.77 (4.80)		
Week 52 Mean (SD)	0.97 (2.22)	0.92 (2.23)		
Week 52 Adjusted Mean Change (SE)	-2.83 (0.32)	-3.29 (0.32)	0.46 [-0.45; 1.36]	0.322
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	3.36 (3.53)	4.08 (4.42)		
Week 52 Mean (SD)	1.20 (2.54)	0.80 (2.44)		
Week 52 Adjusted Mean Change (SE)	-2.68 (0.32)	-3.13 (0.44)	0.45 [-0.63; 1.53]	0.410
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.12 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.684</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	3.39 (3.40)	4.64 (4.96)		
Week 52 Mean (SD)	1.07 (2.41)	0.80 (2.16)		
Week 52 Adjusted Mean Change (SE)	-2.86 (0.26)	-3.35 (0.30)	0.49 [-0.30; 1.28]	0.221
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	3.65 (4.04)	3.94 (3.42)		
Week 52 Mean (SD)	1.05 (2.41)	0.53 (0.94)		
Week 52 Adjusted Mean Change (SE)	-2.73 (0.45)	-3.35 (0.47)	0.63 [-0.66; 1.91]	0.337
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 22.13 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.203</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	3.24 (3.49)	4.14 (4.42)		
Week 52 Mean (SD)	0.93 (2.29)	0.57 (1.40)		
Week 52 Adjusted Mean Change (SE)	-2.97 (0.27)	-3.52 (0.30)	0.55 [-0.25; 1.35]	0.177
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	4.05 (3.81)	6.83 (5.61)		
Week 52 Mean (SD)	1.63 (2.75)	2.25 (4.14)		
Week 52 Adjusted Mean Change (SE)	-2.38 (0.47)	-2.28 (0.61)	-0.09 [-1.62; 1.43]	0.903
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 22.14 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.679</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	3.55 (3.48)	4.94 (4.97)		
Week 52 Mean (SD)	1.15 (2.43)	1.07 (2.54)		
Week 52 Adjusted Mean Change (SE)	-2.82 (0.25)	-3.25 (0.30)	0.43 [-0.34; 1.21]	0.272
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	2.62 (3.75)	3.30 (3.02)		
Week 52 Mean (SD)	0.85 (2.23)	0.10 (0.32)		
Week 52 Adjusted Mean Change (SE)	-2.72 (0.58)	-3.78 (0.65)	1.07 [-0.65; 2.79]	0.222
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.15 SPARCC Enthesitis Index - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.602</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	3.32 (3.29)	4.46 (5.16)		
Week 52 Mean (SD)	0.84 (2.03)	0.95 (1.88)		
Week 52 Adjusted Mean Change (SE)	-2.97 (0.46)	-3.27 (0.44)	0.30 [-0.95; 1.55]	0.638
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	3.38 (3.62)	4.56 (4.35)		
Week 52 Mean (SD)	1.16 (2.48)	0.85 (2.49)		
Week 52 Adjusted Mean Change (SE)	-2.68 (0.26)	-3.17 (0.33)	0.49 [-0.34; 1.32]	0.245
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.16 SPARCC Enthesitis Index - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.899</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	3.45 (3.61)	4.43 (4.50)		
Week 52 Mean (SD)	0.90 (2.12)	0.62 (2.04)		
Week 52 Adjusted Mean Change (SE)	-3.02 (0.29)	-3.39 (0.36)	0.37 [-0.55; 1.29]	0.429
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	3.24 (3.43)	4.63 (4.86)		
Week 52 Mean (SD)	1.39 (2.74)	1.13 (2.50)		
Week 52 Adjusted Mean Change (SE)	-2.33 (0.36)	-3.06 (0.37)	0.74 [-0.28; 1.76]	0.156
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.17 SPARCC Enthesitis Index - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.582</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	4.07 (3.82)	5.35 (5.67)		
Week 52 Mean (SD)	1.21 (2.57)	1.38 (2.72)		
Week 52 Adjusted Mean Change (SE)	-2.84 (0.38)	-3.01 (0.41)	0.17 [-0.92; 1.27]	0.758
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	2.98 (3.31)	3.81 (3.46)		
Week 52 Mean (SD)	1.02 (2.28)	0.54 (1.90)		
Week 52 Adjusted Mean Change (SE)	-2.70 (0.29)	-3.34 (0.35)	0.64 [-0.24; 1.53]	0.152
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.18 SPARCC Enthesitis Index - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.467</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	3.37 (3.55)	4.77 (4.80)		
Week 52 Mean (SD)	0.97 (2.22)	0.92 (2.23)		
Week 52 Adjusted Mean Change (SE)	-2.83 (0.32)	-3.29 (0.32)	0.46 [-0.45; 1.36]	0.322
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	3.36 (3.53)	4.08 (4.42)		
Week 52 Mean (SD)	1.20 (2.54)	0.80 (2.44)		
Week 52 Adjusted Mean Change (SE)	-2.68 (0.32)	-3.13 (0.44)	0.45 [-0.63; 1.53]	0.410
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 22.19 SPARCC Enthesitis Index - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.265</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	3.35 (3.42)	4.49 (4.91)		
Week 52 Mean (SD)	1.03 (2.36)	0.83 (2.14)		
Week 52 Adjusted Mean Change (SE)	-2.81 (0.25)	-3.20 (0.30)	0.39 [-0.38; 1.16]	0.315
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	2.72 (2.70)	4.61 (3.94)		
Week 52 Mean (SD)	0.59 (1.12)	1.00 (2.67)		
Week 52 Adjusted Mean Change (SE)	-2.90 (0.48)	-2.97 (0.47)	0.08 [-1.25; 1.41]	0.909
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 23.1 SPARCC Resolution of Enthesitis (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SPARCC Resolution of Enthesitis Week 52, N' n (%)	105 79.04 (71.85)	85 67.65 (66.98)	1.29 [0.70; 2.37] 0.411	1.07 [0.89; 1.29] 0.456	0.049 [-0.079; 0.176] 0.454
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>OR from logistic regression model with predictors treatment and weight. RR and RD calculated directly without adjustment.</p> <p>All results are combined over MI: n and % are averages of all imputations. Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.2 SPARCC Resolution of Enthesitis by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.924				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	99 73.84 (71.69)	78 62.65 (66.65)	1.30 [0.70; 2.45] 0.408	1.08 [0.89; 1.31] 0.459	0.050 [-0.083; 0.183] 0.457
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	6 5.20 (74.29)	7 5.00 (71.43)	1.15 [0.09; 14.06] 0.913	1.04 [0.54; 2.00] 0.914	0.029 [-0.449; 0.506] 0.907
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale                      with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,                      subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of                      imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 23.3 SPARCC Resolution of Enthesitis by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.961				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	64 50.73 (76.86)	49 42.41 (74.40)	1.28 [0.53; 3.06] 0.581	1.03 [0.84; 1.27] 0.758	0.025 [-0.133; 0.182] 0.759
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	41 28.31 (64.34)	36 25.24 (57.36)	1.24 [0.50; 3.08] 0.645	1.12 [0.79; 1.59] 0.519	0.070 [-0.142; 0.281] 0.517
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.4 SPARCC Resolution of Enthesitis by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.516				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	23 17.69 (73.71)	17 16.59 (79.00)	0.81 [0.18; 3.69] 0.789	0.93 [0.66; 1.32] 0.697	-0.053 [-0.314; 0.208] 0.691
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	82 61.35 (71.34)	68 51.06 (63.83)	1.41 [0.72; 2.77] 0.314	1.12 [0.90; 1.39] 0.318	0.075 [-0.071; 0.221] 0.313
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale  with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,  subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of  imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.5 SPARCC Resolution of Enthesitis by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.622				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	39 29.13 (69.36)	40 30.70 (60.20)	1.44 [0.58; 3.53] 0.431	1.15 [0.84; 1.57] 0.372	0.092 [-0.108; 0.292] 0.369
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	66 49.91 (73.40)	45 36.95 (73.90)	1.05 [0.44; 2.48] 0.918	0.99 [0.79; 1.24] 0.954	-0.005 [-0.170; 0.160] 0.952
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.6 SPARCC Resolution of Enthesitis by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.552				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	70 51.73 (71.85)	38 30.85 (62.96)	1.56 [0.69; 3.50] 0.282	1.14 [0.87; 1.50] 0.335	0.089 [-0.088; 0.266] 0.324
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	35 27.31 (71.87)	47 36.80 (70.77)	1.06 [0.41; 2.78] 0.901	1.02 [0.77; 1.34] 0.913	0.011 [-0.184; 0.206] 0.912
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.7 SPARCC Resolution of Enthesitis by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.589				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	49 43.44 (85.18)	28 25.29 (79.03)	1.50 [0.44; 5.06] 0.518	1.08 [0.86; 1.35] 0.510	0.061 [-0.119; 0.242] 0.504
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	56 35.60 (60.34)	57 42.36 (61.39)	1.00 [0.48; 2.11] 0.991	0.98 [0.74; 1.31] 0.907	-0.011 [-0.185; 0.164] 0.906
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale  with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,  subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of  imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.8 SPARCC Resolution of Enthesitis by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.498				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	49 33.60 (65.88)	37 28.73 (70.07)	0.83 [0.33; 2.08] 0.698	0.94 [0.70; 1.26] 0.677	-0.042 [-0.238; 0.155] 0.676
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	31 24.44 (71.88)	22 16.89 (64.96)	1.39 [0.44; 4.44] 0.573	1.11 [0.77; 1.60] 0.589	0.069 [-0.179; 0.317] 0.584
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.9 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.329				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	43 32.24 (71.64)	21 16.56 (61.33)	1.67 [0.57; 4.87] 0.348	1.17 [0.81; 1.70] 0.408	0.103 [-0.134; 0.340] 0.393
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	35 24.80 (65.26)	28 21.06 (70.20)	0.78 [0.27; 2.27] 0.653	0.93 [0.66; 1.30] 0.673	-0.049 [-0.278; 0.179] 0.672
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.10 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.174				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	29 19.71 (65.70)	26 18.10 (54.85)	1.57 [0.55; 4.54] 0.402	1.20 [0.79; 1.82] 0.396	0.109 [-0.140; 0.357] 0.391
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	49 35.44 (69.49)	33 27.52 (80.94)	0.55 [0.19; 1.61] 0.279	0.86 [0.67; 1.10] 0.229	-0.115 [-0.300; 0.071] 0.227
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 23.11 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.852				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	39 31.51 (73.28)	39 30.21 (70.26)	1.14 [0.43; 3.05] 0.791	1.04 [0.79; 1.37] 0.764	0.030 [-0.167; 0.228] 0.764
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	41 26.53 (63.17)	20 15.41 (64.21)	0.99 [0.33; 2.95] 0.990	0.98 [0.67; 1.46] 0.938	-0.010 [-0.259; 0.239] 0.935
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.12 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.846				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	58 43.33 (69.89)	40 32.40 (68.94)	1.11 [0.47; 2.61] 0.818	1.01 [0.78; 1.32] 0.916	0.010 [-0.171; 0.190] 0.918
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	19 13.71 (68.55)	17 12.22 (67.89)	0.94 [0.23; 3.87] 0.929	1.01 [0.65; 1.58] 0.966	0.007 [-0.296; 0.309] 0.966
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.13 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.632				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	58 45.04 (71.49)	44 36.33 (71.24)	1.01 [0.43; 2.37] 0.987	1.00 [0.79; 1.28] 0.976	0.003 [-0.171; 0.176] 0.977
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	19 11.00 (57.89)	12 6.00 (50.00)	1.53 [0.35; 6.69] 0.573	1.16 [0.58; 2.29] 0.674	0.079 [-0.281; 0.439] 0.667
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) SPARCC Resolution of Enthesitis, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

### 23.14 SPARCC Resolution of Enthesitis by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.371				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	66 47.04 (66.25)	46 34.40 (64.91)	1.09 [0.50; 2.38] 0.822	1.02 [0.78; 1.33] 0.879	0.013 [-0.161; 0.188] 0.879
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	13 10.00 (76.92)	10 9.00 (90.00)	0.34 [0.03; 3.89] 0.385	0.85 [0.59; 1.23] 0.396	-0.131 [-0.426; 0.164] 0.385
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) SPARCC Resolution of Enthesitis, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

### 23.15 SPARCC Resolution of Enthesitis by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.307				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	19 15.60 (70.91)	20 15.11 (58.12)	1.69 [0.46; 6.21] 0.426	1.22 [0.78; 1.92] 0.388	0.128 [-0.158; 0.414] 0.380
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	61 42.44 (67.37)	39 30.51 (74.41)	0.74 [0.30; 1.82] 0.509	0.91 [0.70; 1.17] 0.442	-0.070 [-0.251; 0.110] 0.444
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.16 SPARCC Resolution of Enthesitis by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.298				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	49 37.24 (73.02)	29 23.56 (67.31)	1.43 [0.53; 3.87] 0.480	1.09 [0.81; 1.46] 0.589	0.057 [-0.148; 0.262] 0.586
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	31 20.80 (61.18)	30 22.06 (68.94)	0.66 [0.23; 1.89] 0.435	0.89 [0.62; 1.28] 0.520	-0.078 [-0.312; 0.157] 0.517
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.17 SPARCC Resolution of Enthesitis by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.224				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	29 19.71 (65.70)	24 17.10 (55.16)	1.55 [0.53; 4.54] 0.426	1.19 [0.78; 1.83] 0.419	0.105 [-0.147; 0.358] 0.413
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	51 38.33 (69.69)	35 28.52 (79.22)	0.62 [0.22; 1.70] 0.353	0.88 [0.69; 1.13] 0.308	-0.095 [-0.278; 0.088] 0.308
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 23.18 SPARCC Resolution of Enthesitis by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.852				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	39 31.51 (73.28)	39 30.21 (70.26)	1.14 [0.43; 3.05] 0.791	1.04 [0.79; 1.37] 0.764	0.030 [-0.167; 0.228] 0.764
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	41 26.53 (63.17)	20 15.41 (64.21)	0.99 [0.33; 2.95] 0.990	0.98 [0.67; 1.46] 0.938	-0.010 [-0.259; 0.239] 0.935
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 23.19 SPARCC Resolution of Enthesitis by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SPARCC Resolution of Enthesitis Week 52	p=0.908				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	61 45.33 (69.74)	42 33.40 (68.16)	1.14 [0.49; 2.63] 0.758	1.02 [0.79; 1.32] 0.860	0.016 [-0.161; 0.193] 0.861
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
SPARCC Resolution of Enthesitis Week 52, N' n (%)	17 12.71 (70.61)	17 12.22 (67.89)	1.03 [0.24; 4.50] 0.967	1.04 [0.67; 1.63] 0.863	0.027 [-0.281; 0.336] 0.863
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 24.0 TJC28 - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	109 (99.1)	100 (99.0)	209 (99.1)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	108 (98.2)	93 (92.1)	201 (95.3)
Week 20 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	100 (90.9)	84 (83.2)	184 (87.2)
Week 32 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 36 Returns	100 (90.9)	83 (82.2)	183 (86.7)
Week 40 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 44 Returns	102 (92.7)	82 (81.2)	184 (87.2)
Week 48 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 52 Returns	104 (94.5)	83 (82.2)	187 (88.6)

## 24.1 TJC28 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	8.93 (5.58)	9.24 (5.99)		
Week 52 Mean (SD)	1.63 (2.88)	2.24 (3.26)		
Week 52 Adjusted Mean Change (SE)	-7.48 (0.28)	-6.95 (0.31)	-0.53 [-1.35; 0.29]	0.204
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 24.2 TJC28 - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.537</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	8.60 (5.34)	9.16 (6.04)		
Week 52 Mean (SD)	1.64 (2.93)	2.26 (3.32)		
Week 52 Adjusted Mean Change (SE)	-7.42 (0.29)	-6.91 (0.32)	-0.51 [-1.36; 0.35]	0.242
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	13.71 (7.18)	10.29 (5.59)		
Week 52 Mean (SD)	1.50 (1.97)	2.00 (2.65)		
Week 52 Adjusted Mean Change (SE)	-8.38 (1.16)	-7.32 (1.09)	-1.05 [-4.17; 2.07]	0.506
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 24.3 TJC28 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.937</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	8.45 (5.45)	8.70 (5.98)		
Week 52 Mean (SD)	1.02 (1.58)	1.43 (2.81)		
Week 52 Adjusted Mean Change (SE)	-8.13 (0.35)	-7.72 (0.39)	-0.41 [-1.44; 0.61]	0.428
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	9.64 (5.76)	9.93 (6.00)		
Week 52 Mean (SD)	2.59 (3.99)	3.31 (3.52)		
Week 52 Adjusted Mean Change (SE)	-6.50 (0.43)	-5.91 (0.45)	-0.59 [-1.81; 0.63]	0.342
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.4 TJC28 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.349</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	7.58 (4.64)	5.10 (3.75)		
Week 52 Mean (SD)	0.87 (1.77)	1.69 (2.12)		
Week 52 Adjusted Mean Change (SE)	-8.13 (0.60)	-6.78 (0.71)	-1.35 [-3.16; 0.47]	0.145
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	9.30 (5.78)	10.33 (6.01)		
Week 52 Mean (SD)	1.85 (3.09)	2.37 (3.47)		
Week 52 Adjusted Mean Change (SE)	-7.30 (0.32)	-6.99 (0.35)	-0.31 [-1.23; 0.62]	0.511
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.5 TJC28 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.753</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	8.57 (5.29)	10.24 (6.78)		
Week 52 Mean (SD)	1.72 (3.05)	2.74 (3.68)		
Week 52 Adjusted Mean Change (SE)	-7.33 (0.46)	-6.73 (0.45)	-0.60 [-1.87; 0.68]	0.356
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	9.15 (5.78)	8.22 (4.93)		
Week 52 Mean (SD)	1.58 (2.79)	1.80 (2.80)		
Week 52 Adjusted Mean Change (SE)	-7.57 (0.35)	-7.14 (0.43)	-0.43 [-1.53; 0.67]	0.442
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment            x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters,            subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.6 TJC28 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=1.000</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	8.65 (5.37)	7.90 (5.80)		
Week 52 Mean (SD)	1.43 (2.63)	2.22 (3.44)		
Week 52 Adjusted Mean Change (SE)	-7.66 (0.34)	-6.64 (0.46)	-1.02 [-2.15; 0.11]	0.075
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	9.45 (5.99)	10.50 (5.96)		
Week 52 Mean (SD)	2.06 (3.33)	2.26 (3.14)		
Week 52 Adjusted Mean Change (SE)	-7.11 (0.48)	-7.14 (0.42)	0.02 [-1.24; 1.29]	0.969
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 24.7 TJC28 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.702</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	7.55 (5.05)	5.50 (4.24)		
Week 52 Mean (SD)	1.48 (3.00)	1.61 (3.06)		
Week 52 Adjusted Mean Change (SE)	-7.30 (0.42)	-7.09 (0.55)	-0.21 [-1.55; 1.12]	0.753
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	10.12 (5.78)	10.97 (5.92)		
Week 52 Mean (SD)	1.77 (2.78)	2.56 (3.33)		
Week 52 Adjusted Mean Change (SE)	-7.63 (0.38)	-6.88 (0.39)	-0.75 [-1.81; 0.31]	0.165
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.8 TJC28 - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.865</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	8.43 (5.09)	9.63 (5.45)		
Week 52 Mean (SD)	1.75 (2.90)	1.86 (2.52)		
Week 52 Adjusted Mean Change (SE)	-6.83 (0.41)	-6.93 (0.47)	0.10 [-1.14; 1.34]	0.878
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	8.74 (5.62)	7.46 (5.64)		
Week 52 Mean (SD)	1.94 (3.41)	2.00 (3.49)		
Week 52 Adjusted Mean Change (SE)	-6.85 (0.51)	-6.53 (0.60)	-0.32 [-1.88; 1.24]	0.690
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.9 TJC28 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.818</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	9.51 (5.70)	9.07 (5.11)		
Week 52 Mean (SD)	1.35 (2.23)	1.29 (1.87)		
Week 52 Adjusted Mean Change (SE)	-7.58 (0.44)	-7.49 (0.61)	-0.09 [-1.56; 1.39]	0.907
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	7.42 (4.58)	8.37 (5.73)		
Week 52 Mean (SD)	2.41 (3.91)	2.56 (3.72)		
Week 52 Adjusted Mean Change (SE)	-5.91 (0.49)	-6.18 (0.54)	0.27 [-1.18; 1.71]	0.714
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.10 TJC28 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.391</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	9.33 (5.97)	8.61 (5.46)		
Week 52 Mean (SD)	2.00 (2.62)	1.58 (2.14)		
Week 52 Adjusted Mean Change (SE)	-6.95 (0.54)	-7.16 (0.55)	0.21 [-1.31; 1.73]	0.786
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	8.22 (4.70)	8.97 (5.79)		
Week 52 Mean (SD)	1.79 (3.40)	2.19 (3.43)		
Week 52 Adjusted Mean Change (SE)	-6.76 (0.42)	-6.52 (0.51)	-0.24 [-1.55; 1.06]	0.711
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.11 TJC28 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.149</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	8.42 (5.95)	8.70 (5.73)		
Week 52 Mean (SD)	1.28 (2.37)	2.08 (2.93)		
Week 52 Adjusted Mean Change (SE)	-7.43 (0.45)	-6.59 (0.45)	-0.83 [-2.10; 0.43]	0.195
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	8.69 (4.56)	8.96 (5.45)		
Week 52 Mean (SD)	2.35 (3.61)	1.60 (2.91)		
Week 52 Adjusted Mean Change (SE)	-6.27 (0.45)	-7.16 (0.63)	0.89 [-0.63; 2.41]	0.250
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.12 TJC28 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.203</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	8.53 (5.10)	8.94 (5.21)		
Week 52 Mean (SD)	1.98 (3.52)	1.66 (2.11)		
Week 52 Adjusted Mean Change (SE)	-6.65 (0.36)	-6.98 (0.43)	0.33 [-0.79; 1.45]	0.559
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	8.70 (5.96)	7.44 (5.33)		
Week 52 Mean (SD)	1.42 (1.57)	1.82 (2.86)		
Week 52 Adjusted Mean Change (SE)	-7.20 (0.63)	-6.65 (0.67)	-0.54 [-2.36; 1.28]	0.556
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 24.13 TJC28 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.172</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	8.94 (5.32)	8.25 (5.14)		
Week 52 Mean (SD)	1.84 (2.78)	1.33 (2.32)		
Week 52 Adjusted Mean Change (SE)	-7.02 (0.37)	-7.24 (0.43)	0.22 [-0.90; 1.35]	0.698
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	7.26 (4.28)	11.75 (7.01)		
Week 52 Mean (SD)	1.94 (4.18)	3.92 (4.06)		
Week 52 Adjusted Mean Change (SE)	-6.15 (0.67)	-5.31 (0.84)	-0.84 [-2.99; 1.31]	0.442
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.14 TJC28 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.823</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	8.92 (5.05)	8.91 (5.70)		
Week 52 Mean (SD)	1.94 (3.33)	2.09 (3.13)		
Week 52 Adjusted Mean Change (SE)	-6.90 (0.36)	-6.78 (0.42)	-0.12 [-1.21; 0.97]	0.831
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	7.08 (6.28)	9.50 (5.08)		
Week 52 Mean (SD)	1.38 (1.56)	1.50 (1.69)		
Week 52 Adjusted Mean Change (SE)	-7.06 (0.81)	-7.02 (0.98)	-0.04 [-2.56; 2.47]	0.973
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 24.15 TJC28 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.919</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	9.14 (5.37)	8.00 (4.73)		
Week 52 Mean (SD)	1.37 (3.04)	1.10 (1.37)		
Week 52 Adjusted Mean Change (SE)	-7.48 (0.64)	-7.53 (0.62)	0.05 [-1.71; 1.82]	0.953
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	8.35 (5.27)	9.29 (6.07)		
Week 52 Mean (SD)	1.97 (3.11)	2.35 (3.40)		
Week 52 Adjusted Mean Change (SE)	-6.63 (0.36)	-6.37 (0.46)	-0.26 [-1.43; 0.90]	0.654
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.16 TJC28 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.989</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	9.14 (5.65)	9.26 (5.44)		
Week 52 Mean (SD)	1.43 (2.19)	1.29 (1.74)		
Week 52 Adjusted Mean Change (SE)	-7.46 (0.40)	-7.38 (0.51)	-0.08 [-1.36; 1.20]	0.899
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	7.68 (4.60)	8.28 (5.79)		
Week 52 Mean (SD)	2.47 (4.13)	2.52 (3.63)		
Week 52 Adjusted Mean Change (SE)	-5.84 (0.50)	-6.21 (0.51)	0.37 [-1.05; 1.78]	0.607
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.17 TJC28 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.493</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	9.33 (5.97)	8.52 (5.62)		
Week 52 Mean (SD)	2.00 (2.62)	1.71 (2.18)		
Week 52 Adjusted Mean Change (SE)	-6.92 (0.54)	-6.99 (0.57)	0.06 [-1.48; 1.61]	0.937
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	8.13 (4.86)	9.03 (5.63)		
Week 52 Mean (SD)	1.72 (3.35)	2.06 (3.36)		
Week 52 Adjusted Mean Change (SE)	-6.77 (0.40)	-6.64 (0.49)	-0.13 [-1.39; 1.13]	0.839
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.18 TJC28 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.149</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	8.42 (5.95)	8.70 (5.73)		
Week 52 Mean (SD)	1.28 (2.37)	2.08 (2.93)		
Week 52 Adjusted Mean Change (SE)	-7.43 (0.45)	-6.59 (0.45)	-0.83 [-2.10; 0.43]	0.195
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	8.69 (4.56)	8.96 (5.45)		
Week 52 Mean (SD)	2.35 (3.61)	1.60 (2.91)		
Week 52 Adjusted Mean Change (SE)	-6.27 (0.45)	-7.16 (0.63)	0.89 [-0.63; 2.41]	0.250
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 24.19 TJC28 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.227</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	8.57 (5.04)	8.86 (5.13)		
Week 52 Mean (SD)	1.93 (3.44)	1.70 (2.14)		
Week 52 Adjusted Mean Change (SE)	-6.65 (0.37)	-6.92 (0.44)	0.27 [-0.87; 1.40]	0.645
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	7.83 (4.33)	8.61 (6.84)		
Week 52 Mean (SD)	1.35 (1.50)	2.41 (4.24)		
Week 52 Adjusted Mean Change (SE)	-7.12 (0.70)	-6.24 (0.69)	-0.87 [-2.82; 1.07]	0.377
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.0 TJC68 - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	109 (99.1)	100 (99.0)	209 (99.1)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	108 (98.2)	93 (92.1)	201 (95.3)
Week 20 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	100 (90.9)	84 (83.2)	184 (87.2)
Week 32 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 36 Returns	100 (90.9)	83 (82.2)	183 (86.7)
Week 40 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 44 Returns	102 (92.7)	82 (81.2)	184 (87.2)
Week 48 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 52 Returns	104 (94.5)	83 (82.2)	187 (88.6)

## 25.1 TJC68 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	16.49 (9.41)	18.40 (11.41)		
Week 52 Mean (SD)	3.10 (4.69)	3.86 (5.89)		
Week 52 Adjusted Mean Change (SE)	-14.01 (0.49)	-13.55 (0.53)	-0.45 [-1.88; 0.98]	0.533
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 25.2 TJC68 - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.563</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	15.89 (8.70)	18.46 (11.41)		
Week 52 Mean (SD)	3.05 (4.73)	3.91 (6.01)		
Week 52 Adjusted Mean Change (SE)	-13.97 (0.51)	-13.51 (0.56)	-0.47 [-1.96; 1.03]	0.538
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	25.29 (15.07)	17.57 (12.22)		
Week 52 Mean (SD)	3.83 (4.17)	3.29 (4.68)		
Week 52 Adjusted Mean Change (SE)	-14.51 (2.01)	-14.06 (1.91)	-0.45 [-5.92; 5.01]	0.870
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 25.3 TJC68 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.938</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	15.80 (8.78)	17.96 (11.05)		
Week 52 Mean (SD)	2.03 (2.90)	2.60 (4.07)		
Week 52 Adjusted Mean Change (SE)	-15.08 (0.61)	-14.82 (0.68)	-0.26 [-2.06; 1.54]	0.776
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	17.52 (10.31)	18.95 (11.96)		
Week 52 Mean (SD)	4.73 (6.25)	5.50 (7.39)		
Week 52 Adjusted Mean Change (SE)	-12.40 (0.75)	-11.84 (0.79)	-0.56 [-2.69; 1.57]	0.607
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.4 TJC68 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.764</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	13.96 (7.84)	11.76 (6.10)		
Week 52 Mean (SD)	2.48 (4.05)	2.94 (4.06)		
Week 52 Adjusted Mean Change (SE)	-14.42 (1.05)	-13.34 (1.21)	-1.09 [-4.23; 2.05]	0.495
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	17.20 (9.73)	20.14 (11.85)		
Week 52 Mean (SD)	3.27 (4.86)	4.07 (6.25)		
Week 52 Adjusted Mean Change (SE)	-13.89 (0.55)	-13.61 (0.61)	-0.28 [-1.90; 1.34]	0.736
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.5 TJC68 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.552</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	16.21 (8.42)	19.82 (12.62)		
Week 52 Mean (SD)	3.18 (3.75)	4.95 (7.50)		
Week 52 Adjusted Mean Change (SE)	-13.98 (0.80)	-12.76 (0.78)	-1.23 [-3.43; 0.98]	0.274
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	16.66 (10.04)	16.94 (9.94)		
Week 52 Mean (SD)	3.05 (5.20)	2.89 (3.78)		
Week 52 Adjusted Mean Change (SE)	-14.03 (0.62)	-14.24 (0.74)	0.21 [-1.70; 2.12]	0.826
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.6 TJC68 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.973</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	15.97 (8.94)	16.37 (11.52)		
Week 52 Mean (SD)	2.74 (4.05)	3.17 (4.63)		
Week 52 Adjusted Mean Change (SE)	-14.39 (0.60)	-13.55 (0.79)	-0.84 [-2.79; 1.11]	0.396
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	17.47 (10.31)	20.31 (11.07)		
Week 52 Mean (SD)	3.82 (5.80)	4.38 (6.70)		
Week 52 Adjusted Mean Change (SE)	-13.25 (0.84)	-13.42 (0.74)	0.17 [-2.04; 2.37]	0.880
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.7 TJC68 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.458</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	14.67 (7.49)	11.81 (5.87)		
Week 52 Mean (SD)	2.71 (4.64)	2.43 (3.99)		
Week 52 Adjusted Mean Change (SE)	-13.92 (0.72)	-14.22 (0.95)	0.30 [-2.02; 2.63]	0.798
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	18.07 (10.62)	21.45 (12.07)		
Week 52 Mean (SD)	3.43 (4.75)	4.58 (6.56)		
Week 52 Adjusted Mean Change (SE)	-14.10 (0.67)	-13.20 (0.67)	-0.90 [-2.75; 0.96]	0.340
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.8 TJC68 - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.920</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	16.35 (8.80)	18.54 (11.40)		
Week 52 Mean (SD)	3.38 (5.12)	3.26 (6.09)		
Week 52 Adjusted Mean Change (SE)	-13.02 (0.78)	-13.56 (0.89)	0.54 [-1.81; 2.88]	0.651
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	15.06 (8.04)	17.38 (11.31)		
Week 52 Mean (SD)	3.26 (4.75)	4.05 (6.94)		
Week 52 Adjusted Mean Change (SE)	-13.22 (0.97)	-12.53 (1.14)	-0.70 [-3.65; 2.26]	0.643
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.9 TJC68 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.304</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	18.00 (10.08)	18.04 (10.86)		
Week 52 Mean (SD)	2.37 (3.51)	2.67 (6.70)		
Week 52 Adjusted Mean Change (SE)	-14.81 (0.84)	-13.92 (1.14)	-0.88 [-3.68; 1.91]	0.532
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	13.39 (5.28)	18.03 (11.41)		
Week 52 Mean (SD)	4.50 (6.27)	4.63 (6.98)		
Week 52 Adjusted Mean Change (SE)	-11.02 (0.94)	-12.48 (1.04)	1.47 [-1.32; 4.25]	0.301
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.10 TJC68 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.594</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	17.70 (10.15)	18.21 (11.44)		
Week 52 Mean (SD)	3.72 (4.36)	3.23 (6.33)		
Week 52 Adjusted Mean Change (SE)	-13.46 (1.03)	-13.38 (1.04)	-0.08 [-2.97; 2.80]	0.955
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	15.04 (7.17)	17.97 (11.33)		
Week 52 Mean (SD)	3.23 (5.36)	3.84 (6.52)		
Week 52 Adjusted Mean Change (SE)	-12.99 (0.80)	-13.21 (0.97)	0.22 [-2.27; 2.72]	0.860
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 25.11 TJC68 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.407</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	15.30 (8.72)	17.47 (11.40)		
Week 52 Mean (SD)	2.72 (4.05)	3.78 (5.75)		
Week 52 Adjusted Mean Change (SE)	-13.75 (0.86)	-12.87 (0.86)	-0.88 [-3.29; 1.52]	0.469
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	16.38 (8.29)	19.21 (11.26)		
Week 52 Mean (SD)	3.93 (5.68)	3.15 (7.56)		
Week 52 Adjusted Mean Change (SE)	-12.46 (0.85)	-13.81 (1.19)	1.35 [-1.56; 4.25]	0.361
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.12 TJC68 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.113</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	15.79 (7.78)	18.11 (10.72)		
Week 52 Mean (SD)	3.53 (5.53)	3.45 (5.92)		
Week 52 Adjusted Mean Change (SE)	-12.76 (0.68)	-12.96 (0.81)	0.20 [-1.91; 2.30]	0.853
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	15.75 (10.91)	16.33 (10.84)		
Week 52 Mean (SD)	2.63 (2.87)	2.53 (4.37)		
Week 52 Adjusted Mean Change (SE)	-13.77 (1.19)	-13.96 (1.26)	0.20 [-3.23; 3.62]	0.910
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 25.13 TJC68 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.063</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	16.40 (8.90)	17.76 (10.25)		
Week 52 Mean (SD)	3.33 (5.06)	2.31 (4.04)		
Week 52 Adjusted Mean Change (SE)	-13.67 (0.70)	-14.37 (0.80)	0.70 [-1.40; 2.81]	0.510
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	14.37 (7.39)	22.42 (15.33)		
Week 52 Mean (SD)	3.61 (5.07)	8.17 (10.75)		
Week 52 Adjusted Mean Change (SE)	-11.79 (1.27)	-9.85 (1.60)	-1.93 [-5.99; 2.13]	0.348
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.14 TJC68 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.913</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	16.01 (8.76)	18.68 (11.32)		
Week 52 Mean (SD)	3.63 (5.32)	3.83 (6.89)		
Week 52 Adjusted Mean Change (SE)	-12.98 (0.68)	-13.25 (0.80)	0.27 [-1.81; 2.36]	0.796
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	15.00 (7.34)	18.50 (12.41)		
Week 52 Mean (SD)	2.08 (2.22)	3.13 (4.09)		
Week 52 Adjusted Mean Change (SE)	-14.44 (1.55)	-13.37 (1.83)	-1.07 [-5.81; 3.68]	0.657
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.15 TJC68 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.551</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	16.82 (8.31)	16.50 (8.69)		
Week 52 Mean (SD)	2.47 (4.41)	2.20 (3.04)		
Week 52 Adjusted Mean Change (SE)	-14.20 (1.21)	-13.90 (1.16)	-0.29 [-3.60; 3.02]	0.861
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	15.49 (8.57)	19.10 (12.68)		
Week 52 Mean (SD)	3.60 (5.11)	4.30 (7.55)		
Week 52 Adjusted Mean Change (SE)	-12.74 (0.70)	-12.80 (0.88)	0.06 [-2.18; 2.29]	0.960
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.16 TJC68 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.643</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	17.31 (9.94)	18.43 (11.25)		
Week 52 Mean (SD)	2.59 (3.66)	2.43 (5.86)		
Week 52 Adjusted Mean Change (SE)	-14.45 (0.75)	-14.06 (0.96)	-0.39 [-2.80; 2.01]	0.748
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	13.62 (4.99)	17.72 (11.51)		
Week 52 Mean (SD)	4.53 (6.43)	4.66 (6.77)		
Week 52 Adjusted Mean Change (SE)	-10.90 (0.95)	-12.42 (0.96)	1.51 [-1.18; 4.21]	0.269
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.17 TJC68 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.752</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	17.70 (10.15)	18.29 (11.80)		
Week 52 Mean (SD)	3.72 (4.36)	3.46 (6.54)		
Week 52 Adjusted Mean Change (SE)	-13.37 (1.02)	-13.06 (1.07)	-0.31 [-3.22; 2.60]	0.833
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	14.82 (7.32)	17.92 (11.02)		
Week 52 Mean (SD)	3.10 (5.29)	3.64 (6.37)		
Week 52 Adjusted Mean Change (SE)	-12.89 (0.77)	-13.30 (0.94)	0.41 [-1.99; 2.82]	0.734
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 25.18 TJC68 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.407</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	15.30 (8.72)	17.47 (11.40)		
Week 52 Mean (SD)	2.72 (4.05)	3.78 (5.75)		
Week 52 Adjusted Mean Change (SE)	-13.75 (0.86)	-12.87 (0.86)	-0.88 [-3.29; 1.52]	0.469
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	16.38 (8.29)	19.21 (11.26)		
Week 52 Mean (SD)	3.93 (5.68)	3.15 (7.56)		
Week 52 Adjusted Mean Change (SE)	-12.46 (0.85)	-13.81 (1.19)	1.35 [-1.56; 4.25]	0.361
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 25.19 TJC68 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.276</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	15.88 (7.67)	17.82 (10.64)		
Week 52 Mean (SD)	3.40 (5.42)	3.43 (5.81)		
Week 52 Adjusted Mean Change (SE)	-12.75 (0.70)	-12.97 (0.83)	0.22 [-1.93; 2.38]	0.839
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	14.06 (7.45)	18.83 (13.24)		
Week 52 Mean (SD)	2.29 (2.08)	3.88 (7.76)		
Week 52 Adjusted Mean Change (SE)	-13.68 (1.33)	-13.20 (1.33)	-0.49 [-4.22; 3.24]	0.797
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.0 TJC78 - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	109 (99.1)	100 (99.0)	209 (99.1)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	108 (98.2)	93 (92.1)	201 (95.3)
Week 20 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	100 (90.9)	84 (83.2)	184 (87.2)
Week 32 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 36 Returns	100 (90.9)	83 (82.2)	183 (86.7)
Week 40 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 44 Returns	102 (92.7)	82 (81.2)	184 (87.2)
Week 48 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 52 Returns	104 (94.5)	83 (82.2)	187 (88.6)

## 26.1 TJC78 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	17.40 (9.96)	19.70 (12.54)		
Week 52 Mean (SD)	3.23 (4.86)	4.02 (6.25)		
Week 52 Adjusted Mean Change (SE)	-14.92 (0.51)	-14.48 (0.56)	-0.44 [-1.94; 1.06]	0.564
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 26.2 TJC78 - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.626</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	16.83 (9.29)	19.82 (12.54)		
Week 52 Mean (SD)	3.16 (4.89)	4.09 (6.39)		
Week 52 Adjusted Mean Change (SE)	-14.92 (0.53)	-14.42 (0.59)	-0.50 [-2.07; 1.07]	0.531
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	25.86 (15.64)	18.14 (13.47)		
Week 52 Mean (SD)	4.33 (4.76)	3.29 (4.68)		
Week 52 Adjusted Mean Change (SE)	-14.90 (2.11)	-15.03 (2.01)	0.14 [-5.61; 5.88]	0.963
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.3 TJC78 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.971</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	16.73 (9.22)	19.39 (12.62)		
Week 52 Mean (SD)	2.14 (3.05)	2.70 (4.18)		
Week 52 Adjusted Mean Change (SE)	-16.03 (0.64)	-15.87 (0.71)	-0.16 [-2.05; 1.74]	0.871
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	18.41 (11.01)	20.11 (12.57)		
Week 52 Mean (SD)	4.90 (6.46)	5.75 (7.95)		
Week 52 Adjusted Mean Change (SE)	-13.25 (0.79)	-12.59 (0.82)	-0.66 [-2.90; 1.58]	0.562
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.4 TJC78 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.828</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	14.58 (8.35)	12.57 (6.49)		
Week 52 Mean (SD)	2.57 (4.30)	2.94 (4.06)		
Week 52 Adjusted Mean Change (SE)	-15.36 (1.11)	-14.42 (1.27)	-0.94 [-4.23; 2.36]	0.577
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	18.19 (10.27)	21.58 (13.09)		
Week 52 Mean (SD)	3.42 (5.02)	4.28 (6.66)		
Week 52 Adjusted Mean Change (SE)	-14.80 (0.58)	-14.49 (0.64)	-0.30 [-2.01; 1.40]	0.727
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.5 TJC78 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.477</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	17.24 (9.64)	21.00 (13.62)		
Week 52 Mean (SD)	3.33 (4.02)	5.15 (8.09)		
Week 52 Adjusted Mean Change (SE)	-14.91 (0.84)	-13.56 (0.81)	-1.35 [-3.67; 0.96]	0.250
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	17.50 (10.22)	18.38 (11.32)		
Week 52 Mean (SD)	3.17 (5.34)	3.02 (3.81)		
Week 52 Adjusted Mean Change (SE)	-14.92 (0.65)	-15.26 (0.78)	0.34 [-1.67; 2.35]	0.738
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment            x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters,            subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.6 TJC78 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.820</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	16.99 (9.74)	17.65 (12.44)		
Week 52 Mean (SD)	2.91 (4.33)	3.19 (4.71)		
Week 52 Adjusted Mean Change (SE)	-15.30 (0.63)	-14.61 (0.83)	-0.69 [-2.74; 1.36]	0.510
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	18.18 (10.44)	21.63 (12.45)		
Week 52 Mean (SD)	3.88 (5.82)	4.66 (7.19)		
Week 52 Adjusted Mean Change (SE)	-14.16 (0.89)	-14.20 (0.77)	0.04 [-2.28; 2.36]	0.972
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 26.7 TJC78 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.492</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	15.76 (8.08)	13.19 (7.00)		
Week 52 Mean (SD)	2.81 (4.90)	2.64 (4.06)		
Week 52 Adjusted Mean Change (SE)	-14.91 (0.76)	-15.17 (1.00)	0.26 [-2.19; 2.70]	0.836
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	18.81 (11.21)	22.72 (13.41)		
Week 52 Mean (SD)	3.59 (4.85)	4.73 (7.04)		
Week 52 Adjusted Mean Change (SE)	-14.94 (0.70)	-14.11 (0.70)	-0.83 [-2.78; 1.12]	0.404
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.8 TJC78 - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.960</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	17.16 (9.44)	19.88 (12.69)		
Week 52 Mean (SD)	3.42 (5.21)	3.46 (6.58)		
Week 52 Adjusted Mean Change (SE)	-13.97 (0.83)	-14.44 (0.95)	0.47 [-2.02; 2.96]	0.710
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	16.15 (8.66)	18.81 (11.95)		
Week 52 Mean (SD)	3.42 (5.08)	4.18 (7.46)		
Week 52 Adjusted Mean Change (SE)	-14.18 (1.03)	-13.47 (1.21)	-0.72 [-3.86; 2.42]	0.652
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.9 TJC78 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.335</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	19.09 (10.90)	19.37 (11.39)		
Week 52 Mean (SD)	2.40 (3.51)	2.90 (7.34)		
Week 52 Adjusted Mean Change (SE)	-15.84 (0.89)	-14.76 (1.22)	-1.07 [-4.06; 1.91]	0.478
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	14.16 (5.48)	19.43 (12.59)		
Week 52 Mean (SD)	4.68 (6.56)	4.81 (7.47)		
Week 52 Adjusted Mean Change (SE)	-11.89 (1.00)	-13.35 (1.11)	1.46 [-1.53; 4.44]	0.336
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.10 TJC78 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.633</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	18.70 (10.87)	19.67 (12.16)		
Week 52 Mean (SD)	3.83 (4.51)	3.46 (6.87)		
Week 52 Adjusted Mean Change (SE)	-14.39 (1.09)	-14.20 (1.10)	-0.19 [-3.25; 2.88]	0.904
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	15.92 (7.85)	19.26 (12.66)		
Week 52 Mean (SD)	3.31 (5.55)	3.97 (6.98)		
Week 52 Adjusted Mean Change (SE)	-13.97 (0.85)	-14.19 (1.04)	0.22 [-2.43; 2.88]	0.869
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.11 TJC78 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.372</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	16.14 (8.88)	18.77 (12.79)		
Week 52 Mean (SD)	2.82 (4.28)	3.89 (6.14)		
Week 52 Adjusted Mean Change (SE)	-14.70 (0.91)	-13.89 (0.92)	-0.81 [-3.37; 1.75]	0.533
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	17.38 (9.38)	20.71 (11.61)		
Week 52 Mean (SD)	4.00 (5.83)	3.45 (8.23)		
Week 52 Adjusted Mean Change (SE)	-13.43 (0.91)	-14.48 (1.27)	1.06 [-2.03; 4.15]	0.500
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.12 TJC78 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.166</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	16.74 (8.71)	19.57 (12.07)		
Week 52 Mean (SD)	3.60 (5.70)	3.61 (6.31)		
Week 52 Adjusted Mean Change (SE)	-13.72 (0.72)	-13.86 (0.85)	0.14 [-2.07; 2.34]	0.903
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	16.65 (10.84)	17.33 (10.98)		
Week 52 Mean (SD)	2.63 (2.87)	2.59 (4.58)		
Week 52 Adjusted Mean Change (SE)	-14.84 (1.25)	-14.94 (1.32)	0.09 [-3.50; 3.69]	0.959
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.13 TJC78 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.051</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	17.41 (9.62)	19.27 (11.42)		
Week 52 Mean (SD)	3.38 (5.18)	2.38 (4.14)		
Week 52 Adjusted Mean Change (SE)	-14.71 (0.74)	-15.45 (0.85)	0.74 [-1.49; 2.97]	0.511
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	15.00 (7.61)	23.50 (16.18)		
Week 52 Mean (SD)	3.83 (5.44)	8.75 (11.85)		
Week 52 Adjusted Mean Change (SE)	-12.56 (1.34)	-10.30 (1.68)	-2.26 [-6.54; 2.03]	0.299
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.14 TJC78 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.950</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	16.83 (9.40)	20.02 (12.26)		
Week 52 Mean (SD)	3.74 (5.51)	4.04 (7.44)		
Week 52 Adjusted Mean Change (SE)	-13.89 (0.72)	-14.09 (0.85)	0.20 [-2.02; 2.41]	0.862
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	16.54 (7.94)	20.10 (14.26)		
Week 52 Mean (SD)	2.08 (2.22)	3.13 (4.09)		
Week 52 Adjusted Mean Change (SE)	-15.65 (1.65)	-14.56 (1.94)	-1.10 [-6.13; 3.93]	0.667
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 26.15 TJC78 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.614</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	17.95 (9.53)	17.88 (9.55)		
Week 52 Mean (SD)	2.53 (4.41)	2.30 (3.06)		
Week 52 Adjusted Mean Change (SE)	-15.19 (1.29)	-14.89 (1.23)	-0.30 [-3.82; 3.21]	0.864
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	16.33 (8.98)	20.46 (13.82)		
Week 52 Mean (SD)	3.70 (5.33)	4.51 (8.17)		
Week 52 Adjusted Mean Change (SE)	-13.68 (0.74)	-13.65 (0.94)	-0.03 [-2.41; 2.35]	0.982
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.16 TJC78 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.614</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	18.47 (10.68)	19.83 (12.22)		
Week 52 Mean (SD)	2.65 (3.78)	2.61 (6.41)		
Week 52 Adjusted Mean Change (SE)	-15.46 (0.80)	-15.01 (1.02)	-0.46 [-3.01; 2.10]	0.725
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	14.18 (5.14)	19.06 (12.62)		
Week 52 Mean (SD)	4.67 (6.66)	4.83 (7.24)		
Week 52 Adjusted Mean Change (SE)	-11.78 (1.01)	-13.29 (1.03)	1.51 [-1.36; 4.38]	0.300
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.17 TJC78 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.769</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	18.70 (10.87)	19.84 (12.53)		
Week 52 Mean (SD)	3.83 (4.51)	3.71 (7.10)		
Week 52 Adjusted Mean Change (SE)	-14.29 (1.08)	-13.87 (1.14)	-0.42 [-3.51; 2.67]	0.789
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	15.69 (7.88)	19.14 (12.31)		
Week 52 Mean (SD)	3.18 (5.48)	3.76 (6.81)		
Week 52 Adjusted Mean Change (SE)	-13.87 (0.82)	-14.27 (0.99)	0.40 [-2.15; 2.95]	0.758
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.18 TJC78 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.372</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	16.14 (8.88)	18.77 (12.79)		
Week 52 Mean (SD)	2.82 (4.28)	3.89 (6.14)		
Week 52 Adjusted Mean Change (SE)	-14.70 (0.91)	-13.89 (0.92)	-0.81 [-3.37; 1.75]	0.533
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	17.38 (9.38)	20.71 (11.61)		
Week 52 Mean (SD)	4.00 (5.83)	3.45 (8.23)		
Week 52 Adjusted Mean Change (SE)	-13.43 (0.91)	-14.48 (1.27)	1.06 [-2.03; 4.15]	0.500
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 26.19 TJC78 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.429</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	16.80 (8.57)	19.29 (11.95)		
Week 52 Mean (SD)	3.48 (5.59)	3.58 (6.19)		
Week 52 Adjusted Mean Change (SE)	-13.70 (0.74)	-13.91 (0.88)	0.22 [-2.06; 2.50]	0.850
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	15.06 (7.57)	19.94 (13.64)		
Week 52 Mean (SD)	2.29 (2.08)	4.12 (8.48)		
Week 52 Adjusted Mean Change (SE)	-14.83 (1.41)	-13.99 (1.41)	-0.84 [-4.79; 3.11]	0.676
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 27.1 ACR Response ACR20 / ACR50 / ACR70 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
ACR20 Week 52, N' n (%)	104 88.71 (80.65)	80 81.22 (80.42)	1.06 [0.50; 2.23] 0.881	1.00 [0.87; 1.16] 0.966	0.002 [-0.113; 0.117] 0.969
ACR50 Week 52, N' n (%)	104 63.01 (57.28)	80 56.58 (56.02)	1.10 [0.61; 1.98] 0.757	1.02 [0.80; 1.31] 0.857	0.013 [-0.127; 0.152] 0.859
ACR70 Week 52, N' n (%)	104 35.52 (32.29)	80 31.97 (31.65)	1.05 [0.57; 1.93] 0.873	1.02 [0.68; 1.53] 0.921	0.006 [-0.122; 0.135] 0.923

N': Number of patients with available response value  
N-N' is the number of values with MI.  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
MI: Multiple Imputation  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.  
RR and RD calculated directly without adjustment.

All results are combined over MI:  
n and % are averages of all imputations.  
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

## 27.2 ACR Response ACR20 / ACR50 / ACR70 by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.915				
ACR50 Week 52	p=0.826				
ACR70 Week 52	p=0.625				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
ACR20 Week 52, N' n (%)	98 82.77 (80.36)	74 75.22 (80.02)	1.07 [0.50; 2.31] 0.861	1.00 [0.86; 1.17] 0.953	0.003 [-0.117; 0.124] 0.956
ACR50 Week 52, N' n (%)	98 58.38 (56.68)	74 52.61 (55.97)	1.08 [0.59; 1.99] 0.805	1.01 [0.78; 1.31] 0.921	0.007 [-0.138; 0.152] 0.923
ACR70 Week 52, N' n (%)	98 34.34 (33.34)	74 30.19 (32.12)	1.09 [0.58; 2.03] 0.787	1.04 [0.69; 1.57] 0.856	0.012 [-0.122; 0.146] 0.858
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
ACR20 Week 52, N' n (%)	6 5.94 (84.86)	6 6.00 (85.71)	0.90 [0.04; 18.62] 0.948	0.99 [0.63; 1.54] 0.962	-0.009 [-0.385; 0.368] 0.964
ACR50 Week 52, N' n (%)	6 4.63 (66.14)	6 3.97 (56.71)	1.42 [0.14; 14.71] 0.771	1.16 [0.48; 2.80] 0.739	0.094 [-0.432; 0.621] 0.726
ACR70 Week 52, N' n (%)	6 1.18 (16.86)	6 1.78 (25.43)	0.52 [0.03; 9.49] 0.659	0.66 [0.07; 6.66] 0.724	-0.086 [-0.536; 0.365] 0.709
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 27.3 ACR Response ACR20 / ACR50 / ACR70 by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.986				
ACR50 Week 52	p=0.565				
ACR70 Week 52	p=0.344				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
ACR20 Week 52, N' n (%)	63 54.33 (82.32)	46 47.82 (83.89)	1.03 [0.36; 2.96] 0.956	0.98 [0.83; 1.16] 0.831	-0.016 [-0.158; 0.126] 0.828
ACR50 Week 52, N' n (%)	63 39.31 (59.56)	46 37.23 (65.32)	0.91 [0.41; 2.03] 0.822	0.91 [0.69; 1.21] 0.526	-0.058 [-0.235; 0.120] 0.524
ACR70 Week 52, N' n (%)	63 22.41 (33.95)	46 23.44 (41.12)	0.83 [0.38; 1.80] 0.634	0.83 [0.52; 1.32] 0.424	-0.072 [-0.247; 0.104] 0.423
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
ACR20 Week 52, N' n (%)	41 34.38 (78.14)	34 33.40 (75.91)	1.02 [0.33; 3.09] 0.978	1.03 [0.80; 1.32] 0.816	0.022 [-0.170; 0.214] 0.820
ACR50 Week 52, N' n (%)	41 23.70 (53.86)	34 19.35 (43.98)	1.31 [0.52; 3.28] 0.571	1.23 [0.78; 1.94] 0.378	0.099 [-0.119; 0.317] 0.374
ACR70 Week 52, N' n (%)	41 13.11 (29.80)	34 8.53 (19.39)	1.56 [0.55; 4.44] 0.408	1.54 [0.71; 3.37] 0.277	0.104 [-0.079; 0.287] 0.265
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



## 27.4 ACR Response ACR20 / ACR50 / ACR70 by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.480				
ACR50 Week 52	p=0.249				
ACR70 Week 52	p=0.421				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
ACR20 Week 52, N' n (%)	23 18.50 (77.08)	16 14.81 (70.52)	1.69 [0.38; 7.43] 0.487	1.09 [0.75; 1.60] 0.641	0.066 [-0.210; 0.341] 0.641
ACR50 Week 52, N' n (%)	23 14.25 (59.37)	16 9.87 (47.00)	2.18 [0.59; 8.08] 0.243	1.27 [0.70; 2.30] 0.435	0.124 [-0.180; 0.428] 0.425
ACR70 Week 52, N' n (%)	23 7.07 (29.46)	16 4.80 (22.86)	1.79 [0.42; 7.58] 0.428	1.30 [0.46; 3.70] 0.622	0.066 [-0.197; 0.329] 0.623
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
ACR20 Week 52, N' n (%)	81 70.21 (81.64)	64 66.41 (83.01)	0.91 [0.38; 2.19] 0.838	0.98 [0.85; 1.14] 0.831	-0.014 [-0.138; 0.111] 0.829
ACR50 Week 52, N' n (%)	81 48.76 (56.70)	64 46.71 (58.39)	0.92 [0.47; 1.79] 0.800	0.97 [0.74; 1.28] 0.836	-0.017 [-0.174; 0.140] 0.833
ACR70 Week 52, N' n (%)	81 28.45 (33.08)	64 27.17 (33.96)	0.93 [0.47; 1.83] 0.831	0.97 [0.63; 1.51] 0.908	-0.009 [-0.156; 0.138] 0.906
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 27.5 ACR Response ACR20 / ACR50 / ACR70 by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.332				
ACR50 Week 52	p=0.823				
ACR70 Week 52	p=0.128				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
ACR20 Week 52, N' n (%)	39 33.44 (79.62)	37 42.72 (83.76)	0.69 [0.21; 2.31] 0.552	0.95 [0.77; 1.18] 0.644	-0.041 [-0.215; 0.132] 0.639
ACR50 Week 52, N' n (%)	39 22.91 (54.55)	37 25.04 (49.10)	1.12 [0.46; 2.72] 0.806	1.11 [0.74; 1.68] 0.614	0.054 [-0.159; 0.268] 0.616
ACR70 Week 52, N' n (%)	39 10.20 (24.29)	37 16.57 (32.49)	0.57 [0.22; 1.52] 0.262	0.75 [0.38; 1.48] 0.403	-0.082 [-0.270; 0.105] 0.391
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
ACR20 Week 52, N' n (%)	65 55.27 (81.28)	43 38.50 (77.00)	1.49 [0.57; 3.88] 0.417	1.06 [0.87; 1.29] 0.591	0.043 [-0.112; 0.198] 0.589
ACR50 Week 52, N' n (%)	65 40.10 (58.97)	43 31.54 (63.08)	0.97 [0.44; 2.18] 0.951	0.94 [0.69; 1.26] 0.661	-0.041 [-0.224; 0.142] 0.660
ACR70 Week 52, N' n (%)	65 25.32 (37.24)	43 15.40 (30.80)	1.55 [0.68; 3.53] 0.296	1.21 [0.71; 2.06] 0.481	0.064 [-0.112; 0.240] 0.474
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



## 27.6 ACR Response ACR20 / ACR50 / ACR70 by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.729				
ACR50 Week 52	p=0.110				
ACR70 Week 52	p=0.215				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
ACR20 Week 52, N' n (%)	70 59.88 (83.17)	34 40.32 (82.29)	1.12 [0.38; 3.31] 0.832	1.01 [0.84; 1.21] 0.904	0.009 [-0.142; 0.160] 0.909
ACR50 Week 52, N' n (%)	70 45.30 (62.92)	34 26.10 (53.27)	1.63 [0.72; 3.73] 0.244	1.18 [0.84; 1.66] 0.334	0.097 [-0.095; 0.288] 0.322
ACR70 Week 52, N' n (%)	70 26.41 (36.68)	34 14.79 (30.18)	1.42 [0.62; 3.25] 0.408	1.22 [0.71; 2.10] 0.478	0.065 [-0.111; 0.241] 0.469
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
ACR20 Week 52, N' n (%)	34 28.83 (75.87)	46 40.90 (78.65)	0.86 [0.30; 2.49] 0.786	0.96 [0.76; 1.23] 0.768	-0.028 [-0.212; 0.156] 0.767
ACR50 Week 52, N' n (%)	34 17.71 (46.61)	46 30.48 (58.62)	0.61 [0.25; 1.48] 0.271	0.79 [0.52; 1.21] 0.285	-0.120 [-0.333; 0.093] 0.269
ACR70 Week 52, N' n (%)	34 9.11 (23.97)	46 17.18 (33.04)	0.63 [0.24; 1.68] 0.353	0.73 [0.36; 1.46] 0.370	-0.091 [-0.281; 0.100] 0.352
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 27.7 ACR Response ACR20 / ACR50 / ACR70 by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.574				
ACR50 Week 52	p=0.579				
ACR70 Week 52	p=0.542				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
ACR20 Week 52, N' n (%)	48 40.39 (79.20)	25 26.19 (81.84)	0.80 [0.23; 2.81] 0.734	0.97 [0.77; 1.22] 0.787	-0.026 [-0.214; 0.161] 0.782
ACR50 Week 52, N' n (%)	48 32.67 (64.06)	25 18.22 (56.94)	1.30 [0.49; 3.45] 0.603	1.13 [0.77; 1.65] 0.541	0.071 [-0.154; 0.296] 0.535
ACR70 Week 52, N' n (%)	48 20.13 (39.47)	25 10.69 (33.41)	1.24 [0.46; 3.32] 0.665	1.18 [0.64; 2.20] 0.591	0.061 [-0.157; 0.279] 0.586
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
ACR20 Week 52, N' n (%)	56 48.32 (81.90)	55 55.03 (79.75)	1.26 [0.49; 3.26] 0.636	1.03 [0.86; 1.23] 0.769	0.021 [-0.122; 0.165] 0.770
ACR50 Week 52, N' n (%)	56 30.34 (51.42)	55 38.36 (55.59)	0.92 [0.44; 1.93] 0.823	0.93 [0.66; 1.29] 0.650	-0.042 [-0.220; 0.137] 0.647
ACR70 Week 52, N' n (%)	56 15.39 (26.08)	55 21.28 (30.84)	0.84 [0.37; 1.87] 0.664	0.85 [0.48; 1.49] 0.564	-0.048 [-0.207; 0.112] 0.559
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 27.8 ACR Response ACR20 / ACR50 / ACR70 by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.930				
ACR50 Week 52	p=0.543				
ACR70 Week 52	p=0.995				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
ACR20 Week 52, N' n (%)	48 43.95 (86.18)	34 35.07 (85.54)	1.11 [0.30; 4.04] 0.878	1.01 [0.84; 1.21] 0.933	0.006 [-0.147; 0.159] 0.935
ACR50 Week 52, N' n (%)	48 30.25 (59.31)	34 25.66 (62.59)	0.89 [0.37; 2.16] 0.798	0.95 [0.68; 1.33] 0.756	-0.033 [-0.238; 0.172] 0.755
ACR70 Week 52, N' n (%)	48 15.97 (31.31)	34 14.26 (34.78)	0.86 [0.34; 2.15] 0.743	0.90 [0.50; 1.63] 0.731	-0.035 [-0.231; 0.162] 0.730
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
ACR20 Week 52, N' n (%)	31 25.76 (75.76)	21 19.76 (76.00)	1.02 [0.28; 3.72] 0.975	1.00 [0.74; 1.35] 0.988	-0.002 [-0.232; 0.227] 0.984
ACR50 Week 52, N' n (%)	31 17.76 (52.24)	21 11.50 (44.23)	1.39 [0.46; 4.22] 0.565	1.18 [0.67; 2.10] 0.564	0.080 [-0.189; 0.349] 0.559
ACR70 Week 52, N' n (%)	31 11.55 (33.97)	21 9.39 (36.12)	0.86 [0.27; 2.72] 0.800	0.94 [0.46; 1.94] 0.871	-0.021 [-0.274; 0.231] 0.868
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 27.9 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.300				
ACR50 Week 52	p=0.959				
ACR70 Week 52	p=0.959				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
ACR20 Week 52, N' n (%)	43 39.82 (88.49)	19 21.64 (80.15)	2.15 [0.49; 9.53] 0.313	1.11 [0.87; 1.41] 0.416	0.083 [-0.113; 0.279] 0.404
ACR50 Week 52, N' n (%)	43 26.13 (58.07)	19 15.95 (59.07)	1.05 [0.36; 3.01] 0.931	0.98 [0.64; 1.50] 0.942	-0.010 [-0.258; 0.237] 0.936
ACR70 Week 52, N' n (%)	43 15.37 (34.16)	19 11.47 (42.48)	0.76 [0.26; 2.21] 0.620	0.81 [0.43; 1.51] 0.499	-0.083 [-0.326; 0.160] 0.502
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
ACR20 Week 52, N' n (%)	34 27.89 (73.39)	27 23.22 (77.40)	0.79 [0.24; 2.62] 0.695	0.95 [0.71; 1.26] 0.716	-0.040 [-0.254; 0.174] 0.714
ACR50 Week 52, N' n (%)	34 20.88 (54.95)	27 15.53 (51.77)	1.09 [0.40; 2.98] 0.868	1.06 [0.67; 1.68] 0.799	0.032 [-0.213; 0.276] 0.799
ACR70 Week 52, N' n (%)	34 11.15 (29.34)	27 10.10 (33.67)	0.73 [0.25; 2.15] 0.574	0.87 [0.43; 1.78] 0.704	-0.043 [-0.269; 0.182] 0.707
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 27.10 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.372				
ACR50 Week 52	p=0.422				
ACR70 Week 52	p=0.311				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
ACR20 Week 52, N' n (%)	29 24.88 (82.93)	24 24.63 (74.64)	1.69 [0.44; 6.59] 0.448	1.11 [0.84; 1.47] 0.454	0.083 [-0.133; 0.299] 0.451
ACR50 Week 52, N' n (%)	29 15.46 (51.53)	24 18.70 (56.67)	0.78 [0.27; 2.28] 0.652	0.91 [0.57; 1.47] 0.699	-0.051 [-0.307; 0.205] 0.694
ACR70 Week 52, N' n (%)	29 8.14 (27.13)	24 12.13 (36.76)	0.58 [0.18; 1.83] 0.354	0.74 [0.35; 1.57] 0.434	-0.096 [-0.331; 0.139] 0.422
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
ACR20 Week 52, N' n (%)	48 42.39 (83.12)	31 30.20 (88.82)	0.70 [0.17; 2.81] 0.614	0.94 [0.78; 1.12] 0.468	-0.057 [-0.211; 0.096] 0.466
ACR50 Week 52, N' n (%)	48 30.67 (60.14)	31 18.46 (54.29)	1.40 [0.56; 3.51] 0.476	1.11 [0.75; 1.64] 0.606	0.058 [-0.161; 0.278] 0.602
ACR70 Week 52, N' n (%)	48 19.13 (37.51)	31 11.52 (33.88)	1.26 [0.48; 3.29] 0.634	1.11 [0.61; 2.02] 0.738	0.036 [-0.175; 0.248] 0.736
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



## 27.11 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.867				
ACR50 Week 52	p=0.923				
ACR70 Week 52	p=0.623				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
ACR20 Week 52, N' n (%)	39 33.32 (77.49)	37 33.99 (79.05)	0.88 [0.29; 2.64] 0.822	0.98 [0.78; 1.24] 0.868	-0.016 [-0.196; 0.165] 0.866
ACR50 Week 52, N' n (%)	39 25.33 (58.91)	37 23.82 (55.40)	1.10 [0.44; 2.72] 0.841	1.06 [0.73; 1.55] 0.749	0.035 [-0.181; 0.251] 0.750
ACR70 Week 52, N' n (%)	39 15.29 (35.56)	37 14.32 (33.30)	1.00 [0.39; 2.57] 0.996	1.07 [0.59; 1.95] 0.830	0.023 [-0.183; 0.228] 0.830
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
ACR20 Week 52, N' n (%)	40 36.39 (86.64)	18 20.84 (86.83)	1.06 [0.17; 6.69] 0.952	1.00 [0.80; 1.25] 0.993	-0.002 [-0.195; 0.192] 0.985
ACR50 Week 52, N' n (%)	40 22.68 (54.00)	18 13.34 (55.58)	1.02 [0.35; 3.00] 0.966	0.97 [0.61; 1.56] 0.910	-0.016 [-0.275; 0.243] 0.905
ACR70 Week 52, N' n (%)	40 12.23 (29.12)	18 9.33 (38.87)	0.69 [0.22; 2.12] 0.517	0.75 [0.37; 1.52] 0.427	-0.098 [-0.343; 0.148] 0.436
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 27.12 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.317				
ACR50 Week 52	p=0.185				
ACR70 Week 52	p=0.041				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
ACR20 Week 52, N' n (%)	57 50.83 (81.98)	36 38.14 (81.15)	1.24 [0.41; 3.72] 0.707	1.01 [0.83; 1.23] 0.915	0.008 [-0.150; 0.167] 0.918
ACR50 Week 52, N' n (%)	57 33.55 (54.11)	36 22.83 (48.57)	1.40 [0.62; 3.17] 0.420	1.12 [0.76; 1.65] 0.584	0.055 [-0.142; 0.252] 0.581
ACR70 Week 52, N' n (%)	57 19.38 (31.26)	36 12.62 (26.85)	1.39 [0.57; 3.42] 0.473	1.17 [0.63; 2.17] 0.627	0.044 [-0.133; 0.221] 0.625
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
ACR20 Week 52, N' n (%)	19 16.88 (84.40)	17 16.69 (92.72)	0.33 [0.03; 3.50] 0.355	0.91 [0.72; 1.16] 0.441	-0.083 [-0.291; 0.124] 0.432
ACR50 Week 52, N' n (%)	19 13.46 (67.30)	17 14.33 (79.61)	0.42 [0.09; 2.02] 0.280	0.85 [0.57; 1.25] 0.404	-0.123 [-0.407; 0.161] 0.395
ACR70 Week 52, N' n (%)	19 7.14 (35.70)	17 11.03 (61.28)	0.24 [0.06; 0.99] 0.049	0.58 [0.29; 1.17] 0.130	-0.256 [-0.566; 0.054] 0.106
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 27.13 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.818				
ACR50 Week 52	p=0.612				
ACR70 Week 52	p=0.166				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
ACR20 Week 52, N' n (%)	58 52.26 (82.95)	40 41.60 (81.57)	1.09 [0.38; 3.16] 0.868	1.02 [0.84; 1.23] 0.856	0.014 [-0.138; 0.166] 0.859
ACR50 Week 52, N' n (%)	58 35.00 (55.56)	40 30.09 (59.00)	0.85 [0.38; 1.89] 0.688	0.94 [0.68; 1.31] 0.725	-0.034 [-0.225; 0.156] 0.723
ACR70 Week 52, N' n (%)	58 20.52 (32.57)	40 21.65 (42.45)	0.61 [0.27; 1.39] 0.242	0.77 [0.47; 1.26] 0.292	-0.099 [-0.282; 0.085] 0.292
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
ACR20 Week 52, N' n (%)	18 14.45 (76.05)	12 10.00 (83.33)	0.84 [0.12; 5.95] 0.864	0.91 [0.63; 1.31] 0.620	-0.073 [-0.362; 0.217] 0.622
ACR50 Week 52, N' n (%)	18 10.01 (52.68)	12 6.00 (50.00)	1.32 [0.29; 5.92] 0.717	1.05 [0.52; 2.14] 0.885	0.027 [-0.334; 0.388] 0.884
ACR70 Week 52, N' n (%)	18 6.00 (31.58)	12 2.00 (16.67)	2.58 [0.40; 16.65] 0.320	1.89 [0.45; 7.90] 0.380	0.149 [-0.148; 0.446] 0.325

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) ACR70, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>				

### 27.14 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.698				
ACR50 Week 52	p=0.984				
ACR70 Week 52	p=0.234				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
ACR20 Week 52, N' n (%)	65 56.71 (79.87)	44 42.78 (80.72)	1.03 [0.38; 2.75] 0.955	0.99 [0.82; 1.19] 0.915	-0.008 [-0.158; 0.142] 0.912
ACR50 Week 52, N' n (%)	65 40.01 (56.35)	44 30.00 (56.60)	1.05 [0.49; 2.25] 0.904	1.00 [0.72; 1.38] 0.980	-0.003 [-0.185; 0.180] 0.978
ACR70 Week 52, N' n (%)	65 20.52 (28.90)	44 19.50 (36.79)	0.71 [0.31; 1.59] 0.401	0.79 [0.47; 1.33] 0.367	-0.079 [-0.251; 0.094] 0.370
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
ACR20 Week 52, N' n (%)	13 12.00 (92.31)	8 8.36 (83.60)	1.86 [0.11; 31.28] 0.665	1.11 [0.79; 1.55] 0.561	0.087 [-0.200; 0.374] 0.552
ACR50 Week 52, N' n (%)	13 7.00 (53.85)	8 4.83 (48.30)	1.03 [0.18; 5.93] 0.975	1.12 [0.47; 2.66] 0.790	0.055 [-0.372; 0.483] 0.799
ACR70 Week 52, N' n (%)	13 6.00 (46.15)	8 2.12 (21.20)	2.53 [0.37; 17.44] 0.346	2.20 [0.56; 8.64] 0.259	0.250 [-0.126; 0.625] 0.193
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 27.15 ACR Response ACR20 / ACR50 / ACR70 by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.861				
ACR50 Week 52	p=0.903				
ACR70 Week 52	p=0.793				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
ACR20 Week 52, N' n (%)	19 17.32 (78.73)	18 19.55 (75.19)	1.09 [0.24; 4.84] 0.911	1.05 [0.75; 1.47] 0.784	0.035 [-0.220; 0.291] 0.786
ACR50 Week 52, N' n (%)	19 12.34 (56.09)	18 13.93 (53.58)	0.99 [0.28; 3.48] 0.994	1.05 [0.60; 1.82] 0.869	0.025 [-0.275; 0.325] 0.870
ACR70 Week 52, N' n (%)	19 6.39 (29.05)	18 8.50 (32.69)	0.73 [0.19; 2.83] 0.653	0.89 [0.36; 2.20] 0.803	-0.036 [-0.312; 0.239] 0.795
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
ACR20 Week 52, N' n (%)	60 52.39 (83.16)	37 35.28 (86.05)	0.92 [0.28; 3.02] 0.889	0.97 [0.81; 1.15] 0.701	-0.029 [-0.176; 0.118] 0.700
ACR50 Week 52, N' n (%)	60 35.67 (56.62)	37 23.23 (56.66)	1.09 [0.48; 2.51] 0.834	1.00 [0.70; 1.42] 0.999	-0.000 [-0.199; 0.199] 0.997
ACR70 Week 52, N' n (%)	60 21.13 (33.54)	37 15.15 (36.95)	0.91 [0.39; 2.13] 0.826	0.91 [0.53; 1.55] 0.722	-0.034 [-0.224; 0.156] 0.724
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 27.16 ACR Response ACR20 / ACR50 / ACR70 by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.793				
ACR50 Week 52	p=0.753				
ACR70 Week 52	p=0.918				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
ACR20 Week 52, N' n (%)	49 42.82 (83.96)	26 29.61 (84.60)	1.14 [0.29; 4.45] 0.848	0.99 [0.81; 1.22] 0.947	-0.006 [-0.176; 0.163] 0.941
ACR50 Week 52, N' n (%)	49 29.13 (57.12)	26 21.63 (61.80)	0.93 [0.36; 2.41] 0.884	0.92 [0.64; 1.34] 0.679	-0.047 [-0.267; 0.173] 0.676
ACR70 Week 52, N' n (%)	49 17.37 (34.06)	26 14.55 (41.57)	0.81 [0.31; 2.12] 0.673	0.82 [0.47; 1.45] 0.494	-0.075 [-0.291; 0.141] 0.496
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
ACR20 Week 52, N' n (%)	30 26.89 (79.09)	29 25.22 (78.81)	0.89 [0.25; 3.18] 0.857	1.00 [0.77; 1.30] 0.978	0.003 [-0.203; 0.209] 0.979
ACR50 Week 52, N' n (%)	30 18.88 (55.53)	29 15.53 (48.53)	1.17 [0.42; 3.22] 0.768	1.14 [0.71; 1.85] 0.581	0.070 [-0.176; 0.316] 0.578
ACR70 Week 52, N' n (%)	30 10.15 (29.85)	29 9.10 (28.44)	0.88 [0.29; 2.68] 0.821	1.05 [0.49; 2.25] 0.903	0.014 [-0.208; 0.237] 0.901
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 27.17 ACR Response ACR20 / ACR50 / ACR70 by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.453				
ACR50 Week 52	p=0.446				
ACR70 Week 52	p=0.459				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
ACR20 Week 52, N' n (%)	29 24.88 (82.93)	22 23.63 (76.23)	1.52 [0.38; 6.15] 0.558	1.09 [0.82; 1.44] 0.548	0.067 [-0.152; 0.286] 0.548
ACR50 Week 52, N' n (%)	29 15.46 (51.53)	22 17.70 (57.10)	0.76 [0.26; 2.27] 0.627	0.90 [0.56; 1.46] 0.681	-0.056 [-0.316; 0.205] 0.675
ACR70 Week 52, N' n (%)	29 8.14 (27.13)	22 11.13 (35.90)	0.60 [0.19; 1.94] 0.397	0.76 [0.35; 1.64] 0.480	-0.088 [-0.327; 0.151] 0.472
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
ACR20 Week 52, N' n (%)	50 44.83 (81.51)	33 31.20 (86.67)	0.74 [0.21; 2.60] 0.639	0.94 [0.78; 1.13] 0.521	-0.052 [-0.209; 0.106] 0.521
ACR50 Week 52, N' n (%)	50 32.55 (59.18)	33 19.46 (54.06)	1.32 [0.54; 3.23] 0.539	1.10 [0.75; 1.61] 0.642	0.051 [-0.163; 0.265] 0.639
ACR70 Week 52, N' n (%)	50 19.38 (35.24)	33 12.52 (34.78)	1.06 [0.42; 2.68] 0.899	1.01 [0.56; 1.82] 0.964	0.005 [-0.200; 0.209] 0.965
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



## 27.18 ACR Response ACR20 / ACR50 / ACR70 by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.867				
ACR50 Week 52	p=0.923				
ACR70 Week 52	p=0.623				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
ACR20 Week 52, N' n (%)	39 33.32 (77.49)	37 33.99 (79.05)	0.88 [0.29; 2.64] 0.822	0.98 [0.78; 1.24] 0.868	-0.016 [-0.196; 0.165] 0.866
ACR50 Week 52, N' n (%)	39 25.33 (58.91)	37 23.82 (55.40)	1.10 [0.44; 2.72] 0.841	1.06 [0.73; 1.55] 0.749	0.035 [-0.181; 0.251] 0.750
ACR70 Week 52, N' n (%)	39 15.29 (35.56)	37 14.32 (33.30)	1.00 [0.39; 2.57] 0.996	1.07 [0.59; 1.95] 0.830	0.023 [-0.183; 0.228] 0.830
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
ACR20 Week 52, N' n (%)	40 36.39 (86.64)	18 20.84 (86.83)	1.06 [0.17; 6.69] 0.952	1.00 [0.80; 1.25] 0.993	-0.002 [-0.195; 0.192] 0.985
ACR50 Week 52, N' n (%)	40 22.68 (54.00)	18 13.34 (55.58)	1.02 [0.35; 3.00] 0.966	0.97 [0.61; 1.56] 0.910	-0.016 [-0.275; 0.243] 0.905
ACR70 Week 52, N' n (%)	40 12.23 (29.12)	18 9.33 (38.87)	0.69 [0.22; 2.12] 0.517	0.75 [0.37; 1.52] 0.427	-0.098 [-0.343; 0.148] 0.436
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 27.19 ACR Response ACR20 / ACR50 / ACR70 by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
ACR20 Week 52	p=0.198				
ACR50 Week 52	p=0.116				
ACR70 Week 52	p=0.027				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
ACR20 Week 52, N' n (%)	60 53.83 (82.82)	38 38.14 (77.84)	1.60 [0.56; 4.55] 0.375	1.06 [0.87; 1.30] 0.541	0.050 [-0.109; 0.208] 0.538
ACR50 Week 52, N' n (%)	60 35.55 (54.69)	38 22.83 (46.59)	1.52 [0.69; 3.38] 0.299	1.17 [0.80; 1.73] 0.416	0.081 [-0.111; 0.273] 0.408
ACR70 Week 52, N' n (%)	60 21.38 (32.89)	38 12.62 (25.76)	1.56 [0.65; 3.78] 0.321	1.28 [0.69; 2.36] 0.429	0.071 [-0.101; 0.244] 0.418
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
ACR20 Week 52, N' n (%)	17 14.88 (82.67)	17 16.69 (92.72)	0.29 [0.03; 3.17] 0.312	0.89 [0.69; 1.15] 0.385	-0.101 [-0.321; 0.120] 0.371
ACR50 Week 52, N' n (%)	17 11.46 (63.67)	17 14.33 (79.61)	0.37 [0.07; 1.79] 0.214	0.80 [0.52; 1.23] 0.309	-0.159 [-0.456; 0.137] 0.292
ACR70 Week 52, N' n (%)	17 6.14 (34.11)	17 11.03 (61.28)	0.22 [0.05; 0.98] 0.047	0.56 [0.26; 1.18] 0.124	-0.272 [-0.588; 0.045] 0.093
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 28.0 DAPSA - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	107 (97.3)	98 (97.0)	205 (97.2)
Week 4 Returns	108 (98.2)	97 (96.0)	205 (97.2)
Week 8 Returns	107 (97.3)	96 (95.0)	203 (96.2)
Week 12 Returns	105 (95.5)	98 (97.0)	203 (96.2)
Week 16 Returns	107 (97.3)	91 (90.1)	198 (93.8)
Week 20 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	100 (90.9)	84 (83.2)	184 (87.2)
Week 32 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 36 Returns	100 (90.9)	82 (81.2)	182 (86.3)
Week 40 Returns	104 (94.5)	82 (81.2)	186 (88.2)
Week 44 Returns	102 (92.7)	82 (81.2)	184 (87.2)
Week 48 Returns	99 (90.0)	80 (79.2)	179 (84.8)
Week 52 Returns	104 (94.5)	80 (79.2)	184 (87.2)

## 28.1 DAPSA - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	38.46 (15.40)	41.96 (18.50)		
Week 52 Mean (SD)	10.10 (9.37)	11.18 (10.83)		
Week 52 Adjusted Mean Change (SE)	-29.33 (0.92)	-28.60 (1.01)	-0.73 [-3.44; 1.98]	0.596
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 28.2 DAPSA - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.833</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	37.51 (13.45)	42.25 (18.80)		
Week 52 Mean (SD)	9.99 (9.30)	11.26 (11.11)		
Week 52 Adjusted Mean Change (SE)	-29.26 (0.96)	-28.51 (1.06)	-0.74 [-3.58; 2.09]	0.605
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	52.49 (31.40)	38.08 (14.48)		
Week 52 Mean (SD)	11.90 (11.38)	10.17 (7.07)		
Week 52 Adjusted Mean Change (SE)	-30.40 (3.78)	-29.79 (3.70)	-0.61 [-11.06; 9.84]	0.909
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 28.3 DAPSA - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.887</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	36.61 (14.17)	40.13 (17.39)		
Week 52 Mean (SD)	7.97 (6.00)	8.50 (8.79)		
Week 52 Adjusted Mean Change (SE)	-31.43 (1.16)	-31.14 (1.28)	-0.30 [-3.69; 3.10]	0.863
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	41.24 (16.86)	44.33 (19.80)		
Week 52 Mean (SD)	13.36 (12.34)	14.80 (12.32)		
Week 52 Adjusted Mean Change (SE)	-26.26 (1.42)	-25.08 (1.50)	-1.18 [-5.21; 2.86]	0.565
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.4 DAPSA - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.735</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	29.88 (10.43)	26.84 (10.63)		
Week 52 Mean (SD)	7.70 (6.34)	7.31 (7.20)		
Week 52 Adjusted Mean Change (SE)	-30.56 (2.03)	-29.13 (2.32)	-1.43 [-7.35; 4.49]	0.634
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	40.86 (15.75)	45.93 (18.11)		
Week 52 Mean (SD)	10.78 (10.00)	12.14 (11.40)		
Week 52 Adjusted Mean Change (SE)	-29.00 (1.05)	-28.45 (1.17)	-0.55 [-3.63; 2.53]	0.725
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.5 DAPSA - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.965</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	37.01 (12.77)	45.06 (20.91)		
Week 52 Mean (SD)	10.06 (6.70)	12.22 (12.82)		
Week 52 Adjusted Mean Change (SE)	-29.23 (1.52)	-28.41 (1.49)	-0.82 [-5.04; 3.41]	0.703
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	39.36 (16.84)	38.80 (15.25)		
Week 52 Mean (SD)	10.12 (10.71)	10.27 (8.82)		
Week 52 Adjusted Mean Change (SE)	-29.39 (1.18)	-28.75 (1.42)	-0.64 [-4.28; 3.00]	0.729
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 28.6 DAPSA - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.637</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	37.75 (14.49)	38.21 (17.94)		
Week 52 Mean (SD)	9.24 (7.96)	9.29 (8.29)		
Week 52 Adjusted Mean Change (SE)	-30.23 (1.14)	-28.86 (1.50)	-1.37 [-5.06; 2.32]	0.465
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	39.81 (17.10)	45.49 (18.50)		
Week 52 Mean (SD)	11.87 (11.70)	12.57 (12.28)		
Week 52 Adjusted Mean Change (SE)	-27.55 (1.59)	-28.11 (1.40)	0.56 [-3.61; 4.74]	0.791
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.7 DAPSA - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.342</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	35.32 (12.19)	32.00 (12.37)		
Week 52 Mean (SD)	8.54 (8.22)	8.22 (7.89)		
Week 52 Adjusted Mean Change (SE)	-29.87 (1.37)	-29.86 (1.83)	-0.01 [-4.46; 4.44]	0.997
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	41.17 (17.35)	46.57 (19.12)		
Week 52 Mean (SD)	11.43 (10.14)	12.52 (11.74)		
Week 52 Adjusted Mean Change (SE)	-28.88 (1.26)	-27.97 (1.26)	-0.92 [-4.42; 2.59]	0.606
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.8 DAPSA - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.845</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	37.73 (12.02)	41.86 (18.29)		
Week 52 Mean (SD)	10.58 (10.03)	9.69 (9.46)		
Week 52 Adjusted Mean Change (SE)	-27.86 (1.41)	-29.25 (1.63)	1.39 [-2.88; 5.66]	0.522
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	36.87 (14.96)	40.95 (18.65)		
Week 52 Mean (SD)	10.17 (9.65)	12.37 (13.13)		
Week 52 Adjusted Mean Change (SE)	-28.47 (1.75)	-26.82 (2.07)	-1.64 [-7.02; 3.73]	0.547
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.9 DAPSA - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.267</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	40.54 (15.54)	42.25 (16.48)		
Week 52 Mean (SD)	9.22 (7.45)	10.21 (10.90)		
Week 52 Adjusted Mean Change (SE)	-30.38 (1.54)	-28.70 (2.16)	-1.68 [-6.92; 3.56]	0.527
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	33.87 (8.80)	41.37 (18.56)		
Week 52 Mean (SD)	11.87 (12.22)	11.99 (12.37)		
Week 52 Adjusted Mean Change (SE)	-25.56 (1.73)	-27.82 (1.92)	2.26 [-2.89; 7.41]	0.388
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.10 DAPSA - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.680</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	40.29 (13.18)	42.01 (18.17)		
Week 52 Mean (SD)	11.58 (8.41)	11.04 (10.40)		
Week 52 Adjusted Mean Change (SE)	-28.10 (1.87)	-27.84 (1.92)	-0.26 [-5.55; 5.03]	0.924
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	36.61 (12.63)	41.02 (18.67)		
Week 52 Mean (SD)	9.97 (10.74)	10.46 (11.56)		
Week 52 Adjusted Mean Change (SE)	-28.38 (1.45)	-29.20 (1.77)	0.82 [-3.72; 5.36]	0.722
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.11 DAPSA - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.293</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	35.95 (12.73)	39.25 (18.13)		
Week 52 Mean (SD)	9.20 (7.98)	11.47 (10.79)		
Week 52 Adjusted Mean Change (SE)	-29.14 (1.56)	-27.36 (1.56)	-1.79 [-6.15; 2.58]	0.420
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	38.85 (13.65)	45.54 (18.25)		
Week 52 Mean (SD)	11.60 (11.31)	9.16 (11.47)		
Week 52 Adjusted Mean Change (SE)	-27.03 (1.55)	-30.26 (2.22)	3.23 [-2.13; 8.60]	0.236
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.12 DAPSA - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.100</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	37.25 (12.48)	40.93 (17.53)		
Week 52 Mean (SD)	10.84 (10.61)	10.78 (9.18)		
Week 52 Adjusted Mean Change (SE)	-27.54 (1.21)	-27.59 (1.45)	0.05 [-3.70; 3.79]	0.981
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	36.93 (15.82)	40.61 (18.70)		
Week 52 Mean (SD)	8.51 (7.02)	7.28 (7.08)		
Week 52 Adjusted Mean Change (SE)	-29.32 (2.12)	-31.65 (2.22)	2.33 [-3.75; 8.40]	0.450
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 28.13 DAPSA - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.102</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	38.56 (14.09)	40.13 (15.81)		
Week 52 Mean (SD)	10.69 (10.49)	8.48 (6.83)		
Week 52 Adjusted Mean Change (SE)	-28.82 (1.28)	-30.21 (1.48)	1.39 [-2.47; 5.25]	0.477
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	33.76 (10.16)	52.59 (25.14)		
Week 52 Mean (SD)	10.02 (8.29)	18.97 (18.04)		
Week 52 Adjusted Mean Change (SE)	-26.65 (2.32)	-22.64 (2.97)	-4.01 [-11.59; 3.57]	0.298
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 28.14 DAPSA - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.921</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	37.10 (13.34)	42.74 (18.89)		
Week 52 Mean (SD)	10.87 (10.42)	11.05 (11.92)		
Week 52 Adjusted Mean Change (SE)	-27.72 (1.23)	-28.44 (1.47)	0.72 [-3.10; 4.54]	0.710
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	39.16 (13.27)	38.68 (16.74)		
Week 52 Mean (SD)	8.82 (6.10)	9.45 (6.73)		
Week 52 Adjusted Mean Change (SE)	-30.09 (2.81)	-28.47 (3.31)	-1.62 [-10.20; 6.96]	0.709
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.15 DAPSA - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.587</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	37.95 (12.26)	39.73 (14.50)		
Week 52 Mean (SD)	10.33 (9.31)	10.97 (6.28)		
Week 52 Adjusted Mean Change (SE)	-28.36 (2.22)	-27.46 (2.16)	-0.90 [-7.01; 5.22]	0.772
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	37.19 (13.60)	42.63 (20.43)		
Week 52 Mean (SD)	10.44 (10.05)	10.59 (12.72)		
Week 52 Adjusted Mean Change (SE)	-27.97 (1.28)	-28.83 (1.62)	0.87 [-3.24; 4.97]	0.677
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.16 DAPSA - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.558</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	39.44 (15.26)	41.69 (16.60)		
Week 52 Mean (SD)	9.41 (7.48)	8.96 (9.67)		
Week 52 Adjusted Mean Change (SE)	-29.97 (1.39)	-29.24 (1.78)	-0.73 [-5.21; 3.74]	0.746
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	34.30 (8.61)	41.30 (20.25)		
Week 52 Mean (SD)	12.06 (12.74)	12.29 (11.96)		
Week 52 Adjusted Mean Change (SE)	-25.08 (1.75)	-27.50 (1.78)	2.43 [-2.54; 7.39]	0.336
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.17 DAPSA - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.749</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	40.29 (13.18)	42.17 (18.74)		
Week 52 Mean (SD)	11.58 (8.41)	11.31 (10.82)		
Week 52 Adjusted Mean Change (SE)	-27.87 (1.85)	-27.36 (1.98)	-0.50 [-5.84; 4.83]	0.853
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	35.80 (13.05)	40.93 (18.14)		
Week 52 Mean (SD)	9.74 (10.58)	10.32 (11.21)		
Week 52 Adjusted Mean Change (SE)	-28.14 (1.40)	-29.07 (1.70)	0.93 [-3.44; 5.31]	0.673
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.18 DAPSA - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.293</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	35.95 (12.73)	39.25 (18.13)		
Week 52 Mean (SD)	9.20 (7.98)	11.47 (10.79)		
Week 52 Adjusted Mean Change (SE)	-29.14 (1.56)	-27.36 (1.56)	-1.79 [-6.15; 2.58]	0.420
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	38.85 (13.65)	45.54 (18.25)		
Week 52 Mean (SD)	11.60 (11.31)	9.16 (11.47)		
Week 52 Adjusted Mean Change (SE)	-27.03 (1.55)	-30.26 (2.22)	3.23 [-2.13; 8.60]	0.236
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 28.19 DAPSA - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.138</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	37.48 (12.44)	40.48 (17.43)		
Week 52 Mean (SD)	10.60 (10.44)	11.20 (9.12)		
Week 52 Adjusted Mean Change (SE)	-27.75 (1.25)	-27.37 (1.50)	-0.38 [-4.26; 3.49]	0.845
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	35.23 (13.23)	44.29 (20.75)		
Week 52 Mean (SD)	8.29 (6.55)	9.64 (14.56)		
Week 52 Adjusted Mean Change (SE)	-29.20 (2.38)	-30.42 (2.39)	1.22 [-5.49; 7.94]	0.719
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 29.1 DAPSA Low Disease Activity / Remission (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
DAPSA Low Disease Activity Week 52, N' n (%)	104 84.51 (76.83)	80 70.86 (70.16)	1.47 [0.76; 2.84] 0.248	1.10 [0.92; 1.30] 0.301	0.067 [-0.059; 0.192] 0.297
DAPSA Remission Week 52, N' n (%)	104 29.00 (26.36)	80 28.92 (28.63)	0.90 [0.48; 1.69] 0.754	0.92 [0.59; 1.44] 0.721	-0.023 [-0.146; 0.101] 0.719
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>OR from logistic regression model with predictors treatment and weight. RR and RD calculated directly without adjustment.</p> <p>All results are combined over MI: n and % are averages of all imputations. Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.2 DAPSA Low Disease Activity / Remission by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.973				
DAPSA Remission Week 52	p=0.475				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	98 79.08 (76.78)	74 65.88 (70.09)	1.48 [0.75; 2.92] 0.257	1.10 [0.92; 1.31] 0.317	0.067 [-0.063; 0.197] 0.313
DAPSA Remission Week 52, N' n (%)	98 27.97 (27.16)	74 26.71 (28.41)	0.96 [0.50; 1.83] 0.899	0.96 [0.60; 1.52] 0.850	-0.013 [-0.141; 0.116] 0.848
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	6 5.43 (77.57)	6 4.98 (71.14)	1.41 [0.10; 20.23] 0.799	1.09 [0.57; 2.09] 0.804	0.064 [-0.413; 0.542] 0.792
DAPSA Remission Week 52, N' n (%)	6 1.03 (14.71)	6 2.21 (31.57)	0.34 [0.02; 5.30] 0.444	0.47 [0.05; 4.05] 0.491	-0.169 [-0.618; 0.281] 0.462
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 29.3 DAPSA Low Disease Activity / Remission by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.528				
DAPSA Remission Week 52	p=0.244				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	63 53.06 (80.39)	46 46.03 (80.75)	1.14 [0.42; 3.09] 0.799	1.00 [0.83; 1.20] 0.965	-0.004 [-0.154; 0.146] 0.962
DAPSA Remission Week 52, N' n (%)	63 20.14 (30.52)	46 23.64 (41.47)	0.68 [0.31; 1.49] 0.337	0.74 [0.45; 1.20] 0.218	-0.110 [-0.283; 0.064] 0.216
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	41 31.45 (71.48)	34 24.83 (56.43)	1.77 [0.69; 4.55] 0.232	1.27 [0.91; 1.77] 0.165	0.150 [-0.056; 0.357] 0.153
DAPSA Remission Week 52, N' n (%)	41 8.86 (20.14)	34 5.28 (12.00)	1.66 [0.47; 5.90] 0.433	1.69 [0.58; 4.91] 0.332	0.081 [-0.079; 0.242] 0.319
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.4 DAPSA Low Disease Activity / Remission by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.474				
DAPSA Remission Week 52	p=0.607				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	23 20.77 (86.54)	16 15.87 (75.57)	2.52 [0.49; 12.92] 0.268	1.15 [0.85; 1.55] 0.378	0.110 [-0.128; 0.347] 0.365
DAPSA Remission Week 52, N' n (%)	23 8.15 (33.96)	16 9.76 (46.48)	0.67 [0.19; 2.44] 0.548	0.73 [0.34; 1.56] 0.421	-0.125 [-0.425; 0.175] 0.413
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	81 63.74 (74.12)	64 54.99 (68.74)	1.31 [0.64; 2.70] 0.461	1.08 [0.88; 1.32] 0.469	0.054 [-0.091; 0.199] 0.467
DAPSA Remission Week 52, N' n (%)	81 20.85 (24.24)	64 19.16 (23.95)	1.00 [0.48; 2.08] 0.993	1.01 [0.58; 1.76] 0.964	0.003 [-0.130; 0.136] 0.965
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.5 DAPSA Low Disease Activity / Remission by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.350				
DAPSA Remission Week 52	p=0.106				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	39 33.36 (79.43)	37 32.91 (64.53)	2.03 [0.74; 5.55] 0.167	1.23 [0.94; 1.62] 0.133	0.149 [-0.041; 0.339] 0.124
DAPSA Remission Week 52, N' n (%)	39 7.87 (18.74)	37 15.78 (30.94)	0.46 [0.16; 1.30] 0.145	0.61 [0.28; 1.32] 0.209	-0.122 [-0.303; 0.059] 0.186
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	65 51.15 (75.22)	43 37.95 (75.90)	1.07 [0.43; 2.64] 0.891	0.99 [0.80; 1.23] 0.937	-0.007 [-0.170; 0.157] 0.935
DAPSA Remission Week 52, N' n (%)	65 21.13 (31.07)	43 13.14 (26.28)	1.41 [0.60; 3.27] 0.428	1.18 [0.65; 2.15] 0.579	0.048 [-0.119; 0.215] 0.575
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.6 DAPSA Low Disease Activity / Remission by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.923				
DAPSA Remission Week 52	p=0.687				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	70 56.04 (77.83)	34 35.77 (73.00)	1.37 [0.54; 3.47] 0.504	1.07 [0.85; 1.34] 0.578	0.048 [-0.122; 0.218] 0.577
DAPSA Remission Week 52, N' n (%)	70 21.14 (29.36)	34 15.21 (31.04)	0.95 [0.42; 2.17] 0.906	0.95 [0.54; 1.67] 0.853	-0.017 [-0.189; 0.155] 0.848
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	34 28.47 (74.92)	46 35.09 (67.48)	1.47 [0.55; 3.88] 0.441	1.11 [0.85; 1.46] 0.450	0.074 [-0.119; 0.267] 0.450
DAPSA Remission Week 52, N' n (%)	34 7.86 (20.68)	46 13.71 (26.37)	0.72 [0.26; 2.05] 0.543	0.78 [0.35; 1.74] 0.549	-0.057 [-0.239; 0.125] 0.540
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.7 DAPSA Low Disease Activity / Remission by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.678				
DAPSA Remission Week 52	p=0.387				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	48 43.61 (85.51)	25 24.86 (77.69)	1.66 [0.49; 5.69] 0.419	1.10 [0.87; 1.39] 0.416	0.078 [-0.107; 0.263] 0.407
DAPSA Remission Week 52, N' n (%)	48 14.72 (28.86)	25 12.45 (38.91)	0.60 [0.22; 1.62] 0.317	0.74 [0.39; 1.40] 0.359	-0.100 [-0.319; 0.118] 0.367
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	56 40.90 (69.32)	55 46.00 (66.67)	1.22 [0.55; 2.70] 0.627	1.04 [0.81; 1.33] 0.757	0.027 [-0.143; 0.196] 0.758
DAPSA Remission Week 52, N' n (%)	56 14.28 (24.20)	55 16.47 (23.87)	1.07 [0.46; 2.48] 0.872	1.02 [0.54; 1.91] 0.963	0.003 [-0.148; 0.155] 0.966
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.8 DAPSA Low Disease Activity / Remission by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.335				
DAPSA Remission Week 52	p=0.694				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	48 37.77 (74.06)	34 31.09 (75.83)	0.92 [0.34; 2.50] 0.877	0.98 [0.76; 1.25] 0.853	-0.018 [-0.202; 0.167] 0.851
DAPSA Remission Week 52, N' n (%)	48 12.76 (25.02)	34 13.83 (33.73)	0.65 [0.25; 1.68] 0.375	0.74 [0.39; 1.43] 0.371	-0.087 [-0.278; 0.104] 0.372
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	31 26.74 (78.65)	21 16.94 (65.15)	2.02 [0.59; 6.92] 0.263	1.21 [0.85; 1.71] 0.291	0.135 [-0.107; 0.376] 0.273
DAPSA Remission Week 52, N' n (%)	31 8.24 (24.24)	21 6.65 (25.58)	0.89 [0.26; 3.12] 0.861	0.95 [0.38; 2.39] 0.915	-0.013 [-0.243; 0.216] 0.909
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.9 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.769				
DAPSA Remission Week 52	p=0.729				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	43 36.31 (80.69)	19 19.86 (73.56)	1.59 [0.47; 5.37] 0.456	1.10 [0.83; 1.46] 0.521	0.071 [-0.143; 0.286] 0.515
DAPSA Remission Week 52, N' n (%)	43 12.21 (27.13)	19 9.07 (33.59)	0.80 [0.26; 2.40] 0.688	0.81 [0.39; 1.71] 0.580	-0.065 [-0.294; 0.165] 0.581
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	34 27.20 (71.58)	27 20.00 (66.67)	1.24 [0.42; 3.67] 0.694	1.07 [0.77; 1.50] 0.676	0.049 [-0.180; 0.278] 0.675
DAPSA Remission Week 52, N' n (%)	34 7.79 (20.50)	27 8.41 (28.03)	0.60 [0.18; 1.95] 0.393	0.73 [0.30; 1.76] 0.483	-0.075 [-0.287; 0.136] 0.485
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.10 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.614				
DAPSA Remission Week 52	p=0.643				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	29 19.70 (65.67)	24 21.95 (66.52)	0.95 [0.32; 2.87] 0.933	0.99 [0.68; 1.43] 0.949	-0.008 [-0.252; 0.235] 0.946
DAPSA Remission Week 52, N' n (%)	29 5.10 (17.00)	24 8.62 (26.12)	0.54 [0.15; 1.96] 0.349	0.65 [0.24; 1.78] 0.403	-0.091 [-0.299; 0.116] 0.389
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	48 41.61 (81.59)	31 26.08 (76.71)	1.42 [0.48; 4.26] 0.528	1.06 [0.84; 1.34] 0.600	0.049 [-0.132; 0.230] 0.597
DAPSA Remission Week 52, N' n (%)	48 14.72 (28.86)	31 11.86 (34.88)	0.79 [0.30; 2.08] 0.633	0.83 [0.44; 1.58] 0.565	-0.060 [-0.267; 0.147] 0.569
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 29.11 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.160				
DAPSA Remission Week 52	p=0.279				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	39 34.88 (81.12)	37 28.88 (67.16)	2.08 [0.73; 5.93] 0.168	1.21 [0.93; 1.57] 0.161	0.140 [-0.050; 0.329] 0.150
DAPSA Remission Week 52, N' n (%)	39 12.89 (29.98)	37 11.87 (27.60)	1.04 [0.39; 2.77] 0.935	1.09 [0.55; 2.15] 0.812	0.024 [-0.172; 0.220] 0.812
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	40 29.63 (70.55)	18 19.15 (79.79)	0.63 [0.17; 2.31] 0.482	0.88 [0.66; 1.19] 0.421	-0.092 [-0.317; 0.132] 0.420
DAPSA Remission Week 52, N' n (%)	40 8.11 (19.31)	18 8.61 (35.88)	0.45 [0.14; 1.45] 0.180	0.54 [0.23; 1.24] 0.147	-0.166 [-0.398; 0.067] 0.162
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.12 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.584				
DAPSA Remission Week 52	p=0.178				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	57 46.81 (75.50)	36 33.50 (71.28)	1.33 [0.53; 3.32] 0.539	1.06 [0.83; 1.35] 0.638	0.042 [-0.133; 0.218] 0.637
DAPSA Remission Week 52, N' n (%)	57 14.90 (24.03)	36 11.41 (24.28)	1.07 [0.42; 2.71] 0.889	0.99 [0.50; 1.99] 0.982	-0.002 [-0.170; 0.165] 0.977
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	19 15.70 (78.50)	17 14.53 (80.72)	0.78 [0.15; 4.13] 0.770	0.97 [0.70; 1.36] 0.871	-0.022 [-0.287; 0.242] 0.869
DAPSA Remission Week 52, N' n (%)	19 6.10 (30.50)	17 9.07 (50.39)	0.34 [0.08; 1.36] 0.126	0.60 [0.27; 1.36] 0.225	-0.199 [-0.508; 0.110] 0.207
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 29.13 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.183				
DAPSA Remission Week 52	p=0.126				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	58 47.49 (75.38)	40 38.65 (75.78)	0.97 [0.39; 2.42] 0.952	0.99 [0.80; 1.24] 0.963	-0.004 [-0.170; 0.162] 0.962
DAPSA Remission Week 52, N' n (%)	58 14.00 (22.22)	40 17.44 (34.20)	0.52 [0.22; 1.25] 0.147	0.65 [0.35; 1.20] 0.170	-0.120 [-0.290; 0.051] 0.169
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	18 14.02 (73.79)	12 6.00 (50.00)	3.34 [0.69; 16.14] 0.133	1.48 [0.79; 2.76] 0.223	0.238 [-0.108; 0.583] 0.177
DAPSA Remission Week 52, N' n (%)	18 6.00 (31.58)	12 2.00 (16.67)	2.57 [0.41; 16.20] 0.314	1.89 [0.45; 7.90] 0.380	0.149 [-0.148; 0.446] 0.325
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) DAPSA Remission, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

### 29.14 DAPSA Low Disease Activity / Remission by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.911				
DAPSA Remission Week 52	p=0.471				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	65 53.51 (75.37)	44 37.36 (70.49)	1.34 [0.58; 3.12] 0.498	1.07 [0.85; 1.34] 0.564	0.049 [-0.116; 0.213] 0.561
DAPSA Remission Week 52, N' n (%)	65 16.00 (22.54)	44 18.12 (34.19)	0.56 [0.25; 1.30] 0.178	0.66 [0.37; 1.18] 0.162	-0.117 [-0.281; 0.048] 0.165
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	13 10.00 (76.92)	8 7.14 (71.40)	1.19 [0.17; 8.32] 0.864	1.08 [0.65; 1.79] 0.768	0.055 [-0.314; 0.425] 0.770
DAPSA Remission Week 52, N' n (%)	13 4.00 (30.77)	8 2.29 (22.90)	1.24 [0.17; 9.05] 0.829	1.37 [0.32; 5.92] 0.675	0.079 [-0.293; 0.450] 0.678
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.15 DAPSA Low Disease Activity / Remission by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.836				
DAPSA Remission Week 52	p=0.399				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	19 15.90 (72.27)	18 17.98 (69.15)	1.10 [0.28; 4.25] 0.891	1.05 [0.71; 1.55] 0.825	0.031 [-0.244; 0.307] 0.824
DAPSA Remission Week 52, N' n (%)	19 5.28 (24.00)	18 5.08 (19.54)	1.20 [0.27; 5.30] 0.808	1.24 [0.39; 3.90] 0.714	0.045 [-0.202; 0.291] 0.722
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	60 48.61 (77.16)	37 30.05 (73.29)	1.31 [0.51; 3.39] 0.578	1.05 [0.83; 1.33] 0.669	0.039 [-0.138; 0.215] 0.668
DAPSA Remission Week 52, N' n (%)	60 15.72 (24.95)	37 15.40 (37.56)	0.57 [0.24; 1.38] 0.211	0.66 [0.37; 1.20] 0.176	-0.126 [-0.312; 0.060] 0.183
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.16 DAPSA Low Disease Activity / Remission by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.987				
DAPSA Remission Week 52	p=0.986				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	49 40.31 (79.04)	26 27.03 (77.23)	1.22 [0.39; 3.74] 0.733	1.02 [0.80; 1.30] 0.848	0.018 [-0.170; 0.206] 0.850
DAPSA Remission Week 52, N' n (%)	49 14.21 (27.86)	26 13.07 (37.34)	0.71 [0.27; 1.87] 0.490	0.75 [0.40; 1.41] 0.367	-0.095 [-0.303; 0.113] 0.372
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	30 24.20 (71.18)	29 21.00 (65.63)	1.20 [0.40; 3.57] 0.743	1.08 [0.77; 1.53] 0.641	0.056 [-0.176; 0.287] 0.639
DAPSA Remission Week 52, N' n (%)	30 6.79 (19.97)	29 7.41 (23.16)	0.70 [0.20; 2.43] 0.575	0.86 [0.33; 2.24] 0.760	-0.032 [-0.237; 0.173] 0.760
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.17 DAPSA Low Disease Activity / Remission by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.788				
DAPSA Remission Week 52	p=0.506				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	29 19.70 (65.67)	22 19.95 (64.35)	1.05 [0.34; 3.18] 0.935	1.02 [0.69; 1.50] 0.915	0.013 [-0.237; 0.263] 0.918
DAPSA Remission Week 52, N' n (%)	29 5.10 (17.00)	22 8.62 (27.81)	0.49 [0.13; 1.81] 0.286	0.61 [0.23; 1.66] 0.336	-0.108 [-0.322; 0.106] 0.322
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	50 44.81 (81.47)	33 28.08 (78.00)	1.30 [0.44; 3.84] 0.640	1.04 [0.84; 1.30] 0.700	0.035 [-0.140; 0.210] 0.697
DAPSA Remission Week 52, N' n (%)	50 15.90 (28.91)	33 11.86 (32.94)	0.85 [0.33; 2.18] 0.735	0.88 [0.46; 1.66] 0.689	-0.040 [-0.239; 0.158] 0.690
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 29.18 DAPSA Low Disease Activity / Remission by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.160				
DAPSA Remission Week 52	p=0.279				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	39 34.88 (81.12)	37 28.88 (67.16)	2.08 [0.73; 5.93] 0.168	1.21 [0.93; 1.57] 0.161	0.140 [-0.050; 0.329] 0.150
DAPSA Remission Week 52, N' n (%)	39 12.89 (29.98)	37 11.87 (27.60)	1.04 [0.39; 2.77] 0.935	1.09 [0.55; 2.15] 0.812	0.024 [-0.172; 0.220] 0.812
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	40 29.63 (70.55)	18 19.15 (79.79)	0.63 [0.17; 2.31] 0.482	0.88 [0.66; 1.19] 0.421	-0.092 [-0.317; 0.132] 0.420
DAPSA Remission Week 52, N' n (%)	40 8.11 (19.31)	18 8.61 (35.88)	0.45 [0.14; 1.45] 0.180	0.54 [0.23; 1.24] 0.147	-0.166 [-0.398; 0.067] 0.162
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



## 29.19 DAPSA Low Disease Activity / Remission by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DAPSA Low Disease Activity Week 52	p=0.591				
DAPSA Remission Week 52	p=0.130				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	60 49.81 (76.63)	38 33.50 (68.37)	1.64 [0.68; 3.99] 0.273	1.12 [0.88; 1.43] 0.357	0.083 [-0.090; 0.256] 0.349
DAPSA Remission Week 52, N' n (%)	60 15.90 (24.46)	38 11.41 (23.29)	1.14 [0.46; 2.85] 0.779	1.05 [0.53; 2.09] 0.883	0.012 [-0.151; 0.174] 0.887
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
DAPSA Low Disease Activity Week 52, N' n (%)	17 14.70 (81.67)	17 14.53 (80.72)	0.95 [0.16; 5.57] 0.957	1.01 [0.73; 1.40] 0.944	0.009 [-0.255; 0.274] 0.944
DAPSA Remission Week 52, N' n (%)	17 5.10 (28.33)	17 9.07 (50.39)	0.30 [0.07; 1.29] 0.106	0.56 [0.23; 1.35] 0.197	-0.221 [-0.534; 0.093] 0.168
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 30.0 DAS28 - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	108 (98.2)	100 (99.0)	208 (98.6)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	105 (95.5)	98 (97.0)	203 (96.2)
Week 16 Returns	108 (98.2)	93 (92.1)	201 (95.3)
Week 20 Returns	106 (96.4)	90 (89.1)	196 (92.9)
Week 24 Returns	106 (96.4)	91 (90.1)	197 (93.4)
Week 28 Returns	100 (90.9)	84 (83.2)	184 (87.2)
Week 32 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 36 Returns	100 (90.9)	83 (82.2)	183 (86.7)
Week 40 Returns	104 (94.5)	83 (82.2)	187 (88.6)
Week 44 Returns	102 (92.7)	82 (81.2)	184 (87.2)
Week 48 Returns	100 (90.9)	81 (80.2)	181 (85.8)
Week 52 Returns	104 (94.5)	80 (79.2)	184 (87.2)

### 30.1 DAS28 - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	4.69 (0.88)	4.75 (1.02)		
Week 52 Mean (SD)	2.41 (0.97)	2.52 (0.99)		
Week 52 Adjusted Mean Change (SE)	-2.28 (0.09)	-2.18 (0.10)	-0.10 [-0.35; 0.16]	0.456
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

### 30.2 DAS28 - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.955</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	4.66 (0.85)	4.76 (1.02)		
Week 52 Mean (SD)	2.40 (0.96)	2.54 (1.01)		
Week 52 Adjusted Mean Change (SE)	-2.28 (0.09)	-2.16 (0.10)	-0.12 [-0.39; 0.15]	0.380
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	5.12 (1.24)	4.58 (1.08)		
Week 52 Mean (SD)	2.55 (1.14)	2.37 (0.88)		
Week 52 Adjusted Mean Change (SE)	-2.21 (0.36)	-2.38 (0.35)	0.16 [-0.83; 1.16]	0.743
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.3 DAS28 - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.364</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	4.58 (0.87)	4.65 (1.02)		
Week 52 Mean (SD)	2.20 (0.73)	2.20 (0.88)		
Week 52 Adjusted Mean Change (SE)	-2.47 (0.11)	-2.50 (0.12)	0.03 [-0.29; 0.35]	0.849
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	4.86 (0.89)	4.87 (1.03)		
Week 52 Mean (SD)	2.74 (1.18)	2.97 (0.98)		
Week 52 Adjusted Mean Change (SE)	-1.99 (0.13)	-1.75 (0.14)	-0.24 [-0.62; 0.13]	0.204
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.4 DAS28 - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.631</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	4.12 (0.52)	3.60 (0.96)		
Week 52 Mean (SD)	2.08 (0.75)	2.20 (0.93)		
Week 52 Adjusted Mean Change (SE)	-2.38 (0.19)	-2.01 (0.23)	-0.38 [-0.94; 0.19]	0.191
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	4.85 (0.90)	5.05 (0.81)		
Week 52 Mean (SD)	2.51 (1.00)	2.61 (1.00)		
Week 52 Adjusted Mean Change (SE)	-2.24 (0.10)	-2.22 (0.11)	-0.02 [-0.31; 0.27]	0.882
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.5 DAS28 - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.974</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	4.55 (0.76)	4.86 (1.03)		
Week 52 Mean (SD)	2.46 (0.82)	2.64 (1.03)		
Week 52 Adjusted Mean Change (SE)	-2.18 (0.14)	-2.14 (0.14)	-0.04 [-0.43; 0.36]	0.854
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	4.77 (0.95)	4.63 (1.01)		
Week 52 Mean (SD)	2.39 (1.05)	2.42 (0.96)		
Week 52 Adjusted Mean Change (SE)	-2.33 (0.11)	-2.22 (0.13)	-0.12 [-0.46; 0.23]	0.510
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.6 DAS28 - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.501</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	4.66 (0.88)	4.44 (1.21)		
Week 52 Mean (SD)	2.33 (0.90)	2.40 (0.96)		
Week 52 Adjusted Mean Change (SE)	-2.35 (0.11)	-2.10 (0.14)	-0.25 [-0.60; 0.10]	0.165
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	4.73 (0.90)	5.03 (0.71)		
Week 52 Mean (SD)	2.58 (1.08)	2.62 (1.02)		
Week 52 Adjusted Mean Change (SE)	-2.12 (0.15)	-2.22 (0.13)	0.10 [-0.30; 0.49]	0.637
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 30.7 DAS28 - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.922</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	4.47 (0.80)	4.15 (1.11)		
Week 52 Mean (SD)	2.25 (0.92)	2.31 (1.02)		
Week 52 Adjusted Mean Change (SE)	-2.33 (0.13)	-2.21 (0.18)	-0.12 [-0.54; 0.31]	0.588
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	4.87 (0.91)	5.02 (0.86)		
Week 52 Mean (SD)	2.56 (0.99)	2.62 (0.98)		
Week 52 Adjusted Mean Change (SE)	-2.23 (0.12)	-2.16 (0.12)	-0.07 [-0.40; 0.27]	0.698
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.8 DAS28 - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.754</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	4.65 (0.83)	4.73 (0.81)		
Week 52 Mean (SD)	2.44 (1.01)	2.43 (0.79)		
Week 52 Adjusted Mean Change (SE)	-2.19 (0.13)	-2.27 (0.15)	0.07 [-0.32; 0.47]	0.706
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	4.64 (0.92)	4.62 (1.17)		
Week 52 Mean (SD)	2.50 (1.01)	2.54 (1.14)		
Week 52 Adjusted Mean Change (SE)	-2.15 (0.16)	-2.08 (0.19)	-0.07 [-0.56; 0.42]	0.779
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.9 DAS28 - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.406</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	4.79 (0.89)	4.76 (0.80)		
Week 52 Mean (SD)	2.35 (0.83)	2.35 (0.77)		
Week 52 Adjusted Mean Change (SE)	-2.40 (0.14)	-2.35 (0.19)	-0.04 [-0.51; 0.42]	0.850
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	4.48 (0.82)	4.68 (0.95)		
Week 52 Mean (SD)	2.62 (1.17)	2.62 (1.06)		
Week 52 Adjusted Mean Change (SE)	-1.92 (0.15)	-2.11 (0.17)	0.18 [-0.27; 0.64]	0.432
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.10 DAS28 - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.241</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	4.78 (0.92)	4.70 (1.01)		
Week 52 Mean (SD)	2.68 (0.94)	2.42 (0.82)		
Week 52 Adjusted Mean Change (SE)	-2.06 (0.17)	-2.25 (0.17)	0.20 [-0.28; 0.67]	0.422
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	4.62 (0.78)	4.66 (0.93)		
Week 52 Mean (SD)	2.38 (1.03)	2.52 (1.02)		
Week 52 Adjusted Mean Change (SE)	-2.26 (0.13)	-2.17 (0.16)	-0.09 [-0.50; 0.32]	0.661
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.11 DAS28 - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.079</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	4.57 (0.94)	4.61 (1.00)		
Week 52 Mean (SD)	2.25 (0.86)	2.62 (0.97)		
Week 52 Adjusted Mean Change (SE)	-2.36 (0.14)	-2.05 (0.14)	-0.31 [-0.70; 0.09]	0.125
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	4.73 (0.77)	4.81 (0.90)		
Week 52 Mean (SD)	2.67 (1.09)	2.18 (0.78)		
Week 52 Adjusted Mean Change (SE)	-2.00 (0.14)	-2.49 (0.20)	0.49 [0.01; 0.97]	0.046
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.12 DAS28 - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.590</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	4.63 (0.82)	4.64 (0.96)		
Week 52 Mean (SD)	2.50 (1.04)	2.45 (0.83)		
Week 52 Adjusted Mean Change (SE)	-2.14 (0.12)	-2.20 (0.14)	0.06 [-0.30; 0.42]	0.732
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	4.67 (1.04)	4.67 (0.94)		
Week 52 Mean (SD)	2.29 (0.96)	2.34 (0.87)		
Week 52 Adjusted Mean Change (SE)	-2.34 (0.21)	-2.31 (0.22)	-0.03 [-0.62; 0.57]	0.933
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.13 DAS28 - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.121</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	4.74 (0.89)	4.66 (0.97)		
Week 52 Mean (SD)	2.49 (1.03)	2.31 (0.84)		
Week 52 Adjusted Mean Change (SE)	-2.23 (0.12)	-2.37 (0.14)	0.14 [-0.21; 0.49]	0.439
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	4.37 (0.53)	5.05 (0.87)		
Week 52 Mean (SD)	2.39 (0.99)	3.13 (1.03)		
Week 52 Adjusted Mean Change (SE)	-2.06 (0.21)	-1.65 (0.26)	-0.41 [-1.09; 0.26]	0.228
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.14 DAS28 - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.751</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	4.68 (0.82)	4.71 (0.93)		
Week 52 Mean (SD)	2.52 (1.03)	2.52 (0.95)		
Week 52 Adjusted Mean Change (SE)	-2.15 (0.11)	-2.17 (0.13)	0.02 [-0.32; 0.36]	0.903
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	4.52 (1.13)	4.71 (1.12)		
Week 52 Mean (SD)	2.28 (0.83)	2.26 (0.78)		
Week 52 Adjusted Mean Change (SE)	-2.31 (0.25)	-2.42 (0.30)	0.12 [-0.66; 0.90]	0.762
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 30.15 DAS28 - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.933</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	4.76 (0.88)	4.63 (1.00)		
Week 52 Mean (SD)	2.43 (1.03)	2.47 (0.81)		
Week 52 Adjusted Mean Change (SE)	-2.23 (0.20)	-2.22 (0.20)	-0.01 [-0.57; 0.56]	0.986
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	4.61 (0.86)	4.72 (0.94)		
Week 52 Mean (SD)	2.48 (1.00)	2.48 (1.00)		
Week 52 Adjusted Mean Change (SE)	-2.16 (0.12)	-2.18 (0.15)	0.02 [-0.35; 0.39]	0.900
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.16 DAS28 - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.723</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	4.74 (0.90)	4.76 (0.83)		
Week 52 Mean (SD)	2.38 (0.87)	2.29 (0.71)		
Week 52 Adjusted Mean Change (SE)	-2.34 (0.13)	-2.35 (0.16)	0.01 [-0.40; 0.42]	0.967
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	4.52 (0.79)	4.60 (1.09)		
Week 52 Mean (SD)	2.60 (1.19)	2.64 (1.08)		
Week 52 Adjusted Mean Change (SE)	-1.92 (0.16)	-2.05 (0.16)	0.12 [-0.33; 0.57]	0.587
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.17 DAS28 - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.283</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	4.78 (0.92)	4.71 (1.03)		
Week 52 Mean (SD)	2.68 (0.94)	2.47 (0.83)		
Week 52 Adjusted Mean Change (SE)	-2.05 (0.17)	-2.19 (0.18)	0.14 [-0.35; 0.63]	0.568
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	4.58 (0.83)	4.66 (0.91)		
Week 52 Mean (SD)	2.34 (1.02)	2.48 (1.00)		
Week 52 Adjusted Mean Change (SE)	-2.24 (0.13)	-2.21 (0.16)	-0.04 [-0.43; 0.36]	0.845
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.18 DAS28 - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.079</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	4.57 (0.94)	4.61 (1.00)		
Week 52 Mean (SD)	2.25 (0.86)	2.62 (0.97)		
Week 52 Adjusted Mean Change (SE)	-2.36 (0.14)	-2.05 (0.14)	-0.31 [-0.70; 0.09]	0.125
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	4.73 (0.77)	4.81 (0.90)		
Week 52 Mean (SD)	2.67 (1.09)	2.18 (0.78)		
Week 52 Adjusted Mean Change (SE)	-2.00 (0.14)	-2.49 (0.20)	0.49 [0.01; 0.97]	0.046
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 30.19 DAS28 - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.351</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	4.65 (0.81)	4.64 (0.94)		
Week 52 Mean (SD)	2.49 (1.02)	2.50 (0.86)		
Week 52 Adjusted Mean Change (SE)	-2.14 (0.12)	-2.16 (0.14)	0.02 [-0.33; 0.38]	0.895
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	4.57 (0.96)	4.80 (1.04)		
Week 52 Mean (SD)	2.31 (0.98)	2.43 (1.11)		
Week 52 Adjusted Mean Change (SE)	-2.28 (0.22)	-2.28 (0.22)	-0.00 [-0.62; 0.62]	0.999
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 31.1 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
EULAR Low Disease Activity Week 52, N' n (%)	104 93.91 (85.37)	80 75.90 (75.15)	2.13 [1.01; 4.52] 0.048	1.14 [0.98; 1.31] 0.080	0.102 [-0.010; 0.214] 0.073
EULAR Remission Week 52, N' n (%)	104 66.91 (60.83)	80 60.02 (59.43)	1.09 [0.61; 1.94] 0.778	1.02 [0.81; 1.29] 0.840	0.014 [-0.123; 0.151] 0.841
EULAR Moderate-to-Good Response Week 52, N' n (%)	104 104.35 (94.86)	80 90.89 (89.99)	2.26 [0.68; 7.50] 0.181	1.05 [0.97; 1.15] 0.231	0.049 [-0.030; 0.128] 0.226
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>OR from logistic regression model with predictors treatment and weight. RR and RD calculated directly without adjustment.</p> <p>All results are combined over MI: n and % are averages of all imputations. Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 31.2 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.361				
EULAR Remission Week 52	p=0.285				
EULAR Moderate-to-Good Response Week 52	N.E.				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
EULAR Low Disease Activity Week 52, N' n (%)	98 88.49 (85.91)	74 69.90 (74.36)	2.36 [1.08; 5.15] 0.031	1.16 [1.00; 1.34] 0.058	0.116 [-0.001; 0.232] 0.051
EULAR Remission Week 52, N' n (%)	98 63.70 (61.84)	74 55.06 (58.57)	1.18 [0.65; 2.16] 0.581	1.06 [0.83; 1.34] 0.651	0.033 [-0.109; 0.175] 0.651
EULAR Moderate-to-Good Response Week 52, N' n (%)	98 97.38 (94.54)	74 83.89 (89.24)	2.31 [0.69; 7.69] 0.173	1.06 [0.97; 1.16] 0.224	0.053 [-0.031; 0.137] 0.218
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
EULAR Low Disease Activity Week 52, N' n (%)	6 5.42 (77.43)	6 6.00 (85.71)	0.56 [0.03; 11.11] 0.701	0.90 [0.53; 1.54] 0.700	-0.083 [-0.507; 0.341] 0.702
EULAR Remission Week 52, N' n (%)	6 3.21 (45.86)	6 4.96 (70.86)	0.32 [0.03; 3.23] 0.337	0.64 [0.24; 1.71] 0.376	-0.250 [-0.764; 0.264] 0.340
EULAR Moderate-to-Good Response Week 52, N' n (%)	6 6.97 (99.57)	6 7.00 (100.00)	N.E.	N.E.	N.E.

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value            N-N' is the number of values with MI.            n (%): Number and percentage of patients with event            CI: Confidence Interval            MI: Multiple Imputation            N.E.: Not estimable            OR: Odds Ratio            RR: Relative Risk            RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.            If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.            RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:            n and % are averages of all imputations.            P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.            OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.            RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				



### 31.3 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.563				
EULAR Remission Week 52	p=0.538				
EULAR Moderate-to-Good Response Week 52	p=0.574				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
EULAR Low Disease Activity Week 52, N' n (%)	63 58.28 (88.30)	46 49.22 (86.35)	1.59 [0.48; 5.33] 0.451	1.02 [0.89; 1.18] 0.759	0.020 [-0.106; 0.145] 0.760
EULAR Remission Week 52, N' n (%)	63 45.75 (69.32)	46 42.70 (74.91)	0.87 [0.37; 2.03] 0.742	0.93 [0.74; 1.16] 0.503	-0.056 [-0.219; 0.107] 0.502
EULAR Moderate-to-Good Response Week 52, N' n (%)	63 64.56 (97.82)	46 54.10 (94.91)	3.76 [0.29; 48.80] 0.311	1.03 [0.95; 1.12] 0.464	0.029 [-0.048; 0.106] 0.460
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
EULAR Low Disease Activity Week 52, N' n (%)	41 35.63 (80.98)	34 26.68 (60.64)	2.55 [0.90; 7.21] 0.078	1.34 [1.00; 1.79] 0.051	0.203 [0.011; 0.396] 0.038
EULAR Remission Week 52, N' n (%)	41 21.16 (48.09)	34 17.32 (39.36)	1.28 [0.52; 3.17] 0.593	1.22 [0.74; 2.02] 0.429	0.087 [-0.127; 0.302] 0.425
EULAR Moderate-to-Good Response Week 52, N' n (%)	41 39.79 (90.43)	34 36.79 (83.61)	1.62 [0.40; 6.62] 0.502	1.08 [0.91; 1.29] 0.377	0.068 [-0.082; 0.218] 0.372

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 31.4 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.714				
EULAR Remission Week 52	p=0.920				
EULAR Moderate-to-Good Response Week 52	p=0.451				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
EULAR Low Disease Activity Week 52, N' n (%)	23 21.79 (90.79)	16 17.24 (82.10)	2.95 [0.42; 20.83] 0.278	1.11 [0.86; 1.42] 0.428	0.087 [-0.123; 0.297] 0.418
EULAR Remission Week 52, N' n (%)	23 17.54 (73.08)	16 15.86 (75.52)	1.00 [0.24; 4.19] 0.995	0.97 [0.68; 1.38] 0.858	-0.024 [-0.290; 0.241] 0.857
EULAR Moderate-to-Good Response Week 52, N' n (%)	23 22.79 (94.96)	16 17.59 (83.76)	5.15 [0.43; 61.41] 0.195	1.13 [0.91; 1.42] 0.274	0.112 [-0.081; 0.305] 0.255
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
EULAR Low Disease Activity Week 52, N' n (%)	81 72.12 (83.86)	64 58.66 (73.33)	1.99 [0.88; 4.49] 0.100	1.14 [0.96; 1.36] 0.122	0.105 [-0.025; 0.236] 0.114
EULAR Remission Week 52, N' n (%)	81 49.37 (57.41)	64 44.16 (55.20)	1.09 [0.57; 2.07] 0.795	1.04 [0.79; 1.37] 0.781	0.022 [-0.134; 0.179] 0.782
EULAR Moderate-to-Good Response Week 52, N' n (%)	81 81.56 (94.84)	64 73.30 (91.63)	1.74 [0.43; 7.04] 0.437	1.04 [0.94; 1.14] 0.463	0.032 [-0.053; 0.118] 0.462

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 31.5 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.510				
EULAR Remission Week 52	p=0.562				
EULAR Moderate-to-Good Response Week 52	p=0.538				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
EULAR Low Disease Activity Week 52, N' n (%)	39 36.60 (87.14)	37 35.96 (70.51)	2.74 [0.86; 8.78] 0.090	1.24 [0.99; 1.55] 0.067	0.166 [-0.004; 0.337] 0.056
EULAR Remission Week 52, N' n (%)	39 24.04 (57.24)	37 25.90 (50.78)	1.23 [0.51; 2.94] 0.646	1.13 [0.76; 1.68] 0.551	0.065 [-0.148; 0.277] 0.552
EULAR Moderate-to-Good Response Week 52, N' n (%)	39 40.79 (97.12)	37 45.51 (89.24)	4.05 [0.42; 39.05] 0.226	1.09 [0.96; 1.23] 0.182	0.079 [-0.034; 0.192] 0.171
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
EULAR Low Disease Activity Week 52, N' n (%)	65 57.31 (84.28)	43 39.94 (79.88)	1.63 [0.59; 4.49] 0.343	1.06 [0.88; 1.26] 0.554	0.044 [-0.101; 0.189] 0.551
EULAR Remission Week 52, N' n (%)	65 42.87 (63.04)	43 34.12 (68.24)	0.86 [0.39; 1.93] 0.718	0.92 [0.71; 1.21] 0.565	-0.052 [-0.229; 0.125] 0.565
EULAR Moderate-to-Good Response Week 52, N' n (%)	65 63.56 (93.47)	43 45.38 (90.76)	1.74 [0.40; 7.63] 0.461	1.03 [0.92; 1.16] 0.615	0.027 [-0.078; 0.132] 0.613

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 31.6 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.724				
EULAR Remission Week 52	p=0.553				
EULAR Moderate-to-Good Response Week 52	p=0.540				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
EULAR Low Disease Activity Week 52, N' n (%)	70 61.23 (85.04)	34 38.07 (77.69)	1.84 [0.65; 5.15] 0.248	1.10 [0.90; 1.33] 0.353	0.073 [-0.079; 0.226] 0.345
EULAR Remission Week 52, N' n (%)	70 45.74 (63.53)	34 29.15 (59.49)	1.24 [0.56; 2.71] 0.599	1.07 [0.79; 1.44] 0.667	0.040 [-0.143; 0.224] 0.666
EULAR Moderate-to-Good Response Week 52, N' n (%)	70 68.97 (95.79)	34 43.77 (89.33)	3.07 [0.60; 15.53] 0.176	1.07 [0.95; 1.21] 0.261	0.065 [-0.046; 0.175] 0.250
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
EULAR Low Disease Activity Week 52, N' n (%)	34 32.68 (86.00)	46 37.83 (72.75)	2.43 [0.76; 7.81] 0.136	1.18 [0.95; 1.47] 0.134	0.133 [-0.038; 0.303] 0.127
EULAR Remission Week 52, N' n (%)	34 21.17 (55.71)	46 30.87 (59.37)	0.86 [0.36; 2.09] 0.746	0.94 [0.64; 1.37] 0.740	-0.037 [-0.251; 0.178] 0.738
EULAR Moderate-to-Good Response Week 52, N' n (%)	34 35.38 (93.11)	46 47.12 (90.62)	1.47 [0.26; 8.41] 0.663	1.03 [0.90; 1.17] 0.691	0.025 [-0.098; 0.147] 0.690

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				



### 31.7 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.563				
EULAR Remission Week 52	p=0.695				
EULAR Moderate-to-Good Response Week 52	p=0.703				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
EULAR Low Disease Activity Week 52, N' n (%)	48 44.86 (87.96)	25 26.66 (83.31)	1.44 [0.37; 5.66] 0.604	1.06 [0.87; 1.29] 0.588	0.046 [-0.121; 0.214] 0.585
EULAR Remission Week 52, N' n (%)	48 34.51 (67.67)	25 22.57 (70.53)	0.84 [0.30; 2.34] 0.745	0.96 [0.71; 1.30] 0.794	-0.029 [-0.241; 0.184] 0.791
EULAR Moderate-to-Good Response Week 52, N' n (%)	48 47.59 (93.31)	25 26.30 (82.19)	3.07 [0.67; 14.14] 0.150	1.14 [0.94; 1.37] 0.182	0.111 [-0.046; 0.268] 0.164
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
EULAR Low Disease Activity Week 52, N' n (%)	56 49.05 (83.14)	55 49.24 (71.36)	2.34 [0.92; 5.94] 0.073	1.17 [0.96; 1.42] 0.127	0.118 [-0.031; 0.266] 0.121
EULAR Remission Week 52, N' n (%)	56 32.40 (54.92)	55 37.45 (54.28)	1.09 [0.52; 2.26] 0.827	1.01 [0.73; 1.40] 0.943	0.006 [-0.172; 0.185] 0.944
EULAR Moderate-to-Good Response Week 52, N' n (%)	56 56.76 (96.20)	55 64.59 (93.61)	1.93 [0.29; 12.87] 0.499	1.03 [0.94; 1.13] 0.553	0.026 [-0.060; 0.112] 0.552

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 31.8 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.912				
EULAR Remission Week 52	p=0.841				
EULAR Moderate-to-Good Response Week 52	p=0.321				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
EULAR Low Disease Activity Week 52, N' n (%)	48 42.84 (84.00)	34 32.22 (78.59)	1.51 [0.49; 4.61] 0.472	1.07 [0.87; 1.32] 0.528	0.054 [-0.113; 0.221] 0.525
EULAR Remission Week 52, N' n (%)	48 31.52 (61.80)	34 26.30 (64.15)	0.91 [0.38; 2.21] 0.843	0.96 [0.70; 1.33] 0.823	-0.023 [-0.227; 0.180] 0.821
EULAR Moderate-to-Good Response Week 52, N' n (%)	48 48.38 (94.86)	34 39.04 (95.22)	0.92 [0.09; 9.13] 0.943	1.00 [0.90; 1.11] 0.946	-0.004 [-0.104; 0.097] 0.945
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
EULAR Low Disease Activity Week 52, N' n (%)	31 29.07 (85.50)	21 20.53 (78.96)	1.68 [0.38; 7.47] 0.499	1.08 [0.83; 1.41] 0.551	0.065 [-0.147; 0.278] 0.546
EULAR Remission Week 52, N' n (%)	31 17.39 (51.15)	21 14.79 (56.88)	0.79 [0.26; 2.37] 0.677	0.90 [0.55; 1.48] 0.678	-0.057 [-0.326; 0.212] 0.676
EULAR Moderate-to-Good Response Week 52, N' n (%)	31 31.97 (94.03)	21 21.00 (80.77)	3.96 [0.65; 24.07] 0.136	1.16 [0.94; 1.45] 0.173	0.133 [-0.048; 0.314] 0.151

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 31.9 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.881				
EULAR Remission Week 52	p=0.777				
EULAR Moderate-to-Good Response Week 52	p=0.493				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
EULAR Low Disease Activity Week 52, N' n (%)	43 40.65 (90.33)	19 22.90 (84.81)	1.82 [0.35; 9.45] 0.477	1.07 [0.87; 1.31] 0.547	0.055 [-0.123; 0.233] 0.543
EULAR Remission Week 52, N' n (%)	43 27.18 (60.40)	19 16.88 (62.52)	0.95 [0.33; 2.71] 0.922	0.97 [0.65; 1.44] 0.871	-0.021 [-0.266; 0.224] 0.865
EULAR Moderate-to-Good Response Week 52, N' n (%)	43 44.00 (97.78)	19 24.73 (91.59)	4.00 [0.27; 59.13] 0.313	1.07 [0.92; 1.24] 0.373	0.062 [-0.070; 0.194] 0.359
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
EULAR Low Disease Activity Week 52, N' n (%)	34 30.26 (79.63)	27 21.49 (71.63)	1.56 [0.48; 5.05] 0.459	1.11 [0.84; 1.48] 0.465	0.080 [-0.131; 0.291] 0.458
EULAR Remission Week 52, N' n (%)	34 20.73 (54.55)	27 18.14 (60.47)	0.77 [0.28; 2.10] 0.608	0.90 [0.59; 1.37] 0.632	-0.059 [-0.301; 0.183] 0.632
EULAR Moderate-to-Good Response Week 52, N' n (%)	34 34.35 (90.39)	27 26.32 (87.73)	1.34 [0.25; 7.06] 0.733	1.03 [0.86; 1.23] 0.744	0.027 [-0.133; 0.186] 0.743

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 31.10 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.535				
EULAR Remission Week 52	p=0.084				
EULAR Moderate-to-Good Response Week 52	p=0.265				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
EULAR Low Disease Activity Week 52, N' n (%)	29 23.84 (79.47)	24 25.43 (77.06)	1.15 [0.31; 4.30] 0.832	1.03 [0.78; 1.37] 0.824	0.024 [-0.194; 0.242] 0.828
EULAR Remission Week 52, N' n (%)	29 12.65 (42.17)	24 21.09 (63.91)	0.40 [0.14; 1.18] 0.097	0.66 [0.40; 1.10] 0.111	-0.217 [-0.470; 0.035] 0.091
EULAR Moderate-to-Good Response Week 52, N' n (%)	29 29.00 (96.67)	24 28.06 (85.03)	5.11 [0.51; 51.11] 0.165	1.14 [0.95; 1.36] 0.154	0.116 [-0.036; 0.269] 0.136
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
EULAR Low Disease Activity Week 52, N' n (%)	48 44.86 (87.96)	31 27.32 (80.35)	2.05 [0.58; 7.18] 0.262	1.09 [0.90; 1.34] 0.374	0.076 [-0.088; 0.241] 0.365
EULAR Remission Week 52, N' n (%)	48 33.51 (65.71)	31 20.00 (58.82)	1.40 [0.56; 3.48] 0.471	1.12 [0.79; 1.58] 0.533	0.069 [-0.144; 0.281] 0.526
EULAR Moderate-to-Good Response Week 52, N' n (%)	48 47.59 (93.31)	31 31.98 (94.06)	0.96 [0.15; 6.20] 0.970	0.99 [0.89; 1.11] 0.891	-0.007 [-0.114; 0.099] 0.891

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				



### 31.11 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.295				
EULAR Remission Week 52	p=0.153				
EULAR Moderate-to-Good Response Week 52	N.E.				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
EULAR Low Disease Activity Week 52, N' n (%)	39 38.05 (88.49)	37 32.67 (75.98)	2.49 [0.71; 8.71] 0.154	1.16 [0.95; 1.43] 0.149	0.125 [-0.040; 0.290] 0.138
EULAR Remission Week 52, N' n (%)	39 28.37 (65.98)	37 25.01 (58.16)	1.37 [0.56; 3.39] 0.490	1.13 [0.81; 1.59] 0.469	0.078 [-0.131; 0.288] 0.465
EULAR Moderate-to-Good Response Week 52, N' n (%)	39 41.76 (97.12)	37 37.50 (87.21)	5.28 [0.57; 48.64] 0.142	1.11 [0.98; 1.27] 0.112	0.099 [-0.019; 0.217] 0.100
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
EULAR Low Disease Activity Week 52, N' n (%)	40 33.86 (80.62)	18 20.08 (83.67)	0.87 [0.19; 3.99] 0.854	0.96 [0.75; 1.25] 0.783	-0.030 [-0.240; 0.179] 0.775
EULAR Remission Week 52, N' n (%)	40 20.54 (48.90)	18 16.08 (67.00)	0.48 [0.16; 1.48] 0.204	0.73 [0.47; 1.13] 0.163	-0.181 [-0.437; 0.075] 0.166
EULAR Moderate-to-Good Response Week 52, N' n (%)	40 38.59 (91.88)	18 22.54 (93.92)	N.E.	0.98 [0.83; 1.15] 0.799	-0.020 [-0.170; 0.130] 0.790

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 31.12 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.679				
EULAR Remission Week 52	p=0.670				
EULAR Moderate-to-Good Response Week 52	N.E.				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
EULAR Low Disease Activity Week 52, N' n (%)	57 52.07 (83.98)	36 37.06 (78.85)	1.60 [0.55; 4.63] 0.390	1.07 [0.88; 1.30] 0.525	0.051 [-0.106; 0.208] 0.522
EULAR Remission Week 52, N' n (%)	57 37.26 (60.10)	36 28.63 (60.91)	1.02 [0.45; 2.31] 0.964	0.99 [0.72; 1.36] 0.936	-0.008 [-0.201; 0.184] 0.934
EULAR Moderate-to-Good Response Week 52, N' n (%)	57 57.35 (92.50)	36 42.52 (90.47)	1.35 [0.29; 6.38] 0.703	1.02 [0.90; 1.16] 0.734	0.020 [-0.097; 0.138] 0.734
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
EULAR Low Disease Activity Week 52, N' n (%)	19 16.84 (84.20)	17 14.69 (81.61)	1.03 [0.17; 6.10] 0.977	1.03 [0.76; 1.39] 0.838	0.026 [-0.222; 0.274] 0.838
EULAR Remission Week 52, N' n (%)	19 11.65 (58.25)	17 11.46 (63.67)	0.72 [0.18; 2.83] 0.638	0.92 [0.54; 1.55] 0.741	-0.054 [-0.373; 0.265] 0.739
EULAR Moderate-to-Good Response Week 52, N' n (%)	19 20.00 (100.00)	17 16.52 (91.78)	N.E.	1.09 [0.94; 1.27] 0.264	0.082 [-0.056; 0.220] 0.242

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 31.13 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.293				
EULAR Remission Week 52	p=0.056				
EULAR Moderate-to-Good Response Week 52	p=0.636				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
EULAR Low Disease Activity Week 52, N' n (%)	58 52.86 (83.90)	40 41.21 (80.80)	1.24 [0.44; 3.53] 0.682	1.04 [0.87; 1.25] 0.684	0.031 [-0.118; 0.180] 0.684
EULAR Remission Week 52, N' n (%)	58 36.90 (58.57)	40 34.77 (68.18)	0.65 [0.29; 1.47] 0.301	0.86 [0.64; 1.15] 0.309	-0.096 [-0.281; 0.088] 0.307
EULAR Moderate-to-Good Response Week 52, N' n (%)	58 59.76 (94.86)	40 46.57 (91.31)	1.75 [0.34; 8.96] 0.501	1.04 [0.93; 1.16] 0.507	0.035 [-0.069; 0.139] 0.504
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
EULAR Low Disease Activity Week 52, N' n (%)	18 16.05 (84.47)	12 8.00 (66.67)	3.89 [0.60; 25.11] 0.153	1.27 [0.81; 1.98] 0.297	0.178 [-0.135; 0.491] 0.265
EULAR Remission Week 52, N' n (%)	18 10.01 (52.68)	12 3.00 (25.00)	3.79 [0.75; 19.05] 0.106	2.11 [0.72; 6.14] 0.172	0.277 [-0.056; 0.609] 0.103
EULAR Moderate-to-Good Response Week 52, N' n (%)	18 17.59 (92.58)	12 10.00 (83.33)	3.68 [0.25; 53.15] 0.339	1.11 [0.83; 1.48] 0.477	0.092 [-0.154; 0.339] 0.463

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 31.14 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.646				
EULAR Remission Week 52	p=0.697				
EULAR Moderate-to-Good Response Week 52	N.E.				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
EULAR Low Disease Activity Week 52, N' n (%)	65 59.91 (84.38)	44 41.70 (78.68)	1.61 [0.59; 4.38] 0.348	1.07 [0.89; 1.29] 0.450	0.057 [-0.089; 0.203] 0.445
EULAR Remission Week 52, N' n (%)	65 39.91 (56.21)	44 31.56 (59.55)	0.89 [0.42; 1.89] 0.769	0.94 [0.69; 1.29] 0.719	-0.033 [-0.215; 0.148] 0.718
EULAR Moderate-to-Good Response Week 52, N' n (%)	65 66.35 (93.45)	44 46.53 (87.79)	2.14 [0.53; 8.61] 0.282	1.06 [0.94; 1.21] 0.336	0.057 [-0.057; 0.170] 0.329
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
EULAR Low Disease Activity Week 52, N' n (%)	13 11.00 (84.62)	8 8.36 (83.60)	0.86 [0.07; 10.06] 0.905	1.01 [0.69; 1.48] 0.943	0.010 [-0.305; 0.325] 0.950
EULAR Remission Week 52, N' n (%)	13 8.00 (61.54)	8 7.07 (70.70)	0.61 [0.10; 3.65] 0.585	0.87 [0.48; 1.57] 0.647	-0.092 [-0.481; 0.298] 0.645
EULAR Moderate-to-Good Response Week 52, N' n (%)	13 13.00 (100.00)	8 9.99 (99.90)	N.E.	N.E.	N.E.

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				



### 31.15 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.425				
EULAR Remission Week 52	p=0.755				
EULAR Moderate-to-Good Response Week 52	p=0.965				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
EULAR Low Disease Activity Week 52, N' n (%)	19 18.05 (82.05)	18 21.16 (81.38)	0.93 [0.18; 4.76] 0.930	1.01 [0.75; 1.35] 0.955	0.007 [-0.229; 0.243] 0.956
EULAR Remission Week 52, N' n (%)	19 12.40 (56.36)	18 16.24 (62.46)	0.74 [0.21; 2.54] 0.628	0.90 [0.55; 1.49] 0.688	-0.061 [-0.355; 0.233] 0.684
EULAR Moderate-to-Good Response Week 52, N' n (%)	19 20.76 (94.36)	18 23.06 (88.69)	2.00 [0.17; 23.80] 0.584	1.06 [0.88; 1.29] 0.529	0.057 [-0.118; 0.231] 0.523
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
EULAR Low Disease Activity Week 52, N' n (%)	60 53.86 (85.49)	37 31.59 (77.05)	2.07 [0.70; 6.10] 0.189	1.11 [0.91; 1.36] 0.314	0.084 [-0.076; 0.245] 0.304
EULAR Remission Week 52, N' n (%)	60 36.51 (57.95)	37 24.85 (60.61)	0.93 [0.41; 2.13] 0.870	0.96 [0.69; 1.33] 0.793	-0.027 [-0.224; 0.171] 0.792
EULAR Moderate-to-Good Response Week 52, N' n (%)	60 59.59 (94.59)	37 36.98 (90.20)	2.14 [0.41; 11.17] 0.368	1.05 [0.93; 1.19] 0.454	0.044 [-0.070; 0.158] 0.449

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value            N-N' is the number of values with MI.            n (%): Number and percentage of patients with event            CI: Confidence Interval            MI: Multiple Imputation            N.E.: Not estimable            OR: Odds Ratio            RR: Relative Risk            RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.            RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:            n and % are averages of all imputations.            P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.            OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.            RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 31.16 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.871				
EULAR Remission Week 52	p=0.900				
EULAR Moderate-to-Good Response Week 52	p=0.479				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
EULAR Low Disease Activity Week 52, N' n (%)	49 44.65 (87.55)	26 30.26 (86.46)	1.31 [0.30; 5.67] 0.717	1.01 [0.84; 1.22] 0.889	0.011 [-0.147; 0.169] 0.892
EULAR Remission Week 52, N' n (%)	49 30.18 (59.18)	26 22.95 (65.57)	0.81 [0.31; 2.08] 0.656	0.90 [0.64; 1.28] 0.564	-0.064 [-0.281; 0.153] 0.563
EULAR Moderate-to-Good Response Week 52, N' n (%)	49 50.00 (98.04)	26 32.72 (93.49)	4.04 [0.26; 63.38] 0.320	1.05 [0.94; 1.17] 0.404	0.046 [-0.059; 0.150] 0.395
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
EULAR Low Disease Activity Week 52, N' n (%)	30 27.26 (80.18)	29 22.49 (70.28)	1.53 [0.47; 5.05] 0.481	1.14 [0.86; 1.52] 0.371	0.099 [-0.114; 0.312] 0.363
EULAR Remission Week 52, N' n (%)	30 18.73 (55.09)	29 18.14 (56.69)	0.88 [0.32; 2.41] 0.805	0.97 [0.63; 1.51] 0.898	-0.016 [-0.262; 0.230] 0.898
EULAR Moderate-to-Good Response Week 52, N' n (%)	30 30.35 (89.26)	29 27.32 (85.38)	1.28 [0.26; 6.23] 0.757	1.05 [0.86; 1.27] 0.655	0.039 [-0.130; 0.208] 0.652

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value            N-N' is the number of values with MI.            n (%): Number and percentage of patients with event            CI: Confidence Interval            MI: Multiple Imputation            N.E.: Not estimable            OR: Odds Ratio            RR: Relative Risk            RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.            RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:            n and % are averages of all imputations.            P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.            OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.            RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 31.17 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.707				
EULAR Remission Week 52	p=0.143				
EULAR Moderate-to-Good Response Week 52	p=0.229				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
EULAR Low Disease Activity Week 52, N' n (%)	29 23.84 (79.47)	22 23.43 (75.58)	1.24 [0.33; 4.65] 0.748	1.05 [0.79; 1.41] 0.731	0.039 [-0.185; 0.263] 0.734
EULAR Remission Week 52, N' n (%)	29 12.65 (42.17)	22 19.09 (61.58)	0.44 [0.15; 1.32] 0.144	0.69 [0.41; 1.16] 0.158	-0.194 [-0.453; 0.064] 0.141
EULAR Moderate-to-Good Response Week 52, N' n (%)	29 29.00 (96.67)	22 26.06 (84.06)	5.48 [0.55; 55.01] 0.148	1.15 [0.95; 1.39] 0.144	0.126 [-0.034; 0.286] 0.123
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
EULAR Low Disease Activity Week 52, N' n (%)	50 48.07 (87.40)	33 29.32 (81.44)	1.76 [0.52; 5.99] 0.368	1.07 [0.89; 1.30] 0.469	0.060 [-0.100; 0.219] 0.463
EULAR Remission Week 52, N' n (%)	50 36.26 (65.93)	33 22.00 (61.11)	1.27 [0.52; 3.10] 0.598	1.08 [0.78; 1.50] 0.651	0.048 [-0.158; 0.254] 0.647
EULAR Moderate-to-Good Response Week 52, N' n (%)	50 51.35 (93.36)	33 33.98 (94.39)	0.91 [0.14; 5.76] 0.919	0.99 [0.89; 1.10] 0.844	-0.010 [-0.113; 0.092] 0.845

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 31.18 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.295				
EULAR Remission Week 52	p=0.153				
EULAR Moderate-to-Good Response Week 52	N.E.				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
EULAR Low Disease Activity Week 52, N' n (%)	39 38.05 (88.49)	37 32.67 (75.98)	2.49 [0.71; 8.71] 0.154	1.16 [0.95; 1.43] 0.149	0.125 [-0.040; 0.290] 0.138
EULAR Remission Week 52, N' n (%)	39 28.37 (65.98)	37 25.01 (58.16)	1.37 [0.56; 3.39] 0.490	1.13 [0.81; 1.59] 0.469	0.078 [-0.131; 0.288] 0.465
EULAR Moderate-to-Good Response Week 52, N' n (%)	39 41.76 (97.12)	37 37.50 (87.21)	5.28 [0.57; 48.64] 0.142	1.11 [0.98; 1.27] 0.112	0.099 [-0.019; 0.217] 0.100
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
EULAR Low Disease Activity Week 52, N' n (%)	40 33.86 (80.62)	18 20.08 (83.67)	0.87 [0.19; 3.99] 0.854	0.96 [0.75; 1.25] 0.783	-0.030 [-0.240; 0.179] 0.775
EULAR Remission Week 52, N' n (%)	40 20.54 (48.90)	18 16.08 (67.00)	0.48 [0.16; 1.48] 0.204	0.73 [0.47; 1.13] 0.163	-0.181 [-0.437; 0.075] 0.166
EULAR Moderate-to-Good Response Week 52, N' n (%)	40 38.59 (91.88)	18 22.54 (93.92)	N.E.	0.98 [0.83; 1.15] 0.799	-0.020 [-0.170; 0.130] 0.790

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				



### 31.19 DAS28 - EULAR Low Disease Activity / Remission / Moderate-to-Good Response by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
EULAR Low Disease Activity Week 52	p=0.523				
EULAR Remission Week 52	p=0.748				
EULAR Moderate-to-Good Response Week 52	N.E.				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
EULAR Low Disease Activity Week 52, N' n (%)	60 55.07 (84.72)	38 38.06 (77.67)	1.80 [0.64; 5.09] 0.265	1.09 [0.90; 1.32] 0.377	0.070 [-0.084; 0.225] 0.370
EULAR Remission Week 52, N' n (%)	60 38.26 (58.86)	38 29.63 (60.47)	0.98 [0.44; 2.17] 0.960	0.97 [0.71; 1.34] 0.869	-0.016 [-0.205; 0.172] 0.867
EULAR Moderate-to-Good Response Week 52, N' n (%)	60 60.35 (92.85)	38 43.52 (88.82)	1.74 [0.40; 7.49] 0.457	1.05 [0.92; 1.19] 0.507	0.040 [-0.078; 0.158] 0.503
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
EULAR Low Disease Activity Week 52, N' n (%)	17 14.84 (82.44)	17 14.69 (81.61)	0.92 [0.15; 5.51] 0.923	1.01 [0.74; 1.39] 0.949	0.008 [-0.251; 0.267] 0.950
EULAR Remission Week 52, N' n (%)	17 10.65 (59.17)	17 11.46 (63.67)	0.75 [0.18; 3.07] 0.691	0.93 [0.54; 1.59] 0.789	-0.045 [-0.373; 0.283] 0.788
EULAR Moderate-to-Good Response Week 52, N' n (%)	17 18.00 (100.00)	17 16.52 (91.78)	N.E.	1.09 [0.94; 1.27] 0.264	0.082 [-0.056; 0.220] 0.242

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>				

### 32.0 mCPDAI - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	96 (95.0)	206 (97.6)
Week 12 Returns	105 (95.5)	95 (94.1)	200 (94.8)
Week 16 Returns	107 (97.3)	91 (90.1)	198 (93.8)
Week 24 Returns	104 (94.5)	89 (88.1)	193 (91.5)
Week 32 Returns	99 (90.0)	81 (80.2)	180 (85.3)
Week 40 Returns	104 (94.5)	81 (80.2)	185 (87.7)
Week 52 Returns	103 (93.6)	80 (79.2)	183 (86.7)

### 32.1 mCPDAI - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	9.29 (1.63)	9.05 (1.88)		
Week 52 Mean (SD)	4.93 (2.88)	5.44 (2.78)		
Week 52 Adjusted Mean Change (SE)	-4.27 (0.26)	-3.65 (0.28)	-0.62 [-1.37; 0.13]	0.103
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

### 32.2 mCPDAI - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.994</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	9.33 (1.64)	9.06 (1.92)		
Week 52 Mean (SD)	4.96 (2.86)	5.36 (2.80)		
Week 52 Adjusted Mean Change (SE)	-4.31 (0.26)	-3.72 (0.29)	-0.59 [-1.37; 0.19]	0.139
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	8.71 (1.50)	8.86 (1.35)		
Week 52 Mean (SD)	4.40 (3.58)	6.33 (2.58)		
Week 52 Adjusted Mean Change (SE)	-3.83 (1.07)	-2.70 (1.03)	-1.13 [-4.06; 1.81]	0.449
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.3 mCPDAI - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.561</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	9.15 (1.76)	8.88 (2.10)		
Week 52 Mean (SD)	4.32 (2.88)	4.70 (2.89)		
Week 52 Adjusted Mean Change (SE)	-4.84 (0.32)	-4.38 (0.36)	-0.47 [-1.41; 0.48]	0.331
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	9.50 (1.42)	9.27 (1.56)		
Week 52 Mean (SD)	5.85 (2.66)	6.44 (2.30)		
Week 52 Adjusted Mean Change (SE)	-3.40 (0.40)	-2.69 (0.41)	-0.71 [-1.83; 0.41]	0.215
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.4 mCPDAI - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.694</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	8.13 (2.05)	7.00 (2.49)		
Week 52 Mean (SD)	3.70 (2.88)	4.69 (2.75)		
Week 52 Adjusted Mean Change (SE)	-4.99 (0.56)	-3.88 (0.66)	-1.11 [-2.76; 0.54]	0.185
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	9.62 (1.34)	9.59 (1.23)		
Week 52 Mean (SD)	5.29 (2.80)	5.63 (2.77)		
Week 52 Adjusted Mean Change (SE)	-4.06 (0.29)	-3.59 (0.32)	-0.46 [-1.31; 0.38]	0.278
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.5 mCPDAI - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.451</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	8.64 (1.71)	8.63 (1.94)		
Week 52 Mean (SD)	5.10 (2.69)	5.19 (3.04)		
Week 52 Adjusted Mean Change (SE)	-3.74 (0.42)	-3.56 (0.41)	-0.18 [-1.33; 0.96]	0.754
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	9.69 (1.46)	9.48 (1.74)		
Week 52 Mean (SD)	4.83 (3.01)	5.65 (2.55)		
Week 52 Adjusted Mean Change (SE)	-4.60 (0.33)	-3.72 (0.39)	-0.88 [-1.88; 0.12]	0.086
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment            x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters,            subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 32.6 mCPDAI - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.074</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	9.57 (1.55)	8.88 (1.87)		
Week 52 Mean (SD)	4.71 (2.82)	5.29 (2.83)		
Week 52 Adjusted Mean Change (SE)	-4.67 (0.32)	-3.34 (0.42)	-1.33 [-2.37; -0.29]	0.012
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	8.76 (1.68)	9.21 (1.90)		
Week 52 Mean (SD)	5.39 (2.99)	5.54 (2.76)		
Week 52 Adjusted Mean Change (SE)	-3.54 (0.45)	-3.83 (0.38)	0.29 [-0.87; 1.45]	0.621
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.7 mCPDAI - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.486</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	8.86 (1.72)	8.41 (2.15)		
Week 52 Mean (SD)	4.26 (2.86)	5.04 (2.75)		
Week 52 Adjusted Mean Change (SE)	-4.69 (0.38)	-3.78 (0.51)	-0.90 [-2.14; 0.33]	0.150
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	9.66 (1.47)	9.35 (1.68)		
Week 52 Mean (SD)	5.50 (2.80)	5.62 (2.80)		
Week 52 Adjusted Mean Change (SE)	-3.91 (0.35)	-3.60 (0.34)	-0.32 [-1.28; 0.65]	0.518
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.8 mCPDAI - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.632</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	9.35 (1.56)	8.76 (2.09)		
Week 52 Mean (SD)	5.21 (2.86)	5.03 (2.79)		
Week 52 Adjusted Mean Change (SE)	-4.00 (0.37)	-4.05 (0.42)	0.05 [-1.06; 1.16]	0.927
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	9.26 (1.69)	8.88 (1.58)		
Week 52 Mean (SD)	4.90 (2.77)	5.52 (2.46)		
Week 52 Adjusted Mean Change (SE)	-4.20 (0.45)	-3.16 (0.54)	-1.04 [-2.44; 0.35]	0.142
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.9 mCPDAI - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.940</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	9.38 (1.53)	8.89 (2.03)		
Week 52 Mean (SD)	4.95 (2.87)	5.37 (2.71)		
Week 52 Adjusted Mean Change (SE)	-4.30 (0.40)	-3.69 (0.56)	-0.60 [-1.97; 0.76]	0.384
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	9.24 (1.75)	8.80 (1.88)		
Week 52 Mean (SD)	5.21 (2.80)	5.11 (2.65)		
Week 52 Adjusted Mean Change (SE)	-3.87 (0.44)	-3.88 (0.50)	0.01 [-1.31; 1.33]	0.990
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.10 mCPDAI - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.466</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	9.17 (1.53)	8.91 (1.93)		
Week 52 Mean (SD)	5.03 (2.96)	5.29 (2.71)		
Week 52 Adjusted Mean Change (SE)	-4.14 (0.48)	-3.48 (0.50)	-0.66 [-2.03; 0.70]	0.338
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	9.59 (1.47)	8.71 (1.90)		
Week 52 Mean (SD)	5.25 (2.72)	5.16 (2.66)		
Week 52 Adjusted Mean Change (SE)	-4.10 (0.37)	-3.90 (0.46)	-0.20 [-1.38; 0.98]	0.736
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.11 mCPDAI - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.710</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	9.35 (1.67)	8.93 (1.91)		
Week 52 Mean (SD)	4.97 (2.92)	5.41 (2.47)		
Week 52 Adjusted Mean Change (SE)	-4.20 (0.41)	-3.72 (0.41)	-0.47 [-1.62; 0.67]	0.413
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	9.29 (1.55)	8.58 (1.91)		
Week 52 Mean (SD)	5.20 (2.74)	4.83 (3.05)		
Week 52 Adjusted Mean Change (SE)	-3.96 (0.40)	-3.69 (0.58)	-0.27 [-1.67; 1.13]	0.707
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.12 mCPDAI - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.910</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	9.34 (1.60)	8.81 (2.00)		
Week 52 Mean (SD)	5.30 (2.83)	5.47 (2.59)		
Week 52 Adjusted Mean Change (SE)	-3.87 (0.34)	-3.52 (0.40)	-0.35 [-1.40; 0.69]	0.504
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	9.10 (1.71)	8.61 (1.69)		
Week 52 Mean (SD)	4.32 (2.75)	4.35 (2.67)		
Week 52 Adjusted Mean Change (SE)	-4.66 (0.59)	-4.33 (0.62)	-0.33 [-2.03; 1.37]	0.701
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.13 mCPDAI - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.177</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	9.27 (1.54)	8.69 (2.10)		
Week 52 Mean (SD)	5.12 (2.90)	4.93 (2.61)		
Week 52 Adjusted Mean Change (SE)	-4.06 (0.33)	-3.93 (0.38)	-0.13 [-1.13; 0.87]	0.802
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	9.37 (1.92)	9.25 (1.06)		
Week 52 Mean (SD)	5.11 (2.52)	5.92 (2.81)		
Week 52 Adjusted Mean Change (SE)	-3.93 (0.59)	-3.16 (0.74)	-0.77 [-2.64; 1.10]	0.416
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 32.14 mCPDAI - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.715</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	9.27 (1.63)	8.83 (1.97)		
Week 52 Mean (SD)	5.09 (2.70)	5.18 (2.78)		
Week 52 Adjusted Mean Change (SE)	-4.05 (0.32)	-3.77 (0.38)	-0.28 [-1.26; 0.70]	0.577
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	9.54 (1.56)	8.70 (1.57)		
Week 52 Mean (SD)	5.15 (3.51)	5.63 (2.20)		
Week 52 Adjusted Mean Change (SE)	-4.13 (0.73)	-3.53 (0.86)	-0.60 [-2.84; 1.64]	0.596
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.15 mCPDAI - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.600</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	8.82 (1.82)	9.19 (1.98)		
Week 52 Mean (SD)	4.32 (3.09)	5.72 (2.47)		
Week 52 Adjusted Mean Change (SE)	-4.41 (0.57)	-3.62 (0.56)	-0.79 [-2.38; 0.80]	0.327
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	9.49 (1.50)	8.56 (1.83)		
Week 52 Mean (SD)	5.33 (2.70)	4.97 (2.74)		
Week 52 Adjusted Mean Change (SE)	-3.97 (0.33)	-3.73 (0.42)	-0.24 [-1.31; 0.83]	0.663
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.16 mCPDAI - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.780</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	9.41 (1.44)	8.86 (1.93)		
Week 52 Mean (SD)	5.04 (2.83)	5.38 (2.71)		
Week 52 Adjusted Mean Change (SE)	-4.26 (0.37)	-3.53 (0.47)	-0.73 [-1.91; 0.46]	0.228
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	9.18 (1.83)	8.75 (1.90)		
Week 52 Mean (SD)	5.17 (2.83)	5.07 (2.64)		
Week 52 Adjusted Mean Change (SE)	-3.80 (0.46)	-3.85 (0.47)	0.05 [-1.25; 1.35]	0.940
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.17 mCPDAI - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.325</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	9.17 (1.53)	8.94 (1.95)		
Week 52 Mean (SD)	5.03 (2.96)	5.14 (2.77)		
Week 52 Adjusted Mean Change (SE)	-4.12 (0.48)	-3.58 (0.51)	-0.54 [-1.94; 0.85]	0.442
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	9.40 (1.65)	8.69 (1.88)		
Week 52 Mean (SD)	5.12 (2.75)	5.27 (2.63)		
Week 52 Adjusted Mean Change (SE)	-4.04 (0.36)	-3.77 (0.45)	-0.27 [-1.41; 0.88]	0.646
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.18 mCPDAI - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.710</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	9.35 (1.67)	8.93 (1.91)		
Week 52 Mean (SD)	4.97 (2.92)	5.41 (2.47)		
Week 52 Adjusted Mean Change (SE)	-4.20 (0.41)	-3.72 (0.41)	-0.47 [-1.62; 0.67]	0.413
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	9.29 (1.55)	8.58 (1.91)		
Week 52 Mean (SD)	5.20 (2.74)	4.83 (3.05)		
Week 52 Adjusted Mean Change (SE)	-3.96 (0.40)	-3.69 (0.58)	-0.27 [-1.67; 1.13]	0.707
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 32.19 mCPDAI - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.865</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	9.31 (1.67)	8.84 (1.96)		
Week 52 Mean (SD)	5.23 (2.85)	5.58 (2.56)		
Week 52 Adjusted Mean Change (SE)	-3.93 (0.33)	-3.45 (0.39)	-0.48 [-1.49; 0.54]	0.355
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	9.22 (1.44)	8.72 (1.78)		
Week 52 Mean (SD)	4.24 (2.54)	4.41 (2.76)		
Week 52 Adjusted Mean Change (SE)	-4.81 (0.62)	-4.34 (0.62)	-0.47 [-2.20; 1.26]	0.592
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 33.1 mCPDAI Low Disease Activity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
mCPDAI Low Disease Activity Week 52, N' n (%)	103 29.94 (27.22)	80 20.26 (20.06)	1.53 [0.78; 3.01] 0.220	1.36 [0.81; 2.28] 0.244	0.072 [-0.047; 0.190] 0.236
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR from logistic regression model with predictors treatment and weight.  RR and RD calculated directly without adjustment.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.2 mCPDAI Low Disease Activity by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	N.E.				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	98 27.90 (27.09)	74 20.22 (21.51)	1.40 [0.70; 2.80] 0.342	1.26 [0.75; 2.12] 0.382	0.056 [-0.068; 0.180] 0.377
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	5 2.04 (29.14)	6 0.04 (0.57)	N.E.	4.89 [0.28; 86.29] 0.279	0.286 [-0.064; 0.635] 0.109
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 33.3 mCPDAI Low Disease Activity by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.841				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	62 22.10 (33.48)	46 15.92 (27.93)	1.50 [0.66; 3.43] 0.336	1.20 [0.69; 2.10] 0.518	0.056 [-0.112; 0.223] 0.516
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	41 7.84 (17.82)	34 4.34 (9.86)	1.77 [0.45; 6.99] 0.416	1.83 [0.56; 5.99] 0.317	0.080 [-0.072; 0.231] 0.304
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale  with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,  subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of  imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.4 mCPDAI Low Disease Activity by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.482				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	23 11.17 (46.54)	16 6.61 (31.48)	2.32 [0.61; 8.79] 0.215	1.49 [0.66; 3.37] 0.337	0.151 [-0.144; 0.445] 0.315
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	80 18.77 (21.83)	64 13.65 (17.06)	1.33 [0.59; 2.99] 0.491	1.28 [0.67; 2.46] 0.453	0.048 [-0.076; 0.171] 0.450
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.5 mCPDAI Low Disease Activity by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.104				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	39 10.73 (25.55)	37 13.46 (26.39)	0.87 [0.32; 2.35] 0.780	0.97 [0.47; 2.00] 0.933	-0.008 [-0.196; 0.179] 0.930
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	64 19.21 (28.25)	43 6.80 (13.60)	2.85 [1.03; 7.90] 0.045	2.09 [0.91; 4.79] 0.081	0.147 [0.001; 0.292] 0.049
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.6 mCPDAI Low Disease Activity by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.635				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	70 20.08 (27.89)	34 9.05 (18.47)	1.79 [0.70; 4.59] 0.223	1.52 [0.73; 3.15] 0.263	0.094 [-0.061; 0.249] 0.235
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	33 9.86 (25.95)	46 11.21 (21.56)	1.28 [0.46; 3.60] 0.640	1.20 [0.55; 2.63] 0.640	0.044 [-0.142; 0.230] 0.643
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.7 mCPDAI Low Disease Activity by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.555				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	47 17.58 (34.47)	25 7.08 (22.13)	1.81 [0.61; 5.35] 0.282	1.57 [0.71; 3.48] 0.268	0.123 [-0.079; 0.325] 0.231
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	56 12.36 (20.95)	55 13.18 (19.10)	1.18 [0.48; 2.94] 0.716	1.10 [0.54; 2.26] 0.796	0.018 [-0.125; 0.162] 0.801
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale  with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,  subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of  imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.8 mCPDAI Low Disease Activity by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.615				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	48 12.67 (24.84)	34 10.42 (25.41)	0.98 [0.36; 2.71] 0.971	0.98 [0.46; 2.07] 0.960	-0.006 [-0.193; 0.182] 0.952
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	31 8.25 (24.26)	21 4.42 (17.00)	1.52 [0.39; 5.92] 0.547	1.44 [0.49; 4.22] 0.510	0.073 [-0.138; 0.283] 0.498
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale  with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,  subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of  imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.9 mCPDAI Low Disease Activity by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.955				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	43 11.23 (24.96)	19 6.22 (23.04)	1.27 [0.36; 4.42] 0.709	1.10 [0.44; 2.76] 0.845	0.019 [-0.197; 0.235] 0.862
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	34 9.69 (25.50)	27 5.61 (18.70)	1.33 [0.38; 4.67] 0.651	1.37 [0.52; 3.57] 0.523	0.068 [-0.135; 0.271] 0.512
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale  with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,  subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of  imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.10 mCPDAI Low Disease Activity by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.892				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	29 8.17 (27.23)	24 7.45 (22.58)	1.24 [0.36; 4.22] 0.732	1.21 [0.49; 2.99] 0.673	0.047 [-0.175; 0.268] 0.681
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	48 11.56 (22.67)	31 7.39 (21.74)	1.11 [0.37; 3.30] 0.857	1.04 [0.45; 2.42] 0.918	0.009 [-0.175; 0.194] 0.921
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale  with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,  subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of  imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 33.11 mCPDAI Low Disease Activity by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.145				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	39 11.86 (27.58)	37 6.74 (15.67)	1.92 [0.62; 5.99] 0.261	1.77 [0.72; 4.33] 0.211	0.119 [-0.061; 0.299] 0.194
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	40 9.06 (21.57)	18 8.10 (33.75)	0.57 [0.17; 1.85] 0.350	0.64 [0.28; 1.47] 0.293	-0.122 [-0.356; 0.113] 0.309
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale  with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,  subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of  imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.12 mCPDAI Low Disease Activity by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.705				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	57 14.75 (23.79)	36 9.79 (20.83)	1.30 [0.48; 3.51] 0.608	1.15 [0.54; 2.46] 0.721	0.030 [-0.137; 0.196] 0.728
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	19 6.17 (30.85)	17 5.05 (28.06)	0.92 [0.21; 3.97] 0.910	1.10 [0.40; 2.99] 0.854	0.028 [-0.265; 0.321] 0.852
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale  with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,  subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of  imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.13 mCPDAI Low Disease Activity by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.481				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	58 16.92 (26.86)	40 11.81 (23.16)	1.20 [0.48; 3.01] 0.700	1.16 [0.59; 2.30] 0.662	0.037 [-0.130; 0.204] 0.664
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	18 3.00 (15.79)	12 3.00 (25.00)	0.57 [0.09; 3.60] 0.552	0.63 [0.15; 2.63] 0.528	-0.092 [-0.387; 0.203] 0.540
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) mCPDAI Low Disease Activity, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

### 33.14 mCPDAI Low Disease Activity by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	N.E.				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	65 16.92 (23.83)	44 13.22 (24.94)	0.97 [0.40; 2.32] 0.940	0.96 [0.50; 1.84] 0.895	-0.011 [-0.170; 0.148] 0.891
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	13 4.00 (30.77)	8 0.57 (5.70)	N.E.	4.41 [0.35; 56.19] 0.253	0.251 [-0.054; 0.556] 0.107
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.15 mCPDAI Low Disease Activity by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.422				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	19 7.36 (33.45)	18 5.19 (19.96)	1.89 [0.44; 8.03] 0.389	1.70 [0.59; 4.93] 0.327	0.135 [-0.130; 0.400] 0.318
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	60 13.56 (21.52)	37 9.65 (23.54)	0.93 [0.35; 2.45] 0.876	0.92 [0.44; 1.92] 0.815	-0.020 [-0.188; 0.148] 0.815
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.16 mCPDAI Low Disease Activity by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.975				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	49 12.23 (23.98)	26 8.23 (23.51)	1.15 [0.39; 3.43] 0.798	1.03 [0.46; 2.32] 0.950	0.005 [-0.187; 0.196] 0.962
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	30 8.69 (25.56)	29 6.61 (20.66)	1.12 [0.33; 3.82] 0.853	1.24 [0.49; 3.11] 0.650	0.049 [-0.161; 0.259] 0.647
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.17 mCPDAI Low Disease Activity by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.942				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	29 8.17 (27.23)	22 7.45 (24.03)	1.13 [0.33; 3.89] 0.842	1.14 [0.47; 2.80] 0.774	0.032 [-0.196; 0.260] 0.783
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	50 12.75 (23.18)	33 7.39 (20.53)	1.20 [0.41; 3.51] 0.735	1.13 [0.49; 2.59] 0.771	0.027 [-0.151; 0.204] 0.770
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 33.18 mCPDAI Low Disease Activity by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.145				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	39 11.86 (27.58)	37 6.74 (15.67)	1.92 [0.62; 5.99] 0.261	1.77 [0.72; 4.33] 0.211	0.119 [-0.061; 0.299] 0.194
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	40 9.06 (21.57)	18 8.10 (33.75)	0.57 [0.17; 1.85] 0.350	0.64 [0.28; 1.47] 0.293	-0.122 [-0.356; 0.113] 0.309
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale  with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,  subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of  imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 33.19 mCPDAI Low Disease Activity by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
mCPDAI Low Disease Activity Week 52	p=0.584				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	60 15.75 (24.23)	38 9.79 (19.98)	1.38 [0.52; 3.69] 0.517	1.22 [0.57; 2.60] 0.605	0.043 [-0.119; 0.204] 0.607
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
mCPDAI Low Disease Activity Week 52, N' n (%)	17 5.17 (28.72)	17 5.05 (28.06)	0.83 [0.18; 3.81] 0.810	1.02 [0.36; 2.93] 0.967	0.007 [-0.291; 0.305] 0.965
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale  with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters,  subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of  imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.1 MDA Minimal Disease Activity / Very Low Disease Activity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Minimal Disease Activity Week 52, N' n (%)	105 51.04 (46.40)	85 39.90 (39.50)	1.37 [0.78; 2.43] 0.276	1.17 [0.85; 1.62] 0.325	0.069 [-0.067; 0.205] 0.320
Very Low Disease Activity Week 52, N' n (%)	105 16.29 (14.81)	85 15.90 (15.74)	0.94 [0.43; 2.04] 0.868	0.94 [0.49; 1.80] 0.855	-0.009 [-0.108; 0.090] 0.853

N': Number of patients with available response value  
N-N' is the number of values with MI.  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
MI: Multiple Imputation  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.  
RR and RD calculated directly without adjustment.

All results are combined over MI:  
n and % are averages of all imputations.  
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

### 34.2 MDA Minimal Disease Activity / Very Low Disease Activity by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.784				
Very Low Disease Activity Week 52	p=0.466				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
Minimal Disease Activity Week 52, N' n (%)	99 47.93 (46.53)	78 37.90 (40.32)	1.34 [0.75; 2.42] 0.326	1.15 [0.83; 1.60] 0.391	0.062 [-0.079; 0.203] 0.388
Very Low Disease Activity Week 52, N' n (%)	99 15.28 (14.83)	78 13.90 (14.79)	1.02 [0.45; 2.32] 0.955	1.00 [0.51; 1.99] 0.990	0.000 [-0.101; 0.102] 0.993
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
Minimal Disease Activity Week 52, N' n (%)	6 3.11 (44.43)	7 2.00 (28.57)	1.87 [0.19; 18.33] 0.591	1.55 [0.36; 6.60] 0.554	0.159 [-0.346; 0.663] 0.538
Very Low Disease Activity Week 52, N' n (%)	6 1.01 (14.43)	7 2.00 (28.57)	0.36 [0.02; 5.45] 0.458	0.50 [0.06; 4.36] 0.533	-0.141 [-0.566; 0.283] 0.514
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.3 MDA Minimal Disease Activity / Very Low Disease Activity by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.342				
Very Low Disease Activity Week 52	p=0.572				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
Minimal Disease Activity Week 52, N' n (%)	64 35.46 (53.73)	49 31.47 (55.21)	1.11 [0.51; 2.38] 0.798	0.97 [0.70; 1.36] 0.874	-0.015 [-0.196; 0.166] 0.872
Very Low Disease Activity Week 52, N' n (%)	64 11.04 (16.73)	49 12.51 (21.95)	0.82 [0.32; 2.09] 0.671	0.76 [0.37; 1.59] 0.471	-0.052 [-0.194; 0.090] 0.471
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
Minimal Disease Activity Week 52, N' n (%)	41 15.58 (35.41)	36 8.43 (19.16)	2.06 [0.74; 5.72] 0.167	1.85 [0.88; 3.89] 0.104	0.162 [-0.023; 0.348] 0.087
Very Low Disease Activity Week 52, N' n (%)	41 5.25 (11.93)	36 3.39 (7.70)	1.37 [0.30; 6.25] 0.687	1.56 [0.40; 6.02] 0.518	0.042 [-0.085; 0.170] 0.516
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.4 MDA Minimal Disease Activity / Very Low Disease Activity by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.596				
Very Low Disease Activity Week 52	p=0.644				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
Minimal Disease Activity Week 52, N' n (%)	23 14.54 (60.58)	17 13.59 (64.71)	1.00 [0.27; 3.70] 0.995	0.94 [0.59; 1.50] 0.785	-0.041 [-0.334; 0.252] 0.782
Very Low Disease Activity Week 52, N' n (%)	23 5.03 (20.96)	17 6.54 (31.14)	0.72 [0.17; 2.98] 0.652	0.68 [0.24; 1.87] 0.451	-0.102 [-0.364; 0.160] 0.446
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
Minimal Disease Activity Week 52, N' n (%)	82 36.50 (42.44)	68 26.31 (32.89)	1.49 [0.77; 2.89] 0.233	1.29 [0.86; 1.94] 0.219	0.096 [-0.054; 0.245] 0.211
Very Low Disease Activity Week 52, N' n (%)	82 11.26 (13.09)	68 9.36 (11.70)	1.08 [0.42; 2.81] 0.875	1.12 [0.49; 2.55] 0.788	0.014 [-0.088; 0.116] 0.788
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.5 MDA Minimal Disease Activity / Very Low Disease Activity by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.271				
Very Low Disease Activity Week 52	p=0.550				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
Minimal Disease Activity Week 52, N' n (%)	39 15.82 (37.67)	40 19.15 (37.55)	0.90 [0.37; 2.19] 0.820	1.00 [0.58; 1.72] 0.992	0.001 [-0.201; 0.204] 0.991
Very Low Disease Activity Week 52, N' n (%)	39 7.28 (17.33)	40 9.70 (19.02)	0.76 [0.25; 2.34] 0.633	0.91 [0.37; 2.22] 0.839	-0.017 [-0.178; 0.144] 0.837
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
Minimal Disease Activity Week 52, N' n (%)	66 35.22 (51.79)	45 20.75 (41.50)	1.75 [0.81; 3.81] 0.155	1.25 [0.83; 1.88] 0.288	0.103 [-0.081; 0.287] 0.273
Very Low Disease Activity Week 52, N' n (%)	66 9.01 (13.25)	45 6.20 (12.40)	1.24 [0.40; 3.83] 0.708	1.07 [0.41; 2.81] 0.890	0.008 [-0.114; 0.131] 0.892
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.6 MDA Minimal Disease Activity / Very Low Disease Activity by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.963				
Very Low Disease Activity Week 52	p=0.823				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
Minimal Disease Activity Week 52, N' n (%)	70 36.46 (50.64)	38 22.46 (45.84)	1.28 [0.60; 2.74] 0.527	1.11 [0.75; 1.63] 0.613	0.048 [-0.137; 0.233] 0.610
Very Low Disease Activity Week 52, N' n (%)	70 12.04 (16.72)	38 8.83 (18.02)	0.95 [0.35; 2.57] 0.913	0.93 [0.42; 2.09] 0.862	-0.013 [-0.154; 0.128] 0.857
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
Minimal Disease Activity Week 52, N' n (%)	35 14.58 (38.37)	47 17.44 (33.54)	1.24 [0.50; 3.07] 0.637	1.14 [0.65; 2.02] 0.643	0.048 [-0.157; 0.254] 0.645
Very Low Disease Activity Week 52, N' n (%)	35 4.25 (11.18)	47 7.07 (13.60)	0.78 [0.21; 2.94] 0.718	0.82 [0.26; 2.59] 0.734	-0.024 [-0.163; 0.115] 0.734
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.7 MDA Minimal Disease Activity / Very Low Disease Activity by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.856				
Very Low Disease Activity Week 52	p=0.601				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
Minimal Disease Activity Week 52, N' n (%)	49 29.28 (57.41)	28 17.05 (53.28)	1.13 [0.45; 2.88] 0.791	1.08 [0.71; 1.63] 0.719	0.041 [-0.183; 0.266] 0.718
Very Low Disease Activity Week 52, N' n (%)	49 9.25 (18.14)	28 7.40 (23.13)	0.67 [0.21; 2.11] 0.495	0.79 [0.33; 1.89] 0.589	-0.050 [-0.234; 0.134] 0.595
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
Minimal Disease Activity Week 52, N' n (%)	56 21.76 (36.88)	57 22.85 (33.12)	1.27 [0.59; 2.72] 0.542	1.11 [0.69; 1.81] 0.662	0.038 [-0.132; 0.208] 0.664
Very Low Disease Activity Week 52, N' n (%)	56 7.04 (11.93)	57 8.50 (12.32)	1.02 [0.34; 3.06] 0.966	0.97 [0.38; 2.51] 0.951	-0.004 [-0.119; 0.111] 0.947
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 34.8 MDA Minimal Disease Activity / Very Low Disease Activity by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.826				
Very Low Disease Activity Week 52	p=0.497				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
Minimal Disease Activity Week 52, N' n (%)	49 24.47 (47.98)	37 17.90 (43.66)	1.22 [0.52; 2.87] 0.644	1.10 [0.70; 1.73] 0.685	0.043 [-0.164; 0.250] 0.683
Very Low Disease Activity Week 52, N' n (%)	49 9.25 (18.14)	37 10.45 (25.49)	0.63 [0.22; 1.81] 0.395	0.71 [0.32; 1.58] 0.404	-0.074 [-0.247; 0.100] 0.407
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
Minimal Disease Activity Week 52, N' n (%)	31 15.57 (45.79)	22 11.53 (44.35)	1.05 [0.36; 3.07] 0.932	1.03 [0.58; 1.84] 0.912	0.014 [-0.245; 0.274] 0.913
Very Low Disease Activity Week 52, N' n (%)	31 2.04 (6.00)	22 4.01 (15.42)	0.31 [0.05; 1.89] 0.202	0.39 [0.08; 1.96] 0.251	-0.094 [-0.255; 0.066] 0.250
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.9 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.693				
Very Low Disease Activity Week 52	p=0.639				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
Minimal Disease Activity Week 52, N' n (%)	43 21.46 (47.69)	21 11.31 (41.89)	1.40 [0.51; 3.85] 0.516	1.14 [0.66; 1.98] 0.643	0.058 [-0.184; 0.300] 0.638
Very Low Disease Activity Week 52, N' n (%)	43 6.03 (13.40)	21 5.46 (20.22)	0.68 [0.18; 2.59] 0.570	0.67 [0.23; 1.96] 0.460	-0.068 [-0.254; 0.118] 0.472
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
Minimal Disease Activity Week 52, N' n (%)	35 17.58 (46.26)	28 13.12 (43.73)	1.05 [0.39; 2.84] 0.926	1.06 [0.62; 1.81] 0.839	0.025 [-0.216; 0.267] 0.837
Very Low Disease Activity Week 52, N' n (%)	35 5.26 (13.84)	28 7.00 (23.33)	0.43 [0.12; 1.62] 0.213	0.59 [0.21; 1.67] 0.322	-0.095 [-0.283; 0.094] 0.324
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.10 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.479				
Very Low Disease Activity Week 52	p=0.067				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
Minimal Disease Activity Week 52, N' n (%)	29 12.11 (40.37)	26 14.55 (44.09)	0.83 [0.29; 2.34] 0.720	0.92 [0.51; 1.65] 0.771	-0.037 [-0.285; 0.210] 0.768
Very Low Disease Activity Week 52, N' n (%)	29 5.00 (16.67)	26 3.31 (10.03)	1.71 [0.36; 8.13] 0.502	1.68 [0.44; 6.35] 0.447	0.066 [-0.104; 0.237] 0.445
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
Minimal Disease Activity Week 52, N' n (%)	49 25.28 (49.57)	33 14.88 (43.76)	1.36 [0.56; 3.33] 0.501	1.13 [0.70; 1.82] 0.607	0.058 [-0.159; 0.275] 0.601
Very Low Disease Activity Week 52, N' n (%)	49 6.25 (12.25)	33 11.15 (32.79)	0.28 [0.09; 0.88] 0.030	0.37 [0.15; 0.91] 0.030	-0.205 [-0.389; -0.022] 0.028
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.11 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.811				
Very Low Disease Activity Week 52	p=0.390				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
Minimal Disease Activity Week 52, N' n (%)	39 21.69 (50.44)	39 20.02 (46.56)	1.11 [0.46; 2.67] 0.824	1.08 [0.69; 1.69] 0.724	0.039 [-0.176; 0.254] 0.723
Very Low Disease Activity Week 52, N' n (%)	39 7.26 (16.88)	39 8.45 (19.65)	0.72 [0.23; 2.31] 0.585	0.86 [0.34; 2.15] 0.747	-0.028 [-0.195; 0.139] 0.745
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
Minimal Disease Activity Week 52, N' n (%)	41 18.35 (43.69)	20 9.41 (39.21)	1.31 [0.45; 3.77] 0.618	1.12 [0.60; 2.06] 0.728	0.045 [-0.205; 0.295] 0.725
Very Low Disease Activity Week 52, N' n (%)	41 4.03 (9.60)	20 6.01 (25.04)	0.33 [0.08; 1.34] 0.120	0.38 [0.12; 1.22] 0.105	-0.154 [-0.350; 0.041] 0.121
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.12 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.328				
Very Low Disease Activity Week 52	p=0.591				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
Minimal Disease Activity Week 52, N' n (%)	58 27.93 (45.05)	40 18.37 (39.09)	1.41 [0.63; 3.15] 0.402	1.15 [0.73; 1.83] 0.544	0.060 [-0.130; 0.250] 0.538
Very Low Disease Activity Week 52, N' n (%)	58 6.29 (10.15)	40 7.46 (15.87)	0.64 [0.20; 2.09] 0.459	0.64 [0.23; 1.77] 0.388	-0.057 [-0.189; 0.075] 0.395
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
Minimal Disease Activity Week 52, N' n (%)	19 11.11 (55.55)	17 11.06 (61.44)	0.64 [0.17; 2.47] 0.518	0.90 [0.53; 1.55] 0.714	-0.059 [-0.374; 0.256] 0.714
Very Low Disease Activity Week 52, N' n (%)	19 5.00 (25.00)	17 7.00 (38.89)	0.38 [0.09; 1.66] 0.198	0.64 [0.25; 1.67] 0.364	-0.139 [-0.433; 0.156] 0.355
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) Very Low Disease Activity, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

### 34.13 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.660				
Very Low Disease Activity Week 52	p=0.909				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
Minimal Disease Activity Week 52, N' n (%)	58 31.04 (49.27)	44 23.43 (45.94)	1.13 [0.52; 2.44] 0.759	1.07 [0.72; 1.59] 0.729	0.033 [-0.154; 0.221] 0.728
Very Low Disease Activity Week 52, N' n (%)	58 8.29 (13.16)	44 11.46 (22.47)	0.48 [0.17; 1.36] 0.167	0.59 [0.26; 1.34] 0.206	-0.093 [-0.238; 0.051] 0.206
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
Minimal Disease Activity Week 52, N' n (%)	19 8.00 (42.11)	12 4.00 (33.33)	1.66 [0.35; 7.86] 0.520	1.26 [0.48; 3.29] 0.633	0.088 [-0.259; 0.435] 0.620
Very Low Disease Activity Week 52, N' n (%)	19 2.00 (10.53)	12 2.00 (16.67)	0.55 [0.06; 4.89] 0.594	0.63 [0.10; 3.91] 0.621	-0.061 [-0.313; 0.191] 0.633
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) Minimal Disease Activity, Very Low Disease Activity, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

### 34.14 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.927				
Very Low Disease Activity Week 52	p=0.913				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
Minimal Disease Activity Week 52, N' n (%)	66 33.04 (46.54)	46 23.37 (44.09)	1.16 [0.55; 2.45] 0.696	1.06 [0.71; 1.57] 0.791	0.024 [-0.156; 0.204] 0.790
Very Low Disease Activity Week 52, N' n (%)	66 8.29 (11.68)	46 11.46 (21.62)	0.47 [0.17; 1.30] 0.146	0.54 [0.23; 1.24] 0.148	-0.099 [-0.236; 0.037] 0.152
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
Minimal Disease Activity Week 52, N' n (%)	13 6.00 (46.15)	10 4.00 (40.00)	1.06 [0.20; 5.75] 0.942	1.15 [0.44; 3.01] 0.770	0.062 [-0.345; 0.469] 0.767
Very Low Disease Activity Week 52, N' n (%)	13 2.00 (15.38)	10 2.00 (20.00)	0.53 [0.06; 4.80] 0.576	0.77 [0.13; 4.55] 0.772	-0.046 [-0.362; 0.270] 0.775
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) Minimal Disease Activity, Very Low Disease Activity, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

### 34.15 MDA Minimal Disease Activity / Very Low Disease Activity by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.185				
Very Low Disease Activity Week 52	p=0.212				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
Minimal Disease Activity Week 52, N' n (%)	19 12.76 (58.00)	20 9.37 (36.04)	2.30 [0.67; 7.87] 0.185	1.61 [0.84; 3.08] 0.149	0.220 [-0.066; 0.505] 0.132
Very Low Disease Activity Week 52, N' n (%)	19 3.04 (13.82)	20 2.46 (9.46)	1.42 [0.21; 9.59] 0.720	1.50 [0.28; 7.95] 0.636	0.044 [-0.145; 0.232] 0.651
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
Minimal Disease Activity Week 52, N' n (%)	61 27.28 (43.30)	39 20.06 (48.93)	0.85 [0.38; 1.90] 0.688	0.88 [0.58; 1.35] 0.572	-0.056 [-0.253; 0.141] 0.576
Very Low Disease Activity Week 52, N' n (%)	61 8.25 (13.10)	39 12.00 (29.27)	0.36 [0.13; 1.00] 0.051	0.45 [0.20; 1.00] 0.049	-0.162 [-0.325; 0.001] 0.052
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 34.16 MDA Minimal Disease Activity / Very Low Disease Activity by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.887				
Very Low Disease Activity Week 52	p=0.935				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
Minimal Disease Activity Week 52, N' n (%)	49 23.46 (46.00)	29 16.31 (46.60)	1.10 [0.44; 2.70] 0.843	0.99 [0.62; 1.58] 0.958	-0.006 [-0.224; 0.212] 0.957
Very Low Disease Activity Week 52, N' n (%)	49 6.03 (11.82)	29 7.46 (21.31)	0.54 [0.16; 1.84] 0.327	0.56 [0.21; 1.51] 0.249	-0.095 [-0.260; 0.070] 0.260
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
Minimal Disease Activity Week 52, N' n (%)	31 16.58 (48.76)	30 13.12 (41.00)	1.21 [0.44; 3.32] 0.712	1.19 [0.69; 2.06] 0.536	0.078 [-0.165; 0.321] 0.531
Very Low Disease Activity Week 52, N' n (%)	31 5.26 (15.47)	30 7.00 (21.88)	0.50 [0.13; 1.89] 0.309	0.70 [0.25; 1.99] 0.509	-0.064 [-0.254; 0.126] 0.508
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.17 MDA Minimal Disease Activity / Very Low Disease Activity by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.279				
Very Low Disease Activity Week 52	p=0.076				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
Minimal Disease Activity Week 52, N' n (%)	29 12.11 (40.37)	24 14.55 (46.94)	0.73 [0.25; 2.10] 0.556	0.86 [0.48; 1.54] 0.614	-0.066 [-0.318; 0.187] 0.610
Very Low Disease Activity Week 52, N' n (%)	29 5.00 (16.67)	24 3.31 (10.68)	1.58 [0.33; 7.56] 0.566	1.58 [0.42; 5.95] 0.503	0.060 [-0.115; 0.234] 0.501
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
Minimal Disease Activity Week 52, N' n (%)	51 27.93 (50.78)	35 14.88 (41.33)	1.56 [0.65; 3.74] 0.321	1.23 [0.76; 1.97] 0.395	0.094 [-0.116; 0.305] 0.380
Very Low Disease Activity Week 52, N' n (%)	51 6.29 (11.44)	35 11.15 (30.97)	0.28 [0.09; 0.86] 0.027	0.37 [0.15; 0.91] 0.030	-0.195 [-0.370; -0.020] 0.029
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.18 MDA Minimal Disease Activity / Very Low Disease Activity by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.811				
Very Low Disease Activity Week 52	p=0.390				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
Minimal Disease Activity Week 52, N' n (%)	39 21.69 (50.44)	39 20.02 (46.56)	1.11 [0.46; 2.67] 0.824	1.08 [0.69; 1.69] 0.724	0.039 [-0.176; 0.254] 0.723
Very Low Disease Activity Week 52, N' n (%)	39 7.26 (16.88)	39 8.45 (19.65)	0.72 [0.23; 2.31] 0.585	0.86 [0.34; 2.15] 0.747	-0.028 [-0.195; 0.139] 0.745
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
Minimal Disease Activity Week 52, N' n (%)	41 18.35 (43.69)	20 9.41 (39.21)	1.31 [0.45; 3.77] 0.618	1.12 [0.60; 2.06] 0.728	0.045 [-0.205; 0.295] 0.725
Very Low Disease Activity Week 52, N' n (%)	41 4.03 (9.60)	20 6.01 (25.04)	0.33 [0.08; 1.34] 0.120	0.38 [0.12; 1.22] 0.105	-0.154 [-0.350; 0.041] 0.121
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 34.19 MDA Minimal Disease Activity / Very Low Disease Activity by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
Minimal Disease Activity Week 52	p=0.301				
Very Low Disease Activity Week 52	p=0.394				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
Minimal Disease Activity Week 52, N' n (%)	61 29.93 (46.05)	42 18.37 (37.49)	1.56 [0.71; 3.43] 0.273	1.23 [0.78; 1.94] 0.376	0.086 [-0.099; 0.271] 0.365
Very Low Disease Activity Week 52, N' n (%)	61 7.29 (11.22)	42 7.46 (15.22)	0.74 [0.24; 2.32] 0.605	0.74 [0.28; 1.95] 0.540	-0.040 [-0.170; 0.090] 0.544
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
Minimal Disease Activity Week 52, N' n (%)	17 10.11 (56.17)	17 11.06 (61.44)	0.67 [0.17; 2.67] 0.567	0.91 [0.53; 1.59] 0.750	-0.053 [-0.376; 0.271] 0.749
Very Low Disease Activity Week 52, N' n (%)	17 4.00 (22.22)	17 7.00 (38.89)	0.32 [0.07; 1.52] 0.151	0.57 [0.20; 1.62] 0.292	-0.167 [-0.463; 0.129] 0.270
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) Very Low Disease Activity, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

### 35.0 PASDAS - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	108 (98.2)	94 (93.1)	202 (95.7)
Week 12 Returns	105 (95.5)	97 (96.0)	202 (95.7)
Week 16 Returns	106 (96.4)	89 (88.1)	195 (92.4)
Week 24 Returns	105 (95.5)	89 (88.1)	194 (91.9)
Week 32 Returns	98 (89.1)	79 (78.2)	177 (83.9)
Week 40 Returns	104 (94.5)	78 (77.2)	182 (86.3)
Week 52 Returns	103 (93.6)	80 (79.2)	183 (86.7)

### 35.1 PASDAS - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	6.11 (0.87)	6.21 (0.95)		
Week 52 Mean (SD)	3.03 (1.31)	3.11 (1.24)		
Week 52 Adjusted Mean Change (SE)	-3.09 (0.12)	-2.94 (0.13)	-0.14 [-0.49; 0.21]	0.426
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

### 35.2 PASDAS - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.747</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	6.10 (0.84)	6.24 (0.94)		
Week 52 Mean (SD)	3.02 (1.28)	3.13 (1.24)		
Week 52 Adjusted Mean Change (SE)	-3.11 (0.12)	-2.92 (0.14)	-0.19 [-0.56; 0.18]	0.310
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	6.34 (1.35)	5.86 (1.15)		
Week 52 Mean (SD)	3.27 (1.84)	2.86 (1.21)		
Week 52 Adjusted Mean Change (SE)	-2.76 (0.50)	-3.16 (0.49)	0.40 [-0.98; 1.77]	0.571
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.3 PASDAS - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.450</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	5.98 (0.83)	6.15 (0.91)		
Week 52 Mean (SD)	2.72 (1.12)	2.84 (1.25)		
Week 52 Adjusted Mean Change (SE)	-3.42 (0.15)	-3.27 (0.16)	-0.15 [-0.59; 0.29]	0.503
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	6.31 (0.91)	6.29 (1.00)		
Week 52 Mean (SD)	3.50 (1.43)	3.47 (1.14)		
Week 52 Adjusted Mean Change (SE)	-2.60 (0.18)	-2.50 (0.19)	-0.10 [-0.62; 0.42]	0.714
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 35.4 PASDAS - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.391</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	5.00 (0.33)	4.84 (0.54)		
Week 52 Mean (SD)	2.60 (1.08)	2.59 (1.23)		
Week 52 Adjusted Mean Change (SE)	-3.28 (0.31)	-3.19 (0.34)	-0.09 [-0.86; 0.68]	0.819
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	6.42 (0.70)	6.57 (0.67)		
Week 52 Mean (SD)	3.15 (1.34)	3.24 (1.21)		
Week 52 Adjusted Mean Change (SE)	-3.04 (0.14)	-2.87 (0.16)	-0.17 [-0.57; 0.23]	0.413
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.5 PASDAS - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.950</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	5.83 (0.75)	6.20 (0.97)		
Week 52 Mean (SD)	3.14 (1.10)	3.05 (1.25)		
Week 52 Adjusted Mean Change (SE)	-2.89 (0.20)	-2.93 (0.19)	0.03 [-0.51; 0.58]	0.899
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	6.29 (0.90)	6.23 (0.94)		
Week 52 Mean (SD)	2.96 (1.42)	3.16 (1.23)		
Week 52 Adjusted Mean Change (SE)	-3.20 (0.15)	-2.98 (0.18)	-0.22 [-0.69; 0.25]	0.350
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.6 PASDAS - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.503</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	6.11 (0.89)	6.08 (1.09)		
Week 52 Mean (SD)	2.83 (1.17)	2.88 (1.14)		
Week 52 Adjusted Mean Change (SE)	-3.31 (0.15)	-3.00 (0.19)	-0.31 [-0.78; 0.17]	0.208
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	6.13 (0.84)	6.34 (0.80)		
Week 52 Mean (SD)	3.45 (1.48)	3.28 (1.29)		
Week 52 Adjusted Mean Change (SE)	-2.64 (0.21)	-2.88 (0.18)	0.23 [-0.30; 0.77]	0.394
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.7 PASDAS - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.471</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	5.75 (0.74)	5.64 (1.01)		
Week 52 Mean (SD)	2.78 (1.21)	2.75 (1.28)		
Week 52 Adjusted Mean Change (SE)	-3.22 (0.18)	-3.08 (0.24)	-0.14 [-0.72; 0.44]	0.626
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	6.43 (0.86)	6.48 (0.80)		
Week 52 Mean (SD)	3.24 (1.36)	3.28 (1.19)		
Week 52 Adjusted Mean Change (SE)	-2.97 (0.17)	-2.88 (0.16)	-0.10 [-0.55; 0.36]	0.671
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.8 PASDAS - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.690</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	6.20 (0.72)	6.14 (0.98)		
Week 52 Mean (SD)	3.03 (1.41)	2.91 (1.18)		
Week 52 Adjusted Mean Change (SE)	-3.07 (0.18)	-3.14 (0.21)	0.08 [-0.47; 0.62]	0.783
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	5.97 (0.91)	6.13 (0.97)		
Week 52 Mean (SD)	3.03 (1.27)	3.18 (1.28)		
Week 52 Adjusted Mean Change (SE)	-3.03 (0.22)	-2.74 (0.27)	-0.29 [-0.98; 0.40]	0.405
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.9 PASDAS - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.129</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	6.17 (0.81)	6.13 (0.88)		
Week 52 Mean (SD)	2.90 (1.23)	2.95 (1.13)		
Week 52 Adjusted Mean Change (SE)	-3.25 (0.20)	-2.89 (0.27)	-0.36 [-1.03; 0.31]	0.293
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	6.03 (0.80)	6.20 (0.98)		
Week 52 Mean (SD)	3.15 (1.45)	3.13 (1.35)		
Week 52 Adjusted Mean Change (SE)	-2.86 (0.22)	-3.01 (0.24)	0.15 [-0.50; 0.80]	0.651
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.10 PASDAS - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.307</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	6.21 (0.92)	6.27 (0.92)		
Week 52 Mean (SD)	3.32 (1.36)	3.06 (1.18)		
Week 52 Adjusted Mean Change (SE)	-2.83 (0.24)	-2.76 (0.24)	-0.07 [-0.74; 0.60]	0.832
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	6.07 (0.71)	6.00 (1.00)		
Week 52 Mean (SD)	2.91 (1.32)	2.98 (1.26)		
Week 52 Adjusted Mean Change (SE)	-3.18 (0.18)	-3.16 (0.22)	-0.01 [-0.58; 0.56]	0.969
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.11 PASDAS - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.891</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	6.07 (0.85)	5.97 (0.96)		
Week 52 Mean (SD)	2.82 (1.34)	3.06 (1.23)		
Week 52 Adjusted Mean Change (SE)	-3.22 (0.20)	-3.00 (0.20)	-0.22 [-0.78; 0.33]	0.427
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	6.15 (0.76)	6.44 (0.92)		
Week 52 Mean (SD)	3.24 (1.34)	2.92 (1.21)		
Week 52 Adjusted Mean Change (SE)	-2.88 (0.20)	-2.98 (0.28)	0.10 [-0.59; 0.78]	0.779
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 35.12 PASDAS - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.792</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	6.15 (0.77)	6.12 (1.05)		
Week 52 Mean (SD)	3.12 (1.39)	3.09 (1.13)		
Week 52 Adjusted Mean Change (SE)	-2.99 (0.16)	-2.87 (0.19)	-0.13 [-0.62; 0.37]	0.618
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	6.01 (0.95)	6.13 (0.79)		
Week 52 Mean (SD)	2.71 (1.26)	2.61 (1.03)		
Week 52 Adjusted Mean Change (SE)	-3.27 (0.28)	-3.45 (0.30)	0.18 [-0.64; 0.99]	0.663
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.13 PASDAS - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.368</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	6.18 (0.78)	6.14 (1.03)		
Week 52 Mean (SD)	3.04 (1.42)	2.88 (1.07)		
Week 52 Adjusted Mean Change (SE)	-3.10 (0.16)	-3.13 (0.19)	0.02 [-0.46; 0.51]	0.923
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	5.84 (0.80)	6.31 (0.56)		
Week 52 Mean (SD)	3.11 (1.13)	3.53 (1.54)		
Week 52 Adjusted Mean Change (SE)	-2.78 (0.29)	-2.56 (0.36)	-0.23 [-1.15; 0.69]	0.627
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.14 PASDAS - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.856</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	6.04 (0.78)	6.19 (0.96)		
Week 52 Mean (SD)	3.10 (1.32)	3.06 (1.27)		
Week 52 Adjusted Mean Change (SE)	-2.96 (0.15)	-2.93 (0.18)	-0.04 [-0.51; 0.44]	0.878
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	6.52 (0.84)	5.85 (1.12)		
Week 52 Mean (SD)	2.78 (1.49)	2.81 (1.01)		
Week 52 Adjusted Mean Change (SE)	-3.40 (0.36)	-3.36 (0.42)	-0.04 [-1.14; 1.05]	0.936
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.15 PASDAS - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.905</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	6.20 (0.74)	6.22 (1.03)		
Week 52 Mean (SD)	3.08 (1.49)	3.18 (1.00)		
Week 52 Adjusted Mean Change (SE)	-2.94 (0.28)	-2.75 (0.28)	-0.20 [-0.98; 0.58]	0.620
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	6.08 (0.83)	6.08 (0.93)		
Week 52 Mean (SD)	3.01 (1.31)	2.93 (1.31)		
Week 52 Adjusted Mean Change (SE)	-3.09 (0.16)	-3.11 (0.20)	0.02 [-0.50; 0.54]	0.941
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.16 PASDAS - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.292</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	6.15 (0.83)	6.13 (0.91)		
Week 52 Mean (SD)	2.92 (1.26)	2.83 (1.07)		
Week 52 Adjusted Mean Change (SE)	-3.24 (0.18)	-3.03 (0.23)	-0.21 [-0.78; 0.37]	0.476
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	6.04 (0.76)	6.14 (1.04)		
Week 52 Mean (SD)	3.20 (1.49)	3.18 (1.32)		
Week 52 Adjusted Mean Change (SE)	-2.76 (0.22)	-2.95 (0.23)	0.19 [-0.45; 0.82]	0.563
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.17 PASDAS - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.267</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	6.21 (0.92)	6.27 (0.95)		
Week 52 Mean (SD)	3.32 (1.36)	3.05 (1.22)		
Week 52 Adjusted Mean Change (SE)	-2.83 (0.24)	-2.73 (0.25)	-0.10 [-0.78; 0.58]	0.775
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	6.05 (0.74)	6.02 (0.98)		
Week 52 Mean (SD)	2.86 (1.33)	2.99 (1.23)		
Week 52 Adjusted Mean Change (SE)	-3.17 (0.18)	-3.15 (0.22)	-0.02 [-0.58; 0.53]	0.929
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.18 PASDAS - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.891</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	6.07 (0.85)	5.97 (0.96)		
Week 52 Mean (SD)	2.82 (1.34)	3.06 (1.23)		
Week 52 Adjusted Mean Change (SE)	-3.22 (0.20)	-3.00 (0.20)	-0.22 [-0.78; 0.33]	0.427
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	6.15 (0.76)	6.44 (0.92)		
Week 52 Mean (SD)	3.24 (1.34)	2.92 (1.21)		
Week 52 Adjusted Mean Change (SE)	-2.88 (0.20)	-2.98 (0.28)	0.10 [-0.59; 0.78]	0.779
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 35.19 PASDAS - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.768</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	6.15 (0.76)	6.12 (1.03)		
Week 52 Mean (SD)	3.08 (1.37)	3.15 (1.15)		
Week 52 Adjusted Mean Change (SE)	-3.02 (0.16)	-2.83 (0.19)	-0.19 [-0.68; 0.30]	0.446
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	5.93 (0.96)	6.19 (0.81)		
Week 52 Mean (SD)	2.67 (1.24)	2.71 (1.33)		
Week 52 Adjusted Mean Change (SE)	-3.29 (0.30)	-3.37 (0.30)	0.08 [-0.77; 0.93]	0.857
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 36.1 PASDAS Good Response / Moderate-to-Good Response (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASDAS Good Response Week 52, N' n (%)	103 59.32 (53.93)	80 49.74 (49.25)	1.24 [0.70; 2.20] 0.463	1.10 [0.83; 1.44] 0.516	0.047 [-0.094; 0.188] 0.515
PASDAS Moderate-to-Good Response Week 52, N' n (%)	103 102.06 (92.78)	80 89.87 (88.98)	1.78 [0.63; 5.08] 0.279	1.04 [0.95; 1.14] 0.371	0.038 [-0.045; 0.121] 0.368
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>OR from logistic regression model with predictors treatment and weight. RR and RD calculated directly without adjustment.</p> <p>All results are combined over MI: n and % are averages of all imputations. Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.2 PASDAS Good Response / Moderate-to-Good Response by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.823				
PASDAS Moderate-to-Good Response Week 52	N.E.				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
PASDAS Good Response Week 52, N' n (%)	98 55.68 (54.06)	74 46.11 (49.05)	1.26 [0.70; 2.28] 0.438	1.10 [0.83; 1.46] 0.500	0.050 [-0.095; 0.195] 0.499
PASDAS Moderate-to-Good Response Week 52, N' n (%)	98 95.09 (92.32)	74 82.88 (88.17)	1.81 [0.63; 5.19] 0.268	1.05 [0.95; 1.16] 0.360	0.042 [-0.047; 0.130] 0.357
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
PASDAS Good Response Week 52, N' n (%)	5 3.64 (52.00)	6 3.63 (51.86)	0.96 [0.09; 10.23] 0.970	1.00 [0.32; 3.09] 0.994	0.001 [-0.567; 0.570] 0.996
PASDAS Moderate-to-Good Response Week 52, N' n (%)	5 6.97 (99.57)	6 6.99 (99.86)	N.E.	N.E.	N.E.
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.3 PASDAS Good Response / Moderate-to-Good Response by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.915				
PASDAS Moderate-to-Good Response Week 52	p=0.441				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
PASDAS Good Response Week 52, N' n (%)	62 41.42 (62.76)	46 34.66 (60.81)	1.26 [0.57; 2.77] 0.574	1.03 [0.77; 1.38] 0.830	0.020 [-0.161; 0.200] 0.832
PASDAS Moderate-to-Good Response Week 52, N' n (%)	62 63.41 (96.08)	46 52.89 (92.79)	2.97 [0.45; 19.53] 0.258	1.04 [0.94; 1.14] 0.463	0.033 [-0.054; 0.120] 0.460
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
PASDAS Good Response Week 52, N' n (%)	41 17.90 (40.68)	34 15.08 (34.27)	1.17 [0.46; 2.98] 0.736	1.19 [0.67; 2.11] 0.551	0.064 [-0.147; 0.275] 0.552
PASDAS Moderate-to-Good Response Week 52, N' n (%)	41 38.65 (87.84)	34 36.98 (84.05)	1.17 [0.30; 4.55] 0.823	1.05 [0.87; 1.26] 0.633	0.038 [-0.118; 0.194] 0.634
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.4 PASDAS Good Response / Moderate-to-Good Response by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.859				
PASDAS Moderate-to-Good Response Week 52	p=0.195				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
PASDAS Good Response Week 52, N' n (%)	23 14.37 (59.87)	16 12.73 (60.62)	1.11 [0.31; 3.97] 0.868	0.99 [0.60; 1.62] 0.965	-0.007 [-0.304; 0.290] 0.961
PASDAS Moderate-to-Good Response Week 52, N' n (%)	23 22.65 (94.38)	16 16.64 (79.24)	6.81 [0.64; 72.88] 0.113	1.19 [0.92; 1.54] 0.181	0.151 [-0.058; 0.360] 0.156
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
PASDAS Good Response Week 52, N' n (%)	80 44.95 (52.27)	64 37.01 (46.26)	1.27 [0.67; 2.41] 0.471	1.13 [0.82; 1.56] 0.459	0.060 [-0.098; 0.218] 0.456
PASDAS Moderate-to-Good Response Week 52, N' n (%)	80 79.41 (92.34)	64 73.23 (91.54)	1.17 [0.34; 4.03] 0.808	1.01 [0.92; 1.11] 0.859	0.008 [-0.081; 0.097] 0.861
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.5 PASDAS Good Response / Moderate-to-Good Response by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.319				
PASDAS Moderate-to-Good Response Week 52	p=0.724				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
PASDAS Good Response Week 52, N' n (%)	39 19.13 (45.55)	37 24.27 (47.59)	0.85 [0.35; 2.05] 0.722	0.96 [0.60; 1.52] 0.857	-0.020 [-0.235; 0.194] 0.852
PASDAS Moderate-to-Good Response Week 52, N' n (%)	39 38.64 (92.00)	37 43.41 (85.12)	1.93 [0.44; 8.54] 0.386	1.08 [0.92; 1.27] 0.334	0.069 [-0.069; 0.207] 0.329
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
PASDAS Good Response Week 52, N' n (%)	64 40.19 (59.10)	43 25.47 (50.94)	1.55 [0.71; 3.37] 0.267	1.16 [0.82; 1.65] 0.401	0.082 [-0.106; 0.269] 0.393
PASDAS Moderate-to-Good Response Week 52, N' n (%)	64 63.42 (93.26)	43 46.46 (92.92)	1.30 [0.27; 6.25] 0.739	1.00 [0.90; 1.11] 0.944	0.003 [-0.094; 0.101] 0.945
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.6 PASDAS Good Response / Moderate-to-Good Response by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.598				
PASDAS Moderate-to-Good Response Week 52	p=0.354				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
PASDAS Good Response Week 52, N' n (%)	70 42.00 (58.33)	34 25.64 (52.33)	1.33 [0.61; 2.92] 0.471	1.12 [0.79; 1.59] 0.539	0.060 [-0.130; 0.250] 0.535
PASDAS Moderate-to-Good Response Week 52, N' n (%)	70 68.96 (95.78)	34 44.38 (90.57)	2.83 [0.52; 15.33] 0.228	1.06 [0.94; 1.19] 0.340	0.052 [-0.053; 0.157] 0.333
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
PASDAS Good Response Week 52, N' n (%)	33 17.32 (45.58)	46 24.10 (46.35)	0.97 [0.40; 2.34] 0.952	0.98 [0.61; 1.58] 0.944	-0.008 [-0.223; 0.208] 0.944
PASDAS Moderate-to-Good Response Week 52, N' n (%)	33 33.10 (87.11)	46 45.49 (87.48)	1.01 [0.26; 3.95] 0.993	1.00 [0.84; 1.18] 0.960	-0.004 [-0.151; 0.144] 0.960
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.7 PASDAS Good Response / Moderate-to-Good Response by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.969				
PASDAS Moderate-to-Good Response Week 52	p=0.566				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
PASDAS Good Response Week 52, N' n (%)	47 30.18 (59.18)	25 17.32 (54.13)	1.19 [0.46; 3.13] 0.718	1.10 [0.72; 1.66] 0.670	0.051 [-0.182; 0.283] 0.670
PASDAS Moderate-to-Good Response Week 52, N' n (%)	47 46.44 (91.06)	25 28.37 (88.66)	1.27 [0.24; 6.56] 0.779	1.03 [0.87; 1.21] 0.748	0.024 [-0.124; 0.172] 0.750
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
PASDAS Good Response Week 52, N' n (%)	56 29.14 (49.39)	55 32.42 (46.99)	1.17 [0.56; 2.42] 0.680	1.05 [0.72; 1.53] 0.791	0.024 [-0.155; 0.203] 0.793
PASDAS Moderate-to-Good Response Week 52, N' n (%)	56 55.62 (94.27)	55 61.50 (89.13)	2.43 [0.56; 10.53] 0.236	1.06 [0.95; 1.18] 0.320	0.051 [-0.049; 0.152] 0.317
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.8 PASDAS Good Response / Moderate-to-Good Response by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.806				
PASDAS Moderate-to-Good Response Week 52	p=0.139				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
PASDAS Good Response Week 52, N' n (%)	48 28.37 (55.63)	34 23.93 (58.37)	0.91 [0.38; 2.18] 0.832	0.95 [0.66; 1.38] 0.802	-0.027 [-0.238; 0.183] 0.799
PASDAS Moderate-to-Good Response Week 52, N' n (%)	48 45.10 (88.43)	34 38.76 (94.54)	0.44 [0.06; 3.19] 0.417	0.94 [0.82; 1.07] 0.329	-0.061 [-0.182; 0.060] 0.324
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
PASDAS Good Response Week 52, N' n (%)	31 17.54 (51.59)	21 12.89 (49.58)	1.08 [0.36; 3.23] 0.886	1.04 [0.61; 1.78] 0.880	0.020 [-0.248; 0.288] 0.883
PASDAS Moderate-to-Good Response Week 52, N' n (%)	31 31.96 (94.00)	21 22.01 (84.65)	3.54 [0.51; 24.72] 0.203	1.11 [0.91; 1.36] 0.300	0.093 [-0.078; 0.265] 0.285
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 36.9 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.584				
PASDAS Moderate-to-Good Response Week 52	p=0.444				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
PASDAS Good Response Week 52, N' n (%)	43 25.31 (56.24)	19 14.09 (52.19)	1.27 [0.43; 3.73] 0.660	1.08 [0.66; 1.76] 0.752	0.041 [-0.219; 0.300] 0.759
PASDAS Moderate-to-Good Response Week 52, N' n (%)	43 42.99 (95.53)	19 24.21 (89.67)	2.72 [0.28; 26.03] 0.385	1.07 [0.90; 1.26] 0.455	0.059 [-0.093; 0.210] 0.447
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
PASDAS Good Response Week 52, N' n (%)	34 19.60 (51.58)	27 16.46 (54.87)	0.84 [0.31; 2.28] 0.734	0.94 [0.59; 1.49] 0.792	-0.033 [-0.277; 0.211] 0.792
PASDAS Moderate-to-Good Response Week 52, N' n (%)	34 33.07 (87.03)	27 26.56 (88.53)	0.92 [0.19; 4.55] 0.920	0.98 [0.82; 1.18] 0.856	-0.015 [-0.178; 0.148] 0.856
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.10 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.704				
PASDAS Moderate-to-Good Response Week 52	p=0.488				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
PASDAS Good Response Week 52, N' n (%)	29 13.54 (45.13)	24 16.70 (50.61)	0.78 [0.27; 2.28] 0.653	0.89 [0.52; 1.55] 0.688	-0.055 [-0.315; 0.206] 0.681
PASDAS Moderate-to-Good Response Week 52, N' n (%)	29 26.00 (86.67)	24 29.79 (90.27)	0.67 [0.09; 4.72] 0.684	0.96 [0.79; 1.17] 0.691	-0.036 [-0.209; 0.137] 0.683
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
PASDAS Good Response Week 52, N' n (%)	48 29.77 (58.37)	31 20.12 (59.18)	1.03 [0.41; 2.55] 0.954	0.99 [0.68; 1.43] 0.943	-0.008 [-0.225; 0.209] 0.942
PASDAS Moderate-to-Good Response Week 52, N' n (%)	48 47.44 (93.02)	31 30.98 (91.12)	1.69 [0.30; 9.44] 0.550	1.02 [0.90; 1.16] 0.758	0.019 [-0.101; 0.139] 0.757
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.11 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.844				
PASDAS Moderate-to-Good Response Week 52	p=0.928				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
PASDAS Good Response Week 52, N' n (%)	39 25.13 (58.44)	37 25.15 (58.49)	0.96 [0.39; 2.37] 0.928	1.00 [0.69; 1.45] 0.998	-0.000 [-0.216; 0.215] 0.997
PASDAS Moderate-to-Good Response Week 52, N' n (%)	39 39.62 (92.14)	37 39.27 (91.33)	1.20 [0.22; 6.40] 0.835	1.01 [0.88; 1.15] 0.895	0.008 [-0.113; 0.129] 0.895
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
PASDAS Good Response Week 52, N' n (%)	40 20.78 (49.48)	18 11.67 (48.63)	1.11 [0.37; 3.26] 0.856	1.02 [0.59; 1.76] 0.941	0.009 [-0.257; 0.274] 0.950
PASDAS Moderate-to-Good Response Week 52, N' n (%)	40 37.44 (89.14)	18 21.50 (89.58)	1.06 [0.14; 8.15] 0.955	1.00 [0.82; 1.21] 0.968	-0.004 [-0.178; 0.169] 0.960
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.12 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.812				
PASDAS Moderate-to-Good Response Week 52	N.E.				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
PASDAS Good Response Week 52, N' n (%)	57 31.37 (50.60)	36 24.47 (52.06)	1.01 [0.45; 2.28] 0.971	0.97 [0.66; 1.43] 0.889	-0.015 [-0.213; 0.184] 0.885
PASDAS Moderate-to-Good Response Week 52, N' n (%)	57 55.06 (88.81)	36 42.00 (89.36)	1.15 [0.28; 4.75] 0.842	0.99 [0.86; 1.15] 0.934	-0.006 [-0.132; 0.121] 0.932
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
PASDAS Good Response Week 52, N' n (%)	19 13.54 (67.70)	17 12.35 (68.61)	0.83 [0.20; 3.48] 0.800	0.99 [0.63; 1.54] 0.953	-0.009 [-0.313; 0.295] 0.953
PASDAS Moderate-to-Good Response Week 52, N' n (%)	19 19.00 (95.00)	17 17.77 (98.72)	N.E.	0.96 [0.85; 1.09] 0.545	-0.037 [-0.155; 0.080] 0.535
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.13 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.562				
PASDAS Moderate-to-Good Response Week 52	p=0.481				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
PASDAS Good Response Week 52, N' n (%)	58 34.90 (55.40)	40 29.74 (58.31)	0.87 [0.39; 1.95] 0.739	0.95 [0.68; 1.33] 0.770	-0.029 [-0.222; 0.163] 0.766
PASDAS Moderate-to-Good Response Week 52, N' n (%)	58 57.61 (91.44)	40 47.10 (92.35)	0.88 [0.18; 4.23] 0.870	0.99 [0.88; 1.12] 0.874	-0.009 [-0.118; 0.100] 0.871
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
PASDAS Good Response Week 52, N' n (%)	18 9.01 (47.42)	12 5.00 (41.67)	1.44 [0.32; 6.45] 0.632	1.14 [0.50; 2.58] 0.757	0.058 [-0.301; 0.416] 0.753
PASDAS Moderate-to-Good Response Week 52, N' n (%)	18 16.45 (86.58)	12 10.00 (83.33)	2.43 [0.23; 25.78] 0.462	1.04 [0.76; 1.42] 0.814	0.032 [-0.233; 0.298] 0.811
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.14 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.289				
PASDAS Moderate-to-Good Response Week 52	N.E.				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
PASDAS Good Response Week 52, N' n (%)	65 37.91 (53.39)	44 27.26 (51.43)	1.13 [0.53; 2.42] 0.746	1.04 [0.73; 1.48] 0.834	0.020 [-0.166; 0.205] 0.836
PASDAS Moderate-to-Good Response Week 52, N' n (%)	65 63.06 (88.82)	44 48.01 (90.58)	0.95 [0.25; 3.70] 0.944	0.98 [0.86; 1.12] 0.766	-0.018 [-0.133; 0.098] 0.764
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
PASDAS Good Response Week 52, N' n (%)	13 7.00 (53.85)	8 7.21 (72.10)	0.38 [0.06; 2.45] 0.308	0.75 [0.39; 1.44] 0.384	-0.183 [-0.583; 0.218] 0.371
PASDAS Moderate-to-Good Response Week 52, N' n (%)	13 13.00 (100.00)	8 8.99 (89.90)	N.E.	1.11 [0.90; 1.37] 0.318	0.101 [-0.087; 0.289] 0.292
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.15 PASDAS Good Response / Moderate-to-Good Response by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.542				
PASDAS Moderate-to-Good Response Week 52	N.E.				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
PASDAS Good Response Week 52, N' n (%)	19 12.14 (55.18)	18 12.18 (46.85)	1.30 [0.37; 4.59] 0.679	1.18 [0.64; 2.17] 0.593	0.083 [-0.222; 0.389] 0.593
PASDAS Moderate-to-Good Response Week 52, N' n (%)	19 18.62 (84.64)	18 24.34 (93.62)	N.E.	0.90 [0.72; 1.13] 0.380	-0.090 [-0.285; 0.105] 0.366
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
PASDAS Good Response Week 52, N' n (%)	60 33.77 (53.60)	37 24.64 (60.10)	0.81 [0.36; 1.86] 0.626	0.89 [0.63; 1.26] 0.518	-0.065 [-0.263; 0.133] 0.520
PASDAS Moderate-to-Good Response Week 52, N' n (%)	60 58.44 (92.76)	37 36.43 (88.85)	2.13 [0.46; 9.83] 0.332	1.04 [0.91; 1.19] 0.526	0.039 [-0.081; 0.159] 0.522
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.16 PASDAS Good Response / Moderate-to-Good Response by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.904				
PASDAS Moderate-to-Good Response Week 52	p=0.378				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
PASDAS Good Response Week 52, N' n (%)	49 28.31 (55.51)	26 20.36 (58.17)	0.99 [0.38; 2.59] 0.987	0.96 [0.64; 1.43] 0.826	-0.027 [-0.255; 0.202] 0.819
PASDAS Moderate-to-Good Response Week 52, N' n (%)	49 47.99 (94.10)	26 32.21 (92.03)	2.03 [0.23; 18.14] 0.525	1.02 [0.89; 1.17] 0.744	0.021 [-0.105; 0.147] 0.747
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
PASDAS Good Response Week 52, N' n (%)	30 17.60 (51.76)	29 16.46 (51.44)	0.91 [0.33; 2.49] 0.853	1.01 [0.62; 1.62] 0.980	0.003 [-0.244; 0.250] 0.979
PASDAS Moderate-to-Good Response Week 52, N' n (%)	30 29.07 (85.50)	29 28.56 (89.25)	0.59 [0.12; 2.89] 0.512	0.96 [0.79; 1.16] 0.660	-0.037 [-0.204; 0.129] 0.659
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 36.17 PASDAS Good Response / Moderate-to-Good Response by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.667				
PASDAS Moderate-to-Good Response Week 52	p=0.573				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
PASDAS Good Response Week 52, N' n (%)	29 13.54 (45.13)	22 15.70 (50.65)	0.78 [0.26; 2.31] 0.649	0.89 [0.51; 1.56] 0.692	-0.055 [-0.321; 0.211] 0.684
PASDAS Moderate-to-Good Response Week 52, N' n (%)	29 26.00 (86.67)	22 27.79 (89.65)	0.71 [0.10; 5.03] 0.728	0.97 [0.79; 1.19] 0.752	-0.030 [-0.209; 0.149] 0.744
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
PASDAS Good Response Week 52, N' n (%)	50 32.37 (58.85)	33 21.12 (58.67)	1.06 [0.44; 2.56] 0.902	1.00 [0.70; 1.44] 0.986	0.002 [-0.209; 0.213] 0.986
PASDAS Moderate-to-Good Response Week 52, N' n (%)	50 51.06 (92.84)	33 32.98 (91.61)	1.50 [0.28; 8.23] 0.637	1.01 [0.89; 1.15] 0.838	0.012 [-0.104; 0.129] 0.837
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.18 PASDAS Good Response / Moderate-to-Good Response by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.844				
PASDAS Moderate-to-Good Response Week 52	p=0.928				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
PASDAS Good Response Week 52, N' n (%)	39 25.13 (58.44)	37 25.15 (58.49)	0.96 [0.39; 2.37] 0.928	1.00 [0.69; 1.45] 0.998	-0.000 [-0.216; 0.215] 0.997
PASDAS Moderate-to-Good Response Week 52, N' n (%)	39 39.62 (92.14)	37 39.27 (91.33)	1.20 [0.22; 6.40] 0.835	1.01 [0.88; 1.15] 0.895	0.008 [-0.113; 0.129] 0.895
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
PASDAS Good Response Week 52, N' n (%)	40 20.78 (49.48)	18 11.67 (48.63)	1.11 [0.37; 3.26] 0.856	1.02 [0.59; 1.76] 0.941	0.009 [-0.257; 0.274] 0.950
PASDAS Moderate-to-Good Response Week 52, N' n (%)	40 37.44 (89.14)	18 21.50 (89.58)	1.06 [0.14; 8.15] 0.955	1.00 [0.82; 1.21] 0.968	-0.004 [-0.178; 0.169] 0.960
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 36.19 PASDAS Good Response / Moderate-to-Good Response by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PASDAS Good Response Week 52	p=0.812				
PASDAS Moderate-to-Good Response Week 52	p=0.935				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
PASDAS Good Response Week 52, N' n (%)	60 33.37 (51.34)	38 24.47 (49.94)	1.13 [0.51; 2.50] 0.761	1.03 [0.70; 1.51] 0.884	0.014 [-0.180; 0.208] 0.888
PASDAS Moderate-to-Good Response Week 52, N' n (%)	60 58.06 (89.32)	38 44.00 (89.80)	1.15 [0.28; 4.67] 0.847	0.99 [0.87; 1.14] 0.942	-0.005 [-0.126; 0.117] 0.939
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
PASDAS Good Response Week 52, N' n (%)	17 12.54 (69.67)	17 12.35 (68.61)	0.92 [0.21; 4.08] 0.915	1.02 [0.65; 1.59] 0.947	0.011 [-0.299; 0.320] 0.947
PASDAS Moderate-to-Good Response Week 52, N' n (%)	17 17.00 (94.44)	17 16.77 (93.17)	1.00 [0.06; 17.87] 0.998	1.01 [0.85; 1.21] 0.876	0.013 [-0.151; 0.177] 0.878
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.1 PsARC Response (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PsARC Response Week 52, N' n (%)	103 102.47 (93.15)	80 92.19 (91.28)	1.37 [0.45; 4.17] 0.583	1.02 [0.94; 1.11] 0.640	0.019 [-0.060; 0.097] 0.640
<p>N': Number of patients with available response value            N-N' is the number of values with MI.            n (%): Number and percentage of patients with event            CI: Confidence Interval            MI: Multiple Imputation            N.E.: Not estimable            OR: Odds Ratio            RR: Relative Risk            RD: Risk Difference</p> <p>OR from logistic regression model with predictors treatment and weight.            RR and RD calculated directly without adjustment.</p> <p>All results are combined over MI:            n and % are averages of all imputations.            Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-            transformation. All CIs and p-values are Wald-type.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.            RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.2 PsARC Response by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	N.E.				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
PsARC Response Week 52, N' n (%)	98 95.48 (92.70)	74 86.19 (91.69)	1.22 [0.38; 3.94] 0.734	1.01 [0.92; 1.11] 0.809	0.010 [-0.072; 0.092] 0.810
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
PsARC Response Week 52, N' n (%)	5 6.99 (99.86)	6 6.00 (85.71)	N.E.	1.16 [0.86; 1.58] 0.327	0.141 [-0.121; 0.403] 0.290
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.3 PsARC Response by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	p=0.226				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
PsARC Response Week 52, N' n (%)	62 63.81 (96.68)	46 52.64 (92.35)	3.11 [0.48; 19.93] 0.232	1.05 [0.95; 1.15] 0.341	0.043 [-0.045; 0.131] 0.335
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
PsARC Response Week 52, N' n (%)	41 38.66 (87.86)	34 39.55 (89.89)	0.70 [0.15; 3.17] 0.642	0.98 [0.83; 1.15] 0.784	-0.020 [-0.162; 0.122] 0.780
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.4 PsARC Response by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	N.E.				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
PsARC Response Week 52, N' n (%)	23 23.67 (98.63)	16 19.02 (90.57)	N.E.	1.09 [0.92; 1.29] 0.322	0.081 [-0.073; 0.234] 0.303
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
PsARC Response Week 52, N' n (%)	80 78.80 (91.63)	64 73.17 (91.46)	1.03 [0.31; 3.37] 0.964	1.00 [0.91; 1.11] 0.969	0.002 [-0.089; 0.092] 0.971
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.5 PsARC Response by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	p=0.896				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
PsARC Response Week 52, N' n (%)	39 39.67 (94.45)	37 46.55 (91.27)	1.52 [0.23; 10.00] 0.661	1.04 [0.91; 1.18] 0.600	0.032 [-0.087; 0.151] 0.600
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
PsARC Response Week 52, N' n (%)	64 62.80 (92.35)	43 45.64 (91.28)	1.30 [0.32; 5.28] 0.710	1.01 [0.90; 1.13] 0.839	0.011 [-0.093; 0.115] 0.840
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 37.6 PsARC Response by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	N.E.				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
PsARC Response Week 52, N' n (%)	70 68.99 (95.82)	34 47.34 (96.61)	N.E.	0.99 [0.91; 1.08] 0.857	-0.008 [-0.090; 0.075] 0.851
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
PsARC Response Week 52, N' n (%)	33 33.48 (88.11)	46 44.85 (86.25)	1.28 [0.31; 5.20] 0.732	1.02 [0.86; 1.21] 0.806	0.019 [-0.129; 0.166] 0.806
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.7 PsARC Response by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	N.E.				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
PsARC Response Week 52, N' n (%)	47 47.82 (93.76)	25 31.20 (97.50)	N.E.	0.96 [0.87; 1.07] 0.471	-0.037 [-0.137; 0.063] 0.464
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
PsARC Response Week 52, N' n (%)	56 54.65 (92.63)	55 60.99 (88.39)	1.79 [0.47; 6.83] 0.395	1.05 [0.93; 1.18] 0.444	0.042 [-0.066; 0.150] 0.442
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.8 PsARC Response by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	p=0.627				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
PsARC Response Week 52, N' n (%)	48 46.49 (91.16)	34 37.73 (92.02)	0.91 [0.18; 4.64] 0.906	0.99 [0.87; 1.13] 0.890	-0.009 [-0.130; 0.113] 0.889
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
PsARC Response Week 52, N' n (%)	31 30.98 (91.12)	21 22.51 (86.58)	1.63 [0.29; 8.96] 0.577	1.05 [0.87; 1.28] 0.602	0.045 [-0.124; 0.215] 0.599
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.9 PsARC Response by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	p=0.598				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
PsARC Response Week 52, N' n (%)	43 41.99 (93.31)	19 23.85 (88.33)	1.92 [0.32; 11.63] 0.478	1.06 [0.89; 1.26] 0.528	0.050 [-0.103; 0.202] 0.522
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
PsARC Response Week 52, N' n (%)	34 33.48 (88.11)	27 26.40 (88.00)	1.01 [0.21; 4.86] 0.992	1.00 [0.83; 1.21] 0.989	0.001 [-0.162; 0.164] 0.990
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.10 PsARC Response by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	p=0.423				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
PsARC Response Week 52, N' n (%)	29 27.99 (93.30)	24 28.35 (85.91)	2.31 [0.37; 14.40] 0.369	1.09 [0.91; 1.30] 0.368	0.074 [-0.084; 0.232] 0.360
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
PsARC Response Week 52, N' n (%)	48 46.82 (91.80)	31 31.89 (93.79)	0.82 [0.14; 4.85] 0.824	0.98 [0.87; 1.11] 0.731	-0.020 [-0.133; 0.093] 0.731
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.11 PsARC Response by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	p=0.607				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
PsARC Response Week 52, N' n (%)	39 39.65 (92.21)	37 38.12 (88.65)	1.51 [0.32; 7.07] 0.599	1.04 [0.90; 1.20] 0.592	0.036 [-0.094; 0.165] 0.590
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
PsARC Response Week 52, N' n (%)	40 37.82 (90.05)	18 22.12 (92.17)	0.75 [0.09; 6.44] 0.797	0.98 [0.82; 1.16] 0.797	-0.021 [-0.177; 0.135] 0.790
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.12 PsARC Response by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	N.E.				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
PsARC Response Week 52, N' n (%)	57 56.48 (91.10)	36 41.42 (88.13)	1.59 [0.40; 6.35] 0.509	1.03 [0.90; 1.19] 0.638	0.030 [-0.094; 0.153] 0.637
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
PsARC Response Week 52, N' n (%)	19 18.99 (94.95)	17 17.82 (99.00)	N.E.	0.96 [0.85; 1.08] 0.499	-0.040 [-0.155; 0.074] 0.489
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.13 PsARC Response by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	p=0.613				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
PsARC Response Week 52, N' n (%)	58 57.65 (91.51)	40 46.64 (91.45)	0.99 [0.24; 4.14] 0.994	1.00 [0.89; 1.13] 0.990	0.001 [-0.109; 0.110] 0.992
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
PsARC Response Week 52, N' n (%)	18 16.82 (88.53)	12 10.00 (83.33)	1.95 [0.22; 17.57] 0.553	1.06 [0.78; 1.44] 0.698	0.052 [-0.206; 0.310] 0.693
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 37.14 PsARC Response by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	N.E.				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
PsARC Response Week 52, N' n (%)	65 63.47 (89.39)	44 47.51 (89.64)	1.02 [0.29; 3.58] 0.974	1.00 [0.88; 1.13] 0.968	-0.002 [-0.117; 0.112] 0.966
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
PsARC Response Week 52, N' n (%)	13 13.00 (100.00)	8 8.91 (89.10)	N.E.	1.12 [0.89; 1.42] 0.325	0.109 [-0.093; 0.311] 0.291
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.15 PsARC Response by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	p=0.951				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
PsARC Response Week 52, N' n (%)	19 18.65 (84.77)	18 21.91 (84.27)	0.97 [0.18; 5.24] 0.968	1.01 [0.78; 1.30] 0.963	0.005 [-0.213; 0.223] 0.964
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
PsARC Response Week 52, N' n (%)	60 58.82 (93.37)	37 38.33 (93.49)	1.04 [0.19; 5.86] 0.962	1.00 [0.89; 1.12] 0.983	-0.001 [-0.104; 0.102] 0.981
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.16 PsARC Response by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	p=0.482				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
PsARC Response Week 52, N' n (%)	49 47.99 (94.10)	26 31.84 (90.97)	1.80 [0.29; 11.01] 0.527	1.03 [0.90; 1.18] 0.620	0.031 [-0.092; 0.154] 0.618
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
PsARC Response Week 52, N' n (%)	30 29.48 (86.71)	29 28.40 (88.75)	0.75 [0.15; 3.64] 0.718	0.98 [0.81; 1.18] 0.810	-0.020 [-0.186; 0.146] 0.809
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.17 PsARC Response by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	p=0.576				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
PsARC Response Week 52, N' n (%)	29 27.99 (93.30)	22 27.35 (88.23)	1.82 [0.26; 12.50] 0.544	1.06 [0.89; 1.26] 0.526	0.051 [-0.105; 0.206] 0.523
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
PsARC Response Week 52, N' n (%)	50 49.48 (89.96)	33 32.89 (91.36)	0.90 [0.20; 4.10] 0.894	0.98 [0.86; 1.13] 0.826	-0.014 [-0.139; 0.111] 0.826
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.18 PsARC Response by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	p=0.607				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
PsARC Response Week 52, N' n (%)	39 39.65 (92.21)	37 38.12 (88.65)	1.51 [0.32; 7.07] 0.599	1.04 [0.90; 1.20] 0.592	0.036 [-0.094; 0.165] 0.590
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
PsARC Response Week 52, N' n (%)	40 37.82 (90.05)	18 22.12 (92.17)	0.75 [0.09; 6.44] 0.797	0.98 [0.82; 1.16] 0.797	-0.021 [-0.177; 0.135] 0.790
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 37.19 PsARC Response by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
PsARC Response Week 52	p=0.798				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
PsARC Response Week 52, N' n (%)	60 59.48 (91.51)	38 43.42 (88.61)	1.54 [0.39; 5.98] 0.536	1.03 [0.90; 1.18] 0.633	0.029 [-0.089; 0.147] 0.632
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
PsARC Response Week 52, N' n (%)	17 16.99 (94.39)	17 16.82 (93.44)	1.01 [0.06; 17.85] 0.993	1.01 [0.85; 1.20] 0.907	0.009 [-0.152; 0.171] 0.909
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 38.0 DLQI - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

### 38.1 DLQI - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	13.84 (8.69)	13.29 (6.98)		
Week 52 Mean (SD)	3.37 (4.96)	4.78 (6.41)		
Week 4 Adjusted Mean Change (SE)	-7.18 (0.53)	-5.34 (0.56)		
Week 12 Adjusted Mean Change (SE)	-9.58 (0.51)	-7.95 (0.54)		
Week 16 Adjusted Mean Change (SE)	-9.55 (0.49)	-7.61 (0.52)		
Week 24 Adjusted Mean Change (SE)	-9.64 (0.55)	-7.71 (0.59)		
Week 32 Adjusted Mean Change (SE)	-10.10 (0.48)	-8.73 (0.52)		
Week 40 Adjusted Mean Change (SE)	-10.04 (0.48)	-8.67 (0.52)		
Week 52 Adjusted Mean Change (SE)	-10.27 (0.52)	-8.29 (0.58)	-1.98 [-3.52; -0.44]	0.012
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				



### 38.2 DLQI - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.487</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	14.17 (8.75)	13.57 (7.03)		
Week 52 Mean (SD)	3.45 (5.07)	4.74 (6.48)		
Week 4 Adjusted Mean Change (SE)	-7.31 (0.55)	-5.32 (0.58)		
Week 12 Adjusted Mean Change (SE)	-9.70 (0.53)	-7.90 (0.56)		
Week 16 Adjusted Mean Change (SE)	-9.64 (0.51)	-7.52 (0.54)		
Week 24 Adjusted Mean Change (SE)	-9.67 (0.57)	-7.63 (0.62)		
Week 32 Adjusted Mean Change (SE)	-10.14 (0.50)	-8.68 (0.54)		
Week 40 Adjusted Mean Change (SE)	-10.02 (0.49)	-8.52 (0.54)		
Week 52 Adjusted Mean Change (SE)	-10.29 (0.54)	-8.34 (0.60)	-1.95 [-3.55; -0.35]	0.017
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	8.86 (6.26)	9.43 (5.26)		
Week 52 Mean (SD)	2.00 (2.45)	5.33 (5.99)		
Week 4 Adjusted Mean Change (SE)	-5.31 (2.12)	-5.46 (2.11)		
Week 12 Adjusted Mean Change (SE)	-7.90 (2.04)	-8.66 (2.04)		
Week 16 Adjusted Mean Change (SE)	-8.11 (2.02)	-8.68 (1.97)		
Week 24 Adjusted Mean Change (SE)	-9.23 (2.19)	-8.71 (2.19)		
Week 32 Adjusted Mean Change (SE)	-9.51 (1.90)	-9.40 (1.90)		
Week 40 Adjusted Mean Change (SE)	-10.28 (1.88)	-10.45 (1.88)		
Week 52 Adjusted Mean Change (SE)	-9.83 (2.14)	-7.52 (2.13)	-2.31 [-8.24; 3.61]	0.443
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.3 DLQI - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.415</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	13.23 (8.09)	12.67 (6.47)		
Week 52 Mean (SD)	3.20 (5.09)	4.71 (6.30)		
Week 4 Adjusted Mean Change (SE)	-8.15 (0.69)	-4.95 (0.74)		
Week 12 Adjusted Mean Change (SE)	-10.20 (0.67)	-8.17 (0.72)		
Week 16 Adjusted Mean Change (SE)	-9.70 (0.65)	-7.68 (0.70)		
Week 24 Adjusted Mean Change (SE)	-10.53 (0.71)	-7.89 (0.78)		
Week 32 Adjusted Mean Change (SE)	-10.36 (0.63)	-8.72 (0.69)		
Week 40 Adjusted Mean Change (SE)	-10.45 (0.62)	-8.95 (0.69)		
Week 52 Adjusted Mean Change (SE)	-10.37 (0.68)	-8.56 (0.76)	-1.81 [-3.83; 0.20]	0.077
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	14.75 (9.54)	14.09 (7.58)		
Week 52 Mean (SD)	3.63 (4.80)	4.88 (6.67)		
Week 4 Adjusted Mean Change (SE)	-5.74 (0.84)	-5.84 (0.84)		
Week 12 Adjusted Mean Change (SE)	-8.66 (0.82)	-7.67 (0.82)		
Week 16 Adjusted Mean Change (SE)	-9.32 (0.80)	-7.51 (0.80)		
Week 24 Adjusted Mean Change (SE)	-8.26 (0.89)	-7.42 (0.91)		
Week 32 Adjusted Mean Change (SE)	-9.73 (0.78)	-8.74 (0.80)		
Week 40 Adjusted Mean Change (SE)	-9.42 (0.77)	-8.29 (0.80)		
Week 52 Adjusted Mean Change (SE)	-10.11 (0.85)	-7.90 (0.89)	-2.21 [-4.63; 0.21]	0.073
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.4 DLQI - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.456</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	10.83 (7.59)	8.57 (4.56)		
Week 52 Mean (SD)	1.91 (2.97)	2.71 (4.51)		
Week 4 Adjusted Mean Change (SE)	-6.89 (1.15)	-6.47 (1.24)		
Week 12 Adjusted Mean Change (SE)	-10.03 (1.12)	-9.84 (1.19)		
Week 16 Adjusted Mean Change (SE)	-10.64 (1.06)	-9.48 (1.15)		
Week 24 Adjusted Mean Change (SE)	-9.95 (1.21)	-8.76 (1.32)		
Week 32 Adjusted Mean Change (SE)	-9.96 (1.05)	-9.86 (1.17)		
Week 40 Adjusted Mean Change (SE)	-11.29 (1.04)	-9.72 (1.16)		
Week 52 Adjusted Mean Change (SE)	-10.81 (1.14)	-9.47 (1.29)	-1.33 [-4.69; 2.02]	0.434
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	14.67 (8.83)	14.53 (7.00)		
Week 52 Mean (SD)	3.78 (5.34)	5.32 (6.75)		
Week 4 Adjusted Mean Change (SE)	-7.26 (0.60)	-5.04 (0.63)		
Week 12 Adjusted Mean Change (SE)	-9.44 (0.58)	-7.46 (0.61)		
Week 16 Adjusted Mean Change (SE)	-9.23 (0.56)	-7.11 (0.59)		
Week 24 Adjusted Mean Change (SE)	-9.55 (0.62)	-7.43 (0.67)		
Week 32 Adjusted Mean Change (SE)	-10.14 (0.55)	-8.43 (0.58)		
Week 40 Adjusted Mean Change (SE)	-9.70 (0.54)	-8.42 (0.58)		
Week 52 Adjusted Mean Change (SE)	-10.11 (0.60)	-7.98 (0.65)	-2.13 [-3.87; -0.40]	0.016
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.5 DLQI - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.305</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	10.50 (7.86)	12.39 (7.06)		
Week 52 Mean (SD)	2.59 (4.41)	3.47 (5.28)		
Week 4 Adjusted Mean Change (SE)	-7.67 (0.87)	-6.15 (0.79)		
Week 12 Adjusted Mean Change (SE)	-9.41 (0.85)	-8.49 (0.76)		
Week 16 Adjusted Mean Change (SE)	-9.32 (0.81)	-8.08 (0.74)		
Week 24 Adjusted Mean Change (SE)	-9.60 (0.91)	-8.02 (0.84)		
Week 32 Adjusted Mean Change (SE)	-9.84 (0.79)	-9.30 (0.74)		
Week 40 Adjusted Mean Change (SE)	-10.13 (0.79)	-9.33 (0.75)		
Week 52 Adjusted Mean Change (SE)	-10.14 (0.87)	-9.17 (0.83)	-0.97 [-3.32; 1.39]	0.419
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	15.90 (8.59)	14.20 (6.85)		
Week 52 Mean (SD)	3.83 (5.24)	5.91 (7.12)		
Week 4 Adjusted Mean Change (SE)	-6.88 (0.68)	-4.52 (0.79)		
Week 12 Adjusted Mean Change (SE)	-9.69 (0.67)	-7.41 (0.77)		
Week 16 Adjusted Mean Change (SE)	-9.69 (0.64)	-7.13 (0.74)		
Week 24 Adjusted Mean Change (SE)	-9.67 (0.71)	-7.39 (0.84)		
Week 32 Adjusted Mean Change (SE)	-10.27 (0.62)	-8.15 (0.73)		
Week 40 Adjusted Mean Change (SE)	-9.99 (0.61)	-8.06 (0.72)		
Week 52 Adjusted Mean Change (SE)	-10.35 (0.67)	-7.47 (0.80)	-2.87 [-4.94; -0.81]	0.007
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.6 DLQI - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.728</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	14.97 (8.34)	12.22 (6.30)		
Week 52 Mean (SD)	3.31 (5.13)	3.39 (5.05)		
Week 4 Adjusted Mean Change (SE)	-7.58 (0.66)	-5.34 (0.80)		
Week 12 Adjusted Mean Change (SE)	-9.72 (0.64)	-8.36 (0.77)		
Week 16 Adjusted Mean Change (SE)	-10.13 (0.61)	-7.78 (0.75)		
Week 24 Adjusted Mean Change (SE)	-10.24 (0.67)	-8.52 (0.85)		
Week 32 Adjusted Mean Change (SE)	-10.71 (0.59)	-9.69 (0.74)		
Week 40 Adjusted Mean Change (SE)	-10.72 (0.58)	-9.11 (0.76)		
Week 52 Adjusted Mean Change (SE)	-10.59 (0.65)	-8.98 (0.85)	-1.62 [-3.73; 0.50]	0.133
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	11.68 (9.04)	14.29 (7.49)		
Week 52 Mean (SD)	3.49 (4.67)	5.87 (7.17)		
Week 4 Adjusted Mean Change (SE)	-6.44 (0.91)	-5.32 (0.79)		
Week 12 Adjusted Mean Change (SE)	-9.28 (0.88)	-7.55 (0.76)		
Week 16 Adjusted Mean Change (SE)	-8.45 (0.84)	-7.43 (0.73)		
Week 24 Adjusted Mean Change (SE)	-8.51 (0.94)	-6.97 (0.82)		
Week 32 Adjusted Mean Change (SE)	-8.93 (0.82)	-7.89 (0.71)		
Week 40 Adjusted Mean Change (SE)	-8.74 (0.81)	-8.25 (0.71)		
Week 52 Adjusted Mean Change (SE)	-9.65 (0.90)	-7.66 (0.79)	-1.98 [-4.35; 0.38]	0.100
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.7 DLQI - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.310</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	13.80 (8.42)	12.25 (7.71)		
Week 52 Mean (SD)	3.12 (5.03)	2.72 (4.48)		
Week 4 Adjusted Mean Change (SE)	-7.38 (0.78)	-6.79 (1.00)		
Week 12 Adjusted Mean Change (SE)	-9.96 (0.76)	-8.94 (0.97)		
Week 16 Adjusted Mean Change (SE)	-9.36 (0.72)	-8.91 (0.93)		
Week 24 Adjusted Mean Change (SE)	-9.97 (0.81)	-8.83 (1.05)		
Week 32 Adjusted Mean Change (SE)	-10.11 (0.71)	-9.68 (0.92)		
Week 40 Adjusted Mean Change (SE)	-10.69 (0.69)	-9.78 (0.91)		
Week 52 Adjusted Mean Change (SE)	-10.58 (0.76)	-9.57 (1.03)	-1.01 [-3.54; 1.52]	0.430
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	13.86 (8.98)	13.77 (6.62)		
Week 52 Mean (SD)	3.59 (4.94)	5.68 (6.94)		
Week 4 Adjusted Mean Change (SE)	-7.01 (0.72)	-4.68 (0.67)		
Week 12 Adjusted Mean Change (SE)	-9.27 (0.70)	-7.50 (0.65)		
Week 16 Adjusted Mean Change (SE)	-9.72 (0.67)	-7.01 (0.63)		
Week 24 Adjusted Mean Change (SE)	-9.35 (0.75)	-7.18 (0.72)		
Week 32 Adjusted Mean Change (SE)	-10.09 (0.66)	-8.29 (0.63)		
Week 40 Adjusted Mean Change (SE)	-9.48 (0.65)	-8.15 (0.63)		
Week 52 Adjusted Mean Change (SE)	-9.98 (0.72)	-7.70 (0.69)	-2.28 [-4.25; -0.32]	0.023
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.8 DLQI - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.880</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	14.18 (8.91)	12.78 (7.02)		
Week 52 Mean (SD)	3.10 (4.66)	2.53 (3.77)		
Week 4 Adjusted Mean Change (SE)	-8.03 (0.77)	-5.66 (0.86)		
Week 12 Adjusted Mean Change (SE)	-9.97 (0.76)	-8.48 (0.85)		
Week 16 Adjusted Mean Change (SE)	-10.01 (0.73)	-8.25 (0.82)		
Week 24 Adjusted Mean Change (SE)	-10.61 (0.75)	-9.07 (0.85)		
Week 32 Adjusted Mean Change (SE)	-10.65 (0.67)	-9.44 (0.76)		
Week 40 Adjusted Mean Change (SE)	-10.42 (0.66)	-10.26 (0.75)		
Week 52 Adjusted Mean Change (SE)	-10.55 (0.73)	-10.27 (0.84)	-0.28 [-2.49; 1.92]	0.801
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	13.38 (8.17)	13.65 (8.12)		
Week 52 Mean (SD)	3.81 (6.16)	5.81 (7.85)		
Week 4 Adjusted Mean Change (SE)	-6.58 (0.94)	-5.04 (1.10)		
Week 12 Adjusted Mean Change (SE)	-9.34 (0.94)	-7.76 (1.08)		
Week 16 Adjusted Mean Change (SE)	-8.89 (0.90)	-7.90 (1.04)		
Week 24 Adjusted Mean Change (SE)	-8.79 (0.92)	-7.89 (1.09)		
Week 32 Adjusted Mean Change (SE)	-10.33 (0.84)	-8.84 (0.98)		
Week 40 Adjusted Mean Change (SE)	-10.13 (0.81)	-8.53 (0.98)		
Week 52 Adjusted Mean Change (SE)	-9.76 (0.91)	-7.60 (1.09)	-2.16 [-4.96; 0.63]	0.128
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.9 DLQI - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.404</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	13.24 (8.23)	13.48 (7.12)		
Week 52 Mean (SD)	3.21 (5.46)	3.16 (6.01)		
Week 4 Adjusted Mean Change (SE)	-7.16 (0.83)	-5.79 (1.09)		
Week 12 Adjusted Mean Change (SE)	-10.53 (0.78)	-9.86 (1.03)		
Week 16 Adjusted Mean Change (SE)	-10.48 (0.78)	-8.87 (1.03)		
Week 24 Adjusted Mean Change (SE)	-10.26 (0.81)	-9.03 (1.10)		
Week 32 Adjusted Mean Change (SE)	-10.70 (0.69)	-10.94 (0.94)		
Week 40 Adjusted Mean Change (SE)	-10.91 (0.70)	-10.62 (0.96)		
Week 52 Adjusted Mean Change (SE)	-10.28 (0.82)	-9.44 (1.17)	-0.84 [-3.66; 1.98]	0.556
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	14.45 (8.97)	12.63 (8.02)		
Week 52 Mean (SD)	3.46 (5.11)	4.18 (6.16)		
Week 4 Adjusted Mean Change (SE)	-7.53 (0.91)	-5.29 (1.02)		
Week 12 Adjusted Mean Change (SE)	-8.96 (0.86)	-6.62 (0.97)		
Week 16 Adjusted Mean Change (SE)	-8.73 (0.85)	-7.06 (0.96)		
Week 24 Adjusted Mean Change (SE)	-9.66 (0.89)	-7.67 (1.01)		
Week 32 Adjusted Mean Change (SE)	-10.61 (0.76)	-7.42 (0.86)		
Week 40 Adjusted Mean Change (SE)	-9.83 (0.76)	-8.55 (0.88)		
Week 52 Adjusted Mean Change (SE)	-10.13 (0.90)	-8.61 (1.02)	-1.53 [-4.23; 1.17]	0.265
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 38.10 DLQI - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.495</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	12.67 (9.37)	15.27 (7.77)		
Week 52 Mean (SD)	2.76 (4.86)	3.38 (5.75)		
Week 4 Adjusted Mean Change (SE)	-9.02 (1.00)	-6.38 (0.97)		
Week 12 Adjusted Mean Change (SE)	-10.51 (0.96)	-9.31 (0.94)		
Week 16 Adjusted Mean Change (SE)	-10.30 (0.95)	-8.70 (0.92)		
Week 24 Adjusted Mean Change (SE)	-10.31 (1.00)	-9.06 (1.00)		
Week 32 Adjusted Mean Change (SE)	-10.26 (0.86)	-10.54 (0.86)		
Week 40 Adjusted Mean Change (SE)	-9.94 (0.86)	-10.15 (0.88)		
Week 52 Adjusted Mean Change (SE)	-10.68 (0.97)	-9.64 (1.02)	-1.04 [-3.82; 1.74]	0.461
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	14.88 (8.27)	11.03 (6.52)		
Week 52 Mean (SD)	3.71 (5.58)	4.00 (5.88)		
Week 4 Adjusted Mean Change (SE)	-6.68 (0.77)	-4.60 (0.96)		
Week 12 Adjusted Mean Change (SE)	-9.74 (0.74)	-7.28 (0.91)		
Week 16 Adjusted Mean Change (SE)	-9.45 (0.73)	-7.66 (0.90)		
Week 24 Adjusted Mean Change (SE)	-9.99 (0.75)	-8.28 (0.94)		
Week 32 Adjusted Mean Change (SE)	-11.07 (0.66)	-8.12 (0.82)		
Week 40 Adjusted Mean Change (SE)	-10.83 (0.66)	-9.23 (0.83)		
Week 52 Adjusted Mean Change (SE)	-10.34 (0.74)	-8.96 (0.92)	-1.39 [-3.75; 0.97]	0.247
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.11 DLQI - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.746</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	14.91 (8.42)	13.44 (7.29)		
Week 52 Mean (SD)	3.46 (4.92)	3.72 (6.23)		
Week 4 Adjusted Mean Change (SE)	-7.37 (0.84)	-5.99 (0.84)		
Week 12 Adjusted Mean Change (SE)	-9.95 (0.83)	-8.13 (0.83)		
Week 16 Adjusted Mean Change (SE)	-9.89 (0.80)	-8.32 (0.80)		
Week 24 Adjusted Mean Change (SE)	-10.26 (0.83)	-8.60 (0.84)		
Week 32 Adjusted Mean Change (SE)	-10.48 (0.75)	-9.50 (0.75)		
Week 40 Adjusted Mean Change (SE)	-10.69 (0.73)	-10.12 (0.73)		
Week 52 Adjusted Mean Change (SE)	-10.31 (0.83)	-9.76 (0.83)	-0.55 [-2.87; 1.77]	0.640
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	12.79 (8.71)	12.54 (7.77)		
Week 52 Mean (SD)	3.29 (5.64)	3.78 (4.85)		
Week 4 Adjusted Mean Change (SE)	-7.53 (0.85)	-4.37 (1.15)		
Week 12 Adjusted Mean Change (SE)	-9.48 (0.84)	-8.32 (1.13)		
Week 16 Adjusted Mean Change (SE)	-9.22 (0.81)	-7.73 (1.10)		
Week 24 Adjusted Mean Change (SE)	-9.52 (0.83)	-8.66 (1.15)		
Week 32 Adjusted Mean Change (SE)	-10.52 (0.74)	-8.68 (1.03)		
Week 40 Adjusted Mean Change (SE)	-9.91 (0.72)	-8.61 (1.02)		
Week 52 Adjusted Mean Change (SE)	-10.14 (0.82)	-8.24 (1.18)	-1.90 [-4.73; 0.93]	0.187
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.12 DLQI - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.832</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	13.71 (8.31)	13.23 (7.06)		
Week 52 Mean (SD)	3.34 (4.92)	4.18 (5.64)		
Week 4 Adjusted Mean Change (SE)	-7.01 (0.69)	-5.42 (0.80)		
Week 12 Adjusted Mean Change (SE)	-8.97 (0.67)	-7.47 (0.76)		
Week 16 Adjusted Mean Change (SE)	-8.69 (0.64)	-7.92 (0.74)		
Week 24 Adjusted Mean Change (SE)	-9.20 (0.64)	-7.92 (0.76)		
Week 32 Adjusted Mean Change (SE)	-10.25 (0.59)	-8.82 (0.69)		
Week 40 Adjusted Mean Change (SE)	-9.98 (0.57)	-8.88 (0.67)		
Week 52 Adjusted Mean Change (SE)	-9.95 (0.63)	-8.48 (0.76)	-1.47 [-3.42; 0.49]	0.140
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	13.30 (9.40)	10.94 (6.36)		
Week 52 Mean (SD)	3.11 (5.78)	1.53 (1.87)		
Week 4 Adjusted Mean Change (SE)	-7.74 (1.22)	-4.50 (1.28)		
Week 12 Adjusted Mean Change (SE)	-10.72 (1.17)	-9.51 (1.24)		
Week 16 Adjusted Mean Change (SE)	-10.98 (1.13)	-8.40 (1.20)		
Week 24 Adjusted Mean Change (SE)	-11.14 (1.16)	-9.90 (1.22)		
Week 32 Adjusted Mean Change (SE)	-10.25 (1.04)	-9.68 (1.10)		
Week 40 Adjusted Mean Change (SE)	-10.17 (1.01)	-11.00 (1.07)		
Week 52 Adjusted Mean Change (SE)	-10.06 (1.11)	-11.10 (1.17)	1.03 [-2.17; 4.24]	0.524
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.13 DLQI - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.683</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	13.68 (8.45)	12.86 (7.44)		
Week 52 Mean (SD)	3.26 (5.05)	2.88 (3.74)		
Week 4 Adjusted Mean Change (SE)	-7.41 (0.69)	-5.54 (0.77)		
Week 12 Adjusted Mean Change (SE)	-9.71 (0.67)	-8.34 (0.75)		
Week 16 Adjusted Mean Change (SE)	-9.51 (0.63)	-8.19 (0.71)		
Week 24 Adjusted Mean Change (SE)	-9.70 (0.68)	-9.08 (0.77)		
Week 32 Adjusted Mean Change (SE)	-10.46 (0.60)	-9.41 (0.69)		
Week 40 Adjusted Mean Change (SE)	-10.07 (0.60)	-9.91 (0.69)		
Week 52 Adjusted Mean Change (SE)	-10.31 (0.66)	-10.15 (0.76)	-0.16 [-2.15; 1.84]	0.876
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	13.89 (9.49)	14.75 (8.29)		
Week 52 Mean (SD)	3.74 (6.09)	6.58 (9.80)		
Week 4 Adjusted Mean Change (SE)	-7.62 (1.25)	-5.91 (1.58)		
Week 12 Adjusted Mean Change (SE)	-9.29 (1.21)	-8.61 (1.54)		
Week 16 Adjusted Mean Change (SE)	-9.11 (1.15)	-8.79 (1.45)		
Week 24 Adjusted Mean Change (SE)	-10.30 (1.21)	-7.47 (1.54)		
Week 32 Adjusted Mean Change (SE)	-10.56 (1.08)	-9.49 (1.39)		
Week 40 Adjusted Mean Change (SE)	-10.87 (1.07)	-8.94 (1.38)		
Week 52 Adjusted Mean Change (SE)	-9.87 (1.17)	-7.09 (1.48)	-2.78 [-6.51; 0.95]	0.143
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.14 DLQI - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.318</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	13.35 (8.66)	13.85 (7.67)		
Week 52 Mean (SD)	3.38 (5.38)	3.89 (6.23)		
Week 4 Adjusted Mean Change (SE)	-7.37 (0.66)	-5.79 (0.77)		
Week 12 Adjusted Mean Change (SE)	-9.50 (0.64)	-8.55 (0.75)		
Week 16 Adjusted Mean Change (SE)	-9.34 (0.62)	-8.16 (0.73)		
Week 24 Adjusted Mean Change (SE)	-9.65 (0.64)	-8.74 (0.76)		
Week 32 Adjusted Mean Change (SE)	-10.24 (0.57)	-9.46 (0.68)		
Week 40 Adjusted Mean Change (SE)	-10.10 (0.56)	-9.68 (0.68)		
Week 52 Adjusted Mean Change (SE)	-10.14 (0.64)	-9.22 (0.78)	-0.92 [-2.92; 1.07]	0.363
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	16.62 (8.26)	10.20 (6.30)		
Week 52 Mean (SD)	3.54 (5.03)	3.50 (4.53)		
Week 4 Adjusted Mean Change (SE)	-8.23 (1.54)	-4.84 (1.76)		
Week 12 Adjusted Mean Change (SE)	-11.25 (1.52)	-8.13 (1.71)		
Week 16 Adjusted Mean Change (SE)	-11.43 (1.46)	-8.33 (1.66)		
Week 24 Adjusted Mean Change (SE)	-11.44 (1.50)	-7.40 (1.70)		
Week 32 Adjusted Mean Change (SE)	-12.22 (1.32)	-9.08 (1.50)		
Week 40 Adjusted Mean Change (SE)	-11.79 (1.31)	-9.83 (1.49)		
Week 52 Adjusted Mean Change (SE)	-10.75 (1.49)	-9.27 (1.69)	-1.48 [-5.97; 3.01]	0.515
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.15 DLQI - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.219</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	12.73 (8.65)	15.23 (7.25)		
Week 52 Mean (SD)	3.74 (5.52)	4.00 (6.51)		
Week 4 Adjusted Mean Change (SE)	-7.63 (1.18)	-6.07 (1.11)		
Week 12 Adjusted Mean Change (SE)	-9.28 (1.15)	-8.66 (1.09)		
Week 16 Adjusted Mean Change (SE)	-8.64 (1.12)	-8.90 (1.05)		
Week 24 Adjusted Mean Change (SE)	-9.26 (1.17)	-9.00 (1.12)		
Week 32 Adjusted Mean Change (SE)	-9.07 (1.03)	-10.17 (0.99)		
Week 40 Adjusted Mean Change (SE)	-9.54 (1.03)	-10.13 (0.99)		
Week 52 Adjusted Mean Change (SE)	-9.30 (1.17)	-9.38 (1.16)	0.09 [-3.18; 3.35]	0.959
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	14.25 (8.59)	11.78 (7.30)		
Week 52 Mean (SD)	3.26 (5.23)	3.62 (5.50)		
Week 4 Adjusted Mean Change (SE)	-7.39 (0.70)	-5.03 (0.87)		
Week 12 Adjusted Mean Change (SE)	-9.87 (0.69)	-7.92 (0.86)		
Week 16 Adjusted Mean Change (SE)	-9.88 (0.66)	-7.64 (0.82)		
Week 24 Adjusted Mean Change (SE)	-10.11 (0.68)	-8.38 (0.86)		
Week 32 Adjusted Mean Change (SE)	-11.00 (0.60)	-8.66 (0.76)		
Week 40 Adjusted Mean Change (SE)	-10.56 (0.59)	-9.32 (0.76)		
Week 52 Adjusted Mean Change (SE)	-10.54 (0.67)	-9.14 (0.84)	-1.40 [-3.54; 0.73]	0.195
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.16 DLQI - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.494</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	12.78 (8.27)	13.80 (6.98)		
Week 52 Mean (SD)	3.14 (5.22)	3.33 (5.64)		
Week 4 Adjusted Mean Change (SE)	-7.45 (0.78)	-5.67 (0.95)		
Week 12 Adjusted Mean Change (SE)	-10.48 (0.74)	-9.88 (0.90)		
Week 16 Adjusted Mean Change (SE)	-10.39 (0.72)	-9.09 (0.88)		
Week 24 Adjusted Mean Change (SE)	-10.30 (0.75)	-9.25 (0.94)		
Week 32 Adjusted Mean Change (SE)	-10.75 (0.65)	-10.97 (0.81)		
Week 40 Adjusted Mean Change (SE)	-10.89 (0.66)	-10.58 (0.82)		
Week 52 Adjusted Mean Change (SE)	-10.30 (0.75)	-9.68 (0.96)	-0.62 [-3.03; 1.79]	0.612
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	15.47 (8.90)	12.38 (7.91)		
Week 52 Mean (SD)	3.74 (5.42)	4.10 (5.98)		
Week 4 Adjusted Mean Change (SE)	-7.45 (0.96)	-5.16 (0.98)		
Week 12 Adjusted Mean Change (SE)	-8.57 (0.91)	-6.42 (0.93)		
Week 16 Adjusted Mean Change (SE)	-8.29 (0.89)	-7.10 (0.91)		
Week 24 Adjusted Mean Change (SE)	-9.28 (0.94)	-7.97 (0.97)		
Week 32 Adjusted Mean Change (SE)	-10.22 (0.81)	-7.35 (0.84)		
Week 40 Adjusted Mean Change (SE)	-9.42 (0.81)	-8.65 (0.85)		
Week 52 Adjusted Mean Change (SE)	-10.15 (0.93)	-8.69 (0.95)	-1.46 [-4.12; 1.20]	0.279
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.17 DLQI - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.375</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	12.67 (9.37)	15.45 (7.68)		
Week 52 Mean (SD)	2.76 (4.86)	3.14 (5.67)		
Week 4 Adjusted Mean Change (SE)	-8.98 (0.99)	-6.63 (0.99)		
Week 12 Adjusted Mean Change (SE)	-10.46 (0.97)	-9.74 (0.98)		
Week 16 Adjusted Mean Change (SE)	-10.26 (0.95)	-9.07 (0.96)		
Week 24 Adjusted Mean Change (SE)	-10.26 (0.98)	-9.95 (1.02)		
Week 32 Adjusted Mean Change (SE)	-10.21 (0.86)	-10.53 (0.90)		
Week 40 Adjusted Mean Change (SE)	-9.89 (0.86)	-10.14 (0.91)		
Week 52 Adjusted Mean Change (SE)	-10.62 (0.97)	-9.68 (1.06)	-0.94 [-3.78; 1.90]	0.515
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	14.51 (8.13)	11.11 (6.65)		
Week 52 Mean (SD)	3.73 (5.50)	4.11 (5.90)		
Week 4 Adjusted Mean Change (SE)	-6.62 (0.73)	-4.42 (0.91)		
Week 12 Adjusted Mean Change (SE)	-9.31 (0.72)	-6.94 (0.90)		
Week 16 Adjusted Mean Change (SE)	-9.18 (0.70)	-7.32 (0.88)		
Week 24 Adjusted Mean Change (SE)	-9.71 (0.72)	-7.60 (0.90)		
Week 32 Adjusted Mean Change (SE)	-10.71 (0.64)	-8.16 (0.80)		
Week 40 Adjusted Mean Change (SE)	-10.53 (0.64)	-9.17 (0.80)		
Week 52 Adjusted Mean Change (SE)	-10.01 (0.72)	-8.82 (0.89)	-1.18 [-3.47; 1.11]	0.309
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 38.18 DLQI - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.746</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	14.91 (8.42)	13.44 (7.29)		
Week 52 Mean (SD)	3.46 (4.92)	3.72 (6.23)		
Week 4 Adjusted Mean Change (SE)	-7.37 (0.84)	-5.99 (0.84)		
Week 12 Adjusted Mean Change (SE)	-9.95 (0.83)	-8.13 (0.83)		
Week 16 Adjusted Mean Change (SE)	-9.89 (0.80)	-8.32 (0.80)		
Week 24 Adjusted Mean Change (SE)	-10.26 (0.83)	-8.60 (0.84)		
Week 32 Adjusted Mean Change (SE)	-10.48 (0.75)	-9.50 (0.75)		
Week 40 Adjusted Mean Change (SE)	-10.69 (0.73)	-10.12 (0.73)		
Week 52 Adjusted Mean Change (SE)	-10.31 (0.83)	-9.76 (0.83)	-0.55 [-2.87; 1.77]	0.640
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	12.79 (8.71)	12.54 (7.77)		
Week 52 Mean (SD)	3.29 (5.64)	3.78 (4.85)		
Week 4 Adjusted Mean Change (SE)	-7.53 (0.85)	-4.37 (1.15)		
Week 12 Adjusted Mean Change (SE)	-9.48 (0.84)	-8.32 (1.13)		
Week 16 Adjusted Mean Change (SE)	-9.22 (0.81)	-7.73 (1.10)		
Week 24 Adjusted Mean Change (SE)	-9.52 (0.83)	-8.66 (1.15)		
Week 32 Adjusted Mean Change (SE)	-10.52 (0.74)	-8.68 (1.03)		
Week 40 Adjusted Mean Change (SE)	-9.91 (0.72)	-8.61 (1.02)		
Week 52 Adjusted Mean Change (SE)	-10.14 (0.82)	-8.24 (1.18)	-1.90 [-4.73; 0.93]	0.187
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 38.19 DLQI - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.680</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	13.69 (8.33)	13.43 (7.39)		
Week 52 Mean (SD)	3.48 (5.14)	4.08 (5.52)		
Week 4 Adjusted Mean Change (SE)	-7.03 (0.68)	-5.77 (0.79)		
Week 12 Adjusted Mean Change (SE)	-9.08 (0.67)	-7.76 (0.78)		
Week 16 Adjusted Mean Change (SE)	-8.80 (0.64)	-8.01 (0.74)		
Week 24 Adjusted Mean Change (SE)	-9.19 (0.66)	-8.20 (0.79)		
Week 32 Adjusted Mean Change (SE)	-10.29 (0.60)	-8.95 (0.71)		
Week 40 Adjusted Mean Change (SE)	-10.00 (0.59)	-9.17 (0.70)		
Week 52 Adjusted Mean Change (SE)	-9.97 (0.66)	-8.73 (0.80)	-1.24 [-3.29; 0.82]	0.236
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	13.06 (9.09)	12.28 (7.65)		
Week 52 Mean (SD)	3.29 (6.10)	2.94 (6.47)		
Week 4 Adjusted Mean Change (SE)	-7.74 (1.29)	-4.09 (1.29)		
Week 12 Adjusted Mean Change (SE)	-10.69 (1.28)	-8.84 (1.27)		
Week 16 Adjusted Mean Change (SE)	-10.83 (1.22)	-7.92 (1.22)		
Week 24 Adjusted Mean Change (SE)	-11.68 (1.29)	-9.23 (1.27)		
Week 32 Adjusted Mean Change (SE)	-10.74 (1.15)	-9.35 (1.15)		
Week 40 Adjusted Mean Change (SE)	-10.53 (1.13)	-10.29 (1.15)		
Week 52 Adjusted Mean Change (SE)	-9.96 (1.27)	-10.09 (1.26)	0.14 [-3.40; 3.68]	0.939
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 39.1 DLQI 0/1 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
DLQI 0/1 Week 52, N' n (%)	105 56.17 (51.06)	82 40.31 (39.91)	1.60 [0.91; 2.82] 0.101	1.28 [0.94; 1.75] 0.118	0.112 [-0.025; 0.248] 0.110
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>OR from logistic regression model with predictors treatment and weight.                      RR and RD calculated directly without adjustment.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.2 DLQI 0/1 by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.758				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
DLQI 0/1 Week 52, N' n (%)	99 52.09 (50.57)	76 36.53 (38.86)	1.65 [0.92; 2.97] 0.095	1.30 [0.94; 1.81] 0.115	0.117 [-0.025; 0.259] 0.106
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
DLQI 0/1 Week 52, N' n (%)	6 4.08 (58.29)	6 3.78 (54.00)	1.15 [0.13; 10.41] 0.900	1.08 [0.41; 2.86] 0.870	0.043 [-0.490; 0.576] 0.875
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.3 DLQI 0/1 by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.864				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
DLQI 0/1 Week 52, N' n (%)	64 36.44 (55.21)	48 25.51 (44.75)	1.67 [0.79; 3.53] 0.182	1.23 [0.85; 1.80] 0.271	0.105 [-0.078; 0.287] 0.261
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
DLQI 0/1 Week 52, N' n (%)	41 19.73 (44.84)	34 14.80 (33.64)	1.50 [0.61; 3.71] 0.378	1.34 [0.77; 2.32] 0.303	0.112 [-0.097; 0.321] 0.294
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.4 DLQI 0/1 by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.972				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
DLQI 0/1 Week 52, N' n (%)	23 15.03 (62.63)	17 11.38 (54.19)	1.57 [0.44; 5.57] 0.481	1.16 [0.68; 1.96] 0.583	0.084 [-0.216; 0.384] 0.582
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
DLQI 0/1 Week 52, N' n (%)	82 41.14 (47.84)	65 28.93 (36.16)	1.62 [0.85; 3.08] 0.144	1.32 [0.91; 1.93] 0.145	0.117 [-0.036; 0.270] 0.135
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.5 DLQI 0/1 by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.783				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
DLQI 0/1 Week 52, N' n (%)	39 23.28 (55.43)	38 22.39 (43.90)	1.53 [0.64; 3.61] 0.337	1.26 [0.82; 1.94] 0.286	0.115 [-0.095; 0.326] 0.284
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
DLQI 0/1 Week 52, N' n (%)	66 32.89 (48.37)	44 17.92 (35.84)	1.80 [0.83; 3.89] 0.137	1.35 [0.86; 2.13] 0.196	0.125 [-0.057; 0.307] 0.177
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.6 DLQI 0/1 by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.698				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
DLQI 0/1 Week 52, N' n (%)	70 39.44 (54.78)	36 23.67 (48.31)	1.34 [0.63; 2.85] 0.455	1.14 [0.78; 1.65] 0.503	0.065 [-0.122; 0.252] 0.498
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
DLQI 0/1 Week 52, N' n (%)	35 16.73 (44.03)	46 16.64 (32.00)	1.68 [0.69; 4.11] 0.252	1.38 [0.80; 2.38] 0.254	0.120 [-0.087; 0.327] 0.255
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 39.7 DLQI 0/1 by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.258				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
DLQI 0/1 Week 52, N' n (%)	49 27.25 (53.43)	25 16.99 (53.09)	0.99 [0.39; 2.51] 0.981	1.01 [0.65; 1.55] 0.973	0.003 [-0.226; 0.233] 0.977
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
DLQI 0/1 Week 52, N' n (%)	56 28.92 (49.02)	57 23.32 (33.80)	1.98 [0.94; 4.14] 0.071	1.45 [0.94; 2.24] 0.092	0.152 [-0.021; 0.326] 0.085
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.8 DLQI 0/1 by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.107				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
DLQI 0/1 Week 52, N' n (%)	49 26.92 (52.78)	36 22.91 (55.88)	0.89 [0.38; 2.07] 0.789	0.95 [0.65; 1.38] 0.772	-0.031 [-0.239; 0.177] 0.770
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
DLQI 0/1 Week 52, N' n (%)	31 19.25 (56.62)	21 8.30 (31.92)	2.81 [0.92; 8.57] 0.069	1.78 [0.92; 3.46] 0.089	0.247 [-0.006; 0.500] 0.055
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.9 DLQI 0/1 by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.810				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
DLQI 0/1 Week 52, N' n (%)	43 26.17 (58.16)	19 13.16 (48.74)	1.52 [0.55; 4.20] 0.420	1.20 [0.74; 1.95] 0.471	0.094 [-0.155; 0.344] 0.459
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
DLQI 0/1 Week 52, N' n (%)	35 19.00 (50.00)	28 13.05 (43.50)	1.28 [0.48; 3.37] 0.620	1.15 [0.68; 1.93] 0.599	0.065 [-0.174; 0.304] 0.594
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.10 DLQI 0/1 by Lead Candidate Variant rs11937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.875				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
DLQI 0/1 Week 52, N' n (%)	29 16.81 (56.03)	24 14.84 (44.97)	1.55 [0.55; 4.36] 0.402	1.25 [0.75; 2.08] 0.394	0.111 [-0.142; 0.363] 0.390
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
DLQI 0/1 Week 52, N' n (%)	49 28.25 (55.39)	33 16.37 (48.15)	1.39 [0.57; 3.39] 0.465	1.15 [0.75; 1.77] 0.525	0.072 [-0.147; 0.292] 0.517
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.11 DLQI 0/1 by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.158				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
DLQI 0/1 Week 52, N' n (%)	39 19.81 (46.07)	39 20.94 (48.70)	0.87 [0.36; 2.09] 0.758	0.95 [0.60; 1.49] 0.812	-0.026 [-0.241; 0.189] 0.811
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
DLQI 0/1 Week 52, N' n (%)	41 26.36 (62.76)	18 10.27 (42.79)	2.39 [0.82; 7.00] 0.112	1.47 [0.85; 2.53] 0.164	0.200 [-0.056; 0.456] 0.126
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.12 DLQI 0/1 by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.880				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
DLQI 0/1 Week 52, N' n (%)	58 30.36 (48.97)	38 19.05 (40.53)	1.46 [0.66; 3.22] 0.351	1.21 [0.78; 1.88] 0.399	0.084 [-0.108; 0.277] 0.390
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
DLQI 0/1 Week 52, N' n (%)	19 13.81 (69.05)	17 11.16 (62.00)	1.29 [0.33; 5.10] 0.718	1.11 [0.69; 1.79] 0.655	0.070 [-0.236; 0.377] 0.652
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.13 DLQI 0/1 by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.534				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
DLQI 0/1 Week 52, N' n (%)	58 33.17 (52.65)	42 24.20 (47.45)	1.23 [0.57; 2.63] 0.600	1.11 [0.76; 1.63] 0.592	0.052 [-0.137; 0.241] 0.590
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
DLQI 0/1 Week 52, N' n (%)	19 11.00 (57.89)	12 5.00 (41.67)	2.08 [0.47; 9.16] 0.332	1.39 [0.64; 3.01] 0.403	0.162 [-0.194; 0.519] 0.372
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) DLQI 0/1, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

### 39.14 DLQI 0/1 by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.518				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
DLQI 0/1 Week 52, N' n (%)	66 39.17 (55.17)	44 25.05 (47.26)	1.42 [0.68; 2.96] 0.353	1.17 [0.81; 1.68] 0.401	0.079 [-0.102; 0.260] 0.393
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
DLQI 0/1 Week 52, N' n (%)	13 6.00 (46.15)	10 5.00 (50.00)	0.78 [0.15; 4.09] 0.767	0.92 [0.39; 2.17] 0.854	-0.038 [-0.450; 0.373] 0.855
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) DLQI 0/1, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					



### 39.15 DLQI 0/1 by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.671				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
DLQI 0/1 Week 52, N' n (%)	19 9.92 (45.09)	18 11.04 (42.46)	1.07 [0.32; 3.52] 0.917	1.06 [0.55; 2.08] 0.855	0.026 [-0.265; 0.317] 0.859
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
DLQI 0/1 Week 52, N' n (%)	61 36.25 (57.54)	39 20.17 (49.20)	1.46 [0.65; 3.26] 0.358	1.17 [0.80; 1.71] 0.419	0.083 [-0.114; 0.281] 0.408
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.16 DLQI 0/1 by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.726				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
DLQI 0/1 Week 52, N' n (%)	49 28.17 (55.24)	27 18.16 (51.89)	1.21 [0.49; 3.01] 0.676	1.07 [0.70; 1.62] 0.767	0.033 [-0.189; 0.256] 0.768
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
DLQI 0/1 Week 52, N' n (%)	31 18.00 (52.94)	30 13.05 (40.78)	1.54 [0.58; 4.14] 0.388	1.30 [0.77; 2.20] 0.331	0.122 [-0.118; 0.362] 0.321
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.17 DLQI 0/1 by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.752				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
DLQI 0/1 Week 52, N' n (%)	29 16.81 (56.03)	22 13.84 (44.65)	1.57 [0.55; 4.48] 0.399	1.26 [0.75; 2.12] 0.390	0.114 [-0.143; 0.371] 0.384
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
DLQI 0/1 Week 52, N' n (%)	51 29.36 (53.38)	35 17.37 (48.25)	1.26 [0.54; 2.97] 0.595	1.11 [0.72; 1.69] 0.640	0.051 [-0.161; 0.264] 0.636
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.18 DLQI 0/1 by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.158				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
DLQI 0/1 Week 52, N' n (%)	39 19.81 (46.07)	39 20.94 (48.70)	0.87 [0.36; 2.09] 0.758	0.95 [0.60; 1.49] 0.812	-0.026 [-0.241; 0.189] 0.811
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
DLQI 0/1 Week 52, N' n (%)	41 26.36 (62.76)	18 10.27 (42.79)	2.39 [0.82; 7.00] 0.112	1.47 [0.85; 2.53] 0.164	0.200 [-0.056; 0.456] 0.126
<p>N': Number of patients with available response value  N'-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 39.19 DLQI 0/1 by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
DLQI 0/1 Week 52	p=0.964				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
DLQI 0/1 Week 52, N' n (%)	61 32.36 (49.78)	40 20.05 (40.92)	1.48 [0.68; 3.21] 0.319	1.22 [0.79; 1.87] 0.366	0.089 [-0.099; 0.277] 0.355
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
DLQI 0/1 Week 52, N' n (%)	17 12.81 (71.17)	17 11.16 (62.00)	1.43 [0.34; 5.95] 0.627	1.15 [0.71; 1.84] 0.568	0.092 [-0.220; 0.403] 0.564
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

#### 40.0 EQ-5D VAS Score - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

#### 40.1 EQ-5D VAS Score - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	46.45 (21.80)	46.50 (21.28)		
Week 52 Mean (SD)	66.49 (22.07)	70.50 (19.84)		
Week 4 Adjusted Mean Change (SE)	13.53 (1.59)	14.07 (1.67)		
Week 12 Adjusted Mean Change (SE)	18.33 (1.85)	15.01 (1.94)		
Week 16 Adjusted Mean Change (SE)	18.94 (1.79)	16.16 (1.89)		
Week 24 Adjusted Mean Change (SE)	19.73 (1.90)	17.87 (2.04)		
Week 32 Adjusted Mean Change (SE)	18.64 (1.87)	18.98 (2.02)		
Week 40 Adjusted Mean Change (SE)	19.56 (1.88)	20.87 (2.05)		
Week 52 Adjusted Mean Change (SE)	20.31 (1.93)	22.57 (2.14)	-2.26 [-7.95; 3.42]	0.433
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 40.2 EQ-5D VAS Score - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.914</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	45.31 (21.19)	46.77 (21.46)		
Week 52 Mean (SD)	66.02 (22.01)	70.75 (20.01)		
Week 4 Adjusted Mean Change (SE)	13.82 (1.65)	13.73 (1.74)		
Week 12 Adjusted Mean Change (SE)	18.14 (1.92)	15.37 (2.02)		
Week 16 Adjusted Mean Change (SE)	19.13 (1.85)	15.84 (1.97)		
Week 24 Adjusted Mean Change (SE)	19.30 (1.97)	17.98 (2.12)		
Week 32 Adjusted Mean Change (SE)	18.61 (1.95)	18.62 (2.12)		
Week 40 Adjusted Mean Change (SE)	19.65 (1.96)	20.62 (2.15)		
Week 52 Adjusted Mean Change (SE)	20.18 (2.00)	22.65 (2.23)	-2.47 [-8.39; 3.45]	0.412
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	63.14 (25.62)	42.86 (19.81)		
Week 52 Mean (SD)	74.17 (23.66)	67.33 (18.82)		
Week 4 Adjusted Mean Change (SE)	9.33 (6.39)	18.45 (6.31)		
Week 12 Adjusted Mean Change (SE)	20.94 (7.38)	10.31 (7.30)		
Week 16 Adjusted Mean Change (SE)	15.50 (7.39)	20.11 (7.11)		
Week 24 Adjusted Mean Change (SE)	25.63 (7.59)	16.60 (7.51)		
Week 32 Adjusted Mean Change (SE)	19.00 (7.40)	23.18 (7.31)		
Week 40 Adjusted Mean Change (SE)	18.38 (7.52)	23.63 (7.44)		
Week 52 Adjusted Mean Change (SE)	22.45 (7.99)	21.35 (7.92)	1.10 [-21.11; 23.31]	0.922
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 40.3 EQ-5D VAS Score - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.554</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	50.92 (21.40)	48.42 (21.57)		
Week 52 Mean (SD)	70.09 (19.75)	74.04 (20.54)		
Week 4 Adjusted Mean Change (SE)	15.99 (2.08)	15.88 (2.22)		
Week 12 Adjusted Mean Change (SE)	20.22 (2.44)	16.18 (2.59)		
Week 16 Adjusted Mean Change (SE)	21.73 (2.32)	19.71 (2.47)		
Week 24 Adjusted Mean Change (SE)	22.92 (2.41)	23.79 (2.61)		
Week 32 Adjusted Mean Change (SE)	22.44 (2.37)	24.86 (2.60)		
Week 40 Adjusted Mean Change (SE)	21.33 (2.41)	26.51 (2.65)		
Week 52 Adjusted Mean Change (SE)	23.46 (2.47)	26.42 (2.77)	-2.96 [-10.25; 4.33]	0.424
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	39.73 (20.86)	44.00 (20.86)		
Week 52 Mean (SD)	60.85 (24.46)	65.50 (17.93)		
Week 4 Adjusted Mean Change (SE)	9.91 (2.57)	11.67 (2.54)		
Week 12 Adjusted Mean Change (SE)	15.59 (2.99)	13.48 (2.97)		
Week 16 Adjusted Mean Change (SE)	14.84 (2.84)	11.42 (2.86)		
Week 24 Adjusted Mean Change (SE)	14.85 (3.02)	9.79 (3.05)		
Week 32 Adjusted Mean Change (SE)	12.74 (2.97)	11.19 (3.00)		
Week 40 Adjusted Mean Change (SE)	16.92 (3.00)	13.19 (3.09)		
Week 52 Adjusted Mean Change (SE)	15.51 (3.10)	17.42 (3.26)	-1.91 [-10.73; 6.90]	0.669
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 40.4 EQ-5D VAS Score - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.356</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	62.50 (23.25)	63.67 (22.29)		
Week 52 Mean (SD)	73.43 (20.33)	77.24 (20.43)		
Week 4 Adjusted Mean Change (SE)	15.10 (3.49)	22.17 (3.74)		
Week 12 Adjusted Mean Change (SE)	20.75 (4.17)	17.15 (4.38)		
Week 16 Adjusted Mean Change (SE)	21.98 (3.93)	24.64 (4.21)		
Week 24 Adjusted Mean Change (SE)	25.31 (4.22)	25.42 (4.55)		
Week 32 Adjusted Mean Change (SE)	18.78 (4.16)	26.34 (4.66)		
Week 40 Adjusted Mean Change (SE)	22.77 (4.21)	27.78 (4.66)		
Week 52 Adjusted Mean Change (SE)	22.41 (4.29)	26.58 (4.86)	-4.17 [-16.58; 8.24]	0.508
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	41.97 (19.24)	41.99 (18.66)		
Week 52 Mean (SD)	64.54 (22.26)	68.74 (19.46)		
Week 4 Adjusted Mean Change (SE)	13.07 (1.80)	11.91 (1.88)		
Week 12 Adjusted Mean Change (SE)	17.65 (2.11)	14.46 (2.21)		
Week 16 Adjusted Mean Change (SE)	18.07 (2.03)	13.86 (2.14)		
Week 24 Adjusted Mean Change (SE)	18.20 (2.15)	15.88 (2.29)		
Week 32 Adjusted Mean Change (SE)	18.56 (2.13)	17.09 (2.28)		
Week 40 Adjusted Mean Change (SE)	18.65 (2.14)	19.06 (2.32)		
Week 52 Adjusted Mean Change (SE)	19.72 (2.22)	21.50 (2.42)	-1.78 [-8.21; 4.64]	0.584
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 40.5 EQ-5D VAS Score - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.879</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	49.90 (22.24)	46.84 (20.12)		
Week 52 Mean (SD)	67.74 (18.30)	72.18 (17.84)		
Week 4 Adjusted Mean Change (SE)	14.99 (2.58)	16.41 (2.35)		
Week 12 Adjusted Mean Change (SE)	16.47 (3.01)	16.21 (2.73)		
Week 16 Adjusted Mean Change (SE)	19.60 (2.91)	16.28 (2.68)		
Week 24 Adjusted Mean Change (SE)	20.51 (3.11)	17.14 (2.89)		
Week 32 Adjusted Mean Change (SE)	18.77 (3.06)	16.97 (2.88)		
Week 40 Adjusted Mean Change (SE)	21.26 (3.08)	18.78 (2.95)		
Week 52 Adjusted Mean Change (SE)	20.19 (3.18)	23.47 (3.11)	-3.29 [-12.06; 5.49]	0.461
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	44.31 (21.41)	46.14 (22.60)		
Week 52 Mean (SD)	65.74 (24.12)	69.05 (21.51)		
Week 4 Adjusted Mean Change (SE)	12.63 (2.03)	11.68 (2.38)		
Week 12 Adjusted Mean Change (SE)	19.52 (2.37)	13.75 (2.77)		
Week 16 Adjusted Mean Change (SE)	18.53 (2.30)	16.01 (2.70)		
Week 24 Adjusted Mean Change (SE)	19.25 (2.43)	18.57 (2.90)		
Week 32 Adjusted Mean Change (SE)	18.57 (2.40)	20.95 (2.88)		
Week 40 Adjusted Mean Change (SE)	18.52 (2.41)	22.74 (2.87)		
Week 52 Adjusted Mean Change (SE)	20.37 (2.46)	21.82 (2.97)	-1.45 [-9.07; 6.17]	0.708
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 40.6 EQ-5D VAS Score - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.382</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	46.60 (21.58)	50.33 (20.56)		
Week 52 Mean (SD)	68.57 (21.50)	71.94 (20.09)		
Week 4 Adjusted Mean Change (SE)	16.28 (1.94)	16.21 (2.36)		
Week 12 Adjusted Mean Change (SE)	20.47 (2.29)	14.83 (2.76)		
Week 16 Adjusted Mean Change (SE)	20.75 (2.20)	18.71 (2.70)		
Week 24 Adjusted Mean Change (SE)	20.98 (2.31)	21.88 (2.91)		
Week 32 Adjusted Mean Change (SE)	19.61 (2.32)	18.32 (2.97)		
Week 40 Adjusted Mean Change (SE)	22.04 (2.32)	20.74 (3.01)		
Week 52 Adjusted Mean Change (SE)	22.27 (2.38)	20.63 (3.20)	1.64 [-6.23; 9.52]	0.681
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	46.16 (22.50)	42.88 (21.50)		
Week 52 Mean (SD)	62.31 (22.91)	69.37 (19.79)		
Week 4 Adjusted Mean Change (SE)	8.31 (2.67)	11.97 (2.33)		
Week 12 Adjusted Mean Change (SE)	14.33 (3.12)	15.22 (2.74)		
Week 16 Adjusted Mean Change (SE)	15.51 (3.02)	13.69 (2.65)		
Week 24 Adjusted Mean Change (SE)	17.39 (3.25)	14.18 (2.82)		
Week 32 Adjusted Mean Change (SE)	16.86 (3.22)	19.43 (2.81)		
Week 40 Adjusted Mean Change (SE)	14.81 (3.23)	20.77 (2.83)		
Week 52 Adjusted Mean Change (SE)	16.56 (3.34)	23.85 (2.92)	-7.29 [-16.03; 1.46]	0.102
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 40.7 EQ-5D VAS Score - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.756</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	47.18 (22.93)	49.19 (21.55)		
Week 52 Mean (SD)	67.92 (21.47)	73.52 (22.52)		
Week 4 Adjusted Mean Change (SE)	16.01 (2.32)	16.77 (2.99)		
Week 12 Adjusted Mean Change (SE)	20.51 (2.74)	13.42 (3.50)		
Week 16 Adjusted Mean Change (SE)	18.95 (2.62)	19.66 (3.39)		
Week 24 Adjusted Mean Change (SE)	20.99 (2.80)	18.27 (3.63)		
Week 32 Adjusted Mean Change (SE)	21.47 (2.74)	19.58 (3.58)		
Week 40 Adjusted Mean Change (SE)	21.49 (2.77)	21.57 (3.62)		
Week 52 Adjusted Mean Change (SE)	21.53 (2.84)	24.91 (3.87)	-3.38 [-12.83; 6.07]	0.482
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	45.81 (20.95)	45.25 (21.19)		
Week 52 Mean (SD)	65.23 (22.70)	69.18 (18.60)		
Week 4 Adjusted Mean Change (SE)	11.38 (2.16)	12.84 (2.02)		
Week 12 Adjusted Mean Change (SE)	16.47 (2.52)	15.66 (2.34)		
Week 16 Adjusted Mean Change (SE)	18.96 (2.44)	14.55 (2.28)		
Week 24 Adjusted Mean Change (SE)	18.61 (2.61)	17.68 (2.48)		
Week 32 Adjusted Mean Change (SE)	16.16 (2.56)	18.70 (2.46)		
Week 40 Adjusted Mean Change (SE)	17.87 (2.58)	20.55 (2.51)		
Week 52 Adjusted Mean Change (SE)	19.24 (2.65)	21.52 (2.59)	-2.29 [-9.60; 5.03]	0.538
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 40.8 EQ-5D VAS Score - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.622</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	43.12 (22.18)	48.27 (22.79)		
Week 52 Mean (SD)	66.76 (23.48)	69.97 (19.24)		
Week 4 Adjusted Mean Change (SE)	11.42 (2.37)	16.89 (2.63)		
Week 12 Adjusted Mean Change (SE)	18.60 (2.63)	12.51 (2.95)		
Week 16 Adjusted Mean Change (SE)	20.37 (2.59)	15.69 (2.92)		
Week 24 Adjusted Mean Change (SE)	22.55 (2.82)	17.00 (3.19)		
Week 32 Adjusted Mean Change (SE)	21.71 (2.87)	18.65 (3.27)		
Week 40 Adjusted Mean Change (SE)	21.74 (2.89)	20.98 (3.28)		
Week 52 Adjusted Mean Change (SE)	21.72 (2.86)	22.99 (3.27)	-1.27 [-9.87; 7.34]	0.772
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	47.59 (20.55)	49.15 (22.48)		
Week 52 Mean (SD)	67.06 (21.37)	72.71 (20.59)		
Week 4 Adjusted Mean Change (SE)	16.80 (2.89)	14.78 (3.38)		
Week 12 Adjusted Mean Change (SE)	19.00 (3.27)	21.02 (3.76)		
Week 16 Adjusted Mean Change (SE)	18.29 (3.19)	19.32 (3.70)		
Week 24 Adjusted Mean Change (SE)	16.15 (3.46)	17.23 (4.09)		
Week 32 Adjusted Mean Change (SE)	17.84 (3.60)	17.88 (4.18)		
Week 40 Adjusted Mean Change (SE)	19.87 (3.56)	20.37 (4.28)		
Week 52 Adjusted Mean Change (SE)	20.75 (3.55)	22.69 (4.28)	-1.94 [-12.93; 9.04]	0.727
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 40.9 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.295</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	43.58 (21.90)	48.70 (21.07)		
Week 52 Mean (SD)	65.26 (25.51)	69.16 (20.70)		
Week 4 Adjusted Mean Change (SE)	15.02 (2.51)	8.98 (3.30)		
Week 12 Adjusted Mean Change (SE)	18.39 (2.82)	13.19 (3.71)		
Week 16 Adjusted Mean Change (SE)	20.14 (2.81)	15.75 (3.73)		
Week 24 Adjusted Mean Change (SE)	20.83 (2.90)	12.72 (3.91)		
Week 32 Adjusted Mean Change (SE)	20.77 (2.96)	17.03 (4.00)		
Week 40 Adjusted Mean Change (SE)	23.32 (3.00)	16.11 (4.08)		
Week 52 Adjusted Mean Change (SE)	20.10 (3.08)	20.57 (4.40)	-0.47 [-11.11; 10.17]	0.931
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	46.66 (21.75)	48.30 (22.78)		
Week 52 Mean (SD)	68.00 (18.69)	72.04 (18.79)		
Week 4 Adjusted Mean Change (SE)	11.65 (2.72)	21.57 (3.07)		
Week 12 Adjusted Mean Change (SE)	19.60 (3.10)	18.59 (3.47)		
Week 16 Adjusted Mean Change (SE)	19.32 (3.06)	17.25 (3.46)		
Week 24 Adjusted Mean Change (SE)	21.64 (3.17)	20.46 (3.61)		
Week 32 Adjusted Mean Change (SE)	22.69 (3.24)	17.11 (3.65)		
Week 40 Adjusted Mean Change (SE)	19.97 (3.25)	23.61 (3.75)		
Week 52 Adjusted Mean Change (SE)	22.31 (3.37)	24.32 (3.80)	-2.01 [-12.08; 8.06]	0.694
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 40.10 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.333</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	41.17 (20.38)	47.21 (24.95)		
Week 52 Mean (SD)	65.45 (21.28)	73.33 (22.42)		
Week 4 Adjusted Mean Change (SE)	12.16 (3.06)	16.82 (2.96)		
Week 12 Adjusted Mean Change (SE)	18.95 (3.38)	22.15 (3.29)		
Week 16 Adjusted Mean Change (SE)	20.09 (3.36)	20.38 (3.27)		
Week 24 Adjusted Mean Change (SE)	22.00 (3.77)	19.14 (3.74)		
Week 32 Adjusted Mean Change (SE)	19.54 (3.79)	20.59 (3.79)		
Week 40 Adjusted Mean Change (SE)	22.80 (3.80)	23.25 (3.81)		
Week 52 Adjusted Mean Change (SE)	21.56 (3.74)	24.10 (3.93)	-2.53 [-13.29; 8.23]	0.642
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	43.75 (19.48)	49.97 (20.13)		
Week 52 Mean (SD)	66.73 (23.37)	69.27 (17.46)		
Week 4 Adjusted Mean Change (SE)	16.10 (2.34)	16.27 (2.89)		
Week 12 Adjusted Mean Change (SE)	20.39 (2.61)	10.98 (3.18)		
Week 16 Adjusted Mean Change (SE)	20.99 (2.57)	14.97 (3.19)		
Week 24 Adjusted Mean Change (SE)	19.97 (2.84)	15.83 (3.52)		
Week 32 Adjusted Mean Change (SE)	21.97 (2.91)	17.14 (3.59)		
Week 40 Adjusted Mean Change (SE)	21.23 (2.89)	19.31 (3.61)		
Week 52 Adjusted Mean Change (SE)	22.41 (2.86)	22.48 (3.52)	-0.07 [-9.06; 8.93]	0.989
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 40.11 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.833</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	45.26 (22.58)	51.98 (24.21)		
Week 52 Mean (SD)	68.77 (23.44)	72.03 (19.68)		
Week 4 Adjusted Mean Change (SE)	12.28 (2.58)	17.45 (2.60)		
Week 12 Adjusted Mean Change (SE)	18.76 (2.90)	14.38 (2.93)		
Week 16 Adjusted Mean Change (SE)	17.98 (2.82)	15.43 (2.84)		
Week 24 Adjusted Mean Change (SE)	20.39 (3.12)	16.39 (3.17)		
Week 32 Adjusted Mean Change (SE)	21.09 (3.19)	20.74 (3.22)		
Week 40 Adjusted Mean Change (SE)	21.43 (3.17)	21.96 (3.23)		
Week 52 Adjusted Mean Change (SE)	23.00 (3.16)	24.37 (3.18)	-1.37 [-10.26; 7.51]	0.760
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	44.55 (20.66)	42.58 (18.00)		
Week 52 Mean (SD)	65.07 (21.80)	68.72 (19.83)		
Week 4 Adjusted Mean Change (SE)	14.89 (2.62)	13.55 (3.53)		
Week 12 Adjusted Mean Change (SE)	18.78 (2.94)	18.24 (3.94)		
Week 16 Adjusted Mean Change (SE)	21.17 (2.85)	20.18 (3.87)		
Week 24 Adjusted Mean Change (SE)	19.68 (3.13)	18.18 (4.31)		
Week 32 Adjusted Mean Change (SE)	19.26 (3.16)	13.85 (4.37)		
Week 40 Adjusted Mean Change (SE)	20.52 (3.18)	18.33 (4.47)		
Week 52 Adjusted Mean Change (SE)	19.74 (3.13)	19.69 (4.52)	0.05 [-10.81; 10.91]	0.993
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 40.12 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.627</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	47.11 (21.39)	51.15 (22.51)		
Week 52 Mean (SD)	65.38 (22.74)	70.00 (19.33)		
Week 4 Adjusted Mean Change (SE)	12.29 (2.14)	15.04 (2.49)		
Week 12 Adjusted Mean Change (SE)	17.54 (2.45)	16.01 (2.83)		
Week 16 Adjusted Mean Change (SE)	18.08 (2.34)	16.15 (2.73)		
Week 24 Adjusted Mean Change (SE)	19.66 (2.52)	13.77 (2.99)		
Week 32 Adjusted Mean Change (SE)	19.48 (2.66)	18.83 (3.14)		
Week 40 Adjusted Mean Change (SE)	19.92 (2.58)	18.24 (3.08)		
Week 52 Adjusted Mean Change (SE)	19.28 (2.57)	20.71 (3.12)	-1.43 [-9.44; 6.58]	0.725
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	38.60 (22.53)	44.11 (22.38)		
Week 52 Mean (SD)	71.63 (22.52)	75.53 (17.61)		
Week 4 Adjusted Mean Change (SE)	13.64 (3.82)	19.19 (3.95)		
Week 12 Adjusted Mean Change (SE)	19.15 (4.33)	13.35 (4.55)		
Week 16 Adjusted Mean Change (SE)	22.66 (4.16)	21.78 (4.36)		
Week 24 Adjusted Mean Change (SE)	20.68 (4.59)	27.78 (4.76)		
Week 32 Adjusted Mean Change (SE)	19.30 (4.74)	17.89 (5.00)		
Week 40 Adjusted Mean Change (SE)	22.99 (4.64)	29.07 (4.87)		
Week 52 Adjusted Mean Change (SE)	26.85 (4.57)	28.74 (4.75)	-1.89 [-14.88; 11.09]	0.774
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 40.13 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.585</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	45.13 (22.47)	48.84 (24.76)		
Week 52 Mean (SD)	66.00 (24.17)	72.43 (19.89)		
Week 4 Adjusted Mean Change (SE)	12.95 (2.12)	17.70 (2.39)		
Week 12 Adjusted Mean Change (SE)	19.21 (2.43)	15.11 (2.73)		
Week 16 Adjusted Mean Change (SE)	19.07 (2.29)	19.80 (2.59)		
Week 24 Adjusted Mean Change (SE)	20.37 (2.53)	18.99 (2.89)		
Week 32 Adjusted Mean Change (SE)	21.53 (2.56)	21.09 (2.89)		
Week 40 Adjusted Mean Change (SE)	21.42 (2.59)	23.15 (2.97)		
Week 52 Adjusted Mean Change (SE)	20.49 (2.60)	24.27 (3.01)	-3.78 [-11.67; 4.11]	0.345
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	46.00 (19.75)	47.33 (15.29)		
Week 52 Mean (SD)	67.37 (18.04)	67.83 (19.49)		
Week 4 Adjusted Mean Change (SE)	12.79 (3.86)	7.89 (4.89)		
Week 12 Adjusted Mean Change (SE)	15.20 (4.40)	17.12 (5.56)		
Week 16 Adjusted Mean Change (SE)	18.55 (4.15)	10.92 (5.25)		
Week 24 Adjusted Mean Change (SE)	14.71 (4.55)	13.19 (5.75)		
Week 32 Adjusted Mean Change (SE)	12.26 (4.55)	8.17 (5.89)		
Week 40 Adjusted Mean Change (SE)	16.00 (4.64)	13.94 (5.95)		
Week 52 Adjusted Mean Change (SE)	20.72 (4.60)	19.90 (5.82)	0.82 [-13.84; 15.48]	0.912
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 40.14 EQ-5D VAS Score - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.575</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	45.77 (22.02)	47.34 (23.77)		
Week 52 Mean (SD)	66.29 (23.33)	71.61 (21.00)		
Week 4 Adjusted Mean Change (SE)	13.69 (2.04)	16.52 (2.38)		
Week 12 Adjusted Mean Change (SE)	18.99 (2.26)	16.02 (2.64)		
Week 16 Adjusted Mean Change (SE)	19.23 (2.20)	18.02 (2.59)		
Week 24 Adjusted Mean Change (SE)	19.56 (2.41)	17.68 (2.86)		
Week 32 Adjusted Mean Change (SE)	19.74 (2.46)	17.87 (2.90)		
Week 40 Adjusted Mean Change (SE)	20.70 (2.47)	20.97 (2.96)		
Week 52 Adjusted Mean Change (SE)	20.69 (2.45)	23.98 (2.95)	-3.29 [-10.86; 4.29]	0.393
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	38.38 (17.90)	57.80 (13.29)		
Week 52 Mean (SD)	68.23 (18.86)	69.00 (13.22)		
Week 4 Adjusted Mean Change (SE)	12.76 (4.80)	15.77 (5.48)		
Week 12 Adjusted Mean Change (SE)	16.13 (5.40)	13.74 (6.04)		
Week 16 Adjusted Mean Change (SE)	20.59 (5.17)	9.61 (5.91)		
Week 24 Adjusted Mean Change (SE)	21.26 (5.61)	13.81 (6.41)		
Week 32 Adjusted Mean Change (SE)	22.11 (5.66)	17.40 (6.47)		
Week 40 Adjusted Mean Change (SE)	21.44 (5.75)	19.09 (6.57)		
Week 52 Adjusted Mean Change (SE)	23.94 (5.62)	19.05 (6.43)	4.89 [-12.15; 21.93]	0.571
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 40.15 EQ-5D VAS Score - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.564</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	48.95 (26.11)	47.04 (27.14)		
Week 52 Mean (SD)	65.42 (25.15)	68.22 (23.25)		
Week 4 Adjusted Mean Change (SE)	9.33 (3.60)	14.19 (3.38)		
Week 12 Adjusted Mean Change (SE)	17.51 (4.02)	18.53 (3.78)		
Week 16 Adjusted Mean Change (SE)	13.37 (3.95)	18.47 (3.71)		
Week 24 Adjusted Mean Change (SE)	18.89 (4.36)	12.77 (4.14)		
Week 32 Adjusted Mean Change (SE)	18.98 (4.46)	22.60 (4.25)		
Week 40 Adjusted Mean Change (SE)	19.97 (4.47)	18.30 (4.28)		
Week 52 Adjusted Mean Change (SE)	18.40 (4.48)	21.41 (4.46)	-3.01 [-15.51; 9.49]	0.635
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	43.49 (19.73)	49.61 (19.31)		
Week 52 Mean (SD)	67.33 (21.88)	72.26 (17.88)		
Week 4 Adjusted Mean Change (SE)	15.08 (2.13)	17.19 (2.65)		
Week 12 Adjusted Mean Change (SE)	19.17 (2.40)	14.04 (2.98)		
Week 16 Adjusted Mean Change (SE)	21.67 (2.32)	16.27 (2.89)		
Week 24 Adjusted Mean Change (SE)	20.45 (2.53)	19.40 (3.19)		
Week 32 Adjusted Mean Change (SE)	20.77 (2.59)	15.72 (3.26)		
Week 40 Adjusted Mean Change (SE)	21.38 (2.58)	22.09 (3.27)		
Week 52 Adjusted Mean Change (SE)	22.35 (2.56)	23.54 (3.20)	-1.19 [-9.33; 6.94]	0.772
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 40.16 EQ-5D VAS Score - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.762</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	44.04 (21.39)	48.77 (20.19)		
Week 52 Mean (SD)	66.22 (24.75)	71.56 (20.09)		
Week 4 Adjusted Mean Change (SE)	15.03 (2.36)	12.41 (2.88)		
Week 12 Adjusted Mean Change (SE)	18.26 (2.67)	13.88 (3.25)		
Week 16 Adjusted Mean Change (SE)	19.44 (2.61)	17.28 (3.21)		
Week 24 Adjusted Mean Change (SE)	19.38 (2.84)	15.80 (3.54)		
Week 32 Adjusted Mean Change (SE)	18.89 (2.89)	19.23 (3.60)		
Week 40 Adjusted Mean Change (SE)	21.22 (2.89)	19.26 (3.63)		
Week 52 Adjusted Mean Change (SE)	21.10 (2.86)	23.44 (3.72)	-2.34 [-11.64; 6.97]	0.621
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	46.21 (21.99)	48.44 (25.12)		
Week 52 Mean (SD)	67.90 (18.90)	70.47 (19.51)		
Week 4 Adjusted Mean Change (SE)	11.43 (2.88)	19.93 (2.96)		
Week 12 Adjusted Mean Change (SE)	19.51 (3.27)	17.80 (3.37)		
Week 16 Adjusted Mean Change (SE)	19.71 (3.21)	16.88 (3.30)		
Week 24 Adjusted Mean Change (SE)	20.97 (3.50)	18.37 (3.64)		
Week 32 Adjusted Mean Change (SE)	22.37 (3.58)	17.36 (3.71)		
Week 40 Adjusted Mean Change (SE)	20.61 (3.54)	22.41 (3.72)		
Week 52 Adjusted Mean Change (SE)	21.70 (3.55)	22.55 (3.63)	-0.85 [-10.93; 9.22]	0.867
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 40.17 EQ-5D VAS Score - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.361</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	41.17 (20.38)	47.00 (25.26)		
Week 52 Mean (SD)	65.45 (21.28)	73.14 (23.44)		
Week 4 Adjusted Mean Change (SE)	11.48 (3.11)	17.33 (3.10)		
Week 12 Adjusted Mean Change (SE)	18.19 (3.41)	21.93 (3.42)		
Week 16 Adjusted Mean Change (SE)	19.38 (3.37)	20.97 (3.38)		
Week 24 Adjusted Mean Change (SE)	21.44 (3.76)	18.97 (3.85)		
Week 32 Adjusted Mean Change (SE)	18.87 (3.78)	19.42 (3.91)		
Week 40 Adjusted Mean Change (SE)	22.16 (3.79)	22.28 (3.93)		
Week 52 Adjusted Mean Change (SE)	20.93 (3.74)	23.03 (4.07)	-2.10 [-13.05; 8.85]	0.705
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	46.95 (22.05)	50.00 (20.10)		
Week 52 Mean (SD)	67.69 (23.40)	69.63 (17.00)		
Week 4 Adjusted Mean Change (SE)	14.72 (2.28)	15.04 (2.84)		
Week 12 Adjusted Mean Change (SE)	19.08 (2.52)	10.77 (3.10)		
Week 16 Adjusted Mean Change (SE)	19.67 (2.48)	13.86 (3.09)		
Week 24 Adjusted Mean Change (SE)	19.28 (2.73)	15.23 (3.39)		
Week 32 Adjusted Mean Change (SE)	20.95 (2.80)	17.27 (3.46)		
Week 40 Adjusted Mean Change (SE)	20.33 (2.78)	19.28 (3.48)		
Week 52 Adjusted Mean Change (SE)	21.56 (2.78)	22.28 (3.40)	-0.72 [-9.41; 7.96]	0.870
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 40.18 EQ-5D VAS Score - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.833</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	45.26 (22.58)	51.98 (24.21)		
Week 52 Mean (SD)	68.77 (23.44)	72.03 (19.68)		
Week 4 Adjusted Mean Change (SE)	12.28 (2.58)	17.45 (2.60)		
Week 12 Adjusted Mean Change (SE)	18.76 (2.90)	14.38 (2.93)		
Week 16 Adjusted Mean Change (SE)	17.98 (2.82)	15.43 (2.84)		
Week 24 Adjusted Mean Change (SE)	20.39 (3.12)	16.39 (3.17)		
Week 32 Adjusted Mean Change (SE)	21.09 (3.19)	20.74 (3.22)		
Week 40 Adjusted Mean Change (SE)	21.43 (3.17)	21.96 (3.23)		
Week 52 Adjusted Mean Change (SE)	23.00 (3.16)	24.37 (3.18)	-1.37 [-10.26; 7.51]	0.760
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	44.55 (20.66)	42.58 (18.00)		
Week 52 Mean (SD)	65.07 (21.80)	68.72 (19.83)		
Week 4 Adjusted Mean Change (SE)	14.89 (2.62)	13.55 (3.53)		
Week 12 Adjusted Mean Change (SE)	18.78 (2.94)	18.24 (3.94)		
Week 16 Adjusted Mean Change (SE)	21.17 (2.85)	20.18 (3.87)		
Week 24 Adjusted Mean Change (SE)	19.68 (3.13)	18.18 (4.31)		
Week 32 Adjusted Mean Change (SE)	19.26 (3.16)	13.85 (4.37)		
Week 40 Adjusted Mean Change (SE)	20.52 (3.18)	18.33 (4.47)		
Week 52 Adjusted Mean Change (SE)	19.74 (3.13)	19.69 (4.52)	0.05 [-10.81; 10.91]	0.993
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



#### 40.19 EQ-5D VAS Score - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.316</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	47.00 (20.99)	50.27 (22.55)		
Week 52 Mean (SD)	65.89 (22.74)	68.58 (20.29)		
Week 4 Adjusted Mean Change (SE)	13.20 (2.11)	15.04 (2.46)		
Week 12 Adjusted Mean Change (SE)	18.29 (2.39)	15.59 (2.78)		
Week 16 Adjusted Mean Change (SE)	18.26 (2.29)	14.81 (2.68)		
Week 24 Adjusted Mean Change (SE)	19.72 (2.46)	12.41 (2.94)		
Week 32 Adjusted Mean Change (SE)	20.16 (2.58)	17.34 (3.05)		
Week 40 Adjusted Mean Change (SE)	20.13 (2.51)	16.95 (2.99)		
Week 52 Adjusted Mean Change (SE)	19.78 (2.51)	19.74 (3.05)	0.04 [-7.78; 7.86]	0.992
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	39.56 (22.60)	44.11 (22.38)		
Week 52 Mean (SD)	69.94 (23.24)	76.65 (17.16)		
Week 4 Adjusted Mean Change (SE)	13.25 (4.05)	18.00 (4.00)		
Week 12 Adjusted Mean Change (SE)	18.60 (4.54)	15.44 (4.49)		
Week 16 Adjusted Mean Change (SE)	21.59 (4.39)	22.15 (4.39)		
Week 24 Adjusted Mean Change (SE)	20.62 (4.83)	28.16 (4.72)		
Week 32 Adjusted Mean Change (SE)	19.05 (4.97)	19.77 (4.99)		
Week 40 Adjusted Mean Change (SE)	21.18 (4.85)	30.26 (4.90)		
Week 52 Adjusted Mean Change (SE)	25.17 (4.81)	29.90 (4.76)	-4.73 [-18.09; 8.62]	0.484
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 41.0 FACIT Fatigue - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

### 41.1 FACIT Fatigue - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	28.90 (11.36)	28.96 (10.69)		
Week 52 Mean (SD)	37.63 (10.23)	36.44 (10.77)		
Week 4 Adjusted Mean Change (SE)	6.14 (0.73)	4.96 (0.77)		
Week 12 Adjusted Mean Change (SE)	7.02 (0.80)	5.42 (0.84)		
Week 16 Adjusted Mean Change (SE)	8.00 (0.81)	5.41 (0.86)		
Week 24 Adjusted Mean Change (SE)	7.71 (0.85)	6.50 (0.91)		
Week 32 Adjusted Mean Change (SE)	8.17 (0.85)	6.83 (0.91)		
Week 40 Adjusted Mean Change (SE)	8.39 (0.85)	7.23 (0.92)		
Week 52 Adjusted Mean Change (SE)	8.82 (0.90)	6.82 (0.98)	2.00 [-0.63; 4.62]	0.135
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

#### 41.2 FACIT Fatigue - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.257</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	28.56 (11.43)	28.77 (10.71)		
Week 52 Mean (SD)	37.56 (10.36)	36.34 (10.79)		
Week 4 Adjusted Mean Change (SE)	6.30 (0.76)	4.83 (0.80)		
Week 12 Adjusted Mean Change (SE)	7.07 (0.83)	5.22 (0.88)		
Week 16 Adjusted Mean Change (SE)	8.12 (0.84)	5.12 (0.90)		
Week 24 Adjusted Mean Change (SE)	7.66 (0.88)	6.26 (0.95)		
Week 32 Adjusted Mean Change (SE)	8.24 (0.89)	6.61 (0.95)		
Week 40 Adjusted Mean Change (SE)	8.77 (0.88)	7.10 (0.95)		
Week 52 Adjusted Mean Change (SE)	8.98 (0.93)	6.73 (1.02)	2.24 [-0.48; 4.97]	0.107
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	33.86 (9.65)	31.57 (10.85)		
Week 52 Mean (SD)	38.83 (8.30)	37.67 (11.50)		
Week 4 Adjusted Mean Change (SE)	3.82 (2.91)	6.64 (2.90)		
Week 12 Adjusted Mean Change (SE)	6.22 (3.19)	8.15 (3.18)		
Week 16 Adjusted Mean Change (SE)	6.01 (3.35)	9.17 (3.23)		
Week 24 Adjusted Mean Change (SE)	8.36 (3.38)	9.50 (3.37)		
Week 32 Adjusted Mean Change (SE)	7.09 (3.37)	9.65 (3.36)		
Week 40 Adjusted Mean Change (SE)	3.03 (3.35)	9.13 (3.34)		
Week 52 Adjusted Mean Change (SE)	6.76 (3.64)	8.01 (3.63)	-1.25 [-11.36; 8.87]	0.808
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 41.3 FACIT Fatigue - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.731</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	31.00 (10.71)	30.86 (10.09)		
Week 52 Mean (SD)	39.50 (10.08)	37.65 (10.21)		
Week 4 Adjusted Mean Change (SE)	6.54 (0.97)	5.17 (1.03)		
Week 12 Adjusted Mean Change (SE)	8.08 (1.06)	6.67 (1.12)		
Week 16 Adjusted Mean Change (SE)	8.41 (1.07)	6.74 (1.14)		
Week 24 Adjusted Mean Change (SE)	8.39 (1.11)	8.16 (1.20)		
Week 32 Adjusted Mean Change (SE)	8.90 (1.12)	7.99 (1.22)		
Week 40 Adjusted Mean Change (SE)	9.03 (1.12)	8.14 (1.22)		
Week 52 Adjusted Mean Change (SE)	9.82 (1.17)	7.70 (1.30)	2.12 [-1.30; 5.55]	0.222
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	25.75 (11.71)	26.50 (11.05)		
Week 52 Mean (SD)	34.71 (9.88)	34.74 (11.45)		
Week 4 Adjusted Mean Change (SE)	5.54 (1.19)	4.67 (1.18)		
Week 12 Adjusted Mean Change (SE)	5.47 (1.29)	3.79 (1.29)		
Week 16 Adjusted Mean Change (SE)	7.40 (1.31)	3.64 (1.33)		
Week 24 Adjusted Mean Change (SE)	6.71 (1.38)	4.24 (1.40)		
Week 32 Adjusted Mean Change (SE)	7.08 (1.39)	5.29 (1.40)		
Week 40 Adjusted Mean Change (SE)	7.43 (1.38)	6.03 (1.42)		
Week 52 Adjusted Mean Change (SE)	7.30 (1.46)	5.66 (1.51)	1.63 [-2.47; 5.73]	0.433
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 41.4 FACIT Fatigue - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.807</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	37.21 (9.21)	38.57 (7.48)		
Week 52 Mean (SD)	42.04 (8.77)	39.12 (10.65)		
Week 4 Adjusted Mean Change (SE)	6.05 (1.63)	4.87 (1.76)		
Week 12 Adjusted Mean Change (SE)	7.90 (1.82)	6.38 (1.92)		
Week 16 Adjusted Mean Change (SE)	9.24 (1.82)	6.36 (1.96)		
Week 24 Adjusted Mean Change (SE)	7.71 (1.92)	5.58 (2.07)		
Week 32 Adjusted Mean Change (SE)	8.41 (1.92)	6.86 (2.11)		
Week 40 Adjusted Mean Change (SE)	9.38 (1.92)	7.58 (2.11)		
Week 52 Adjusted Mean Change (SE)	9.73 (2.01)	6.38 (2.24)	3.35 [-2.39; 9.08]	0.251
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	26.58 (10.85)	26.44 (9.97)		
Week 52 Mean (SD)	36.39 (10.31)	35.74 (10.78)		
Week 4 Adjusted Mean Change (SE)	6.16 (0.84)	4.98 (0.88)		
Week 12 Adjusted Mean Change (SE)	6.78 (0.92)	5.17 (0.97)		
Week 16 Adjusted Mean Change (SE)	7.65 (0.93)	5.15 (0.99)		
Week 24 Adjusted Mean Change (SE)	7.70 (0.97)	6.74 (1.04)		
Week 32 Adjusted Mean Change (SE)	8.11 (0.98)	6.82 (1.04)		
Week 40 Adjusted Mean Change (SE)	8.11 (0.97)	7.15 (1.05)		
Week 52 Adjusted Mean Change (SE)	8.56 (1.03)	6.94 (1.12)	1.62 [-1.35; 4.59]	0.283
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 41.5 FACIT Fatigue - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.633</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	29.31 (12.37)	27.51 (9.85)		
Week 52 Mean (SD)	37.85 (9.47)	36.92 (9.01)		
Week 4 Adjusted Mean Change (SE)	7.29 (1.18)	5.92 (1.08)		
Week 12 Adjusted Mean Change (SE)	6.52 (1.30)	6.47 (1.19)		
Week 16 Adjusted Mean Change (SE)	7.11 (1.32)	5.58 (1.22)		
Week 24 Adjusted Mean Change (SE)	7.86 (1.39)	6.90 (1.29)		
Week 32 Adjusted Mean Change (SE)	8.27 (1.39)	7.04 (1.30)		
Week 40 Adjusted Mean Change (SE)	7.87 (1.39)	7.23 (1.33)		
Week 52 Adjusted Mean Change (SE)	9.15 (1.47)	7.22 (1.42)	1.93 [-2.11; 5.96]	0.348
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	28.65 (10.78)	30.44 (11.39)		
Week 52 Mean (SD)	37.50 (10.72)	36.02 (12.18)		
Week 4 Adjusted Mean Change (SE)	5.43 (0.93)	3.97 (1.09)		
Week 12 Adjusted Mean Change (SE)	7.33 (1.03)	4.34 (1.21)		
Week 16 Adjusted Mean Change (SE)	8.56 (1.04)	5.22 (1.23)		
Week 24 Adjusted Mean Change (SE)	7.63 (1.09)	6.05 (1.30)		
Week 32 Adjusted Mean Change (SE)	8.11 (1.09)	6.58 (1.31)		
Week 40 Adjusted Mean Change (SE)	8.69 (1.09)	7.14 (1.30)		
Week 52 Adjusted Mean Change (SE)	8.62 (1.15)	6.39 (1.38)	2.23 [-1.32; 5.77]	0.217
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 41.6 FACIT Fatigue - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.145</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	29.35 (10.04)	30.76 (11.31)		
Week 52 Mean (SD)	39.26 (9.73)	38.86 (9.53)		
Week 4 Adjusted Mean Change (SE)	6.83 (0.90)	4.56 (1.10)		
Week 12 Adjusted Mean Change (SE)	8.05 (1.00)	5.66 (1.20)		
Week 16 Adjusted Mean Change (SE)	8.81 (1.01)	5.86 (1.23)		
Week 24 Adjusted Mean Change (SE)	8.92 (1.04)	6.38 (1.31)		
Week 32 Adjusted Mean Change (SE)	9.16 (1.05)	6.64 (1.32)		
Week 40 Adjusted Mean Change (SE)	9.73 (1.04)	7.18 (1.33)		
Week 52 Adjusted Mean Change (SE)	10.07 (1.10)	6.98 (1.44)	3.10 [-0.47; 6.66]	0.088
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	28.05 (13.63)	27.27 (9.88)		
Week 52 Mean (SD)	34.37 (10.56)	34.54 (11.40)		
Week 4 Adjusted Mean Change (SE)	4.83 (1.24)	5.34 (1.08)		
Week 12 Adjusted Mean Change (SE)	5.08 (1.36)	5.19 (1.19)		
Week 16 Adjusted Mean Change (SE)	6.47 (1.38)	4.97 (1.21)		
Week 24 Adjusted Mean Change (SE)	5.38 (1.46)	6.59 (1.27)		
Week 32 Adjusted Mean Change (SE)	6.29 (1.46)	6.99 (1.27)		
Week 40 Adjusted Mean Change (SE)	5.79 (1.45)	7.29 (1.27)		
Week 52 Adjusted Mean Change (SE)	6.39 (1.53)	6.74 (1.34)	-0.35 [-4.37; 3.66]	0.862
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 41.7 FACIT Fatigue - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.343</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	29.16 (12.05)	32.34 (11.75)		
Week 52 Mean (SD)	38.06 (10.02)	41.56 (8.92)		
Week 4 Adjusted Mean Change (SE)	6.65 (1.07)	6.84 (1.38)		
Week 12 Adjusted Mean Change (SE)	7.89 (1.18)	8.08 (1.52)		
Week 16 Adjusted Mean Change (SE)	8.60 (1.18)	9.08 (1.54)		
Week 24 Adjusted Mean Change (SE)	8.35 (1.25)	7.67 (1.63)		
Week 32 Adjusted Mean Change (SE)	9.05 (1.25)	9.18 (1.63)		
Week 40 Adjusted Mean Change (SE)	10.15 (1.24)	9.10 (1.62)		
Week 52 Adjusted Mean Change (SE)	9.22 (1.30)	10.20 (1.75)	-0.99 [-5.29; 3.31]	0.651
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	28.68 (10.83)	27.39 (9.86)		
Week 52 Mean (SD)	37.25 (10.48)	34.19 (10.81)		
Week 4 Adjusted Mean Change (SE)	5.69 (0.99)	4.10 (0.93)		
Week 12 Adjusted Mean Change (SE)	6.27 (1.09)	4.22 (1.01)		
Week 16 Adjusted Mean Change (SE)	7.49 (1.10)	3.75 (1.03)		
Week 24 Adjusted Mean Change (SE)	7.16 (1.17)	5.97 (1.11)		
Week 32 Adjusted Mean Change (SE)	7.42 (1.16)	5.77 (1.11)		
Week 40 Adjusted Mean Change (SE)	6.87 (1.15)	6.42 (1.11)		
Week 52 Adjusted Mean Change (SE)	8.47 (1.22)	5.34 (1.18)	3.13 [-0.21; 6.47]	0.066
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 41.8 FACIT Fatigue - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.561</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	26.84 (11.72)	30.61 (11.45)		
Week 52 Mean (SD)	36.69 (10.77)	40.31 (8.67)		
Week 4 Adjusted Mean Change (SE)	6.86 (1.02)	7.08 (1.14)		
Week 12 Adjusted Mean Change (SE)	7.26 (1.16)	6.75 (1.30)		
Week 16 Adjusted Mean Change (SE)	8.05 (1.19)	6.42 (1.35)		
Week 24 Adjusted Mean Change (SE)	8.41 (1.25)	7.98 (1.41)		
Week 32 Adjusted Mean Change (SE)	8.27 (1.24)	8.63 (1.41)		
Week 40 Adjusted Mean Change (SE)	9.18 (1.25)	9.33 (1.41)		
Week 52 Adjusted Mean Change (SE)	9.17 (1.27)	10.59 (1.44)	-1.42 [-5.22; 2.38]	0.460
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	30.06 (9.80)	29.08 (10.93)		
Week 52 Mean (SD)	37.71 (9.59)	35.19 (11.72)		
Week 4 Adjusted Mean Change (SE)	6.11 (1.25)	4.82 (1.45)		
Week 12 Adjusted Mean Change (SE)	6.77 (1.44)	5.32 (1.65)		
Week 16 Adjusted Mean Change (SE)	7.92 (1.47)	5.86 (1.70)		
Week 24 Adjusted Mean Change (SE)	7.22 (1.53)	6.26 (1.80)		
Week 32 Adjusted Mean Change (SE)	9.06 (1.54)	6.25 (1.79)		
Week 40 Adjusted Mean Change (SE)	7.80 (1.53)	7.91 (1.82)		
Week 52 Adjusted Mean Change (SE)	7.86 (1.56)	6.05 (1.85)	1.80 [-2.98; 6.59]	0.457
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 41.9 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.771</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	26.89 (10.11)	30.00 (10.69)		
Week 52 Mean (SD)	36.58 (11.19)	37.95 (10.23)		
Week 4 Adjusted Mean Change (SE)	6.85 (1.11)	6.93 (1.46)		
Week 12 Adjusted Mean Change (SE)	7.91 (1.25)	6.58 (1.65)		
Week 16 Adjusted Mean Change (SE)	8.14 (1.29)	4.75 (1.71)		
Week 24 Adjusted Mean Change (SE)	7.89 (1.34)	5.00 (1.80)		
Week 32 Adjusted Mean Change (SE)	9.14 (1.36)	7.89 (1.82)		
Week 40 Adjusted Mean Change (SE)	8.42 (1.36)	8.19 (1.83)		
Week 52 Adjusted Mean Change (SE)	8.44 (1.41)	8.90 (1.95)	-0.46 [-5.22; 4.30]	0.848
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	29.58 (11.96)	30.27 (12.57)		
Week 52 Mean (SD)	37.77 (9.33)	38.96 (10.81)		
Week 4 Adjusted Mean Change (SE)	6.09 (1.21)	5.29 (1.36)		
Week 12 Adjusted Mean Change (SE)	6.26 (1.38)	6.48 (1.54)		
Week 16 Adjusted Mean Change (SE)	7.99 (1.41)	6.86 (1.59)		
Week 24 Adjusted Mean Change (SE)	8.34 (1.46)	8.36 (1.66)		
Week 32 Adjusted Mean Change (SE)	8.31 (1.48)	6.80 (1.67)		
Week 40 Adjusted Mean Change (SE)	9.31 (1.46)	9.13 (1.69)		
Week 52 Adjusted Mean Change (SE)	9.00 (1.53)	9.09 (1.73)	-0.09 [-4.66; 4.47]	0.968
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 41.10 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.965</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	25.23 (12.04)	28.09 (13.11)		
Week 52 Mean (SD)	37.24 (10.76)	39.13 (12.00)		
Week 4 Adjusted Mean Change (SE)	7.12 (1.34)	7.49 (1.29)		
Week 12 Adjusted Mean Change (SE)	8.24 (1.54)	6.78 (1.49)		
Week 16 Adjusted Mean Change (SE)	8.74 (1.58)	6.51 (1.52)		
Week 24 Adjusted Mean Change (SE)	8.75 (1.67)	6.49 (1.64)		
Week 32 Adjusted Mean Change (SE)	8.93 (1.65)	9.23 (1.62)		
Week 40 Adjusted Mean Change (SE)	9.28 (1.65)	9.31 (1.63)		
Week 52 Adjusted Mean Change (SE)	9.95 (1.68)	10.35 (1.70)	-0.40 [-5.12; 4.33]	0.868
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	28.92 (10.10)	31.88 (8.74)		
Week 52 Mean (SD)	36.73 (10.22)	37.91 (8.64)		
Week 4 Adjusted Mean Change (SE)	6.51 (1.02)	5.13 (1.27)		
Week 12 Adjusted Mean Change (SE)	6.64 (1.18)	5.82 (1.45)		
Week 16 Adjusted Mean Change (SE)	7.61 (1.20)	6.14 (1.50)		
Week 24 Adjusted Mean Change (SE)	7.48 (1.25)	8.10 (1.56)		
Week 32 Adjusted Mean Change (SE)	8.45 (1.25)	6.47 (1.56)		
Week 40 Adjusted Mean Change (SE)	8.70 (1.25)	8.44 (1.56)		
Week 52 Adjusted Mean Change (SE)	8.19 (1.27)	7.87 (1.58)	0.32 [-3.68; 4.33]	0.874
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 41.11 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.875</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	27.65 (11.39)	31.33 (11.79)		
Week 52 Mean (SD)	37.10 (11.33)	38.85 (11.29)		
Week 4 Adjusted Mean Change (SE)	6.51 (1.12)	6.04 (1.12)		
Week 12 Adjusted Mean Change (SE)	6.52 (1.27)	5.91 (1.27)		
Week 16 Adjusted Mean Change (SE)	7.12 (1.30)	5.75 (1.30)		
Week 24 Adjusted Mean Change (SE)	7.07 (1.36)	6.48 (1.37)		
Week 32 Adjusted Mean Change (SE)	8.24 (1.38)	8.32 (1.39)		
Week 40 Adjusted Mean Change (SE)	8.17 (1.36)	8.32 (1.38)		
Week 52 Adjusted Mean Change (SE)	8.86 (1.41)	9.40 (1.42)	-0.54 [-4.51; 3.43]	0.789
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	28.62 (10.80)	27.67 (9.82)		
Week 52 Mean (SD)	37.07 (9.32)	37.50 (7.11)		
Week 4 Adjusted Mean Change (SE)	6.62 (1.13)	6.57 (1.52)		
Week 12 Adjusted Mean Change (SE)	7.63 (1.28)	6.75 (1.72)		
Week 16 Adjusted Mean Change (SE)	8.89 (1.31)	7.07 (1.78)		
Week 24 Adjusted Mean Change (SE)	8.83 (1.36)	8.90 (1.86)		
Week 32 Adjusted Mean Change (SE)	8.86 (1.38)	6.61 (1.89)		
Week 40 Adjusted Mean Change (SE)	9.10 (1.37)	9.74 (1.90)		
Week 52 Adjusted Mean Change (SE)	8.46 (1.41)	7.76 (1.99)	0.70 [-4.11; 5.50]	0.775
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 41.12 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.746</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	28.74 (11.00)	30.23 (11.10)		
Week 52 Mean (SD)	36.71 (9.53)	38.68 (9.85)		
Week 4 Adjusted Mean Change (SE)	5.95 (0.90)	6.89 (1.04)		
Week 12 Adjusted Mean Change (SE)	5.87 (1.03)	6.39 (1.18)		
Week 16 Adjusted Mean Change (SE)	7.37 (1.05)	6.24 (1.22)		
Week 24 Adjusted Mean Change (SE)	7.89 (1.08)	7.02 (1.27)		
Week 32 Adjusted Mean Change (SE)	8.14 (1.12)	8.35 (1.31)		
Week 40 Adjusted Mean Change (SE)	8.39 (1.08)	9.11 (1.27)		
Week 52 Adjusted Mean Change (SE)	8.14 (1.11)	9.01 (1.33)	-0.87 [-4.30; 2.56]	0.618
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	26.20 (12.03)	31.50 (10.42)		
Week 52 Mean (SD)	39.16 (11.35)	40.82 (6.78)		
Week 4 Adjusted Mean Change (SE)	7.65 (1.61)	5.97 (1.67)		
Week 12 Adjusted Mean Change (SE)	9.36 (1.81)	7.03 (1.91)		
Week 16 Adjusted Mean Change (SE)	9.16 (1.86)	7.43 (1.97)		
Week 24 Adjusted Mean Change (SE)	8.06 (1.94)	10.15 (2.03)		
Week 32 Adjusted Mean Change (SE)	8.93 (1.98)	7.35 (2.09)		
Week 40 Adjusted Mean Change (SE)	9.48 (1.92)	10.16 (2.02)		
Week 52 Adjusted Mean Change (SE)	10.38 (1.97)	10.26 (2.06)	0.12 [-5.54; 5.78]	0.966
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 41.13 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.030</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	27.63 (10.88)	30.84 (11.49)		
Week 52 Mean (SD)	36.10 (10.28)	39.71 (9.81)		
Week 4 Adjusted Mean Change (SE)	5.66 (0.90)	7.47 (1.01)		
Week 12 Adjusted Mean Change (SE)	6.43 (1.05)	7.25 (1.19)		
Week 16 Adjusted Mean Change (SE)	7.40 (1.07)	7.33 (1.22)		
Week 24 Adjusted Mean Change (SE)	6.87 (1.12)	8.23 (1.28)		
Week 32 Adjusted Mean Change (SE)	7.90 (1.13)	9.11 (1.27)		
Week 40 Adjusted Mean Change (SE)	7.68 (1.12)	9.78 (1.28)		
Week 52 Adjusted Mean Change (SE)	7.96 (1.16)	10.09 (1.33)	-2.13 [-5.64; 1.37]	0.231
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	31.11 (11.31)	26.33 (9.85)		
Week 52 Mean (SD)	40.05 (10.31)	34.67 (11.18)		
Week 4 Adjusted Mean Change (SE)	8.49 (1.63)	2.52 (2.06)		
Week 12 Adjusted Mean Change (SE)	8.10 (1.91)	3.40 (2.41)		
Week 16 Adjusted Mean Change (SE)	9.33 (1.94)	3.14 (2.46)		
Week 24 Adjusted Mean Change (SE)	10.01 (2.02)	5.25 (2.56)		
Week 32 Adjusted Mean Change (SE)	9.72 (2.02)	4.07 (2.58)		
Week 40 Adjusted Mean Change (SE)	10.80 (2.02)	5.75 (2.58)		
Week 52 Adjusted Mean Change (SE)	10.07 (2.07)	6.22 (2.62)	3.84 [-2.76; 10.45]	0.252
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 41.14 FACIT Fatigue - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.912</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	28.21 (11.25)	29.11 (11.83)		
Week 52 Mean (SD)	36.83 (10.67)	38.93 (10.40)		
Week 4 Adjusted Mean Change (SE)	6.70 (0.87)	6.25 (1.02)		
Week 12 Adjusted Mean Change (SE)	7.42 (0.98)	6.30 (1.15)		
Week 16 Adjusted Mean Change (SE)	8.27 (1.00)	6.50 (1.17)		
Week 24 Adjusted Mean Change (SE)	8.10 (1.07)	7.77 (1.26)		
Week 32 Adjusted Mean Change (SE)	8.64 (1.06)	7.43 (1.25)		
Week 40 Adjusted Mean Change (SE)	8.68 (1.06)	8.60 (1.27)		
Week 52 Adjusted Mean Change (SE)	8.57 (1.08)	10.15 (1.28)	-1.57 [-4.89; 1.74]	0.349
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	27.23 (10.61)	32.30 (7.41)		
Week 52 Mean (SD)	37.77 (8.54)	36.30 (8.87)		
Week 4 Adjusted Mean Change (SE)	6.39 (2.05)	6.64 (2.33)		
Week 12 Adjusted Mean Change (SE)	5.64 (2.34)	5.50 (2.62)		
Week 16 Adjusted Mean Change (SE)	7.03 (2.33)	3.87 (2.66)		
Week 24 Adjusted Mean Change (SE)	7.43 (2.48)	6.22 (2.83)		
Week 32 Adjusted Mean Change (SE)	8.29 (2.46)	8.88 (2.80)		
Week 40 Adjusted Mean Change (SE)	8.68 (2.47)	9.69 (2.82)		
Week 52 Adjusted Mean Change (SE)	9.43 (2.49)	6.13 (2.84)	3.30 [-4.18; 10.78]	0.385
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 41.15 FACIT Fatigue - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.875</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	25.82 (13.00)	29.62 (13.25)		
Week 52 Mean (SD)	37.00 (11.06)	37.44 (13.00)		
Week 4 Adjusted Mean Change (SE)	7.22 (1.55)	8.08 (1.45)		
Week 12 Adjusted Mean Change (SE)	8.17 (1.76)	7.37 (1.65)		
Week 16 Adjusted Mean Change (SE)	8.83 (1.84)	6.16 (1.72)		
Week 24 Adjusted Mean Change (SE)	9.12 (1.92)	5.57 (1.80)		
Week 32 Adjusted Mean Change (SE)	9.56 (1.93)	9.17 (1.82)		
Week 40 Adjusted Mean Change (SE)	8.34 (1.93)	7.97 (1.83)		
Week 52 Adjusted Mean Change (SE)	9.33 (2.01)	9.53 (1.94)	-0.20 [-5.73; 5.32]	0.942
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	28.94 (10.27)	30.27 (9.83)		
Week 52 Mean (SD)	37.11 (10.12)	38.87 (8.62)		
Week 4 Adjusted Mean Change (SE)	6.33 (0.91)	5.08 (1.13)		
Week 12 Adjusted Mean Change (SE)	6.68 (1.05)	5.48 (1.30)		
Week 16 Adjusted Mean Change (SE)	7.71 (1.07)	6.23 (1.34)		
Week 24 Adjusted Mean Change (SE)	7.54 (1.11)	8.32 (1.39)		
Week 32 Adjusted Mean Change (SE)	8.20 (1.12)	6.81 (1.40)		
Week 40 Adjusted Mean Change (SE)	8.69 (1.11)	9.20 (1.41)		
Week 52 Adjusted Mean Change (SE)	8.41 (1.14)	8.56 (1.43)	-0.15 [-3.78; 3.47]	0.934
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 41.16 FACIT Fatigue - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.897</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	27.43 (10.24)	29.03 (9.88)		
Week 52 Mean (SD)	36.76 (10.61)	38.19 (9.49)		
Week 4 Adjusted Mean Change (SE)	6.52 (1.03)	7.10 (1.25)		
Week 12 Adjusted Mean Change (SE)	8.00 (1.16)	6.21 (1.41)		
Week 16 Adjusted Mean Change (SE)	8.22 (1.19)	5.74 (1.47)		
Week 24 Adjusted Mean Change (SE)	8.07 (1.24)	6.10 (1.54)		
Week 32 Adjusted Mean Change (SE)	8.80 (1.25)	8.57 (1.55)		
Week 40 Adjusted Mean Change (SE)	8.48 (1.25)	8.70 (1.56)		
Week 52 Adjusted Mean Change (SE)	8.53 (1.28)	9.47 (1.63)	-0.94 [-5.05; 3.16]	0.651
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	29.18 (12.24)	31.09 (12.54)		
Week 52 Mean (SD)	37.61 (9.88)	38.63 (10.79)		
Week 4 Adjusted Mean Change (SE)	6.63 (1.25)	5.28 (1.29)		
Week 12 Adjusted Mean Change (SE)	5.64 (1.43)	6.20 (1.47)		
Week 16 Adjusted Mean Change (SE)	7.66 (1.47)	6.71 (1.52)		
Week 24 Adjusted Mean Change (SE)	7.74 (1.53)	8.68 (1.59)		
Week 32 Adjusted Mean Change (SE)	8.14 (1.54)	6.77 (1.60)		
Week 40 Adjusted Mean Change (SE)	8.85 (1.53)	8.90 (1.61)		
Week 52 Adjusted Mean Change (SE)	8.84 (1.58)	8.39 (1.63)	0.45 [-4.05; 4.95]	0.844
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 41.17 FACIT Fatigue - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.978</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	25.23 (12.04)	28.35 (13.48)		
Week 52 Mean (SD)	37.24 (10.76)	39.18 (12.48)		
Week 4 Adjusted Mean Change (SE)	7.03 (1.34)	7.18 (1.33)		
Week 12 Adjusted Mean Change (SE)	8.13 (1.52)	6.91 (1.52)		
Week 16 Adjusted Mean Change (SE)	8.67 (1.56)	7.07 (1.56)		
Week 24 Adjusted Mean Change (SE)	8.69 (1.66)	6.87 (1.68)		
Week 32 Adjusted Mean Change (SE)	8.84 (1.64)	8.61 (1.67)		
Week 40 Adjusted Mean Change (SE)	9.16 (1.64)	8.90 (1.68)		
Week 52 Adjusted Mean Change (SE)	9.84 (1.67)	10.15 (1.76)	-0.31 [-5.10; 4.48]	0.899
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	29.71 (10.23)	31.44 (8.70)		
Week 52 Mean (SD)	37.00 (10.10)	37.94 (8.46)		
Week 4 Adjusted Mean Change (SE)	6.31 (0.98)	5.40 (1.22)		
Week 12 Adjusted Mean Change (SE)	6.48 (1.12)	5.60 (1.38)		
Week 16 Adjusted Mean Change (SE)	7.64 (1.15)	5.48 (1.43)		
Week 24 Adjusted Mean Change (SE)	7.53 (1.20)	7.54 (1.50)		
Week 32 Adjusted Mean Change (SE)	8.40 (1.21)	6.94 (1.50)		
Week 40 Adjusted Mean Change (SE)	8.35 (1.20)	8.63 (1.51)		
Week 52 Adjusted Mean Change (SE)	8.00 (1.23)	8.00 (1.52)	-0.00 [-3.86; 3.85]	0.999
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 41.18 FACIT Fatigue - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.875</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	27.65 (11.39)	31.33 (11.79)		
Week 52 Mean (SD)	37.10 (11.33)	38.85 (11.29)		
Week 4 Adjusted Mean Change (SE)	6.51 (1.12)	6.04 (1.12)		
Week 12 Adjusted Mean Change (SE)	6.52 (1.27)	5.91 (1.27)		
Week 16 Adjusted Mean Change (SE)	7.12 (1.30)	5.75 (1.30)		
Week 24 Adjusted Mean Change (SE)	7.07 (1.36)	6.48 (1.37)		
Week 32 Adjusted Mean Change (SE)	8.24 (1.38)	8.32 (1.39)		
Week 40 Adjusted Mean Change (SE)	8.17 (1.36)	8.32 (1.38)		
Week 52 Adjusted Mean Change (SE)	8.86 (1.41)	9.40 (1.42)	-0.54 [-4.51; 3.43]	0.789
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	28.62 (10.80)	27.67 (9.82)		
Week 52 Mean (SD)	37.07 (9.32)	37.50 (7.11)		
Week 4 Adjusted Mean Change (SE)	6.62 (1.13)	6.57 (1.52)		
Week 12 Adjusted Mean Change (SE)	7.63 (1.28)	6.75 (1.72)		
Week 16 Adjusted Mean Change (SE)	8.89 (1.31)	7.07 (1.78)		
Week 24 Adjusted Mean Change (SE)	8.83 (1.36)	8.90 (1.86)		
Week 32 Adjusted Mean Change (SE)	8.86 (1.38)	6.61 (1.89)		
Week 40 Adjusted Mean Change (SE)	9.10 (1.37)	9.74 (1.90)		
Week 52 Adjusted Mean Change (SE)	8.46 (1.41)	7.76 (1.99)	0.70 [-4.11; 5.50]	0.775
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 41.19 FACIT Fatigue - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.569</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	28.63 (10.76)	30.02 (11.45)		
Week 52 Mean (SD)	36.69 (10.13)	38.13 (10.59)		
Week 4 Adjusted Mean Change (SE)	6.04 (0.90)	6.67 (1.04)		
Week 12 Adjusted Mean Change (SE)	6.15 (1.03)	6.25 (1.19)		
Week 16 Adjusted Mean Change (SE)	7.48 (1.06)	5.86 (1.23)		
Week 24 Adjusted Mean Change (SE)	7.77 (1.10)	6.56 (1.30)		
Week 32 Adjusted Mean Change (SE)	8.38 (1.11)	8.12 (1.31)		
Week 40 Adjusted Mean Change (SE)	8.29 (1.11)	8.65 (1.31)		
Week 52 Adjusted Mean Change (SE)	8.23 (1.13)	8.64 (1.35)	-0.41 [-3.91; 3.09]	0.818
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	27.33 (11.78)	30.00 (10.75)		
Week 52 Mean (SD)	39.71 (10.18)	39.12 (9.16)		
Week 4 Adjusted Mean Change (SE)	7.87 (1.72)	4.83 (1.70)		
Week 12 Adjusted Mean Change (SE)	9.35 (1.95)	5.77 (1.93)		
Week 16 Adjusted Mean Change (SE)	8.48 (2.01)	6.82 (2.02)		
Week 24 Adjusted Mean Change (SE)	8.69 (2.14)	9.01 (2.11)		
Week 32 Adjusted Mean Change (SE)	8.66 (2.13)	6.30 (2.13)		
Week 40 Adjusted Mean Change (SE)	10.00 (2.12)	8.87 (2.14)		
Week 52 Adjusted Mean Change (SE)	10.47 (2.17)	9.25 (2.15)	1.22 [-4.83; 7.26]	0.691
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 42.1 FACIT 4-Point Response (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
FACIT 4-Point Response Week 52, N' n (%)	105 72.45 (65.86)	82 61.46 (60.85)	1.30 [0.71; 2.36] 0.391	1.08 [0.87; 1.34] 0.469	0.050 [-0.085; 0.185] 0.468
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR from logistic regression model with predictors treatment and weight.  RR and RD calculated directly without adjustment.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 42.2 FACIT 4-Point Response by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.530				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
FACIT 4-Point Response Week 52, N' n (%)	99 69.09 (67.08)	76 57.50 (61.17)	1.37 [0.73; 2.56] 0.323	1.10 [0.88; 1.37] 0.410	0.059 [-0.081; 0.199] 0.407
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
FACIT 4-Point Response Week 52, N' n (%)	6 3.36 (48.00)	6 3.96 (56.57)	0.65 [0.07; 6.13] 0.704	0.84 [0.29; 2.45] 0.751	-0.086 [-0.627; 0.455] 0.756
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 42.3 FACIT 4-Point Response by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.535				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
FACIT 4-Point Response Week 52, N' n (%)	64 44.74 (67.79)	48 35.20 (61.75)	1.52 [0.68; 3.40] 0.310	1.10 [0.83; 1.45] 0.505	0.060 [-0.116; 0.237] 0.503
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
FACIT 4-Point Response Week 52, N' n (%)	41 27.71 (62.98)	34 26.26 (59.68)	1.03 [0.41; 2.58] 0.953	1.06 [0.75; 1.50] 0.758	0.033 [-0.179; 0.245] 0.761
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



#### 42.4 FACIT 4-Point Response by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.469				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
FACIT 4-Point Response Week 52, N' n (%)	23 13.05 (54.38)	17 8.93 (42.52)	2.01 [0.56; 7.14] 0.282	1.28 [0.67; 2.44] 0.447	0.119 [-0.181; 0.418] 0.437
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
FACIT 4-Point Response Week 52, N' n (%)	82 59.40 (69.07)	65 52.53 (65.66)	1.17 [0.59; 2.36] 0.651	1.05 [0.84; 1.32] 0.655	0.034 [-0.116; 0.184] 0.656
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 42.5 FACIT 4-Point Response by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.147				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
FACIT 4-Point Response Week 52, N' n (%)	39 27.43 (65.31)	38 34.76 (68.16)	0.80 [0.31; 2.04] 0.639	0.96 [0.71; 1.30] 0.786	-0.028 [-0.231; 0.174] 0.783
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
FACIT 4-Point Response Week 52, N' n (%)	66 45.02 (66.21)	44 26.70 (53.40)	2.01 [0.90; 4.49] 0.089	1.24 [0.90; 1.71] 0.190	0.128 [-0.056; 0.313] 0.174
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 42.6 FACIT 4-Point Response by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.210				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
FACIT 4-Point Response Week 52, N' n (%)	70 50.74 (70.47)	36 29.07 (59.33)	1.77 [0.77; 4.11] 0.181	1.19 [0.88; 1.60] 0.254	0.111 [-0.074; 0.297] 0.239
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
FACIT 4-Point Response Week 52, N' n (%)	35 21.71 (57.13)	46 32.39 (62.29)	0.81 [0.33; 1.97] 0.641	0.92 [0.64; 1.31] 0.634	-0.052 [-0.261; 0.158] 0.630
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 42.7 FACIT 4-Point Response by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.379				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
FACIT 4-Point Response Week 52, N' n (%)	49 34.38 (67.41)	25 16.70 (52.19)	1.87 [0.71; 4.88] 0.203	1.29 [0.87; 1.93] 0.206	0.152 [-0.071; 0.376] 0.182
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
FACIT 4-Point Response Week 52, N' n (%)	56 38.07 (64.53)	57 44.76 (64.87)	1.07 [0.49; 2.33] 0.868	1.00 [0.76; 1.30] 0.972	-0.003 [-0.177; 0.170] 0.969
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 42.8 FACIT 4-Point Response by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.765				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
FACIT 4-Point Response Week 52, N' n (%)	49 34.05 (66.76)	36 28.08 (68.49)	0.95 [0.37; 2.41] 0.915	0.98 [0.73; 1.31] 0.869	-0.017 [-0.216; 0.181] 0.865
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
FACIT 4-Point Response Week 52, N' n (%)	31 22.40 (65.88)	21 16.20 (62.31)	1.19 [0.38; 3.78] 0.765	1.06 [0.70; 1.59] 0.785	0.036 [-0.223; 0.295] 0.787
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 42.9 FACIT 4-Point Response by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.731				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
FACIT 4-Point Response Week 52, N' n (%)	43 34.04 (75.64)	19 20.04 (74.22)	1.20 [0.35; 4.14] 0.775	1.02 [0.75; 1.38] 0.896	0.014 [-0.210; 0.239] 0.901
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
FACIT 4-Point Response Week 52, N' n (%)	35 21.41 (56.34)	28 17.24 (57.47)	0.91 [0.33; 2.50] 0.848	0.98 [0.64; 1.50] 0.929	-0.011 [-0.253; 0.231] 0.927
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

#### 42.10 FACIT 4-Point Response by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.718				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
FACIT 4-Point Response Week 52, N' n (%)	29 22.66 (75.53)	24 22.92 (69.45)	1.37 [0.40; 4.66] 0.616	1.09 [0.78; 1.51] 0.612	0.061 [-0.175; 0.297] 0.613
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
FACIT 4-Point Response Week 52, N' n (%)	49 31.38 (61.53)	33 21.36 (62.82)	1.03 [0.41; 2.61] 0.949	0.98 [0.70; 1.38] 0.906	-0.013 [-0.226; 0.200] 0.905
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 42.11 FACIT 4-Point Response by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.170				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
FACIT 4-Point Response Week 52, N' n (%)	39 31.07 (72.26)	39 26.29 (61.14)	1.62 [0.62; 4.27] 0.325	1.18 [0.86; 1.62] 0.298	0.111 [-0.095; 0.317] 0.290
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
FACIT 4-Point Response Week 52, N' n (%)	41 25.38 (60.43)	18 17.99 (74.96)	0.54 [0.16; 1.85] 0.328	0.81 [0.56; 1.15] 0.240	-0.145 [-0.388; 0.097] 0.241
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



#### 42.12 FACIT 4-Point Response by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.887				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
FACIT 4-Point Response Week 52, N' n (%)	58 38.79 (62.56)	38 30.97 (65.89)	0.95 [0.40; 2.24] 0.909	0.95 [0.71; 1.28] 0.734	-0.033 [-0.223; 0.157] 0.731
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
FACIT 4-Point Response Week 52, N' n (%)	19 15.66 (78.30)	17 13.31 (73.94)	1.08 [0.22; 5.26] 0.920	1.06 [0.73; 1.53] 0.761	0.044 [-0.236; 0.323] 0.760
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 42.13 FACIT 4-Point Response by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.852				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
FACIT 4-Point Response Week 52, N' n (%)	58 42.45 (67.38)	42 34.68 (68.00)	0.96 [0.41; 2.24] 0.925	0.99 [0.76; 1.30] 0.949	-0.006 [-0.187; 0.175] 0.947
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
FACIT 4-Point Response Week 52, N' n (%)	19 11.00 (57.89)	12 8.00 (66.67)	0.81 [0.17; 3.84] 0.792	0.87 [0.50; 1.51] 0.618	-0.088 [-0.435; 0.259] 0.620
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) FACIT 4-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

#### 42.14 FACIT 4-Point Response by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.080				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
FACIT 4-Point Response Week 52, N' n (%)	66 44.45 (62.61)	44 37.97 (71.64)	0.69 [0.30; 1.59] 0.387	0.87 [0.67; 1.13] 0.309	-0.090 [-0.264; 0.083] 0.308
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
FACIT 4-Point Response Week 52, N' n (%)	13 11.00 (84.62)	10 5.00 (50.00)	4.66 [0.65; 33.15] 0.125	1.69 [0.87; 3.28] 0.119	0.346 [-0.021; 0.713] 0.064
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) FACIT 4-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

#### 42.15 FACIT 4-Point Response by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.567				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
FACIT 4-Point Response Week 52, N' n (%)	19 17.07 (77.59)	18 17.37 (66.81)	1.57 [0.37; 6.64] 0.540	1.16 [0.79; 1.71] 0.445	0.108 [-0.165; 0.381] 0.439
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
FACIT 4-Point Response Week 52, N' n (%)	61 39.38 (62.51)	39 26.91 (65.63)	0.96 [0.41; 2.27] 0.929	0.95 [0.71; 1.28] 0.750	-0.031 [-0.223; 0.161] 0.749
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

#### 42.16 FACIT 4-Point Response by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.914				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
FACIT 4-Point Response Week 52, N' n (%)	49 37.04 (72.63)	27 27.04 (77.26)	0.91 [0.30; 2.79] 0.868	0.94 [0.72; 1.22] 0.648	-0.046 [-0.244; 0.151] 0.645
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
FACIT 4-Point Response Week 52, N' n (%)	31 19.41 (57.09)	30 17.24 (53.88)	0.99 [0.36; 2.73] 0.982	1.06 [0.68; 1.65] 0.796	0.032 [-0.213; 0.277] 0.797
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

#### 42.17 FACIT 4-Point Response by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.536				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
FACIT 4-Point Response Week 52, N' n (%)	29 22.66 (75.53)	22 20.92 (67.48)	1.49 [0.43; 5.14] 0.526	1.12 [0.79; 1.59] 0.517	0.080 [-0.162; 0.323] 0.515
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
FACIT 4-Point Response Week 52, N' n (%)	51 33.79 (61.44)	35 23.36 (64.89)	0.92 [0.37; 2.28] 0.856	0.95 [0.68; 1.31] 0.741	-0.035 [-0.240; 0.171] 0.742
<p>N': Number of patients with available response value                      N-N' is the number of values with MI.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      MI: Multiple Imputation                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.                      RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:                      n and % are averages of all imputations.                      P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.                      OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

#### 42.18 FACIT 4-Point Response by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.170				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
FACIT 4-Point Response Week 52, N' n (%)	39 31.07 (72.26)	39 26.29 (61.14)	1.62 [0.62; 4.27] 0.325	1.18 [0.86; 1.62] 0.298	0.111 [-0.095; 0.317] 0.290
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
FACIT 4-Point Response Week 52, N' n (%)	41 25.38 (60.43)	18 17.99 (74.96)	0.54 [0.16; 1.85] 0.328	0.81 [0.56; 1.15] 0.240	-0.145 [-0.388; 0.097] 0.241
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 42.19 FACIT 4-Point Response by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
FACIT 4-Point Response Week 52	p=0.916				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
FACIT 4-Point Response Week 52, N' n (%)	61 40.79 (62.75)	40 30.97 (63.20)	1.06 [0.47; 2.42] 0.884	0.99 [0.74; 1.34] 0.966	-0.005 [-0.192; 0.183] 0.962
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
FACIT 4-Point Response Week 52, N' n (%)	17 13.66 (75.89)	17 13.31 (73.94)	0.97 [0.20; 4.74] 0.965	1.03 [0.69; 1.52] 0.897	0.019 [-0.272; 0.311] 0.896
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 43.0 SF-36 Bodily Pain - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

### 43.1 SF-36 Bodily Pain - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	34.85 (20.05)	34.87 (19.70)		
Week 52 Mean (SD)	61.40 (24.17)	59.65 (23.69)		
Week 4 Adjusted Mean Change (SE)	17.91 (1.61)	14.45 (1.70)		
Week 12 Adjusted Mean Change (SE)	24.39 (1.84)	18.04 (1.93)		
Week 16 Adjusted Mean Change (SE)	24.64 (1.83)	19.42 (1.94)		
Week 24 Adjusted Mean Change (SE)	24.35 (2.01)	19.63 (2.16)		
Week 32 Adjusted Mean Change (SE)	26.20 (2.19)	23.84 (2.36)		
Week 40 Adjusted Mean Change (SE)	28.05 (2.02)	23.20 (2.20)		
Week 52 Adjusted Mean Change (SE)	26.49 (2.11)	23.00 (2.35)	3.49 [-2.73; 9.72]	0.270
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

### 43.2 SF-36 Bodily Pain - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.992</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	34.15 (19.44)	35.04 (19.75)		
Week 52 Mean (SD)	61.06 (24.18)	60.00 (24.18)		
Week 4 Adjusted Mean Change (SE)	18.29 (1.67)	14.95 (1.76)		
Week 12 Adjusted Mean Change (SE)	24.57 (1.91)	18.01 (2.01)		
Week 16 Adjusted Mean Change (SE)	24.76 (1.89)	19.90 (2.02)		
Week 24 Adjusted Mean Change (SE)	24.73 (2.07)	20.51 (2.24)		
Week 32 Adjusted Mean Change (SE)	27.12 (2.26)	24.01 (2.45)		
Week 40 Adjusted Mean Change (SE)	28.53 (2.09)	23.73 (2.30)		
Week 52 Adjusted Mean Change (SE)	26.74 (2.19)	23.36 (2.45)	3.38 [-3.09; 9.85]	0.304
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	45.14 (27.33)	32.57 (20.44)		
Week 52 Mean (SD)	67.00 (25.47)	55.17 (17.24)		
Week 4 Adjusted Mean Change (SE)	12.29 (6.43)	7.80 (6.39)		
Week 12 Adjusted Mean Change (SE)	21.87 (7.30)	18.37 (7.26)		
Week 16 Adjusted Mean Change (SE)	23.07 (7.55)	13.05 (7.25)		
Week 24 Adjusted Mean Change (SE)	18.84 (7.94)	8.95 (7.89)		
Week 32 Adjusted Mean Change (SE)	13.34 (8.57)	21.14 (8.53)		
Week 40 Adjusted Mean Change (SE)	21.16 (7.97)	16.55 (7.93)		
Week 52 Adjusted Mean Change (SE)	23.46 (8.68)	18.49 (8.63)	4.97 [-19.15; 29.09]	0.685
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.3 SF-36 Bodily Pain - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.984</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	37.30 (21.58)	38.74 (19.54)		
Week 52 Mean (SD)	66.47 (24.55)	64.40 (25.47)		
Week 4 Adjusted Mean Change (SE)	21.51 (2.08)	17.19 (2.24)		
Week 12 Adjusted Mean Change (SE)	28.38 (2.38)	21.02 (2.53)		
Week 16 Adjusted Mean Change (SE)	28.45 (2.35)	23.51 (2.52)		
Week 24 Adjusted Mean Change (SE)	27.91 (2.52)	26.30 (2.76)		
Week 32 Adjusted Mean Change (SE)	29.61 (2.80)	28.46 (3.09)		
Week 40 Adjusted Mean Change (SE)	32.17 (2.57)	27.22 (2.85)		
Week 52 Adjusted Mean Change (SE)	31.41 (2.66)	27.21 (3.00)	4.20 [-3.66; 12.07]	0.293
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	31.16 (17.08)	29.86 (18.98)		
Week 52 Mean (SD)	53.49 (21.54)	52.94 (19.37)		
Week 4 Adjusted Mean Change (SE)	12.57 (2.56)	10.81 (2.56)		
Week 12 Adjusted Mean Change (SE)	18.51 (2.90)	14.09 (2.91)		
Week 16 Adjusted Mean Change (SE)	18.99 (2.87)	13.98 (2.93)		
Week 24 Adjusted Mean Change (SE)	19.02 (3.16)	10.48 (3.24)		
Week 32 Adjusted Mean Change (SE)	21.22 (3.49)	17.58 (3.57)		
Week 40 Adjusted Mean Change (SE)	21.90 (3.18)	17.80 (3.34)		
Week 52 Adjusted Mean Change (SE)	19.01 (3.32)	17.32 (3.54)	1.70 [-7.80; 11.19]	0.725
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.4 SF-36 Bodily Pain - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.814</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	51.50 (21.16)	57.86 (18.22)		
Week 52 Mean (SD)	72.78 (19.49)	65.59 (28.34)		
Week 4 Adjusted Mean Change (SE)	20.55 (3.63)	19.61 (4.02)		
Week 12 Adjusted Mean Change (SE)	26.24 (4.22)	24.57 (4.55)		
Week 16 Adjusted Mean Change (SE)	26.23 (4.13)	20.00 (4.57)		
Week 24 Adjusted Mean Change (SE)	26.52 (4.58)	18.23 (5.11)		
Week 32 Adjusted Mean Change (SE)	33.86 (4.95)	27.17 (5.63)		
Week 40 Adjusted Mean Change (SE)	32.66 (4.61)	29.13 (5.25)		
Week 52 Adjusted Mean Change (SE)	30.17 (4.76)	20.16 (5.56)	10.01 [-3.61; 23.62]	0.149
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	30.20 (17.15)	28.84 (15.17)		
Week 52 Mean (SD)	58.21 (24.49)	58.09 (22.31)		
Week 4 Adjusted Mean Change (SE)	17.15 (1.85)	13.07 (1.96)		
Week 12 Adjusted Mean Change (SE)	23.84 (2.10)	16.27 (2.22)		
Week 16 Adjusted Mean Change (SE)	24.19 (2.11)	19.28 (2.25)		
Week 24 Adjusted Mean Change (SE)	23.74 (2.31)	20.01 (2.49)		
Week 32 Adjusted Mean Change (SE)	24.09 (2.50)	22.96 (2.70)		
Week 40 Adjusted Mean Change (SE)	26.78 (2.31)	21.66 (2.52)		
Week 52 Adjusted Mean Change (SE)	25.48 (2.42)	23.73 (2.68)	1.74 [-5.27; 8.75]	0.624
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.5 SF-36 Bodily Pain - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.232</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	37.33 (20.00)	33.61 (19.99)		
Week 52 Mean (SD)	61.18 (25.55)	62.92 (20.78)		
Week 4 Adjusted Mean Change (SE)	17.76 (2.63)	15.91 (2.40)		
Week 12 Adjusted Mean Change (SE)	22.00 (2.97)	20.74 (2.70)		
Week 16 Adjusted Mean Change (SE)	22.16 (2.97)	19.99 (2.74)		
Week 24 Adjusted Mean Change (SE)	23.09 (3.29)	18.96 (3.06)		
Week 32 Adjusted Mean Change (SE)	25.74 (3.57)	25.49 (3.34)		
Week 40 Adjusted Mean Change (SE)	23.68 (3.28)	23.05 (3.17)		
Week 52 Adjusted Mean Change (SE)	25.04 (3.45)	26.32 (3.40)	-1.28 [-10.84; 8.28]	0.792
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	33.31 (20.07)	36.16 (19.52)		
Week 52 Mean (SD)	61.53 (23.52)	56.82 (25.85)		
Week 4 Adjusted Mean Change (SE)	18.00 (2.06)	12.95 (2.43)		
Week 12 Adjusted Mean Change (SE)	25.88 (2.35)	15.24 (2.75)		
Week 16 Adjusted Mean Change (SE)	26.18 (2.34)	18.80 (2.76)		
Week 24 Adjusted Mean Change (SE)	25.13 (2.57)	20.25 (3.07)		
Week 32 Adjusted Mean Change (SE)	26.50 (2.79)	22.13 (3.35)		
Week 40 Adjusted Mean Change (SE)	30.73 (2.56)	23.13 (3.07)		
Week 52 Adjusted Mean Change (SE)	27.38 (2.67)	20.02 (3.24)	7.36 [-0.94; 15.67]	0.082
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.6 SF-36 Bodily Pain - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.247</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	34.46 (19.53)	37.80 (21.42)		
Week 52 Mean (SD)	64.83 (23.23)	62.94 (23.82)		
Week 4 Adjusted Mean Change (SE)	18.35 (2.00)	14.69 (2.43)		
Week 12 Adjusted Mean Change (SE)	25.63 (2.29)	19.75 (2.74)		
Week 16 Adjusted Mean Change (SE)	26.65 (2.25)	21.45 (2.76)		
Week 24 Adjusted Mean Change (SE)	28.81 (2.40)	22.75 (3.03)		
Week 32 Adjusted Mean Change (SE)	30.44 (2.66)	25.14 (3.38)		
Week 40 Adjusted Mean Change (SE)	30.33 (2.48)	24.60 (3.22)		
Week 52 Adjusted Mean Change (SE)	29.89 (2.58)	21.40 (3.49)	8.49 [-0.08; 17.06]	0.052
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	35.58 (21.25)	32.12 (17.71)		
Week 52 Mean (SD)	54.54 (24.88)	57.07 (23.53)		
Week 4 Adjusted Mean Change (SE)	17.07 (2.75)	14.21 (2.41)		
Week 12 Adjusted Mean Change (SE)	21.99 (3.10)	16.36 (2.73)		
Week 16 Adjusted Mean Change (SE)	20.81 (3.09)	17.45 (2.71)		
Week 24 Adjusted Mean Change (SE)	15.46 (3.37)	16.75 (2.94)		
Week 32 Adjusted Mean Change (SE)	17.90 (3.70)	22.61 (3.23)		
Week 40 Adjusted Mean Change (SE)	23.60 (3.45)	21.84 (3.03)		
Week 52 Adjusted Mean Change (SE)	19.80 (3.62)	24.05 (3.17)	-4.25 [-13.75; 5.26]	0.379
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment            x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters,            subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.7 SF-36 Bodily Pain - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.739</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	36.31 (22.60)	40.84 (23.41)		
Week 52 Mean (SD)	64.43 (23.29)	66.12 (26.11)		
Week 4 Adjusted Mean Change (SE)	19.50 (2.36)	18.86 (3.05)		
Week 12 Adjusted Mean Change (SE)	26.77 (2.71)	23.33 (3.47)		
Week 16 Adjusted Mean Change (SE)	25.31 (2.66)	25.42 (3.47)		
Week 24 Adjusted Mean Change (SE)	26.41 (2.94)	23.09 (3.85)		
Week 32 Adjusted Mean Change (SE)	30.36 (3.18)	28.00 (4.17)		
Week 40 Adjusted Mean Change (SE)	32.24 (2.94)	26.81 (3.87)		
Week 52 Adjusted Mean Change (SE)	28.89 (3.09)	25.96 (4.24)	2.92 [-7.40; 13.25]	0.577
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	33.58 (17.66)	32.10 (17.22)		
Week 52 Mean (SD)	58.75 (24.82)	56.81 (22.20)		
Week 4 Adjusted Mean Change (SE)	16.53 (2.19)	12.43 (2.05)		
Week 12 Adjusted Mean Change (SE)	22.34 (2.49)	15.65 (2.31)		
Week 16 Adjusted Mean Change (SE)	24.07 (2.49)	16.68 (2.33)		
Week 24 Adjusted Mean Change (SE)	22.53 (2.75)	18.07 (2.63)		
Week 32 Adjusted Mean Change (SE)	22.57 (2.98)	21.95 (2.86)		
Week 40 Adjusted Mean Change (SE)	24.42 (2.74)	21.59 (2.67)		
Week 52 Adjusted Mean Change (SE)	24.39 (2.90)	21.68 (2.84)	2.71 [-5.27; 10.70]	0.504
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 43.8 SF-36 Bodily Pain - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.357</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	32.00 (18.43)	37.07 (18.95)		
Week 52 Mean (SD)	61.67 (24.94)	64.86 (20.78)		
Week 4 Adjusted Mean Change (SE)	17.71 (2.28)	15.14 (2.54)		
Week 12 Adjusted Mean Change (SE)	24.16 (2.65)	19.76 (2.96)		
Week 16 Adjusted Mean Change (SE)	25.58 (2.48)	18.18 (2.79)		
Week 24 Adjusted Mean Change (SE)	25.39 (3.01)	18.70 (3.41)		
Week 32 Adjusted Mean Change (SE)	25.03 (3.14)	23.30 (3.57)		
Week 40 Adjusted Mean Change (SE)	28.95 (2.85)	24.31 (3.25)		
Week 52 Adjusted Mean Change (SE)	28.64 (2.95)	28.15 (3.38)	0.49 [-8.39; 9.38]	0.913
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	37.44 (20.45)	35.35 (24.30)		
Week 52 Mean (SD)	60.84 (22.38)	60.10 (23.65)		
Week 4 Adjusted Mean Change (SE)	14.95 (2.78)	14.55 (3.24)		
Week 12 Adjusted Mean Change (SE)	24.18 (3.29)	17.53 (3.76)		
Week 16 Adjusted Mean Change (SE)	18.71 (3.05)	26.20 (3.53)		
Week 24 Adjusted Mean Change (SE)	20.63 (3.70)	23.65 (4.35)		
Week 32 Adjusted Mean Change (SE)	27.22 (3.92)	26.69 (4.55)		
Week 40 Adjusted Mean Change (SE)	22.49 (3.52)	27.41 (4.24)		
Week 52 Adjusted Mean Change (SE)	23.74 (3.66)	21.93 (4.39)	1.81 [-9.48; 13.09]	0.752
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.9 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.371</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	34.36 (19.34)	33.00 (19.73)		
Week 52 Mean (SD)	61.84 (24.36)	62.47 (20.86)		
Week 4 Adjusted Mean Change (SE)	17.44 (2.43)	9.05 (3.21)		
Week 12 Adjusted Mean Change (SE)	27.31 (2.78)	18.35 (3.66)		
Week 16 Adjusted Mean Change (SE)	24.46 (2.70)	17.53 (3.59)		
Week 24 Adjusted Mean Change (SE)	24.15 (3.24)	20.49 (4.39)		
Week 32 Adjusted Mean Change (SE)	27.04 (3.40)	22.71 (4.60)		
Week 40 Adjusted Mean Change (SE)	28.32 (3.11)	22.43 (4.26)		
Week 52 Adjusted Mean Change (SE)	27.29 (3.22)	26.17 (4.63)	1.12 [-10.04; 12.28]	0.843
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	33.24 (18.86)	37.53 (21.52)		
Week 52 Mean (SD)	61.26 (23.56)	62.61 (24.08)		
Week 4 Adjusted Mean Change (SE)	16.08 (2.65)	18.34 (2.99)		
Week 12 Adjusted Mean Change (SE)	21.42 (3.07)	19.01 (3.45)		
Week 16 Adjusted Mean Change (SE)	22.30 (2.96)	22.81 (3.34)		
Week 24 Adjusted Mean Change (SE)	23.72 (3.56)	19.16 (4.06)		
Week 32 Adjusted Mean Change (SE)	25.37 (3.73)	25.85 (4.22)		
Week 40 Adjusted Mean Change (SE)	25.78 (3.37)	26.66 (3.92)		
Week 52 Adjusted Mean Change (SE)	27.80 (3.54)	26.09 (4.00)	1.70 [-8.89; 12.30]	0.751
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.10 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.279</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	31.80 (20.45)	33.09 (24.16)		
Week 52 Mean (SD)	57.59 (24.09)	64.58 (22.38)		
Week 4 Adjusted Mean Change (SE)	16.97 (2.99)	16.22 (2.89)		
Week 12 Adjusted Mean Change (SE)	24.73 (3.44)	22.36 (3.36)		
Week 16 Adjusted Mean Change (SE)	24.37 (3.32)	22.40 (3.24)		
Week 24 Adjusted Mean Change (SE)	20.79 (3.98)	23.87 (3.96)		
Week 32 Adjusted Mean Change (SE)	23.43 (4.08)	26.88 (4.07)		
Week 40 Adjusted Mean Change (SE)	26.27 (3.74)	26.61 (3.79)		
Week 52 Adjusted Mean Change (SE)	24.11 (3.86)	27.61 (4.06)	-3.50 [-14.58; 7.57]	0.533
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	33.55 (17.33)	39.62 (17.21)		
Week 52 Mean (SD)	62.86 (23.91)	62.03 (21.64)		
Week 4 Adjusted Mean Change (SE)	17.46 (2.29)	13.99 (2.83)		
Week 12 Adjusted Mean Change (SE)	25.05 (2.66)	16.10 (3.26)		
Week 16 Adjusted Mean Change (SE)	22.21 (2.54)	20.72 (3.16)		
Week 24 Adjusted Mean Change (SE)	25.81 (2.99)	18.13 (3.73)		
Week 32 Adjusted Mean Change (SE)	28.84 (3.13)	22.90 (3.88)		
Week 40 Adjusted Mean Change (SE)	27.49 (2.85)	24.89 (3.59)		
Week 52 Adjusted Mean Change (SE)	29.32 (2.95)	24.67 (3.65)	4.64 [-4.66; 13.94]	0.325
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.11 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.613</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	33.79 (17.79)	39.42 (21.47)		
Week 52 Mean (SD)	63.21 (25.46)	61.56 (22.93)		
Week 4 Adjusted Mean Change (SE)	18.19 (2.46)	17.21 (2.46)		
Week 12 Adjusted Mean Change (SE)	24.03 (2.89)	17.88 (2.90)		
Week 16 Adjusted Mean Change (SE)	22.59 (2.77)	20.76 (2.78)		
Week 24 Adjusted Mean Change (SE)	24.37 (3.30)	19.38 (3.35)		
Week 32 Adjusted Mean Change (SE)	29.04 (3.44)	24.78 (3.46)		
Week 40 Adjusted Mean Change (SE)	28.49 (3.14)	26.70 (3.20)		
Week 52 Adjusted Mean Change (SE)	28.20 (3.27)	24.83 (3.28)	3.36 [-5.81; 12.54]	0.470
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	34.57 (20.99)	31.00 (19.48)		
Week 52 Mean (SD)	59.59 (22.36)	66.44 (19.29)		
Week 4 Adjusted Mean Change (SE)	14.95 (2.49)	10.70 (3.36)		
Week 12 Adjusted Mean Change (SE)	24.22 (2.93)	20.73 (3.93)		
Week 16 Adjusted Mean Change (SE)	23.09 (2.79)	22.43 (3.81)		
Week 24 Adjusted Mean Change (SE)	22.65 (3.31)	22.78 (4.57)		
Week 32 Adjusted Mean Change (SE)	22.49 (3.42)	24.41 (4.72)		
Week 40 Adjusted Mean Change (SE)	24.27 (3.15)	23.03 (4.47)		
Week 52 Adjusted Mean Change (SE)	25.18 (3.23)	28.13 (4.68)	-2.95 [-14.18; 8.29]	0.605
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.12 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.147</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	35.00 (19.27)	38.98 (21.94)		
Week 52 Mean (SD)	61.83 (23.01)	64.13 (20.88)		
Week 4 Adjusted Mean Change (SE)	17.01 (2.04)	15.26 (2.37)		
Week 12 Adjusted Mean Change (SE)	25.16 (2.36)	16.77 (2.72)		
Week 16 Adjusted Mean Change (SE)	23.38 (2.29)	19.66 (2.66)		
Week 24 Adjusted Mean Change (SE)	25.60 (2.66)	18.15 (3.15)		
Week 32 Adjusted Mean Change (SE)	25.61 (2.87)	26.12 (3.37)		
Week 40 Adjusted Mean Change (SE)	27.18 (2.56)	23.93 (3.06)		
Week 52 Adjusted Mean Change (SE)	27.20 (2.65)	24.75 (3.22)	2.45 [-5.82; 10.72]	0.559
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	32.45 (21.10)	33.17 (16.29)		
Week 52 Mean (SD)	62.89 (25.85)	65.71 (20.68)		
Week 4 Adjusted Mean Change (SE)	11.87 (3.62)	13.84 (3.77)		
Week 12 Adjusted Mean Change (SE)	17.68 (4.15)	26.08 (4.40)		
Week 16 Adjusted Mean Change (SE)	20.71 (4.04)	24.67 (4.28)		
Week 24 Adjusted Mean Change (SE)	18.27 (4.80)	28.48 (5.03)		
Week 32 Adjusted Mean Change (SE)	23.77 (5.07)	22.36 (5.38)		
Week 40 Adjusted Mean Change (SE)	23.80 (4.57)	30.53 (4.86)		
Week 52 Adjusted Mean Change (SE)	26.74 (4.68)	30.23 (4.91)	-3.49 [-16.89; 9.92]	0.608
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.13 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.701</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	34.73 (20.07)	37.00 (22.88)		
Week 52 Mean (SD)	61.86 (23.98)	65.57 (21.97)		
Week 4 Adjusted Mean Change (SE)	16.50 (2.00)	17.40 (2.25)		
Week 12 Adjusted Mean Change (SE)	25.83 (2.36)	20.29 (2.66)		
Week 16 Adjusted Mean Change (SE)	23.75 (2.27)	23.68 (2.56)		
Week 24 Adjusted Mean Change (SE)	22.48 (2.70)	22.10 (3.08)		
Week 32 Adjusted Mean Change (SE)	24.54 (2.75)	27.61 (3.11)		
Week 40 Adjusted Mean Change (SE)	27.33 (2.51)	27.89 (2.89)		
Week 52 Adjusted Mean Change (SE)	26.95 (2.65)	28.16 (3.07)	-1.21 [-9.23; 6.81]	0.766
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	34.26 (18.17)	34.67 (14.41)		
Week 52 Mean (SD)	58.79 (23.64)	58.08 (20.49)		
Week 4 Adjusted Mean Change (SE)	14.24 (3.64)	7.45 (4.61)		
Week 12 Adjusted Mean Change (SE)	16.54 (4.28)	18.00 (5.41)		
Week 16 Adjusted Mean Change (SE)	19.82 (4.11)	17.99 (5.20)		
Week 24 Adjusted Mean Change (SE)	24.00 (4.85)	20.78 (6.12)		
Week 32 Adjusted Mean Change (SE)	23.66 (4.92)	19.91 (6.31)		
Week 40 Adjusted Mean Change (SE)	19.27 (4.50)	18.38 (5.80)		
Week 52 Adjusted Mean Change (SE)	23.61 (4.68)	21.51 (5.92)	2.10 [-12.81; 17.01]	0.781
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.14 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.321</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	35.66 (19.06)	34.53 (21.79)		
Week 52 Mean (SD)	61.14 (24.24)	63.59 (21.91)		
Week 4 Adjusted Mean Change (SE)	16.59 (1.93)	14.72 (2.26)		
Week 12 Adjusted Mean Change (SE)	24.53 (2.22)	20.08 (2.59)		
Week 16 Adjusted Mean Change (SE)	22.69 (2.11)	21.07 (2.47)		
Week 24 Adjusted Mean Change (SE)	22.56 (2.49)	21.68 (2.96)		
Week 32 Adjusted Mean Change (SE)	25.49 (2.68)	25.68 (3.17)		
Week 40 Adjusted Mean Change (SE)	25.80 (2.45)	24.67 (2.95)		
Week 52 Adjusted Mean Change (SE)	26.07 (2.52)	27.26 (3.04)	-1.18 [-9.00; 6.63]	0.765
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	24.77 (19.05)	44.40 (18.82)		
Week 52 Mean (SD)	61.46 (23.34)	58.40 (20.40)		
Week 4 Adjusted Mean Change (SE)	17.34 (4.58)	18.45 (5.19)		
Week 12 Adjusted Mean Change (SE)	22.00 (5.33)	10.08 (5.92)		
Week 16 Adjusted Mean Change (SE)	23.96 (4.97)	14.97 (5.63)		
Week 24 Adjusted Mean Change (SE)	28.94 (5.84)	13.81 (6.62)		
Week 32 Adjusted Mean Change (SE)	28.51 (6.23)	19.80 (7.07)		
Week 40 Adjusted Mean Change (SE)	30.10 (5.72)	26.72 (6.48)		
Week 52 Adjusted Mean Change (SE)	30.68 (5.82)	19.20 (6.60)	11.49 [-6.10; 29.08]	0.199
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.15 SF-36 Bodily Pain - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.898</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	35.36 (22.50)	33.58 (25.08)		
Week 52 Mean (SD)	62.26 (26.90)	60.06 (22.80)		
Week 4 Adjusted Mean Change (SE)	17.62 (3.46)	15.02 (3.26)		
Week 12 Adjusted Mean Change (SE)	29.01 (3.97)	21.05 (3.74)		
Week 16 Adjusted Mean Change (SE)	24.64 (3.88)	22.93 (3.65)		
Week 24 Adjusted Mean Change (SE)	22.45 (4.67)	20.50 (4.45)		
Week 32 Adjusted Mean Change (SE)	23.56 (4.87)	26.58 (4.63)		
Week 40 Adjusted Mean Change (SE)	30.00 (4.45)	23.66 (4.28)		
Week 52 Adjusted Mean Change (SE)	25.28 (4.68)	24.43 (4.65)	0.85 [-12.20; 13.89]	0.898
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	33.76 (18.28)	38.20 (18.10)		
Week 52 Mean (SD)	61.07 (23.04)	64.51 (21.47)		
Week 4 Adjusted Mean Change (SE)	16.24 (2.05)	14.87 (2.55)		
Week 12 Adjusted Mean Change (SE)	22.34 (2.37)	17.55 (2.95)		
Week 16 Adjusted Mean Change (SE)	22.21 (2.27)	20.37 (2.84)		
Week 24 Adjusted Mean Change (SE)	23.74 (2.70)	20.57 (3.42)		
Week 32 Adjusted Mean Change (SE)	26.40 (2.83)	23.44 (3.55)		
Week 40 Adjusted Mean Change (SE)	25.16 (2.56)	26.48 (3.27)		
Week 52 Adjusted Mean Change (SE)	27.07 (2.65)	26.51 (3.34)	0.57 [-7.88; 9.02]	0.894
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 43.16 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.910</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	35.61 (20.14)	33.43 (18.63)		
Week 52 Mean (SD)	62.14 (23.39)	64.89 (19.17)		
Week 4 Adjusted Mean Change (SE)	16.90 (2.27)	12.84 (2.78)		
Week 12 Adjusted Mean Change (SE)	26.01 (2.64)	20.13 (3.21)		
Week 16 Adjusted Mean Change (SE)	23.34 (2.53)	20.65 (3.11)		
Week 24 Adjusted Mean Change (SE)	24.18 (3.01)	23.56 (3.76)		
Week 32 Adjusted Mean Change (SE)	26.56 (3.14)	24.91 (3.91)		
Week 40 Adjusted Mean Change (SE)	27.14 (2.88)	25.87 (3.63)		
Week 52 Adjusted Mean Change (SE)	26.95 (2.95)	28.18 (3.84)	-1.23 [-10.83; 8.37]	0.801
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	32.03 (18.12)	39.66 (23.22)		
Week 52 Mean (SD)	60.10 (24.87)	61.50 (24.13)		
Week 4 Adjusted Mean Change (SE)	16.13 (2.79)	17.17 (2.88)		
Week 12 Adjusted Mean Change (SE)	21.21 (3.26)	17.52 (3.36)		
Week 16 Adjusted Mean Change (SE)	22.10 (3.13)	22.08 (3.22)		
Week 24 Adjusted Mean Change (SE)	22.51 (3.74)	17.34 (3.89)		
Week 32 Adjusted Mean Change (SE)	24.46 (3.90)	24.43 (4.04)		
Week 40 Adjusted Mean Change (SE)	25.27 (3.54)	25.13 (3.75)		
Week 52 Adjusted Mean Change (SE)	26.39 (3.68)	23.63 (3.79)	2.76 [-7.75; 13.26]	0.604
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.17 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.273</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	31.80 (20.45)	33.84 (24.64)		
Week 52 Mean (SD)	57.59 (24.09)	64.27 (23.32)		
Week 4 Adjusted Mean Change (SE)	16.74 (2.97)	16.79 (2.97)		
Week 12 Adjusted Mean Change (SE)	24.39 (3.41)	23.02 (3.44)		
Week 16 Adjusted Mean Change (SE)	24.19 (3.28)	24.19 (3.30)		
Week 24 Adjusted Mean Change (SE)	20.53 (3.93)	25.08 (4.05)		
Week 32 Adjusted Mean Change (SE)	23.07 (4.09)	25.76 (4.22)		
Week 40 Adjusted Mean Change (SE)	25.94 (3.76)	26.34 (3.94)		
Week 52 Adjusted Mean Change (SE)	23.79 (3.85)	26.18 (4.21)	-2.39 [-13.67; 8.89]	0.676
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	35.47 (18.75)	38.61 (17.39)		
Week 52 Mean (SD)	63.49 (23.67)	62.37 (21.09)		
Week 4 Adjusted Mean Change (SE)	16.54 (2.19)	13.35 (2.72)		
Week 12 Adjusted Mean Change (SE)	23.95 (2.54)	15.49 (3.12)		
Week 16 Adjusted Mean Change (SE)	22.10 (2.43)	18.92 (3.02)		
Week 24 Adjusted Mean Change (SE)	25.05 (2.86)	17.03 (3.56)		
Week 32 Adjusted Mean Change (SE)	27.18 (3.03)	23.56 (3.76)		
Week 40 Adjusted Mean Change (SE)	26.62 (2.77)	24.62 (3.48)		
Week 52 Adjusted Mean Change (SE)	28.31 (2.87)	25.32 (3.51)	2.99 [-5.98; 11.95]	0.511
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.18 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.613</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	33.79 (17.79)	39.42 (21.47)		
Week 52 Mean (SD)	63.21 (25.46)	61.56 (22.93)		
Week 4 Adjusted Mean Change (SE)	18.19 (2.46)	17.21 (2.46)		
Week 12 Adjusted Mean Change (SE)	24.03 (2.89)	17.88 (2.90)		
Week 16 Adjusted Mean Change (SE)	22.59 (2.77)	20.76 (2.78)		
Week 24 Adjusted Mean Change (SE)	24.37 (3.30)	19.38 (3.35)		
Week 32 Adjusted Mean Change (SE)	29.04 (3.44)	24.78 (3.46)		
Week 40 Adjusted Mean Change (SE)	28.49 (3.14)	26.70 (3.20)		
Week 52 Adjusted Mean Change (SE)	28.20 (3.27)	24.83 (3.28)	3.36 [-5.81; 12.54]	0.470
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	34.57 (20.99)	31.00 (19.48)		
Week 52 Mean (SD)	59.59 (22.36)	66.44 (19.29)		
Week 4 Adjusted Mean Change (SE)	14.95 (2.49)	10.70 (3.36)		
Week 12 Adjusted Mean Change (SE)	24.22 (2.93)	20.73 (3.93)		
Week 16 Adjusted Mean Change (SE)	23.09 (2.79)	22.43 (3.81)		
Week 24 Adjusted Mean Change (SE)	22.65 (3.31)	22.78 (4.57)		
Week 32 Adjusted Mean Change (SE)	22.49 (3.42)	24.41 (4.72)		
Week 40 Adjusted Mean Change (SE)	24.27 (3.15)	23.03 (4.47)		
Week 52 Adjusted Mean Change (SE)	25.18 (3.23)	28.13 (4.68)	-2.95 [-14.18; 8.29]	0.605
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 43.19 SF-36 Bodily Pain - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.048</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	35.00 (19.00)	38.22 (22.19)		
Week 52 Mean (SD)	62.15 (23.36)	62.50 (21.68)		
Week 4 Adjusted Mean Change (SE)	17.89 (2.01)	14.72 (2.34)		
Week 12 Adjusted Mean Change (SE)	26.07 (2.32)	15.92 (2.69)		
Week 16 Adjusted Mean Change (SE)	23.81 (2.23)	18.73 (2.60)		
Week 24 Adjusted Mean Change (SE)	25.26 (2.59)	17.10 (3.09)		
Week 32 Adjusted Mean Change (SE)	25.99 (2.81)	24.30 (3.31)		
Week 40 Adjusted Mean Change (SE)	27.74 (2.51)	22.69 (3.00)		
Week 52 Adjusted Mean Change (SE)	27.58 (2.59)	23.96 (3.16)	3.62 [-4.47; 11.71]	0.378
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	32.67 (21.16)	31.44 (17.03)		
Week 52 Mean (SD)	62.00 (25.19)	64.53 (22.65)		
Week 4 Adjusted Mean Change (SE)	10.30 (3.84)	14.99 (3.82)		
Week 12 Adjusted Mean Change (SE)	16.32 (4.38)	26.07 (4.36)		
Week 16 Adjusted Mean Change (SE)	20.15 (4.24)	27.74 (4.28)		
Week 24 Adjusted Mean Change (SE)	20.13 (5.07)	29.00 (4.98)		
Week 32 Adjusted Mean Change (SE)	23.19 (5.38)	24.67 (5.42)		
Week 40 Adjusted Mean Change (SE)	22.86 (4.83)	32.61 (4.95)		
Week 52 Adjusted Mean Change (SE)	26.13 (4.96)	30.20 (4.94)	-4.06 [-17.89; 9.76]	0.562
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.0 SF-36 General Health - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

#### 44.1 SF-36 General Health - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	40.48 (17.56)	39.53 (17.96)		
Week 52 Mean (SD)	51.93 (20.10)	52.89 (18.88)		
Week 4 Adjusted Mean Change (SE)	9.73 (1.24)	8.56 (1.30)		
Week 12 Adjusted Mean Change (SE)	11.63 (1.49)	12.29 (1.56)		
Week 16 Adjusted Mean Change (SE)	12.65 (1.52)	10.99 (1.61)		
Week 24 Adjusted Mean Change (SE)	12.08 (1.53)	10.80 (1.63)		
Week 32 Adjusted Mean Change (SE)	12.26 (1.46)	9.64 (1.57)		
Week 40 Adjusted Mean Change (SE)	11.92 (1.54)	10.51 (1.67)		
Week 52 Adjusted Mean Change (SE)	11.90 (1.68)	11.99 (1.83)	-0.10 [-4.99; 4.80]	0.969
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

#### 44.2 SF-36 General Health - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.306</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	39.36 (16.36)	39.43 (18.15)		
Week 52 Mean (SD)	51.61 (19.37)	52.71 (19.17)		
Week 4 Adjusted Mean Change (SE)	10.04 (1.28)	8.62 (1.35)		
Week 12 Adjusted Mean Change (SE)	12.08 (1.54)	12.20 (1.62)		
Week 16 Adjusted Mean Change (SE)	13.48 (1.55)	10.73 (1.65)		
Week 24 Adjusted Mean Change (SE)	12.50 (1.58)	10.82 (1.70)		
Week 32 Adjusted Mean Change (SE)	12.39 (1.52)	9.71 (1.64)		
Week 40 Adjusted Mean Change (SE)	12.11 (1.60)	9.95 (1.74)		
Week 52 Adjusted Mean Change (SE)	12.04 (1.74)	11.75 (1.90)	0.30 [-4.79; 5.38]	0.909
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	57.00 (26.68)	41.00 (16.29)		
Week 52 Mean (SD)	57.33 (31.89)	55.17 (16.04)		
Week 4 Adjusted Mean Change (SE)	5.26 (5.00)	7.76 (4.91)		
Week 12 Adjusted Mean Change (SE)	5.08 (5.96)	13.36 (5.86)		
Week 16 Adjusted Mean Change (SE)	-0.70 (6.25)	14.38 (5.96)		
Week 24 Adjusted Mean Change (SE)	5.82 (6.14)	10.64 (6.04)		
Week 32 Adjusted Mean Change (SE)	10.09 (5.86)	8.86 (5.76)		
Week 40 Adjusted Mean Change (SE)	9.02 (6.18)	16.68 (6.07)		
Week 52 Adjusted Mean Change (SE)	9.75 (6.89)	14.74 (6.79)	-4.99 [-24.04; 14.06]	0.606
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 44.3 SF-36 General Health - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.659</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	44.76 (17.53)	41.98 (19.17)		
Week 52 Mean (SD)	55.53 (20.58)	52.92 (17.93)		
Week 4 Adjusted Mean Change (SE)	11.49 (1.64)	8.86 (1.74)		
Week 12 Adjusted Mean Change (SE)	12.36 (1.98)	12.21 (2.08)		
Week 16 Adjusted Mean Change (SE)	14.43 (2.00)	11.67 (2.12)		
Week 24 Adjusted Mean Change (SE)	12.82 (2.01)	11.80 (2.16)		
Week 32 Adjusted Mean Change (SE)	13.24 (1.93)	11.18 (2.09)		
Week 40 Adjusted Mean Change (SE)	12.98 (2.03)	11.42 (2.20)		
Week 52 Adjusted Mean Change (SE)	13.25 (2.20)	11.38 (2.41)	1.87 [-4.52; 8.26]	0.564
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	34.07 (15.73)	36.36 (15.91)		
Week 52 Mean (SD)	46.32 (18.18)	52.85 (20.43)		
Week 4 Adjusted Mean Change (SE)	7.15 (2.02)	8.13 (1.99)		
Week 12 Adjusted Mean Change (SE)	10.57 (2.41)	12.38 (2.39)		
Week 16 Adjusted Mean Change (SE)	10.05 (2.44)	10.03 (2.47)		
Week 24 Adjusted Mean Change (SE)	11.08 (2.50)	9.39 (2.52)		
Week 32 Adjusted Mean Change (SE)	10.83 (2.40)	7.55 (2.41)		
Week 40 Adjusted Mean Change (SE)	10.41 (2.51)	9.24 (2.57)		
Week 52 Adjusted Mean Change (SE)	9.93 (2.73)	12.88 (2.81)	-2.94 [-10.59; 4.70]	0.449
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



#### 44.4 SF-36 General Health - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.458</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	50.13 (21.33)	56.19 (18.42)		
Week 52 Mean (SD)	61.17 (17.91)	64.59 (17.37)		
Week 4 Adjusted Mean Change (SE)	14.20 (2.69)	11.90 (2.95)		
Week 12 Adjusted Mean Change (SE)	15.91 (3.26)	19.80 (3.51)		
Week 16 Adjusted Mean Change (SE)	15.78 (3.28)	18.49 (3.61)		
Week 24 Adjusted Mean Change (SE)	14.07 (3.38)	15.44 (3.71)		
Week 32 Adjusted Mean Change (SE)	14.06 (3.21)	14.82 (3.62)		
Week 40 Adjusted Mean Change (SE)	13.41 (3.39)	15.35 (3.81)		
Week 52 Adjusted Mean Change (SE)	15.96 (3.66)	18.54 (4.15)	-2.58 [-13.19; 8.04]	0.633
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	37.79 (15.46)	35.16 (15.14)		
Week 52 Mean (SD)	49.34 (20.02)	49.83 (18.17)		
Week 4 Adjusted Mean Change (SE)	8.51 (1.39)	7.64 (1.48)		
Week 12 Adjusted Mean Change (SE)	10.50 (1.66)	10.23 (1.76)		
Week 16 Adjusted Mean Change (SE)	11.80 (1.71)	8.94 (1.82)		
Week 24 Adjusted Mean Change (SE)	11.52 (1.73)	9.53 (1.86)		
Week 32 Adjusted Mean Change (SE)	11.76 (1.66)	8.24 (1.79)		
Week 40 Adjusted Mean Change (SE)	11.50 (1.74)	9.18 (1.89)		
Week 52 Adjusted Mean Change (SE)	10.77 (1.90)	10.21 (2.07)	0.56 [-4.94; 6.06]	0.841
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.5 SF-36 General Health - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.230</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	37.60 (19.41)	40.14 (18.31)		
Week 52 Mean (SD)	50.00 (19.15)	56.21 (17.80)		
Week 4 Adjusted Mean Change (SE)	9.30 (2.00)	11.07 (1.83)		
Week 12 Adjusted Mean Change (SE)	12.40 (2.41)	13.38 (2.19)		
Week 16 Adjusted Mean Change (SE)	9.37 (2.45)	10.87 (2.26)		
Week 24 Adjusted Mean Change (SE)	10.53 (2.49)	12.72 (2.30)		
Week 32 Adjusted Mean Change (SE)	12.93 (2.38)	11.34 (2.22)		
Week 40 Adjusted Mean Change (SE)	10.51 (2.51)	12.45 (2.38)		
Week 52 Adjusted Mean Change (SE)	11.94 (2.74)	14.47 (2.62)	-2.53 [-10.01; 4.95]	0.505
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	42.26 (16.21)	38.92 (17.75)		
Week 52 Mean (SD)	53.08 (20.71)	50.02 (19.52)		
Week 4 Adjusted Mean Change (SE)	10.01 (1.57)	5.99 (1.85)		
Week 12 Adjusted Mean Change (SE)	11.13 (1.91)	11.17 (2.23)		
Week 16 Adjusted Mean Change (SE)	14.71 (1.93)	11.08 (2.27)		
Week 24 Adjusted Mean Change (SE)	13.03 (1.95)	8.84 (2.32)		
Week 32 Adjusted Mean Change (SE)	11.86 (1.87)	7.91 (2.23)		
Week 40 Adjusted Mean Change (SE)	12.81 (1.96)	8.58 (2.33)		
Week 52 Adjusted Mean Change (SE)	11.92 (2.13)	9.57 (2.55)	2.35 [-4.22; 8.92]	0.482
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.6 SF-36 General Health - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.274</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	40.90 (16.17)	42.33 (18.85)		
Week 52 Mean (SD)	54.89 (17.74)	57.72 (19.61)		
Week 4 Adjusted Mean Change (SE)	11.30 (1.52)	9.19 (1.85)		
Week 12 Adjusted Mean Change (SE)	12.96 (1.85)	11.95 (2.22)		
Week 16 Adjusted Mean Change (SE)	14.87 (1.87)	11.29 (2.28)		
Week 24 Adjusted Mean Change (SE)	13.83 (1.87)	11.55 (2.35)		
Week 32 Adjusted Mean Change (SE)	13.67 (1.81)	9.96 (2.28)		
Week 40 Adjusted Mean Change (SE)	12.66 (1.90)	11.14 (2.43)		
Week 52 Adjusted Mean Change (SE)	14.55 (2.05)	12.22 (2.66)	2.33 [-4.29; 8.95]	0.488
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	39.68 (20.15)	36.90 (16.82)		
Week 52 Mean (SD)	46.03 (23.32)	49.11 (17.59)		
Week 4 Adjusted Mean Change (SE)	6.77 (2.10)	7.93 (1.83)		
Week 12 Adjusted Mean Change (SE)	9.13 (2.51)	12.63 (2.21)		
Week 16 Adjusted Mean Change (SE)	8.48 (2.56)	10.71 (2.25)		
Week 24 Adjusted Mean Change (SE)	8.76 (2.62)	10.10 (2.28)		
Week 32 Adjusted Mean Change (SE)	9.59 (2.51)	9.35 (2.19)		
Week 40 Adjusted Mean Change (SE)	10.58 (2.64)	9.93 (2.32)		
Week 52 Adjusted Mean Change (SE)	6.77 (2.86)	11.74 (2.50)	-4.97 [-12.45; 2.52]	0.192
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.7 SF-36 General Health - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.858</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	39.86 (17.73)	42.97 (19.94)		
Week 52 Mean (SD)	53.39 (22.15)	59.56 (19.44)		
Week 4 Adjusted Mean Change (SE)	11.39 (1.81)	11.45 (2.32)		
Week 12 Adjusted Mean Change (SE)	13.83 (2.19)	15.00 (2.80)		
Week 16 Adjusted Mean Change (SE)	12.87 (2.21)	15.50 (2.87)		
Week 24 Adjusted Mean Change (SE)	12.31 (2.25)	10.73 (2.92)		
Week 32 Adjusted Mean Change (SE)	13.90 (2.15)	9.99 (2.80)		
Week 40 Adjusted Mean Change (SE)	13.55 (2.26)	12.13 (2.95)		
Week 52 Adjusted Mean Change (SE)	13.77 (2.46)	15.45 (3.27)	-1.68 [-9.75; 6.39]	0.682
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	41.02 (17.56)	37.94 (16.87)		
Week 52 Mean (SD)	50.66 (18.24)	49.96 (18.04)		
Week 4 Adjusted Mean Change (SE)	8.31 (1.68)	7.23 (1.57)		
Week 12 Adjusted Mean Change (SE)	9.78 (2.02)	11.05 (1.88)		
Week 16 Adjusted Mean Change (SE)	12.48 (2.07)	8.94 (1.94)		
Week 24 Adjusted Mean Change (SE)	11.89 (2.10)	10.90 (1.99)		
Week 32 Adjusted Mean Change (SE)	10.84 (2.01)	9.54 (1.92)		
Week 40 Adjusted Mean Change (SE)	10.54 (2.11)	9.81 (2.03)		
Week 52 Adjusted Mean Change (SE)	10.28 (2.29)	10.49 (2.21)	-0.20 [-6.49; 6.08]	0.949
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.8 SF-36 General Health - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.851</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	37.37 (17.71)	40.00 (18.86)		
Week 52 Mean (SD)	52.27 (21.45)	53.89 (18.11)		
Week 4 Adjusted Mean Change (SE)	10.92 (1.80)	9.44 (2.00)		
Week 12 Adjusted Mean Change (SE)	12.83 (2.25)	12.59 (2.51)		
Week 16 Adjusted Mean Change (SE)	12.97 (2.23)	12.84 (2.50)		
Week 24 Adjusted Mean Change (SE)	13.25 (2.39)	10.93 (2.69)		
Week 32 Adjusted Mean Change (SE)	13.60 (2.32)	10.08 (2.62)		
Week 40 Adjusted Mean Change (SE)	13.87 (2.41)	12.15 (2.71)		
Week 52 Adjusted Mean Change (SE)	13.87 (2.54)	14.62 (2.86)	-0.75 [-8.29; 6.80]	0.845
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	43.44 (17.01)	44.50 (18.17)		
Week 52 Mean (SD)	50.06 (19.31)	53.71 (22.77)		
Week 4 Adjusted Mean Change (SE)	8.13 (2.20)	6.42 (2.57)		
Week 12 Adjusted Mean Change (SE)	9.37 (2.79)	12.43 (3.21)		
Week 16 Adjusted Mean Change (SE)	10.67 (2.74)	8.76 (3.19)		
Week 24 Adjusted Mean Change (SE)	10.37 (2.94)	8.89 (3.46)		
Week 32 Adjusted Mean Change (SE)	10.33 (2.88)	9.78 (3.36)		
Week 40 Adjusted Mean Change (SE)	8.50 (2.96)	8.61 (3.54)		
Week 52 Adjusted Mean Change (SE)	8.19 (3.12)	8.18 (3.72)	0.01 [-9.54; 9.57]	0.998
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.9 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.649</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	40.84 (16.69)	43.67 (15.20)		
Week 52 Mean (SD)	53.56 (20.72)	57.89 (20.45)		
Week 4 Adjusted Mean Change (SE)	9.62 (1.92)	8.15 (2.54)		
Week 12 Adjusted Mean Change (SE)	13.48 (2.43)	14.26 (3.21)		
Week 16 Adjusted Mean Change (SE)	13.21 (2.40)	10.92 (3.19)		
Week 24 Adjusted Mean Change (SE)	13.14 (2.56)	10.80 (3.45)		
Week 32 Adjusted Mean Change (SE)	13.68 (2.48)	13.88 (3.33)		
Week 40 Adjusted Mean Change (SE)	12.03 (2.58)	13.06 (3.49)		
Week 52 Adjusted Mean Change (SE)	12.54 (2.74)	16.69 (3.79)	-4.14 [-13.40; 5.11]	0.378
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	38.95 (18.70)	40.57 (19.93)		
Week 52 Mean (SD)	49.23 (20.79)	51.29 (19.14)		
Week 4 Adjusted Mean Change (SE)	9.84 (2.10)	7.93 (2.36)		
Week 12 Adjusted Mean Change (SE)	8.91 (2.67)	9.90 (2.99)		
Week 16 Adjusted Mean Change (SE)	10.48 (2.63)	9.47 (2.96)		
Week 24 Adjusted Mean Change (SE)	11.13 (2.81)	7.44 (3.18)		
Week 32 Adjusted Mean Change (SE)	10.66 (2.72)	5.20 (3.06)		
Week 40 Adjusted Mean Change (SE)	11.59 (2.81)	8.59 (3.21)		
Week 52 Adjusted Mean Change (SE)	10.48 (3.00)	8.83 (3.38)	1.65 [-7.30; 10.60]	0.716
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.10 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.873</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	37.67 (20.40)	40.15 (20.15)		
Week 52 Mean (SD)	50.59 (18.07)	53.71 (20.85)		
Week 4 Adjusted Mean Change (SE)	8.61 (2.38)	9.55 (2.30)		
Week 12 Adjusted Mean Change (SE)	12.65 (2.89)	12.94 (2.81)		
Week 16 Adjusted Mean Change (SE)	10.42 (2.88)	12.70 (2.80)		
Week 24 Adjusted Mean Change (SE)	10.90 (3.14)	8.81 (3.10)		
Week 32 Adjusted Mean Change (SE)	12.81 (3.06)	10.34 (3.02)		
Week 40 Adjusted Mean Change (SE)	12.99 (3.16)	9.28 (3.14)		
Week 52 Adjusted Mean Change (SE)	11.72 (3.34)	12.33 (3.38)	-0.61 [-10.01; 8.79]	0.899
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	38.76 (13.67)	43.29 (17.10)		
Week 52 Mean (SD)	50.76 (21.65)	53.91 (19.23)		
Week 4 Adjusted Mean Change (SE)	10.93 (1.82)	7.56 (2.25)		
Week 12 Adjusted Mean Change (SE)	11.99 (2.23)	12.51 (2.72)		
Week 16 Adjusted Mean Change (SE)	14.18 (2.21)	10.33 (2.73)		
Week 24 Adjusted Mean Change (SE)	13.45 (2.38)	11.51 (2.95)		
Week 32 Adjusted Mean Change (SE)	12.87 (2.35)	10.03 (2.90)		
Week 40 Adjusted Mean Change (SE)	11.57 (2.41)	12.62 (3.00)		
Week 52 Adjusted Mean Change (SE)	11.80 (2.56)	12.73 (3.15)	-0.93 [-8.97; 7.12]	0.820
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.11 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.405</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	40.88 (19.21)	42.91 (18.90)		
Week 52 Mean (SD)	52.44 (22.59)	52.23 (20.02)		
Week 4 Adjusted Mean Change (SE)	11.06 (1.96)	8.46 (1.96)		
Week 12 Adjusted Mean Change (SE)	13.92 (2.45)	12.21 (2.45)		
Week 16 Adjusted Mean Change (SE)	14.05 (2.43)	12.08 (2.43)		
Week 24 Adjusted Mean Change (SE)	13.82 (2.61)	9.63 (2.63)		
Week 32 Adjusted Mean Change (SE)	12.62 (2.55)	9.16 (2.56)		
Week 40 Adjusted Mean Change (SE)	11.85 (2.63)	8.82 (2.65)		
Week 52 Adjusted Mean Change (SE)	12.28 (2.80)	11.66 (2.81)	0.61 [-7.23; 8.46]	0.877
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	38.69 (15.92)	39.67 (18.23)		
Week 52 Mean (SD)	50.44 (18.64)	57.28 (19.24)		
Week 4 Adjusted Mean Change (SE)	8.50 (1.99)	8.06 (2.68)		
Week 12 Adjusted Mean Change (SE)	8.91 (2.48)	13.17 (3.32)		
Week 16 Adjusted Mean Change (SE)	9.99 (2.46)	9.76 (3.33)		
Week 24 Adjusted Mean Change (SE)	10.27 (2.63)	11.24 (3.59)		
Week 32 Adjusted Mean Change (SE)	11.86 (2.55)	11.59 (3.49)		
Week 40 Adjusted Mean Change (SE)	11.56 (2.65)	14.99 (3.66)		
Week 52 Adjusted Mean Change (SE)	10.87 (2.81)	13.31 (3.93)	-2.45 [-11.99; 7.10]	0.613
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



#### 44.12 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.983</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	41.63 (18.22)	43.06 (18.22)		
Week 52 Mean (SD)	52.29 (20.35)	53.74 (19.15)		
Week 4 Adjusted Mean Change (SE)	9.30 (1.64)	7.70 (1.90)		
Week 12 Adjusted Mean Change (SE)	9.23 (2.02)	13.06 (2.32)		
Week 16 Adjusted Mean Change (SE)	11.22 (2.06)	11.53 (2.39)		
Week 24 Adjusted Mean Change (SE)	12.15 (2.14)	8.43 (2.51)		
Week 32 Adjusted Mean Change (SE)	12.69 (2.12)	10.71 (2.47)		
Week 40 Adjusted Mean Change (SE)	11.27 (2.19)	11.80 (2.59)		
Week 52 Adjusted Mean Change (SE)	11.45 (2.30)	11.63 (2.74)	-0.18 [-7.25; 6.90]	0.961
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	33.85 (15.55)	40.17 (19.76)		
Week 52 Mean (SD)	50.42 (22.48)	58.00 (18.78)		
Week 4 Adjusted Mean Change (SE)	10.96 (2.93)	11.23 (3.03)		
Week 12 Adjusted Mean Change (SE)	16.28 (3.57)	13.63 (3.74)		
Week 16 Adjusted Mean Change (SE)	14.19 (3.66)	12.29 (3.83)		
Week 24 Adjusted Mean Change (SE)	13.10 (3.86)	17.33 (4.01)		
Week 32 Adjusted Mean Change (SE)	11.97 (3.78)	9.99 (3.95)		
Week 40 Adjusted Mean Change (SE)	13.71 (3.93)	11.35 (4.11)		
Week 52 Adjusted Mean Change (SE)	13.49 (4.11)	16.21 (4.27)	-2.73 [-14.43; 8.98]	0.646
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 44.13 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.763</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	39.63 (18.39)	42.37 (20.52)		
Week 52 Mean (SD)	49.24 (20.16)	52.76 (19.17)		
Week 4 Adjusted Mean Change (SE)	8.03 (1.60)	8.79 (1.80)		
Week 12 Adjusted Mean Change (SE)	10.81 (2.04)	12.60 (2.29)		
Week 16 Adjusted Mean Change (SE)	10.21 (2.02)	10.63 (2.28)		
Week 24 Adjusted Mean Change (SE)	9.99 (2.13)	9.29 (2.42)		
Week 32 Adjusted Mean Change (SE)	10.30 (2.08)	9.30 (2.34)		
Week 40 Adjusted Mean Change (SE)	10.23 (2.15)	9.51 (2.45)		
Week 52 Adjusted Mean Change (SE)	9.61 (2.28)	11.21 (2.61)	-1.60 [-8.46; 5.25]	0.644
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	42.16 (13.45)	40.50 (10.95)		
Week 52 Mean (SD)	55.68 (20.31)	54.83 (22.59)		
Week 4 Adjusted Mean Change (SE)	13.10 (2.91)	6.70 (3.69)		
Week 12 Adjusted Mean Change (SE)	10.40 (3.70)	13.59 (4.67)		
Week 16 Adjusted Mean Change (SE)	15.98 (3.67)	12.17 (4.63)		
Week 24 Adjusted Mean Change (SE)	15.19 (3.84)	13.62 (4.86)		
Week 32 Adjusted Mean Change (SE)	14.95 (3.72)	12.69 (4.77)		
Week 40 Adjusted Mean Change (SE)	13.28 (3.88)	13.84 (4.95)		
Week 52 Adjusted Mean Change (SE)	14.20 (4.09)	14.41 (5.16)	-0.21 [-13.22; 12.79]	0.974
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.14 SF-36 General Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.442</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	40.55 (17.76)	40.51 (18.71)		
Week 52 Mean (SD)	51.05 (20.90)	54.77 (20.79)		
Week 4 Adjusted Mean Change (SE)	10.47 (1.53)	9.31 (1.79)		
Week 12 Adjusted Mean Change (SE)	11.65 (1.91)	13.46 (2.23)		
Week 16 Adjusted Mean Change (SE)	11.65 (1.87)	11.21 (2.19)		
Week 24 Adjusted Mean Change (SE)	11.87 (2.05)	10.47 (2.41)		
Week 32 Adjusted Mean Change (SE)	12.01 (1.98)	10.99 (2.32)		
Week 40 Adjusted Mean Change (SE)	11.49 (2.07)	11.64 (2.46)		
Week 52 Adjusted Mean Change (SE)	10.92 (2.16)	14.40 (2.56)	-3.49 [-10.11; 3.13]	0.300
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	36.08 (17.47)	46.30 (16.85)		
Week 52 Mean (SD)	52.85 (20.24)	50.60 (14.64)		
Week 4 Adjusted Mean Change (SE)	6.04 (3.59)	4.27 (4.09)		
Week 12 Adjusted Mean Change (SE)	10.46 (4.54)	6.72 (5.09)		
Week 16 Adjusted Mean Change (SE)	14.40 (4.37)	9.03 (4.98)		
Week 24 Adjusted Mean Change (SE)	13.30 (4.76)	8.43 (5.43)		
Week 32 Adjusted Mean Change (SE)	13.26 (4.57)	8.11 (5.21)		
Week 40 Adjusted Mean Change (SE)	12.89 (4.81)	8.29 (5.48)		
Week 52 Adjusted Mean Change (SE)	14.97 (5.00)	6.89 (5.70)	8.09 [-6.96; 23.13]	0.290
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.15 SF-36 General Health - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.948</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	42.45 (24.59)	43.65 (21.18)		
Week 52 Mean (SD)	53.47 (20.54)	51.50 (22.59)		
Week 4 Adjusted Mean Change (SE)	9.64 (2.75)	8.86 (2.60)		
Week 12 Adjusted Mean Change (SE)	12.22 (3.41)	14.08 (3.22)		
Week 16 Adjusted Mean Change (SE)	9.20 (3.41)	12.43 (3.21)		
Week 24 Adjusted Mean Change (SE)	11.13 (3.66)	7.64 (3.47)		
Week 32 Adjusted Mean Change (SE)	12.42 (3.58)	9.95 (3.40)		
Week 40 Adjusted Mean Change (SE)	11.55 (3.71)	8.08 (3.54)		
Week 52 Adjusted Mean Change (SE)	12.33 (3.94)	10.47 (3.83)	1.86 [-9.00; 12.72]	0.736
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	38.87 (14.53)	40.54 (16.91)		
Week 52 Mean (SD)	50.77 (20.68)	54.90 (18.51)		
Week 4 Adjusted Mean Change (SE)	9.85 (1.63)	7.98 (2.02)		
Week 12 Adjusted Mean Change (SE)	11.15 (2.03)	11.60 (2.52)		
Week 16 Adjusted Mean Change (SE)	12.99 (2.00)	10.61 (2.49)		
Week 24 Adjusted Mean Change (SE)	12.43 (2.13)	11.59 (2.67)		
Week 32 Adjusted Mean Change (SE)	12.26 (2.09)	9.93 (2.61)		
Week 40 Adjusted Mean Change (SE)	11.82 (2.16)	12.36 (2.71)		
Week 52 Adjusted Mean Change (SE)	11.41 (2.28)	13.18 (2.84)	-1.77 [-8.98; 5.44]	0.629
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.16 SF-36 General Health - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.422</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	41.51 (16.30)	41.29 (16.62)		
Week 52 Mean (SD)	53.24 (20.22)	56.67 (20.00)		
Week 4 Adjusted Mean Change (SE)	9.31 (1.81)	8.88 (2.21)		
Week 12 Adjusted Mean Change (SE)	12.47 (2.25)	14.08 (2.74)		
Week 16 Adjusted Mean Change (SE)	12.88 (2.24)	11.70 (2.75)		
Week 24 Adjusted Mean Change (SE)	11.79 (2.39)	11.67 (2.96)		
Week 32 Adjusted Mean Change (SE)	12.64 (2.30)	14.17 (2.84)		
Week 40 Adjusted Mean Change (SE)	11.25 (2.42)	12.96 (3.01)		
Week 52 Adjusted Mean Change (SE)	11.93 (2.53)	16.68 (3.20)	-4.75 [-12.81; 3.31]	0.246
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	37.24 (19.33)	42.25 (20.78)		
Week 52 Mean (SD)	48.52 (21.07)	51.27 (19.50)		
Week 4 Adjusted Mean Change (SE)	10.54 (2.22)	7.70 (2.28)		
Week 12 Adjusted Mean Change (SE)	9.87 (2.78)	10.94 (2.85)		
Week 16 Adjusted Mean Change (SE)	10.72 (2.77)	10.85 (2.84)		
Week 24 Adjusted Mean Change (SE)	12.58 (2.96)	8.62 (3.05)		
Week 32 Adjusted Mean Change (SE)	11.73 (2.85)	5.53 (2.93)		
Week 40 Adjusted Mean Change (SE)	12.46 (2.97)	8.71 (3.10)		
Week 52 Adjusted Mean Change (SE)	11.03 (3.14)	8.01 (3.21)	3.02 [-5.90; 11.93]	0.505
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.17 SF-36 General Health - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.731</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	37.67 (20.40)	39.52 (20.61)		
Week 52 Mean (SD)	50.59 (18.07)	54.32 (21.66)		
Week 4 Adjusted Mean Change (SE)	8.35 (2.35)	9.80 (2.35)		
Week 12 Adjusted Mean Change (SE)	12.26 (2.93)	13.53 (2.94)		
Week 16 Adjusted Mean Change (SE)	10.06 (2.90)	13.41 (2.91)		
Week 24 Adjusted Mean Change (SE)	10.61 (3.15)	9.65 (3.21)		
Week 32 Adjusted Mean Change (SE)	12.49 (3.04)	9.87 (3.11)		
Week 40 Adjusted Mean Change (SE)	12.67 (3.17)	9.73 (3.26)		
Week 52 Adjusted Mean Change (SE)	11.44 (3.33)	12.67 (3.50)	-1.23 [-10.77; 8.31]	0.800
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	40.96 (15.93)	43.67 (16.72)		
Week 52 Mean (SD)	51.88 (22.00)	53.51 (18.77)		
Week 4 Adjusted Mean Change (SE)	10.59 (1.73)	7.07 (2.15)		
Week 12 Adjusted Mean Change (SE)	10.97 (2.17)	11.73 (2.68)		
Week 16 Adjusted Mean Change (SE)	13.15 (2.14)	9.51 (2.67)		
Week 24 Adjusted Mean Change (SE)	12.85 (2.30)	10.37 (2.86)		
Week 32 Adjusted Mean Change (SE)	12.16 (2.25)	9.93 (2.79)		
Week 40 Adjusted Mean Change (SE)	11.21 (2.33)	11.55 (2.91)		
Week 52 Adjusted Mean Change (SE)	11.68 (2.47)	11.82 (3.05)	-0.13 [-7.88; 7.61]	0.973
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.18 SF-36 General Health - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.405</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	40.88 (19.21)	42.91 (18.90)		
Week 52 Mean (SD)	52.44 (22.59)	52.23 (20.02)		
Week 4 Adjusted Mean Change (SE)	11.06 (1.96)	8.46 (1.96)		
Week 12 Adjusted Mean Change (SE)	13.92 (2.45)	12.21 (2.45)		
Week 16 Adjusted Mean Change (SE)	14.05 (2.43)	12.08 (2.43)		
Week 24 Adjusted Mean Change (SE)	13.82 (2.61)	9.63 (2.63)		
Week 32 Adjusted Mean Change (SE)	12.62 (2.55)	9.16 (2.56)		
Week 40 Adjusted Mean Change (SE)	11.85 (2.63)	8.82 (2.65)		
Week 52 Adjusted Mean Change (SE)	12.28 (2.80)	11.66 (2.81)	0.61 [-7.23; 8.46]	0.877
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	38.69 (15.92)	39.67 (18.23)		
Week 52 Mean (SD)	50.44 (18.64)	57.28 (19.24)		
Week 4 Adjusted Mean Change (SE)	8.50 (1.99)	8.06 (2.68)		
Week 12 Adjusted Mean Change (SE)	8.91 (2.48)	13.17 (3.32)		
Week 16 Adjusted Mean Change (SE)	9.99 (2.46)	9.76 (3.33)		
Week 24 Adjusted Mean Change (SE)	10.27 (2.63)	11.24 (3.59)		
Week 32 Adjusted Mean Change (SE)	11.86 (2.55)	11.59 (3.49)		
Week 40 Adjusted Mean Change (SE)	11.56 (2.65)	14.99 (3.66)		
Week 52 Adjusted Mean Change (SE)	10.87 (2.81)	13.31 (3.93)	-2.45 [-11.99; 7.10]	0.613
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 44.19 SF-36 General Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.915</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	41.40 (18.13)	42.22 (18.37)		
Week 52 Mean (SD)	51.84 (20.05)	52.73 (19.27)		
Week 4 Adjusted Mean Change (SE)	9.19 (1.60)	7.97 (1.86)		
Week 12 Adjusted Mean Change (SE)	9.61 (2.00)	12.71 (2.31)		
Week 16 Adjusted Mean Change (SE)	11.15 (1.99)	11.15 (2.31)		
Week 24 Adjusted Mean Change (SE)	11.89 (2.11)	7.80 (2.49)		
Week 32 Adjusted Mean Change (SE)	12.29 (2.09)	9.95 (2.44)		
Week 40 Adjusted Mean Change (SE)	11.10 (2.17)	10.86 (2.57)		
Week 52 Adjusted Mean Change (SE)	11.11 (2.28)	11.22 (2.71)	-0.10 [-7.11; 6.90]	0.977
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	35.67 (15.31)	40.44 (19.65)		
Week 52 Mean (SD)	51.24 (23.67)	56.41 (21.20)		
Week 4 Adjusted Mean Change (SE)	10.41 (3.08)	8.98 (3.03)		
Week 12 Adjusted Mean Change (SE)	16.79 (3.80)	11.79 (3.76)		
Week 16 Adjusted Mean Change (SE)	13.02 (3.79)	11.21 (3.79)		
Week 24 Adjusted Mean Change (SE)	12.55 (4.10)	15.98 (4.02)		
Week 32 Adjusted Mean Change (SE)	11.78 (4.00)	9.69 (4.00)		
Week 40 Adjusted Mean Change (SE)	13.48 (4.19)	10.26 (4.20)		
Week 52 Adjusted Mean Change (SE)	13.24 (4.38)	14.55 (4.33)	-1.31 [-13.48; 10.86]	0.832
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



#### 45.0 SF-36 Mental Health - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

### 45.1 SF-36 Mental Health - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	50.18 (22.49)	54.26 (21.75)		
Week 52 Mean (SD)	66.43 (21.91)	64.76 (20.82)		
Week 4 Adjusted Mean Change (SE)	11.63 (1.57)	9.40 (1.65)		
Week 12 Adjusted Mean Change (SE)	14.07 (1.62)	11.22 (1.70)		
Week 16 Adjusted Mean Change (SE)	13.34 (1.57)	11.50 (1.67)		
Week 24 Adjusted Mean Change (SE)	14.28 (1.79)	9.94 (1.93)		
Week 32 Adjusted Mean Change (SE)	15.72 (1.70)	11.07 (1.84)		
Week 40 Adjusted Mean Change (SE)	13.76 (1.72)	10.68 (1.88)		
Week 52 Adjusted Mean Change (SE)	15.62 (1.82)	10.95 (2.01)	4.67 [-0.69; 10.03]	0.087
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 45.2 SF-36 Mental Health - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.544</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	49.08 (22.07)	54.47 (22.17)		
Week 52 Mean (SD)	66.57 (22.38)	65.00 (20.53)		
Week 4 Adjusted Mean Change (SE)	11.95 (1.63)	9.42 (1.72)		
Week 12 Adjusted Mean Change (SE)	14.60 (1.68)	10.92 (1.77)		
Week 16 Adjusted Mean Change (SE)	13.10 (1.63)	11.37 (1.74)		
Week 24 Adjusted Mean Change (SE)	14.07 (1.87)	9.69 (2.02)		
Week 32 Adjusted Mean Change (SE)	15.46 (1.77)	10.85 (1.93)		
Week 40 Adjusted Mean Change (SE)	14.31 (1.79)	10.44 (1.96)		
Week 52 Adjusted Mean Change (SE)	16.20 (1.88)	10.95 (2.09)	5.25 [-0.32; 10.82]	0.065
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	66.43 (24.10)	51.43 (16.00)		
Week 52 Mean (SD)	64.17 (12.81)	61.67 (26.20)		
Week 4 Adjusted Mean Change (SE)	7.01 (6.27)	8.87 (6.22)		
Week 12 Adjusted Mean Change (SE)	6.78 (6.41)	14.59 (6.36)		
Week 16 Adjusted Mean Change (SE)	18.00 (6.48)	13.17 (6.22)		
Week 24 Adjusted Mean Change (SE)	17.24 (7.14)	13.15 (7.08)		
Week 32 Adjusted Mean Change (SE)	18.87 (6.68)	13.85 (6.62)		
Week 40 Adjusted Mean Change (SE)	6.28 (6.79)	13.15 (6.73)		
Week 52 Adjusted Mean Change (SE)	6.83 (7.39)	10.76 (7.35)	-3.93 [-24.47; 16.61]	0.706
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 45.3 SF-36 Mental Health - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.677</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	55.23 (20.37)	57.89 (21.85)		
Week 52 Mean (SD)	68.36 (22.09)	66.25 (19.47)		
Week 4 Adjusted Mean Change (SE)	13.84 (2.04)	11.84 (2.20)		
Week 12 Adjusted Mean Change (SE)	13.83 (2.13)	12.68 (2.28)		
Week 16 Adjusted Mean Change (SE)	14.55 (2.06)	12.77 (2.22)		
Week 24 Adjusted Mean Change (SE)	15.12 (2.33)	12.53 (2.56)		
Week 32 Adjusted Mean Change (SE)	16.59 (2.22)	12.38 (2.47)		
Week 40 Adjusted Mean Change (SE)	14.50 (2.24)	12.87 (2.50)		
Week 52 Adjusted Mean Change (SE)	15.59 (2.37)	11.00 (2.67)	4.59 [-2.39; 11.57]	0.196
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	42.61 (23.61)	49.55 (20.93)		
Week 52 Mean (SD)	63.41 (21.55)	62.65 (22.70)		
Week 4 Adjusted Mean Change (SE)	8.21 (2.54)	6.39 (2.49)		
Week 12 Adjusted Mean Change (SE)	14.40 (2.65)	9.33 (2.59)		
Week 16 Adjusted Mean Change (SE)	11.50 (2.56)	9.98 (2.55)		
Week 24 Adjusted Mean Change (SE)	12.99 (2.96)	6.51 (2.98)		
Week 32 Adjusted Mean Change (SE)	14.37 (2.83)	9.39 (2.82)		
Week 40 Adjusted Mean Change (SE)	12.60 (2.83)	7.81 (2.89)		
Week 52 Adjusted Mean Change (SE)	15.76 (3.01)	11.01 (3.11)	4.75 [-3.70; 13.20]	0.269
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 45.4 SF-36 Mental Health - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.837</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	57.92 (25.62)	58.81 (22.19)		
Week 52 Mean (SD)	69.57 (23.59)	67.94 (20.16)		
Week 4 Adjusted Mean Change (SE)	16.50 (3.36)	9.70 (3.59)		
Week 12 Adjusted Mean Change (SE)	14.17 (3.55)	12.17 (3.71)		
Week 16 Adjusted Mean Change (SE)	16.07 (3.37)	14.45 (3.61)		
Week 24 Adjusted Mean Change (SE)	13.54 (3.92)	10.09 (4.23)		
Week 32 Adjusted Mean Change (SE)	18.66 (3.68)	11.92 (4.10)		
Week 40 Adjusted Mean Change (SE)	13.78 (3.74)	16.64 (4.15)		
Week 52 Adjusted Mean Change (SE)	15.65 (3.92)	15.58 (4.43)	0.08 [-11.58; 11.74]	0.990
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	48.02 (21.20)	53.06 (21.62)		
Week 52 Mean (SD)	65.55 (21.49)	63.92 (21.06)		
Week 4 Adjusted Mean Change (SE)	10.24 (1.78)	9.36 (1.85)		
Week 12 Adjusted Mean Change (SE)	13.98 (1.85)	10.97 (1.92)		
Week 16 Adjusted Mean Change (SE)	12.55 (1.79)	10.72 (1.88)		
Week 24 Adjusted Mean Change (SE)	14.42 (2.04)	9.91 (2.18)		
Week 32 Adjusted Mean Change (SE)	14.88 (1.93)	10.86 (2.07)		
Week 40 Adjusted Mean Change (SE)	13.74 (1.95)	9.18 (2.11)		
Week 52 Adjusted Mean Change (SE)	15.60 (2.07)	9.80 (2.26)	5.80 [-0.27; 11.87]	0.061
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 45.5 SF-36 Mental Health - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.735</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	52.86 (24.84)	51.76 (20.68)		
Week 52 Mean (SD)	68.72 (21.60)	65.00 (20.92)		
Week 4 Adjusted Mean Change (SE)	12.62 (2.54)	9.86 (2.33)		
Week 12 Adjusted Mean Change (SE)	15.04 (2.62)	10.26 (2.38)		
Week 16 Adjusted Mean Change (SE)	12.12 (2.54)	10.59 (2.35)		
Week 24 Adjusted Mean Change (SE)	12.59 (2.92)	11.41 (2.73)		
Week 32 Adjusted Mean Change (SE)	15.47 (2.77)	11.52 (2.61)		
Week 40 Adjusted Mean Change (SE)	12.79 (2.79)	12.69 (2.70)		
Week 52 Adjusted Mean Change (SE)	16.90 (2.97)	12.49 (2.90)	4.41 [-3.79; 12.60]	0.290
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	48.53 (20.93)	56.80 (22.72)		
Week 52 Mean (SD)	65.08 (22.14)	64.55 (20.96)		
Week 4 Adjusted Mean Change (SE)	11.01 (2.01)	8.92 (2.37)		
Week 12 Adjusted Mean Change (SE)	13.43 (2.08)	12.23 (2.44)		
Week 16 Adjusted Mean Change (SE)	14.10 (2.02)	12.41 (2.38)		
Week 24 Adjusted Mean Change (SE)	15.32 (2.29)	8.46 (2.75)		
Week 32 Adjusted Mean Change (SE)	15.88 (2.18)	10.65 (2.63)		
Week 40 Adjusted Mean Change (SE)	14.38 (2.19)	8.83 (2.64)		
Week 52 Adjusted Mean Change (SE)	14.88 (2.32)	9.47 (2.81)	5.41 [-1.83; 12.64]	0.142
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 45.6 SF-36 Mental Health - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.648</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	49.72 (20.98)	56.73 (18.75)		
Week 52 Mean (SD)	68.00 (22.27)	70.56 (20.10)		
Week 4 Adjusted Mean Change (SE)	13.13 (1.93)	10.53 (2.35)		
Week 12 Adjusted Mean Change (SE)	15.70 (2.02)	11.17 (2.41)		
Week 16 Adjusted Mean Change (SE)	14.25 (1.94)	13.46 (2.38)		
Week 24 Adjusted Mean Change (SE)	17.07 (2.19)	11.02 (2.77)		
Week 32 Adjusted Mean Change (SE)	16.67 (2.10)	11.74 (2.69)		
Week 40 Adjusted Mean Change (SE)	15.97 (2.09)	13.87 (2.72)		
Week 52 Adjusted Mean Change (SE)	17.26 (2.21)	14.45 (2.95)	2.81 [-4.49; 10.11]	0.449
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	51.05 (25.39)	51.92 (24.20)		
Week 52 Mean (SD)	63.29 (21.14)	60.22 (20.44)		
Week 4 Adjusted Mean Change (SE)	8.79 (2.66)	8.28 (2.32)		
Week 12 Adjusted Mean Change (SE)	11.04 (2.73)	11.27 (2.39)		
Week 16 Adjusted Mean Change (SE)	11.58 (2.66)	9.63 (2.33)		
Week 24 Adjusted Mean Change (SE)	8.73 (3.07)	8.91 (2.66)		
Week 32 Adjusted Mean Change (SE)	13.88 (2.91)	10.40 (2.54)		
Week 40 Adjusted Mean Change (SE)	9.43 (2.91)	7.97 (2.54)		
Week 52 Adjusted Mean Change (SE)	12.41 (3.10)	8.05 (2.70)	4.36 [-3.75; 12.47]	0.290
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 45.7 SF-36 Mental Health - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.639</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	52.35 (23.33)	56.88 (22.82)		
Week 52 Mean (SD)	68.47 (21.36)	72.00 (22.50)		
Week 4 Adjusted Mean Change (SE)	15.07 (2.27)	12.86 (2.93)		
Week 12 Adjusted Mean Change (SE)	16.50 (2.38)	15.36 (3.04)		
Week 16 Adjusted Mean Change (SE)	13.78 (2.30)	14.57 (2.99)		
Week 24 Adjusted Mean Change (SE)	15.64 (2.63)	11.82 (3.43)		
Week 32 Adjusted Mean Change (SE)	18.17 (2.47)	15.90 (3.23)		
Week 40 Adjusted Mean Change (SE)	16.51 (2.50)	14.48 (3.28)		
Week 52 Adjusted Mean Change (SE)	16.53 (2.64)	16.62 (3.57)	-0.09 [-8.84; 8.66]	0.984
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	48.31 (21.77)	53.04 (21.30)		
Week 52 Mean (SD)	64.64 (22.42)	61.58 (19.39)		
Week 4 Adjusted Mean Change (SE)	8.61 (2.12)	7.86 (1.97)		
Week 12 Adjusted Mean Change (SE)	11.95 (2.19)	9.39 (2.03)		
Week 16 Adjusted Mean Change (SE)	12.96 (2.16)	10.12 (2.01)		
Week 24 Adjusted Mean Change (SE)	13.07 (2.47)	9.09 (2.35)		
Week 32 Adjusted Mean Change (SE)	13.56 (2.31)	8.87 (2.22)		
Week 40 Adjusted Mean Change (SE)	11.34 (2.34)	8.97 (2.28)		
Week 52 Adjusted Mean Change (SE)	14.80 (2.48)	8.42 (2.41)	6.39 [-0.45; 13.23]	0.067
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



#### 45.8 SF-36 Mental Health - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.537</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	46.57 (21.87)	56.46 (19.01)		
Week 52 Mean (SD)	66.63 (22.90)	70.56 (17.52)		
Week 4 Adjusted Mean Change (SE)	16.19 (2.30)	12.18 (2.59)		
Week 12 Adjusted Mean Change (SE)	15.49 (2.43)	10.93 (2.75)		
Week 16 Adjusted Mean Change (SE)	13.57 (2.30)	12.83 (2.61)		
Week 24 Adjusted Mean Change (SE)	16.32 (2.61)	13.81 (2.98)		
Week 32 Adjusted Mean Change (SE)	16.25 (2.52)	13.45 (2.89)		
Week 40 Adjusted Mean Change (SE)	13.81 (2.54)	14.35 (2.91)		
Week 52 Adjusted Mean Change (SE)	18.85 (2.63)	17.18 (3.01)	1.67 [-6.29; 9.64]	0.679
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	52.21 (22.64)	48.85 (21.51)		
Week 52 Mean (SD)	67.58 (20.93)	57.14 (23.38)		
Week 4 Adjusted Mean Change (SE)	8.95 (2.81)	7.25 (3.27)		
Week 12 Adjusted Mean Change (SE)	15.01 (3.02)	11.67 (3.46)		
Week 16 Adjusted Mean Change (SE)	14.65 (2.82)	11.89 (3.26)		
Week 24 Adjusted Mean Change (SE)	15.59 (3.21)	8.79 (3.78)		
Week 32 Adjusted Mean Change (SE)	16.98 (3.15)	7.64 (3.66)		
Week 40 Adjusted Mean Change (SE)	16.07 (3.12)	11.36 (3.74)		
Week 52 Adjusted Mean Change (SE)	16.12 (3.24)	8.33 (3.87)	7.79 [-2.19; 17.78]	0.125
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 45.9 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.391</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	47.33 (20.10)	55.74 (19.60)		
Week 52 Mean (SD)	66.63 (25.97)	66.05 (18.75)		
Week 4 Adjusted Mean Change (SE)	13.70 (2.53)	11.26 (3.35)		
Week 12 Adjusted Mean Change (SE)	14.04 (2.63)	15.02 (3.48)		
Week 16 Adjusted Mean Change (SE)	13.29 (2.48)	13.53 (3.32)		
Week 24 Adjusted Mean Change (SE)	14.54 (2.77)	13.89 (3.76)		
Week 32 Adjusted Mean Change (SE)	16.67 (2.73)	15.24 (3.70)		
Week 40 Adjusted Mean Change (SE)	13.66 (2.73)	13.85 (3.74)		
Week 52 Adjusted Mean Change (SE)	17.47 (2.92)	14.02 (4.10)	3.45 [-6.54; 13.45]	0.496
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	50.92 (24.79)	51.17 (22.84)		
Week 52 Mean (SD)	67.29 (16.95)	65.18 (24.17)		
Week 4 Adjusted Mean Change (SE)	13.27 (2.74)	9.29 (3.09)		
Week 12 Adjusted Mean Change (SE)	16.94 (2.90)	8.74 (3.24)		
Week 16 Adjusted Mean Change (SE)	15.04 (2.71)	11.90 (3.06)		
Week 24 Adjusted Mean Change (SE)	18.81 (3.02)	11.36 (3.44)		
Week 32 Adjusted Mean Change (SE)	16.34 (2.98)	8.83 (3.37)		
Week 40 Adjusted Mean Change (SE)	16.41 (2.95)	14.30 (3.41)		
Week 52 Adjusted Mean Change (SE)	18.10 (3.18)	13.73 (3.60)	4.37 [-5.14; 13.89]	0.365
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 45.10 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.440</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	46.50 (22.40)	55.30 (18.79)		
Week 52 Mean (SD)	67.41 (19.35)	69.58 (22.55)		
Week 4 Adjusted Mean Change (SE)	11.38 (2.97)	12.28 (2.90)		
Week 12 Adjusted Mean Change (SE)	16.51 (3.10)	15.61 (3.05)		
Week 16 Adjusted Mean Change (SE)	14.79 (3.01)	13.70 (2.96)		
Week 24 Adjusted Mean Change (SE)	14.20 (3.46)	10.21 (3.47)		
Week 32 Adjusted Mean Change (SE)	16.57 (3.29)	14.40 (3.32)		
Week 40 Adjusted Mean Change (SE)	12.99 (3.32)	12.71 (3.37)		
Week 52 Adjusted Mean Change (SE)	18.74 (3.47)	16.09 (3.61)	2.65 [-7.29; 12.59]	0.599
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	47.94 (21.03)	51.76 (21.63)		
Week 52 Mean (SD)	66.22 (23.93)	62.73 (19.13)		
Week 4 Adjusted Mean Change (SE)	14.98 (2.28)	8.79 (2.79)		
Week 12 Adjusted Mean Change (SE)	15.49 (2.40)	7.54 (2.91)		
Week 16 Adjusted Mean Change (SE)	13.64 (2.30)	11.67 (2.85)		
Week 24 Adjusted Mean Change (SE)	17.31 (2.61)	13.44 (3.23)		
Week 32 Adjusted Mean Change (SE)	16.51 (2.53)	8.57 (3.11)		
Week 40 Adjusted Mean Change (SE)	16.63 (2.53)	13.62 (3.14)		
Week 52 Adjusted Mean Change (SE)	17.68 (2.66)	12.41 (3.26)	5.27 [-3.05; 13.59]	0.212
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 45.11 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.996</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	47.44 (23.56)	52.79 (20.57)		
Week 52 Mean (SD)	64.10 (24.49)	64.62 (22.84)		
Week 4 Adjusted Mean Change (SE)	15.37 (2.54)	10.74 (2.53)		
Week 12 Adjusted Mean Change (SE)	15.53 (2.66)	11.39 (2.66)		
Week 16 Adjusted Mean Change (SE)	13.68 (2.51)	10.85 (2.50)		
Week 24 Adjusted Mean Change (SE)	15.26 (2.87)	11.14 (2.89)		
Week 32 Adjusted Mean Change (SE)	16.34 (2.82)	11.78 (2.81)		
Week 40 Adjusted Mean Change (SE)	13.62 (2.80)	12.89 (2.82)		
Week 52 Adjusted Mean Change (SE)	15.82 (2.93)	14.17 (2.93)	1.64 [-6.55; 9.84]	0.692
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	50.24 (20.95)	54.79 (19.92)		
Week 52 Mean (SD)	69.76 (19.30)	67.78 (15.55)		
Week 4 Adjusted Mean Change (SE)	11.17 (2.57)	9.50 (3.48)		
Week 12 Adjusted Mean Change (SE)	15.07 (2.69)	10.96 (3.62)		
Week 16 Adjusted Mean Change (SE)	14.27 (2.51)	15.62 (3.44)		
Week 24 Adjusted Mean Change (SE)	16.80 (2.87)	13.32 (3.98)		
Week 32 Adjusted Mean Change (SE)	16.67 (2.78)	10.16 (3.87)		
Week 40 Adjusted Mean Change (SE)	15.76 (2.79)	13.64 (3.95)		
Week 52 Adjusted Mean Change (SE)	19.63 (2.90)	13.34 (4.15)	6.29 [-3.73; 16.31]	0.217
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 45.12 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.294</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	49.84 (21.46)	53.51 (18.99)		
Week 52 Mean (SD)	66.98 (21.23)	64.61 (19.57)		
Week 4 Adjusted Mean Change (SE)	13.24 (2.12)	9.72 (2.45)		
Week 12 Adjusted Mean Change (SE)	12.93 (2.12)	9.21 (2.44)		
Week 16 Adjusted Mean Change (SE)	13.68 (2.02)	11.24 (2.34)		
Week 24 Adjusted Mean Change (SE)	17.03 (2.29)	9.81 (2.72)		
Week 32 Adjusted Mean Change (SE)	16.13 (2.27)	11.15 (2.66)		
Week 40 Adjusted Mean Change (SE)	14.76 (2.23)	11.51 (2.65)		
Week 52 Adjusted Mean Change (SE)	17.57 (2.36)	12.93 (2.83)	4.64 [-2.67; 11.95]	0.212
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	45.75 (25.82)	58.33 (18.71)		
Week 52 Mean (SD)	68.95 (23.78)	73.24 (17.04)		
Week 4 Adjusted Mean Change (SE)	11.05 (3.76)	12.23 (3.94)		
Week 12 Adjusted Mean Change (SE)	21.59 (3.74)	16.53 (3.97)		
Week 16 Adjusted Mean Change (SE)	14.12 (3.57)	18.49 (3.79)		
Week 24 Adjusted Mean Change (SE)	14.00 (4.15)	19.61 (4.36)		
Week 32 Adjusted Mean Change (SE)	16.53 (4.02)	13.21 (4.29)		
Week 40 Adjusted Mean Change (SE)	14.40 (3.99)	20.34 (4.23)		
Week 52 Adjusted Mean Change (SE)	18.78 (4.19)	18.62 (4.41)	0.17 [-11.91; 12.25]	0.978
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 45.13 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.061</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	48.81 (22.78)	55.39 (20.34)		
Week 52 Mean (SD)	65.86 (23.23)	67.38 (21.48)		
Week 4 Adjusted Mean Change (SE)	12.07 (2.09)	12.03 (2.37)		
Week 12 Adjusted Mean Change (SE)	13.41 (2.15)	13.27 (2.43)		
Week 16 Adjusted Mean Change (SE)	11.96 (2.07)	13.35 (2.35)		
Week 24 Adjusted Mean Change (SE)	13.68 (2.35)	13.20 (2.70)		
Week 32 Adjusted Mean Change (SE)	14.06 (2.30)	13.04 (2.61)		
Week 40 Adjusted Mean Change (SE)	12.58 (2.30)	14.80 (2.65)		
Week 52 Adjusted Mean Change (SE)	16.85 (2.43)	15.04 (2.81)	1.81 [-5.56; 9.18]	0.628
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	50.00 (21.15)	47.92 (22.00)		
Week 52 Mean (SD)	69.21 (19.10)	61.25 (18.84)		
Week 4 Adjusted Mean Change (SE)	14.23 (3.80)	3.95 (4.81)		
Week 12 Adjusted Mean Change (SE)	18.48 (3.89)	7.87 (4.92)		
Week 16 Adjusted Mean Change (SE)	18.77 (3.74)	10.06 (4.73)		
Week 24 Adjusted Mean Change (SE)	21.38 (4.22)	10.78 (5.34)		
Week 32 Adjusted Mean Change (SE)	22.13 (4.08)	5.03 (5.27)		
Week 40 Adjusted Mean Change (SE)	19.80 (4.12)	8.32 (5.28)		
Week 52 Adjusted Mean Change (SE)	18.71 (4.31)	11.05 (5.45)	7.66 [-6.08; 21.40]	0.272
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 45.14 SF-36 Mental Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.801</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	49.65 (23.32)	53.21 (21.62)		
Week 52 Mean (SD)	67.50 (21.67)	66.36 (20.53)		
Week 4 Adjusted Mean Change (SE)	13.97 (1.97)	11.28 (2.31)		
Week 12 Adjusted Mean Change (SE)	15.67 (2.04)	12.80 (2.39)		
Week 16 Adjusted Mean Change (SE)	15.67 (1.91)	12.45 (2.26)		
Week 24 Adjusted Mean Change (SE)	16.98 (2.22)	12.50 (2.65)		
Week 32 Adjusted Mean Change (SE)	16.88 (2.15)	10.59 (2.54)		
Week 40 Adjusted Mean Change (SE)	14.53 (2.17)	12.47 (2.61)		
Week 52 Adjusted Mean Change (SE)	18.23 (2.24)	14.92 (2.69)	3.31 [-3.61; 10.24]	0.346
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	45.00 (16.07)	49.50 (11.89)		
Week 52 Mean (SD)	63.85 (25.18)	61.00 (20.66)		
Week 4 Adjusted Mean Change (SE)	10.30 (4.63)	6.50 (5.25)		
Week 12 Adjusted Mean Change (SE)	14.53 (4.88)	5.53 (5.40)		
Week 16 Adjusted Mean Change (SE)	5.29 (4.47)	9.54 (5.08)		
Week 24 Adjusted Mean Change (SE)	11.30 (5.15)	8.53 (5.85)		
Week 32 Adjusted Mean Change (SE)	15.35 (4.93)	16.51 (5.59)		
Week 40 Adjusted Mean Change (SE)	15.25 (5.03)	16.04 (5.71)		
Week 52 Adjusted Mean Change (SE)	15.72 (5.14)	11.51 (5.84)	4.22 [-11.19; 19.62]	0.589
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 45.15 SF-36 Mental Health - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.802</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	50.45 (26.41)	55.77 (20.13)		
Week 52 Mean (SD)	71.05 (22.77)	64.17 (24.87)		
Week 4 Adjusted Mean Change (SE)	14.08 (3.54)	13.71 (3.36)		
Week 12 Adjusted Mean Change (SE)	17.25 (3.65)	14.98 (3.47)		
Week 16 Adjusted Mean Change (SE)	16.34 (3.51)	10.52 (3.32)		
Week 24 Adjusted Mean Change (SE)	15.00 (4.03)	9.14 (3.85)		
Week 32 Adjusted Mean Change (SE)	18.08 (3.93)	12.45 (3.76)		
Week 40 Adjusted Mean Change (SE)	11.34 (3.91)	9.20 (3.77)		
Week 52 Adjusted Mean Change (SE)	21.19 (4.13)	13.15 (4.06)	8.04 [-3.42; 19.49]	0.168
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	48.25 (20.77)	52.07 (20.37)		
Week 52 Mean (SD)	65.74 (21.83)	66.28 (18.84)		
Week 4 Adjusted Mean Change (SE)	13.00 (2.09)	8.30 (2.60)		
Week 12 Adjusted Mean Change (SE)	14.58 (2.18)	8.94 (2.70)		
Week 16 Adjusted Mean Change (SE)	13.21 (2.05)	13.64 (2.56)		
Week 24 Adjusted Mean Change (SE)	16.34 (2.33)	13.43 (2.94)		
Week 32 Adjusted Mean Change (SE)	15.91 (2.28)	10.40 (2.86)		
Week 40 Adjusted Mean Change (SE)	15.76 (2.25)	15.26 (2.85)		
Week 52 Adjusted Mean Change (SE)	16.75 (2.36)	14.30 (2.95)	2.45 [-5.04; 9.94]	0.519
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 45.16 SF-36 Mental Health - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.251</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	48.73 (19.77)	54.29 (17.95)		
Week 52 Mean (SD)	66.94 (24.72)	65.74 (17.69)		
Week 4 Adjusted Mean Change (SE)	12.63 (2.34)	11.60 (2.87)		
Week 12 Adjusted Mean Change (SE)	13.64 (2.41)	14.90 (2.94)		
Week 16 Adjusted Mean Change (SE)	13.07 (2.29)	14.27 (2.83)		
Week 24 Adjusted Mean Change (SE)	14.84 (2.60)	12.56 (3.26)		
Week 32 Adjusted Mean Change (SE)	16.95 (2.53)	14.23 (3.15)		
Week 40 Adjusted Mean Change (SE)	13.75 (2.55)	14.05 (3.20)		
Week 52 Adjusted Mean Change (SE)	17.24 (2.66)	14.25 (3.41)	2.99 [-5.57; 11.55]	0.491
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	48.97 (25.78)	52.66 (22.68)		
Week 52 Mean (SD)	67.10 (17.31)	65.50 (23.43)		
Week 4 Adjusted Mean Change (SE)	14.26 (2.86)	8.99 (2.94)		
Week 12 Adjusted Mean Change (SE)	17.76 (2.96)	7.32 (3.04)		
Week 16 Adjusted Mean Change (SE)	15.35 (2.82)	10.60 (2.90)		
Week 24 Adjusted Mean Change (SE)	17.89 (3.22)	11.21 (3.35)		
Week 32 Adjusted Mean Change (SE)	15.70 (3.14)	7.98 (3.24)		
Week 40 Adjusted Mean Change (SE)	16.13 (3.12)	12.15 (3.28)		
Week 52 Adjusted Mean Change (SE)	18.61 (3.29)	13.36 (3.38)	5.25 [-4.10; 14.60]	0.269
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 45.17 SF-36 Mental Health - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.412</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	46.50 (22.40)	55.32 (19.01)		
Week 52 Mean (SD)	67.41 (19.35)	69.09 (23.08)		
Week 4 Adjusted Mean Change (SE)	11.04 (3.02)	13.91 (3.04)		
Week 12 Adjusted Mean Change (SE)	16.26 (3.10)	16.47 (3.15)		
Week 16 Adjusted Mean Change (SE)	14.58 (2.97)	15.03 (3.02)		
Week 24 Adjusted Mean Change (SE)	14.01 (3.44)	10.40 (3.57)		
Week 32 Adjusted Mean Change (SE)	16.29 (3.31)	12.95 (3.45)		
Week 40 Adjusted Mean Change (SE)	12.76 (3.33)	11.16 (3.49)		
Week 52 Adjusted Mean Change (SE)	18.47 (3.45)	15.28 (3.72)	3.19 [-6.88; 13.26]	0.533
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	50.09 (22.23)	51.94 (21.32)		
Week 52 Mean (SD)	66.76 (23.60)	63.43 (19.13)		
Week 4 Adjusted Mean Change (SE)	14.49 (2.22)	7.41 (2.76)		
Week 12 Adjusted Mean Change (SE)	14.74 (2.31)	7.04 (2.83)		
Week 16 Adjusted Mean Change (SE)	13.64 (2.20)	10.37 (2.73)		
Week 24 Adjusted Mean Change (SE)	17.12 (2.51)	12.62 (3.11)		
Week 32 Adjusted Mean Change (SE)	16.58 (2.46)	9.63 (3.03)		
Week 40 Adjusted Mean Change (SE)	15.76 (2.45)	14.27 (3.05)		
Week 52 Adjusted Mean Change (SE)	17.35 (2.56)	12.78 (3.14)	4.58 [-3.44; 12.60]	0.261
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 45.18 SF-36 Mental Health - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.996</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	47.44 (23.56)	52.79 (20.57)		
Week 52 Mean (SD)	64.10 (24.49)	64.62 (22.84)		
Week 4 Adjusted Mean Change (SE)	15.37 (2.54)	10.74 (2.53)		
Week 12 Adjusted Mean Change (SE)	15.53 (2.66)	11.39 (2.66)		
Week 16 Adjusted Mean Change (SE)	13.68 (2.51)	10.85 (2.50)		
Week 24 Adjusted Mean Change (SE)	15.26 (2.87)	11.14 (2.89)		
Week 32 Adjusted Mean Change (SE)	16.34 (2.82)	11.78 (2.81)		
Week 40 Adjusted Mean Change (SE)	13.62 (2.80)	12.89 (2.82)		
Week 52 Adjusted Mean Change (SE)	15.82 (2.93)	14.17 (2.93)	1.64 [-6.55; 9.84]	0.692
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	50.24 (20.95)	54.79 (19.92)		
Week 52 Mean (SD)	69.76 (19.30)	67.78 (15.55)		
Week 4 Adjusted Mean Change (SE)	11.17 (2.57)	9.50 (3.48)		
Week 12 Adjusted Mean Change (SE)	15.07 (2.69)	10.96 (3.62)		
Week 16 Adjusted Mean Change (SE)	14.27 (2.51)	15.62 (3.44)		
Week 24 Adjusted Mean Change (SE)	16.80 (2.87)	13.32 (3.98)		
Week 32 Adjusted Mean Change (SE)	16.67 (2.78)	10.16 (3.87)		
Week 40 Adjusted Mean Change (SE)	15.76 (2.79)	13.64 (3.95)		
Week 52 Adjusted Mean Change (SE)	19.63 (2.90)	13.34 (4.15)	6.29 [-3.73; 16.31]	0.217
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 45.19 SF-36 Mental Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.510</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	50.23 (21.13)	53.37 (19.59)		
Week 52 Mean (SD)	66.80 (21.83)	63.75 (20.78)		
Week 4 Adjusted Mean Change (SE)	13.12 (2.05)	9.34 (2.39)		
Week 12 Adjusted Mean Change (SE)	12.76 (2.12)	9.54 (2.46)		
Week 16 Adjusted Mean Change (SE)	13.54 (2.03)	10.48 (2.37)		
Week 24 Adjusted Mean Change (SE)	16.34 (2.29)	8.96 (2.73)		
Week 32 Adjusted Mean Change (SE)	15.63 (2.21)	10.61 (2.60)		
Week 40 Adjusted Mean Change (SE)	14.09 (2.24)	10.69 (2.67)		
Week 52 Adjusted Mean Change (SE)	17.28 (2.37)	12.29 (2.84)	4.99 [-2.34; 12.31]	0.180
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	46.39 (25.83)	53.89 (22.40)		
Week 52 Mean (SD)	69.12 (23.93)	70.00 (20.54)		
Week 4 Adjusted Mean Change (SE)	11.09 (3.93)	12.13 (3.90)		
Week 12 Adjusted Mean Change (SE)	22.70 (4.01)	15.02 (3.98)		
Week 16 Adjusted Mean Change (SE)	13.98 (3.87)	17.16 (3.89)		
Week 24 Adjusted Mean Change (SE)	15.24 (4.47)	18.89 (4.39)		
Week 32 Adjusted Mean Change (SE)	19.23 (4.22)	12.21 (4.25)		
Week 40 Adjusted Mean Change (SE)	16.87 (4.32)	19.18 (4.38)		
Week 52 Adjusted Mean Change (SE)	18.91 (4.54)	17.53 (4.51)	1.38 [-11.28; 14.03]	0.830
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 46.0 SF-36 Physical Functioning - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

#### 46.1 SF-36 Physical Functioning - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	42.09 (24.57)	40.50 (26.90)		
Week 52 Mean (SD)	65.52 (27.26)	63.72 (27.94)		
Week 4 Adjusted Mean Change (SE)	12.92 (1.65)	12.09 (1.74)		
Week 12 Adjusted Mean Change (SE)	19.06 (1.93)	16.50 (2.03)		
Week 16 Adjusted Mean Change (SE)	20.42 (1.93)	15.85 (2.04)		
Week 24 Adjusted Mean Change (SE)	21.28 (2.03)	18.71 (2.17)		
Week 32 Adjusted Mean Change (SE)	22.68 (2.11)	20.10 (2.27)		
Week 40 Adjusted Mean Change (SE)	24.15 (2.05)	19.26 (2.23)		
Week 52 Adjusted Mean Change (SE)	23.72 (2.20)	21.08 (2.40)	2.64 [-3.78; 9.07]	0.418
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 46.2 SF-36 Physical Functioning - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.969</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	41.07 (24.34)	40.75 (27.13)		
Week 52 Mean (SD)	65.05 (27.26)	64.34 (28.00)		
Week 4 Adjusted Mean Change (SE)	13.50 (1.70)	12.40 (1.80)		
Week 12 Adjusted Mean Change (SE)	19.58 (2.00)	17.00 (2.10)		
Week 16 Adjusted Mean Change (SE)	20.86 (1.99)	16.42 (2.12)		
Week 24 Adjusted Mean Change (SE)	21.46 (2.10)	19.22 (2.26)		
Week 32 Adjusted Mean Change (SE)	23.37 (2.18)	20.88 (2.35)		
Week 40 Adjusted Mean Change (SE)	24.63 (2.13)	19.73 (2.32)		
Week 52 Adjusted Mean Change (SE)	24.25 (2.27)	22.00 (2.49)	2.25 [-4.40; 8.89]	0.505
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	57.14 (24.81)	37.15 (25.31)		
Week 52 Mean (SD)	73.33 (28.58)	55.83 (28.36)		
Week 4 Adjusted Mean Change (SE)	4.43 (6.58)	8.04 (6.54)		
Week 12 Adjusted Mean Change (SE)	11.33 (7.66)	9.87 (7.61)		
Week 16 Adjusted Mean Change (SE)	13.75 (7.89)	8.49 (7.63)		
Week 24 Adjusted Mean Change (SE)	18.47 (8.08)	12.02 (8.03)		
Week 32 Adjusted Mean Change (SE)	12.88 (8.32)	10.55 (8.27)		
Week 40 Adjusted Mean Change (SE)	17.10 (8.15)	13.05 (8.09)		
Week 52 Adjusted Mean Change (SE)	16.08 (8.91)	9.39 (8.85)	6.69 [-18.08; 31.47]	0.595
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 46.3 SF-36 Physical Functioning - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.604</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	45.38 (25.50)	46.84 (26.21)		
Week 52 Mean (SD)	69.45 (27.02)	70.10 (27.04)		
Week 4 Adjusted Mean Change (SE)	16.52 (2.16)	14.53 (2.30)		
Week 12 Adjusted Mean Change (SE)	21.42 (2.51)	20.47 (2.67)		
Week 16 Adjusted Mean Change (SE)	22.91 (2.50)	19.87 (2.67)		
Week 24 Adjusted Mean Change (SE)	23.70 (2.63)	22.08 (2.85)		
Week 32 Adjusted Mean Change (SE)	25.24 (2.72)	24.56 (2.98)		
Week 40 Adjusted Mean Change (SE)	26.75 (2.65)	23.98 (2.91)		
Week 52 Adjusted Mean Change (SE)	26.47 (2.83)	25.27 (3.14)	1.20 [-7.06; 9.46]	0.775
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	37.16 (22.50)	32.27 (25.80)		
Week 52 Mean (SD)	59.39 (26.81)	54.71 (27.05)		
Week 4 Adjusted Mean Change (SE)	7.68 (2.64)	8.78 (2.65)		
Week 12 Adjusted Mean Change (SE)	15.66 (3.07)	11.18 (3.09)		
Week 16 Adjusted Mean Change (SE)	16.84 (3.05)	10.39 (3.12)		
Week 24 Adjusted Mean Change (SE)	17.79 (3.27)	14.20 (3.35)		
Week 32 Adjusted Mean Change (SE)	18.99 (3.37)	14.13 (3.45)		
Week 40 Adjusted Mean Change (SE)	20.38 (3.27)	12.90 (3.41)		
Week 52 Adjusted Mean Change (SE)	19.75 (3.50)	15.47 (3.68)	4.27 [-5.63; 14.17]	0.396
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



#### 46.4 SF-36 Physical Functioning - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.800</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	62.29 (22.16)	71.19 (24.79)		
Week 52 Mean (SD)	74.78 (23.52)	76.76 (25.18)		
Week 4 Adjusted Mean Change (SE)	14.57 (3.75)	11.13 (4.13)		
Week 12 Adjusted Mean Change (SE)	14.92 (4.42)	14.82 (4.80)		
Week 16 Adjusted Mean Change (SE)	16.73 (4.36)	17.47 (4.81)		
Week 24 Adjusted Mean Change (SE)	16.56 (4.62)	14.12 (5.11)		
Week 32 Adjusted Mean Change (SE)	16.82 (4.78)	16.19 (5.38)		
Week 40 Adjusted Mean Change (SE)	21.43 (4.69)	17.75 (5.31)		
Week 52 Adjusted Mean Change (SE)	20.72 (4.99)	18.12 (5.70)	2.59 [-11.47; 16.66]	0.717
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	36.45 (22.23)	32.44 (21.08)		
Week 52 Mean (SD)	62.93 (27.80)	60.31 (27.79)		
Week 4 Adjusted Mean Change (SE)	12.46 (1.89)	12.35 (2.03)		
Week 12 Adjusted Mean Change (SE)	20.16 (2.21)	16.99 (2.36)		
Week 16 Adjusted Mean Change (SE)	21.44 (2.21)	15.38 (2.38)		
Week 24 Adjusted Mean Change (SE)	22.55 (2.31)	19.97 (2.52)		
Week 32 Adjusted Mean Change (SE)	24.26 (2.41)	21.17 (2.61)		
Week 40 Adjusted Mean Change (SE)	24.89 (2.35)	19.70 (2.58)		
Week 52 Adjusted Mean Change (SE)	24.53 (2.52)	21.89 (2.78)	2.64 [-4.64; 9.92]	0.475
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 46.5 SF-36 Physical Functioning - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.366</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	43.69 (23.87)	36.67 (27.40)		
Week 52 Mean (SD)	64.62 (27.85)	66.84 (28.20)		
Week 4 Adjusted Mean Change (SE)	14.44 (2.65)	15.86 (2.43)		
Week 12 Adjusted Mean Change (SE)	19.77 (3.12)	19.34 (2.85)		
Week 16 Adjusted Mean Change (SE)	18.75 (3.11)	18.50 (2.88)		
Week 24 Adjusted Mean Change (SE)	22.35 (3.32)	19.56 (3.09)		
Week 32 Adjusted Mean Change (SE)	23.63 (3.44)	21.84 (3.22)		
Week 40 Adjusted Mean Change (SE)	22.94 (3.36)	19.95 (3.22)		
Week 52 Adjusted Mean Change (SE)	22.29 (3.58)	24.14 (3.45)	-1.85 [-11.68; 7.98]	0.711
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	41.10 (25.12)	44.40 (26.08)		
Week 52 Mean (SD)	66.06 (27.11)	61.02 (27.76)		
Week 4 Adjusted Mean Change (SE)	11.98 (2.09)	8.25 (2.46)		
Week 12 Adjusted Mean Change (SE)	18.60 (2.46)	13.59 (2.89)		
Week 16 Adjusted Mean Change (SE)	21.47 (2.45)	13.15 (2.89)		
Week 24 Adjusted Mean Change (SE)	20.64 (2.59)	17.77 (3.10)		
Week 32 Adjusted Mean Change (SE)	22.10 (2.70)	18.26 (3.22)		
Week 40 Adjusted Mean Change (SE)	24.86 (2.63)	18.32 (3.14)		
Week 52 Adjusted Mean Change (SE)	24.55 (2.78)	18.15 (3.35)	6.41 [-2.20; 15.01]	0.144
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 46.6 SF-36 Physical Functioning - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.081</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	42.71 (22.80)	44.70 (27.92)		
Week 52 Mean (SD)	69.14 (26.17)	68.89 (27.15)		
Week 4 Adjusted Mean Change (SE)	14.94 (2.03)	12.15 (2.47)		
Week 12 Adjusted Mean Change (SE)	21.99 (2.38)	15.04 (2.86)		
Week 16 Adjusted Mean Change (SE)	23.92 (2.36)	16.69 (2.88)		
Week 24 Adjusted Mean Change (SE)	24.28 (2.48)	20.17 (3.10)		
Week 32 Adjusted Mean Change (SE)	24.67 (2.61)	18.89 (3.28)		
Week 40 Adjusted Mean Change (SE)	27.67 (2.50)	20.23 (3.22)		
Week 52 Adjusted Mean Change (SE)	26.50 (2.71)	18.24 (3.54)	8.26 [-0.52; 17.03]	0.065
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	40.92 (27.92)	36.54 (25.54)		
Week 52 Mean (SD)	58.29 (28.34)	59.67 (28.17)		
Week 4 Adjusted Mean Change (SE)	9.11 (2.80)	12.03 (2.45)		
Week 12 Adjusted Mean Change (SE)	13.55 (3.24)	17.96 (2.85)		
Week 16 Adjusted Mean Change (SE)	13.82 (3.23)	15.06 (2.84)		
Week 24 Adjusted Mean Change (SE)	15.55 (3.46)	17.36 (3.02)		
Week 32 Adjusted Mean Change (SE)	18.98 (3.62)	21.14 (3.17)		
Week 40 Adjusted Mean Change (SE)	17.43 (3.47)	18.62 (3.06)		
Week 52 Adjusted Mean Change (SE)	18.44 (3.78)	23.35 (3.32)	-4.91 [-14.82; 5.00]	0.330
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 46.7 SF-36 Physical Functioning - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.385</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	45.29 (27.10)	46.56 (27.72)		
Week 52 Mean (SD)	68.57 (27.74)	70.20 (28.78)		
Week 4 Adjusted Mean Change (SE)	11.75 (2.43)	14.55 (3.13)		
Week 12 Adjusted Mean Change (SE)	19.99 (2.87)	17.94 (3.67)		
Week 16 Adjusted Mean Change (SE)	18.69 (2.81)	21.83 (3.63)		
Week 24 Adjusted Mean Change (SE)	19.30 (2.99)	19.54 (3.88)		
Week 32 Adjusted Mean Change (SE)	21.58 (3.12)	20.79 (4.05)		
Week 40 Adjusted Mean Change (SE)	24.66 (3.03)	22.48 (3.96)		
Week 52 Adjusted Mean Change (SE)	25.33 (3.24)	24.01 (4.33)	1.31 [-9.31; 11.94]	0.808
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	39.32 (22.02)	37.68 (26.24)		
Week 52 Mean (SD)	62.86 (26.80)	60.88 (27.34)		
Week 4 Adjusted Mean Change (SE)	13.95 (2.26)	10.96 (2.11)		
Week 12 Adjusted Mean Change (SE)	18.34 (2.64)	15.80 (2.46)		
Week 16 Adjusted Mean Change (SE)	21.95 (2.62)	13.11 (2.45)		
Week 24 Adjusted Mean Change (SE)	23.02 (2.79)	18.38 (2.65)		
Week 32 Adjusted Mean Change (SE)	23.66 (2.91)	19.83 (2.78)		
Week 40 Adjusted Mean Change (SE)	23.71 (2.82)	17.76 (2.73)		
Week 52 Adjusted Mean Change (SE)	22.35 (3.02)	19.75 (2.92)	2.60 [-5.68; 10.87]	0.537
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 46.8 SF-36 Physical Functioning - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.740</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	38.14 (25.24)	44.63 (26.30)		
Week 52 Mean (SD)	64.18 (28.11)	67.78 (29.14)		
Week 4 Adjusted Mean Change (SE)	15.32 (2.39)	16.22 (2.66)		
Week 12 Adjusted Mean Change (SE)	21.70 (2.84)	18.05 (3.18)		
Week 16 Adjusted Mean Change (SE)	24.42 (2.77)	17.33 (3.11)		
Week 24 Adjusted Mean Change (SE)	25.64 (3.07)	20.07 (3.47)		
Week 32 Adjusted Mean Change (SE)	26.10 (3.15)	22.56 (3.57)		
Week 40 Adjusted Mean Change (SE)	25.76 (2.96)	22.87 (3.36)		
Week 52 Adjusted Mean Change (SE)	25.69 (3.23)	25.52 (3.67)	0.17 [-9.51; 9.84]	0.973
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	44.12 (22.95)	41.35 (32.30)		
Week 52 Mean (SD)	68.23 (27.46)	68.09 (29.05)		
Week 4 Adjusted Mean Change (SE)	11.62 (2.92)	10.39 (3.40)		
Week 12 Adjusted Mean Change (SE)	20.64 (3.52)	15.04 (4.05)		
Week 16 Adjusted Mean Change (SE)	17.64 (3.40)	17.21 (3.95)		
Week 24 Adjusted Mean Change (SE)	15.25 (3.77)	18.78 (4.43)		
Week 32 Adjusted Mean Change (SE)	19.77 (3.91)	21.68 (4.56)		
Week 40 Adjusted Mean Change (SE)	22.54 (3.65)	19.66 (4.36)		
Week 52 Adjusted Mean Change (SE)	23.20 (3.99)	19.68 (4.75)	3.52 [-8.73; 15.77]	0.571
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 46.9 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.527</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	42.11 (25.33)	39.44 (26.18)		
Week 52 Mean (SD)	67.33 (27.26)	63.95 (28.99)		
Week 4 Adjusted Mean Change (SE)	16.07 (2.56)	13.16 (3.37)		
Week 12 Adjusted Mean Change (SE)	23.86 (3.07)	16.76 (4.04)		
Week 16 Adjusted Mean Change (SE)	22.34 (3.01)	15.83 (3.99)		
Week 24 Adjusted Mean Change (SE)	23.05 (3.39)	17.62 (4.54)		
Week 32 Adjusted Mean Change (SE)	23.45 (3.45)	23.26 (4.65)		
Week 40 Adjusted Mean Change (SE)	24.75 (3.22)	22.01 (4.37)		
Week 52 Adjusted Mean Change (SE)	25.08 (3.52)	22.63 (4.93)	2.45 [-9.54; 14.44]	0.686
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	38.68 (23.07)	43.33 (29.84)		
Week 52 Mean (SD)	63.86 (28.16)	70.00 (28.54)		
Week 4 Adjusted Mean Change (SE)	10.95 (2.78)	17.23 (3.13)		
Week 12 Adjusted Mean Change (SE)	19.17 (3.38)	17.79 (3.79)		
Week 16 Adjusted Mean Change (SE)	21.90 (3.29)	20.52 (3.71)		
Week 24 Adjusted Mean Change (SE)	20.36 (3.70)	21.64 (4.20)		
Week 32 Adjusted Mean Change (SE)	24.75 (3.78)	22.32 (4.27)		
Week 40 Adjusted Mean Change (SE)	25.46 (3.49)	22.92 (4.03)		
Week 52 Adjusted Mean Change (SE)	24.81 (3.85)	25.58 (4.35)	-0.76 [-12.29; 10.76]	0.896
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 46.10 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.609</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	35.50 (25.68)	40.61 (30.54)		
Week 52 Mean (SD)	63.28 (27.98)	70.00 (30.29)		
Week 4 Adjusted Mean Change (SE)	13.94 (3.17)	15.48 (3.06)		
Week 12 Adjusted Mean Change (SE)	22.10 (3.67)	19.29 (3.56)		
Week 16 Adjusted Mean Change (SE)	22.27 (3.66)	19.38 (3.55)		
Week 24 Adjusted Mean Change (SE)	23.05 (4.13)	21.36 (4.06)		
Week 32 Adjusted Mean Change (SE)	24.98 (4.15)	22.47 (4.11)		
Week 40 Adjusted Mean Change (SE)	24.26 (3.89)	24.19 (3.88)		
Week 52 Adjusted Mean Change (SE)	25.32 (4.22)	24.78 (4.33)	0.54 [-11.42; 12.51]	0.929
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	41.08 (22.01)	46.03 (26.74)		
Week 52 Mean (SD)	65.92 (27.66)	66.36 (28.13)		
Week 4 Adjusted Mean Change (SE)	14.41 (2.42)	12.84 (2.98)		
Week 12 Adjusted Mean Change (SE)	22.47 (2.83)	14.91 (3.45)		
Week 16 Adjusted Mean Change (SE)	22.15 (2.79)	15.60 (3.46)		
Week 24 Adjusted Mean Change (SE)	21.47 (3.11)	18.13 (3.85)		
Week 32 Adjusted Mean Change (SE)	24.08 (3.17)	22.15 (3.91)		
Week 40 Adjusted Mean Change (SE)	25.88 (2.95)	19.69 (3.68)		
Week 52 Adjusted Mean Change (SE)	25.48 (3.22)	22.29 (3.96)	3.19 [-6.91; 13.30]	0.533
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 46.11 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.436</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	39.65 (24.58)	48.02 (28.75)		
Week 52 Mean (SD)	66.15 (28.43)	67.56 (29.24)		
Week 4 Adjusted Mean Change (SE)	16.08 (2.62)	13.61 (2.63)		
Week 12 Adjusted Mean Change (SE)	22.46 (3.11)	16.21 (3.12)		
Week 16 Adjusted Mean Change (SE)	21.02 (3.05)	15.54 (3.06)		
Week 24 Adjusted Mean Change (SE)	22.10 (3.39)	17.11 (3.43)		
Week 32 Adjusted Mean Change (SE)	25.26 (3.48)	21.01 (3.51)		
Week 40 Adjusted Mean Change (SE)	23.83 (3.25)	20.63 (3.30)		
Week 52 Adjusted Mean Change (SE)	25.09 (3.57)	22.84 (3.59)	2.25 [-7.77; 12.28]	0.658
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	41.43 (24.45)	35.00 (26.87)		
Week 52 Mean (SD)	65.37 (27.44)	68.61 (28.79)		
Week 4 Adjusted Mean Change (SE)	11.55 (2.65)	14.76 (3.58)		
Week 12 Adjusted Mean Change (SE)	19.97 (3.14)	18.22 (4.23)		
Week 16 Adjusted Mean Change (SE)	22.37 (3.07)	20.61 (4.18)		
Week 24 Adjusted Mean Change (SE)	20.96 (3.41)	24.17 (4.68)		
Week 32 Adjusted Mean Change (SE)	21.92 (3.47)	24.51 (4.79)		
Week 40 Adjusted Mean Change (SE)	25.08 (3.26)	23.63 (4.58)		
Week 52 Adjusted Mean Change (SE)	24.22 (3.55)	24.12 (5.04)	0.10 [-12.08; 12.29]	0.986
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 46.12 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.438</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	39.44 (24.31)	44.36 (30.76)		
Week 52 Mean (SD)	63.54 (27.93)	68.55 (27.70)		
Week 4 Adjusted Mean Change (SE)	13.49 (2.17)	13.23 (2.50)		
Week 12 Adjusted Mean Change (SE)	19.66 (2.60)	15.55 (2.98)		
Week 16 Adjusted Mean Change (SE)	20.98 (2.54)	16.17 (2.93)		
Week 24 Adjusted Mean Change (SE)	22.22 (2.83)	18.55 (3.32)		
Week 32 Adjusted Mean Change (SE)	22.42 (2.90)	21.37 (3.39)		
Week 40 Adjusted Mean Change (SE)	24.83 (2.70)	20.44 (3.19)		
Week 52 Adjusted Mean Change (SE)	23.79 (2.94)	22.89 (3.50)	0.89 [-8.16; 9.94]	0.846
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	43.25 (26.17)	45.28 (20.18)		
Week 52 Mean (SD)	71.84 (28.44)	74.12 (23.67)		
Week 4 Adjusted Mean Change (SE)	12.59 (3.84)	17.20 (4.00)		
Week 12 Adjusted Mean Change (SE)	23.43 (4.56)	22.30 (4.82)		
Week 16 Adjusted Mean Change (SE)	23.14 (4.47)	21.77 (4.71)		
Week 24 Adjusted Mean Change (SE)	19.62 (5.05)	24.93 (5.30)		
Week 32 Adjusted Mean Change (SE)	23.81 (5.13)	27.01 (5.42)		
Week 40 Adjusted Mean Change (SE)	22.83 (4.79)	27.47 (5.07)		
Week 52 Adjusted Mean Change (SE)	26.29 (5.18)	28.46 (5.43)	-2.17 [-17.01; 12.67]	0.773
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 46.13 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.617</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	40.48 (25.73)	45.88 (29.12)		
Week 52 Mean (SD)	65.26 (26.92)	72.02 (27.67)		
Week 4 Adjusted Mean Change (SE)	11.83 (2.06)	15.09 (2.33)		
Week 12 Adjusted Mean Change (SE)	19.87 (2.47)	17.93 (2.80)		
Week 16 Adjusted Mean Change (SE)	19.92 (2.47)	18.42 (2.80)		
Week 24 Adjusted Mean Change (SE)	19.25 (2.75)	19.89 (3.13)		
Week 32 Adjusted Mean Change (SE)	22.18 (2.79)	23.34 (3.18)		
Week 40 Adjusted Mean Change (SE)	22.95 (2.67)	23.96 (3.06)		
Week 52 Adjusted Mean Change (SE)	24.31 (2.90)	26.09 (3.34)	-1.78 [-10.55; 6.98]	0.688
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	42.90 (20.71)	33.33 (21.78)		
Week 52 Mean (SD)	66.05 (31.87)	57.92 (28.08)		
Week 4 Adjusted Mean Change (SE)	16.98 (3.76)	14.53 (4.79)		
Week 12 Adjusted Mean Change (SE)	21.76 (4.49)	19.51 (5.71)		
Week 16 Adjusted Mean Change (SE)	25.17 (4.48)	19.25 (5.71)		
Week 24 Adjusted Mean Change (SE)	23.34 (4.95)	23.28 (6.30)		
Week 32 Adjusted Mean Change (SE)	23.35 (5.02)	25.79 (6.46)		
Week 40 Adjusted Mean Change (SE)	26.61 (4.80)	17.41 (6.19)		
Week 52 Adjusted Mean Change (SE)	23.18 (5.18)	19.78 (6.58)	3.40 [-13.17; 19.96]	0.685
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 46.14 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.140</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	41.83 (23.04)	40.76 (28.44)		
Week 52 Mean (SD)	66.59 (26.52)	68.75 (28.43)		
Week 4 Adjusted Mean Change (SE)	14.00 (2.03)	16.52 (2.37)		
Week 12 Adjusted Mean Change (SE)	21.47 (2.37)	19.10 (2.77)		
Week 16 Adjusted Mean Change (SE)	21.21 (2.34)	18.97 (2.74)		
Week 24 Adjusted Mean Change (SE)	21.73 (2.63)	21.33 (3.10)		
Week 32 Adjusted Mean Change (SE)	23.76 (2.67)	24.80 (3.15)		
Week 40 Adjusted Mean Change (SE)	24.80 (2.47)	23.86 (2.96)		
Week 52 Adjusted Mean Change (SE)	24.80 (2.72)	25.70 (3.25)	-0.90 [-9.28; 7.48]	0.832
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	33.85 (31.70)	56.50 (30.00)		
Week 52 Mean (SD)	60.77 (34.99)	63.50 (27.99)		
Week 4 Adjusted Mean Change (SE)	12.43 (4.77)	4.88 (5.46)		
Week 12 Adjusted Mean Change (SE)	20.21 (5.65)	4.58 (6.36)		
Week 16 Adjusted Mean Change (SE)	24.87 (5.48)	5.35 (6.28)		
Week 24 Adjusted Mean Change (SE)	20.39 (6.13)	10.33 (7.03)		
Week 32 Adjusted Mean Change (SE)	22.30 (6.18)	10.36 (7.09)		
Week 40 Adjusted Mean Change (SE)	21.16 (5.76)	11.26 (6.60)		
Week 52 Adjusted Mean Change (SE)	23.14 (6.28)	12.65 (7.19)	10.49 [-8.56; 29.54]	0.278
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 46.15 SF-36 Physical Functioning - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.947</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	44.77 (30.37)	41.92 (31.72)		
Week 52 Mean (SD)	66.58 (29.35)	63.05 (33.70)		
Week 4 Adjusted Mean Change (SE)	12.30 (3.66)	12.46 (3.45)		
Week 12 Adjusted Mean Change (SE)	18.20 (4.31)	16.15 (4.05)		
Week 16 Adjusted Mean Change (SE)	17.34 (4.25)	14.65 (4.00)		
Week 24 Adjusted Mean Change (SE)	22.80 (4.79)	16.97 (4.53)		
Week 32 Adjusted Mean Change (SE)	22.64 (4.89)	19.52 (4.64)		
Week 40 Adjusted Mean Change (SE)	22.37 (4.59)	19.47 (4.39)		
Week 52 Adjusted Mean Change (SE)	20.46 (5.03)	21.43 (4.92)	-0.97 [-14.87; 12.94]	0.891
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	39.05 (22.01)	44.27 (26.78)		
Week 52 Mean (SD)	65.49 (27.49)	70.13 (26.49)		
Week 4 Adjusted Mean Change (SE)	14.38 (2.17)	14.96 (2.69)		
Week 12 Adjusted Mean Change (SE)	22.28 (2.57)	17.34 (3.18)		
Week 16 Adjusted Mean Change (SE)	23.17 (2.50)	18.94 (3.11)		
Week 24 Adjusted Mean Change (SE)	21.18 (2.79)	21.15 (3.50)		
Week 32 Adjusted Mean Change (SE)	23.95 (2.84)	23.86 (3.56)		
Week 40 Adjusted Mean Change (SE)	25.21 (2.65)	22.98 (3.36)		
Week 52 Adjusted Mean Change (SE)	26.08 (2.89)	24.49 (3.61)	1.59 [-7.59; 10.76]	0.733
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 46.16 SF-36 Physical Functioning - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.762</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	42.35 (24.67)	42.14 (26.93)		
Week 52 Mean (SD)	66.63 (27.49)	67.41 (27.99)		
Week 4 Adjusted Mean Change (SE)	15.89 (2.40)	12.67 (2.93)		
Week 12 Adjusted Mean Change (SE)	23.03 (2.84)	17.76 (3.46)		
Week 16 Adjusted Mean Change (SE)	22.09 (2.78)	15.61 (3.42)		
Week 24 Adjusted Mean Change (SE)	22.68 (3.11)	18.40 (3.85)		
Week 32 Adjusted Mean Change (SE)	22.93 (3.17)	23.50 (3.94)		
Week 40 Adjusted Mean Change (SE)	24.42 (2.98)	22.75 (3.72)		
Week 52 Adjusted Mean Change (SE)	24.40 (3.23)	23.77 (4.12)	0.62 [-9.73; 10.98]	0.905
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	37.79 (24.06)	44.69 (30.66)		
Week 52 Mean (SD)	64.36 (28.57)	68.33 (30.07)		
Week 4 Adjusted Mean Change (SE)	10.75 (2.95)	15.47 (3.02)		
Week 12 Adjusted Mean Change (SE)	18.47 (3.50)	15.98 (3.59)		
Week 16 Adjusted Mean Change (SE)	21.17 (3.44)	19.16 (3.53)		
Week 24 Adjusted Mean Change (SE)	19.66 (3.84)	20.90 (3.97)		
Week 32 Adjusted Mean Change (SE)	24.59 (3.93)	20.90 (4.06)		
Week 40 Adjusted Mean Change (SE)	24.50 (3.66)	20.52 (3.83)		
Week 52 Adjusted Mean Change (SE)	25.09 (4.00)	22.85 (4.11)	2.24 [-9.16; 13.63]	0.699
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 46.17 SF-36 Physical Functioning - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.460</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	35.50 (25.68)	40.97 (31.40)		
Week 52 Mean (SD)	63.28 (27.98)	71.36 (31.29)		
Week 4 Adjusted Mean Change (SE)	13.86 (3.15)	16.18 (3.14)		
Week 12 Adjusted Mean Change (SE)	21.89 (3.68)	20.91 (3.69)		
Week 16 Adjusted Mean Change (SE)	22.14 (3.61)	21.70 (3.62)		
Week 24 Adjusted Mean Change (SE)	22.92 (4.08)	23.12 (4.15)		
Week 32 Adjusted Mean Change (SE)	24.80 (4.16)	22.91 (4.26)		
Week 40 Adjusted Mean Change (SE)	24.00 (3.87)	25.04 (4.00)		
Week 52 Adjusted Mean Change (SE)	25.09 (4.22)	24.75 (4.48)	0.34 [-11.84; 12.51]	0.956
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	43.27 (23.44)	45.42 (26.20)		
Week 52 Mean (SD)	67.16 (27.81)	65.71 (27.44)		
Week 4 Adjusted Mean Change (SE)	13.84 (2.31)	12.21 (2.87)		
Week 12 Adjusted Mean Change (SE)	20.86 (2.73)	13.59 (3.35)		
Week 16 Adjusted Mean Change (SE)	21.49 (2.66)	13.66 (3.31)		
Week 24 Adjusted Mean Change (SE)	20.78 (2.97)	16.61 (3.69)		
Week 32 Adjusted Mean Change (SE)	22.85 (3.07)	21.41 (3.80)		
Week 40 Adjusted Mean Change (SE)	24.72 (2.84)	18.85 (3.55)		
Week 52 Adjusted Mean Change (SE)	24.43 (3.12)	21.86 (3.83)	2.57 [-7.20; 12.34]	0.603
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 46.18 SF-36 Physical Functioning - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.436</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	39.65 (24.58)	48.02 (28.75)		
Week 52 Mean (SD)	66.15 (28.43)	67.56 (29.24)		
Week 4 Adjusted Mean Change (SE)	16.08 (2.62)	13.61 (2.63)		
Week 12 Adjusted Mean Change (SE)	22.46 (3.11)	16.21 (3.12)		
Week 16 Adjusted Mean Change (SE)	21.02 (3.05)	15.54 (3.06)		
Week 24 Adjusted Mean Change (SE)	22.10 (3.39)	17.11 (3.43)		
Week 32 Adjusted Mean Change (SE)	25.26 (3.48)	21.01 (3.51)		
Week 40 Adjusted Mean Change (SE)	23.83 (3.25)	20.63 (3.30)		
Week 52 Adjusted Mean Change (SE)	25.09 (3.57)	22.84 (3.59)	2.25 [-7.77; 12.28]	0.658
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	41.43 (24.45)	35.00 (26.87)		
Week 52 Mean (SD)	65.37 (27.44)	68.61 (28.79)		
Week 4 Adjusted Mean Change (SE)	11.55 (2.65)	14.76 (3.58)		
Week 12 Adjusted Mean Change (SE)	19.97 (3.14)	18.22 (4.23)		
Week 16 Adjusted Mean Change (SE)	22.37 (3.07)	20.61 (4.18)		
Week 24 Adjusted Mean Change (SE)	20.96 (3.41)	24.17 (4.68)		
Week 32 Adjusted Mean Change (SE)	21.92 (3.47)	24.51 (4.79)		
Week 40 Adjusted Mean Change (SE)	25.08 (3.26)	23.63 (4.58)		
Week 52 Adjusted Mean Change (SE)	24.22 (3.55)	24.12 (5.04)	0.10 [-12.08; 12.29]	0.986
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 46.19 SF-36 Physical Functioning - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.431</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	40.08 (24.08)	43.57 (30.79)		
Week 52 Mean (SD)	64.59 (27.72)	66.87 (29.08)		
Week 4 Adjusted Mean Change (SE)	13.60 (2.09)	13.01 (2.42)		
Week 12 Adjusted Mean Change (SE)	20.32 (2.53)	14.95 (2.93)		
Week 16 Adjusted Mean Change (SE)	20.97 (2.47)	15.67 (2.87)		
Week 24 Adjusted Mean Change (SE)	22.25 (2.75)	17.72 (3.25)		
Week 32 Adjusted Mean Change (SE)	23.10 (2.81)	20.38 (3.30)		
Week 40 Adjusted Mean Change (SE)	24.79 (2.62)	19.78 (3.11)		
Week 52 Adjusted Mean Change (SE)	24.48 (2.89)	22.06 (3.45)	2.42 [-6.49; 11.33]	0.592
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	43.06 (27.18)	42.78 (22.24)		
Week 52 Mean (SD)	72.06 (28.83)	70.29 (29.02)		
Week 4 Adjusted Mean Change (SE)	13.43 (3.99)	16.45 (3.95)		
Week 12 Adjusted Mean Change (SE)	22.12 (4.79)	21.79 (4.76)		
Week 16 Adjusted Mean Change (SE)	21.80 (4.70)	21.50 (4.71)		
Week 24 Adjusted Mean Change (SE)	20.22 (5.32)	24.09 (5.25)		
Week 32 Adjusted Mean Change (SE)	24.01 (5.38)	27.06 (5.39)		
Week 40 Adjusted Mean Change (SE)	23.77 (5.03)	26.50 (5.10)		
Week 52 Adjusted Mean Change (SE)	26.69 (5.51)	26.36 (5.49)	0.34 [-15.04; 15.72]	0.965
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



#### 47.0 SF-36 Role Emotional - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

#### 47.1 SF-36 Role Emotional - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	58.49 (28.42)	60.40 (24.56)		
Week 52 Mean (SD)	78.33 (23.76)	74.09 (25.15)		
Week 4 Adjusted Mean Change (SE)	11.61 (1.96)	12.97 (2.07)		
Week 12 Adjusted Mean Change (SE)	15.43 (1.97)	13.22 (2.06)		
Week 16 Adjusted Mean Change (SE)	16.34 (1.87)	13.54 (1.98)		
Week 24 Adjusted Mean Change (SE)	15.95 (2.11)	12.96 (2.27)		
Week 32 Adjusted Mean Change (SE)	17.78 (2.03)	13.36 (2.19)		
Week 40 Adjusted Mean Change (SE)	17.71 (2.10)	15.51 (2.31)		
Week 52 Adjusted Mean Change (SE)	19.58 (2.15)	15.47 (2.39)	4.11 [-2.24; 10.45]	0.203
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 47.2 SF-36 Role Emotional - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.561</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	57.44 (27.83)	60.73 (24.79)		
Week 52 Mean (SD)	77.78 (24.13)	74.67 (25.18)		
Week 4 Adjusted Mean Change (SE)	11.60 (2.03)	13.25 (2.15)		
Week 12 Adjusted Mean Change (SE)	15.73 (2.04)	13.90 (2.14)		
Week 16 Adjusted Mean Change (SE)	16.37 (1.94)	13.30 (2.07)		
Week 24 Adjusted Mean Change (SE)	15.78 (2.19)	12.97 (2.37)		
Week 32 Adjusted Mean Change (SE)	17.52 (2.11)	13.40 (2.29)		
Week 40 Adjusted Mean Change (SE)	17.17 (2.18)	16.12 (2.41)		
Week 52 Adjusted Mean Change (SE)	19.26 (2.23)	15.71 (2.49)	3.55 [-3.06; 10.16]	0.291
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	73.81 (34.84)	55.95 (22.42)		
Week 52 Mean (SD)	87.50 (14.67)	66.67 (25.82)		
Week 4 Adjusted Mean Change (SE)	11.79 (7.84)	9.24 (7.80)		
Week 12 Adjusted Mean Change (SE)	11.26 (7.78)	4.34 (7.73)		
Week 16 Adjusted Mean Change (SE)	15.61 (7.78)	16.39 (7.42)		
Week 24 Adjusted Mean Change (SE)	18.45 (8.38)	12.66 (8.33)		
Week 32 Adjusted Mean Change (SE)	21.28 (7.97)	12.57 (7.92)		
Week 40 Adjusted Mean Change (SE)	25.27 (8.28)	8.91 (8.23)		
Week 52 Adjusted Mean Change (SE)	24.35 (8.88)	12.59 (8.85)	11.76 [-12.99; 36.50]	0.350
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 47.3 SF-36 Role Emotional - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.845</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	63.76 (26.77)	63.89 (22.23)		
Week 52 Mean (SD)	82.29 (23.50)	74.83 (25.47)		
Week 4 Adjusted Mean Change (SE)	12.99 (2.58)	13.79 (2.77)		
Week 12 Adjusted Mean Change (SE)	15.80 (2.59)	15.66 (2.75)		
Week 16 Adjusted Mean Change (SE)	18.00 (2.46)	15.76 (2.62)		
Week 24 Adjusted Mean Change (SE)	17.38 (2.75)	13.68 (3.00)		
Week 32 Adjusted Mean Change (SE)	18.92 (2.65)	16.17 (2.91)		
Week 40 Adjusted Mean Change (SE)	18.23 (2.74)	19.21 (3.04)		
Week 52 Adjusted Mean Change (SE)	21.53 (2.81)	14.78 (3.15)	6.75 [-1.51; 15.01]	0.109
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	50.57 (29.28)	55.87 (26.87)		
Week 52 Mean (SD)	72.15 (23.09)	73.04 (25.05)		
Week 4 Adjusted Mean Change (SE)	9.56 (3.19)	11.92 (3.15)		
Week 12 Adjusted Mean Change (SE)	14.85 (3.19)	10.01 (3.15)		
Week 16 Adjusted Mean Change (SE)	13.86 (3.02)	10.63 (3.05)		
Week 24 Adjusted Mean Change (SE)	13.79 (3.47)	12.16 (3.52)		
Week 32 Adjusted Mean Change (SE)	16.06 (3.33)	9.72 (3.35)		
Week 40 Adjusted Mean Change (SE)	16.94 (3.42)	10.51 (3.56)		
Week 52 Adjusted Mean Change (SE)	16.61 (3.53)	16.66 (3.71)	-0.05 [-10.04; 9.93]	0.992
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 47.4 SF-36 Role Emotional - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.799</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	73.96 (24.73)	71.03 (21.67)		
Week 52 Mean (SD)	85.15 (21.90)	80.39 (20.19)		
Week 4 Adjusted Mean Change (SE)	13.04 (4.30)	14.52 (4.56)		
Week 12 Adjusted Mean Change (SE)	11.36 (4.36)	16.92 (4.52)		
Week 16 Adjusted Mean Change (SE)	11.37 (4.07)	15.88 (4.32)		
Week 24 Adjusted Mean Change (SE)	16.95 (4.65)	6.30 (4.96)		
Week 32 Adjusted Mean Change (SE)	17.14 (4.47)	13.74 (4.91)		
Week 40 Adjusted Mean Change (SE)	20.64 (4.67)	14.13 (5.15)		
Week 52 Adjusted Mean Change (SE)	20.41 (4.71)	19.62 (5.28)	0.79 [-13.06; 14.64]	0.911
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	54.17 (28.00)	57.60 (24.64)		
Week 52 Mean (SD)	76.42 (24.03)	72.44 (26.18)		
Week 4 Adjusted Mean Change (SE)	11.21 (2.24)	12.57 (2.33)		
Week 12 Adjusted Mean Change (SE)	16.53 (2.24)	12.21 (2.32)		
Week 16 Adjusted Mean Change (SE)	17.75 (2.13)	12.85 (2.24)		
Week 24 Adjusted Mean Change (SE)	15.72 (2.39)	14.71 (2.55)		
Week 32 Adjusted Mean Change (SE)	17.98 (2.32)	13.26 (2.46)		
Week 40 Adjusted Mean Change (SE)	16.95 (2.39)	15.88 (2.60)		
Week 52 Adjusted Mean Change (SE)	19.35 (2.46)	14.38 (2.69)	4.97 [-2.21; 12.15]	0.174
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 47.5 SF-36 Role Emotional - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.969</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	61.11 (30.39)	58.01 (25.82)		
Week 52 Mean (SD)	78.85 (24.32)	76.10 (22.69)		
Week 4 Adjusted Mean Change (SE)	12.29 (3.19)	12.13 (2.92)		
Week 12 Adjusted Mean Change (SE)	14.71 (3.20)	12.95 (2.90)		
Week 16 Adjusted Mean Change (SE)	15.27 (3.02)	10.86 (2.80)		
Week 24 Adjusted Mean Change (SE)	16.02 (3.44)	14.58 (3.21)		
Week 32 Adjusted Mean Change (SE)	17.75 (3.31)	11.24 (3.11)		
Week 40 Adjusted Mean Change (SE)	16.92 (3.44)	14.07 (3.36)		
Week 52 Adjusted Mean Change (SE)	19.18 (3.52)	19.01 (3.47)	0.17 [-9.58; 9.92]	0.973
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	56.86 (27.24)	62.83 (23.22)		
Week 52 Mean (SD)	78.03 (23.60)	72.35 (27.24)		
Week 4 Adjusted Mean Change (SE)	11.19 (2.51)	13.83 (2.96)		
Week 12 Adjusted Mean Change (SE)	15.87 (2.53)	13.48 (2.96)		
Week 16 Adjusted Mean Change (SE)	17.00 (2.39)	16.22 (2.82)		
Week 24 Adjusted Mean Change (SE)	15.93 (2.69)	11.33 (3.23)		
Week 32 Adjusted Mean Change (SE)	17.79 (2.59)	15.55 (3.12)		
Week 40 Adjusted Mean Change (SE)	18.19 (2.69)	16.84 (3.24)		
Week 52 Adjusted Mean Change (SE)	19.84 (2.73)	12.51 (3.31)	7.33 [-1.16; 15.82]	0.090
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 47.6 SF-36 Role Emotional - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.714</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	55.09 (25.70)	64.12 (23.64)		
Week 52 Mean (SD)	80.36 (21.70)	81.94 (20.17)		
Week 4 Adjusted Mean Change (SE)	13.40 (2.42)	15.82 (2.94)		
Week 12 Adjusted Mean Change (SE)	16.49 (2.46)	16.08 (2.93)		
Week 16 Adjusted Mean Change (SE)	17.93 (2.30)	17.95 (2.81)		
Week 24 Adjusted Mean Change (SE)	18.77 (2.57)	17.04 (3.24)		
Week 32 Adjusted Mean Change (SE)	19.26 (2.50)	16.42 (3.18)		
Week 40 Adjusted Mean Change (SE)	20.18 (2.57)	20.62 (3.36)		
Week 52 Adjusted Mean Change (SE)	22.85 (2.61)	21.05 (3.50)	1.80 [-6.84; 10.45]	0.682
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	64.91 (32.37)	56.89 (25.12)		
Week 52 Mean (SD)	74.29 (27.29)	67.94 (27.10)		
Week 4 Adjusted Mean Change (SE)	8.24 (3.33)	10.17 (2.89)		
Week 12 Adjusted Mean Change (SE)	13.36 (3.33)	10.43 (2.90)		
Week 16 Adjusted Mean Change (SE)	13.31 (3.15)	9.27 (2.75)		
Week 24 Adjusted Mean Change (SE)	10.44 (3.61)	9.06 (3.12)		
Week 32 Adjusted Mean Change (SE)	14.94 (3.47)	10.39 (3.02)		
Week 40 Adjusted Mean Change (SE)	12.94 (3.57)	10.90 (3.13)		
Week 52 Adjusted Mean Change (SE)	13.22 (3.65)	10.60 (3.18)	2.62 [-6.96; 12.20]	0.591
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 47.7 SF-36 Role Emotional - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.181</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	63.07 (29.07)	65.89 (24.81)		
Week 52 Mean (SD)	80.61 (23.59)	81.00 (23.39)		
Week 4 Adjusted Mean Change (SE)	11.59 (2.86)	20.37 (3.68)		
Week 12 Adjusted Mean Change (SE)	16.01 (2.91)	18.86 (3.72)		
Week 16 Adjusted Mean Change (SE)	17.15 (2.73)	19.30 (3.56)		
Week 24 Adjusted Mean Change (SE)	17.90 (3.10)	15.26 (4.04)		
Week 32 Adjusted Mean Change (SE)	19.59 (2.93)	21.90 (3.82)		
Week 40 Adjusted Mean Change (SE)	19.70 (3.08)	20.85 (4.04)		
Week 52 Adjusted Mean Change (SE)	20.04 (3.16)	20.19 (4.31)	-0.15 [-10.65; 10.35]	0.978
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	54.52 (27.48)	57.85 (24.21)		
Week 52 Mean (SD)	76.34 (23.93)	71.05 (25.50)		
Week 4 Adjusted Mean Change (SE)	11.62 (2.66)	9.62 (2.47)		
Week 12 Adjusted Mean Change (SE)	14.92 (2.68)	10.68 (2.47)		
Week 16 Adjusted Mean Change (SE)	15.63 (2.56)	10.94 (2.38)		
Week 24 Adjusted Mean Change (SE)	14.23 (2.91)	11.97 (2.76)		
Week 32 Adjusted Mean Change (SE)	16.18 (2.75)	9.41 (2.62)		
Week 40 Adjusted Mean Change (SE)	15.97 (2.88)	13.06 (2.81)		
Week 52 Adjusted Mean Change (SE)	19.18 (2.97)	13.35 (2.88)	5.83 [-2.31; 13.97]	0.160
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



#### 47.8 SF-36 Role Emotional - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.667</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	53.27 (29.82)	62.40 (24.52)		
Week 52 Mean (SD)	76.87 (23.77)	78.94 (23.44)		
Week 4 Adjusted Mean Change (SE)	16.95 (2.81)	13.12 (3.13)		
Week 12 Adjusted Mean Change (SE)	16.32 (2.95)	13.76 (3.31)		
Week 16 Adjusted Mean Change (SE)	17.87 (2.73)	12.19 (3.09)		
Week 24 Adjusted Mean Change (SE)	18.09 (3.18)	13.71 (3.62)		
Week 32 Adjusted Mean Change (SE)	17.49 (3.11)	14.78 (3.53)		
Week 40 Adjusted Mean Change (SE)	17.41 (3.19)	16.22 (3.63)		
Week 52 Adjusted Mean Change (SE)	21.21 (3.16)	20.34 (3.60)	0.87 [-8.62; 10.35]	0.857
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	64.95 (23.64)	57.69 (24.37)		
Week 52 Mean (SD)	82.53 (22.81)	70.63 (28.70)		
Week 4 Adjusted Mean Change (SE)	6.36 (3.45)	12.95 (3.99)		
Week 12 Adjusted Mean Change (SE)	15.38 (3.68)	12.98 (4.19)		
Week 16 Adjusted Mean Change (SE)	15.64 (3.38)	17.27 (3.88)		
Week 24 Adjusted Mean Change (SE)	15.68 (3.93)	12.26 (4.60)		
Week 32 Adjusted Mean Change (SE)	19.48 (3.89)	13.88 (4.49)		
Week 40 Adjusted Mean Change (SE)	16.29 (3.95)	21.11 (4.73)		
Week 52 Adjusted Mean Change (SE)	20.74 (3.92)	14.88 (4.67)	5.86 [-6.20; 17.92]	0.339
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 47.9 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.519</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	56.30 (23.65)	64.51 (27.40)		
Week 52 Mean (SD)	79.84 (24.48)	78.07 (20.64)		
Week 4 Adjusted Mean Change (SE)	14.81 (3.06)	16.25 (4.06)		
Week 12 Adjusted Mean Change (SE)	15.61 (3.21)	16.35 (4.25)		
Week 16 Adjusted Mean Change (SE)	17.08 (2.98)	13.04 (3.99)		
Week 24 Adjusted Mean Change (SE)	15.28 (3.30)	15.95 (4.49)		
Week 32 Adjusted Mean Change (SE)	18.93 (3.36)	16.13 (4.54)		
Week 40 Adjusted Mean Change (SE)	16.44 (3.46)	20.36 (4.76)		
Week 52 Adjusted Mean Change (SE)	21.49 (3.43)	22.33 (4.92)	-0.84 [-12.71; 11.03]	0.889
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	60.53 (32.34)	57.50 (22.99)		
Week 52 Mean (SD)	78.33 (23.06)	72.32 (30.69)		
Week 4 Adjusted Mean Change (SE)	9.11 (3.33)	10.88 (3.75)		
Week 12 Adjusted Mean Change (SE)	16.50 (3.55)	12.51 (3.97)		
Week 16 Adjusted Mean Change (SE)	17.00 (3.26)	14.83 (3.68)		
Week 24 Adjusted Mean Change (SE)	19.66 (3.61)	9.48 (4.13)		
Week 32 Adjusted Mean Change (SE)	16.82 (3.68)	11.80 (4.14)		
Week 40 Adjusted Mean Change (SE)	17.39 (3.75)	17.64 (4.36)		
Week 52 Adjusted Mean Change (SE)	20.23 (3.76)	13.37 (4.24)	6.86 [-4.36; 18.08]	0.229
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 47.10 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.745</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	51.67 (28.73)	62.12 (27.09)		
Week 52 Mean (SD)	78.45 (24.55)	80.21 (23.03)		
Week 4 Adjusted Mean Change (SE)	17.09 (3.69)	16.83 (3.57)		
Week 12 Adjusted Mean Change (SE)	20.24 (3.77)	17.26 (3.68)		
Week 16 Adjusted Mean Change (SE)	19.79 (3.56)	18.25 (3.48)		
Week 24 Adjusted Mean Change (SE)	20.86 (4.21)	10.83 (4.20)		
Week 32 Adjusted Mean Change (SE)	22.27 (4.04)	19.89 (4.03)		
Week 40 Adjusted Mean Change (SE)	20.27 (4.15)	22.65 (4.20)		
Week 52 Adjusted Mean Change (SE)	22.75 (4.14)	23.01 (4.33)	-0.26 [-12.13; 11.60]	0.965
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	58.82 (26.43)	59.07 (21.75)		
Week 52 Mean (SD)	78.91 (23.27)	72.73 (27.19)		
Week 4 Adjusted Mean Change (SE)	11.69 (2.81)	10.20 (3.45)		
Week 12 Adjusted Mean Change (SE)	15.13 (2.91)	10.49 (3.53)		
Week 16 Adjusted Mean Change (SE)	16.71 (2.72)	10.93 (3.37)		
Week 24 Adjusted Mean Change (SE)	16.24 (3.15)	15.20 (3.90)		
Week 32 Adjusted Mean Change (SE)	16.61 (3.09)	10.15 (3.80)		
Week 40 Adjusted Mean Change (SE)	16.66 (3.14)	14.50 (3.93)		
Week 52 Adjusted Mean Change (SE)	20.89 (3.15)	15.18 (3.86)	5.71 [-4.14; 15.56]	0.254
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 47.11 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.938</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	59.11 (28.45)	60.66 (25.22)		
Week 52 Mean (SD)	78.42 (24.83)	76.07 (27.78)		
Week 4 Adjusted Mean Change (SE)	12.74 (3.11)	13.16 (3.11)		
Week 12 Adjusted Mean Change (SE)	15.83 (3.22)	13.42 (3.22)		
Week 16 Adjusted Mean Change (SE)	13.48 (2.96)	12.45 (2.96)		
Week 24 Adjusted Mean Change (SE)	14.74 (3.41)	9.13 (3.45)		
Week 32 Adjusted Mean Change (SE)	14.68 (3.41)	15.98 (3.42)		
Week 40 Adjusted Mean Change (SE)	16.47 (3.48)	15.75 (3.53)		
Week 52 Adjusted Mean Change (SE)	20.52 (3.49)	18.55 (3.50)	1.96 [-7.80; 11.73]	0.692
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	56.75 (27.74)	60.42 (23.35)		
Week 52 Mean (SD)	79.67 (22.29)	75.46 (20.70)		
Week 4 Adjusted Mean Change (SE)	12.67 (3.15)	13.04 (4.25)		
Week 12 Adjusted Mean Change (SE)	16.00 (3.26)	13.54 (4.37)		
Week 16 Adjusted Mean Change (SE)	20.47 (2.98)	17.42 (4.08)		
Week 24 Adjusted Mean Change (SE)	19.57 (3.42)	20.69 (4.72)		
Week 32 Adjusted Mean Change (SE)	21.55 (3.39)	11.63 (4.67)		
Week 40 Adjusted Mean Change (SE)	17.45 (3.49)	22.45 (4.95)		
Week 52 Adjusted Mean Change (SE)	21.53 (3.45)	17.40 (5.00)	4.12 [-7.89; 16.14]	0.498
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 47.12 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.228</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	58.06 (26.82)	61.88 (23.87)		
Week 52 Mean (SD)	79.02 (22.20)	77.63 (20.42)		
Week 4 Adjusted Mean Change (SE)	12.97 (2.45)	11.97 (2.83)		
Week 12 Adjusted Mean Change (SE)	12.75 (2.59)	11.27 (2.96)		
Week 16 Adjusted Mean Change (SE)	17.28 (2.41)	12.79 (2.80)		
Week 24 Adjusted Mean Change (SE)	17.24 (2.81)	11.89 (3.34)		
Week 32 Adjusted Mean Change (SE)	18.93 (2.76)	13.00 (3.23)		
Week 40 Adjusted Mean Change (SE)	17.16 (2.79)	17.43 (3.32)		
Week 52 Adjusted Mean Change (SE)	20.44 (2.79)	19.35 (3.36)	1.09 [-7.56; 9.73]	0.804
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	60.42 (32.65)	62.50 (21.63)		
Week 52 Mean (SD)	81.14 (25.59)	79.41 (27.97)		
Week 4 Adjusted Mean Change (SE)	7.28 (4.33)	14.06 (4.52)		
Week 12 Adjusted Mean Change (SE)	20.68 (4.53)	20.05 (4.82)		
Week 16 Adjusted Mean Change (SE)	12.26 (4.24)	18.07 (4.51)		
Week 24 Adjusted Mean Change (SE)	13.90 (5.10)	19.30 (5.35)		
Week 32 Adjusted Mean Change (SE)	12.51 (4.86)	18.88 (5.17)		
Week 40 Adjusted Mean Change (SE)	14.44 (4.97)	23.35 (5.29)		
Week 52 Adjusted Mean Change (SE)	20.61 (4.90)	19.84 (5.14)	0.78 [-13.27; 14.82]	0.913
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 47.13 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.025</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	58.33 (26.94)	62.74 (24.34)		
Week 52 Mean (SD)	77.01 (24.50)	77.98 (25.16)		
Week 4 Adjusted Mean Change (SE)	11.88 (2.56)	15.55 (2.89)		
Week 12 Adjusted Mean Change (SE)	15.10 (2.57)	17.43 (2.91)		
Week 16 Adjusted Mean Change (SE)	14.56 (2.42)	16.24 (2.75)		
Week 24 Adjusted Mean Change (SE)	14.51 (2.83)	14.40 (3.24)		
Week 32 Adjusted Mean Change (SE)	16.53 (2.77)	18.28 (3.15)		
Week 40 Adjusted Mean Change (SE)	16.11 (2.86)	21.80 (3.30)		
Week 52 Adjusted Mean Change (SE)	18.99 (2.86)	20.34 (3.31)	-1.36 [-10.01; 7.29]	0.757
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	55.26 (31.08)	53.47 (27.63)		
Week 52 Mean (SD)	82.46 (20.58)	70.83 (27.41)		
Week 4 Adjusted Mean Change (SE)	15.43 (4.66)	6.99 (5.90)		
Week 12 Adjusted Mean Change (SE)	16.61 (4.67)	6.78 (5.91)		
Week 16 Adjusted Mean Change (SE)	24.32 (4.39)	5.10 (5.55)		
Week 24 Adjusted Mean Change (SE)	23.86 (5.08)	13.40 (6.42)		
Week 32 Adjusted Mean Change (SE)	23.16 (4.96)	4.61 (6.40)		
Week 40 Adjusted Mean Change (SE)	19.57 (5.12)	6.67 (6.61)		
Week 52 Adjusted Mean Change (SE)	25.31 (5.06)	14.32 (6.40)	11.00 [-5.10; 27.10]	0.179
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 47.14 SF-36 Role Emotional - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.968</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	59.04 (29.64)	60.69 (25.39)		
Week 52 Mean (SD)	79.29 (23.72)	76.89 (26.41)		
Week 4 Adjusted Mean Change (SE)	12.57 (2.44)	13.09 (2.86)		
Week 12 Adjusted Mean Change (SE)	16.43 (2.50)	15.01 (2.93)		
Week 16 Adjusted Mean Change (SE)	17.05 (2.34)	12.97 (2.76)		
Week 24 Adjusted Mean Change (SE)	18.34 (2.67)	12.00 (3.18)		
Week 32 Adjusted Mean Change (SE)	17.86 (2.62)	14.89 (3.10)		
Week 40 Adjusted Mean Change (SE)	17.26 (2.74)	16.28 (3.30)		
Week 52 Adjusted Mean Change (SE)	20.77 (2.66)	19.40 (3.21)	1.37 [-6.87; 9.61]	0.743
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	53.21 (17.19)	55.83 (20.43)		
Week 52 Mean (SD)	78.21 (23.70)	74.17 (19.43)		
Week 4 Adjusted Mean Change (SE)	12.73 (5.72)	10.39 (6.50)		
Week 12 Adjusted Mean Change (SE)	13.82 (5.98)	6.11 (6.62)		
Week 16 Adjusted Mean Change (SE)	16.13 (5.46)	14.65 (6.20)		
Week 24 Adjusted Mean Change (SE)	10.26 (6.19)	10.44 (7.04)		
Week 32 Adjusted Mean Change (SE)	20.23 (6.03)	15.30 (6.86)		
Week 40 Adjusted Mean Change (SE)	14.94 (6.32)	21.88 (7.18)		
Week 52 Adjusted Mean Change (SE)	22.00 (6.10)	16.89 (6.93)	5.11 [-13.16; 23.38]	0.581
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 47.15 SF-36 Role Emotional - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.839</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	57.58 (30.64)	64.10 (28.06)		
Week 52 Mean (SD)	81.58 (24.31)	79.63 (25.28)		
Week 4 Adjusted Mean Change (SE)	18.50 (4.26)	18.12 (4.04)		
Week 12 Adjusted Mean Change (SE)	20.75 (4.41)	17.38 (4.18)		
Week 16 Adjusted Mean Change (SE)	19.41 (4.20)	16.84 (3.97)		
Week 24 Adjusted Mean Change (SE)	19.81 (4.92)	12.23 (4.69)		
Week 32 Adjusted Mean Change (SE)	21.74 (4.80)	15.35 (4.58)		
Week 40 Adjusted Mean Change (SE)	20.32 (4.95)	17.22 (4.78)		
Week 52 Adjusted Mean Change (SE)	23.45 (4.96)	23.72 (4.94)	-0.27 [-14.11; 13.57]	0.969
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	58.07 (27.23)	58.33 (21.81)		
Week 52 Mean (SD)	78.28 (23.29)	74.15 (25.85)		
Week 4 Adjusted Mean Change (SE)	10.67 (2.52)	10.10 (3.13)		
Week 12 Adjusted Mean Change (SE)	14.20 (2.64)	11.09 (3.27)		
Week 16 Adjusted Mean Change (SE)	16.11 (2.45)	12.60 (3.06)		
Week 24 Adjusted Mean Change (SE)	16.18 (2.83)	13.62 (3.58)		
Week 32 Adjusted Mean Change (SE)	16.92 (2.78)	13.80 (3.49)		
Week 40 Adjusted Mean Change (SE)	15.79 (2.83)	18.38 (3.61)		
Week 52 Adjusted Mean Change (SE)	20.13 (2.81)	15.70 (3.52)	4.43 [-4.48; 13.34]	0.327
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 47.16 SF-36 Role Emotional - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.507</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	57.68 (22.96)	62.62 (25.19)		
Week 52 Mean (SD)	80.10 (23.92)	78.70 (19.66)		
Week 4 Adjusted Mean Change (SE)	14.16 (2.84)	14.74 (3.49)		
Week 12 Adjusted Mean Change (SE)	15.30 (2.95)	15.43 (3.60)		
Week 16 Adjusted Mean Change (SE)	16.15 (2.74)	13.46 (3.39)		
Week 24 Adjusted Mean Change (SE)	15.55 (3.16)	14.34 (3.96)		
Week 32 Adjusted Mean Change (SE)	18.52 (3.11)	16.87 (3.87)		
Week 40 Adjusted Mean Change (SE)	17.21 (3.20)	19.14 (4.03)		
Week 52 Adjusted Mean Change (SE)	21.31 (3.14)	22.77 (4.09)	-1.46 [-11.67; 8.74]	0.777
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	58.33 (34.51)	58.33 (23.67)		
Week 52 Mean (SD)	77.42 (22.89)	73.33 (30.04)		
Week 4 Adjusted Mean Change (SE)	10.52 (3.48)	11.41 (3.58)		
Week 12 Adjusted Mean Change (SE)	16.83 (3.63)	11.38 (3.73)		
Week 16 Adjusted Mean Change (SE)	18.24 (3.38)	14.96 (3.48)		
Week 24 Adjusted Mean Change (SE)	19.61 (3.91)	12.00 (4.07)		
Week 32 Adjusted Mean Change (SE)	17.61 (3.86)	11.88 (3.98)		
Week 40 Adjusted Mean Change (SE)	16.58 (3.91)	16.89 (4.14)		
Week 52 Adjusted Mean Change (SE)	20.53 (3.91)	14.16 (4.00)	6.36 [-4.70; 17.43]	0.258
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 47.17 SF-36 Role Emotional - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.778</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	51.67 (28.73)	63.98 (26.12)		
Week 52 Mean (SD)	78.45 (24.55)	81.06 (23.03)		
Week 4 Adjusted Mean Change (SE)	16.57 (3.67)	18.25 (3.68)		
Week 12 Adjusted Mean Change (SE)	19.65 (3.78)	18.82 (3.82)		
Week 16 Adjusted Mean Change (SE)	19.31 (3.54)	18.62 (3.58)		
Week 24 Adjusted Mean Change (SE)	20.46 (4.18)	9.45 (4.32)		
Week 32 Adjusted Mean Change (SE)	21.84 (4.01)	19.70 (4.15)		
Week 40 Adjusted Mean Change (SE)	19.71 (4.17)	20.77 (4.38)		
Week 52 Adjusted Mean Change (SE)	22.28 (4.11)	22.49 (4.48)	-0.21 [-12.27; 11.85]	0.973
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	61.36 (27.19)	57.64 (22.75)		
Week 52 Mean (SD)	79.41 (22.99)	72.62 (26.86)		
Week 4 Adjusted Mean Change (SE)	10.60 (2.70)	8.84 (3.34)		
Week 12 Adjusted Mean Change (SE)	13.85 (2.81)	9.04 (3.43)		
Week 16 Adjusted Mean Change (SE)	15.70 (2.61)	10.51 (3.24)		
Week 24 Adjusted Mean Change (SE)	15.32 (3.03)	15.28 (3.75)		
Week 32 Adjusted Mean Change (SE)	16.18 (2.97)	10.13 (3.66)		
Week 40 Adjusted Mean Change (SE)	15.45 (3.06)	15.66 (3.83)		
Week 52 Adjusted Mean Change (SE)	20.34 (3.05)	15.25 (3.72)	5.09 [-4.43; 14.60]	0.292
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 47.18 SF-36 Role Emotional - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.938</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	59.11 (28.45)	60.66 (25.22)		
Week 52 Mean (SD)	78.42 (24.83)	76.07 (27.78)		
Week 4 Adjusted Mean Change (SE)	12.74 (3.11)	13.16 (3.11)		
Week 12 Adjusted Mean Change (SE)	15.83 (3.22)	13.42 (3.22)		
Week 16 Adjusted Mean Change (SE)	13.48 (2.96)	12.45 (2.96)		
Week 24 Adjusted Mean Change (SE)	14.74 (3.41)	9.13 (3.45)		
Week 32 Adjusted Mean Change (SE)	14.68 (3.41)	15.98 (3.42)		
Week 40 Adjusted Mean Change (SE)	16.47 (3.48)	15.75 (3.53)		
Week 52 Adjusted Mean Change (SE)	20.52 (3.49)	18.55 (3.50)	1.96 [-7.80; 11.73]	0.692
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	56.75 (27.74)	60.42 (23.35)		
Week 52 Mean (SD)	79.67 (22.29)	75.46 (20.70)		
Week 4 Adjusted Mean Change (SE)	12.67 (3.15)	13.04 (4.25)		
Week 12 Adjusted Mean Change (SE)	16.00 (3.26)	13.54 (4.37)		
Week 16 Adjusted Mean Change (SE)	20.47 (2.98)	17.42 (4.08)		
Week 24 Adjusted Mean Change (SE)	19.57 (3.42)	20.69 (4.72)		
Week 32 Adjusted Mean Change (SE)	21.55 (3.39)	11.63 (4.67)		
Week 40 Adjusted Mean Change (SE)	17.45 (3.49)	22.45 (4.95)		
Week 52 Adjusted Mean Change (SE)	21.53 (3.45)	17.40 (5.00)	4.12 [-7.89; 16.14]	0.498
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 47.19 SF-36 Role Emotional - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.548</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	57.95 (26.37)	61.05 (23.96)		
Week 52 Mean (SD)	78.83 (23.05)	76.88 (21.88)		
Week 4 Adjusted Mean Change (SE)	13.35 (2.49)	13.41 (2.89)		
Week 12 Adjusted Mean Change (SE)	13.61 (2.59)	11.75 (3.00)		
Week 16 Adjusted Mean Change (SE)	17.71 (2.39)	12.97 (2.78)		
Week 24 Adjusted Mean Change (SE)	17.71 (2.80)	11.74 (3.34)		
Week 32 Adjusted Mean Change (SE)	19.16 (2.73)	13.64 (3.21)		
Week 40 Adjusted Mean Change (SE)	17.55 (2.81)	16.85 (3.36)		
Week 52 Adjusted Mean Change (SE)	20.70 (2.80)	19.10 (3.38)	1.60 [-7.09; 10.30]	0.716
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	62.04 (32.62)	59.26 (26.18)		
Week 52 Mean (SD)	83.33 (22.63)	73.53 (33.36)		
Week 4 Adjusted Mean Change (SE)	7.56 (4.75)	11.27 (4.71)		
Week 12 Adjusted Mean Change (SE)	20.18 (4.89)	16.84 (4.86)		
Week 16 Adjusted Mean Change (SE)	12.07 (4.55)	16.31 (4.59)		
Week 24 Adjusted Mean Change (SE)	14.43 (5.48)	15.90 (5.37)		
Week 32 Adjusted Mean Change (SE)	13.00 (5.21)	15.35 (5.25)		
Week 40 Adjusted Mean Change (SE)	15.73 (5.42)	20.11 (5.55)		
Week 52 Adjusted Mean Change (SE)	22.10 (5.35)	15.66 (5.32)	6.44 [-8.48; 21.35]	0.395
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 48.0 SF-36 Role Physical - Return Rates (FAS)

<b>Treatment Groups</b>			
	<b>SEC (N=110)</b>	<b>ADA (N=101)</b>	<b>Total (N=211)</b>
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

#### 48.1 SF-36 Role Physical - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	42.84 (24.31)	45.67 (25.15)		
Week 52 Mean (SD)	67.56 (23.72)	65.24 (26.23)		
Week 4 Adjusted Mean Change (SE)	12.30 (1.74)	9.61 (1.83)		
Week 12 Adjusted Mean Change (SE)	18.24 (1.90)	14.21 (1.99)		
Week 16 Adjusted Mean Change (SE)	18.33 (1.79)	12.53 (1.90)		
Week 24 Adjusted Mean Change (SE)	20.28 (2.09)	18.73 (2.25)		
Week 32 Adjusted Mean Change (SE)	22.06 (1.97)	16.93 (2.12)		
Week 40 Adjusted Mean Change (SE)	19.81 (2.00)	16.24 (2.19)		
Week 52 Adjusted Mean Change (SE)	23.80 (2.18)	19.14 (2.40)	4.66 [-1.74; 11.07]	0.153
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 48.2 SF-36 Role Physical - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.423</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	42.60 (23.58)	45.81 (25.06)		
Week 52 Mean (SD)	67.23 (24.06)	65.71 (26.19)		
Week 4 Adjusted Mean Change (SE)	12.40 (1.80)	10.17 (1.90)		
Week 12 Adjusted Mean Change (SE)	18.56 (1.96)	15.12 (2.06)		
Week 16 Adjusted Mean Change (SE)	17.94 (1.84)	13.26 (1.96)		
Week 24 Adjusted Mean Change (SE)	20.29 (2.17)	19.44 (2.34)		
Week 32 Adjusted Mean Change (SE)	22.41 (2.04)	17.32 (2.21)		
Week 40 Adjusted Mean Change (SE)	20.42 (2.07)	16.66 (2.28)		
Week 52 Adjusted Mean Change (SE)	23.86 (2.26)	19.91 (2.50)	3.95 [-2.71; 10.60]	0.243
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	46.43 (35.70)	43.75 (28.41)		
Week 52 Mean (SD)	72.92 (17.97)	59.38 (28.44)		
Week 4 Adjusted Mean Change (SE)	10.85 (6.90)	2.30 (6.89)		
Week 12 Adjusted Mean Change (SE)	13.68 (7.44)	2.27 (7.43)		
Week 16 Adjusted Mean Change (SE)	25.40 (7.34)	3.18 (7.06)		
Week 24 Adjusted Mean Change (SE)	20.13 (8.25)	9.37 (8.24)		
Week 32 Adjusted Mean Change (SE)	17.44 (7.72)	11.16 (7.71)		
Week 40 Adjusted Mean Change (SE)	11.19 (7.86)	10.26 (7.85)		
Week 52 Adjusted Mean Change (SE)	23.63 (8.85)	8.99 (8.84)	14.65 [-10.00; 39.30]	0.243
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 48.3 SF-36 Role Physical - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.542</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	46.21 (24.09)	49.67 (25.45)		
Week 52 Mean (SD)	71.58 (25.32)	71.22 (24.25)		
Week 4 Adjusted Mean Change (SE)	15.30 (2.27)	10.11 (2.45)		
Week 12 Adjusted Mean Change (SE)	19.65 (2.47)	17.78 (2.63)		
Week 16 Adjusted Mean Change (SE)	21.13 (2.32)	15.98 (2.48)		
Week 24 Adjusted Mean Change (SE)	22.26 (2.69)	21.93 (2.95)		
Week 32 Adjusted Mean Change (SE)	24.82 (2.51)	22.37 (2.76)		
Week 40 Adjusted Mean Change (SE)	21.13 (2.58)	20.85 (2.87)		
Week 52 Adjusted Mean Change (SE)	26.73 (2.77)	24.48 (3.12)	2.25 [-5.92; 10.43]	0.587
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	37.78 (24.03)	40.48 (24.06)		
Week 52 Mean (SD)	61.28 (19.68)	56.80 (26.93)		
Week 4 Adjusted Mean Change (SE)	7.81 (2.81)	8.97 (2.79)		
Week 12 Adjusted Mean Change (SE)	16.08 (3.03)	9.57 (3.01)		
Week 16 Adjusted Mean Change (SE)	14.14 (2.85)	7.99 (2.88)		
Week 24 Adjusted Mean Change (SE)	17.35 (3.39)	14.60 (3.44)		
Week 32 Adjusted Mean Change (SE)	17.77 (3.14)	9.87 (3.18)		
Week 40 Adjusted Mean Change (SE)	17.82 (3.22)	10.14 (3.33)		
Week 52 Adjusted Mean Change (SE)	19.28 (3.48)	12.08 (3.65)	7.20 [-2.66; 17.05]	0.151
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



#### 48.4 SF-36 Role Physical - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.354</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	65.63 (20.02)	70.54 (22.46)		
Week 52 Mean (SD)	78.80 (16.93)	72.79 (25.76)		
Week 4 Adjusted Mean Change (SE)	14.66 (3.94)	13.11 (4.27)		
Week 12 Adjusted Mean Change (SE)	16.16 (4.37)	17.17 (4.64)		
Week 16 Adjusted Mean Change (SE)	15.33 (4.05)	14.44 (4.40)		
Week 24 Adjusted Mean Change (SE)	18.44 (4.80)	17.91 (5.24)		
Week 32 Adjusted Mean Change (SE)	16.42 (4.48)	21.22 (4.98)		
Week 40 Adjusted Mean Change (SE)	15.19 (4.59)	20.42 (5.10)		
Week 52 Adjusted Mean Change (SE)	24.79 (4.98)	18.05 (5.60)	6.74 [-7.25; 20.72]	0.343
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	36.48 (21.50)	39.14 (21.58)		
Week 52 Mean (SD)	64.41 (24.47)	63.27 (26.18)		
Week 4 Adjusted Mean Change (SE)	11.58 (2.02)	8.74 (2.08)		
Week 12 Adjusted Mean Change (SE)	18.81 (2.21)	13.42 (2.27)		
Week 16 Adjusted Mean Change (SE)	19.18 (2.08)	12.01 (2.16)		
Week 24 Adjusted Mean Change (SE)	20.83 (2.43)	18.92 (2.56)		
Week 32 Adjusted Mean Change (SE)	23.62 (2.28)	15.85 (2.40)		
Week 40 Adjusted Mean Change (SE)	21.03 (2.32)	15.17 (2.47)		
Week 52 Adjusted Mean Change (SE)	23.51 (2.54)	19.43 (2.72)	4.09 [-3.16; 11.33]	0.268
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 48.5 SF-36 Role Physical - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.736</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	44.64 (24.05)	43.75 (25.98)		
Week 52 Mean (SD)	67.79 (23.67)	67.27 (26.21)		
Week 4 Adjusted Mean Change (SE)	13.71 (2.80)	13.21 (2.56)		
Week 12 Adjusted Mean Change (SE)	18.75 (3.08)	14.83 (2.80)		
Week 16 Adjusted Mean Change (SE)	16.84 (2.90)	12.34 (2.68)		
Week 24 Adjusted Mean Change (SE)	19.07 (3.41)	19.99 (3.18)		
Week 32 Adjusted Mean Change (SE)	20.97 (3.22)	15.70 (3.01)		
Week 40 Adjusted Mean Change (SE)	20.34 (3.28)	15.22 (3.16)		
Week 52 Adjusted Mean Change (SE)	23.51 (3.57)	20.17 (3.48)	3.34 [-6.49; 13.18]	0.503
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	41.73 (24.59)	47.63 (24.38)		
Week 52 Mean (SD)	67.42 (23.93)	63.49 (26.41)		
Week 4 Adjusted Mean Change (SE)	11.44 (2.20)	5.93 (2.59)		
Week 12 Adjusted Mean Change (SE)	17.91 (2.44)	13.56 (2.85)		
Week 16 Adjusted Mean Change (SE)	19.27 (2.29)	12.69 (2.70)		
Week 24 Adjusted Mean Change (SE)	21.03 (2.67)	17.41 (3.20)		
Week 32 Adjusted Mean Change (SE)	22.73 (2.52)	18.18 (3.03)		
Week 40 Adjusted Mean Change (SE)	19.48 (2.56)	17.11 (3.08)		
Week 52 Adjusted Mean Change (SE)	23.98 (2.78)	18.17 (3.36)	5.81 [-2.81; 14.44]	0.185
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 48.6 SF-36 Role Physical - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.275</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	42.71 (21.16)	48.60 (26.52)		
Week 52 Mean (SD)	72.77 (21.55)	73.26 (23.84)		
Week 4 Adjusted Mean Change (SE)	15.16 (2.12)	11.66 (2.58)		
Week 12 Adjusted Mean Change (SE)	20.62 (2.34)	17.07 (2.81)		
Week 16 Adjusted Mean Change (SE)	20.03 (2.21)	13.63 (2.71)		
Week 24 Adjusted Mean Change (SE)	24.38 (2.53)	19.96 (3.20)		
Week 32 Adjusted Mean Change (SE)	24.93 (2.41)	19.36 (3.06)		
Week 40 Adjusted Mean Change (SE)	22.66 (2.45)	18.45 (3.18)		
Week 52 Adjusted Mean Change (SE)	28.72 (2.60)	21.89 (3.49)	6.83 [-1.77; 15.44]	0.119
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	43.09 (29.70)	42.91 (23.71)		
Week 52 Mean (SD)	57.14 (24.73)	58.97 (26.54)		
Week 4 Adjusted Mean Change (SE)	6.88 (2.92)	7.61 (2.55)		
Week 12 Adjusted Mean Change (SE)	13.71 (3.18)	11.38 (2.78)		
Week 16 Adjusted Mean Change (SE)	15.08 (3.03)	11.44 (2.66)		
Week 24 Adjusted Mean Change (SE)	12.25 (3.55)	17.49 (3.08)		
Week 32 Adjusted Mean Change (SE)	16.48 (3.34)	14.65 (2.92)		
Week 40 Adjusted Mean Change (SE)	14.27 (3.40)	14.15 (2.98)		
Week 52 Adjusted Mean Change (SE)	14.11 (3.65)	16.71 (3.19)	-2.60 [-12.17; 6.97]	0.592
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 48.7 SF-36 Role Physical - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.856</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	45.47 (26.16)	50.78 (28.87)		
Week 52 Mean (SD)	71.05 (23.93)	71.25 (27.18)		
Week 4 Adjusted Mean Change (SE)	12.97 (2.50)	18.06 (3.23)		
Week 12 Adjusted Mean Change (SE)	21.83 (2.78)	18.76 (3.57)		
Week 16 Adjusted Mean Change (SE)	19.49 (2.61)	17.13 (3.40)		
Week 24 Adjusted Mean Change (SE)	23.08 (3.06)	18.37 (4.00)		
Week 32 Adjusted Mean Change (SE)	24.59 (2.89)	18.19 (3.77)		
Week 40 Adjusted Mean Change (SE)	23.04 (2.93)	20.25 (3.84)		
Week 52 Adjusted Mean Change (SE)	26.38 (3.19)	22.43 (4.31)	3.95 [-6.61; 14.51]	0.461
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	40.57 (22.58)	43.30 (23.07)		
Week 52 Mean (SD)	64.51 (23.33)	62.61 (25.59)		
Week 4 Adjusted Mean Change (SE)	11.68 (2.33)	5.80 (2.17)		
Week 12 Adjusted Mean Change (SE)	15.16 (2.57)	12.18 (2.37)		
Week 16 Adjusted Mean Change (SE)	17.33 (2.44)	10.47 (2.28)		
Week 24 Adjusted Mean Change (SE)	17.84 (2.87)	19.04 (2.72)		
Week 32 Adjusted Mean Change (SE)	19.84 (2.71)	16.45 (2.58)		
Week 40 Adjusted Mean Change (SE)	16.98 (2.73)	14.45 (2.65)		
Week 52 Adjusted Mean Change (SE)	21.53 (2.99)	17.78 (2.90)	3.75 [-4.47; 11.98]	0.369
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 48.8 SF-36 Role Physical - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.658</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	36.89 (21.26)	49.09 (23.58)		
Week 52 Mean (SD)	64.03 (25.44)	70.83 (24.82)		
Week 4 Adjusted Mean Change (SE)	15.36 (2.55)	12.12 (2.83)		
Week 12 Adjusted Mean Change (SE)	20.65 (2.91)	16.29 (3.25)		
Week 16 Adjusted Mean Change (SE)	20.03 (2.70)	14.58 (3.03)		
Week 24 Adjusted Mean Change (SE)	23.46 (3.10)	20.50 (3.49)		
Week 32 Adjusted Mean Change (SE)	23.93 (2.95)	20.22 (3.33)		
Week 40 Adjusted Mean Change (SE)	20.31 (2.95)	19.69 (3.33)		
Week 52 Adjusted Mean Change (SE)	24.52 (3.26)	24.70 (3.70)	-0.18 [-10.01; 9.66]	0.972
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	47.06 (24.63)	44.47 (29.60)		
Week 52 Mean (SD)	69.35 (23.52)	65.77 (28.55)		
Week 4 Adjusted Mean Change (SE)	8.37 (3.09)	8.57 (3.60)		
Week 12 Adjusted Mean Change (SE)	17.05 (3.58)	13.77 (4.11)		
Week 16 Adjusted Mean Change (SE)	13.07 (3.30)	15.37 (3.81)		
Week 24 Adjusted Mean Change (SE)	17.26 (3.77)	20.77 (4.43)		
Week 32 Adjusted Mean Change (SE)	21.82 (3.65)	19.91 (4.23)		
Week 40 Adjusted Mean Change (SE)	18.90 (3.61)	18.62 (4.31)		
Week 52 Adjusted Mean Change (SE)	22.31 (4.01)	19.10 (4.78)	3.21 [-9.10; 15.51]	0.607
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 48.9 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.718</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	41.53 (21.57)	43.29 (23.89)		
Week 52 Mean (SD)	65.12 (25.99)	63.49 (25.45)		
Week 4 Adjusted Mean Change (SE)	15.07 (2.77)	13.74 (3.65)		
Week 12 Adjusted Mean Change (SE)	21.75 (3.15)	16.83 (4.15)		
Week 16 Adjusted Mean Change (SE)	19.06 (2.90)	15.36 (3.85)		
Week 24 Adjusted Mean Change (SE)	21.80 (3.32)	18.66 (4.49)		
Week 32 Adjusted Mean Change (SE)	22.39 (3.14)	14.54 (4.24)		
Week 40 Adjusted Mean Change (SE)	17.85 (3.12)	14.84 (4.24)		
Week 52 Adjusted Mean Change (SE)	22.39 (3.49)	20.59 (4.96)	1.80 [-10.20; 13.79]	0.767
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	39.64 (24.54)	47.50 (28.46)		
Week 52 Mean (SD)	67.86 (23.15)	68.97 (27.51)		
Week 4 Adjusted Mean Change (SE)	9.97 (3.02)	9.77 (3.41)		
Week 12 Adjusted Mean Change (SE)	17.64 (3.48)	13.99 (3.91)		
Week 16 Adjusted Mean Change (SE)	16.80 (3.18)	14.52 (3.59)		
Week 24 Adjusted Mean Change (SE)	21.67 (3.64)	22.94 (4.16)		
Week 32 Adjusted Mean Change (SE)	25.58 (3.45)	23.32 (3.90)		
Week 40 Adjusted Mean Change (SE)	23.92 (3.39)	23.98 (3.92)		
Week 52 Adjusted Mean Change (SE)	26.99 (3.83)	23.31 (4.34)	3.68 [-7.81; 15.17]	0.527
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 48.10 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.760</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	33.96 (22.72)	43.94 (27.97)		
Week 52 Mean (SD)	63.15 (26.38)	72.92 (30.71)		
Week 4 Adjusted Mean Change (SE)	17.52 (3.34)	14.78 (3.18)		
Week 12 Adjusted Mean Change (SE)	23.66 (3.78)	19.23 (3.64)		
Week 16 Adjusted Mean Change (SE)	19.44 (3.52)	21.30 (3.38)		
Week 24 Adjusted Mean Change (SE)	23.49 (4.15)	20.88 (4.06)		
Week 32 Adjusted Mean Change (SE)	24.59 (3.87)	19.57 (3.79)		
Week 40 Adjusted Mean Change (SE)	23.83 (3.84)	20.80 (3.79)		
Week 52 Adjusted Mean Change (SE)	24.19 (4.27)	27.07 (4.38)	-2.87 [-14.97; 9.23]	0.639
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	43.63 (20.86)	50.55 (23.81)		
Week 52 Mean (SD)	67.35 (24.18)	66.10 (22.26)		
Week 4 Adjusted Mean Change (SE)	10.07 (2.52)	7.08 (3.13)		
Week 12 Adjusted Mean Change (SE)	17.64 (2.88)	11.68 (3.54)		
Week 16 Adjusted Mean Change (SE)	16.21 (2.66)	9.04 (3.32)		
Week 24 Adjusted Mean Change (SE)	19.92 (3.07)	20.08 (3.84)		
Week 32 Adjusted Mean Change (SE)	22.90 (2.93)	20.30 (3.64)		
Week 40 Adjusted Mean Change (SE)	19.05 (2.88)	17.64 (3.63)		
Week 52 Adjusted Mean Change (SE)	24.31 (3.22)	19.22 (3.99)	5.09 [-5.04; 15.22]	0.322
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 48.11 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.806</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	41.86 (22.84)	49.13 (25.57)		
Week 52 Mean (SD)	65.87 (25.96)	68.11 (27.24)		
Week 4 Adjusted Mean Change (SE)	13.65 (2.78)	11.64 (2.79)		
Week 12 Adjusted Mean Change (SE)	22.90 (3.14)	15.85 (3.15)		
Week 16 Adjusted Mean Change (SE)	18.44 (2.95)	15.37 (2.97)		
Week 24 Adjusted Mean Change (SE)	20.43 (3.37)	19.57 (3.41)		
Week 32 Adjusted Mean Change (SE)	22.51 (3.24)	21.07 (3.25)		
Week 40 Adjusted Mean Change (SE)	17.91 (3.18)	22.27 (3.23)		
Week 52 Adjusted Mean Change (SE)	22.60 (3.57)	23.08 (3.60)	-0.48 [-10.51; 9.56]	0.925
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	40.03 (23.55)	44.01 (26.87)		
Week 52 Mean (SD)	66.31 (23.75)	70.83 (24.16)		
Week 4 Adjusted Mean Change (SE)	11.36 (2.82)	9.36 (3.79)		
Week 12 Adjusted Mean Change (SE)	15.35 (3.18)	14.39 (4.25)		
Week 16 Adjusted Mean Change (SE)	15.99 (2.98)	14.26 (4.05)		
Week 24 Adjusted Mean Change (SE)	21.40 (3.39)	22.65 (4.65)		
Week 32 Adjusted Mean Change (SE)	23.49 (3.22)	18.36 (4.43)		
Week 40 Adjusted Mean Change (SE)	21.41 (3.20)	13.29 (4.47)		
Week 52 Adjusted Mean Change (SE)	24.45 (3.55)	21.87 (5.09)	2.58 [-9.71; 14.86]	0.679
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 48.12 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.329</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	40.93 (20.92)	48.40 (26.11)		
Week 52 Mean (SD)	66.38 (24.61)	67.93 (25.09)		
Week 4 Adjusted Mean Change (SE)	11.39 (2.23)	8.44 (2.58)		
Week 12 Adjusted Mean Change (SE)	16.23 (2.59)	13.65 (2.97)		
Week 16 Adjusted Mean Change (SE)	17.51 (2.46)	13.11 (2.85)		
Week 24 Adjusted Mean Change (SE)	19.63 (2.73)	18.78 (3.22)		
Week 32 Adjusted Mean Change (SE)	21.79 (2.65)	19.48 (3.10)		
Week 40 Adjusted Mean Change (SE)	18.40 (2.61)	18.88 (3.08)		
Week 52 Adjusted Mean Change (SE)	23.76 (2.86)	20.13 (3.45)	3.63 [-5.27; 12.53]	0.421
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	42.50 (30.46)	49.65 (22.33)		
Week 52 Mean (SD)	67.76 (25.37)	79.04 (16.67)		
Week 4 Adjusted Mean Change (SE)	11.69 (3.94)	16.02 (4.12)		
Week 12 Adjusted Mean Change (SE)	23.86 (4.52)	22.98 (4.81)		
Week 16 Adjusted Mean Change (SE)	14.40 (4.32)	19.53 (4.58)		
Week 24 Adjusted Mean Change (SE)	23.04 (4.90)	27.59 (5.15)		
Week 32 Adjusted Mean Change (SE)	24.20 (4.67)	25.13 (4.96)		
Week 40 Adjusted Mean Change (SE)	21.61 (4.62)	23.22 (4.90)		
Week 52 Adjusted Mean Change (SE)	22.57 (5.04)	32.82 (5.29)	-10.24 [-24.70; 4.21]	0.163
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 48.13 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.328</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	38.59 (20.47)	49.26 (27.00)		
Week 52 Mean (SD)	65.41 (25.52)	73.36 (24.73)		
Week 4 Adjusted Mean Change (SE)	11.91 (2.33)	12.16 (2.62)		
Week 12 Adjusted Mean Change (SE)	20.23 (2.57)	18.64 (2.89)		
Week 16 Adjusted Mean Change (SE)	18.17 (2.38)	18.95 (2.70)		
Week 24 Adjusted Mean Change (SE)	21.43 (2.80)	21.96 (3.18)		
Week 32 Adjusted Mean Change (SE)	22.85 (2.65)	23.53 (2.99)		
Week 40 Adjusted Mean Change (SE)	20.44 (2.61)	23.66 (2.99)		
Week 52 Adjusted Mean Change (SE)	24.04 (2.90)	26.61 (3.35)	-2.56 [-11.40; 6.28]	0.568
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	48.68 (28.76)	39.06 (21.51)		
Week 52 Mean (SD)	67.43 (22.30)	57.29 (26.09)		
Week 4 Adjusted Mean Change (SE)	13.26 (4.21)	9.58 (5.32)		
Week 12 Adjusted Mean Change (SE)	14.12 (4.63)	8.58 (5.84)		
Week 16 Adjusted Mean Change (SE)	12.76 (4.29)	7.36 (5.42)		
Week 24 Adjusted Mean Change (SE)	17.71 (4.99)	20.07 (6.30)		
Week 32 Adjusted Mean Change (SE)	21.83 (4.71)	10.36 (6.05)		
Week 40 Adjusted Mean Change (SE)	16.42 (4.66)	6.27 (5.98)		
Week 52 Adjusted Mean Change (SE)	21.23 (5.12)	14.88 (6.46)	6.35 [-9.98; 22.69]	0.443
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 48.14 SF-36 Role Physical - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.462</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	41.64 (24.14)	44.22 (26.71)		
Week 52 Mean (SD)	65.72 (24.35)	70.45 (26.87)		
Week 4 Adjusted Mean Change (SE)	13.80 (2.14)	12.12 (2.50)		
Week 12 Adjusted Mean Change (SE)	18.96 (2.43)	16.53 (2.84)		
Week 16 Adjusted Mean Change (SE)	16.94 (2.28)	15.80 (2.68)		
Week 24 Adjusted Mean Change (SE)	21.48 (2.59)	22.01 (3.07)		
Week 32 Adjusted Mean Change (SE)	23.32 (2.51)	19.08 (2.96)		
Week 40 Adjusted Mean Change (SE)	20.26 (2.48)	18.07 (2.96)		
Week 52 Adjusted Mean Change (SE)	23.05 (2.72)	25.30 (3.26)	-2.25 [-10.65; 6.15]	0.597
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	37.50 (17.68)	58.13 (18.88)		
Week 52 Mean (SD)	67.31 (28.20)	61.88 (23.47)		
Week 4 Adjusted Mean Change (SE)	5.99 (5.02)	4.63 (5.77)		
Week 12 Adjusted Mean Change (SE)	20.56 (5.80)	6.10 (6.54)		
Week 16 Adjusted Mean Change (SE)	19.78 (5.33)	6.89 (6.13)		
Week 24 Adjusted Mean Change (SE)	18.31 (6.01)	14.44 (6.91)		
Week 32 Adjusted Mean Change (SE)	22.48 (5.78)	20.47 (6.65)		
Week 40 Adjusted Mean Change (SE)	16.62 (5.75)	18.82 (6.62)		
Week 52 Adjusted Mean Change (SE)	26.69 (6.24)	10.78 (7.18)	15.91 [-3.04; 34.86]	0.099
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 48.15 SF-36 Role Physical - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.588</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	38.07 (23.54)	45.19 (28.52)		
Week 52 Mean (SD)	65.79 (28.29)	67.36 (32.20)		
Week 4 Adjusted Mean Change (SE)	17.34 (3.87)	11.32 (3.64)		
Week 12 Adjusted Mean Change (SE)	24.37 (4.36)	18.09 (4.09)		
Week 16 Adjusted Mean Change (SE)	22.16 (4.12)	18.65 (3.86)		
Week 24 Adjusted Mean Change (SE)	25.11 (4.74)	17.21 (4.48)		
Week 32 Adjusted Mean Change (SE)	23.86 (4.53)	17.41 (4.28)		
Week 40 Adjusted Mean Change (SE)	20.21 (4.55)	20.63 (4.34)		
Week 52 Adjusted Mean Change (SE)	22.59 (5.10)	22.84 (5.01)	-0.25 [-14.39; 13.89]	0.972
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	41.96 (23.02)	48.63 (24.47)		
Week 52 Mean (SD)	66.19 (23.73)	69.71 (23.23)		
Week 4 Adjusted Mean Change (SE)	10.86 (2.28)	10.50 (2.85)		
Week 12 Adjusted Mean Change (SE)	17.36 (2.59)	13.60 (3.23)		
Week 16 Adjusted Mean Change (SE)	15.57 (2.40)	12.73 (3.02)		
Week 24 Adjusted Mean Change (SE)	19.46 (2.73)	22.55 (3.46)		
Week 32 Adjusted Mean Change (SE)	22.66 (2.62)	21.57 (3.30)		
Week 40 Adjusted Mean Change (SE)	19.42 (2.62)	18.41 (3.34)		
Week 52 Adjusted Mean Change (SE)	23.74 (2.89)	22.71 (3.65)	1.03 [-8.19; 10.26]	0.825
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 48.16 SF-36 Role Physical - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.822</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	42.40 (21.55)	44.82 (23.99)		
Week 52 Mean (SD)	65.18 (25.10)	68.98 (24.97)		
Week 4 Adjusted Mean Change (SE)	13.97 (2.54)	13.60 (3.10)		
Week 12 Adjusted Mean Change (SE)	20.63 (2.88)	18.22 (3.51)		
Week 16 Adjusted Mean Change (SE)	18.21 (2.70)	16.71 (3.32)		
Week 24 Adjusted Mean Change (SE)	21.22 (3.07)	20.68 (3.83)		
Week 32 Adjusted Mean Change (SE)	21.61 (2.91)	17.83 (3.61)		
Week 40 Adjusted Mean Change (SE)	17.88 (2.88)	15.82 (3.60)		
Week 52 Adjusted Mean Change (SE)	21.71 (3.22)	24.15 (4.15)	-2.44 [-12.82; 7.95]	0.644
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	38.79 (25.37)	50.00 (28.09)		
Week 52 Mean (SD)	67.54 (24.39)	68.96 (27.54)		
Week 4 Adjusted Mean Change (SE)	10.37 (3.13)	7.88 (3.22)		
Week 12 Adjusted Mean Change (SE)	17.00 (3.56)	12.11 (3.67)		
Week 16 Adjusted Mean Change (SE)	15.73 (3.34)	13.11 (3.44)		
Week 24 Adjusted Mean Change (SE)	20.49 (3.82)	20.57 (3.97)		
Week 32 Adjusted Mean Change (SE)	25.18 (3.62)	22.54 (3.74)		
Week 40 Adjusted Mean Change (SE)	22.35 (3.55)	23.09 (3.74)		
Week 52 Adjusted Mean Change (SE)	26.49 (4.01)	21.31 (4.13)	5.18 [-6.28; 16.63]	0.373
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 48.17 SF-36 Role Physical - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.559</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	33.96 (22.72)	44.15 (28.59)		
Week 52 Mean (SD)	63.15 (26.38)	75.00 (31.28)		
Week 4 Adjusted Mean Change (SE)	17.45 (3.30)	15.98 (3.25)		
Week 12 Adjusted Mean Change (SE)	23.39 (3.74)	20.72 (3.71)		
Week 16 Adjusted Mean Change (SE)	19.31 (3.48)	21.86 (3.46)		
Week 24 Adjusted Mean Change (SE)	23.35 (4.10)	22.64 (4.16)		
Week 32 Adjusted Mean Change (SE)	24.21 (3.87)	20.18 (3.94)		
Week 40 Adjusted Mean Change (SE)	23.53 (3.84)	21.50 (3.94)		
Week 52 Adjusted Mean Change (SE)	23.92 (4.22)	28.29 (4.50)	-4.37 [-16.56; 7.81]	0.479
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	44.77 (22.56)	50.00 (23.53)		
Week 52 Mean (SD)	67.77 (23.80)	65.18 (21.93)		
Week 4 Adjusted Mean Change (SE)	9.96 (2.40)	6.34 (2.99)		
Week 12 Adjusted Mean Change (SE)	16.95 (2.74)	10.74 (3.39)		
Week 16 Adjusted Mean Change (SE)	16.20 (2.54)	9.09 (3.18)		
Week 24 Adjusted Mean Change (SE)	19.69 (2.94)	18.54 (3.68)		
Week 32 Adjusted Mean Change (SE)	22.42 (2.84)	19.61 (3.53)		
Week 40 Adjusted Mean Change (SE)	17.70 (2.79)	17.03 (3.52)		
Week 52 Adjusted Mean Change (SE)	23.49 (3.09)	18.46 (3.81)	5.03 [-4.65; 14.71]	0.306
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 48.18 SF-36 Role Physical - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.806</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	41.86 (22.84)	49.13 (25.57)		
Week 52 Mean (SD)	65.87 (25.96)	68.11 (27.24)		
Week 4 Adjusted Mean Change (SE)	13.65 (2.78)	11.64 (2.79)		
Week 12 Adjusted Mean Change (SE)	22.90 (3.14)	15.85 (3.15)		
Week 16 Adjusted Mean Change (SE)	18.44 (2.95)	15.37 (2.97)		
Week 24 Adjusted Mean Change (SE)	20.43 (3.37)	19.57 (3.41)		
Week 32 Adjusted Mean Change (SE)	22.51 (3.24)	21.07 (3.25)		
Week 40 Adjusted Mean Change (SE)	17.91 (3.18)	22.27 (3.23)		
Week 52 Adjusted Mean Change (SE)	22.60 (3.57)	23.08 (3.60)	-0.48 [-10.51; 9.56]	0.925
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	40.03 (23.55)	44.01 (26.87)		
Week 52 Mean (SD)	66.31 (23.75)	70.83 (24.16)		
Week 4 Adjusted Mean Change (SE)	11.36 (2.82)	9.36 (3.79)		
Week 12 Adjusted Mean Change (SE)	15.35 (3.18)	14.39 (4.25)		
Week 16 Adjusted Mean Change (SE)	15.99 (2.98)	14.26 (4.05)		
Week 24 Adjusted Mean Change (SE)	21.40 (3.39)	22.65 (4.65)		
Week 32 Adjusted Mean Change (SE)	23.49 (3.22)	18.36 (4.43)		
Week 40 Adjusted Mean Change (SE)	21.41 (3.20)	13.29 (4.47)		
Week 52 Adjusted Mean Change (SE)	24.45 (3.55)	21.87 (5.09)	2.58 [-9.71; 14.86]	0.679
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 48.19 SF-36 Role Physical - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.296</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	40.96 (20.55)	47.45 (26.48)		
Week 52 Mean (SD)	66.39 (24.98)	66.72 (26.91)		
Week 4 Adjusted Mean Change (SE)	12.27 (2.20)	9.00 (2.55)		
Week 12 Adjusted Mean Change (SE)	17.12 (2.56)	12.95 (2.96)		
Week 16 Adjusted Mean Change (SE)	17.95 (2.39)	13.47 (2.78)		
Week 24 Adjusted Mean Change (SE)	20.53 (2.73)	18.03 (3.24)		
Week 32 Adjusted Mean Change (SE)	22.47 (2.62)	18.13 (3.06)		
Week 40 Adjusted Mean Change (SE)	18.90 (2.60)	17.66 (3.08)		
Week 52 Adjusted Mean Change (SE)	24.05 (2.88)	19.63 (3.47)	4.41 [-4.53; 13.36]	0.331
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	44.10 (30.28)	46.88 (25.21)		
Week 52 Mean (SD)	68.01 (23.99)	74.26 (24.09)		
Week 4 Adjusted Mean Change (SE)	9.57 (4.18)	14.98 (4.15)		
Week 12 Adjusted Mean Change (SE)	23.11 (4.82)	20.86 (4.79)		
Week 16 Adjusted Mean Change (SE)	13.04 (4.54)	18.31 (4.57)		
Week 24 Adjusted Mean Change (SE)	22.50 (5.30)	26.91 (5.21)		
Week 32 Adjusted Mean Change (SE)	23.82 (4.98)	24.74 (5.01)		
Week 40 Adjusted Mean Change (SE)	21.36 (4.98)	22.70 (5.07)		
Week 52 Adjusted Mean Change (SE)	22.18 (5.49)	29.60 (5.46)	-7.41 [-22.72; 7.89]	0.340
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



#### 49.0 SF-36 Social Functioning - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

#### 49.1 SF-36 Social Functioning - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	56.25 (28.62)	55.82 (25.22)		
Week 52 Mean (SD)	79.52 (23.33)	75.46 (25.42)		
Week 4 Adjusted Mean Change (SE)	14.76 (2.06)	13.49 (2.17)		
Week 12 Adjusted Mean Change (SE)	19.81 (1.96)	17.34 (2.05)		
Week 16 Adjusted Mean Change (SE)	19.03 (2.04)	15.81 (2.16)		
Week 24 Adjusted Mean Change (SE)	19.98 (2.00)	15.36 (2.16)		
Week 32 Adjusted Mean Change (SE)	20.80 (2.09)	19.26 (2.26)		
Week 40 Adjusted Mean Change (SE)	20.92 (2.07)	14.81 (2.26)		
Week 52 Adjusted Mean Change (SE)	23.51 (2.19)	18.19 (2.42)	5.32 [-1.13; 11.76]	0.105
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 49.2 SF-36 Social Functioning - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.813</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	55.10 (28.25)	55.98 (25.32)		
Week 52 Mean (SD)	79.29 (23.63)	75.49 (25.86)		
Week 4 Adjusted Mean Change (SE)	14.74 (2.14)	13.94 (2.26)		
Week 12 Adjusted Mean Change (SE)	20.49 (2.03)	17.54 (2.13)		
Week 16 Adjusted Mean Change (SE)	19.43 (2.10)	15.19 (2.25)		
Week 24 Adjusted Mean Change (SE)	19.93 (2.08)	14.97 (2.25)		
Week 32 Adjusted Mean Change (SE)	20.78 (2.17)	19.35 (2.37)		
Week 40 Adjusted Mean Change (SE)	20.78 (2.15)	15.31 (2.36)		
Week 52 Adjusted Mean Change (SE)	23.76 (2.28)	18.21 (2.53)	5.55 [-1.17; 12.26]	0.105
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	73.21 (30.98)	53.57 (25.73)		
Week 52 Mean (SD)	83.33 (18.82)	75.00 (20.92)		
Week 4 Adjusted Mean Change (SE)	15.15 (8.27)	7.53 (8.21)		
Week 12 Adjusted Mean Change (SE)	10.15 (7.76)	14.63 (7.70)		
Week 16 Adjusted Mean Change (SE)	12.49 (8.46)	23.49 (8.07)		
Week 24 Adjusted Mean Change (SE)	20.49 (7.96)	20.03 (7.90)		
Week 32 Adjusted Mean Change (SE)	21.08 (8.24)	18.17 (8.18)		
Week 40 Adjusted Mean Change (SE)	22.81 (8.21)	9.25 (8.14)		
Week 52 Adjusted Mean Change (SE)	19.27 (9.02)	18.18 (8.97)	1.10 [-23.98; 26.17]	0.931
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 49.3 SF-36 Social Functioning - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.125</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	63.45 (28.19)	57.24 (24.54)		
Week 52 Mean (SD)	81.05 (24.09)	77.86 (26.70)		
Week 4 Adjusted Mean Change (SE)	16.78 (2.74)	14.67 (2.90)		
Week 12 Adjusted Mean Change (SE)	20.28 (2.61)	19.84 (2.72)		
Week 16 Adjusted Mean Change (SE)	19.68 (2.68)	19.88 (2.83)		
Week 24 Adjusted Mean Change (SE)	17.84 (2.63)	17.07 (2.83)		
Week 32 Adjusted Mean Change (SE)	21.10 (2.75)	23.13 (2.99)		
Week 40 Adjusted Mean Change (SE)	20.35 (2.70)	20.39 (2.95)		
Week 52 Adjusted Mean Change (SE)	22.44 (2.89)	20.63 (3.19)	1.81 [-6.65; 10.26]	0.673
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	45.45 (26.01)	53.98 (26.24)		
Week 52 Mean (SD)	77.13 (22.17)	72.06 (23.45)		
Week 4 Adjusted Mean Change (SE)	11.76 (3.37)	11.95 (3.31)		
Week 12 Adjusted Mean Change (SE)	19.13 (3.20)	14.07 (3.13)		
Week 16 Adjusted Mean Change (SE)	18.09 (3.29)	10.31 (3.30)		
Week 24 Adjusted Mean Change (SE)	23.48 (3.31)	13.25 (3.33)		
Week 32 Adjusted Mean Change (SE)	20.41 (3.44)	14.20 (3.46)		
Week 40 Adjusted Mean Change (SE)	21.87 (3.36)	7.33 (3.45)		
Week 52 Adjusted Mean Change (SE)	25.24 (3.62)	15.02 (3.75)	10.22 [0.01; 20.43]	0.050
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 49.4 SF-36 Social Functioning - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.786</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	72.40 (27.08)	76.79 (22.11)		
Week 52 Mean (SD)	87.50 (18.84)	81.62 (27.29)		
Week 4 Adjusted Mean Change (SE)	18.71 (4.54)	15.25 (4.90)		
Week 12 Adjusted Mean Change (SE)	22.57 (4.38)	21.31 (4.61)		
Week 16 Adjusted Mean Change (SE)	23.19 (4.43)	24.70 (4.78)		
Week 24 Adjusted Mean Change (SE)	17.25 (4.47)	16.96 (4.85)		
Week 32 Adjusted Mean Change (SE)	21.90 (4.64)	22.85 (5.18)		
Week 40 Adjusted Mean Change (SE)	26.53 (4.61)	18.86 (5.12)		
Week 52 Adjusted Mean Change (SE)	26.41 (4.83)	20.65 (5.48)	5.76 [-8.33; 19.85]	0.421
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	51.74 (27.53)	50.31 (23.11)		
Week 52 Mean (SD)	77.29 (24.07)	73.85 (24.87)		
Week 4 Adjusted Mean Change (SE)	13.67 (2.35)	13.02 (2.47)		
Week 12 Adjusted Mean Change (SE)	19.06 (2.23)	16.28 (2.34)		
Week 16 Adjusted Mean Change (SE)	17.87 (2.30)	13.35 (2.44)		
Week 24 Adjusted Mean Change (SE)	20.64 (2.27)	14.93 (2.46)		
Week 32 Adjusted Mean Change (SE)	20.50 (2.38)	18.32 (2.57)		
Week 40 Adjusted Mean Change (SE)	19.41 (2.35)	13.74 (2.56)		
Week 52 Adjusted Mean Change (SE)	22.70 (2.50)	17.53 (2.75)	5.17 [-2.12; 12.46]	0.163
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 49.5 SF-36 Social Functioning - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.549</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	59.52 (27.58)	54.66 (23.71)		
Week 52 Mean (SD)	83.33 (21.14)	77.96 (21.64)		
Week 4 Adjusted Mean Change (SE)	15.09 (3.36)	15.42 (3.07)		
Week 12 Adjusted Mean Change (SE)	19.27 (3.19)	18.40 (2.89)		
Week 16 Adjusted Mean Change (SE)	17.96 (3.31)	14.98 (3.06)		
Week 24 Adjusted Mean Change (SE)	17.54 (3.26)	17.95 (3.05)		
Week 32 Adjusted Mean Change (SE)	18.69 (3.41)	20.53 (3.21)		
Week 40 Adjusted Mean Change (SE)	20.82 (3.39)	14.54 (3.28)		
Week 52 Adjusted Mean Change (SE)	26.69 (3.59)	19.90 (3.51)	6.79 [-3.11; 16.70]	0.178
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	54.23 (29.26)	57.00 (26.86)		
Week 52 Mean (SD)	77.27 (24.41)	73.30 (28.35)		
Week 4 Adjusted Mean Change (SE)	14.56 (2.64)	11.51 (3.10)		
Week 12 Adjusted Mean Change (SE)	20.15 (2.52)	16.23 (2.94)		
Week 16 Adjusted Mean Change (SE)	19.69 (2.61)	16.61 (3.08)		
Week 24 Adjusted Mean Change (SE)	21.45 (2.54)	12.74 (3.05)		
Week 32 Adjusted Mean Change (SE)	22.12 (2.66)	17.99 (3.21)		
Week 40 Adjusted Mean Change (SE)	21.01 (2.65)	14.89 (3.18)		
Week 52 Adjusted Mean Change (SE)	21.65 (2.78)	16.62 (3.36)	5.03 [-3.59; 13.66]	0.251
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 49.6 SF-36 Social Functioning - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.928</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	55.03 (25.67)	61.48 (24.98)		
Week 52 Mean (SD)	80.18 (22.67)	81.60 (23.62)		
Week 4 Adjusted Mean Change (SE)	16.03 (2.56)	12.32 (3.11)		
Week 12 Adjusted Mean Change (SE)	20.21 (2.45)	17.88 (2.94)		
Week 16 Adjusted Mean Change (SE)	19.31 (2.52)	19.10 (3.09)		
Week 24 Adjusted Mean Change (SE)	21.23 (2.45)	17.46 (3.12)		
Week 32 Adjusted Mean Change (SE)	21.84 (2.58)	21.07 (3.30)		
Week 40 Adjusted Mean Change (SE)	23.23 (2.54)	17.11 (3.31)		
Week 52 Adjusted Mean Change (SE)	24.41 (2.71)	19.05 (3.63)	5.36 [-3.59; 14.32]	0.239
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	58.55 (33.78)	50.48 (24.50)		
Week 52 Mean (SD)	78.21 (24.88)	70.65 (25.98)		
Week 4 Adjusted Mean Change (SE)	12.36 (3.52)	14.63 (3.08)		
Week 12 Adjusted Mean Change (SE)	19.04 (3.32)	16.82 (2.92)		
Week 16 Adjusted Mean Change (SE)	18.47 (3.46)	12.64 (3.04)		
Week 24 Adjusted Mean Change (SE)	17.50 (3.46)	13.42 (3.01)		
Week 32 Adjusted Mean Change (SE)	18.78 (3.59)	17.63 (3.14)		
Week 40 Adjusted Mean Change (SE)	16.43 (3.53)	12.71 (3.11)		
Week 52 Adjusted Mean Change (SE)	21.76 (3.80)	17.21 (3.33)	4.55 [-5.44; 14.54]	0.370
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 49.7 SF-36 Social Functioning - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.033</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	59.07 (30.01)	58.20 (27.97)		
Week 52 Mean (SD)	81.12 (25.02)	85.00 (20.73)		
Week 4 Adjusted Mean Change (SE)	15.55 (3.02)	19.37 (3.88)		
Week 12 Adjusted Mean Change (SE)	20.75 (2.90)	21.94 (3.70)		
Week 16 Adjusted Mean Change (SE)	19.66 (2.89)	28.11 (3.74)		
Week 24 Adjusted Mean Change (SE)	18.81 (2.91)	21.60 (3.79)		
Week 32 Adjusted Mean Change (SE)	20.43 (3.02)	28.46 (3.93)		
Week 40 Adjusted Mean Change (SE)	22.69 (3.03)	20.61 (3.96)		
Week 52 Adjusted Mean Change (SE)	24.36 (3.18)	26.60 (4.31)	-2.23 [-12.79; 8.32]	0.677
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	53.81 (27.39)	54.71 (23.98)		
Week 52 Mean (SD)	78.13 (21.88)	71.27 (26.30)		
Week 4 Adjusted Mean Change (SE)	14.10 (2.81)	10.80 (2.62)		
Week 12 Adjusted Mean Change (SE)	19.06 (2.66)	15.19 (2.47)		
Week 16 Adjusted Mean Change (SE)	18.52 (2.70)	10.20 (2.52)		
Week 24 Adjusted Mean Change (SE)	21.02 (2.73)	12.47 (2.61)		
Week 32 Adjusted Mean Change (SE)	21.15 (2.82)	15.00 (2.72)		
Week 40 Adjusted Mean Change (SE)	19.43 (2.82)	12.19 (2.75)		
Week 52 Adjusted Mean Change (SE)	22.79 (2.98)	14.38 (2.90)	8.41 [0.22; 16.61]	0.044
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 49.8 SF-36 Social Functioning - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.941</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	52.21 (27.81)	60.67 (21.75)		
Week 52 Mean (SD)	78.06 (24.94)	84.03 (20.18)		
Week 4 Adjusted Mean Change (SE)	18.34 (3.00)	15.83 (3.34)		
Week 12 Adjusted Mean Change (SE)	20.01 (2.74)	18.88 (3.08)		
Week 16 Adjusted Mean Change (SE)	19.32 (2.91)	17.11 (3.29)		
Week 24 Adjusted Mean Change (SE)	20.75 (2.94)	15.21 (3.36)		
Week 32 Adjusted Mean Change (SE)	19.69 (3.00)	23.08 (3.41)		
Week 40 Adjusted Mean Change (SE)	20.26 (2.99)	16.77 (3.41)		
Week 52 Adjusted Mean Change (SE)	23.88 (2.98)	25.44 (3.42)	-1.56 [-10.56; 7.44]	0.732
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	61.76 (27.17)	55.77 (31.27)		
Week 52 Mean (SD)	81.05 (23.91)	72.02 (26.78)		
Week 4 Adjusted Mean Change (SE)	9.96 (3.67)	8.77 (4.26)		
Week 12 Adjusted Mean Change (SE)	15.53 (3.43)	14.76 (3.90)		
Week 16 Adjusted Mean Change (SE)	13.38 (3.60)	17.77 (4.14)		
Week 24 Adjusted Mean Change (SE)	15.53 (3.64)	18.26 (4.28)		
Week 32 Adjusted Mean Change (SE)	20.01 (3.76)	17.94 (4.35)		
Week 40 Adjusted Mean Change (SE)	19.46 (3.70)	15.70 (4.44)		
Week 52 Adjusted Mean Change (SE)	21.24 (3.71)	14.79 (4.44)	6.45 [-4.98; 17.88]	0.266
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 49.9 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.323</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	55.56 (26.72)	58.80 (23.47)		
Week 52 Mean (SD)	78.20 (25.16)	80.26 (20.55)		
Week 4 Adjusted Mean Change (SE)	17.79 (3.25)	10.50 (4.28)		
Week 12 Adjusted Mean Change (SE)	20.62 (2.95)	16.10 (3.88)		
Week 16 Adjusted Mean Change (SE)	18.63 (3.16)	14.03 (4.22)		
Week 24 Adjusted Mean Change (SE)	16.48 (3.19)	15.78 (4.36)		
Week 32 Adjusted Mean Change (SE)	21.34 (3.19)	20.23 (4.33)		
Week 40 Adjusted Mean Change (SE)	19.99 (3.23)	12.78 (4.43)		
Week 52 Adjusted Mean Change (SE)	21.45 (3.30)	23.38 (4.72)	-1.93 [-13.32; 9.46]	0.738
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	56.91 (29.45)	57.92 (29.27)		
Week 52 Mean (SD)	80.00 (24.29)	80.36 (26.45)		
Week 4 Adjusted Mean Change (SE)	11.64 (3.53)	15.93 (3.98)		
Week 12 Adjusted Mean Change (SE)	15.40 (3.26)	21.58 (3.65)		
Week 16 Adjusted Mean Change (SE)	15.06 (3.47)	20.44 (3.92)		
Week 24 Adjusted Mean Change (SE)	21.54 (3.51)	17.51 (4.02)		
Week 32 Adjusted Mean Change (SE)	19.13 (3.49)	24.33 (3.95)		
Week 40 Adjusted Mean Change (SE)	20.38 (3.49)	20.61 (4.06)		
Week 52 Adjusted Mean Change (SE)	24.17 (3.62)	22.44 (4.08)	1.72 [-9.06; 12.51]	0.752
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 49.10 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.302</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	57.50 (29.83)	55.68 (27.08)		
Week 52 Mean (SD)	83.19 (23.45)	82.81 (24.12)		
Week 4 Adjusted Mean Change (SE)	13.75 (3.92)	17.35 (3.80)		
Week 12 Adjusted Mean Change (SE)	20.35 (3.56)	20.25 (3.48)		
Week 16 Adjusted Mean Change (SE)	18.33 (3.80)	21.13 (3.72)		
Week 24 Adjusted Mean Change (SE)	18.62 (3.92)	15.74 (3.95)		
Week 32 Adjusted Mean Change (SE)	20.19 (3.90)	25.68 (3.92)		
Week 40 Adjusted Mean Change (SE)	18.37 (3.91)	19.17 (3.97)		
Week 52 Adjusted Mean Change (SE)	25.79 (3.91)	25.41 (4.12)	0.38 [-10.84; 11.60]	0.947
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	52.70 (26.14)	61.76 (24.41)		
Week 52 Mean (SD)	76.28 (25.16)	77.27 (22.85)		
Week 4 Adjusted Mean Change (SE)	16.41 (3.02)	9.85 (3.71)		
Week 12 Adjusted Mean Change (SE)	18.46 (2.77)	15.06 (3.36)		
Week 16 Adjusted Mean Change (SE)	17.41 (2.92)	14.52 (3.62)		
Week 24 Adjusted Mean Change (SE)	19.72 (2.95)	17.12 (3.66)		
Week 32 Adjusted Mean Change (SE)	20.42 (3.01)	17.62 (3.70)		
Week 40 Adjusted Mean Change (SE)	22.12 (2.99)	14.23 (3.74)		
Week 52 Adjusted Mean Change (SE)	21.98 (3.00)	18.71 (3.68)	3.27 [-6.16; 12.70]	0.494
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 49.11 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.509</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	53.78 (28.81)	59.59 (25.42)		
Week 52 Mean (SD)	78.85 (25.03)	79.49 (25.57)		
Week 4 Adjusted Mean Change (SE)	15.57 (3.30)	15.25 (3.30)		
Week 12 Adjusted Mean Change (SE)	17.95 (3.02)	17.87 (3.01)		
Week 16 Adjusted Mean Change (SE)	13.85 (3.20)	17.43 (3.19)		
Week 24 Adjusted Mean Change (SE)	17.23 (3.23)	15.05 (3.28)		
Week 32 Adjusted Mean Change (SE)	19.33 (3.33)	23.30 (3.33)		
Week 40 Adjusted Mean Change (SE)	18.81 (3.29)	17.00 (3.33)		
Week 52 Adjusted Mean Change (SE)	23.37 (3.35)	22.49 (3.35)	0.88 [-8.49; 10.26]	0.852
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	58.33 (26.86)	57.29 (26.81)		
Week 52 Mean (SD)	79.57 (24.17)	79.86 (18.26)		
Week 4 Adjusted Mean Change (SE)	14.38 (3.34)	9.32 (4.50)		
Week 12 Adjusted Mean Change (SE)	18.49 (3.06)	16.30 (4.08)		
Week 16 Adjusted Mean Change (SE)	20.05 (3.20)	17.47 (4.38)		
Week 24 Adjusted Mean Change (SE)	20.15 (3.23)	18.90 (4.47)		
Week 32 Adjusted Mean Change (SE)	20.14 (3.29)	17.12 (4.56)		
Week 40 Adjusted Mean Change (SE)	21.02 (3.29)	15.20 (4.66)		
Week 52 Adjusted Mean Change (SE)	22.32 (3.30)	19.71 (4.79)	2.62 [-8.88; 14.12]	0.654
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 49.12 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.274</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	55.85 (25.98)	58.78 (25.79)		
Week 52 Mean (SD)	78.23 (23.83)	79.61 (21.44)		
Week 4 Adjusted Mean Change (SE)	15.13 (2.73)	12.30 (3.15)		
Week 12 Adjusted Mean Change (SE)	16.48 (2.50)	15.78 (2.86)		
Week 16 Adjusted Mean Change (SE)	16.33 (2.65)	16.99 (3.07)		
Week 24 Adjusted Mean Change (SE)	18.61 (2.64)	14.24 (3.14)		
Week 32 Adjusted Mean Change (SE)	19.21 (2.69)	19.68 (3.16)		
Week 40 Adjusted Mean Change (SE)	21.20 (2.57)	13.76 (3.06)		
Week 52 Adjusted Mean Change (SE)	22.09 (2.71)	21.07 (3.26)	1.02 [-7.38; 9.41]	0.811
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	56.88 (33.80)	63.89 (22.23)		
Week 52 Mean (SD)	83.55 (26.70)	86.76 (17.94)		
Week 4 Adjusted Mean Change (SE)	12.40 (4.82)	14.16 (5.06)		
Week 12 Adjusted Mean Change (SE)	20.54 (4.38)	22.15 (4.68)		
Week 16 Adjusted Mean Change (SE)	17.37 (4.65)	20.95 (4.97)		
Week 24 Adjusted Mean Change (SE)	19.31 (4.82)	23.19 (5.06)		
Week 32 Adjusted Mean Change (SE)	19.56 (4.76)	26.79 (5.06)		
Week 40 Adjusted Mean Change (SE)	17.64 (4.58)	26.74 (4.86)		
Week 52 Adjusted Mean Change (SE)	24.21 (4.76)	27.12 (5.00)	-2.91 [-16.56; 10.74]	0.674
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 49.13 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.054</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	56.15 (28.12)	59.31 (27.48)		
Week 52 Mean (SD)	78.45 (24.98)	82.74 (22.59)		
Week 4 Adjusted Mean Change (SE)	14.02 (2.66)	17.24 (3.00)		
Week 12 Adjusted Mean Change (SE)	17.48 (2.47)	17.65 (2.79)		
Week 16 Adjusted Mean Change (SE)	15.69 (2.58)	20.92 (2.93)		
Week 24 Adjusted Mean Change (SE)	16.37 (2.65)	16.53 (3.04)		
Week 32 Adjusted Mean Change (SE)	18.24 (2.65)	25.70 (3.00)		
Week 40 Adjusted Mean Change (SE)	18.47 (2.64)	19.84 (3.04)		
Week 52 Adjusted Mean Change (SE)	22.04 (2.72)	24.53 (3.15)	-2.49 [-10.73; 5.75]	0.551
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	58.55 (27.34)	56.25 (20.98)		
Week 52 Mean (SD)	79.61 (24.72)	69.79 (24.69)		
Week 4 Adjusted Mean Change (SE)	16.43 (4.85)	1.44 (6.13)		
Week 12 Adjusted Mean Change (SE)	16.33 (4.48)	16.08 (5.67)		
Week 16 Adjusted Mean Change (SE)	18.41 (4.68)	5.60 (5.92)		
Week 24 Adjusted Mean Change (SE)	22.26 (4.74)	20.24 (5.99)		
Week 32 Adjusted Mean Change (SE)	20.36 (4.72)	8.36 (6.08)		
Week 40 Adjusted Mean Change (SE)	22.27 (4.72)	6.84 (6.08)		
Week 52 Adjusted Mean Change (SE)	21.65 (4.81)	11.88 (6.08)	9.76 [-5.55; 25.08]	0.209
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

#### 49.14 SF-36 Social Functioning - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.470</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	57.22 (28.87)	55.42 (26.46)		
Week 52 Mean (SD)	79.36 (24.46)	81.53 (23.58)		
Week 4 Adjusted Mean Change (SE)	15.46 (2.56)	14.85 (2.99)		
Week 12 Adjusted Mean Change (SE)	18.87 (2.31)	19.31 (2.71)		
Week 16 Adjusted Mean Change (SE)	17.46 (2.46)	19.30 (2.90)		
Week 24 Adjusted Mean Change (SE)	19.84 (2.51)	17.25 (3.00)		
Week 32 Adjusted Mean Change (SE)	20.45 (2.55)	22.52 (3.01)		
Week 40 Adjusted Mean Change (SE)	20.97 (2.56)	17.34 (3.07)		
Week 52 Adjusted Mean Change (SE)	22.89 (2.49)	24.76 (3.00)	-1.88 [-9.59; 5.84]	0.631
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	49.04 (21.93)	68.75 (15.87)		
Week 52 Mean (SD)	77.88 (26.10)	76.25 (19.05)		
Week 4 Adjusted Mean Change (SE)	14.26 (6.02)	3.73 (6.88)		
Week 12 Adjusted Mean Change (SE)	15.44 (5.55)	11.86 (6.18)		
Week 16 Adjusted Mean Change (SE)	16.18 (5.76)	7.48 (6.58)		
Week 24 Adjusted Mean Change (SE)	16.40 (5.80)	13.36 (6.63)		
Week 32 Adjusted Mean Change (SE)	18.99 (5.86)	20.10 (6.69)		
Week 40 Adjusted Mean Change (SE)	16.36 (5.91)	13.43 (6.76)		
Week 52 Adjusted Mean Change (SE)	24.14 (5.70)	14.53 (6.52)	9.61 [-7.64; 26.85]	0.272
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 49.15 SF-36 Social Functioning - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.694</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	57.39 (31.02)	56.25 (28.56)		
Week 52 Mean (SD)	82.24 (26.13)	77.08 (28.20)		
Week 4 Adjusted Mean Change (SE)	18.42 (4.59)	16.94 (4.32)		
Week 12 Adjusted Mean Change (SE)	22.37 (4.15)	16.41 (3.91)		
Week 16 Adjusted Mean Change (SE)	18.69 (4.49)	19.84 (4.22)		
Week 24 Adjusted Mean Change (SE)	15.91 (4.58)	13.44 (4.37)		
Week 32 Adjusted Mean Change (SE)	20.33 (4.68)	21.35 (4.46)		
Week 40 Adjusted Mean Change (SE)	19.83 (4.62)	11.14 (4.45)		
Week 52 Adjusted Mean Change (SE)	24.23 (4.75)	21.53 (4.74)	2.69 [-10.57; 15.96]	0.689
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	55.56 (26.83)	60.37 (24.03)		
Week 52 Mean (SD)	78.28 (24.03)	80.77 (21.04)		
Week 4 Adjusted Mean Change (SE)	13.78 (2.71)	10.88 (3.38)		
Week 12 Adjusted Mean Change (SE)	16.73 (2.48)	17.93 (3.08)		
Week 16 Adjusted Mean Change (SE)	16.36 (2.62)	15.97 (3.28)		
Week 24 Adjusted Mean Change (SE)	19.51 (2.63)	18.05 (3.34)		
Week 32 Adjusted Mean Change (SE)	19.45 (2.71)	20.90 (3.40)		
Week 40 Adjusted Mean Change (SE)	19.87 (2.65)	19.23 (3.38)		
Week 52 Adjusted Mean Change (SE)	22.30 (2.70)	21.58 (3.39)	0.72 [-7.85; 9.29]	0.868
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 49.16 SF-36 Social Functioning - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.509</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	57.35 (26.60)	58.21 (22.47)		
Week 52 Mean (SD)	79.34 (24.68)	80.09 (19.69)		
Week 4 Adjusted Mean Change (SE)	16.37 (3.03)	11.10 (3.71)		
Week 12 Adjusted Mean Change (SE)	19.57 (2.76)	15.77 (3.35)		
Week 16 Adjusted Mean Change (SE)	18.08 (2.91)	15.69 (3.60)		
Week 24 Adjusted Mean Change (SE)	16.63 (2.93)	15.49 (3.69)		
Week 32 Adjusted Mean Change (SE)	21.25 (3.00)	19.93 (3.75)		
Week 40 Adjusted Mean Change (SE)	20.24 (3.00)	14.47 (3.78)		
Week 52 Adjusted Mean Change (SE)	22.08 (3.02)	22.75 (3.92)	-0.67 [-10.47; 9.14]	0.894
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	54.04 (29.79)	59.38 (29.27)		
Week 52 Mean (SD)	79.03 (24.45)	79.17 (26.53)		
Week 4 Adjusted Mean Change (SE)	12.90 (3.72)	15.41 (3.82)		
Week 12 Adjusted Mean Change (SE)	16.15 (3.40)	19.01 (3.49)		
Week 16 Adjusted Mean Change (SE)	15.22 (3.61)	19.27 (3.71)		
Week 24 Adjusted Mean Change (SE)	21.95 (3.65)	17.32 (3.80)		
Week 32 Adjusted Mean Change (SE)	17.32 (3.73)	22.45 (3.86)		
Week 40 Adjusted Mean Change (SE)	19.43 (3.67)	18.40 (3.88)		
Week 52 Adjusted Mean Change (SE)	24.05 (3.76)	20.69 (3.85)	3.36 [-7.32; 14.04]	0.535
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 49.17 SF-36 Social Functioning - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.224</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	57.50 (29.83)	56.05 (27.93)		
Week 52 Mean (SD)	83.19 (23.45)	83.52 (24.82)		
Week 4 Adjusted Mean Change (SE)	13.41 (3.91)	18.83 (3.91)		
Week 12 Adjusted Mean Change (SE)	20.04 (3.52)	22.41 (3.57)		
Week 16 Adjusted Mean Change (SE)	17.99 (3.74)	23.34 (3.79)		
Week 24 Adjusted Mean Change (SE)	18.29 (3.90)	15.63 (4.08)		
Week 32 Adjusted Mean Change (SE)	19.83 (3.90)	24.93 (4.07)		
Week 40 Adjusted Mean Change (SE)	18.07 (3.90)	18.86 (4.11)		
Week 52 Adjusted Mean Change (SE)	25.45 (3.89)	25.15 (4.27)	0.29 [-11.12; 11.71]	0.960
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	55.23 (26.86)	61.11 (23.86)		
Week 52 Mean (SD)	76.96 (24.92)	77.14 (22.38)		
Week 4 Adjusted Mean Change (SE)	15.85 (2.89)	8.44 (3.58)		
Week 12 Adjusted Mean Change (SE)	17.17 (2.63)	13.11 (3.23)		
Week 16 Adjusted Mean Change (SE)	16.41 (2.78)	12.47 (3.46)		
Week 24 Adjusted Mean Change (SE)	18.85 (2.84)	16.40 (3.53)		
Week 32 Adjusted Mean Change (SE)	19.66 (2.91)	17.93 (3.58)		
Week 40 Adjusted Mean Change (SE)	20.92 (2.88)	14.08 (3.61)		
Week 52 Adjusted Mean Change (SE)	21.29 (2.91)	18.59 (3.55)	2.70 [-6.40; 11.81]	0.558
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 49.18 SF-36 Social Functioning - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.509</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	53.78 (28.81)	59.59 (25.42)		
Week 52 Mean (SD)	78.85 (25.03)	79.49 (25.57)		
Week 4 Adjusted Mean Change (SE)	15.57 (3.30)	15.25 (3.30)		
Week 12 Adjusted Mean Change (SE)	17.95 (3.02)	17.87 (3.01)		
Week 16 Adjusted Mean Change (SE)	13.85 (3.20)	17.43 (3.19)		
Week 24 Adjusted Mean Change (SE)	17.23 (3.23)	15.05 (3.28)		
Week 32 Adjusted Mean Change (SE)	19.33 (3.33)	23.30 (3.33)		
Week 40 Adjusted Mean Change (SE)	18.81 (3.29)	17.00 (3.33)		
Week 52 Adjusted Mean Change (SE)	23.37 (3.35)	22.49 (3.35)	0.88 [-8.49; 10.26]	0.852
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	58.33 (26.86)	57.29 (26.81)		
Week 52 Mean (SD)	79.57 (24.17)	79.86 (18.26)		
Week 4 Adjusted Mean Change (SE)	14.38 (3.34)	9.32 (4.50)		
Week 12 Adjusted Mean Change (SE)	18.49 (3.06)	16.30 (4.08)		
Week 16 Adjusted Mean Change (SE)	20.05 (3.20)	17.47 (4.38)		
Week 24 Adjusted Mean Change (SE)	20.15 (3.23)	18.90 (4.47)		
Week 32 Adjusted Mean Change (SE)	20.14 (3.29)	17.12 (4.56)		
Week 40 Adjusted Mean Change (SE)	21.02 (3.29)	15.20 (4.66)		
Week 52 Adjusted Mean Change (SE)	22.32 (3.30)	19.71 (4.79)	2.62 [-8.88; 14.12]	0.654
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 49.19 SF-36 Social Functioning - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.338</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	56.54 (25.78)	57.91 (26.11)		
Week 52 Mean (SD)	78.48 (23.84)	78.75 (22.86)		
Week 4 Adjusted Mean Change (SE)	14.96 (2.67)	12.85 (3.10)		
Week 12 Adjusted Mean Change (SE)	16.62 (2.45)	14.99 (2.83)		
Week 16 Adjusted Mean Change (SE)	16.58 (2.59)	16.22 (3.01)		
Week 24 Adjusted Mean Change (SE)	18.23 (2.60)	13.43 (3.12)		
Week 32 Adjusted Mean Change (SE)	18.90 (2.67)	19.03 (3.14)		
Week 40 Adjusted Mean Change (SE)	20.35 (2.62)	12.82 (3.12)		
Week 52 Adjusted Mean Change (SE)	22.09 (2.71)	20.64 (3.27)	1.45 [-6.95; 9.86]	0.733
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	59.03 (32.60)	61.11 (25.32)		
Week 52 Mean (SD)	84.56 (26.71)	81.62 (25.05)		
Week 4 Adjusted Mean Change (SE)	10.44 (5.09)	12.45 (5.07)		
Week 12 Adjusted Mean Change (SE)	20.10 (4.62)	22.02 (4.59)		
Week 16 Adjusted Mean Change (SE)	14.61 (4.92)	18.99 (4.98)		
Week 24 Adjusted Mean Change (SE)	18.80 (5.14)	22.55 (5.01)		
Week 32 Adjusted Mean Change (SE)	19.17 (5.10)	24.86 (5.13)		
Week 40 Adjusted Mean Change (SE)	17.65 (5.05)	24.73 (5.16)		
Week 52 Adjusted Mean Change (SE)	24.31 (5.17)	22.86 (5.14)	1.45 [-12.96; 15.85]	0.843
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.0 SF-36 Vitality - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

### 50.1 SF-36 Vitality - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	36.93 (20.56)	39.17 (20.76)		
Week 52 Mean (SD)	54.94 (21.99)	52.52 (21.45)		
Week 4 Adjusted Mean Change (SE)	11.13 (1.57)	10.71 (1.65)		
Week 12 Adjusted Mean Change (SE)	14.32 (1.82)	11.71 (1.90)		
Week 16 Adjusted Mean Change (SE)	16.32 (1.64)	12.18 (1.74)		
Week 24 Adjusted Mean Change (SE)	15.99 (1.86)	14.15 (1.99)		
Week 32 Adjusted Mean Change (SE)	16.89 (1.77)	15.27 (1.90)		
Week 40 Adjusted Mean Change (SE)	15.76 (1.74)	13.07 (1.90)		
Week 52 Adjusted Mean Change (SE)	17.37 (1.89)	12.30 (2.08)	5.07 [-0.48; 10.63]	0.073
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 50.2 SF-36 Vitality - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.620</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	36.59 (20.44)	39.16 (21.22)		
Week 52 Mean (SD)	54.92 (22.36)	52.47 (21.36)		
Week 4 Adjusted Mean Change (SE)	11.01 (1.63)	10.55 (1.72)		
Week 12 Adjusted Mean Change (SE)	14.52 (1.89)	11.48 (1.98)		
Week 16 Adjusted Mean Change (SE)	16.26 (1.70)	11.99 (1.81)		
Week 24 Adjusted Mean Change (SE)	15.79 (1.93)	14.43 (2.07)		
Week 32 Adjusted Mean Change (SE)	16.50 (1.83)	14.55 (1.98)		
Week 40 Adjusted Mean Change (SE)	16.37 (1.80)	12.61 (1.97)		
Week 52 Adjusted Mean Change (SE)	17.75 (1.96)	12.13 (2.17)	5.63 [-0.15; 11.40]	0.056
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	41.96 (23.31)	39.29 (14.30)		
Week 52 Mean (SD)	55.21 (16.02)	53.13 (24.61)		
Week 4 Adjusted Mean Change (SE)	12.95 (6.25)	12.87 (6.24)		
Week 12 Adjusted Mean Change (SE)	11.55 (7.16)	14.78 (7.15)		
Week 16 Adjusted Mean Change (SE)	17.33 (6.74)	14.68 (6.50)		
Week 24 Adjusted Mean Change (SE)	18.80 (7.35)	11.24 (7.34)		
Week 32 Adjusted Mean Change (SE)	22.11 (6.90)	23.66 (6.89)		
Week 40 Adjusted Mean Change (SE)	7.23 (6.84)	18.40 (6.83)		
Week 52 Adjusted Mean Change (SE)	11.54 (7.67)	14.04 (7.66)	-2.50 [-23.85; 18.85]	0.818
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.3 SF-36 Vitality - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.237</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	40.91 (20.72)	41.78 (20.50)		
Week 52 Mean (SD)	57.42 (22.18)	55.21 (20.60)		
Week 4 Adjusted Mean Change (SE)	10.95 (2.07)	11.52 (2.22)		
Week 12 Adjusted Mean Change (SE)	14.41 (2.39)	14.18 (2.53)		
Week 16 Adjusted Mean Change (SE)	16.78 (2.15)	14.65 (2.30)		
Week 24 Adjusted Mean Change (SE)	16.27 (2.41)	17.81 (2.62)		
Week 32 Adjusted Mean Change (SE)	16.78 (2.31)	17.58 (2.53)		
Week 40 Adjusted Mean Change (SE)	15.78 (2.28)	15.69 (2.51)		
Week 52 Adjusted Mean Change (SE)	18.11 (2.46)	14.54 (2.75)	3.57 [-3.66; 10.80]	0.331
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	30.97 (19.01)	35.80 (20.85)		
Week 52 Mean (SD)	51.07 (21.37)	48.71 (22.34)		
Week 4 Adjusted Mean Change (SE)	11.41 (2.57)	9.66 (2.53)		
Week 12 Adjusted Mean Change (SE)	14.18 (2.94)	8.50 (2.90)		
Week 16 Adjusted Mean Change (SE)	15.60 (2.66)	8.97 (2.66)		
Week 24 Adjusted Mean Change (SE)	15.53 (3.03)	9.25 (3.05)		
Week 32 Adjusted Mean Change (SE)	17.07 (2.90)	12.20 (2.91)		
Week 40 Adjusted Mean Change (SE)	15.71 (2.85)	9.60 (2.92)		
Week 52 Adjusted Mean Change (SE)	16.19 (3.10)	9.35 (3.21)	6.84 [-1.89; 15.57]	0.124
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



## 50.4 SF-36 Vitality - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.578</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	48.96 (23.43)	48.21 (18.87)		
Week 52 Mean (SD)	56.52 (20.86)	55.15 (23.93)		
Week 4 Adjusted Mean Change (SE)	13.41 (3.44)	10.80 (3.65)		
Week 12 Adjusted Mean Change (SE)	17.70 (3.98)	18.62 (4.14)		
Week 16 Adjusted Mean Change (SE)	17.06 (3.57)	16.70 (3.79)		
Week 24 Adjusted Mean Change (SE)	14.00 (4.09)	14.02 (4.38)		
Week 32 Adjusted Mean Change (SE)	16.77 (3.88)	16.00 (4.26)		
Week 40 Adjusted Mean Change (SE)	15.43 (3.84)	15.33 (4.22)		
Week 52 Adjusted Mean Change (SE)	14.06 (4.13)	14.25 (4.62)	-0.19 [-12.29; 11.90]	0.975
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	33.58 (18.47)	36.80 (20.69)		
Week 52 Mean (SD)	54.50 (22.40)	51.83 (20.90)		
Week 4 Adjusted Mean Change (SE)	10.48 (1.80)	10.70 (1.87)		
Week 12 Adjusted Mean Change (SE)	13.38 (2.05)	9.88 (2.13)		
Week 16 Adjusted Mean Change (SE)	16.09 (1.87)	10.96 (1.96)		
Week 24 Adjusted Mean Change (SE)	16.49 (2.12)	14.16 (2.24)		
Week 32 Adjusted Mean Change (SE)	16.91 (2.02)	15.05 (2.14)		
Week 40 Adjusted Mean Change (SE)	15.83 (1.99)	12.47 (2.13)		
Week 52 Adjusted Mean Change (SE)	18.29 (2.16)	11.75 (2.34)	6.54 [0.26; 12.82]	0.041
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.5 SF-36 Vitality - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.980</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	37.05 (21.97)	35.91 (19.80)		
Week 52 Mean (SD)	56.57 (22.67)	52.30 (21.18)		
Week 4 Adjusted Mean Change (SE)	15.02 (2.53)	10.48 (2.32)		
Week 12 Adjusted Mean Change (SE)	15.17 (2.94)	12.41 (2.68)		
Week 16 Adjusted Mean Change (SE)	16.35 (2.66)	13.01 (2.46)		
Week 24 Adjusted Mean Change (SE)	16.00 (3.02)	16.40 (2.81)		
Week 32 Adjusted Mean Change (SE)	17.25 (2.88)	16.12 (2.70)		
Week 40 Adjusted Mean Change (SE)	14.63 (2.85)	12.95 (2.74)		
Week 52 Adjusted Mean Change (SE)	19.73 (3.10)	12.68 (3.02)	7.06 [-1.47; 15.59]	0.104
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	36.86 (19.80)	42.50 (21.39)		
Week 52 Mean (SD)	53.98 (21.70)	52.70 (21.92)		
Week 4 Adjusted Mean Change (SE)	8.72 (1.99)	10.96 (2.35)		
Week 12 Adjusted Mean Change (SE)	13.78 (2.33)	10.99 (2.73)		
Week 16 Adjusted Mean Change (SE)	16.31 (2.10)	11.35 (2.48)		
Week 24 Adjusted Mean Change (SE)	15.98 (2.36)	11.89 (2.83)		
Week 32 Adjusted Mean Change (SE)	16.68 (2.26)	14.42 (2.72)		
Week 40 Adjusted Mean Change (SE)	16.43 (2.23)	13.07 (2.68)		
Week 52 Adjusted Mean Change (SE)	15.98 (2.41)	11.82 (2.93)	4.16 [-3.34; 11.65]	0.275
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 50.6 SF-36 Vitality - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.317</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	37.93 (18.09)	40.69 (20.18)		
Week 52 Mean (SD)	58.48 (21.86)	56.08 (22.88)		
Week 4 Adjusted Mean Change (SE)	11.20 (1.95)	10.24 (2.36)		
Week 12 Adjusted Mean Change (SE)	16.10 (2.26)	10.90 (2.70)		
Week 16 Adjusted Mean Change (SE)	17.14 (2.03)	13.60 (2.48)		
Week 24 Adjusted Mean Change (SE)	18.21 (2.27)	15.30 (2.85)		
Week 32 Adjusted Mean Change (SE)	17.78 (2.18)	15.76 (2.77)		
Week 40 Adjusted Mean Change (SE)	18.29 (2.13)	12.46 (2.76)		
Week 52 Adjusted Mean Change (SE)	20.16 (2.30)	12.80 (3.05)	7.35 [-0.19; 14.90]	0.056
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	35.03 (24.73)	37.74 (21.40)		
Week 52 Mean (SD)	47.86 (20.78)	49.73 (20.07)		
Week 4 Adjusted Mean Change (SE)	11.01 (2.68)	11.17 (2.33)		
Week 12 Adjusted Mean Change (SE)	11.02 (3.06)	12.53 (2.68)		
Week 16 Adjusted Mean Change (SE)	14.72 (2.79)	10.83 (2.44)		
Week 24 Adjusted Mean Change (SE)	11.57 (3.18)	13.12 (2.76)		
Week 32 Adjusted Mean Change (SE)	15.12 (3.04)	14.85 (2.64)		
Week 40 Adjusted Mean Change (SE)	10.82 (2.97)	13.53 (2.60)		
Week 52 Adjusted Mean Change (SE)	11.86 (3.23)	11.88 (2.81)	-0.02 [-8.48; 8.43]	0.996
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.7 SF-36 Vitality - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.714</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	38.24 (21.82)	44.14 (21.94)		
Week 52 Mean (SD)	55.87 (20.51)	58.75 (20.25)		
Week 4 Adjusted Mean Change (SE)	13.89 (2.29)	14.22 (2.96)		
Week 12 Adjusted Mean Change (SE)	16.66 (2.67)	15.85 (3.43)		
Week 16 Adjusted Mean Change (SE)	16.47 (2.37)	18.64 (3.09)		
Week 24 Adjusted Mean Change (SE)	17.48 (2.73)	15.39 (3.56)		
Week 32 Adjusted Mean Change (SE)	19.79 (2.57)	18.36 (3.37)		
Week 40 Adjusted Mean Change (SE)	18.46 (2.55)	15.81 (3.35)		
Week 52 Adjusted Mean Change (SE)	17.99 (2.77)	15.67 (3.75)	2.32 [-6.86; 11.51]	0.618
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	35.81 (19.52)	36.87 (19.94)		
Week 52 Mean (SD)	54.13 (23.36)	49.78 (21.55)		
Week 4 Adjusted Mean Change (SE)	8.72 (2.13)	9.14 (1.98)		
Week 12 Adjusted Mean Change (SE)	12.29 (2.46)	9.85 (2.28)		
Week 16 Adjusted Mean Change (SE)	16.18 (2.22)	9.28 (2.08)		
Week 24 Adjusted Mean Change (SE)	14.66 (2.55)	13.65 (2.42)		
Week 32 Adjusted Mean Change (SE)	14.35 (2.41)	13.93 (2.30)		
Week 40 Adjusted Mean Change (SE)	13.40 (2.38)	11.89 (2.30)		
Week 52 Adjusted Mean Change (SE)	16.81 (2.59)	10.84 (2.51)	5.97 [-1.15; 13.10]	0.100
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.8 SF-36 Vitality - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.962</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	31.62 (21.67)	41.62 (19.60)		
Week 52 Mean (SD)	53.44 (24.31)	56.08 (19.22)		
Week 4 Adjusted Mean Change (SE)	14.87 (2.38)	15.49 (2.67)		
Week 12 Adjusted Mean Change (SE)	15.62 (2.75)	12.33 (3.10)		
Week 16 Adjusted Mean Change (SE)	18.51 (2.34)	14.75 (2.65)		
Week 24 Adjusted Mean Change (SE)	18.85 (2.84)	17.21 (3.23)		
Week 32 Adjusted Mean Change (SE)	18.43 (2.71)	16.51 (3.09)		
Week 40 Adjusted Mean Change (SE)	18.49 (2.66)	16.29 (3.03)		
Week 52 Adjusted Mean Change (SE)	20.53 (2.81)	16.55 (3.22)	3.99 [-4.55; 12.53]	0.358
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	38.42 (16.37)	32.69 (20.86)		
Week 52 Mean (SD)	55.44 (20.33)	46.13 (24.80)		
Week 4 Adjusted Mean Change (SE)	8.42 (2.90)	8.40 (3.38)		
Week 12 Adjusted Mean Change (SE)	13.67 (3.41)	12.49 (3.91)		
Week 16 Adjusted Mean Change (SE)	14.95 (2.87)	14.46 (3.33)		
Week 24 Adjusted Mean Change (SE)	15.83 (3.48)	15.82 (4.09)		
Week 32 Adjusted Mean Change (SE)	17.65 (3.37)	14.04 (3.91)		
Week 40 Adjusted Mean Change (SE)	16.07 (3.27)	13.54 (3.90)		
Week 52 Adjusted Mean Change (SE)	16.81 (3.47)	10.26 (4.14)	6.55 [-4.13; 17.24]	0.228
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.9 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.937</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	32.50 (18.44)	37.50 (20.66)		
Week 52 Mean (SD)	54.22 (24.99)	52.63 (20.13)		
Week 4 Adjusted Mean Change (SE)	10.58 (2.57)	13.21 (3.38)		
Week 12 Adjusted Mean Change (SE)	15.06 (2.97)	11.84 (3.89)		
Week 16 Adjusted Mean Change (SE)	15.86 (2.55)	14.45 (3.37)		
Week 24 Adjusted Mean Change (SE)	15.57 (3.07)	15.58 (4.12)		
Week 32 Adjusted Mean Change (SE)	18.30 (2.88)	17.52 (3.88)		
Week 40 Adjusted Mean Change (SE)	16.46 (2.81)	13.66 (3.80)		
Week 52 Adjusted Mean Change (SE)	19.65 (3.01)	14.43 (4.22)	5.22 [-5.06; 15.50]	0.317
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	36.84 (21.35)	38.75 (22.47)		
Week 52 Mean (SD)	54.64 (19.49)	52.68 (24.08)		
Week 4 Adjusted Mean Change (SE)	13.84 (2.79)	14.36 (3.15)		
Week 12 Adjusted Mean Change (SE)	14.96 (3.26)	14.67 (3.66)		
Week 16 Adjusted Mean Change (SE)	18.43 (2.78)	15.73 (3.14)		
Week 24 Adjusted Mean Change (SE)	20.39 (3.35)	18.59 (3.82)		
Week 32 Adjusted Mean Change (SE)	18.40 (3.15)	14.46 (3.56)		
Week 40 Adjusted Mean Change (SE)	19.57 (3.03)	18.60 (3.50)		
Week 52 Adjusted Mean Change (SE)	18.63 (3.28)	14.02 (3.71)	4.61 [-5.19; 14.41]	0.354
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.10 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.754</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	30.21 (21.96)	35.42 (22.41)		
Week 52 Mean (SD)	52.80 (22.76)	53.13 (23.31)		
Week 4 Adjusted Mean Change (SE)	13.08 (3.15)	15.71 (3.03)		
Week 12 Adjusted Mean Change (SE)	18.54 (3.55)	15.11 (3.45)		
Week 16 Adjusted Mean Change (SE)	18.37 (3.06)	15.82 (2.97)		
Week 24 Adjusted Mean Change (SE)	15.99 (3.75)	13.93 (3.70)		
Week 32 Adjusted Mean Change (SE)	16.59 (3.53)	18.48 (3.51)		
Week 40 Adjusted Mean Change (SE)	18.23 (3.48)	14.26 (3.46)		
Week 52 Adjusted Mean Change (SE)	19.38 (3.68)	14.73 (3.79)	4.65 [-5.81; 15.11]	0.381
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	34.93 (17.69)	40.81 (18.22)		
Week 52 Mean (SD)	54.97 (23.35)	51.89 (20.93)		
Week 4 Adjusted Mean Change (SE)	12.42 (2.40)	10.37 (2.97)		
Week 12 Adjusted Mean Change (SE)	13.95 (2.74)	10.21 (3.34)		
Week 16 Adjusted Mean Change (SE)	16.85 (2.33)	13.87 (2.90)		
Week 24 Adjusted Mean Change (SE)	19.12 (2.82)	19.07 (3.51)		
Week 32 Adjusted Mean Change (SE)	19.49 (2.70)	13.16 (3.34)		
Week 40 Adjusted Mean Change (SE)	18.40 (2.64)	16.32 (3.31)		
Week 52 Adjusted Mean Change (SE)	20.21 (2.80)	13.96 (3.46)	6.25 [-2.57; 15.08]	0.163
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.11 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.742</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	34.30 (21.62)	40.41 (19.78)		
Week 52 Mean (SD)	52.88 (23.11)	53.37 (22.16)		
Week 4 Adjusted Mean Change (SE)	14.05 (2.62)	13.72 (2.63)		
Week 12 Adjusted Mean Change (SE)	13.61 (3.00)	12.50 (3.01)		
Week 16 Adjusted Mean Change (SE)	15.32 (2.55)	13.66 (2.56)		
Week 24 Adjusted Mean Change (SE)	18.08 (3.09)	16.05 (3.13)		
Week 32 Adjusted Mean Change (SE)	17.72 (2.98)	16.94 (2.99)		
Week 40 Adjusted Mean Change (SE)	17.16 (2.91)	15.32 (2.95)		
Week 52 Adjusted Mean Change (SE)	17.55 (3.10)	15.47 (3.12)	2.08 [-6.64; 10.80]	0.637
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	34.38 (18.22)	34.11 (21.33)		
Week 52 Mean (SD)	55.49 (22.59)	50.35 (21.38)		
Week 4 Adjusted Mean Change (SE)	10.48 (2.65)	11.12 (3.58)		
Week 12 Adjusted Mean Change (SE)	16.04 (3.03)	12.27 (4.06)		
Week 16 Adjusted Mean Change (SE)	18.84 (2.57)	16.61 (3.49)		
Week 24 Adjusted Mean Change (SE)	17.23 (3.11)	17.82 (4.26)		
Week 32 Adjusted Mean Change (SE)	18.41 (2.96)	13.06 (4.08)		
Week 40 Adjusted Mean Change (SE)	17.92 (2.92)	15.16 (4.08)		
Week 52 Adjusted Mean Change (SE)	20.58 (3.08)	11.62 (4.40)	8.96 [-1.65; 19.57]	0.097
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 50.12 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.435</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	33.47 (18.87)	37.50 (20.06)		
Week 52 Mean (SD)	53.45 (22.06)	53.13 (20.17)		
Week 4 Adjusted Mean Change (SE)	13.08 (2.18)	13.64 (2.51)		
Week 12 Adjusted Mean Change (SE)	12.40 (2.46)	11.30 (2.82)		
Week 16 Adjusted Mean Change (SE)	17.27 (2.07)	13.90 (2.38)		
Week 24 Adjusted Mean Change (SE)	18.10 (2.51)	15.59 (2.94)		
Week 32 Adjusted Mean Change (SE)	18.15 (2.44)	16.07 (2.84)		
Week 40 Adjusted Mean Change (SE)	16.85 (2.35)	14.31 (2.77)		
Week 52 Adjusted Mean Change (SE)	19.16 (2.56)	15.16 (3.05)	4.00 [-3.90; 11.90]	0.318
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	36.56 (23.84)	43.06 (20.10)		
Week 52 Mean (SD)	57.24 (24.94)	56.25 (20.73)		
Week 4 Adjusted Mean Change (SE)	8.14 (3.84)	12.91 (4.04)		
Week 12 Adjusted Mean Change (SE)	20.06 (4.30)	16.91 (4.59)		
Week 16 Adjusted Mean Change (SE)	15.65 (3.63)	20.58 (3.87)		
Week 24 Adjusted Mean Change (SE)	15.75 (4.49)	23.96 (4.74)		
Week 32 Adjusted Mean Change (SE)	16.02 (4.29)	17.55 (4.58)		
Week 40 Adjusted Mean Change (SE)	18.81 (4.17)	21.96 (4.44)		
Week 52 Adjusted Mean Change (SE)	18.81 (4.50)	15.49 (4.75)	3.32 [-9.61; 16.24]	0.613
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.13 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.022</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	33.83 (20.07)	38.85 (21.37)		
Week 52 Mean (SD)	51.83 (23.68)	54.32 (21.18)		
Week 4 Adjusted Mean Change (SE)	10.01 (2.13)	15.21 (2.39)		
Week 12 Adjusted Mean Change (SE)	13.05 (2.46)	14.78 (2.77)		
Week 16 Adjusted Mean Change (SE)	14.91 (2.08)	16.81 (2.35)		
Week 24 Adjusted Mean Change (SE)	15.24 (2.54)	18.53 (2.89)		
Week 32 Adjusted Mean Change (SE)	15.97 (2.44)	17.08 (2.76)		
Week 40 Adjusted Mean Change (SE)	15.16 (2.38)	17.14 (2.72)		
Week 52 Adjusted Mean Change (SE)	17.08 (2.54)	15.74 (2.93)	1.34 [-6.36; 9.04]	0.731
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	37.83 (20.36)	35.42 (19.46)		
Week 52 Mean (SD)	60.53 (20.20)	45.83 (23.74)		
Week 4 Adjusted Mean Change (SE)	16.66 (3.87)	4.01 (4.90)		
Week 12 Adjusted Mean Change (SE)	17.21 (4.46)	5.48 (5.63)		
Week 16 Adjusted Mean Change (SE)	21.56 (3.76)	8.72 (4.76)		
Week 24 Adjusted Mean Change (SE)	22.68 (4.56)	12.83 (5.76)		
Week 32 Adjusted Mean Change (SE)	22.25 (4.35)	10.48 (5.60)		
Week 40 Adjusted Mean Change (SE)	22.78 (4.26)	8.96 (5.47)		
Week 52 Adjusted Mean Change (SE)	23.36 (4.51)	9.17 (5.70)	14.19 [-0.18; 28.55]	0.053
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.14 SF-36 Vitality - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.672</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	34.15 (20.78)	37.62 (21.00)		
Week 52 Mean (SD)	53.50 (22.44)	52.41 (21.83)		
Week 4 Adjusted Mean Change (SE)	13.36 (2.02)	14.42 (2.36)		
Week 12 Adjusted Mean Change (SE)	15.16 (2.31)	12.80 (2.70)		
Week 16 Adjusted Mean Change (SE)	18.02 (1.95)	15.05 (2.30)		
Week 24 Adjusted Mean Change (SE)	17.99 (2.39)	15.77 (2.83)		
Week 32 Adjusted Mean Change (SE)	18.72 (2.29)	14.87 (2.70)		
Week 40 Adjusted Mean Change (SE)	17.85 (2.24)	15.07 (2.68)		
Week 52 Adjusted Mean Change (SE)	18.90 (2.35)	14.80 (2.82)	4.10 [-3.18; 11.37]	0.267
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	34.62 (15.65)	34.38 (16.47)		
Week 52 Mean (SD)	56.25 (25.13)	50.63 (18.97)		
Week 4 Adjusted Mean Change (SE)	7.78 (4.73)	9.21 (5.37)		
Week 12 Adjusted Mean Change (SE)	13.94 (5.50)	13.43 (6.12)		
Week 16 Adjusted Mean Change (SE)	12.58 (4.56)	9.83 (5.18)		
Week 24 Adjusted Mean Change (SE)	16.36 (5.54)	19.12 (6.30)		
Week 32 Adjusted Mean Change (SE)	15.46 (5.25)	21.07 (5.97)		
Week 40 Adjusted Mean Change (SE)	16.34 (5.17)	17.83 (5.89)		
Week 52 Adjusted Mean Change (SE)	20.71 (5.39)	16.02 (6.13)	4.69 [-11.47; 20.85]	0.567
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.15 SF-36 Vitality - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.952</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	32.95 (26.11)	37.74 (22.39)		
Week 52 Mean (SD)	53.95 (24.67)	50.00 (22.59)		
Week 4 Adjusted Mean Change (SE)	13.47 (3.65)	16.59 (3.44)		
Week 12 Adjusted Mean Change (SE)	15.31 (4.16)	12.42 (3.91)		
Week 16 Adjusted Mean Change (SE)	17.80 (3.58)	13.39 (3.37)		
Week 24 Adjusted Mean Change (SE)	15.84 (4.34)	12.95 (4.11)		
Week 32 Adjusted Mean Change (SE)	17.36 (4.19)	17.15 (3.97)		
Week 40 Adjusted Mean Change (SE)	14.01 (4.05)	11.25 (3.88)		
Week 52 Adjusted Mean Change (SE)	18.38 (4.40)	12.86 (4.33)	5.52 [-6.70; 17.75]	0.373
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	34.82 (17.45)	38.41 (19.34)		
Week 52 Mean (SD)	54.30 (22.32)	53.53 (21.59)		
Week 4 Adjusted Mean Change (SE)	11.88 (2.15)	10.49 (2.68)		
Week 12 Adjusted Mean Change (SE)	14.62 (2.48)	12.40 (3.08)		
Week 16 Adjusted Mean Change (SE)	16.85 (2.09)	15.45 (2.62)		
Week 24 Adjusted Mean Change (SE)	18.19 (2.51)	18.87 (3.16)		
Week 32 Adjusted Mean Change (SE)	18.24 (2.42)	14.63 (3.04)		
Week 40 Adjusted Mean Change (SE)	18.62 (2.34)	17.57 (2.97)		
Week 52 Adjusted Mean Change (SE)	19.30 (2.51)	15.02 (3.15)	4.27 [-3.70; 12.25]	0.291
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.16 SF-36 Vitality - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.426</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	33.09 (18.13)	35.54 (19.46)		
Week 52 Mean (SD)	54.08 (23.89)	54.63 (20.11)		
Week 4 Adjusted Mean Change (SE)	10.05 (2.41)	13.41 (2.93)		
Week 12 Adjusted Mean Change (SE)	15.17 (2.76)	12.48 (3.34)		
Week 16 Adjusted Mean Change (SE)	15.48 (2.33)	15.13 (2.86)		
Week 24 Adjusted Mean Change (SE)	15.89 (2.82)	16.23 (3.50)		
Week 32 Adjusted Mean Change (SE)	17.91 (2.69)	18.82 (3.34)		
Week 40 Adjusted Mean Change (SE)	16.69 (2.66)	14.69 (3.31)		
Week 52 Adjusted Mean Change (SE)	19.41 (2.81)	17.96 (3.59)	1.45 [-7.56; 10.46]	0.751
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	36.21 (22.44)	41.02 (21.35)		
Week 52 Mean (SD)	54.44 (21.18)	50.42 (23.32)		
Week 4 Adjusted Mean Change (SE)	15.63 (2.94)	12.17 (3.04)		
Week 12 Adjusted Mean Change (SE)	14.26 (3.38)	12.34 (3.50)		
Week 16 Adjusted Mean Change (SE)	19.49 (2.87)	14.19 (2.97)		
Week 24 Adjusted Mean Change (SE)	20.28 (3.47)	17.23 (3.63)		
Week 32 Adjusted Mean Change (SE)	18.27 (3.33)	12.09 (3.46)		
Week 40 Adjusted Mean Change (SE)	18.76 (3.24)	16.03 (3.43)		
Week 52 Adjusted Mean Change (SE)	18.52 (3.46)	10.71 (3.59)	7.81 [-2.06; 17.69]	0.120
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.17 SF-36 Vitality - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.752</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	30.21 (21.96)	35.08 (22.97)		
Week 52 Mean (SD)	52.80 (22.76)	53.13 (24.23)		
Week 4 Adjusted Mean Change (SE)	12.97 (3.14)	16.47 (3.12)		
Week 12 Adjusted Mean Change (SE)	18.25 (3.54)	16.17 (3.55)		
Week 16 Adjusted Mean Change (SE)	18.24 (3.04)	17.06 (3.05)		
Week 24 Adjusted Mean Change (SE)	15.76 (3.75)	14.16 (3.82)		
Week 32 Adjusted Mean Change (SE)	16.38 (3.53)	16.98 (3.63)		
Week 40 Adjusted Mean Change (SE)	17.93 (3.49)	13.75 (3.60)		
Week 52 Adjusted Mean Change (SE)	19.09 (3.69)	14.36 (3.94)	4.73 [-5.94; 15.41]	0.382
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	36.59 (18.49)	40.80 (17.83)		
Week 52 Mean (SD)	55.02 (22.91)	51.96 (20.44)		
Week 4 Adjusted Mean Change (SE)	11.95 (2.30)	9.69 (2.87)		
Week 12 Adjusted Mean Change (SE)	12.92 (2.62)	9.29 (3.23)		
Week 16 Adjusted Mean Change (SE)	16.47 (2.24)	12.67 (2.79)		
Week 24 Adjusted Mean Change (SE)	18.56 (2.72)	18.15 (3.40)		
Week 32 Adjusted Mean Change (SE)	18.98 (2.61)	14.24 (3.24)		
Week 40 Adjusted Mean Change (SE)	17.27 (2.56)	16.13 (3.22)		
Week 52 Adjusted Mean Change (SE)	19.05 (2.73)	13.92 (3.36)	5.12 [-3.43; 13.68]	0.238
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.18 SF-36 Vitality - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.742</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	34.30 (21.62)	40.41 (19.78)		
Week 52 Mean (SD)	52.88 (23.11)	53.37 (22.16)		
Week 4 Adjusted Mean Change (SE)	14.05 (2.62)	13.72 (2.63)		
Week 12 Adjusted Mean Change (SE)	13.61 (3.00)	12.50 (3.01)		
Week 16 Adjusted Mean Change (SE)	15.32 (2.55)	13.66 (2.56)		
Week 24 Adjusted Mean Change (SE)	18.08 (3.09)	16.05 (3.13)		
Week 32 Adjusted Mean Change (SE)	17.72 (2.98)	16.94 (2.99)		
Week 40 Adjusted Mean Change (SE)	17.16 (2.91)	15.32 (2.95)		
Week 52 Adjusted Mean Change (SE)	17.55 (3.10)	15.47 (3.12)	2.08 [-6.64; 10.80]	0.637
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	34.38 (18.22)	34.11 (21.33)		
Week 52 Mean (SD)	55.49 (22.59)	50.35 (21.38)		
Week 4 Adjusted Mean Change (SE)	10.48 (2.65)	11.12 (3.58)		
Week 12 Adjusted Mean Change (SE)	16.04 (3.03)	12.27 (4.06)		
Week 16 Adjusted Mean Change (SE)	18.84 (2.57)	16.61 (3.49)		
Week 24 Adjusted Mean Change (SE)	17.23 (3.11)	17.82 (4.26)		
Week 32 Adjusted Mean Change (SE)	18.41 (2.96)	13.06 (4.08)		
Week 40 Adjusted Mean Change (SE)	17.92 (2.92)	15.16 (4.08)		
Week 52 Adjusted Mean Change (SE)	20.58 (3.08)	11.62 (4.40)	8.96 [-1.65; 19.57]	0.097
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 50.19 SF-36 Vitality - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.715</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	34.04 (18.88)	37.37 (20.47)		
Week 52 Mean (SD)	53.79 (22.57)	52.03 (20.68)		
Week 4 Adjusted Mean Change (SE)	12.91 (2.13)	13.15 (2.47)		
Week 12 Adjusted Mean Change (SE)	12.51 (2.42)	11.48 (2.80)		
Week 16 Adjusted Mean Change (SE)	17.44 (2.07)	13.09 (2.40)		
Week 24 Adjusted Mean Change (SE)	18.13 (2.50)	14.70 (2.95)		
Week 32 Adjusted Mean Change (SE)	18.10 (2.37)	15.00 (2.78)		
Week 40 Adjusted Mean Change (SE)	16.80 (2.34)	13.76 (2.76)		
Week 52 Adjusted Mean Change (SE)	19.40 (2.52)	14.45 (3.02)	4.95 [-2.83; 12.74]	0.211
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	35.07 (24.64)	40.28 (20.70)		
Week 52 Mean (SD)	56.62 (24.85)	53.31 (24.82)		
Week 4 Adjusted Mean Change (SE)	9.43 (4.06)	11.77 (4.03)		
Week 12 Adjusted Mean Change (SE)	21.79 (4.57)	14.85 (4.55)		
Week 16 Adjusted Mean Change (SE)	16.38 (3.92)	18.90 (3.95)		
Week 24 Adjusted Mean Change (SE)	17.05 (4.85)	21.82 (4.78)		
Week 32 Adjusted Mean Change (SE)	18.22 (4.53)	17.08 (4.56)		
Week 40 Adjusted Mean Change (SE)	20.78 (4.48)	19.61 (4.56)		
Week 52 Adjusted Mean Change (SE)	19.01 (4.80)	13.99 (4.79)	5.02 [-8.39; 18.42]	0.460
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 51.0 SF-36 MCS - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

### 51.1 SF-36 MCS - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	40.17 (12.03)	41.74 (10.57)		
Week 52 Mean (SD)	48.10 (10.78)	46.49 (10.48)		
Week 4 Adjusted Mean Change (SE)	5.36 (0.83)	5.28 (0.88)		
Week 12 Adjusted Mean Change (SE)	6.49 (0.84)	5.54 (0.88)		
Week 16 Adjusted Mean Change (SE)	6.52 (0.80)	5.61 (0.85)		
Week 24 Adjusted Mean Change (SE)	6.58 (0.92)	4.69 (0.99)		
Week 32 Adjusted Mean Change (SE)	7.17 (0.90)	5.44 (0.97)		
Week 40 Adjusted Mean Change (SE)	6.47 (0.88)	5.21 (0.96)		
Week 52 Adjusted Mean Change (SE)	7.62 (0.92)	5.32 (1.02)	2.30 [-0.41; 5.01]	0.096
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 51.2 SF-36 MCS - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.685</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	39.68 (11.73)	41.84 (10.69)		
Week 52 Mean (SD)	48.07 (11.06)	46.58 (10.42)		
Week 4 Adjusted Mean Change (SE)	5.38 (0.87)	5.29 (0.92)		
Week 12 Adjusted Mean Change (SE)	6.72 (0.88)	5.51 (0.92)		
Week 16 Adjusted Mean Change (SE)	6.50 (0.83)	5.33 (0.88)		
Week 24 Adjusted Mean Change (SE)	6.48 (0.96)	4.49 (1.04)		
Week 32 Adjusted Mean Change (SE)	6.93 (0.93)	5.22 (1.01)		
Week 40 Adjusted Mean Change (SE)	6.47 (0.91)	5.20 (1.01)		
Week 52 Adjusted Mean Change (SE)	7.73 (0.96)	5.22 (1.06)	2.50 [-0.32; 5.33]	0.082
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	47.45 (14.98)	40.41 (9.50)		
Week 52 Mean (SD)	48.63 (4.79)	45.40 (12.18)		
Week 4 Adjusted Mean Change (SE)	5.04 (3.33)	5.09 (3.31)		
Week 12 Adjusted Mean Change (SE)	3.38 (3.34)	5.80 (3.32)		
Week 16 Adjusted Mean Change (SE)	7.13 (3.30)	9.09 (3.16)		
Week 24 Adjusted Mean Change (SE)	8.04 (3.67)	7.22 (3.65)		
Week 32 Adjusted Mean Change (SE)	10.31 (3.52)	8.05 (3.50)		
Week 40 Adjusted Mean Change (SE)	6.46 (3.48)	5.58 (3.45)		
Week 52 Adjusted Mean Change (SE)	5.83 (3.77)	6.73 (3.76)	-0.90 [-11.40; 9.59]	0.865
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.3 SF-36 MCS - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.385</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	43.05 (10.78)	42.83 (10.31)		
Week 52 Mean (SD)	49.02 (10.74)	46.52 (9.86)		
Week 4 Adjusted Mean Change (SE)	5.50 (1.10)	5.66 (1.18)		
Week 12 Adjusted Mean Change (SE)	5.94 (1.11)	6.14 (1.18)		
Week 16 Adjusted Mean Change (SE)	6.45 (1.06)	6.18 (1.13)		
Week 24 Adjusted Mean Change (SE)	6.12 (1.21)	5.11 (1.32)		
Week 32 Adjusted Mean Change (SE)	6.93 (1.18)	6.00 (1.29)		
Week 40 Adjusted Mean Change (SE)	6.01 (1.15)	6.41 (1.27)		
Week 52 Adjusted Mean Change (SE)	7.26 (1.21)	4.79 (1.35)	2.47 [-1.07; 6.01]	0.171
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	35.86 (12.63)	40.34 (10.86)		
Week 52 Mean (SD)	46.65 (10.82)	46.45 (11.45)		
Week 4 Adjusted Mean Change (SE)	5.14 (1.37)	4.80 (1.34)		
Week 12 Adjusted Mean Change (SE)	7.31 (1.38)	4.74 (1.35)		
Week 16 Adjusted Mean Change (SE)	6.63 (1.31)	4.86 (1.31)		
Week 24 Adjusted Mean Change (SE)	7.32 (1.53)	4.15 (1.54)		
Week 32 Adjusted Mean Change (SE)	7.54 (1.50)	4.71 (1.49)		
Week 40 Adjusted Mean Change (SE)	7.19 (1.45)	3.56 (1.48)		
Week 52 Adjusted Mean Change (SE)	8.22 (1.53)	6.09 (1.58)	2.13 [-2.17; 6.43]	0.331
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.4 SF-36 MCS - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.860</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	44.57 (12.28)	43.31 (10.35)		
Week 52 Mean (SD)	49.41 (10.64)	47.64 (9.27)		
Week 4 Adjusted Mean Change (SE)	6.20 (1.80)	4.43 (1.92)		
Week 12 Adjusted Mean Change (SE)	5.90 (1.85)	6.32 (1.93)		
Week 16 Adjusted Mean Change (SE)	6.08 (1.73)	6.73 (1.84)		
Week 24 Adjusted Mean Change (SE)	5.63 (2.02)	3.03 (2.17)		
Week 32 Adjusted Mean Change (SE)	7.54 (1.95)	5.32 (2.16)		
Week 40 Adjusted Mean Change (SE)	7.11 (1.92)	5.95 (2.12)		
Week 52 Adjusted Mean Change (SE)	7.14 (1.99)	7.13 (2.24)	0.02 [-5.90; 5.94]	0.995
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	38.95 (11.74)	41.33 (10.66)		
Week 52 Mean (SD)	47.73 (10.86)	46.19 (10.82)		
Week 4 Adjusted Mean Change (SE)	5.12 (0.95)	5.51 (0.99)		
Week 12 Adjusted Mean Change (SE)	6.64 (0.96)	5.33 (1.00)		
Week 16 Adjusted Mean Change (SE)	6.64 (0.91)	5.30 (0.96)		
Week 24 Adjusted Mean Change (SE)	6.83 (1.05)	5.13 (1.12)		
Week 32 Adjusted Mean Change (SE)	7.07 (1.02)	5.48 (1.09)		
Week 40 Adjusted Mean Change (SE)	6.31 (1.00)	5.04 (1.08)		
Week 52 Adjusted Mean Change (SE)	7.77 (1.05)	4.86 (1.15)	2.90 [-0.18; 5.98]	0.065
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.5 SF-36 MCS - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.977</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	41.40 (13.22)	40.68 (10.06)		
Week 52 Mean (SD)	49.42 (10.45)	46.68 (10.48)		
Week 4 Adjusted Mean Change (SE)	5.92 (1.35)	4.92 (1.24)		
Week 12 Adjusted Mean Change (SE)	6.60 (1.37)	5.11 (1.24)		
Week 16 Adjusted Mean Change (SE)	6.13 (1.29)	4.69 (1.20)		
Week 24 Adjusted Mean Change (SE)	5.91 (1.50)	5.83 (1.40)		
Week 32 Adjusted Mean Change (SE)	6.79 (1.46)	5.19 (1.38)		
Week 40 Adjusted Mean Change (SE)	6.18 (1.43)	5.36 (1.38)		
Week 52 Adjusted Mean Change (SE)	8.57 (1.51)	6.18 (1.47)	2.38 [-1.77; 6.54]	0.260
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	39.41 (11.27)	42.83 (11.06)		
Week 52 Mean (SD)	47.32 (10.98)	46.33 (10.59)		
Week 4 Adjusted Mean Change (SE)	5.00 (1.07)	5.65 (1.26)		
Week 12 Adjusted Mean Change (SE)	6.41 (1.09)	5.98 (1.27)		
Week 16 Adjusted Mean Change (SE)	6.76 (1.02)	6.54 (1.21)		
Week 24 Adjusted Mean Change (SE)	6.99 (1.17)	3.55 (1.41)		
Week 32 Adjusted Mean Change (SE)	7.41 (1.15)	5.72 (1.39)		
Week 40 Adjusted Mean Change (SE)	6.66 (1.12)	5.05 (1.35)		
Week 52 Adjusted Mean Change (SE)	7.08 (1.17)	4.59 (1.42)	2.49 [-1.16; 6.14]	0.180
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.6 SF-36 MCS - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.891</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	39.33 (11.04)	43.20 (9.74)		
Week 52 Mean (SD)	48.61 (10.74)	49.50 (10.16)		
Week 4 Adjusted Mean Change (SE)	5.89 (1.03)	5.67 (1.26)		
Week 12 Adjusted Mean Change (SE)	6.89 (1.06)	5.90 (1.26)		
Week 16 Adjusted Mean Change (SE)	6.73 (0.99)	7.05 (1.21)		
Week 24 Adjusted Mean Change (SE)	7.57 (1.13)	5.60 (1.43)		
Week 32 Adjusted Mean Change (SE)	7.47 (1.11)	6.23 (1.42)		
Week 40 Adjusted Mean Change (SE)	7.50 (1.07)	6.78 (1.39)		
Week 52 Adjusted Mean Change (SE)	8.46 (1.12)	7.53 (1.49)	0.93 [-2.77; 4.63]	0.622
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	41.78 (13.73)	40.37 (11.22)		
Week 52 Mean (SD)	47.07 (10.97)	44.14 (10.21)		
Week 4 Adjusted Mean Change (SE)	4.36 (1.42)	4.89 (1.24)		
Week 12 Adjusted Mean Change (SE)	5.74 (1.43)	5.20 (1.25)		
Week 16 Adjusted Mean Change (SE)	6.09 (1.35)	4.24 (1.18)		
Week 24 Adjusted Mean Change (SE)	4.63 (1.59)	3.82 (1.38)		
Week 32 Adjusted Mean Change (SE)	6.57 (1.54)	4.68 (1.34)		
Week 40 Adjusted Mean Change (SE)	4.47 (1.49)	3.81 (1.30)		
Week 52 Adjusted Mean Change (SE)	5.98 (1.57)	3.49 (1.37)	2.49 [-1.62; 6.60]	0.233
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.7 SF-36 MCS - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.265</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	41.59 (11.57)	43.21 (10.80)		
Week 52 Mean (SD)	48.76 (10.30)	50.13 (10.20)		
Week 4 Adjusted Mean Change (SE)	6.43 (1.21)	7.51 (1.57)		
Week 12 Adjusted Mean Change (SE)	7.09 (1.24)	7.76 (1.59)		
Week 16 Adjusted Mean Change (SE)	6.78 (1.16)	8.22 (1.51)		
Week 24 Adjusted Mean Change (SE)	7.16 (1.35)	5.93 (1.76)		
Week 32 Adjusted Mean Change (SE)	8.04 (1.29)	9.06 (1.69)		
Week 40 Adjusted Mean Change (SE)	7.52 (1.28)	7.26 (1.68)		
Week 52 Adjusted Mean Change (SE)	7.65 (1.34)	8.16 (1.82)	-0.51 [-4.96; 3.94]	0.820
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	38.95 (12.38)	41.06 (10.48)		
Week 52 Mean (SD)	47.52 (11.25)	44.90 (10.28)		
Week 4 Adjusted Mean Change (SE)	4.42 (1.13)	4.28 (1.05)		
Week 12 Adjusted Mean Change (SE)	5.96 (1.15)	4.54 (1.06)		
Week 16 Adjusted Mean Change (SE)	6.29 (1.09)	4.44 (1.02)		
Week 24 Adjusted Mean Change (SE)	6.07 (1.27)	4.14 (1.21)		
Week 32 Adjusted Mean Change (SE)	6.40 (1.22)	3.77 (1.16)		
Week 40 Adjusted Mean Change (SE)	5.56 (1.20)	4.28 (1.17)		
Week 52 Adjusted Mean Change (SE)	7.61 (1.26)	4.04 (1.22)	3.57 [0.10; 7.04]	0.044
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 51.8 SF-36 MCS - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.918</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	38.03 (12.64)	42.84 (9.23)		
Week 52 Mean (SD)	47.81 (11.08)	49.32 (9.10)		
Week 4 Adjusted Mean Change (SE)	8.11 (1.20)	6.12 (1.34)		
Week 12 Adjusted Mean Change (SE)	6.99 (1.28)	5.39 (1.44)		
Week 16 Adjusted Mean Change (SE)	6.85 (1.18)	5.75 (1.34)		
Week 24 Adjusted Mean Change (SE)	7.55 (1.37)	5.77 (1.56)		
Week 32 Adjusted Mean Change (SE)	7.13 (1.38)	6.39 (1.57)		
Week 40 Adjusted Mean Change (SE)	6.64 (1.33)	6.11 (1.52)		
Week 52 Adjusted Mean Change (SE)	8.94 (1.36)	8.11 (1.55)	0.83 [-3.26; 4.92]	0.689
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	42.20 (10.89)	39.16 (10.62)		
Week 52 Mean (SD)	49.14 (10.99)	42.52 (12.09)		
Week 4 Adjusted Mean Change (SE)	3.22 (1.46)	4.13 (1.70)		
Week 12 Adjusted Mean Change (SE)	6.12 (1.59)	5.51 (1.82)		
Week 16 Adjusted Mean Change (SE)	6.53 (1.45)	6.35 (1.67)		
Week 24 Adjusted Mean Change (SE)	6.95 (1.69)	4.55 (1.98)		
Week 32 Adjusted Mean Change (SE)	7.82 (1.72)	3.95 (2.00)		
Week 40 Adjusted Mean Change (SE)	6.83 (1.64)	6.32 (1.96)		
Week 52 Adjusted Mean Change (SE)	7.83 (1.67)	4.11 (2.00)	3.72 [-1.43; 8.88]	0.156
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.9 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.436</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	38.60 (10.28)	43.30 (10.43)		
Week 52 Mean (SD)	48.15 (12.65)	48.03 (8.14)		
Week 4 Adjusted Mean Change (SE)	6.30 (1.31)	6.34 (1.74)		
Week 12 Adjusted Mean Change (SE)	5.98 (1.40)	6.80 (1.85)		
Week 16 Adjusted Mean Change (SE)	6.35 (1.29)	5.93 (1.73)		
Week 24 Adjusted Mean Change (SE)	5.89 (1.41)	6.44 (1.91)		
Week 32 Adjusted Mean Change (SE)	7.66 (1.48)	7.14 (2.00)		
Week 40 Adjusted Mean Change (SE)	6.20 (1.43)	6.46 (1.96)		
Week 52 Adjusted Mean Change (SE)	8.38 (1.50)	7.91 (2.11)	0.46 [-4.66; 5.59]	0.859
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	41.33 (13.94)	40.16 (10.35)		
Week 52 Mean (SD)	48.48 (9.11)	45.96 (13.08)		
Week 4 Adjusted Mean Change (SE)	5.70 (1.42)	4.72 (1.60)		
Week 12 Adjusted Mean Change (SE)	7.29 (1.54)	5.28 (1.72)		
Week 16 Adjusted Mean Change (SE)	6.98 (1.41)	6.10 (1.59)		
Week 24 Adjusted Mean Change (SE)	9.12 (1.54)	4.57 (1.75)		
Week 32 Adjusted Mean Change (SE)	6.85 (1.61)	4.40 (1.82)		
Week 40 Adjusted Mean Change (SE)	7.21 (1.54)	6.88 (1.79)		
Week 52 Adjusted Mean Change (SE)	8.32 (1.63)	5.38 (1.84)	2.94 [-1.93; 7.81]	0.234
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.10 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.587</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	38.48 (12.93)	42.07 (9.97)		
Week 52 Mean (SD)	49.08 (10.45)	48.63 (10.29)		
Week 4 Adjusted Mean Change (SE)	6.39 (1.56)	7.05 (1.52)		
Week 12 Adjusted Mean Change (SE)	8.19 (1.64)	7.35 (1.61)		
Week 16 Adjusted Mean Change (SE)	7.63 (1.53)	7.13 (1.51)		
Week 24 Adjusted Mean Change (SE)	7.38 (1.81)	3.73 (1.81)		
Week 32 Adjusted Mean Change (SE)	8.13 (1.79)	7.95 (1.80)		
Week 40 Adjusted Mean Change (SE)	6.85 (1.73)	6.86 (1.76)		
Week 52 Adjusted Mean Change (SE)	9.56 (1.79)	8.14 (1.86)	1.41 [-3.69; 6.52]	0.585
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	39.24 (11.02)	40.77 (9.90)		
Week 52 Mean (SD)	47.75 (11.58)	45.49 (10.98)		
Week 4 Adjusted Mean Change (SE)	6.50 (1.20)	4.03 (1.47)		
Week 12 Adjusted Mean Change (SE)	6.34 (1.27)	3.88 (1.54)		
Week 16 Adjusted Mean Change (SE)	6.61 (1.18)	5.11 (1.45)		
Week 24 Adjusted Mean Change (SE)	7.65 (1.36)	6.60 (1.68)		
Week 32 Adjusted Mean Change (SE)	7.08 (1.38)	3.40 (1.69)		
Week 40 Adjusted Mean Change (SE)	7.25 (1.32)	5.66 (1.65)		
Week 52 Adjusted Mean Change (SE)	8.25 (1.37)	5.51 (1.68)	2.74 [-1.54; 7.02]	0.207
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.11 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.751</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	39.40 (12.99)	40.95 (10.03)		
Week 52 Mean (SD)	47.22 (11.83)	46.83 (11.45)		
Week 4 Adjusted Mean Change (SE)	6.64 (1.33)	5.59 (1.33)		
Week 12 Adjusted Mean Change (SE)	6.27 (1.40)	5.50 (1.40)		
Week 16 Adjusted Mean Change (SE)	5.54 (1.28)	5.24 (1.27)		
Week 24 Adjusted Mean Change (SE)	6.54 (1.49)	4.41 (1.50)		
Week 32 Adjusted Mean Change (SE)	6.36 (1.52)	6.28 (1.52)		
Week 40 Adjusted Mean Change (SE)	6.28 (1.46)	5.62 (1.47)		
Week 52 Adjusted Mean Change (SE)	7.80 (1.51)	6.93 (1.51)	0.87 [-3.34; 5.09]	0.682
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	40.01 (11.23)	42.22 (9.76)		
Week 52 Mean (SD)	49.38 (10.17)	46.77 (9.24)		
Week 4 Adjusted Mean Change (SE)	5.64 (1.35)	5.01 (1.83)		
Week 12 Adjusted Mean Change (SE)	6.99 (1.42)	5.35 (1.91)		
Week 16 Adjusted Mean Change (SE)	7.90 (1.28)	7.45 (1.76)		
Week 24 Adjusted Mean Change (SE)	8.10 (1.49)	6.99 (2.06)		
Week 32 Adjusted Mean Change (SE)	8.36 (1.51)	3.92 (2.09)		
Week 40 Adjusted Mean Change (SE)	7.14 (1.46)	7.23 (2.06)		
Week 52 Adjusted Mean Change (SE)	9.19 (1.49)	5.96 (2.14)	3.23 [-1.94; 8.39]	0.219
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.12 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.306</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	39.92 (11.33)	41.36 (9.10)		
Week 52 Mean (SD)	48.29 (10.58)	46.94 (8.81)		
Week 4 Adjusted Mean Change (SE)	6.36 (1.09)	5.13 (1.26)		
Week 12 Adjusted Mean Change (SE)	5.26 (1.13)	4.52 (1.29)		
Week 16 Adjusted Mean Change (SE)	6.73 (1.04)	5.53 (1.20)		
Week 24 Adjusted Mean Change (SE)	7.56 (1.22)	4.47 (1.45)		
Week 32 Adjusted Mean Change (SE)	7.54 (1.23)	5.07 (1.44)		
Week 40 Adjusted Mean Change (SE)	6.86 (1.16)	5.43 (1.37)		
Week 52 Adjusted Mean Change (SE)	8.33 (1.22)	6.90 (1.46)	1.43 [-2.34; 5.19]	0.455
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	39.57 (14.92)	43.86 (9.71)		
Week 52 Mean (SD)	49.31 (11.55)	49.39 (11.87)		
Week 4 Adjusted Mean Change (SE)	4.22 (1.92)	5.68 (2.02)		
Week 12 Adjusted Mean Change (SE)	9.65 (1.98)	7.85 (2.11)		
Week 16 Adjusted Mean Change (SE)	5.82 (1.83)	8.40 (1.95)		
Week 24 Adjusted Mean Change (SE)	6.31 (2.20)	8.60 (2.32)		
Week 32 Adjusted Mean Change (SE)	6.09 (2.17)	7.01 (2.31)		
Week 40 Adjusted Mean Change (SE)	6.16 (2.06)	9.82 (2.19)		
Week 52 Adjusted Mean Change (SE)	8.70 (2.15)	7.57 (2.26)	1.13 [-5.04; 7.31]	0.717
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.13 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.018</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	39.82 (12.14)	42.09 (9.89)		
Week 52 Mean (SD)	47.38 (11.36)	47.54 (11.05)		
Week 4 Adjusted Mean Change (SE)	5.58 (1.08)	6.63 (1.22)		
Week 12 Adjusted Mean Change (SE)	5.75 (1.14)	6.60 (1.29)		
Week 16 Adjusted Mean Change (SE)	5.50 (1.04)	6.74 (1.18)		
Week 24 Adjusted Mean Change (SE)	5.97 (1.22)	5.82 (1.40)		
Week 32 Adjusted Mean Change (SE)	6.24 (1.24)	6.82 (1.41)		
Week 40 Adjusted Mean Change (SE)	5.69 (1.19)	7.28 (1.37)		
Week 52 Adjusted Mean Change (SE)	7.57 (1.24)	7.25 (1.43)	0.32 [-3.43; 4.07]	0.866
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	39.51 (12.36)	39.42 (11.29)		
Week 52 Mean (SD)	50.20 (10.20)	44.62 (10.28)		
Week 4 Adjusted Mean Change (SE)	7.16 (1.97)	1.23 (2.49)		
Week 12 Adjusted Mean Change (SE)	7.99 (2.06)	2.96 (2.61)		
Week 16 Adjusted Mean Change (SE)	9.85 (1.88)	2.44 (2.38)		
Week 24 Adjusted Mean Change (SE)	10.72 (2.20)	5.22 (2.78)		
Week 32 Adjusted Mean Change (SE)	10.36 (2.22)	0.85 (2.85)		
Week 40 Adjusted Mean Change (SE)	9.50 (2.13)	2.62 (2.73)		
Week 52 Adjusted Mean Change (SE)	10.29 (2.21)	4.65 (2.79)	5.63 [-1.39; 12.66]	0.115
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.14 SF-36 MCS - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.767</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	40.02 (12.95)	41.39 (10.40)		
Week 52 Mean (SD)	48.38 (11.22)	47.24 (10.45)		
Week 4 Adjusted Mean Change (SE)	6.30 (1.03)	5.82 (1.21)		
Week 12 Adjusted Mean Change (SE)	6.86 (1.08)	6.14 (1.27)		
Week 16 Adjusted Mean Change (SE)	7.29 (1.00)	5.91 (1.18)		
Week 24 Adjusted Mean Change (SE)	7.87 (1.16)	5.01 (1.38)		
Week 32 Adjusted Mean Change (SE)	7.45 (1.16)	5.32 (1.37)		
Week 40 Adjusted Mean Change (SE)	6.78 (1.14)	5.67 (1.37)		
Week 52 Adjusted Mean Change (SE)	8.54 (1.13)	7.14 (1.36)	1.40 [-2.10; 4.90]	0.431
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	38.25 (6.28)	38.20 (5.83)		
Week 52 Mean (SD)	47.83 (10.66)	45.73 (9.64)		
Week 4 Adjusted Mean Change (SE)	5.65 (2.42)	2.84 (2.75)		
Week 12 Adjusted Mean Change (SE)	6.05 (2.57)	3.68 (2.86)		
Week 16 Adjusted Mean Change (SE)	3.79 (2.33)	5.05 (2.65)		
Week 24 Adjusted Mean Change (SE)	4.73 (2.68)	5.02 (3.05)		
Week 32 Adjusted Mean Change (SE)	7.57 (2.66)	8.23 (3.03)		
Week 40 Adjusted Mean Change (SE)	6.47 (2.63)	8.34 (2.99)		
Week 52 Adjusted Mean Change (SE)	8.62 (2.60)	6.65 (2.96)	1.97 [-5.83; 9.77]	0.618
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.15 SF-36 MCS - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.834</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	39.71 (14.55)	42.66 (10.42)		
Week 52 Mean (SD)	49.98 (11.98)	47.33 (11.06)		
Week 4 Adjusted Mean Change (SE)	7.75 (1.83)	8.14 (1.73)		
Week 12 Adjusted Mean Change (SE)	8.34 (1.93)	6.88 (1.82)		
Week 16 Adjusted Mean Change (SE)	8.17 (1.80)	6.16 (1.70)		
Week 24 Adjusted Mean Change (SE)	6.81 (2.11)	4.05 (2.02)		
Week 32 Adjusted Mean Change (SE)	8.48 (2.14)	6.37 (2.05)		
Week 40 Adjusted Mean Change (SE)	6.22 (2.05)	4.20 (1.97)		
Week 52 Adjusted Mean Change (SE)	10.22 (2.14)	7.69 (2.10)	2.53 [-3.40; 8.46]	0.401
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	39.70 (11.23)	40.62 (9.57)		
Week 52 Mean (SD)	47.81 (10.72)	46.58 (10.69)		
Week 4 Adjusted Mean Change (SE)	5.58 (1.08)	3.74 (1.34)		
Week 12 Adjusted Mean Change (SE)	6.02 (1.15)	4.59 (1.42)		
Week 16 Adjusted Mean Change (SE)	6.24 (1.05)	5.89 (1.32)		
Week 24 Adjusted Mean Change (SE)	7.43 (1.22)	5.99 (1.54)		
Week 32 Adjusted Mean Change (SE)	6.95 (1.24)	4.88 (1.56)		
Week 40 Adjusted Mean Change (SE)	6.83 (1.18)	7.22 (1.49)		
Week 52 Adjusted Mean Change (SE)	7.93 (1.22)	6.09 (1.52)	1.84 [-2.02; 5.70]	0.348
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 51.16 SF-36 MCS - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.315</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	39.35 (10.26)	42.01 (9.64)		
Week 52 Mean (SD)	48.43 (12.10)	47.64 (8.22)		
Week 4 Adjusted Mean Change (SE)	5.81 (1.22)	6.01 (1.50)		
Week 12 Adjusted Mean Change (SE)	5.89 (1.28)	6.37 (1.56)		
Week 16 Adjusted Mean Change (SE)	6.08 (1.17)	6.27 (1.45)		
Week 24 Adjusted Mean Change (SE)	6.09 (1.36)	5.56 (1.70)		
Week 32 Adjusted Mean Change (SE)	7.68 (1.38)	6.85 (1.72)		
Week 40 Adjusted Mean Change (SE)	6.48 (1.33)	6.35 (1.67)		
Week 52 Adjusted Mean Change (SE)	8.41 (1.36)	7.99 (1.75)	0.42 [-3.98; 4.82]	0.850
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	40.23 (14.55)	40.75 (10.26)		
Week 52 Mean (SD)	48.15 (9.17)	46.07 (12.65)		
Week 4 Adjusted Mean Change (SE)	6.64 (1.50)	4.75 (1.54)		
Week 12 Adjusted Mean Change (SE)	7.71 (1.57)	4.47 (1.62)		
Week 16 Adjusted Mean Change (SE)	7.69 (1.45)	5.72 (1.49)		
Week 24 Adjusted Mean Change (SE)	9.21 (1.67)	5.06 (1.74)		
Week 32 Adjusted Mean Change (SE)	6.84 (1.71)	3.98 (1.76)		
Week 40 Adjusted Mean Change (SE)	7.06 (1.63)	5.98 (1.72)		
Week 52 Adjusted Mean Change (SE)	8.62 (1.69)	5.33 (1.73)	3.29 [-1.51; 8.08]	0.177
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.17 SF-36 MCS - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.648</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	38.48 (12.93)	42.38 (10.02)		
Week 52 Mean (SD)	49.08 (10.45)	48.55 (10.29)		
Week 4 Adjusted Mean Change (SE)	6.20 (1.57)	7.84 (1.58)		
Week 12 Adjusted Mean Change (SE)	8.02 (1.63)	7.95 (1.66)		
Week 16 Adjusted Mean Change (SE)	7.49 (1.52)	7.58 (1.54)		
Week 24 Adjusted Mean Change (SE)	7.25 (1.79)	3.23 (1.86)		
Week 32 Adjusted Mean Change (SE)	7.97 (1.79)	7.28 (1.87)		
Week 40 Adjusted Mean Change (SE)	6.70 (1.74)	5.90 (1.82)		
Week 52 Adjusted Mean Change (SE)	9.39 (1.78)	7.76 (1.92)	1.63 [-3.54; 6.80]	0.534
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	40.36 (11.67)	40.57 (9.82)		
Week 52 Mean (SD)	47.90 (11.38)	45.72 (10.98)		
Week 4 Adjusted Mean Change (SE)	6.11 (1.16)	3.38 (1.44)		
Week 12 Adjusted Mean Change (SE)	5.85 (1.22)	3.41 (1.49)		
Week 16 Adjusted Mean Change (SE)	6.31 (1.12)	4.68 (1.40)		
Week 24 Adjusted Mean Change (SE)	7.32 (1.31)	6.56 (1.62)		
Week 32 Adjusted Mean Change (SE)	7.03 (1.33)	3.94 (1.64)		
Week 40 Adjusted Mean Change (SE)	6.71 (1.28)	6.19 (1.60)		
Week 52 Adjusted Mean Change (SE)	7.99 (1.32)	5.69 (1.62)	2.29 [-1.83; 6.42]	0.273
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.18 SF-36 MCS - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.751</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	39.40 (12.99)	40.95 (10.03)		
Week 52 Mean (SD)	47.22 (11.83)	46.83 (11.45)		
Week 4 Adjusted Mean Change (SE)	6.64 (1.33)	5.59 (1.33)		
Week 12 Adjusted Mean Change (SE)	6.27 (1.40)	5.50 (1.40)		
Week 16 Adjusted Mean Change (SE)	5.54 (1.28)	5.24 (1.27)		
Week 24 Adjusted Mean Change (SE)	6.54 (1.49)	4.41 (1.50)		
Week 32 Adjusted Mean Change (SE)	6.36 (1.52)	6.28 (1.52)		
Week 40 Adjusted Mean Change (SE)	6.28 (1.46)	5.62 (1.47)		
Week 52 Adjusted Mean Change (SE)	7.80 (1.51)	6.93 (1.51)	0.87 [-3.34; 5.09]	0.682
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	40.01 (11.23)	42.22 (9.76)		
Week 52 Mean (SD)	49.38 (10.17)	46.77 (9.24)		
Week 4 Adjusted Mean Change (SE)	5.64 (1.35)	5.01 (1.83)		
Week 12 Adjusted Mean Change (SE)	6.99 (1.42)	5.35 (1.91)		
Week 16 Adjusted Mean Change (SE)	7.90 (1.28)	7.45 (1.76)		
Week 24 Adjusted Mean Change (SE)	8.10 (1.49)	6.99 (2.06)		
Week 32 Adjusted Mean Change (SE)	8.36 (1.51)	3.92 (2.09)		
Week 40 Adjusted Mean Change (SE)	7.14 (1.46)	7.23 (2.06)		
Week 52 Adjusted Mean Change (SE)	9.19 (1.49)	5.96 (2.14)	3.23 [-1.94; 8.39]	0.219
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 51.19 SF-36 MCS - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.648</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	40.06 (11.15)	41.20 (9.27)		
Week 52 Mean (SD)	48.16 (10.98)	46.65 (9.38)		
Week 4 Adjusted Mean Change (SE)	6.27 (1.07)	5.38 (1.25)		
Week 12 Adjusted Mean Change (SE)	5.27 (1.12)	4.73 (1.29)		
Week 16 Adjusted Mean Change (SE)	6.77 (1.04)	5.31 (1.21)		
Week 24 Adjusted Mean Change (SE)	7.39 (1.21)	4.25 (1.44)		
Week 32 Adjusted Mean Change (SE)	7.31 (1.21)	5.14 (1.43)		
Week 40 Adjusted Mean Change (SE)	6.62 (1.17)	5.15 (1.39)		
Week 52 Adjusted Mean Change (SE)	8.23 (1.22)	6.70 (1.47)	1.53 [-2.24; 5.31]	0.423
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	40.05 (15.04)	41.97 (11.67)		
Week 52 Mean (SD)	49.83 (11.20)	47.19 (13.69)		
Week 4 Adjusted Mean Change (SE)	4.23 (2.05)	4.95 (2.04)		
Week 12 Adjusted Mean Change (SE)	10.13 (2.11)	6.88 (2.10)		
Week 16 Adjusted Mean Change (SE)	5.65 (1.98)	7.42 (2.00)		
Week 24 Adjusted Mean Change (SE)	6.64 (2.36)	7.70 (2.32)		
Week 32 Adjusted Mean Change (SE)	6.97 (2.32)	5.85 (2.33)		
Week 40 Adjusted Mean Change (SE)	7.14 (2.26)	8.60 (2.29)		
Week 52 Adjusted Mean Change (SE)	9.02 (2.33)	6.28 (2.32)	2.74 [-3.77; 9.24]	0.407
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## 52.1 SF-36 MCS 2.5-Point Response / 5-Point Response (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SF-36 MCS 2.5-Point Response	105	82	1.70	1.21	0.122
Week 52, N' n (%)	77.74 (70.67)	59.10 (58.51)	[0.95; 3.07] 0.076	[0.98; 1.49] 0.080	[-0.011; 0.254] 0.073
SF-36 MCS 5-Point Response	105	82	2.05	1.39	0.174
Week 52, N' n (%)	68.53 (62.30)	45.34 (44.89)	[1.15; 3.63] 0.014	[1.06; 1.83] 0.018	[0.036; 0.312] 0.013

N': Number of patients with available response value  
N-N' is the number of values with MI.  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
MI: Multiple Imputation  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.  
RR and RD calculated directly without adjustment.

All results are combined over MI:  
n and % are averages of all imputations.  
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

## 52.2 SF-36 MCS 2.5-Point Response / 5-Point Response by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.304				
SF-36 MCS 5-Point Response Week 52	p=0.083				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	99 73.74 (71.59)	76 54.14 (57.60)	1.85 [1.00; 3.42] 0.049	1.24 [1.00; 1.55] 0.053	0.140 [0.003; 0.277] 0.046
SF-36 MCS 5-Point Response Week 52, N' n (%)	99 66.53 (64.59)	76 41.39 (44.03)	2.35 [1.29; 4.29] 0.005	1.47 [1.11; 1.95] 0.008	0.206 [0.064; 0.348] 0.005
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	6 4.00 (57.14)	6 4.96 (70.86)	0.55 [0.06; 5.11] 0.599	0.81 [0.36; 1.80] 0.601	-0.137 [-0.638; 0.363] 0.591
SF-36 MCS 5-Point Response Week 52, N' n (%)	6 2.00 (28.57)	6 3.95 (56.43)	0.30 [0.03; 2.83] 0.294	0.51 [0.13; 1.95] 0.323	-0.279 [-0.779; 0.222] 0.275
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 52.3 SF-36 MCS 2.5-Point Response / 5-Point Response by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.759				
SF-36 MCS 5-Point Response Week 52	p=0.434				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	64 44.00 (66.67)	48 31.25 (54.82)	1.61 [0.75; 3.43] 0.219	1.22 [0.90; 1.65] 0.202	0.118 [-0.059; 0.296] 0.191
SF-36 MCS 5-Point Response Week 52, N' n (%)	64 37.00 (56.06)	48 24.40 (42.81)	1.72 [0.82; 3.62] 0.154	1.31 [0.89; 1.92] 0.166	0.133 [-0.049; 0.314] 0.152
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	41 33.74 (76.68)	34 27.85 (63.30)	1.95 [0.74; 5.18] 0.179	1.21 [0.90; 1.63] 0.199	0.134 [-0.065; 0.333] 0.187
SF-36 MCS 5-Point Response Week 52, N' n (%)	41 31.53 (71.66)	34 20.94 (47.59)	2.77 [1.09; 7.03] 0.032	1.51 [1.02; 2.22] 0.038	0.241 [0.030; 0.451] 0.025
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 52.4 SF-36 MCS 2.5-Point Response / 5-Point Response by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.993				
SF-36 MCS 5-Point Response Week 52	p=0.700				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	23 16.11 (67.13)	17 11.33 (53.95)	1.72 [0.49; 6.06] 0.400	1.25 [0.75; 2.07] 0.392	0.132 [-0.162; 0.425] 0.379
SF-36 MCS 5-Point Response Week 52, N' n (%)	23 13.05 (54.38)	17 8.99 (42.81)	1.66 [0.49; 5.68] 0.420	1.27 [0.67; 2.42] 0.458	0.116 [-0.183; 0.415] 0.449
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	82 61.63 (71.66)	65 47.77 (59.71)	1.71 [0.88; 3.33] 0.116	1.20 [0.95; 1.51] 0.123	0.120 [-0.029; 0.268] 0.115
SF-36 MCS 5-Point Response Week 52, N' n (%)	82 55.48 (64.51)	65 36.35 (45.44)	2.18 [1.14; 4.18] 0.019	1.42 [1.05; 1.92] 0.023	0.191 [0.035; 0.346] 0.016
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



## 52.5 SF-36 MCS 2.5-Point Response / 5-Point Response by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.192				
SF-36 MCS 5-Point Response Week 52	p=0.136				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	39 29.09 (69.26)	38 34.10 (66.86)	1.12 [0.45; 2.80] 0.815	1.04 [0.77; 1.39] 0.809	0.024 [-0.175; 0.223] 0.813
SF-36 MCS 5-Point Response Week 52, N' n (%)	39 25.00 (59.52)	38 26.87 (52.69)	1.29 [0.54; 3.05] 0.562	1.13 [0.78; 1.65] 0.522	0.068 [-0.142; 0.279] 0.524
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	66 48.65 (71.54)	44 25.00 (50.00)	2.51 [1.14; 5.52] 0.022	1.43 [1.03; 1.98] 0.031	0.215 [0.035; 0.396] 0.019
SF-36 MCS 5-Point Response Week 52, N' n (%)	66 43.53 (64.01)	44 18.47 (36.94)	3.16 [1.43; 6.99] 0.005	1.74 [1.14; 2.65] 0.011	0.271 [0.089; 0.453] 0.004
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 52.6 SF-36 MCS 2.5-Point Response / 5-Point Response by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.520				
SF-36 MCS 5-Point Response Week 52	p=0.347				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	70 56.00 (77.78)	36 32.07 (65.45)	1.84 [0.79; 4.29] 0.159	1.19 [0.92; 1.53] 0.178	0.123 [-0.050; 0.296] 0.162
SF-36 MCS 5-Point Response Week 52, N' n (%)	70 51.00 (70.83)	36 25.03 (51.08)	2.36 [1.06; 5.24] 0.035	1.39 [1.00; 1.94] 0.053	0.198 [0.013; 0.382] 0.036
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	35 21.74 (57.21)	46 27.03 (51.98)	1.23 [0.52; 2.94] 0.633	1.10 [0.74; 1.63] 0.630	0.052 [-0.161; 0.266] 0.631
SF-36 MCS 5-Point Response Week 52, N' n (%)	35 17.53 (46.13)	46 20.31 (39.06)	1.34 [0.56; 3.21] 0.512	1.18 [0.72; 1.95] 0.511	0.071 [-0.142; 0.283] 0.514
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 52.7 SF-36 MCS 2.5-Point Response / 5-Point Response by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.743				
SF-36 MCS 5-Point Response Week 52	p=0.638				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	49 35.98 (70.55)	25 19.79 (61.84)	1.48 [0.56; 3.89] 0.427	1.14 [0.81; 1.60] 0.442	0.087 [-0.130; 0.304] 0.432
SF-36 MCS 5-Point Response Week 52, N' n (%)	49 29.95 (58.73)	25 14.24 (44.50)	1.76 [0.69; 4.47] 0.233	1.32 [0.82; 2.12] 0.246	0.142 [-0.085; 0.370] 0.220
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	56 41.76 (70.78)	57 39.31 (56.97)	1.82 [0.85; 3.92] 0.125	1.24 [0.94; 1.64] 0.121	0.138 [-0.033; 0.310] 0.114
SF-36 MCS 5-Point Response Week 52, N' n (%)	56 38.58 (65.39)	57 31.10 (45.07)	2.35 [1.11; 4.98] 0.026	1.45 [1.04; 2.04] 0.030	0.203 [0.027; 0.379] 0.024
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 52.8 SF-36 MCS 2.5-Point Response / 5-Point Response by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.722				
SF-36 MCS 5-Point Response Week 52	p=0.988				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	49 38.09 (74.69)	36 24.82 (60.54)	1.92 [0.77; 4.81] 0.161	1.23 [0.91; 1.68] 0.176	0.141 [-0.056; 0.339] 0.160
SF-36 MCS 5-Point Response Week 52, N' n (%)	49 35.00 (68.63)	36 19.34 (47.17)	2.46 [1.03; 5.90] 0.043	1.46 [0.99; 2.14] 0.056	0.215 [0.011; 0.418] 0.039
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	31 24.65 (72.50)	21 16.66 (64.08)	1.48 [0.48; 4.59] 0.499	1.13 [0.78; 1.63] 0.507	0.084 [-0.161; 0.329] 0.500
SF-36 MCS 5-Point Response Week 52, N' n (%)	31 23.53 (69.21)	21 12.35 (47.50)	2.49 [0.83; 7.45] 0.102	1.46 [0.90; 2.36] 0.124	0.217 [-0.038; 0.472] 0.095
<p>N': Number of patients with available response value  N-N' is the number of values with MI.  n (%): Number and percentage of patients with event  CI: Confidence Interval  MI: Multiple Imputation  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup.  RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI:  n and % are averages of all imputations.  P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 52.9 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.614				
SF-36 MCS 5-Point Response Week 52	p=0.457				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	43 35.65 (79.22)	19 17.28 (64.00)	2.14 [0.69; 6.62] 0.187	1.24 [0.88; 1.75] 0.219	0.152 [-0.077; 0.382] 0.193
SF-36 MCS 5-Point Response Week 52, N' n (%)	43 32.53 (72.29)	19 12.68 (46.96)	2.97 [1.03; 8.52] 0.043	1.54 [0.97; 2.47] 0.069	0.253 [0.012; 0.494] 0.039
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	35 25.09 (66.03)	28 17.20 (57.33)	1.45 [0.53; 3.97] 0.473	1.15 [0.78; 1.71] 0.480	0.087 [-0.150; 0.324] 0.473
SF-36 MCS 5-Point Response Week 52, N' n (%)	35 24.00 (63.16)	28 15.01 (50.03)	1.71 [0.63; 4.61] 0.291	1.26 [0.81; 1.97] 0.300	0.131 [-0.109; 0.371] 0.284
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 52.10 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.848				
SF-36 MCS 5-Point Response Week 52	p=0.824				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	29 23.65 (78.83)	24 21.19 (64.21)	2.07 [0.63; 6.79] 0.228	1.23 [0.88; 1.72] 0.229	0.146 [-0.086; 0.378] 0.216
SF-36 MCS 5-Point Response Week 52, N' n (%)	29 21.53 (71.77)	24 16.47 (49.91)	2.55 [0.85; 7.65] 0.094	1.44 [0.93; 2.23] 0.099	0.219 [-0.027; 0.464] 0.081
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	49 36.98 (72.51)	33 20.29 (59.68)	1.79 [0.71; 4.54] 0.220	1.22 [0.88; 1.69] 0.242	0.128 [-0.079; 0.335] 0.225
SF-36 MCS 5-Point Response Week 52, N' n (%)	49 35.95 (70.49)	33 15.22 (44.76)	3.00 [1.20; 7.50] 0.019	1.58 [1.04; 2.39] 0.033	0.257 [0.047; 0.468] 0.017
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 52.11 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.997				
SF-36 MCS 5-Point Response Week 52	p=0.965				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	39 31.74 (73.81)	39 26.61 (61.88)	1.74 [0.67; 4.48] 0.254	1.19 [0.88; 1.62] 0.256	0.119 [-0.083; 0.321] 0.247
SF-36 MCS 5-Point Response Week 52, N' n (%)	39 29.53 (68.67)	39 20.31 (47.23)	2.44 [0.99; 6.01] 0.053	1.45 [0.99; 2.14] 0.057	0.214 [0.006; 0.423] 0.044
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	41 31.00 (73.81)	18 14.87 (61.96)	1.73 [0.56; 5.32] 0.339	1.19 [0.81; 1.75] 0.364	0.119 [-0.128; 0.365] 0.345
SF-36 MCS 5-Point Response Week 52, N' n (%)	41 29.00 (69.05)	18 11.38 (47.42)	2.51 [0.85; 7.43] 0.095	1.46 [0.89; 2.40] 0.134	0.216 [-0.038; 0.471] 0.096
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 52.12 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.647				
SF-36 MCS 5-Point Response Week 52	p=0.784				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	58 46.09 (74.34)	38 28.32 (60.26)	1.93 [0.82; 4.52] 0.132	1.23 [0.93; 1.65] 0.151	0.141 [-0.044; 0.325] 0.135
SF-36 MCS 5-Point Response Week 52, N' n (%)	58 43.00 (69.35)	38 22.60 (48.09)	2.49 [1.10; 5.64] 0.029	1.44 [1.01; 2.06] 0.042	0.213 [0.023; 0.402] 0.028
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	19 14.65 (73.25)	17 12.16 (67.56)	1.30 [0.31; 5.49] 0.723	1.08 [0.71; 1.66] 0.709	0.057 [-0.240; 0.353] 0.707
SF-36 MCS 5-Point Response Week 52, N' n (%)	19 13.53 (67.65)	17 9.09 (50.50)	1.99 [0.52; 7.69] 0.316	1.34 [0.77; 2.34] 0.304	0.171 [-0.142; 0.485] 0.284
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 52.13 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.463				
SF-36 MCS 5-Point Response Week 52	p=0.344				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	58 45.74 (72.60)	42 30.03 (58.88)	1.85 [0.82; 4.17] 0.137	1.23 [0.93; 1.64] 0.150	0.137 [-0.043; 0.318] 0.136
SF-36 MCS 5-Point Response Week 52, N' n (%)	58 42.53 (67.51)	42 26.35 (51.67)	1.94 [0.89; 4.25] 0.097	1.31 [0.94; 1.81] 0.108	0.158 [-0.026; 0.343] 0.093
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	19 14.00 (73.68)	12 9.00 (75.00)	0.93 [0.18; 4.89] 0.927	0.98 [0.64; 1.50] 0.935	-0.013 [-0.328; 0.302] 0.935
SF-36 MCS 5-Point Response Week 52, N' n (%)	19 13.00 (68.42)	12 4.00 (33.33)	4.50 [0.95; 21.23] 0.058	2.05 [0.87; 4.83] 0.100	0.351 [0.012; 0.690] 0.042
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) SF-36 MCS 2.5-Point Response, SF-36 MCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

### 52.14 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.410				
SF-36 MCS 5-Point Response Week 52	p=0.867				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	66 50.74 (71.46)	44 33.32 (62.87)	1.48 [0.67; 3.27] 0.329	1.14 [0.87; 1.48] 0.341	0.086 [-0.088; 0.260] 0.332
SF-36 MCS 5-Point Response Week 52, N' n (%)	66 48.53 (68.35)	44 24.60 (46.42)	2.53 [1.18; 5.44] 0.017	1.47 [1.05; 2.08] 0.027	0.219 [0.041; 0.397] 0.016
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	13 11.00 (84.62)	10 6.00 (60.00)	3.63 [0.50; 26.14] 0.200	1.41 [0.81; 2.46] 0.226	0.246 [-0.115; 0.608] 0.182
SF-36 MCS 5-Point Response Week 52, N' n (%)	13 9.00 (69.23)	10 5.00 (50.00)	2.16 [0.39; 12.00] 0.380	1.38 [0.68; 2.84] 0.374	0.192 [-0.206; 0.591] 0.345
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) SF-36 MCS 2.5-Point Response, SF-36 MCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

### 52.15 SF-36 MCS 2.5-Point Response / 5-Point Response by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.781				
SF-36 MCS 5-Point Response Week 52	p=0.890				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	19 16.76 (76.18)	18 15.87 (61.04)	2.04 [0.53; 7.86] 0.299	1.25 [0.82; 1.90] 0.294	0.151 [-0.125; 0.427] 0.282
SF-36 MCS 5-Point Response Week 52, N' n (%)	19 15.58 (70.82)	18 12.26 (47.15)	2.69 [0.76; 9.54] 0.126	1.51 [0.89; 2.54] 0.124	0.237 [-0.048; 0.521] 0.103
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	61 45.98 (72.98)	39 25.61 (62.46)	1.63 [0.69; 3.83] 0.265	1.17 [0.88; 1.55] 0.283	0.105 [-0.081; 0.292] 0.269
SF-36 MCS 5-Point Response Week 52, N' n (%)	61 42.95 (68.17)	39 19.43 (47.39)	2.41 [1.06; 5.49] 0.035	1.44 [1.00; 2.08] 0.052	0.208 [0.015; 0.401] 0.035
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 52.16 SF-36 MCS 2.5-Point Response / 5-Point Response by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.887				
SF-36 MCS 5-Point Response Week 52	p=0.630				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	49 39.65 (77.75)	27 23.28 (66.51)	1.77 [0.64; 4.89] 0.270	1.17 [0.87; 1.57] 0.292	0.112 [-0.090; 0.315] 0.277
SF-36 MCS 5-Point Response Week 52, N' n (%)	49 36.53 (71.63)	27 16.68 (47.66)	2.86 [1.11; 7.37] 0.030	1.51 [1.00; 2.26] 0.049	0.240 [0.025; 0.454] 0.029
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	31 23.09 (67.91)	30 18.20 (56.88)	1.59 [0.57; 4.46] 0.376	1.19 [0.81; 1.76] 0.370	0.110 [-0.127; 0.347] 0.362
SF-36 MCS 5-Point Response Week 52, N' n (%)	31 22.00 (64.71)	30 15.01 (46.91)	2.02 [0.74; 5.57] 0.172	1.38 [0.88; 2.18] 0.164	0.178 [-0.062; 0.418] 0.146
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 52.17 SF-36 MCS 2.5-Point Response / 5-Point Response by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.839				
SF-36 MCS 5-Point Response Week 52	p=0.995				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	29 23.65 (78.83)	22 20.19 (65.13)	1.99 [0.59; 6.67] 0.265	1.21 [0.86; 1.70] 0.268	0.137 [-0.099; 0.373] 0.255
SF-36 MCS 5-Point Response Week 52, N' n (%)	29 21.53 (71.77)	22 15.47 (49.90)	2.55 [0.84; 7.77] 0.100	1.44 [0.92; 2.25] 0.108	0.219 [-0.032; 0.469] 0.088
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	51 39.09 (71.07)	35 21.29 (59.14)	1.70 [0.70; 4.16] 0.242	1.20 [0.87; 1.66] 0.264	0.119 [-0.083; 0.321] 0.247
SF-36 MCS 5-Point Response Week 52, N' n (%)	51 37.00 (67.27)	35 16.22 (45.06)	2.54 [1.06; 6.08] 0.037	1.49 [0.99; 2.25] 0.054	0.222 [0.016; 0.428] 0.035
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 52.18 SF-36 MCS 2.5-Point Response / 5-Point Response by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.997				
SF-36 MCS 5-Point Response Week 52	p=0.965				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	39 31.74 (73.81)	39 26.61 (61.88)	1.74 [0.67; 4.48] 0.254	1.19 [0.88; 1.62] 0.256	0.119 [-0.083; 0.321] 0.247
SF-36 MCS 5-Point Response Week 52, N' n (%)	39 29.53 (68.67)	39 20.31 (47.23)	2.44 [0.99; 6.01] 0.053	1.45 [0.99; 2.14] 0.057	0.214 [0.006; 0.423] 0.044
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	41 31.00 (73.81)	18 14.87 (61.96)	1.73 [0.56; 5.32] 0.339	1.19 [0.81; 1.75] 0.364	0.119 [-0.128; 0.365] 0.345
SF-36 MCS 5-Point Response Week 52, N' n (%)	41 29.00 (69.05)	18 11.38 (47.42)	2.51 [0.85; 7.43] 0.095	1.46 [0.89; 2.40] 0.134	0.216 [-0.038; 0.471] 0.096
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

## 52.19 SF-36 MCS 2.5-Point Response / 5-Point Response by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 MCS 2.5-Point Response Week 52	p=0.546				
SF-36 MCS 5-Point Response Week 52	p=0.865				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	61 48.09 (73.98)	40 29.32 (59.84)	1.91 [0.83; 4.37] 0.126	1.24 [0.93; 1.64] 0.141	0.141 [-0.039; 0.322] 0.125
SF-36 MCS 5-Point Response Week 52, N' n (%)	61 45.00 (69.23)	40 23.60 (48.16)	2.45 [1.11; 5.45] 0.027	1.44 [1.02; 2.04] 0.040	0.211 [0.026; 0.396] 0.026
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
SF-36 MCS 2.5-Point Response Week 52, N' n (%)	17 12.65 (70.28)	17 12.16 (67.56)	1.14 [0.26; 4.87] 0.864	1.04 [0.66; 1.63] 0.864	0.027 [-0.282; 0.336] 0.863
SF-36 MCS 5-Point Response Week 52, N' n (%)	17 11.53 (64.06)	17 8.09 (44.94)	2.14 [0.54; 8.42] 0.278	1.42 [0.76; 2.67] 0.269	0.191 [-0.134; 0.516] 0.249
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 53.0 SF-36 PCS - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)



### 53.1 SF-36 PCS - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	36.81 (7.50)	36.22 (8.98)		
Week 52 Mean (SD)	44.93 (8.96)	44.77 (8.84)		
Week 4 Adjusted Mean Change (SE)	4.71 (0.54)	3.94 (0.57)		
Week 12 Adjusted Mean Change (SE)	6.93 (0.67)	5.85 (0.70)		
Week 16 Adjusted Mean Change (SE)	7.32 (0.66)	5.51 (0.70)		
Week 24 Adjusted Mean Change (SE)	7.54 (0.71)	6.98 (0.76)		
Week 32 Adjusted Mean Change (SE)	7.92 (0.74)	7.26 (0.79)		
Week 40 Adjusted Mean Change (SE)	8.30 (0.69)	6.87 (0.75)		
Week 52 Adjusted Mean Change (SE)	8.17 (0.74)	7.62 (0.81)	0.55 [-1.60; 2.70]	0.612
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

### 53.2 SF-36 PCS - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.875</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	36.62 (7.06)	36.23 (9.00)		
Week 52 Mean (SD)	44.77 (8.84)	44.87 (8.96)		
Week 4 Adjusted Mean Change (SE)	4.84 (0.56)	4.11 (0.59)		
Week 12 Adjusted Mean Change (SE)	7.04 (0.69)	6.00 (0.73)		
Week 16 Adjusted Mean Change (SE)	7.46 (0.68)	5.77 (0.72)		
Week 24 Adjusted Mean Change (SE)	7.69 (0.74)	7.31 (0.79)		
Week 32 Adjusted Mean Change (SE)	8.23 (0.76)	7.50 (0.82)		
Week 40 Adjusted Mean Change (SE)	8.53 (0.71)	6.98 (0.78)		
Week 52 Adjusted Mean Change (SE)	8.27 (0.76)	7.88 (0.84)	0.39 [-1.84; 2.62]	0.730
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	39.72 (12.80)	36.01 (9.48)		
Week 52 Mean (SD)	47.60 (11.34)	43.45 (7.55)		
Week 4 Adjusted Mean Change (SE)	2.83 (2.15)	1.71 (2.15)		
Week 12 Adjusted Mean Change (SE)	5.32 (2.63)	3.80 (2.63)		
Week 16 Adjusted Mean Change (SE)	5.29 (2.69)	2.20 (2.59)		
Week 24 Adjusted Mean Change (SE)	5.41 (2.82)	2.90 (2.81)		
Week 32 Adjusted Mean Change (SE)	3.53 (2.89)	4.28 (2.88)		
Week 40 Adjusted Mean Change (SE)	5.08 (2.72)	5.26 (2.71)		
Week 52 Adjusted Mean Change (SE)	7.10 (2.99)	4.24 (2.98)	2.86 [-5.45; 11.17]	0.498
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.3 SF-36 PCS - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.920</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	37.56 (7.73)	37.83 (9.17)		
Week 52 Mean (SD)	46.57 (8.79)	46.95 (8.48)		
Week 4 Adjusted Mean Change (SE)	6.08 (0.70)	4.48 (0.75)		
Week 12 Adjusted Mean Change (SE)	8.12 (0.86)	6.89 (0.92)		
Week 16 Adjusted Mean Change (SE)	8.53 (0.85)	6.83 (0.90)		
Week 24 Adjusted Mean Change (SE)	8.57 (0.91)	8.56 (0.99)		
Week 32 Adjusted Mean Change (SE)	9.10 (0.94)	9.06 (1.03)		
Week 40 Adjusted Mean Change (SE)	9.45 (0.88)	8.22 (0.97)		
Week 52 Adjusted Mean Change (SE)	9.68 (0.93)	9.47 (1.03)	0.22 [-2.50; 2.93]	0.874
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	35.70 (7.07)	34.13 (8.38)		
Week 52 Mean (SD)	42.37 (8.71)	41.69 (8.51)		
Week 4 Adjusted Mean Change (SE)	2.71 (0.86)	3.18 (0.86)		
Week 12 Adjusted Mean Change (SE)	5.20 (1.05)	4.44 (1.06)		
Week 16 Adjusted Mean Change (SE)	5.56 (1.03)	3.71 (1.06)		
Week 24 Adjusted Mean Change (SE)	6.07 (1.13)	4.82 (1.16)		
Week 32 Adjusted Mean Change (SE)	6.21 (1.16)	4.82 (1.19)		
Week 40 Adjusted Mean Change (SE)	6.63 (1.09)	5.03 (1.14)		
Week 52 Adjusted Mean Change (SE)	5.93 (1.15)	5.10 (1.21)	0.83 [-2.43; 4.09]	0.615
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.4 SF-36 PCS - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.852</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	43.98 (6.38)	47.65 (7.66)		
Week 52 Mean (SD)	49.33 (7.10)	48.98 (8.51)		
Week 4 Adjusted Mean Change (SE)	5.40 (1.25)	4.58 (1.41)		
Week 12 Adjusted Mean Change (SE)	6.62 (1.55)	6.27 (1.72)		
Week 16 Adjusted Mean Change (SE)	6.68 (1.51)	5.58 (1.71)		
Week 24 Adjusted Mean Change (SE)	6.58 (1.65)	6.22 (1.88)		
Week 32 Adjusted Mean Change (SE)	6.96 (1.71)	7.51 (1.96)		
Week 40 Adjusted Mean Change (SE)	7.49 (1.60)	7.29 (1.86)		
Week 52 Adjusted Mean Change (SE)	8.28 (1.69)	5.82 (1.98)	2.46 [-2.25; 7.17]	0.305
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	34.81 (6.52)	33.22 (6.59)		
Week 52 Mean (SD)	43.69 (9.07)	43.67 (8.65)		
Week 4 Adjusted Mean Change (SE)	4.53 (0.62)	3.75 (0.68)		
Week 12 Adjusted Mean Change (SE)	7.02 (0.77)	5.73 (0.83)		
Week 16 Adjusted Mean Change (SE)	7.50 (0.76)	5.50 (0.83)		
Week 24 Adjusted Mean Change (SE)	7.80 (0.82)	7.20 (0.90)		
Week 32 Adjusted Mean Change (SE)	8.18 (0.85)	7.20 (0.93)		
Week 40 Adjusted Mean Change (SE)	8.52 (0.79)	6.76 (0.88)		
Week 52 Adjusted Mean Change (SE)	8.12 (0.84)	8.08 (0.94)	0.04 [-2.40; 2.47]	0.977
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.5 SF-36 PCS - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.291</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	36.76 (7.72)	35.71 (9.16)		
Week 52 Mean (SD)	44.28 (9.05)	46.09 (8.65)		
Week 4 Adjusted Mean Change (SE)	5.05 (0.87)	5.39 (0.79)		
Week 12 Adjusted Mean Change (SE)	6.89 (1.07)	6.95 (0.98)		
Week 16 Adjusted Mean Change (SE)	6.49 (1.06)	6.27 (0.98)		
Week 24 Adjusted Mean Change (SE)	7.47 (1.17)	7.10 (1.08)		
Week 32 Adjusted Mean Change (SE)	8.06 (1.20)	7.86 (1.12)		
Week 40 Adjusted Mean Change (SE)	7.67 (1.13)	6.97 (1.08)		
Week 52 Adjusted Mean Change (SE)	7.71 (1.20)	8.39 (1.16)	-0.68 [-3.97; 2.62]	0.687
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	36.85 (7.41)	36.74 (8.86)		
Week 52 Mean (SD)	45.31 (8.95)	43.63 (8.93)		
Week 4 Adjusted Mean Change (SE)	4.51 (0.68)	2.46 (0.80)		
Week 12 Adjusted Mean Change (SE)	6.95 (0.85)	4.71 (0.99)		
Week 16 Adjusted Mean Change (SE)	7.85 (0.84)	4.73 (0.99)		
Week 24 Adjusted Mean Change (SE)	7.60 (0.91)	6.83 (1.09)		
Week 32 Adjusted Mean Change (SE)	7.84 (0.94)	6.62 (1.12)		
Week 40 Adjusted Mean Change (SE)	8.69 (0.88)	6.68 (1.05)		
Week 52 Adjusted Mean Change (SE)	8.45 (0.93)	6.85 (1.12)	1.60 [-1.28; 4.48]	0.275
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.6 SF-36 PCS - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.081</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	37.26 (6.86)	37.35 (9.71)		
Week 52 Mean (SD)	46.61 (8.23)	46.25 (8.83)		
Week 4 Adjusted Mean Change (SE)	5.23 (0.67)	3.95 (0.81)		
Week 12 Adjusted Mean Change (SE)	7.69 (0.83)	5.85 (0.99)		
Week 16 Adjusted Mean Change (SE)	8.31 (0.81)	5.47 (0.99)		
Week 24 Adjusted Mean Change (SE)	8.71 (0.87)	7.36 (1.09)		
Week 32 Adjusted Mean Change (SE)	9.02 (0.91)	7.25 (1.13)		
Week 40 Adjusted Mean Change (SE)	9.10 (0.85)	6.79 (1.09)		
Week 52 Adjusted Mean Change (SE)	9.46 (0.90)	6.46 (1.18)	3.00 [0.08; 5.92]	0.044
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	35.97 (8.61)	35.16 (8.19)		
Week 52 Mean (SD)	41.56 (9.52)	43.61 (8.76)		
Week 4 Adjusted Mean Change (SE)	3.75 (0.92)	3.92 (0.81)		
Week 12 Adjusted Mean Change (SE)	5.50 (1.12)	5.83 (0.99)		
Week 16 Adjusted Mean Change (SE)	5.46 (1.11)	5.55 (0.97)		
Week 24 Adjusted Mean Change (SE)	5.29 (1.22)	6.64 (1.06)		
Week 32 Adjusted Mean Change (SE)	5.83 (1.26)	7.27 (1.10)		
Week 40 Adjusted Mean Change (SE)	6.77 (1.18)	6.93 (1.04)		
Week 52 Adjusted Mean Change (SE)	5.66 (1.25)	8.53 (1.10)	-2.87 [-6.15; 0.41]	0.086
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.7 SF-36 PCS - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.935</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	37.15 (8.25)	38.26 (9.86)		
Week 52 Mean (SD)	45.98 (8.93)	46.77 (8.96)		
Week 4 Adjusted Mean Change (SE)	4.77 (0.79)	5.29 (1.02)		
Week 12 Adjusted Mean Change (SE)	7.85 (0.98)	6.60 (1.26)		
Week 16 Adjusted Mean Change (SE)	7.24 (0.96)	7.44 (1.24)		
Week 24 Adjusted Mean Change (SE)	7.62 (1.05)	6.98 (1.37)		
Week 32 Adjusted Mean Change (SE)	8.46 (1.09)	6.83 (1.41)		
Week 40 Adjusted Mean Change (SE)	9.08 (1.01)	7.58 (1.32)		
Week 52 Adjusted Mean Change (SE)	9.21 (1.08)	8.24 (1.45)	0.96 [-2.60; 4.52]	0.595
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	36.53 (6.84)	35.27 (8.45)		
Week 52 Mean (SD)	44.01 (8.96)	43.89 (8.71)		
Week 4 Adjusted Mean Change (SE)	4.67 (0.74)	3.32 (0.69)		
Week 12 Adjusted Mean Change (SE)	6.16 (0.91)	5.50 (0.85)		
Week 16 Adjusted Mean Change (SE)	7.40 (0.89)	4.63 (0.84)		
Week 24 Adjusted Mean Change (SE)	7.48 (0.98)	7.01 (0.93)		
Week 32 Adjusted Mean Change (SE)	7.46 (1.01)	7.49 (0.97)		
Week 40 Adjusted Mean Change (SE)	7.63 (0.94)	6.54 (0.92)		
Week 52 Adjusted Mean Change (SE)	7.28 (1.01)	7.35 (0.98)	-0.07 [-2.83; 2.70]	0.963
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.8 SF-36 PCS - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.547</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	35.53 (7.21)	37.24 (8.22)		
Week 52 Mean (SD)	44.44 (9.07)	45.85 (8.92)		
Week 4 Adjusted Mean Change (SE)	4.58 (0.78)	4.97 (0.86)		
Week 12 Adjusted Mean Change (SE)	7.60 (0.99)	6.58 (1.10)		
Week 16 Adjusted Mean Change (SE)	8.24 (0.93)	6.09 (1.04)		
Week 24 Adjusted Mean Change (SE)	8.56 (1.08)	6.93 (1.22)		
Week 32 Adjusted Mean Change (SE)	8.67 (1.11)	7.75 (1.25)		
Week 40 Adjusted Mean Change (SE)	9.03 (0.98)	7.83 (1.11)		
Week 52 Adjusted Mean Change (SE)	8.64 (1.08)	8.93 (1.22)	-0.30 [-3.52; 2.93]	0.856
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	37.53 (8.15)	37.56 (11.00)		
Week 52 Mean (SD)	44.82 (9.17)	46.76 (8.75)		
Week 4 Adjusted Mean Change (SE)	4.37 (0.95)	3.38 (1.11)		
Week 12 Adjusted Mean Change (SE)	6.76 (1.22)	5.34 (1.41)		
Week 16 Adjusted Mean Change (SE)	5.24 (1.14)	6.17 (1.32)		
Week 24 Adjusted Mean Change (SE)	5.50 (1.33)	7.64 (1.56)		
Week 32 Adjusted Mean Change (SE)	7.12 (1.38)	8.53 (1.60)		
Week 40 Adjusted Mean Change (SE)	6.78 (1.21)	7.03 (1.45)		
Week 52 Adjusted Mean Change (SE)	7.03 (1.33)	7.04 (1.59)	-0.01 [-4.10; 4.08]	0.996
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 53.9 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.464</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	37.08 (7.67)	35.42 (8.44)		
Week 52 Mean (SD)	44.99 (9.16)	44.99 (8.40)		
Week 4 Adjusted Mean Change (SE)	4.92 (0.84)	3.66 (1.11)		
Week 12 Adjusted Mean Change (SE)	8.66 (1.06)	5.93 (1.39)		
Week 16 Adjusted Mean Change (SE)	7.65 (1.01)	5.62 (1.34)		
Week 24 Adjusted Mean Change (SE)	8.12 (1.16)	6.38 (1.55)		
Week 32 Adjusted Mean Change (SE)	8.12 (1.20)	7.36 (1.62)		
Week 40 Adjusted Mean Change (SE)	8.32 (1.06)	6.79 (1.45)		
Week 52 Adjusted Mean Change (SE)	8.00 (1.16)	8.24 (1.62)	-0.23 [-4.17; 3.70]	0.907
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	35.23 (7.35)	37.94 (9.76)		
Week 52 Mean (SD)	44.28 (8.82)	46.55 (8.77)		
Week 4 Adjusted Mean Change (SE)	4.10 (0.92)	5.31 (1.04)		
Week 12 Adjusted Mean Change (SE)	6.01 (1.16)	6.03 (1.31)		
Week 16 Adjusted Mean Change (SE)	6.81 (1.11)	6.44 (1.25)		
Week 24 Adjusted Mean Change (SE)	6.70 (1.27)	7.67 (1.44)		
Week 32 Adjusted Mean Change (SE)	8.50 (1.32)	8.42 (1.49)		
Week 40 Adjusted Mean Change (SE)	8.58 (1.16)	8.03 (1.33)		
Week 52 Adjusted Mean Change (SE)	8.57 (1.27)	8.64 (1.43)	-0.07 [-3.87; 3.74]	0.973
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.10 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.509</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	34.86 (7.95)	35.56 (9.99)		
Week 52 Mean (SD)	43.23 (9.54)	46.37 (9.09)		
Week 4 Adjusted Mean Change (SE)	4.79 (1.03)	5.09 (0.99)		
Week 12 Adjusted Mean Change (SE)	7.63 (1.29)	6.91 (1.25)		
Week 16 Adjusted Mean Change (SE)	7.08 (1.23)	7.28 (1.19)		
Week 24 Adjusted Mean Change (SE)	7.36 (1.45)	8.38 (1.42)		
Week 32 Adjusted Mean Change (SE)	7.75 (1.46)	7.72 (1.44)		
Week 40 Adjusted Mean Change (SE)	8.57 (1.29)	7.92 (1.30)		
Week 52 Adjusted Mean Change (SE)	7.53 (1.42)	8.73 (1.45)	-1.20 [-5.21; 2.80]	0.554
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	36.60 (6.58)	39.13 (8.40)		
Week 52 Mean (SD)	45.00 (8.76)	46.05 (8.71)		
Week 4 Adjusted Mean Change (SE)	4.43 (0.78)	3.73 (0.97)		
Week 12 Adjusted Mean Change (SE)	7.47 (0.99)	5.44 (1.22)		
Week 16 Adjusted Mean Change (SE)	7.19 (0.94)	5.11 (1.17)		
Week 24 Adjusted Mean Change (SE)	7.56 (1.09)	6.19 (1.36)		
Week 32 Adjusted Mean Change (SE)	8.67 (1.12)	8.35 (1.39)		
Week 40 Adjusted Mean Change (SE)	8.22 (0.98)	7.28 (1.24)		
Week 52 Adjusted Mean Change (SE)	8.62 (1.08)	7.88 (1.34)	0.74 [-2.67; 4.15]	0.668
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.11 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.436</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	36.43 (6.92)	38.96 (9.08)		
Week 52 Mean (SD)	45.33 (9.35)	45.76 (8.81)		
Week 4 Adjusted Mean Change (SE)	5.09 (0.85)	4.57 (0.85)		
Week 12 Adjusted Mean Change (SE)	8.12 (1.07)	5.73 (1.08)		
Week 16 Adjusted Mean Change (SE)	7.55 (1.02)	6.12 (1.03)		
Week 24 Adjusted Mean Change (SE)	7.93 (1.19)	6.78 (1.21)		
Week 32 Adjusted Mean Change (SE)	8.94 (1.22)	7.65 (1.23)		
Week 40 Adjusted Mean Change (SE)	8.25 (1.08)	7.78 (1.10)		
Week 52 Adjusted Mean Change (SE)	8.40 (1.19)	7.91 (1.19)	0.49 [-2.84; 3.83]	0.770
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	36.23 (8.34)	34.52 (9.24)		
Week 52 Mean (SD)	43.88 (8.81)	47.11 (8.95)		
Week 4 Adjusted Mean Change (SE)	3.89 (0.86)	4.01 (1.16)		
Week 12 Adjusted Mean Change (SE)	6.36 (1.09)	6.81 (1.47)		
Week 16 Adjusted Mean Change (SE)	6.51 (1.03)	6.15 (1.41)		
Week 24 Adjusted Mean Change (SE)	6.75 (1.20)	7.98 (1.65)		
Week 32 Adjusted Mean Change (SE)	7.12 (1.22)	8.79 (1.67)		
Week 40 Adjusted Mean Change (SE)	8.00 (1.09)	7.01 (1.53)		
Week 52 Adjusted Mean Change (SE)	7.56 (1.18)	8.91 (1.68)	-1.35 [-5.41; 2.70]	0.510
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.12 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.487</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	36.32 (7.60)	38.01 (9.84)		
Week 52 Mean (SD)	44.41 (9.32)	46.25 (8.36)		
Week 4 Adjusted Mean Change (SE)	4.24 (0.70)	4.07 (0.81)		
Week 12 Adjusted Mean Change (SE)	7.01 (0.89)	5.80 (1.03)		
Week 16 Adjusted Mean Change (SE)	6.90 (0.86)	5.71 (1.00)		
Week 24 Adjusted Mean Change (SE)	7.43 (0.99)	6.57 (1.16)		
Week 32 Adjusted Mean Change (SE)	7.66 (1.02)	8.20 (1.19)		
Week 40 Adjusted Mean Change (SE)	8.02 (0.91)	7.38 (1.07)		
Week 52 Adjusted Mean Change (SE)	8.00 (0.97)	7.56 (1.16)	0.43 [-2.57; 3.44]	0.775
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	36.24 (8.38)	36.74 (7.78)		
Week 52 Mean (SD)	45.50 (8.77)	48.12 (8.14)		
Week 4 Adjusted Mean Change (SE)	4.43 (1.24)	5.65 (1.29)		
Week 12 Adjusted Mean Change (SE)	6.95 (1.57)	8.01 (1.65)		
Week 16 Adjusted Mean Change (SE)	7.37 (1.52)	7.23 (1.61)		
Week 24 Adjusted Mean Change (SE)	7.37 (1.77)	9.61 (1.85)		
Week 32 Adjusted Mean Change (SE)	8.51 (1.80)	8.68 (1.90)		
Week 40 Adjusted Mean Change (SE)	8.35 (1.61)	8.60 (1.70)		
Week 52 Adjusted Mean Change (SE)	8.30 (1.72)	10.79 (1.80)	-2.49 [-7.40; 2.43]	0.318
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.13 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.870</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	36.04 (7.91)	37.78 (10.00)		
Week 52 Mean (SD)	44.52 (8.72)	47.23 (8.68)		
Week 4 Adjusted Mean Change (SE)	4.08 (0.69)	4.80 (0.77)		
Week 12 Adjusted Mean Change (SE)	7.60 (0.88)	6.37 (0.98)		
Week 16 Adjusted Mean Change (SE)	7.24 (0.83)	6.80 (0.94)		
Week 24 Adjusted Mean Change (SE)	7.18 (0.98)	7.33 (1.11)		
Week 32 Adjusted Mean Change (SE)	7.83 (0.98)	8.54 (1.11)		
Week 40 Adjusted Mean Change (SE)	8.25 (0.88)	8.16 (1.00)		
Week 52 Adjusted Mean Change (SE)	8.10 (0.96)	9.11 (1.11)	-1.01 [-3.92; 1.89]	0.491
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	38.09 (6.45)	35.56 (5.06)		
Week 52 Mean (SD)	44.49 (9.85)	43.46 (8.35)		
Week 4 Adjusted Mean Change (SE)	4.77 (1.25)	3.99 (1.59)		
Week 12 Adjusted Mean Change (SE)	5.03 (1.59)	6.46 (2.01)		
Week 16 Adjusted Mean Change (SE)	5.81 (1.51)	6.10 (1.91)		
Week 24 Adjusted Mean Change (SE)	6.33 (1.76)	8.04 (2.23)		
Week 32 Adjusted Mean Change (SE)	6.75 (1.76)	8.26 (2.26)		
Week 40 Adjusted Mean Change (SE)	6.49 (1.58)	5.96 (2.03)		
Week 52 Adjusted Mean Change (SE)	6.78 (1.72)	6.85 (2.17)	-0.08 [-5.56; 5.40]	0.978
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.14 SF-36 PCS - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.083</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	36.70 (7.42)	36.22 (9.11)		
Week 52 Mean (SD)	44.53 (8.98)	46.50 (8.64)		
Week 4 Adjusted Mean Change (SE)	4.73 (0.66)	4.98 (0.77)		
Week 12 Adjusted Mean Change (SE)	7.22 (0.83)	6.67 (0.97)		
Week 16 Adjusted Mean Change (SE)	6.68 (0.77)	6.66 (0.91)		
Week 24 Adjusted Mean Change (SE)	7.08 (0.91)	7.95 (1.07)		
Week 32 Adjusted Mean Change (SE)	8.04 (0.94)	8.61 (1.11)		
Week 40 Adjusted Mean Change (SE)	8.15 (0.84)	7.98 (1.00)		
Week 52 Adjusted Mean Change (SE)	7.75 (0.90)	9.22 (1.07)	-1.46 [-4.23; 1.30]	0.298
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	34.08 (8.80)	43.14 (9.09)		
Week 52 Mean (SD)	44.54 (10.03)	44.29 (7.51)		
Week 4 Adjusted Mean Change (SE)	3.35 (1.54)	2.35 (1.78)		
Week 12 Adjusted Mean Change (SE)	7.32 (1.97)	1.90 (2.24)		
Week 16 Adjusted Mean Change (SE)	9.37 (1.81)	1.78 (2.09)		
Week 24 Adjusted Mean Change (SE)	8.87 (2.12)	3.94 (2.46)		
Week 32 Adjusted Mean Change (SE)	8.13 (2.19)	4.40 (2.53)		
Week 40 Adjusted Mean Change (SE)	8.00 (1.95)	4.57 (2.25)		
Week 52 Adjusted Mean Change (SE)	9.16 (2.08)	3.66 (2.40)	5.50 [-0.86; 11.85]	0.089
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.15 SF-36 PCS - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.986</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	36.94 (8.76)	36.17 (10.44)		
Week 52 Mean (SD)	44.35 (10.27)	44.36 (10.13)		
Week 4 Adjusted Mean Change (SE)	4.39 (1.18)	3.72 (1.12)		
Week 12 Adjusted Mean Change (SE)	7.43 (1.50)	6.26 (1.41)		
Week 16 Adjusted Mean Change (SE)	6.37 (1.43)	6.63 (1.35)		
Week 24 Adjusted Mean Change (SE)	7.73 (1.68)	6.66 (1.59)		
Week 32 Adjusted Mean Change (SE)	7.31 (1.71)	7.54 (1.62)		
Week 40 Adjusted Mean Change (SE)	8.36 (1.53)	7.47 (1.47)		
Week 52 Adjusted Mean Change (SE)	6.47 (1.68)	7.31 (1.64)	-0.84 [-5.48; 3.80]	0.720
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	36.12 (7.24)	38.13 (8.58)		
Week 52 Mean (SD)	44.66 (8.73)	47.03 (8.11)		
Week 4 Adjusted Mean Change (SE)	4.53 (0.70)	4.77 (0.87)		
Week 12 Adjusted Mean Change (SE)	7.18 (0.89)	6.02 (1.11)		
Week 16 Adjusted Mean Change (SE)	7.26 (0.84)	5.84 (1.05)		
Week 24 Adjusted Mean Change (SE)	7.22 (0.98)	7.51 (1.23)		
Week 32 Adjusted Mean Change (SE)	8.26 (1.00)	8.35 (1.25)		
Week 40 Adjusted Mean Change (SE)	8.06 (0.88)	7.57 (1.12)		
Week 52 Adjusted Mean Change (SE)	8.46 (0.96)	8.70 (1.21)	-0.24 [-3.31; 2.83]	0.876
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.16 SF-36 PCS - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.947</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	37.19 (7.69)	36.14 (8.63)		
Week 52 Mean (SD)	44.83 (9.03)	46.41 (8.31)		
Week 4 Adjusted Mean Change (SE)	4.86 (0.78)	4.19 (0.95)		
Week 12 Adjusted Mean Change (SE)	8.22 (0.98)	6.56 (1.20)		
Week 16 Adjusted Mean Change (SE)	7.45 (0.93)	6.08 (1.15)		
Week 24 Adjusted Mean Change (SE)	7.79 (1.09)	7.56 (1.35)		
Week 32 Adjusted Mean Change (SE)	7.78 (1.11)	8.16 (1.38)		
Week 40 Adjusted Mean Change (SE)	7.96 (0.99)	7.52 (1.24)		
Week 52 Adjusted Mean Change (SE)	7.76 (1.08)	9.07 (1.37)	-1.31 [-4.76; 2.14]	0.454
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	35.04 (7.42)	38.71 (9.99)		
Week 52 Mean (SD)	44.20 (9.22)	45.99 (9.34)		
Week 4 Adjusted Mean Change (SE)	3.94 (0.96)	4.57 (0.99)		
Week 12 Adjusted Mean Change (SE)	5.78 (1.21)	5.62 (1.25)		
Week 16 Adjusted Mean Change (SE)	6.42 (1.16)	6.20 (1.19)		
Week 24 Adjusted Mean Change (SE)	6.64 (1.36)	6.82 (1.40)		
Week 32 Adjusted Mean Change (SE)	8.42 (1.38)	7.95 (1.42)		
Week 40 Adjusted Mean Change (SE)	8.38 (1.22)	7.58 (1.28)		
Week 52 Adjusted Mean Change (SE)	8.36 (1.34)	7.46 (1.37)	0.90 [-2.92; 4.72]	0.641
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 53.17 SF-36 PCS - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.331</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	34.86 (7.95)	35.49 (10.31)		
Week 52 Mean (SD)	43.23 (9.54)	46.86 (9.32)		
Week 4 Adjusted Mean Change (SE)	4.74 (1.02)	5.22 (1.02)		
Week 12 Adjusted Mean Change (SE)	7.59 (1.28)	7.36 (1.29)		
Week 16 Adjusted Mean Change (SE)	7.06 (1.21)	7.93 (1.21)		
Week 24 Adjusted Mean Change (SE)	7.35 (1.42)	9.28 (1.45)		
Week 32 Adjusted Mean Change (SE)	7.67 (1.46)	7.86 (1.49)		
Week 40 Adjusted Mean Change (SE)	8.52 (1.29)	8.56 (1.34)		
Week 52 Adjusted Mean Change (SE)	7.46 (1.41)	8.91 (1.49)	-1.44 [-5.49; 2.60]	0.482
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	37.13 (7.37)	38.98 (8.18)		
Week 52 Mean (SD)	45.36 (8.76)	45.76 (8.56)		
Week 4 Adjusted Mean Change (SE)	4.37 (0.75)	3.65 (0.93)		
Week 12 Adjusted Mean Change (SE)	7.06 (0.95)	5.07 (1.17)		
Week 16 Adjusted Mean Change (SE)	7.05 (0.89)	4.62 (1.11)		
Week 24 Adjusted Mean Change (SE)	7.36 (1.03)	5.53 (1.29)		
Week 32 Adjusted Mean Change (SE)	8.22 (1.08)	8.09 (1.34)		
Week 40 Adjusted Mean Change (SE)	7.93 (0.95)	6.66 (1.19)		
Week 52 Adjusted Mean Change (SE)	8.30 (1.04)	7.61 (1.29)	0.69 [-2.58; 3.96]	0.678
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.18 SF-36 PCS - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.436</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	36.43 (6.92)	38.96 (9.08)		
Week 52 Mean (SD)	45.33 (9.35)	45.76 (8.81)		
Week 4 Adjusted Mean Change (SE)	5.09 (0.85)	4.57 (0.85)		
Week 12 Adjusted Mean Change (SE)	8.12 (1.07)	5.73 (1.08)		
Week 16 Adjusted Mean Change (SE)	7.55 (1.02)	6.12 (1.03)		
Week 24 Adjusted Mean Change (SE)	7.93 (1.19)	6.78 (1.21)		
Week 32 Adjusted Mean Change (SE)	8.94 (1.22)	7.65 (1.23)		
Week 40 Adjusted Mean Change (SE)	8.25 (1.08)	7.78 (1.10)		
Week 52 Adjusted Mean Change (SE)	8.40 (1.19)	7.91 (1.19)	0.49 [-2.84; 3.83]	0.770
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	36.23 (8.34)	34.52 (9.24)		
Week 52 Mean (SD)	43.88 (8.81)	47.11 (8.95)		
Week 4 Adjusted Mean Change (SE)	3.89 (0.86)	4.01 (1.16)		
Week 12 Adjusted Mean Change (SE)	6.36 (1.09)	6.81 (1.47)		
Week 16 Adjusted Mean Change (SE)	6.51 (1.03)	6.15 (1.41)		
Week 24 Adjusted Mean Change (SE)	6.75 (1.20)	7.98 (1.65)		
Week 32 Adjusted Mean Change (SE)	7.12 (1.22)	8.79 (1.67)		
Week 40 Adjusted Mean Change (SE)	8.00 (1.09)	7.01 (1.53)		
Week 52 Adjusted Mean Change (SE)	7.56 (1.18)	8.91 (1.68)	-1.35 [-5.41; 2.70]	0.510
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 53.19 SF-36 PCS - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.302</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	36.38 (7.43)	37.67 (9.86)		
Week 52 Mean (SD)	44.62 (9.18)	45.66 (8.67)		
Week 4 Adjusted Mean Change (SE)	4.48 (0.69)	3.97 (0.80)		
Week 12 Adjusted Mean Change (SE)	7.33 (0.88)	5.42 (1.02)		
Week 16 Adjusted Mean Change (SE)	7.00 (0.83)	5.60 (0.97)		
Week 24 Adjusted Mean Change (SE)	7.52 (0.96)	6.27 (1.13)		
Week 32 Adjusted Mean Change (SE)	7.91 (0.99)	7.58 (1.17)		
Week 40 Adjusted Mean Change (SE)	8.17 (0.88)	7.02 (1.04)		
Week 52 Adjusted Mean Change (SE)	8.17 (0.95)	7.38 (1.14)	0.79 [-2.15; 3.73]	0.595
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	36.39 (8.79)	36.55 (7.85)		
Week 52 Mean (SD)	45.32 (8.96)	47.43 (9.21)		
Week 4 Adjusted Mean Change (SE)	4.08 (1.31)	5.37 (1.30)		
Week 12 Adjusted Mean Change (SE)	6.46 (1.67)	7.84 (1.66)		
Week 16 Adjusted Mean Change (SE)	6.82 (1.59)	7.48 (1.59)		
Week 24 Adjusted Mean Change (SE)	7.41 (1.86)	9.53 (1.83)		
Week 32 Adjusted Mean Change (SE)	8.08 (1.90)	9.21 (1.90)		
Week 40 Adjusted Mean Change (SE)	7.97 (1.69)	8.78 (1.71)		
Week 52 Adjusted Mean Change (SE)	8.08 (1.82)	10.27 (1.81)	-2.20 [-7.26; 2.87]	0.393
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 54.1 SF-36 PCS 2.5-Point Response / 5-Point Response (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SF-36 PCS 2.5-Point Response	105	82	1.05	1.00	0.002
Week 52, N' n (%)	80.36 (73.05)	73.58 (72.85)	[0.55; 2.01] 0.871	[0.85; 1.19] 0.972	[-0.122; 0.126] 0.974
SF-36 PCS 5-Point Response	105	82	1.00	0.99	-0.007
Week 52, N' n (%)	66.87 (60.79)	62.06 (61.45)	[0.55; 1.79] 0.987	[0.79; 1.24] 0.929	[-0.144; 0.131] 0.926

N': Number of patients with available response value  
N-N' is the number of values with MI.  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
MI: Multiple Imputation  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

OR from logistic regression model with predictors treatment and weight.  
RR and RD calculated directly without adjustment.

All results are combined over MI:  
n and % are averages of all imputations.  
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.

## 54.2 SF-36 PCS 2.5-Point Response / 5-Point Response by Age (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.977				
SF-36 PCS 5-Point Response Week 52	p=0.931				
<b>&lt; 65 years (N)</b>	<b>103</b>	<b>94</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	99 75.47 (73.27)	76 68.92 (73.32)	1.05 [0.54; 2.05] 0.889	1.00 [0.84; 1.19] 0.996	-0.000 [-0.129; 0.128] 0.994
SF-36 PCS 5-Point Response Week 52, N' n (%)	99 63.18 (61.34)	76 58.61 (62.35)	0.99 [0.54; 1.81] 0.961	0.98 [0.78; 1.24] 0.892	-0.010 [-0.152; 0.132] 0.889
<b>≥ 65 years (N)</b>	<b>7</b>	<b>7</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	6 4.89 (69.86)	6 4.66 (66.57)	1.09 [0.10; 12.29] 0.945	1.05 [0.49; 2.27] 0.896	0.033 [-0.478; 0.544] 0.900
SF-36 PCS 5-Point Response Week 52, N' n (%)	6 3.69 (52.71)	6 3.45 (49.29)	1.09 [0.11; 10.48] 0.939	1.07 [0.35; 3.26] 0.903	0.034 [-0.516; 0.584] 0.903
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.3 SF-36 PCS 2.5-Point Response / 5-Point Response by Gender (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.411				
SF-36 PCS 5-Point Response Week 52	p=0.771				
<b>Male (N)</b>	<b>66</b>	<b>57</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	64 50.89 (77.11)	48 42.74 (74.98)	1.33 [0.55; 3.24] 0.531	1.03 [0.84; 1.26] 0.788	0.021 [-0.135; 0.177] 0.790
SF-36 PCS 5-Point Response Week 52, N' n (%)	64 43.69 (66.20)	48 38.52 (67.58)	1.05 [0.47; 2.34] 0.905	0.98 [0.76; 1.27] 0.878	-0.014 [-0.186; 0.159] 0.875
<b>Female (N)</b>	<b>44</b>	<b>44</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	41 29.47 (66.98)	34 30.84 (70.09)	0.76 [0.28; 2.02] 0.579	0.96 [0.71; 1.29] 0.769	-0.031 [-0.235; 0.173] 0.765
SF-36 PCS 5-Point Response Week 52, N' n (%)	41 23.18 (52.68)	34 23.54 (53.50)	0.88 [0.36; 2.16] 0.775	0.99 [0.65; 1.49] 0.948	-0.008 [-0.228; 0.212] 0.942
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.4 SF-36 PCS 2.5-Point Response / 5-Point Response by Disease Severity (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.320				
SF-36 PCS 5-Point Response Week 52	p=0.364				
<b>PASDAS &lt; 5.4 (N)</b>	<b>24</b>	<b>21</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	23 14.64 (61.00)	17 10.64 (50.67)	1.89 [0.53; 6.73] 0.327	1.21 [0.70; 2.09] 0.504	0.103 [-0.195; 0.402] 0.497
SF-36 PCS 5-Point Response Week 52, N' n (%)	23 11.49 (47.88)	17 8.11 (38.62)	1.69 [0.48; 5.96] 0.416	1.24 [0.61; 2.54] 0.548	0.093 [-0.206; 0.391] 0.543
<b>PASDAS ≥ 5.4 (N)</b>	<b>86</b>	<b>80</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	82 65.72 (76.42)	65 62.94 (78.68)	0.88 [0.40; 1.93] 0.751	0.97 [0.82; 1.15] 0.742	-0.023 [-0.156; 0.111] 0.740
SF-36 PCS 5-Point Response Week 52, N' n (%)	82 55.38 (64.40)	65 53.95 (67.44)	0.87 [0.44; 1.72] 0.684	0.96 [0.76; 1.20] 0.697	-0.030 [-0.182; 0.121] 0.694
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.5 SF-36 PCS 2.5-Point Response / 5-Point Response by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.428				
SF-36 PCS 5-Point Response Week 52	p=0.896				
<b>Moderate/Severe Psoriasis (Def D): No (N)</b>	<b>42</b>	<b>51</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	39 29.64 (70.57)	38 37.66 (73.84)	0.78 [0.29; 2.08] 0.614	0.96 [0.73; 1.25] 0.744	-0.033 [-0.225; 0.160] 0.739
SF-36 PCS 5-Point Response Week 52, N' n (%)	39 25.49 (60.69)	38 30.92 (60.63)	0.94 [0.39; 2.31] 0.901	1.00 [0.71; 1.42] 0.990	0.001 [-0.210; 0.211] 0.995
<b>Moderate/Severe Psoriasis (Def D): Yes (N)</b>	<b>68</b>	<b>50</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	66 50.72 (74.59)	44 35.92 (71.84)	1.33 [0.56; 3.16] 0.523	1.04 [0.83; 1.30] 0.746	0.027 [-0.139; 0.194] 0.746
SF-36 PCS 5-Point Response Week 52, N' n (%)	66 41.38 (60.85)	44 31.14 (62.28)	1.02 [0.47; 2.24] 0.955	0.98 [0.73; 1.31] 0.880	-0.014 [-0.197; 0.168] 0.878
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					



### 54.6 SF-36 PCS 2.5-Point Response / 5-Point Response by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.734				
SF-36 PCS 5-Point Response Week 52	p=0.168				
<b>≤ Median (N)</b>	<b>72</b>	<b>49</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	70 52.89 (73.46)	36 35.08 (71.59)	1.17 [0.48; 2.84] 0.735	1.03 [0.81; 1.31] 0.828	0.019 [-0.155; 0.192] 0.833
SF-36 PCS 5-Point Response Week 52, N' n (%)	70 46.69 (64.85)	36 28.28 (57.71)	1.41 [0.63; 3.15] 0.402	1.13 [0.82; 1.54] 0.463	0.071 [-0.117; 0.259] 0.457
<b>&gt; Median (N)</b>	<b>38</b>	<b>52</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	35 27.47 (72.29)	46 38.50 (74.04)	0.93 [0.35; 2.47] 0.878	0.98 [0.75; 1.27] 0.858	-0.017 [-0.208; 0.173] 0.857
SF-36 PCS 5-Point Response Week 52, N' n (%)	35 20.18 (53.11)	46 33.78 (64.96)	0.61 [0.25; 1.48] 0.273	0.82 [0.57; 1.18] 0.284	-0.119 [-0.329; 0.091] 0.269
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.7 SF-36 PCS 2.5-Point Response / 5-Point Response by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.565				
SF-36 PCS 5-Point Response Week 52	p=0.435				
<b>Enthesitis: No (N)</b>	<b>51</b>	<b>32</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	49 38.00 (74.51)	25 25.02 (78.19)	0.77 [0.24; 2.46] 0.661	0.95 [0.73; 1.24] 0.724	-0.037 [-0.236; 0.163] 0.718
SF-36 PCS 5-Point Response Week 52, N' n (%)	49 34.00 (66.67)	25 19.15 (59.84)	1.31 [0.49; 3.47] 0.586	1.12 [0.77; 1.61] 0.555	0.068 [-0.156; 0.293] 0.552
<b>Enthesitis: Yes (N)</b>	<b>59</b>	<b>69</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	56 42.36 (71.80)	57 48.56 (70.38)	1.18 [0.52; 2.66] 0.697	1.02 [0.81; 1.28] 0.863	0.014 [-0.149; 0.177] 0.864
SF-36 PCS 5-Point Response Week 52, N' n (%)	56 32.87 (55.71)	57 42.91 (62.19)	0.80 [0.38; 1.70] 0.563	0.90 [0.66; 1.22] 0.482	-0.065 [-0.243; 0.113] 0.476
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.8 SF-36 PCS 2.5-Point Response / 5-Point Response by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.779				
SF-36 PCS 5-Point Response Week 52	p=0.824				
<b>Non-carrier (N)</b>	<b>51</b>	<b>41</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	49 38.64 (75.76)	36 32.05 (78.17)	0.90 [0.32; 2.52] 0.846	0.97 [0.77; 1.22] 0.791	-0.024 [-0.201; 0.153] 0.790
SF-36 PCS 5-Point Response Week 52, N' n (%)	49 33.49 (65.67)	36 27.58 (67.27)	0.95 [0.38; 2.34] 0.904	0.98 [0.72; 1.32] 0.877	-0.016 [-0.215; 0.183] 0.875
<b>Carrier (N)</b>	<b>34</b>	<b>26</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	31 21.72 (63.88)	21 18.47 (71.04)	0.72 [0.22; 2.38] 0.591	0.90 [0.62; 1.31] 0.581	-0.072 [-0.322; 0.179] 0.576
SF-36 PCS 5-Point Response Week 52, N' n (%)	31 17.38 (51.12)	21 14.66 (56.38)	0.81 [0.27; 2.43] 0.700	0.91 [0.55; 1.50] 0.708	-0.053 [-0.322; 0.217] 0.701
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.9 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.673				
SF-36 PCS 5-Point Response Week 52	p=0.816				
<b>Non-carrier (N)</b>	<b>45</b>	<b>27</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	43 33.83 (75.18)	19 21.41 (79.30)	0.85 [0.24; 3.01] 0.799	0.95 [0.72; 1.25] 0.707	-0.041 [-0.252; 0.169] 0.701
SF-36 PCS 5-Point Response Week 52, N' n (%)	43 28.69 (63.76)	19 17.57 (65.07)	0.99 [0.33; 2.95] 0.986	0.98 [0.67; 1.44] 0.926	-0.013 [-0.258; 0.231] 0.916
<b>Carrier (N)</b>	<b>38</b>	<b>30</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	35 25.53 (67.18)	28 23.11 (77.03)	0.59 [0.19; 1.84] 0.360	0.87 [0.64; 1.18] 0.377	-0.098 [-0.316; 0.119] 0.374
SF-36 PCS 5-Point Response Week 52, N' n (%)	35 22.18 (58.37)	28 18.67 (62.23)	0.83 [0.30; 2.31] 0.721	0.94 [0.63; 1.40] 0.754	-0.039 [-0.280; 0.202] 0.753
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.10 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.516				
SF-36 PCS 5-Point Response Week 52	p=0.389				
<b>Non-carrier (N)</b>	<b>30</b>	<b>33</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	29 20.83 (69.43)	24 25.64 (77.70)	0.63 [0.18; 2.19] 0.469	0.89 [0.65; 1.23] 0.490	-0.083 [-0.313; 0.148] 0.482
SF-36 PCS 5-Point Response Week 52, N' n (%)	29 16.69 (55.63)	24 21.46 (65.03)	0.66 [0.22; 2.00] 0.459	0.86 [0.56; 1.32] 0.485	-0.094 [-0.352; 0.164] 0.475
<b>Carrier (N)</b>	<b>51</b>	<b>34</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	49 37.00 (72.55)	33 24.88 (73.18)	1.07 [0.39; 2.93] 0.890	0.99 [0.76; 1.29] 0.950	-0.006 [-0.200; 0.187] 0.949
SF-36 PCS 5-Point Response Week 52, N' n (%)	49 33.00 (64.71)	33 20.78 (61.12)	1.24 [0.50; 3.09] 0.646	1.06 [0.75; 1.49] 0.740	0.036 [-0.175; 0.247] 0.739
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.11 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.533				
SF-36 PCS 5-Point Response Week 52	p=0.845				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	39 29.36 (68.28)	39 29.95 (69.65)	0.89 [0.34; 2.34] 0.819	0.98 [0.73; 1.31] 0.894	-0.014 [-0.214; 0.186] 0.893
SF-36 PCS 5-Point Response Week 52, N' n (%)	39 25.87 (60.16)	39 26.42 (61.44)	0.92 [0.37; 2.26] 0.855	0.98 [0.69; 1.39] 0.906	-0.013 [-0.225; 0.200] 0.906
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	41 31.00 (73.81)	18 20.57 (85.71)	0.49 [0.10; 2.42] 0.381	0.86 [0.66; 1.13] 0.282	-0.119 [-0.333; 0.095] 0.276
SF-36 PCS 5-Point Response Week 52, N' n (%)	41 25.00 (59.52)	18 15.82 (65.92)	0.79 [0.25; 2.51] 0.695	0.91 [0.60; 1.37] 0.637	-0.064 [-0.323; 0.196] 0.629
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.12 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	N.E.				
SF-36 PCS 5-Point Response Week 52	p=0.192				
<b>Non-carrier (N)</b>	<b>62</b>	<b>47</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	58 41.53 (66.98)	38 31.79 (67.64)	1.10 [0.46; 2.62] 0.825	0.99 [0.75; 1.30] 0.947	-0.007 [-0.190; 0.177] 0.944
SF-36 PCS 5-Point Response Week 52, N' n (%)	58 35.18 (56.74)	38 26.63 (56.66)	1.06 [0.47; 2.41] 0.883	1.00 [0.71; 1.42] 0.988	0.001 [-0.196; 0.198] 0.993
<b>Carrier (N)</b>	<b>20</b>	<b>18</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	19 16.83 (84.15)	17 17.73 (98.50)	N.E.	0.85 [0.69; 1.05] 0.140	-0.144 [-0.322; 0.035] 0.115
SF-36 PCS 5-Point Response Week 52, N' n (%)	19 13.69 (68.45)	17 15.61 (86.72)	0.29 [0.05; 1.69] 0.170	0.79 [0.55; 1.13] 0.197	-0.183 [-0.448; 0.082] 0.176
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. If the interaction test is N.E.: OR from separate logistic regression models for each subgroup with predictors treatment and weight. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.13 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.633				
SF-36 PCS 5-Point Response Week 52	p=0.499				
<b>Non-carrier (N)</b>	<b>63</b>	<b>51</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	58 46.36 (73.59)	42 38.91 (76.29)	0.85 [0.35; 2.11] 0.731	0.96 [0.77; 1.20] 0.750	-0.027 [-0.192; 0.138] 0.748
SF-36 PCS 5-Point Response Week 52, N' n (%)	58 38.87 (61.70)	42 32.80 (64.31)	0.89 [0.39; 1.99] 0.768	0.96 [0.71; 1.29] 0.786	-0.026 [-0.212; 0.160] 0.783
<b>Carrier (N)</b>	<b>19</b>	<b>12</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	19 11.00 (57.89)	12 9.00 (75.00)	0.54 [0.10; 2.79] 0.462	0.77 [0.47; 1.28] 0.314	-0.171 [-0.502; 0.160] 0.311
SF-36 PCS 5-Point Response Week 52, N' n (%)	19 9.00 (47.37)	12 8.00 (66.67)	0.49 [0.11; 2.23] 0.356	0.71 [0.38; 1.32] 0.280	-0.193 [-0.542; 0.156] 0.278
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) SF-36 PCS 2.5-Point Response, SF-36 PCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					



### 54.14 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.041				
SF-36 PCS 5-Point Response Week 52	p=0.043				
<b>Non-carrier (N)</b>	<b>71</b>	<b>53</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	66 49.36 (69.52)	44 43.79 (82.62)	0.50 [0.20; 1.28] 0.149	0.84 [0.69; 1.03] 0.098	-0.131 [-0.285; 0.023] 0.095
SF-36 PCS 5-Point Response Week 52, N' n (%)	66 40.87 (57.56)	44 36.63 (69.11)	0.62 [0.28; 1.38] 0.242	0.83 [0.63; 1.10] 0.205	-0.115 [-0.294; 0.063] 0.204
<b>Carrier (N)</b>	<b>13</b>	<b>10</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	13 10.00 (76.92)	10 4.00 (40.00)	4.23 [0.68; 26.11] 0.121	1.92 [0.85; 4.35] 0.116	0.369 [-0.011; 0.750] 0.057
SF-36 PCS 5-Point Response Week 52, N' n (%)	13 9.00 (69.23)	10 3.00 (30.00)	4.77 [0.79; 28.87] 0.089	2.31 [0.84; 6.36] 0.106	0.392 [0.013; 0.771] 0.042
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p> <p>For parameter(s) SF-36 PCS 2.5-Point Response, SF-36 PCS 5-Point Response, all imputations were equal in at least one subgroup. In this case results were not combined but taken from the first imputation.</p>					

### 54.15 SF-36 PCS 2.5-Point Response / 5-Point Response by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.884				
SF-36 PCS 5-Point Response Week 52	p=0.617				
<b>Low score (N)</b>	<b>22</b>	<b>26</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	19 14.36 (65.27)	18 18.18 (69.92)	0.72 [0.19; 2.66] 0.617	0.93 [0.62; 1.42] 0.747	-0.047 [-0.325; 0.232] 0.743
SF-36 PCS 5-Point Response Week 52, N' n (%)	19 10.87 (49.41)	18 15.19 (58.42)	0.65 [0.19; 2.25] 0.494	0.85 [0.48; 1.50] 0.569	-0.090 [-0.392; 0.211] 0.558
<b>High score (N)</b>	<b>63</b>	<b>41</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	61 46.00 (73.02)	39 32.34 (78.88)	0.81 [0.31; 2.14] 0.670	0.93 [0.74; 1.16] 0.497	-0.059 [-0.228; 0.111] 0.497
SF-36 PCS 5-Point Response Week 52, N' n (%)	61 40.00 (63.49)	39 27.05 (65.98)	0.95 [0.41; 2.22] 0.903	0.96 [0.72; 1.29] 0.799	-0.025 [-0.215; 0.166] 0.798
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.16 SF-36 PCS 2.5-Point Response / 5-Point Response by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.911				
SF-36 PCS 5-Point Response Week 52	p=0.565				
<b>Non-carrier (N)</b>	<b>51</b>	<b>35</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	49 36.83 (72.22)	27 27.41 (78.31)	0.83 [0.28; 2.49] 0.736	0.92 [0.72; 1.19] 0.536	-0.061 [-0.253; 0.131] 0.533
SF-36 PCS 5-Point Response Week 52, N' n (%)	49 29.69 (58.22)	27 23.57 (67.34)	0.72 [0.27; 1.90] 0.511	0.87 [0.61; 1.22] 0.412	-0.091 [-0.308; 0.126] 0.410
<b>Carrier (N)</b>	<b>34</b>	<b>32</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	31 23.53 (69.21)	30 23.11 (72.22)	0.76 [0.25; 2.30] 0.622	0.96 [0.70; 1.32] 0.794	-0.030 [-0.254; 0.194] 0.792
SF-36 PCS 5-Point Response Week 52, N' n (%)	31 21.18 (62.29)	30 18.67 (58.34)	1.10 [0.39; 3.07] 0.861	1.07 [0.71; 1.60] 0.751	0.040 [-0.204; 0.283] 0.750
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.17 SF-36 PCS 2.5-Point Response / 5-Point Response by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.424				
SF-36 PCS 5-Point Response Week 52	p=0.434				
<b>Non-carrier (N)</b>	<b>30</b>	<b>31</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	29 20.83 (69.43)	22 24.64 (79.48)	0.56 [0.15; 2.06] 0.381	0.87 [0.64; 1.20] 0.405	-0.101 [-0.332; 0.131] 0.395
SF-36 PCS 5-Point Response Week 52, N' n (%)	29 16.69 (55.63)	22 20.46 (66.00)	0.63 [0.20; 1.96] 0.422	0.84 [0.55; 1.31] 0.449	-0.104 [-0.366; 0.159] 0.438
<b>Carrier (N)</b>	<b>55</b>	<b>36</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	51 39.53 (71.87)	35 25.88 (71.89)	1.09 [0.41; 2.85] 0.865	1.00 [0.77; 1.30] 0.999	-0.000 [-0.191; 0.190] 0.999
SF-36 PCS 5-Point Response Week 52, N' n (%)	51 34.18 (62.15)	35 21.78 (60.50)	1.12 [0.46; 2.69] 0.806	1.03 [0.73; 1.44] 0.877	0.016 [-0.191; 0.224] 0.876
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.18 SF-36 PCS 2.5-Point Response / 5-Point Response by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.533				
SF-36 PCS 5-Point Response Week 52	p=0.845				
<b>Non-carrier (N)</b>	<b>43</b>	<b>43</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	39 29.36 (68.28)	39 29.95 (69.65)	0.89 [0.34; 2.34] 0.819	0.98 [0.73; 1.31] 0.894	-0.014 [-0.214; 0.186] 0.893
SF-36 PCS 5-Point Response Week 52, N' n (%)	39 25.87 (60.16)	39 26.42 (61.44)	0.92 [0.37; 2.26] 0.855	0.98 [0.69; 1.39] 0.906	-0.013 [-0.225; 0.200] 0.906
<b>Carrier (N)</b>	<b>42</b>	<b>24</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	41 31.00 (73.81)	18 20.57 (85.71)	0.49 [0.10; 2.42] 0.381	0.86 [0.66; 1.13] 0.282	-0.119 [-0.333; 0.095] 0.276
SF-36 PCS 5-Point Response Week 52, N' n (%)	41 25.00 (59.52)	18 15.82 (65.92)	0.79 [0.25; 2.51] 0.695	0.91 [0.60; 1.37] 0.637	-0.064 [-0.323; 0.196] 0.629
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 54.19 SF-36 PCS 2.5-Point Response / 5-Point Response by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Interaction test</b>					
SF-36 PCS 2.5-Point Response Week 52	p=0.303				
SF-36 PCS 5-Point Response Week 52	p=0.225				
<b>Non-carrier (N)</b>	<b>65</b>	<b>49</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	61 44.53 (68.51)	40 33.79 (68.96)	1.08 [0.46; 2.52] 0.861	0.99 [0.77; 1.29] 0.963	-0.005 [-0.182; 0.173] 0.960
SF-36 PCS 5-Point Response Week 52, N' n (%)	61 38.18 (58.74)	40 27.63 (56.39)	1.16 [0.52; 2.58] 0.714	1.04 [0.74; 1.46] 0.807	0.024 [-0.169; 0.216] 0.810
<b>Carrier (N)</b>	<b>18</b>	<b>18</b>			
SF-36 PCS 2.5-Point Response Week 52, N' n (%)	17 14.83 (82.39)	17 16.73 (92.94)	0.29 [0.03; 3.07] 0.302	0.89 [0.68; 1.15] 0.361	-0.106 [-0.325; 0.114] 0.346
SF-36 PCS 5-Point Response Week 52, N' n (%)	17 11.69 (64.94)	17 14.61 (81.17)	0.38 [0.08; 1.90] 0.240	0.80 [0.53; 1.22] 0.296	-0.162 [-0.455; 0.130] 0.277
<p>N': Number of patients with available response value N-N' is the number of values with MI. n (%): Number and percentage of patients with event CI: Confidence Interval MI: Multiple Imputation N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR from logistic regression model with predictors treatment, weight, subgroup and treatment x subgroup. RR and RD calculated directly without adjustment within subgroups.</p> <p>All results are combined over MI: n and % are averages of all imputations. P-value of the interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups in more than 10% of imputations. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups in more than 10% of imputations.</p>					

### 55.0 WPAI-GH Percent Work Time Missed due to Health - Return Rates (FAS)

	Treatment Groups		
	SEC (N=75)	ADA (N=63)	Total (N=138)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	73 (97.3)	63 (100.0)	136 (98.6)
Week 4 Returns	68 (90.7)	51 (81.0)	119 (86.2)
Week 12 Returns	64 (85.3)	48 (76.2)	112 (81.2)
Week 16 Returns	69 (92.0)	49 (77.8)	118 (85.5)
Week 24 Returns	65 (86.7)	41 (65.1)	106 (76.8)
Week 32 Returns	63 (84.0)	42 (66.7)	105 (76.1)
Week 40 Returns	62 (82.7)	40 (63.5)	102 (73.9)
Week 52 Returns	63 (84.0)	38 (60.3)	101 (73.2)
Note: The table is based on all patients who were employed at baseline.			

### 55.1 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
N'	71	57		
Baseline Mean (SD)	17.30 (27.91)	12.28 (23.87)		
Week 52 Mean (SD)	16.87 (26.38)	17.51 (30.10)		
Week 4 Adjusted Mean Change (SE)	-3.33 (2.20)	-3.73 (2.51)		
Week 12 Adjusted Mean Change (SE)	-5.89 (2.34)	-7.02 (2.65)		
Week 16 Adjusted Mean Change (SE)	1.56 (3.15)	0.12 (3.68)		
Week 24 Adjusted Mean Change (SE)	-4.67 (2.72)	-1.36 (3.36)		
Week 32 Adjusted Mean Change (SE)	0.55 (3.23)	-3.93 (3.88)		
Week 40 Adjusted Mean Change (SE)	-1.52 (3.01)	0.43 (3.71)		
Week 52 Adjusted Mean Change (SE)	1.12 (3.39)	3.77 (4.22)	-2.65 [-13.42; 8.11]	0.626
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				



## 55.2 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Age (FAS)

Table is not displayed as the parameter does not fulfill the condition for the subgroup analysis.
---

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.
--

### 55.3 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.464</b>				
<b>Male, N</b>	<b>48</b>	<b>40</b>		
N'	45	36		
Baseline Mean (SD)	13.13 (24.39)	13.46 (24.75)		
Week 52 Mean (SD)	14.80 (27.33)	8.54 (18.61)		
Week 4 Adjusted Mean Change (SE)	-5.20 (2.88)	-6.34 (3.19)		
Week 12 Adjusted Mean Change (SE)	-4.59 (2.98)	-8.12 (3.41)		
Week 16 Adjusted Mean Change (SE)	-5.15 (3.93)	-3.41 (4.37)		
Week 24 Adjusted Mean Change (SE)	-4.34 (3.37)	-6.66 (4.18)		
Week 32 Adjusted Mean Change (SE)	-5.14 (4.00)	-4.36 (4.97)		
Week 40 Adjusted Mean Change (SE)	-1.72 (3.92)	-3.19 (4.72)		
Week 52 Adjusted Mean Change (SE)	-1.18 (4.10)	-4.77 (5.19)	3.59 [-9.50; 16.67]	0.588
<b>Female, N</b>	<b>27</b>	<b>23</b>		
N'	26	21		
Baseline Mean (SD)	24.40 (32.31)	10.23 (22.65)		
Week 52 Mean (SD)	20.73 (24.63)	32.90 (39.53)		
Week 4 Adjusted Mean Change (SE)	-0.21 (3.65)	0.42 (4.13)		
Week 12 Adjusted Mean Change (SE)	-8.20 (3.94)	-5.22 (4.25)		
Week 16 Adjusted Mean Change (SE)	12.45 (5.02)	6.47 (6.18)		
Week 24 Adjusted Mean Change (SE)	-5.22 (4.54)	7.37 (5.50)		
Week 32 Adjusted Mean Change (SE)	10.92 (5.40)	-2.62 (6.06)		
Week 40 Adjusted Mean Change (SE)	-1.03 (4.92)	6.23 (6.07)		
Week 52 Adjusted Mean Change (SE)	5.14 (5.56)	18.27 (6.76)	-13.13 [-30.47; 4.21]	0.136
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.4 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.297</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>15</b>	<b>17</b>		
N'	14	16		
Baseline Mean (SD)	3.53 (7.93)	6.45 (18.09)		
Week 52 Mean (SD)	14.46 (32.07)	12.21 (20.41)		
Week 4 Adjusted Mean Change (SE)	-4.86 (4.85)	-8.67 (4.54)		
Week 12 Adjusted Mean Change (SE)	2.40 (5.51)	-10.28 (4.91)		
Week 16 Adjusted Mean Change (SE)	-1.58 (7.29)	-1.54 (6.77)		
Week 24 Adjusted Mean Change (SE)	-8.35 (6.50)	-11.10 (5.99)		
Week 32 Adjusted Mean Change (SE)	-6.50 (7.29)	-12.90 (7.26)		
Week 40 Adjusted Mean Change (SE)	-0.48 (7.19)	-2.86 (7.21)		
Week 52 Adjusted Mean Change (SE)	1.67 (8.04)	-0.67 (7.95)	2.34 [-19.93; 24.60]	0.836
<b>PASDAS ≥ 5.4, N</b>	<b>60</b>	<b>46</b>		
N'	57	41		
Baseline Mean (SD)	20.86 (30.09)	14.43 (25.51)		
Week 52 Mean (SD)	17.38 (25.35)	19.67 (33.35)		
Week 4 Adjusted Mean Change (SE)	-2.95 (2.49)	-1.60 (3.02)		
Week 12 Adjusted Mean Change (SE)	-7.68 (2.59)	-5.66 (3.13)		
Week 16 Adjusted Mean Change (SE)	2.32 (3.55)	0.76 (4.44)		
Week 24 Adjusted Mean Change (SE)	-3.76 (3.00)	3.09 (4.05)		
Week 32 Adjusted Mean Change (SE)	2.42 (3.61)	-0.47 (4.56)		
Week 40 Adjusted Mean Change (SE)	-1.69 (3.38)	1.70 (4.37)		
Week 52 Adjusted Mean Change (SE)	0.98 (3.82)	5.49 (5.05)	-4.52 [-17.06; 8.03]	0.477
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.5 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.639</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>26</b>	<b>31</b>		
N'	25	29		
Baseline Mean (SD)	13.72 (25.50)	9.57 (14.32)		
Week 52 Mean (SD)	16.14 (28.92)	11.20 (18.20)		
Week 4 Adjusted Mean Change (SE)	-2.31 (3.72)	-5.03 (3.49)		
Week 12 Adjusted Mean Change (SE)	-3.33 (3.85)	-9.89 (3.52)		
Week 16 Adjusted Mean Change (SE)	-0.02 (5.31)	3.71 (5.19)		
Week 24 Adjusted Mean Change (SE)	-6.65 (4.82)	-7.17 (4.96)		
Week 32 Adjusted Mean Change (SE)	-0.04 (5.30)	-7.32 (5.44)		
Week 40 Adjusted Mean Change (SE)	-4.24 (4.99)	4.89 (5.26)		
Week 52 Adjusted Mean Change (SE)	2.09 (5.98)	-1.76 (6.17)	3.85 [-13.16; 20.85]	0.654
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>49</b>	<b>32</b>		
N'	46	28		
Baseline Mean (SD)	19.27 (29.23)	14.90 (30.44)		
Week 52 Mean (SD)	17.19 (25.55)	23.20 (37.37)		
Week 4 Adjusted Mean Change (SE)	-3.91 (2.79)	-2.32 (3.68)		
Week 12 Adjusted Mean Change (SE)	-7.38 (2.96)	-2.89 (4.06)		
Week 16 Adjusted Mean Change (SE)	2.49 (3.96)	-3.68 (5.26)		
Week 24 Adjusted Mean Change (SE)	-3.66 (3.31)	3.62 (4.61)		
Week 32 Adjusted Mean Change (SE)	0.92 (4.13)	-0.52 (5.65)		
Week 40 Adjusted Mean Change (SE)	0.04 (3.77)	-4.36 (5.18)		
Week 52 Adjusted Mean Change (SE)	0.83 (4.13)	8.75 (5.84)	-7.92 [-22.04; 6.21]	0.269
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.6 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.520</b>				
<b>≤ Median, N</b>	<b>52</b>	<b>31</b>		
N'	49	29		
Baseline Mean (SD)	15.77 (27.08)	11.03 (15.81)		
Week 52 Mean (SD)	16.09 (27.16)	11.91 (19.79)		
Week 4 Adjusted Mean Change (SE)	-4.92 (2.71)	-5.70 (3.53)		
Week 12 Adjusted Mean Change (SE)	-6.00 (2.79)	-9.69 (3.68)		
Week 16 Adjusted Mean Change (SE)	3.51 (3.82)	0.71 (4.98)		
Week 24 Adjusted Mean Change (SE)	-6.44 (3.21)	-4.53 (4.69)		
Week 32 Adjusted Mean Change (SE)	1.23 (3.93)	-2.43 (5.41)		
Week 40 Adjusted Mean Change (SE)	-0.94 (3.67)	-2.02 (5.18)		
Week 52 Adjusted Mean Change (SE)	0.05 (3.98)	-2.16 (5.83)	2.21 [-11.83; 16.25]	0.755
<b>&gt; Median, N</b>	<b>23</b>	<b>32</b>		
N'	22	28		
Baseline Mean (SD)	20.62 (29.98)	13.49 (29.91)		
Week 52 Mean (SD)	18.98 (24.78)	23.73 (38.17)		
Week 4 Adjusted Mean Change (SE)	-0.19 (3.85)	-1.57 (3.59)		
Week 12 Adjusted Mean Change (SE)	-5.63 (4.34)	-4.23 (3.84)		
Week 16 Adjusted Mean Change (SE)	-2.66 (5.68)	-0.79 (5.49)		
Week 24 Adjusted Mean Change (SE)	-0.15 (5.08)	1.89 (4.81)		
Week 32 Adjusted Mean Change (SE)	-1.01 (5.83)	-5.53 (5.67)		
Week 40 Adjusted Mean Change (SE)	-2.54 (5.44)	3.19 (5.40)		
Week 52 Adjusted Mean Change (SE)	3.72 (6.35)	10.28 (6.13)	-6.56 [-24.08; 10.95]	0.459
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.7 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.640</b>				
<b>Enthesitis: No, N</b>	<b>36</b>	<b>23</b>		
N'	33	21		
Baseline Mean (SD)	12.80 (21.90)	11.79 (25.40)		
Week 52 Mean (SD)	18.36 (29.92)	25.63 (35.77)		
Week 4 Adjusted Mean Change (SE)	-2.70 (3.21)	-3.92 (4.25)		
Week 12 Adjusted Mean Change (SE)	-3.72 (3.39)	-6.08 (4.35)		
Week 16 Adjusted Mean Change (SE)	4.59 (4.58)	4.75 (5.77)		
Week 24 Adjusted Mean Change (SE)	-5.17 (4.03)	2.83 (5.10)		
Week 32 Adjusted Mean Change (SE)	2.79 (4.79)	-4.91 (5.97)		
Week 40 Adjusted Mean Change (SE)	0.31 (4.51)	4.21 (5.89)		
Week 52 Adjusted Mean Change (SE)	1.52 (4.88)	12.54 (6.68)	-11.02 [-27.45; 5.40]	0.186
<b>Enthesitis: Yes, N</b>	<b>39</b>	<b>40</b>		
N'	38	36		
Baseline Mean (SD)	21.44 (32.22)	12.56 (23.27)		
Week 52 Mean (SD)	15.52 (23.08)	12.22 (25.21)		
Week 4 Adjusted Mean Change (SE)	-3.90 (3.10)	-3.69 (3.15)		
Week 12 Adjusted Mean Change (SE)	-7.89 (3.29)	-7.57 (3.37)		
Week 16 Adjusted Mean Change (SE)	-1.19 (4.38)	-2.96 (4.78)		
Week 24 Adjusted Mean Change (SE)	-4.26 (3.74)	-4.57 (4.51)		
Week 32 Adjusted Mean Change (SE)	-1.42 (4.44)	-3.10 (5.16)		
Week 40 Adjusted Mean Change (SE)	-3.03 (4.10)	-2.19 (4.80)		
Week 52 Adjusted Mean Change (SE)	0.86 (4.71)	-2.06 (5.43)	2.91 [-11.43; 17.26]	0.688
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.8 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.494</b>				
<b>Non-carrier, N</b>	<b>38</b>	<b>27</b>		
N'	35	25		
Baseline Mean (SD)	14.81 (25.99)	13.33 (24.32)		
Week 52 Mean (SD)	17.00 (25.87)	14.27 (28.36)		
Week 4 Adjusted Mean Change (SE)	-5.18 (2.86)	-6.56 (3.64)		
Week 12 Adjusted Mean Change (SE)	-2.46 (3.56)	-8.23 (4.58)		
Week 16 Adjusted Mean Change (SE)	3.80 (4.70)	-1.47 (5.90)		
Week 24 Adjusted Mean Change (SE)	-2.58 (3.55)	-0.99 (4.87)		
Week 32 Adjusted Mean Change (SE)	4.54 (4.67)	-6.67 (6.08)		
Week 40 Adjusted Mean Change (SE)	-0.61 (4.45)	1.53 (6.16)		
Week 52 Adjusted Mean Change (SE)	1.33 (5.01)	2.40 (6.73)	-1.07 [-17.76; 15.62]	0.899
<b>Carrier, N</b>	<b>22</b>	<b>18</b>		
N'	21	18		
Baseline Mean (SD)	15.66 (24.32)	16.03 (31.98)		
Week 52 Mean (SD)	18.82 (28.45)	17.98 (33.98)		
Week 4 Adjusted Mean Change (SE)	-2.39 (3.76)	4.59 (3.88)		
Week 12 Adjusted Mean Change (SE)	-4.27 (4.85)	-1.22 (4.77)		
Week 16 Adjusted Mean Change (SE)	10.99 (6.04)	6.16 (6.57)		
Week 24 Adjusted Mean Change (SE)	-3.45 (4.65)	-1.44 (4.83)		
Week 32 Adjusted Mean Change (SE)	0.98 (6.24)	1.07 (6.43)		
Week 40 Adjusted Mean Change (SE)	-0.30 (6.24)	3.20 (6.15)		
Week 52 Adjusted Mean Change (SE)	5.37 (6.25)	4.57 (6.62)	0.79 [-17.28; 18.87]	0.931
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.9 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.851</b>				
<b>Non-carrier, N</b>	<b>36</b>	<b>17</b>		
N'	32	16		
Baseline Mean (SD)	17.86 (28.63)	16.41 (28.23)		
Week 52 Mean (SD)	17.83 (25.12)	23.12 (40.79)		
Week 4 Adjusted Mean Change (SE)	-6.18 (2.92)	-1.21 (4.24)		
Week 12 Adjusted Mean Change (SE)	-1.34 (3.92)	-6.06 (5.79)		
Week 16 Adjusted Mean Change (SE)	3.99 (5.05)	-2.26 (7.38)		
Week 24 Adjusted Mean Change (SE)	-4.96 (2.89)	-3.12 (4.37)		
Week 32 Adjusted Mean Change (SE)	2.32 (5.05)	-5.19 (7.58)		
Week 40 Adjusted Mean Change (SE)	-0.45 (4.92)	-0.76 (7.26)		
Week 52 Adjusted Mean Change (SE)	2.63 (5.34)	7.62 (8.45)	-4.99 [-24.85; 14.87]	0.618
<b>Carrier, N</b>	<b>22</b>	<b>19</b>		
N'	22	19		
Baseline Mean (SD)	10.00 (17.93)	14.30 (31.53)		
Week 52 Mean (SD)	19.44 (30.38)	14.43 (29.00)		
Week 4 Adjusted Mean Change (SE)	-2.83 (3.55)	-0.53 (3.92)		
Week 12 Adjusted Mean Change (SE)	-6.04 (4.81)	-3.40 (5.11)		
Week 16 Adjusted Mean Change (SE)	8.12 (6.04)	6.71 (6.89)		
Week 24 Adjusted Mean Change (SE)	-1.01 (3.49)	-11.29 (4.02)		
Week 32 Adjusted Mean Change (SE)	3.73 (6.23)	-1.77 (7.03)		
Week 40 Adjusted Mean Change (SE)	-2.06 (5.62)	-2.50 (6.52)		
Week 52 Adjusted Mean Change (SE)	4.91 (6.57)	2.05 (7.48)	2.87 [-16.99; 22.72]	0.774
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				



### 55.10 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.719</b>				
<b>Non-carrier, N</b>	<b>23</b>	<b>20</b>		
N'	22	20		
Baseline Mean (SD)	20.08 (30.15)	11.92 (24.18)		
Week 52 Mean (SD)	14.67 (20.91)	25.00 (42.74)		
Week 4 Adjusted Mean Change (SE)	-8.03 (3.65)	-0.86 (3.92)		
Week 12 Adjusted Mean Change (SE)	-3.58 (4.63)	-4.81 (4.89)		
Week 16 Adjusted Mean Change (SE)	3.03 (5.87)	-5.06 (6.30)		
Week 24 Adjusted Mean Change (SE)	-1.92 (4.81)	-1.57 (5.43)		
Week 32 Adjusted Mean Change (SE)	4.62 (6.09)	-5.52 (6.63)		
Week 40 Adjusted Mean Change (SE)	-3.87 (6.07)	2.19 (6.27)		
Week 52 Adjusted Mean Change (SE)	1.66 (6.43)	11.59 (7.04)	-9.94 [-28.91; 9.03]	0.300
<b>Carrier, N</b>	<b>35</b>	<b>25</b>		
N'	33	23		
Baseline Mean (SD)	11.92 (21.57)	16.40 (29.93)		
Week 52 Mean (SD)	18.18 (29.08)	9.69 (16.68)		
Week 4 Adjusted Mean Change (SE)	-1.25 (3.06)	-1.56 (3.71)		
Week 12 Adjusted Mean Change (SE)	-1.99 (3.78)	-5.21 (4.52)		
Week 16 Adjusted Mean Change (SE)	9.78 (4.82)	8.32 (5.96)		
Week 24 Adjusted Mean Change (SE)	-3.14 (3.58)	-1.64 (4.45)		
Week 32 Adjusted Mean Change (SE)	3.18 (4.84)	-0.84 (5.92)		
Week 40 Adjusted Mean Change (SE)	0.57 (4.57)	2.76 (5.87)		
Week 52 Adjusted Mean Change (SE)	2.91 (4.84)	-3.03 (6.06)	5.95 [-9.48; 21.38]	0.445
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.11 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.305</b>				
<b>Non-carrier, N</b>	<b>31</b>	<b>29</b>		
N'	30	28		
Baseline Mean (SD)	16.74 (26.79)	13.24 (27.98)		
Week 52 Mean (SD)	19.19 (26.03)	23.05 (35.07)		
Week 4 Adjusted Mean Change (SE)	-5.67 (3.17)	-3.05 (3.33)		
Week 12 Adjusted Mean Change (SE)	-4.34 (3.98)	-5.76 (4.20)		
Week 16 Adjusted Mean Change (SE)	6.67 (5.24)	3.69 (5.44)		
Week 24 Adjusted Mean Change (SE)	-2.30 (3.89)	1.90 (4.11)		
Week 32 Adjusted Mean Change (SE)	6.26 (5.29)	-2.85 (5.39)		
Week 40 Adjusted Mean Change (SE)	-4.86 (4.92)	6.34 (5.25)		
Week 52 Adjusted Mean Change (SE)	6.17 (5.15)	9.42 (5.44)	-3.25 [-18.19; 11.70]	0.667
<b>Carrier, N</b>	<b>29</b>	<b>16</b>		
N'	26	15		
Baseline Mean (SD)	13.40 (23.65)	16.53 (26.83)		
Week 52 Mean (SD)	15.94 (27.74)	0.38 (1.22)		
Week 4 Adjusted Mean Change (SE)	-2.44 (3.41)	2.05 (4.60)		
Week 12 Adjusted Mean Change (SE)	-1.54 (4.22)	-4.40 (5.41)		
Week 16 Adjusted Mean Change (SE)	6.29 (5.35)	-1.66 (7.52)		
Week 24 Adjusted Mean Change (SE)	-3.43 (3.97)	-9.40 (5.82)		
Week 32 Adjusted Mean Change (SE)	0.17 (5.28)	-3.75 (7.63)		
Week 40 Adjusted Mean Change (SE)	4.43 (5.12)	-5.79 (7.12)		
Week 52 Adjusted Mean Change (SE)	-1.14 (5.54)	-10.61 (8.21)	9.47 [-10.24; 29.18]	0.342
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.12 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.499</b>				
<b>Non-carrier, N</b>	<b>42</b>	<b>31</b>		
N'	39	30		
Baseline Mean (SD)	12.92 (23.50)	11.45 (25.94)		
Week 52 Mean (SD)	15.57 (25.20)	14.81 (26.86)		
Week 4 Adjusted Mean Change (SE)	-1.33 (2.61)	-1.49 (3.10)		
Week 12 Adjusted Mean Change (SE)	0.27 (3.27)	-5.05 (3.80)		
Week 16 Adjusted Mean Change (SE)	12.27 (4.38)	2.43 (5.22)		
Week 24 Adjusted Mean Change (SE)	-1.77 (3.11)	-1.45 (3.88)		
Week 32 Adjusted Mean Change (SE)	7.09 (4.20)	-8.43 (5.07)		
Week 40 Adjusted Mean Change (SE)	2.51 (4.03)	4.19 (4.99)		
Week 52 Adjusted Mean Change (SE)	3.96 (4.55)	2.63 (5.71)	1.33 [-13.23; 15.88]	0.856
<b>Carrier, N</b>	<b>16</b>	<b>13</b>		
N'	15	12		
Baseline Mean (SD)	16.84 (26.89)	14.87 (20.51)		
Week 52 Mean (SD)	23.95 (31.27)	11.19 (29.80)		
Week 4 Adjusted Mean Change (SE)	-7.57 (4.29)	-2.51 (4.76)		
Week 12 Adjusted Mean Change (SE)	-6.70 (5.14)	-8.47 (5.73)		
Week 16 Adjusted Mean Change (SE)	-3.59 (6.95)	-0.71 (8.01)		
Week 24 Adjusted Mean Change (SE)	-0.26 (5.45)	-5.18 (6.20)		
Week 32 Adjusted Mean Change (SE)	-0.59 (6.92)	4.50 (7.47)		
Week 40 Adjusted Mean Change (SE)	-2.35 (6.70)	-5.70 (7.57)		
Week 52 Adjusted Mean Change (SE)	6.54 (7.34)	1.11 (7.91)	5.43 [-16.11; 26.97]	0.617
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.13 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.982</b>				
<b>Non-carrier, N</b>	<b>46</b>	<b>36</b>		
N'	43	35		
Baseline Mean (SD)	15.58 (24.85)	15.68 (29.50)		
Week 52 Mean (SD)	13.48 (23.32)	13.54 (28.76)		
Week 4 Adjusted Mean Change (SE)	-5.94 (2.67)	-3.26 (3.03)		
Week 12 Adjusted Mean Change (SE)	-5.06 (3.28)	-4.85 (3.68)		
Week 16 Adjusted Mean Change (SE)	7.90 (4.36)	1.32 (4.94)		
Week 24 Adjusted Mean Change (SE)	-3.42 (3.24)	-3.06 (3.83)		
Week 32 Adjusted Mean Change (SE)	2.88 (4.32)	-1.98 (4.86)		
Week 40 Adjusted Mean Change (SE)	-2.63 (4.13)	-0.57 (4.68)		
Week 52 Adjusted Mean Change (SE)	-2.54 (4.24)	-0.15 (4.93)	-2.39 [-15.32; 10.54]	0.714
<b>Carrier, N</b>	<b>12</b>	<b>7</b>		
N'	12	6		
Baseline Mean (SD)	7.40 (11.43)	12.00 (17.67)		
Week 52 Mean (SD)	35.91 (32.81)	33.70 (42.32)		
Week 4 Adjusted Mean Change (SE)	1.47 (4.84)	7.07 (6.89)		
Week 12 Adjusted Mean Change (SE)	3.71 (6.09)	-11.33 (9.01)		
Week 16 Adjusted Mean Change (SE)	2.48 (8.00)	4.29 (12.36)		
Week 24 Adjusted Mean Change (SE)	-1.48 (6.29)	5.51 (8.97)		
Week 32 Adjusted Mean Change (SE)	3.97 (7.72)	-10.77 (11.99)		
Week 40 Adjusted Mean Change (SE)	7.52 (7.54)	18.89 (11.19)		
Week 52 Adjusted Mean Change (SE)	22.66 (8.12)	21.63 (11.55)	1.03 [-27.03; 29.10]	0.942
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.14 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.387</b>				
<b>Non-carrier, N</b>	<b>49</b>	<b>37</b>		
N'	45	35		
Baseline Mean (SD)	15.70 (25.81)	17.19 (29.39)		
Week 52 Mean (SD)	19.29 (27.86)	17.51 (34.11)		
Week 4 Adjusted Mean Change (SE)	-4.08 (2.64)	0.18 (3.07)		
Week 12 Adjusted Mean Change (SE)	-3.06 (3.32)	-4.81 (3.74)		
Week 16 Adjusted Mean Change (SE)	7.97 (4.18)	0.59 (4.86)		
Week 24 Adjusted Mean Change (SE)	-3.80 (2.71)	-5.83 (3.36)		
Week 32 Adjusted Mean Change (SE)	0.68 (3.67)	-8.74 (4.39)		
Week 40 Adjusted Mean Change (SE)	1.22 (4.07)	0.56 (4.84)		
Week 52 Adjusted Mean Change (SE)	4.03 (4.45)	3.46 (5.48)	0.57 [-13.45; 14.60]	0.935
<b>Carrier, N</b>	<b>10</b>	<b>6</b>		
N'	10	6		
Baseline Mean (SD)	13.73 (24.10)	0.00 (0.00)		
Week 52 Mean (SD)	12.56 (21.65)	13.89 (22.15)		
Week 4 Adjusted Mean Change (SE)	-5.11 (5.37)	-7.40 (7.00)		
Week 12 Adjusted Mean Change (SE)	-3.51 (6.54)	-6.97 (9.22)		
Week 16 Adjusted Mean Change (SE)	-3.32 (8.59)	12.20 (12.16)		
Week 24 Adjusted Mean Change (SE)	-0.87 (5.66)	-0.22 (7.08)		
Week 32 Adjusted Mean Change (SE)	5.47 (7.74)	9.13 (9.63)		
Week 40 Adjusted Mean Change (SE)	-7.65 (8.36)	6.55 (10.40)		
Week 52 Adjusted Mean Change (SE)	-1.20 (9.15)	2.27 (11.41)	-3.47 [-32.66; 25.72]	0.814
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.15 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.344</b>				
<b>Low score, N</b>	<b>17</b>	<b>15</b>		
N'	15	15		
Baseline Mean (SD)	21.25 (26.87)	10.46 (25.53)		
Week 52 Mean (SD)	15.28 (19.76)	25.91 (41.99)		
Week 4 Adjusted Mean Change (SE)	-8.48 (4.49)	-2.12 (4.61)		
Week 12 Adjusted Mean Change (SE)	-10.93 (5.73)	-4.25 (5.51)		
Week 16 Adjusted Mean Change (SE)	6.19 (7.57)	0.15 (7.28)		
Week 24 Adjusted Mean Change (SE)	-7.69 (5.56)	6.43 (5.77)		
Week 32 Adjusted Mean Change (SE)	8.04 (7.37)	-4.30 (7.61)		
Week 40 Adjusted Mean Change (SE)	-0.16 (7.90)	6.54 (7.55)		
Week 52 Adjusted Mean Change (SE)	1.32 (7.78)	10.46 (8.44)	-9.14 [-31.97; 13.69]	0.428
<b>High score, N</b>	<b>43</b>	<b>30</b>		
N'	41	28		
Baseline Mean (SD)	12.59 (24.30)	16.39 (28.38)		
Week 52 Mean (SD)	18.46 (28.61)	11.95 (24.70)		
Week 4 Adjusted Mean Change (SE)	-2.64 (2.71)	-0.89 (3.32)		
Week 12 Adjusted Mean Change (SE)	-0.41 (3.28)	-5.67 (4.05)		
Week 16 Adjusted Mean Change (SE)	6.63 (4.32)	2.89 (5.54)		
Week 24 Adjusted Mean Change (SE)	-1.24 (3.16)	-5.89 (4.09)		
Week 32 Adjusted Mean Change (SE)	1.55 (4.33)	-2.46 (5.38)		
Week 40 Adjusted Mean Change (SE)	-0.37 (4.07)	0.23 (5.24)		
Week 52 Adjusted Mean Change (SE)	3.44 (4.46)	0.02 (5.60)	3.42 [-10.83; 17.67]	0.634
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.16 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.680</b>				
<b>Non-carrier, N</b>	<b>40</b>	<b>24</b>		
N'	36	22		
Baseline Mean (SD)	16.11 (27.54)	15.18 (25.29)		
Week 52 Mean (SD)	17.20 (24.79)	18.99 (34.67)		
Week 4 Adjusted Mean Change (SE)	-4.73 (2.88)	-1.02 (3.75)		
Week 12 Adjusted Mean Change (SE)	-2.13 (3.52)	-6.81 (4.72)		
Week 16 Adjusted Mean Change (SE)	6.60 (4.65)	-1.28 (6.05)		
Week 24 Adjusted Mean Change (SE)	-4.75 (3.50)	1.36 (4.71)		
Week 32 Adjusted Mean Change (SE)	2.12 (4.61)	-3.64 (6.08)		
Week 40 Adjusted Mean Change (SE)	-1.65 (4.55)	5.29 (5.89)		
Week 52 Adjusted Mean Change (SE)	2.35 (4.80)	4.73 (6.55)	-2.38 [-18.54; 13.77]	0.770
<b>Carrier, N</b>	<b>20</b>	<b>21</b>		
N'	20	21		
Baseline Mean (SD)	13.27 (20.41)	13.53 (30.08)		
Week 52 Mean (SD)	18.75 (30.96)	13.20 (27.26)		
Week 4 Adjusted Mean Change (SE)	-3.10 (3.95)	-1.48 (3.93)		
Week 12 Adjusted Mean Change (SE)	-5.01 (5.00)	-3.48 (4.63)		
Week 16 Adjusted Mean Change (SE)	6.36 (6.23)	5.41 (6.37)		
Week 24 Adjusted Mean Change (SE)	0.43 (4.61)	-5.04 (4.87)		
Week 32 Adjusted Mean Change (SE)	5.43 (6.42)	-2.50 (6.42)		
Week 40 Adjusted Mean Change (SE)	1.64 (5.89)	-1.25 (6.24)		
Week 52 Adjusted Mean Change (SE)	3.95 (6.75)	1.33 (6.77)	2.62 [-16.44; 21.69]	0.785
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.17 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.710</b>				
<b>Non-carrier, N</b>	<b>23</b>	<b>20</b>		
N'	22	20		
Baseline Mean (SD)	20.08 (30.15)	11.92 (24.18)		
Week 52 Mean (SD)	14.67 (20.91)	25.00 (42.74)		
Week 4 Adjusted Mean Change (SE)	-8.09 (3.63)	-0.92 (3.90)		
Week 12 Adjusted Mean Change (SE)	-3.62 (4.61)	-4.94 (4.88)		
Week 16 Adjusted Mean Change (SE)	3.00 (5.87)	-5.11 (6.30)		
Week 24 Adjusted Mean Change (SE)	-1.99 (4.78)	-1.70 (5.40)		
Week 32 Adjusted Mean Change (SE)	4.50 (6.07)	-5.62 (6.61)		
Week 40 Adjusted Mean Change (SE)	-4.05 (6.11)	2.08 (6.31)		
Week 52 Adjusted Mean Change (SE)	1.40 (6.47)	11.43 (7.08)	-10.04 [-29.11; 9.04]	0.298
<b>Carrier, N</b>	<b>37</b>	<b>25</b>		
N'	34	23		
Baseline Mean (SD)	11.88 (21.10)	16.40 (29.93)		
Week 52 Mean (SD)	19.26 (29.29)	9.69 (16.68)		
Week 4 Adjusted Mean Change (SE)	-1.48 (2.99)	-1.63 (3.69)		
Week 12 Adjusted Mean Change (SE)	-2.51 (3.70)	-5.29 (4.50)		
Week 16 Adjusted Mean Change (SE)	8.87 (4.74)	8.21 (5.96)		
Week 24 Adjusted Mean Change (SE)	-3.08 (3.50)	-1.72 (4.42)		
Week 32 Adjusted Mean Change (SE)	2.54 (4.74)	-0.95 (5.90)		
Week 40 Adjusted Mean Change (SE)	1.61 (4.52)	2.79 (5.91)		
Week 52 Adjusted Mean Change (SE)	4.03 (4.78)	-3.05 (6.10)	7.08 [-8.34; 22.50]	0.363
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				



### 55.18 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.305</b>				
<b>Non-carrier, N</b>	<b>31</b>	<b>29</b>		
N'	30	28		
Baseline Mean (SD)	16.74 (26.79)	13.24 (27.98)		
Week 52 Mean (SD)	19.19 (26.03)	23.05 (35.07)		
Week 4 Adjusted Mean Change (SE)	-5.67 (3.17)	-3.05 (3.33)		
Week 12 Adjusted Mean Change (SE)	-4.34 (3.98)	-5.76 (4.20)		
Week 16 Adjusted Mean Change (SE)	6.67 (5.24)	3.69 (5.44)		
Week 24 Adjusted Mean Change (SE)	-2.30 (3.89)	1.90 (4.11)		
Week 32 Adjusted Mean Change (SE)	6.26 (5.29)	-2.85 (5.39)		
Week 40 Adjusted Mean Change (SE)	-4.86 (4.92)	6.34 (5.25)		
Week 52 Adjusted Mean Change (SE)	6.17 (5.15)	9.42 (5.44)	-3.25 [-18.19; 11.70]	0.667
<b>Carrier, N</b>	<b>29</b>	<b>16</b>		
N'	26	15		
Baseline Mean (SD)	13.40 (23.65)	16.53 (26.83)		
Week 52 Mean (SD)	15.94 (27.74)	0.38 (1.22)		
Week 4 Adjusted Mean Change (SE)	-2.44 (3.41)	2.05 (4.60)		
Week 12 Adjusted Mean Change (SE)	-1.54 (4.22)	-4.40 (5.41)		
Week 16 Adjusted Mean Change (SE)	6.29 (5.35)	-1.66 (7.52)		
Week 24 Adjusted Mean Change (SE)	-3.43 (3.97)	-9.40 (5.82)		
Week 32 Adjusted Mean Change (SE)	0.17 (5.28)	-3.75 (7.63)		
Week 40 Adjusted Mean Change (SE)	4.43 (5.12)	-5.79 (7.12)		
Week 52 Adjusted Mean Change (SE)	-1.14 (5.54)	-10.61 (8.21)	9.47 [-10.24; 29.18]	0.342
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 55.19 WPAI-GH Percent Work Time Missed due to Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.724</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>33</b>		
N'	42	32		
Baseline Mean (SD)	14.20 (24.64)	13.79 (29.57)		
Week 52 Mean (SD)	14.85 (24.40)	22.21 (35.47)		
Week 4 Adjusted Mean Change (SE)	-2.09 (2.60)	-0.22 (3.04)		
Week 12 Adjusted Mean Change (SE)	-0.46 (3.29)	-3.02 (3.84)		
Week 16 Adjusted Mean Change (SE)	10.88 (4.24)	3.48 (4.98)		
Week 24 Adjusted Mean Change (SE)	-2.72 (3.20)	0.61 (4.00)		
Week 32 Adjusted Mean Change (SE)	5.44 (4.26)	-5.45 (5.14)		
Week 40 Adjusted Mean Change (SE)	1.50 (4.15)	6.28 (4.98)		
Week 52 Adjusted Mean Change (SE)	2.50 (4.41)	9.13 (5.50)	-6.63 [-20.66; 7.40]	0.350
<b>Carrier, N</b>	<b>14</b>	<b>12</b>		
N'	13	11		
Baseline Mean (SD)	11.74 (14.68)	16.11 (20.91)		
Week 52 Mean (SD)	27.17 (32.75)	2.31 (4.74)		
Week 4 Adjusted Mean Change (SE)	-5.02 (4.74)	-2.86 (5.10)		
Week 12 Adjusted Mean Change (SE)	-4.78 (5.72)	-8.52 (5.96)		
Week 16 Adjusted Mean Change (SE)	-0.49 (7.38)	-0.93 (8.36)		
Week 24 Adjusted Mean Change (SE)	-2.00 (6.22)	-5.96 (6.53)		
Week 32 Adjusted Mean Change (SE)	-0.08 (7.62)	5.62 (8.30)		
Week 40 Adjusted Mean Change (SE)	-0.94 (7.59)	-4.87 (8.32)		
Week 52 Adjusted Mean Change (SE)	8.50 (8.05)	-8.34 (8.42)	16.84 [-6.38; 40.07]	0.153
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.0 WPAI-GH Percent Impairment while Working due to Health - Return Rates (FAS)

Treatment Groups			
	SEC (N=75)	ADA (N=63)	Total (N=138)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	70 (93.3)	60 (95.2)	130 (94.2)
Week 4 Returns	67 (89.3)	49 (77.8)	116 (84.1)
Week 12 Returns	63 (84.0)	46 (73.0)	109 (79.0)
Week 16 Returns	67 (89.3)	46 (73.0)	113 (81.9)
Week 24 Returns	64 (85.3)	38 (60.3)	102 (73.9)
Week 32 Returns	61 (81.3)	41 (65.1)	102 (73.9)
Week 40 Returns	60 (80.0)	39 (61.9)	99 (71.7)
Week 52 Returns	61 (81.3)	35 (55.6)	96 (69.6)
Note: The table is based on all patients who were employed at baseline.			

### 56.1 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
N'	69	54		
Baseline Mean (SD)	49.71 (24.32)	37.17 (24.36)		
Week 52 Mean (SD)	28.69 (25.06)	23.43 (22.48)		
Week 4 Adjusted Mean Change (SE)	-11.51 (2.73)	-12.46 (3.15)		
Week 12 Adjusted Mean Change (SE)	-18.47 (2.75)	-13.85 (3.14)		
Week 16 Adjusted Mean Change (SE)	-17.24 (2.86)	-17.12 (3.39)		
Week 24 Adjusted Mean Change (SE)	-18.83 (2.80)	-19.58 (3.44)		
Week 32 Adjusted Mean Change (SE)	-16.19 (2.80)	-18.53 (3.31)		
Week 40 Adjusted Mean Change (SE)	-19.18 (2.77)	-18.70 (3.33)		
Week 52 Adjusted Mean Change (SE)	-18.88 (3.00)	-17.01 (3.76)	-1.87 [-11.55; 7.80]	0.702
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

## 56.2 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Age (FAS)

Table is not displayed as the parameter does not fulfill the condition for the subgroup analysis.
---

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.
--

### 56.3 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.744</b>				
<b>Male, N</b>	<b>48</b>	<b>40</b>		
N'	44	34		
Baseline Mean (SD)	46.22 (23.58)	34.21 (24.23)		
Week 52 Mean (SD)	24.62 (23.15)	19.58 (21.56)		
Week 4 Adjusted Mean Change (SE)	-13.98 (3.44)	-12.77 (4.03)		
Week 12 Adjusted Mean Change (SE)	-19.77 (3.45)	-16.56 (4.06)		
Week 16 Adjusted Mean Change (SE)	-19.47 (3.55)	-19.33 (4.15)		
Week 24 Adjusted Mean Change (SE)	-19.38 (3.44)	-25.90 (4.32)		
Week 32 Adjusted Mean Change (SE)	-19.12 (3.47)	-22.05 (4.27)		
Week 40 Adjusted Mean Change (SE)	-18.44 (3.51)	-21.24 (4.28)		
Week 52 Adjusted Mean Change (SE)	-21.98 (3.71)	-20.48 (4.69)	-1.50 [-13.40; 10.40]	0.803
<b>Female, N</b>	<b>27</b>	<b>23</b>		
N'	25	20		
Baseline Mean (SD)	56.00 (24.83)	42.27 (24.29)		
Week 52 Mean (SD)	35.91 (27.20)	31.82 (23.16)		
Week 4 Adjusted Mean Change (SE)	-6.90 (4.64)	-12.60 (5.09)		
Week 12 Adjusted Mean Change (SE)	-15.73 (4.67)	-9.67 (5.03)		
Week 16 Adjusted Mean Change (SE)	-12.75 (4.88)	-14.66 (5.78)		
Week 24 Adjusted Mean Change (SE)	-17.36 (4.74)	-9.63 (5.54)		
Week 32 Adjusted Mean Change (SE)	-10.33 (4.76)	-13.77 (5.19)		
Week 40 Adjusted Mean Change (SE)	-19.67 (4.64)	-14.46 (5.35)		
Week 52 Adjusted Mean Change (SE)	-12.83 (5.07)	-11.67 (6.38)	-1.16 [-17.13; 14.81]	0.886
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.4 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.813</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>15</b>	<b>17</b>		
N'	14	16		
Baseline Mean (SD)	38.67 (23.56)	27.06 (25.44)		
Week 52 Mean (SD)	14.00 (13.50)	22.73 (29.01)		
Week 4 Adjusted Mean Change (SE)	-15.09 (5.85)	-15.80 (5.73)		
Week 12 Adjusted Mean Change (SE)	-20.57 (6.24)	-18.02 (5.91)		
Week 16 Adjusted Mean Change (SE)	-17.76 (6.30)	-21.64 (6.17)		
Week 24 Adjusted Mean Change (SE)	-17.40 (6.42)	-21.83 (6.12)		
Week 32 Adjusted Mean Change (SE)	-16.62 (6.21)	-24.29 (6.19)		
Week 40 Adjusted Mean Change (SE)	-17.26 (6.39)	-19.66 (6.25)		
Week 52 Adjusted Mean Change (SE)	-29.00 (6.93)	-17.76 (6.72)	-11.24 [-30.29; 7.81]	0.245
<b>PASDAS ≥ 5.4, N</b>	<b>60</b>	<b>46</b>		
N'	55	38		
Baseline Mean (SD)	52.73 (23.84)	41.16 (23.01)		
Week 52 Mean (SD)	31.57 (25.87)	23.75 (19.52)		
Week 4 Adjusted Mean Change (SE)	-10.41 (3.12)	-11.18 (3.76)		
Week 12 Adjusted Mean Change (SE)	-17.82 (3.10)	-12.31 (3.72)		
Week 16 Adjusted Mean Change (SE)	-16.97 (3.25)	-15.30 (4.02)		
Week 24 Adjusted Mean Change (SE)	-19.06 (3.16)	-18.78 (4.20)		
Week 32 Adjusted Mean Change (SE)	-16.00 (3.18)	-16.29 (3.92)		
Week 40 Adjusted Mean Change (SE)	-19.55 (3.12)	-18.20 (3.92)		
Week 52 Adjusted Mean Change (SE)	-16.56 (3.31)	-17.05 (4.45)	0.49 [-10.58; 11.57]	0.930
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.5 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.987</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>26</b>	<b>31</b>		
N'	25	29		
Baseline Mean (SD)	52.00 (21.98)	38.71 (26.42)		
Week 52 Mean (SD)	23.33 (21.42)	23.89 (21.73)		
Week 4 Adjusted Mean Change (SE)	-16.10 (4.55)	-13.56 (4.20)		
Week 12 Adjusted Mean Change (SE)	-17.01 (4.59)	-15.81 (4.17)		
Week 16 Adjusted Mean Change (SE)	-18.17 (4.80)	-17.10 (4.62)		
Week 24 Adjusted Mean Change (SE)	-16.61 (4.82)	-18.78 (4.68)		
Week 32 Adjusted Mean Change (SE)	-19.39 (4.60)	-22.29 (4.42)		
Week 40 Adjusted Mean Change (SE)	-19.04 (4.65)	-18.41 (4.52)		
Week 52 Adjusted Mean Change (SE)	-23.78 (5.25)	-17.51 (5.10)	-6.27 [-20.90; 8.37]	0.398
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>49</b>	<b>32</b>		
N'	44	25		
Baseline Mean (SD)	48.44 (25.67)	35.52 (22.29)		
Week 52 Mean (SD)	30.93 (26.35)	22.94 (23.92)		
Week 4 Adjusted Mean Change (SE)	-9.08 (3.40)	-11.13 (4.65)		
Week 12 Adjusted Mean Change (SE)	-19.24 (3.45)	-10.97 (4.81)		
Week 16 Adjusted Mean Change (SE)	-16.71 (3.58)	-17.22 (4.90)		
Week 24 Adjusted Mean Change (SE)	-19.80 (3.44)	-20.84 (5.07)		
Week 32 Adjusted Mean Change (SE)	-14.26 (3.50)	-13.72 (4.91)		
Week 40 Adjusted Mean Change (SE)	-19.24 (3.47)	-19.08 (4.90)		
Week 52 Adjusted Mean Change (SE)	-16.58 (3.63)	-16.07 (5.49)	-0.51 [-13.66; 12.65]	0.939
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				



### 56.6 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.921</b>				
<b>≤ Median, N</b>	<b>52</b>	<b>31</b>		
N'	48	29		
Baseline Mean (SD)	49.59 (24.23)	39.68 (25.49)		
Week 52 Mean (SD)	28.64 (25.84)	21.50 (18.72)		
Week 4 Adjusted Mean Change (SE)	-11.97 (3.30)	-11.29 (4.27)		
Week 12 Adjusted Mean Change (SE)	-18.11 (3.25)	-12.26 (4.18)		
Week 16 Adjusted Mean Change (SE)	-18.18 (3.45)	-18.07 (4.46)		
Week 24 Adjusted Mean Change (SE)	-20.31 (3.29)	-24.23 (4.47)		
Week 32 Adjusted Mean Change (SE)	-18.05 (3.35)	-16.24 (4.41)		
Week 40 Adjusted Mean Change (SE)	-20.41 (3.33)	-19.51 (4.43)		
Week 52 Adjusted Mean Change (SE)	-18.86 (3.55)	-20.38 (4.92)	1.52 [-10.59; 13.63]	0.804
<b>&gt; Median, N</b>	<b>23</b>	<b>32</b>		
N'	21	25		
Baseline Mean (SD)	50.00 (25.10)	34.48 (23.24)		
Week 52 Mean (SD)	28.82 (23.69)	26.00 (27.20)		
Week 4 Adjusted Mean Change (SE)	-10.34 (4.90)	-13.77 (4.66)		
Week 12 Adjusted Mean Change (SE)	-19.98 (5.07)	-15.61 (4.70)		
Week 16 Adjusted Mean Change (SE)	-15.16 (5.14)	-15.68 (5.12)		
Week 24 Adjusted Mean Change (SE)	-15.15 (5.15)	-12.59 (5.22)		
Week 32 Adjusted Mean Change (SE)	-11.93 (5.03)	-21.25 (4.95)		
Week 40 Adjusted Mean Change (SE)	-16.24 (4.98)	-17.47 (4.98)		
Week 52 Adjusted Mean Change (SE)	-19.04 (5.59)	-12.30 (5.78)	-6.74 [-22.79; 9.30]	0.406
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.7 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.515</b>				
<b>Enthesitis: No, N</b>	<b>36</b>	<b>23</b>		
N'	33	20		
Baseline Mean (SD)	50.29 (23.80)	31.36 (26.42)		
Week 52 Mean (SD)	28.21 (25.68)	27.69 (27.43)		
Week 4 Adjusted Mean Change (SE)	-13.26 (3.91)	-12.71 (5.38)		
Week 12 Adjusted Mean Change (SE)	-19.50 (3.96)	-9.59 (5.20)		
Week 16 Adjusted Mean Change (SE)	-19.99 (4.19)	-17.71 (5.50)		
Week 24 Adjusted Mean Change (SE)	-20.78 (4.09)	-17.65 (5.41)		
Week 32 Adjusted Mean Change (SE)	-15.08 (4.12)	-14.79 (5.26)		
Week 40 Adjusted Mean Change (SE)	-19.75 (4.12)	-18.21 (5.42)		
Week 52 Adjusted Mean Change (SE)	-18.91 (4.38)	-15.45 (6.18)	-3.46 [-18.77; 11.84]	0.655
<b>Enthesitis: Yes, N</b>	<b>39</b>	<b>40</b>		
N'	36	34		
Baseline Mean (SD)	49.17 (25.11)	40.53 (22.77)		
Week 52 Mean (SD)	29.09 (24.92)	20.91 (19.25)		
Week 4 Adjusted Mean Change (SE)	-9.83 (3.84)	-12.33 (3.86)		
Week 12 Adjusted Mean Change (SE)	-17.51 (3.82)	-16.20 (3.93)		
Week 16 Adjusted Mean Change (SE)	-14.77 (3.92)	-16.60 (4.24)		
Week 24 Adjusted Mean Change (SE)	-17.12 (3.85)	-20.57 (4.49)		
Week 32 Adjusted Mean Change (SE)	-17.22 (3.81)	-20.86 (4.26)		
Week 40 Adjusted Mean Change (SE)	-18.52 (3.78)	-18.87 (4.23)		
Week 52 Adjusted Mean Change (SE)	-18.84 (4.14)	-17.89 (4.77)	-0.95 [-13.51; 11.61]	0.881
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.8 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.451</b>				
<b>Non-carrier, N</b>	<b>38</b>	<b>27</b>		
N'	34	24		
Baseline Mean (SD)	53.53 (22.14)	37.31 (23.08)		
Week 52 Mean (SD)	27.33 (22.12)	18.67 (18.85)		
Week 4 Adjusted Mean Change (SE)	-14.23 (3.80)	-15.95 (4.73)		
Week 12 Adjusted Mean Change (SE)	-21.02 (3.93)	-16.53 (4.73)		
Week 16 Adjusted Mean Change (SE)	-18.09 (4.27)	-16.43 (5.28)		
Week 24 Adjusted Mean Change (SE)	-21.84 (3.77)	-24.01 (5.06)		
Week 32 Adjusted Mean Change (SE)	-21.14 (4.10)	-17.17 (5.01)		
Week 40 Adjusted Mean Change (SE)	-22.51 (3.80)	-17.68 (4.72)		
Week 52 Adjusted Mean Change (SE)	-22.58 (3.93)	-21.85 (5.00)	-0.72 [-13.59; 12.15]	0.912
<b>Carrier, N</b>	<b>22</b>	<b>18</b>		
N'	21	16		
Baseline Mean (SD)	45.00 (25.02)	40.00 (27.08)		
Week 52 Mean (SD)	27.22 (26.08)	22.67 (19.81)		
Week 4 Adjusted Mean Change (SE)	-6.43 (4.82)	-15.54 (5.33)		
Week 12 Adjusted Mean Change (SE)	-14.17 (4.92)	-14.92 (5.46)		
Week 16 Adjusted Mean Change (SE)	-13.25 (5.32)	-16.85 (6.04)		
Week 24 Adjusted Mean Change (SE)	-18.71 (4.70)	-22.85 (5.22)		
Week 32 Adjusted Mean Change (SE)	-14.29 (5.11)	-20.52 (5.71)		
Week 40 Adjusted Mean Change (SE)	-18.69 (4.85)	-23.32 (5.32)		
Week 52 Adjusted Mean Change (SE)	-16.86 (4.88)	-17.16 (5.53)	0.30 [-14.41; 15.00]	0.968
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.9 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.686</b>				
<b>Non-carrier, N</b>	<b>36</b>	<b>17</b>		
N'	31	15		
Baseline Mean (SD)	48.44 (23.02)	41.25 (24.73)		
Week 52 Mean (SD)	27.59 (24.74)	24.44 (20.07)		
Week 4 Adjusted Mean Change (SE)	-9.57 (3.97)	-12.25 (5.88)		
Week 12 Adjusted Mean Change (SE)	-18.44 (4.14)	-20.72 (6.13)		
Week 16 Adjusted Mean Change (SE)	-19.78 (4.46)	-15.79 (6.56)		
Week 24 Adjusted Mean Change (SE)	-21.41 (3.98)	-26.57 (6.04)		
Week 32 Adjusted Mean Change (SE)	-20.84 (4.36)	-23.41 (6.51)		
Week 40 Adjusted Mean Change (SE)	-21.19 (4.18)	-20.34 (6.20)		
Week 52 Adjusted Mean Change (SE)	-18.77 (4.23)	-22.16 (6.72)	3.39 [-12.44; 19.23]	0.671
<b>Carrier, N</b>	<b>22</b>	<b>19</b>		
N'	22	17		
Baseline Mean (SD)	53.64 (23.41)	35.88 (24.25)		
Week 52 Mean (SD)	27.65 (22.78)	20.00 (20.41)		
Week 4 Adjusted Mean Change (SE)	-14.78 (4.81)	-18.50 (5.61)		
Week 12 Adjusted Mean Change (SE)	-19.80 (5.02)	-13.83 (5.59)		
Week 16 Adjusted Mean Change (SE)	-14.27 (5.36)	-15.32 (6.37)		
Week 24 Adjusted Mean Change (SE)	-21.76 (4.82)	-22.58 (5.79)		
Week 32 Adjusted Mean Change (SE)	-18.07 (5.30)	-14.37 (6.08)		
Week 40 Adjusted Mean Change (SE)	-22.11 (4.99)	-20.81 (5.70)		
Week 52 Adjusted Mean Change (SE)	-24.49 (5.24)	-16.95 (6.09)	-7.54 [-23.85; 8.78]	0.360
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.10 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.762</b>				
<b>Non-carrier, N</b>	<b>23</b>	<b>20</b>		
N'	21	19		
Baseline Mean (SD)	49.52 (21.79)	36.32 (23.62)		
Week 52 Mean (SD)	25.88 (22.38)	13.64 (21.11)		
Week 4 Adjusted Mean Change (SE)	-14.19 (4.79)	-13.72 (5.20)		
Week 12 Adjusted Mean Change (SE)	-16.95 (5.00)	-18.27 (5.30)		
Week 16 Adjusted Mean Change (SE)	-11.93 (5.33)	-14.70 (5.76)		
Week 24 Adjusted Mean Change (SE)	-19.05 (4.94)	-25.69 (5.51)		
Week 32 Adjusted Mean Change (SE)	-15.91 (5.22)	-22.31 (5.59)		
Week 40 Adjusted Mean Change (SE)	-20.17 (4.99)	-19.58 (5.28)		
Week 52 Adjusted Mean Change (SE)	-21.84 (5.04)	-22.60 (5.70)	0.76 [-14.51; 16.03]	0.921
<b>Carrier, N</b>	<b>35</b>	<b>25</b>		
N'	33	21		
Baseline Mean (SD)	53.03 (23.11)	40.00 (25.41)		
Week 52 Mean (SD)	28.33 (24.65)	24.74 (17.12)		
Week 4 Adjusted Mean Change (SE)	-8.93 (3.93)	-18.12 (4.92)		
Week 12 Adjusted Mean Change (SE)	-19.17 (3.97)	-14.16 (4.91)		
Week 16 Adjusted Mean Change (SE)	-18.81 (4.31)	-18.83 (5.46)		
Week 24 Adjusted Mean Change (SE)	-21.47 (3.72)	-22.26 (4.83)		
Week 32 Adjusted Mean Change (SE)	-19.84 (4.08)	-16.44 (5.07)		
Week 40 Adjusted Mean Change (SE)	-21.16 (3.91)	-22.09 (4.92)		
Week 52 Adjusted Mean Change (SE)	-19.84 (3.91)	-17.91 (4.90)	-1.93 [-14.55; 10.69]	0.762
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.11 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.819</b>				
<b>Non-carrier, N</b>	<b>31</b>	<b>29</b>		
N'	29	26		
Baseline Mean (SD)	51.03 (22.57)	39.26 (24.17)		
Week 52 Mean (SD)	26.92 (23.63)	23.50 (21.34)		
Week 4 Adjusted Mean Change (SE)	-14.13 (4.10)	-16.72 (4.35)		
Week 12 Adjusted Mean Change (SE)	-18.18 (4.26)	-13.79 (4.45)		
Week 16 Adjusted Mean Change (SE)	-14.32 (4.65)	-16.08 (4.91)		
Week 24 Adjusted Mean Change (SE)	-18.13 (4.09)	-22.15 (4.42)		
Week 32 Adjusted Mean Change (SE)	-21.59 (4.54)	-19.47 (4.62)		
Week 40 Adjusted Mean Change (SE)	-19.51 (4.20)	-20.13 (4.37)		
Week 52 Adjusted Mean Change (SE)	-20.71 (4.27)	-18.72 (4.51)	-1.99 [-14.45; 10.46]	0.751
<b>Carrier, N</b>	<b>29</b>	<b>16</b>		
N'	26	14		
Baseline Mean (SD)	49.26 (24.80)	36.67 (25.54)		
Week 52 Mean (SD)	27.73 (23.69)	15.00 (12.69)		
Week 4 Adjusted Mean Change (SE)	-7.74 (4.35)	-13.97 (6.07)		
Week 12 Adjusted Mean Change (SE)	-18.28 (4.46)	-19.23 (6.11)		
Week 16 Adjusted Mean Change (SE)	-17.92 (4.76)	-17.58 (6.73)		
Week 24 Adjusted Mean Change (SE)	-22.97 (4.16)	-26.36 (6.15)		
Week 32 Adjusted Mean Change (SE)	-15.62 (4.54)	-17.11 (6.60)		
Week 40 Adjusted Mean Change (SE)	-22.07 (4.34)	-21.72 (6.11)		
Week 52 Adjusted Mean Change (SE)	-19.64 (4.42)	-21.20 (6.55)	1.57 [-14.28; 17.41]	0.845
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.12 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.111</b>				
<b>Non-carrier, N</b>	<b>42</b>	<b>31</b>		
N'	39	28		
Baseline Mean (SD)	51.00 (22.28)	37.24 (23.74)		
Week 52 Mean (SD)	26.97 (23.38)	24.50 (20.64)		
Week 4 Adjusted Mean Change (SE)	-11.83 (3.58)	-15.46 (4.26)		
Week 12 Adjusted Mean Change (SE)	-18.81 (3.67)	-13.08 (4.29)		
Week 16 Adjusted Mean Change (SE)	-18.10 (3.99)	-14.28 (4.68)		
Week 24 Adjusted Mean Change (SE)	-24.41 (3.40)	-19.93 (4.26)		
Week 32 Adjusted Mean Change (SE)	-20.71 (3.92)	-19.81 (4.62)		
Week 40 Adjusted Mean Change (SE)	-23.06 (3.51)	-17.18 (4.18)		
Week 52 Adjusted Mean Change (SE)	-21.02 (3.55)	-14.92 (4.35)	-6.10 [-17.49; 5.29]	0.290
<b>Carrier, N</b>	<b>16</b>	<b>13</b>		
N'	14	12		
Baseline Mean (SD)	46.43 (25.90)	40.77 (26.60)		
Week 52 Mean (SD)	26.15 (19.81)	13.00 (13.37)		
Week 4 Adjusted Mean Change (SE)	-9.28 (5.98)	-17.09 (6.42)		
Week 12 Adjusted Mean Change (SE)	-17.56 (5.95)	-22.44 (6.33)		
Week 16 Adjusted Mean Change (SE)	-11.51 (6.31)	-22.10 (7.24)		
Week 24 Adjusted Mean Change (SE)	-10.72 (5.85)	-31.57 (6.29)		
Week 32 Adjusted Mean Change (SE)	-12.83 (6.28)	-17.06 (6.73)		
Week 40 Adjusted Mean Change (SE)	-15.49 (5.78)	-28.84 (6.14)		
Week 52 Adjusted Mean Change (SE)	-19.14 (5.82)	-29.56 (6.20)	10.42 [-6.63; 27.46]	0.227
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.13 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.296</b>				
<b>Non-carrier, N</b>	<b>46</b>	<b>36</b>		
N'	42	32		
Baseline Mean (SD)	50.47 (22.57)	36.36 (25.10)		
Week 52 Mean (SD)	28.95 (23.57)	20.80 (19.56)		
Week 4 Adjusted Mean Change (SE)	-10.95 (3.34)	-20.37 (3.95)		
Week 12 Adjusted Mean Change (SE)	-15.98 (3.45)	-17.67 (3.96)		
Week 16 Adjusted Mean Change (SE)	-14.18 (3.71)	-19.35 (4.37)		
Week 24 Adjusted Mean Change (SE)	-18.70 (3.22)	-28.32 (3.93)		
Week 32 Adjusted Mean Change (SE)	-18.67 (3.69)	-19.85 (4.22)		
Week 40 Adjusted Mean Change (SE)	-20.14 (3.42)	-21.77 (3.97)		
Week 52 Adjusted Mean Change (SE)	-18.69 (3.48)	-20.63 (4.13)	1.94 [-9.02; 12.90]	0.725
<b>Carrier, N</b>	<b>12</b>	<b>7</b>		
N'	12	6		
Baseline Mean (SD)	48.33 (28.23)	47.14 (23.60)		
Week 52 Mean (SD)	23.33 (22.91)	22.50 (20.62)		
Week 4 Adjusted Mean Change (SE)	-10.29 (5.95)	-1.38 (8.49)		
Week 12 Adjusted Mean Change (SE)	-23.94 (6.27)	-15.13 (9.44)		
Week 16 Adjusted Mean Change (SE)	-21.00 (6.53)	-15.43 (10.04)		
Week 24 Adjusted Mean Change (SE)	-24.38 (6.00)	-7.56 (8.76)		
Week 32 Adjusted Mean Change (SE)	-16.64 (6.49)	-19.41 (9.99)		
Week 40 Adjusted Mean Change (SE)	-20.92 (6.30)	-21.28 (9.28)		
Week 52 Adjusted Mean Change (SE)	-23.15 (6.61)	-17.46 (9.91)	-5.69 [-29.43; 18.04]	0.635
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				



### 56.14 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.428</b>				
<b>Non-carrier, N</b>	<b>49</b>	<b>37</b>		
N'	44	32		
Baseline Mean (SD)	49.33 (24.72)	39.12 (25.03)		
Week 52 Mean (SD)	27.11 (23.59)	18.18 (18.42)		
Week 4 Adjusted Mean Change (SE)	-14.69 (3.25)	-14.10 (3.89)		
Week 12 Adjusted Mean Change (SE)	-20.34 (3.50)	-15.02 (4.09)		
Week 16 Adjusted Mean Change (SE)	-16.27 (3.73)	-14.28 (4.44)		
Week 24 Adjusted Mean Change (SE)	-22.78 (3.24)	-22.01 (4.07)		
Week 32 Adjusted Mean Change (SE)	-18.17 (3.31)	-19.84 (3.95)		
Week 40 Adjusted Mean Change (SE)	-22.48 (3.37)	-20.24 (4.00)		
Week 52 Adjusted Mean Change (SE)	-19.98 (3.51)	-21.61 (4.32)	1.63 [-9.58; 12.85]	0.773
<b>Carrier, N</b>	<b>10</b>	<b>6</b>		
N'	10	6		
Baseline Mean (SD)	55.00 (18.41)	30.00 (15.49)		
Week 52 Mean (SD)	28.89 (25.22)	25.00 (23.45)		
Week 4 Adjusted Mean Change (SE)	-0.20 (6.62)	-16.16 (8.56)		
Week 12 Adjusted Mean Change (SE)	-9.37 (7.11)	-19.21 (9.36)		
Week 16 Adjusted Mean Change (SE)	-15.90 (7.51)	-15.31 (10.37)		
Week 24 Adjusted Mean Change (SE)	-10.99 (6.70)	-28.65 (8.38)		
Week 32 Adjusted Mean Change (SE)	-22.99 (7.01)	-22.68 (8.70)		
Week 40 Adjusted Mean Change (SE)	-12.61 (6.84)	-24.05 (8.74)		
Week 52 Adjusted Mean Change (SE)	-21.22 (7.12)	-16.27 (9.07)	-4.95 [-28.18; 18.28]	0.672
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.15 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.736</b>				
<b>Low score, N</b>	<b>17</b>	<b>15</b>		
N'	15	14		
Baseline Mean (SD)	44.38 (25.29)	37.14 (25.55)		
Week 52 Mean (SD)	24.17 (21.09)	25.00 (23.30)		
Week 4 Adjusted Mean Change (SE)	-12.80 (5.70)	-16.74 (6.10)		
Week 12 Adjusted Mean Change (SE)	-19.95 (5.99)	-15.55 (6.10)		
Week 16 Adjusted Mean Change (SE)	-18.64 (6.64)	-17.06 (6.56)		
Week 24 Adjusted Mean Change (SE)	-22.53 (5.75)	-26.06 (6.32)		
Week 32 Adjusted Mean Change (SE)	-19.05 (6.39)	-20.63 (6.50)		
Week 40 Adjusted Mean Change (SE)	-27.27 (5.94)	-15.76 (6.07)		
Week 52 Adjusted Mean Change (SE)	-19.74 (6.01)	-18.52 (6.65)	-1.22 [-19.08; 16.65]	0.893
<b>High score, N</b>	<b>43</b>	<b>30</b>		
N'	40	26		
Baseline Mean (SD)	52.50 (22.62)	38.93 (24.24)		
Week 52 Mean (SD)	28.33 (24.32)	19.09 (17.70)		
Week 4 Adjusted Mean Change (SE)	-10.63 (3.54)	-15.39 (4.40)		
Week 12 Adjusted Mean Change (SE)	-17.72 (3.62)	-15.84 (4.48)		
Week 16 Adjusted Mean Change (SE)	-15.31 (3.90)	-16.35 (5.02)		
Week 24 Adjusted Mean Change (SE)	-19.87 (3.43)	-22.18 (4.43)		
Week 32 Adjusted Mean Change (SE)	-18.21 (3.73)	-17.95 (4.67)		
Week 40 Adjusted Mean Change (SE)	-18.77 (3.48)	-23.07 (4.36)		
Week 52 Adjusted Mean Change (SE)	-20.55 (3.61)	-20.19 (4.55)	-0.36 [-12.14; 11.41]	0.951
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.16 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.620</b>				
<b>Non-carrier, N</b>	<b>40</b>	<b>24</b>		
N'	35	21		
Baseline Mean (SD)	46.67 (22.80)	40.00 (22.96)		
Week 52 Mean (SD)	27.58 (23.72)	22.00 (18.97)		
Week 4 Adjusted Mean Change (SE)	-10.39 (3.68)	-10.98 (4.84)		
Week 12 Adjusted Mean Change (SE)	-17.22 (3.78)	-18.44 (5.01)		
Week 16 Adjusted Mean Change (SE)	-16.37 (4.11)	-15.85 (5.38)		
Week 24 Adjusted Mean Change (SE)	-18.94 (3.65)	-24.82 (4.91)		
Week 32 Adjusted Mean Change (SE)	-19.28 (3.95)	-22.24 (5.22)		
Week 40 Adjusted Mean Change (SE)	-19.21 (3.71)	-20.91 (4.86)		
Week 52 Adjusted Mean Change (SE)	-17.85 (3.76)	-21.74 (5.14)	3.89 [-8.83; 16.61]	0.544
<b>Carrier, N</b>	<b>20</b>	<b>21</b>		
N'	20	19		
Baseline Mean (SD)	56.50 (23.90)	36.32 (26.50)		
Week 52 Mean (SD)	26.67 (23.50)	19.33 (19.81)		
Week 4 Adjusted Mean Change (SE)	-12.37 (5.06)	-21.27 (5.18)		
Week 12 Adjusted Mean Change (SE)	-20.34 (5.24)	-13.22 (5.10)		
Week 16 Adjusted Mean Change (SE)	-15.70 (5.62)	-18.03 (5.83)		
Week 24 Adjusted Mean Change (SE)	-23.62 (4.94)	-21.70 (5.37)		
Week 32 Adjusted Mean Change (SE)	-16.82 (5.48)	-15.28 (5.49)		
Week 40 Adjusted Mean Change (SE)	-23.81 (5.05)	-20.57 (5.12)		
Week 52 Adjusted Mean Change (SE)	-25.57 (5.32)	-16.94 (5.37)	-8.63 [-23.97; 6.72]	0.267
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.17 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.733</b>				
<b>Non-carrier, N</b>	<b>23</b>	<b>20</b>		
N'	21	19		
Baseline Mean (SD)	49.52 (21.79)	36.32 (23.62)		
Week 52 Mean (SD)	25.88 (22.38)	13.64 (21.11)		
Week 4 Adjusted Mean Change (SE)	-14.04 (4.77)	-13.48 (5.17)		
Week 12 Adjusted Mean Change (SE)	-16.75 (4.98)	-18.01 (5.26)		
Week 16 Adjusted Mean Change (SE)	-11.75 (5.30)	-14.49 (5.71)		
Week 24 Adjusted Mean Change (SE)	-18.79 (4.91)	-25.38 (5.48)		
Week 32 Adjusted Mean Change (SE)	-15.71 (5.19)	-22.04 (5.56)		
Week 40 Adjusted Mean Change (SE)	-19.96 (4.96)	-19.31 (5.25)		
Week 52 Adjusted Mean Change (SE)	-21.60 (5.01)	-22.45 (5.66)	0.85 [-14.32; 16.03]	0.911
<b>Carrier, N</b>	<b>37</b>	<b>25</b>		
N'	34	21		
Baseline Mean (SD)	50.57 (24.73)	40.00 (25.41)		
Week 52 Mean (SD)	28.06 (24.28)	24.74 (17.12)		
Week 4 Adjusted Mean Change (SE)	-9.34 (3.84)	-17.83 (4.90)		
Week 12 Adjusted Mean Change (SE)	-19.27 (3.87)	-13.90 (4.87)		
Week 16 Adjusted Mean Change (SE)	-18.85 (4.20)	-18.61 (5.41)		
Week 24 Adjusted Mean Change (SE)	-21.54 (3.63)	-21.96 (4.80)		
Week 32 Adjusted Mean Change (SE)	-19.92 (3.98)	-16.18 (5.04)		
Week 40 Adjusted Mean Change (SE)	-21.21 (3.82)	-21.82 (4.88)		
Week 52 Adjusted Mean Change (SE)	-19.50 (3.81)	-17.72 (4.86)	-1.78 [-14.19; 10.63]	0.776
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.18 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.819</b>				
<b>Non-carrier, N</b>	<b>31</b>	<b>29</b>		
N'	29	26		
Baseline Mean (SD)	51.03 (22.57)	39.26 (24.17)		
Week 52 Mean (SD)	26.92 (23.63)	23.50 (21.34)		
Week 4 Adjusted Mean Change (SE)	-14.13 (4.10)	-16.72 (4.35)		
Week 12 Adjusted Mean Change (SE)	-18.18 (4.26)	-13.79 (4.45)		
Week 16 Adjusted Mean Change (SE)	-14.32 (4.65)	-16.08 (4.91)		
Week 24 Adjusted Mean Change (SE)	-18.13 (4.09)	-22.15 (4.42)		
Week 32 Adjusted Mean Change (SE)	-21.59 (4.54)	-19.47 (4.62)		
Week 40 Adjusted Mean Change (SE)	-19.51 (4.20)	-20.13 (4.37)		
Week 52 Adjusted Mean Change (SE)	-20.71 (4.27)	-18.72 (4.51)	-1.99 [-14.45; 10.46]	0.751
<b>Carrier, N</b>	<b>29</b>	<b>16</b>		
N'	26	14		
Baseline Mean (SD)	49.26 (24.80)	36.67 (25.54)		
Week 52 Mean (SD)	27.73 (23.69)	15.00 (12.69)		
Week 4 Adjusted Mean Change (SE)	-7.74 (4.35)	-13.97 (6.07)		
Week 12 Adjusted Mean Change (SE)	-18.28 (4.46)	-19.23 (6.11)		
Week 16 Adjusted Mean Change (SE)	-17.92 (4.76)	-17.58 (6.73)		
Week 24 Adjusted Mean Change (SE)	-22.97 (4.16)	-26.36 (6.15)		
Week 32 Adjusted Mean Change (SE)	-15.62 (4.54)	-17.11 (6.60)		
Week 40 Adjusted Mean Change (SE)	-22.07 (4.34)	-21.72 (6.11)		
Week 52 Adjusted Mean Change (SE)	-19.64 (4.42)	-21.20 (6.55)	1.57 [-14.28; 17.41]	0.845
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 56.19 WPAI-GH Percent Impairment while Working due to Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.075</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>33</b>		
N'	42	29		
Baseline Mean (SD)	50.70 (23.03)	37.00 (23.36)		
Week 52 Mean (SD)	26.94 (24.94)	24.50 (20.64)		
Week 4 Adjusted Mean Change (SE)	-11.96 (3.46)	-15.52 (4.19)		
Week 12 Adjusted Mean Change (SE)	-18.76 (3.53)	-12.60 (4.24)		
Week 16 Adjusted Mean Change (SE)	-18.16 (3.82)	-13.64 (4.57)		
Week 24 Adjusted Mean Change (SE)	-23.71 (3.26)	-19.77 (4.22)		
Week 32 Adjusted Mean Change (SE)	-20.91 (3.72)	-19.40 (4.49)		
Week 40 Adjusted Mean Change (SE)	-22.87 (3.42)	-16.77 (4.14)		
Week 52 Adjusted Mean Change (SE)	-21.09 (3.48)	-14.41 (4.42)	-6.68 [-18.06; 4.70]	0.246
<b>Carrier, N</b>	<b>14</b>	<b>12</b>		
N'	13	11		
Baseline Mean (SD)	48.46 (25.77)	41.67 (27.58)		
Week 52 Mean (SD)	24.55 (14.40)	13.00 (13.37)		
Week 4 Adjusted Mean Change (SE)	-9.07 (6.21)	-16.47 (6.73)		
Week 12 Adjusted Mean Change (SE)	-17.01 (6.19)	-23.35 (6.55)		
Week 16 Adjusted Mean Change (SE)	-10.61 (6.51)	-24.06 (7.55)		
Week 24 Adjusted Mean Change (SE)	-10.11 (6.08)	-32.32 (6.37)		
Week 32 Adjusted Mean Change (SE)	-11.00 (6.46)	-17.27 (6.96)		
Week 40 Adjusted Mean Change (SE)	-14.65 (6.05)	-30.10 (6.47)		
Week 52 Adjusted Mean Change (SE)	-17.80 (6.21)	-30.14 (6.54)	12.34 [-5.73; 30.42]	0.178
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.0 WPAI-GH Percent Overall Work Impairment due to Health - Return Rates (FAS)

	Treatment Groups		
	SEC (N=75)	ADA (N=63)	Total (N=138)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	70 (93.3)	60 (95.2)	130 (94.2)
Week 4 Returns	67 (89.3)	49 (77.8)	116 (84.1)
Week 12 Returns	63 (84.0)	46 (73.0)	109 (79.0)
Week 16 Returns	67 (89.3)	46 (73.0)	113 (81.9)
Week 24 Returns	64 (85.3)	38 (60.3)	102 (73.9)
Week 32 Returns	61 (81.3)	41 (65.1)	102 (73.9)
Week 40 Returns	60 (80.0)	39 (61.9)	99 (71.7)
Week 52 Returns	61 (81.3)	35 (55.6)	96 (69.6)
Note: The table is based on all patients who were employed at baseline.			

### 57.1 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
N'	69	54		
Baseline Mean (SD)	53.78 (26.43)	40.18 (27.24)		
Week 52 Mean (SD)	37.45 (29.48)	30.70 (26.09)		
Week 4 Adjusted Mean Change (SE)	-11.05 (2.88)	-12.74 (3.33)		
Week 12 Adjusted Mean Change (SE)	-18.15 (3.05)	-16.33 (3.48)		
Week 16 Adjusted Mean Change (SE)	-14.09 (3.40)	-15.07 (4.04)		
Week 24 Adjusted Mean Change (SE)	-18.31 (3.09)	-19.50 (3.79)		
Week 32 Adjusted Mean Change (SE)	-13.76 (3.44)	-17.94 (4.07)		
Week 40 Adjusted Mean Change (SE)	-17.53 (3.10)	-12.76 (3.79)		
Week 52 Adjusted Mean Change (SE)	-14.69 (3.55)	-12.50 (4.48)	-2.18 [-13.70; 9.34]	0.708
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				



## 57.2 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Age (FAS)

Table is not displayed as the parameter does not fulfill the condition for the subgroup analysis.
---

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.
--

### 57.3 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.970</b>				
<b>Male, N</b>	<b>48</b>	<b>40</b>		
N'	44	34		
Baseline Mean (SD)	49.30 (25.44)	37.77 (27.74)		
Week 52 Mean (SD)	31.25 (27.56)	26.16 (25.93)		
Week 4 Adjusted Mean Change (SE)	-14.06 (3.64)	-13.93 (4.26)		
Week 12 Adjusted Mean Change (SE)	-18.98 (3.84)	-18.81 (4.49)		
Week 16 Adjusted Mean Change (SE)	-17.79 (4.18)	-17.99 (4.89)		
Week 24 Adjusted Mean Change (SE)	-19.38 (3.81)	-25.79 (4.76)		
Week 32 Adjusted Mean Change (SE)	-19.46 (4.19)	-21.86 (5.18)		
Week 40 Adjusted Mean Change (SE)	-19.20 (3.97)	-15.86 (4.88)		
Week 52 Adjusted Mean Change (SE)	-19.41 (4.34)	-17.55 (5.53)	-1.86 [-15.86; 12.13]	0.792
<b>Female, N</b>	<b>27</b>	<b>23</b>		
N'	25	20		
Baseline Mean (SD)	61.85 (26.76)	44.33 (26.45)		
Week 52 Mean (SD)	48.43 (30.19)	40.59 (24.73)		
Week 4 Adjusted Mean Change (SE)	-5.34 (4.93)	-11.70 (5.38)		
Week 12 Adjusted Mean Change (SE)	-16.20 (5.20)	-12.39 (5.57)		
Week 16 Adjusted Mean Change (SE)	-6.66 (5.77)	-12.41 (6.83)		
Week 24 Adjusted Mean Change (SE)	-15.98 (5.26)	-9.54 (6.13)		
Week 32 Adjusted Mean Change (SE)	-2.64 (5.79)	-12.95 (6.32)		
Week 40 Adjusted Mean Change (SE)	-14.06 (5.20)	-8.08 (6.11)		
Week 52 Adjusted Mean Change (SE)	-5.39 (5.96)	-4.58 (7.56)	-0.81 [-19.75; 18.13]	0.933
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.4 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.829</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>15</b>	<b>17</b>		
N'	14	16		
Baseline Mean (SD)	39.97 (24.71)	29.62 (29.66)		
Week 52 Mean (SD)	17.32 (20.97)	30.96 (32.60)		
Week 4 Adjusted Mean Change (SE)	-15.25 (6.17)	-16.94 (6.04)		
Week 12 Adjusted Mean Change (SE)	-15.01 (6.95)	-20.77 (6.53)		
Week 16 Adjusted Mean Change (SE)	-17.22 (7.54)	-17.24 (7.35)		
Week 24 Adjusted Mean Change (SE)	-17.95 (7.09)	-24.42 (6.75)		
Week 32 Adjusted Mean Change (SE)	-16.23 (7.54)	-28.25 (7.56)		
Week 40 Adjusted Mean Change (SE)	-18.59 (7.26)	-15.45 (7.14)		
Week 52 Adjusted Mean Change (SE)	-28.42 (8.18)	-13.04 (7.93)	-15.39 [-37.82; 7.04]	0.177
<b>PASDAS ≥ 5.4, N</b>	<b>60</b>	<b>46</b>		
N'	55	38		
Baseline Mean (SD)	57.55 (25.82)	44.35 (25.38)		
Week 52 Mean (SD)	41.39 (29.44)	30.57 (23.33)		
Week 4 Adjusted Mean Change (SE)	-9.78 (3.30)	-11.11 (3.97)		
Week 12 Adjusted Mean Change (SE)	-18.76 (3.45)	-14.59 (4.12)		
Week 16 Adjusted Mean Change (SE)	-13.16 (3.88)	-14.38 (4.79)		
Week 24 Adjusted Mean Change (SE)	-18.18 (3.50)	-17.37 (4.62)		
Week 32 Adjusted Mean Change (SE)	-12.81 (3.91)	-13.89 (4.81)		
Week 40 Adjusted Mean Change (SE)	-17.20 (3.51)	-11.70 (4.46)		
Week 52 Adjusted Mean Change (SE)	-11.37 (3.91)	-13.06 (5.28)	1.69 [-11.44; 14.83]	0.799
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.5 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.661</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>26</b>	<b>31</b>		
N'	25	29		
Baseline Mean (SD)	54.76 (23.88)	42.33 (29.46)		
Week 52 Mean (SD)	31.34 (27.14)	30.56 (26.68)		
Week 4 Adjusted Mean Change (SE)	-16.36 (4.79)	-13.51 (4.43)		
Week 12 Adjusted Mean Change (SE)	-16.75 (5.06)	-18.54 (4.58)		
Week 16 Adjusted Mean Change (SE)	-15.92 (5.68)	-12.23 (5.49)		
Week 24 Adjusted Mean Change (SE)	-16.39 (5.30)	-19.51 (5.16)		
Week 32 Adjusted Mean Change (SE)	-16.44 (5.61)	-20.85 (5.46)		
Week 40 Adjusted Mean Change (SE)	-20.64 (5.13)	-8.89 (5.10)		
Week 52 Adjusted Mean Change (SE)	-20.00 (6.22)	-12.89 (6.12)	-7.11 [-24.53; 10.31]	0.420
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>49</b>	<b>32</b>		
N'	44	25		
Baseline Mean (SD)	53.24 (27.98)	37.89 (24.96)		
Week 52 Mean (SD)	40.00 (30.34)	30.84 (26.27)		
Week 4 Adjusted Mean Change (SE)	-8.11 (3.59)	-11.76 (4.93)		
Week 12 Adjusted Mean Change (SE)	-18.86 (3.84)	-12.64 (5.38)		
Week 16 Adjusted Mean Change (SE)	-13.05 (4.26)	-18.06 (5.84)		
Week 24 Adjusted Mean Change (SE)	-19.08 (3.82)	-19.71 (5.58)		
Week 32 Adjusted Mean Change (SE)	-12.14 (4.31)	-14.20 (6.04)		
Week 40 Adjusted Mean Change (SE)	-15.63 (3.85)	-17.18 (5.50)		
Week 52 Adjusted Mean Change (SE)	-11.98 (4.30)	-11.67 (6.53)	-0.31 [-15.96; 15.34]	0.969
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.6 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.743</b>				
<b>≤ Median, N</b>	<b>52</b>	<b>31</b>		
N'	48	29		
Baseline Mean (SD)	53.34 (26.73)	44.00 (28.83)		
Week 52 Mean (SD)	36.34 (29.67)	30.38 (24.25)		
Week 4 Adjusted Mean Change (SE)	-11.51 (3.48)	-11.82 (4.51)		
Week 12 Adjusted Mean Change (SE)	-17.26 (3.58)	-13.98 (4.62)		
Week 16 Adjusted Mean Change (SE)	-14.47 (4.09)	-14.22 (5.29)		
Week 24 Adjusted Mean Change (SE)	-20.60 (3.64)	-22.28 (4.92)		
Week 32 Adjusted Mean Change (SE)	-14.43 (4.12)	-14.97 (5.45)		
Week 40 Adjusted Mean Change (SE)	-19.20 (3.72)	-15.19 (5.01)		
Week 52 Adjusted Mean Change (SE)	-15.84 (4.20)	-15.06 (5.87)	-0.78 [-15.19; 13.63]	0.915
<b>&gt; Median, N</b>	<b>23</b>	<b>32</b>		
N'	21	25		
Baseline Mean (SD)	54.81 (26.33)	36.09 (25.27)		
Week 52 Mean (SD)	40.30 (29.68)	31.12 (29.23)		
Week 4 Adjusted Mean Change (SE)	-9.88 (5.19)	-13.76 (4.95)		
Week 12 Adjusted Mean Change (SE)	-20.89 (5.69)	-19.11 (5.23)		
Week 16 Adjusted Mean Change (SE)	-13.02 (6.14)	-16.38 (6.15)		
Week 24 Adjusted Mean Change (SE)	-12.35 (5.69)	-15.31 (5.78)		
Week 32 Adjusted Mean Change (SE)	-11.90 (6.19)	-21.54 (6.14)		
Week 40 Adjusted Mean Change (SE)	-13.46 (5.55)	-9.51 (5.66)		
Week 52 Adjusted Mean Change (SE)	-11.69 (6.64)	-8.98 (6.95)	-2.71 [-21.94; 16.52]	0.780
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.7 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.599</b>				
<b>Enthesitis: No, N</b>	<b>36</b>	<b>23</b>		
N'	33	20		
Baseline Mean (SD)	53.43 (25.36)	34.18 (30.47)		
Week 52 Mean (SD)	36.29 (29.41)	37.71 (30.45)		
Week 4 Adjusted Mean Change (SE)	-12.42 (4.12)	-13.09 (5.68)		
Week 12 Adjusted Mean Change (SE)	-17.72 (4.36)	-13.46 (5.77)		
Week 16 Adjusted Mean Change (SE)	-17.32 (4.97)	-12.94 (6.52)		
Week 24 Adjusted Mean Change (SE)	-20.76 (4.50)	-18.26 (5.95)		
Week 32 Adjusted Mean Change (SE)	-11.58 (5.06)	-17.98 (6.46)		
Week 40 Adjusted Mean Change (SE)	-17.42 (4.61)	-12.50 (6.14)		
Week 52 Adjusted Mean Change (SE)	-15.58 (5.12)	-7.61 (7.28)	-7.96 [-25.91; 9.99]	0.381
<b>Enthesitis: Yes, N</b>	<b>39</b>	<b>40</b>		
N'	36	34		
Baseline Mean (SD)	54.11 (27.75)	43.65 (24.94)		
Week 52 Mean (SD)	38.43 (29.96)	26.55 (22.89)		
Week 4 Adjusted Mean Change (SE)	-9.71 (4.06)	-12.60 (4.09)		
Week 12 Adjusted Mean Change (SE)	-18.63 (4.28)	-17.96 (4.35)		
Week 16 Adjusted Mean Change (SE)	-11.24 (4.66)	-16.20 (5.06)		
Week 24 Adjusted Mean Change (SE)	-16.13 (4.25)	-20.02 (4.93)		
Week 32 Adjusted Mean Change (SE)	-15.66 (4.71)	-17.73 (5.30)		
Week 40 Adjusted Mean Change (SE)	-17.45 (4.22)	-12.85 (4.80)		
Week 52 Adjusted Mean Change (SE)	-13.86 (4.86)	-15.37 (5.65)	1.50 [-13.34; 16.34]	0.841
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.8 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.397</b>				
<b>Non-carrier, N</b>	<b>38</b>	<b>27</b>		
N'	34	24		
Baseline Mean (SD)	56.74 (22.78)	41.53 (26.81)		
Week 52 Mean (SD)	36.29 (27.07)	26.38 (21.44)		
Week 4 Adjusted Mean Change (SE)	-14.45 (4.11)	-18.05 (5.11)		
Week 12 Adjusted Mean Change (SE)	-19.10 (4.42)	-18.10 (5.39)		
Week 16 Adjusted Mean Change (SE)	-14.99 (5.00)	-16.58 (6.14)		
Week 24 Adjusted Mean Change (SE)	-21.02 (4.39)	-22.19 (5.85)		
Week 32 Adjusted Mean Change (SE)	-18.02 (4.98)	-16.14 (6.11)		
Week 40 Adjusted Mean Change (SE)	-20.70 (4.40)	-8.89 (5.67)		
Week 52 Adjusted Mean Change (SE)	-17.36 (4.76)	-15.86 (6.24)	-1.50 [-17.33; 14.33]	0.851
<b>Carrier, N</b>	<b>22</b>	<b>18</b>		
N'	21	16		
Baseline Mean (SD)	49.86 (28.36)	41.49 (28.84)		
Week 52 Mean (SD)	37.34 (29.29)	26.10 (25.33)		
Week 4 Adjusted Mean Change (SE)	-5.37 (5.24)	-13.06 (5.79)		
Week 12 Adjusted Mean Change (SE)	-14.60 (5.65)	-17.36 (6.13)		
Week 16 Adjusted Mean Change (SE)	-5.38 (6.25)	-12.78 (7.10)		
Week 24 Adjusted Mean Change (SE)	-15.70 (5.50)	-21.18 (6.14)		
Week 32 Adjusted Mean Change (SE)	-10.52 (6.24)	-20.61 (6.95)		
Week 40 Adjusted Mean Change (SE)	-17.77 (5.81)	-18.03 (6.20)		
Week 52 Adjusted Mean Change (SE)	-11.45 (5.95)	-18.10 (6.74)	6.64 [-11.35; 24.64]	0.464
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.9 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.451</b>				
<b>Non-carrier, N</b>	<b>36</b>	<b>17</b>		
N'	31	15		
Baseline Mean (SD)	52.90 (24.34)	45.71 (28.04)		
Week 52 Mean (SD)	38.13 (27.58)	28.21 (24.57)		
Week 4 Adjusted Mean Change (SE)	-10.57 (4.24)	-12.48 (6.24)		
Week 12 Adjusted Mean Change (SE)	-16.27 (4.60)	-24.33 (6.79)		
Week 16 Adjusted Mean Change (SE)	-15.72 (5.19)	-14.99 (7.58)		
Week 24 Adjusted Mean Change (SE)	-20.34 (4.47)	-27.10 (6.71)		
Week 32 Adjusted Mean Change (SE)	-18.95 (5.20)	-25.68 (7.70)		
Week 40 Adjusted Mean Change (SE)	-18.26 (4.80)	-19.22 (7.11)		
Week 52 Adjusted Mean Change (SE)	-11.60 (5.05)	-22.01 (8.14)	10.42 [-8.68; 29.51]	0.281
<b>Carrier, N</b>	<b>22</b>	<b>19</b>		
N'	22	17		
Baseline Mean (SD)	56.28 (25.11)	37.15 (26.12)		
Week 52 Mean (SD)	36.18 (29.29)	25.59 (23.47)		
Week 4 Adjusted Mean Change (SE)	-14.61 (5.09)	-17.37 (5.98)		
Week 12 Adjusted Mean Change (SE)	-20.92 (5.55)	-15.95 (6.20)		
Week 16 Adjusted Mean Change (SE)	-8.72 (6.19)	-12.88 (7.41)		
Week 24 Adjusted Mean Change (SE)	-19.07 (5.37)	-23.15 (6.51)		
Week 32 Adjusted Mean Change (SE)	-13.11 (6.26)	-12.25 (7.33)		
Week 40 Adjusted Mean Change (SE)	-23.69 (5.63)	-13.42 (6.65)		
Week 52 Adjusted Mean Change (SE)	-21.50 (6.26)	-11.88 (7.47)	-9.62 [-29.45; 10.20]	0.336
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				



### 57.10 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.482</b>				
<b>Non-carrier, N</b>	<b>23</b>	<b>20</b>		
N'	21	19		
Baseline Mean (SD)	54.07 (22.69)	39.54 (25.55)		
Week 52 Mean (SD)	35.11 (28.39)	18.18 (23.16)		
Week 4 Adjusted Mean Change (SE)	-14.48 (5.21)	-13.92 (5.64)		
Week 12 Adjusted Mean Change (SE)	-15.53 (5.68)	-22.48 (5.97)		
Week 16 Adjusted Mean Change (SE)	-9.61 (6.36)	-17.11 (6.83)		
Week 24 Adjusted Mean Change (SE)	-16.44 (5.75)	-25.05 (6.39)		
Week 32 Adjusted Mean Change (SE)	-16.26 (6.36)	-25.60 (6.80)		
Week 40 Adjusted Mean Change (SE)	-17.14 (5.76)	-14.92 (6.09)		
Week 52 Adjusted Mean Change (SE)	-16.74 (6.08)	-23.13 (7.05)	6.39 [-12.31; 25.08]	0.499
<b>Carrier, N</b>	<b>35</b>	<b>25</b>		
N'	33	21		
Baseline Mean (SD)	56.14 (25.63)	43.15 (29.04)		
Week 52 Mean (SD)	36.69 (27.67)	30.91 (22.27)		
Week 4 Adjusted Mean Change (SE)	-8.22 (4.27)	-17.62 (5.35)		
Week 12 Adjusted Mean Change (SE)	-17.71 (4.45)	-14.10 (5.49)		
Week 16 Adjusted Mean Change (SE)	-11.66 (5.10)	-13.60 (6.45)		
Week 24 Adjusted Mean Change (SE)	-20.25 (4.36)	-19.59 (5.63)		
Week 32 Adjusted Mean Change (SE)	-13.70 (4.91)	-12.80 (6.11)		
Week 40 Adjusted Mean Change (SE)	-21.63 (4.46)	-12.39 (5.69)		
Week 52 Adjusted Mean Change (SE)	-15.25 (4.64)	-12.68 (5.84)	-2.57 [-17.57; 12.43]	0.734
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.11 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.842</b>				
<b>Non-carrier, N</b>	<b>31</b>	<b>29</b>		
N'	29	26		
Baseline Mean (SD)	55.21 (24.46)	41.96 (26.85)		
Week 52 Mean (SD)	38.62 (26.76)	31.75 (25.16)		
Week 4 Adjusted Mean Change (SE)	-14.41 (4.46)	-17.64 (4.73)		
Week 12 Adjusted Mean Change (SE)	-15.51 (4.78)	-15.47 (5.02)		
Week 16 Adjusted Mean Change (SE)	-7.45 (5.47)	-12.93 (5.75)		
Week 24 Adjusted Mean Change (SE)	-15.52 (4.80)	-21.58 (5.17)		
Week 32 Adjusted Mean Change (SE)	-17.69 (5.59)	-18.41 (5.64)		
Week 40 Adjusted Mean Change (SE)	-20.34 (4.89)	-11.51 (5.11)		
Week 52 Adjusted Mean Change (SE)	-12.70 (5.15)	-15.12 (5.49)	2.41 [-12.70; 17.53]	0.751
<b>Carrier, N</b>	<b>29</b>	<b>16</b>		
N'	26	14		
Baseline Mean (SD)	52.77 (26.18)	40.70 (28.89)		
Week 52 Mean (SD)	34.39 (29.05)	15.23 (13.21)		
Week 4 Adjusted Mean Change (SE)	-6.79 (4.72)	-12.11 (6.58)		
Week 12 Adjusted Mean Change (SE)	-19.05 (5.03)	-22.13 (6.76)		
Week 16 Adjusted Mean Change (SE)	-15.15 (5.59)	-18.60 (7.88)		
Week 24 Adjusted Mean Change (SE)	-22.17 (4.89)	-22.50 (7.19)		
Week 32 Adjusted Mean Change (SE)	-13.09 (5.51)	-17.83 (8.11)		
Week 40 Adjusted Mean Change (SE)	-17.87 (5.00)	-18.04 (7.16)		
Week 52 Adjusted Mean Change (SE)	-17.33 (5.31)	-21.21 (8.08)	3.88 [-15.50; 23.26]	0.692
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.12 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.110</b>				
<b>Non-carrier, N</b>	<b>42</b>	<b>31</b>		
N'	39	28		
Baseline Mean (SD)	54.33 (24.60)	39.19 (25.49)		
Week 52 Mean (SD)	35.76 (26.76)	32.03 (24.32)		
Week 4 Adjusted Mean Change (SE)	-10.90 (3.90)	-15.51 (4.67)		
Week 12 Adjusted Mean Change (SE)	-17.02 (4.18)	-14.68 (4.91)		
Week 16 Adjusted Mean Change (SE)	-11.44 (4.67)	-11.30 (5.51)		
Week 24 Adjusted Mean Change (SE)	-22.57 (4.01)	-18.28 (5.01)		
Week 32 Adjusted Mean Change (SE)	-16.67 (4.74)	-20.54 (5.62)		
Week 40 Adjusted Mean Change (SE)	-21.75 (4.08)	-7.84 (4.94)		
Week 52 Adjusted Mean Change (SE)	-16.28 (4.31)	-10.22 (5.42)	-6.06 [-20.10; 7.99]	0.393
<b>Carrier, N</b>	<b>16</b>	<b>13</b>		
N'	14	12		
Baseline Mean (SD)	50.79 (26.19)	46.70 (31.29)		
Week 52 Mean (SD)	38.22 (27.81)	14.66 (15.52)		
Week 4 Adjusted Mean Change (SE)	-9.96 (6.53)	-16.87 (6.98)		
Week 12 Adjusted Mean Change (SE)	-16.97 (6.74)	-24.66 (7.19)		
Week 16 Adjusted Mean Change (SE)	-9.65 (7.41)	-24.41 (8.40)		
Week 24 Adjusted Mean Change (SE)	-8.10 (6.85)	-29.37 (7.38)		
Week 32 Adjusted Mean Change (SE)	-10.62 (7.56)	-13.90 (8.11)		
Week 40 Adjusted Mean Change (SE)	-11.80 (6.73)	-25.80 (7.22)		
Week 52 Adjusted Mean Change (SE)	-10.45 (7.06)	-30.44 (7.56)	19.99 [-0.75; 40.73]	0.059
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.13 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.316</b>				
<b>Non-carrier, N</b>	<b>46</b>	<b>36</b>		
N'	42	32		
Baseline Mean (SD)	54.81 (24.34)	39.56 (27.92)		
Week 52 Mean (SD)	36.12 (27.17)	25.12 (23.62)		
Week 4 Adjusted Mean Change (SE)	-11.72 (3.60)	-21.54 (4.25)		
Week 12 Adjusted Mean Change (SE)	-16.71 (3.95)	-19.44 (4.51)		
Week 16 Adjusted Mean Change (SE)	-8.99 (4.46)	-18.06 (5.20)		
Week 24 Adjusted Mean Change (SE)	-16.84 (3.76)	-27.91 (4.56)		
Week 32 Adjusted Mean Change (SE)	-16.32 (4.51)	-18.83 (5.11)		
Week 40 Adjusted Mean Change (SE)	-18.07 (3.99)	-17.32 (4.66)		
Week 52 Adjusted Mean Change (SE)	-15.73 (4.19)	-18.83 (5.02)	3.09 [-10.18; 16.37]	0.644
<b>Carrier, N</b>	<b>12</b>	<b>7</b>		
N'	12	6		
Baseline Mean (SD)	50.64 (29.48)	51.15 (27.44)		
Week 52 Mean (SD)	43.13 (29.13)	37.31 (20.35)		
Week 4 Adjusted Mean Change (SE)	-6.40 (6.38)	3.80 (9.13)		
Week 12 Adjusted Mean Change (SE)	-17.14 (7.12)	-19.25 (10.73)		
Week 16 Adjusted Mean Change (SE)	-16.31 (7.84)	-9.56 (12.08)		
Week 24 Adjusted Mean Change (SE)	-23.03 (6.97)	-2.58 (10.21)		
Week 32 Adjusted Mean Change (SE)	-10.25 (7.80)	-22.64 (12.08)		
Week 40 Adjusted Mean Change (SE)	-19.56 (7.33)	-0.14 (10.61)		
Week 52 Adjusted Mean Change (SE)	-8.00 (8.06)	-10.29 (12.04)	2.29 [-26.59; 31.17]	0.875
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.14 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.912</b>				
<b>Non-carrier, N</b>	<b>49</b>	<b>37</b>		
N'	44	32		
Baseline Mean (SD)	53.10 (25.99)	42.97 (28.20)		
Week 52 Mean (SD)	36.53 (28.44)	22.89 (22.37)		
Week 4 Adjusted Mean Change (SE)	-14.35 (3.57)	-13.63 (4.27)		
Week 12 Adjusted Mean Change (SE)	-19.51 (3.94)	-18.08 (4.56)		
Week 16 Adjusted Mean Change (SE)	-11.99 (4.37)	-13.91 (5.18)		
Week 24 Adjusted Mean Change (SE)	-21.88 (3.80)	-20.80 (4.73)		
Week 32 Adjusted Mean Change (SE)	-16.36 (3.96)	-22.03 (4.75)		
Week 40 Adjusted Mean Change (SE)	-20.68 (3.99)	-13.96 (4.77)		
Week 52 Adjusted Mean Change (SE)	-14.83 (4.24)	-19.64 (5.33)	4.81 [-8.90; 18.52]	0.487
<b>Carrier, N</b>	<b>10</b>	<b>6</b>		
N'	10	6		
Baseline Mean (SD)	59.50 (22.23)	30.00 (15.49)		
Week 52 Mean (SD)	39.20 (26.41)	34.17 (28.00)		
Week 4 Adjusted Mean Change (SE)	0.27 (7.25)	-17.86 (9.41)		
Week 12 Adjusted Mean Change (SE)	-7.78 (7.86)	-16.34 (10.61)		
Week 16 Adjusted Mean Change (SE)	-12.61 (8.84)	-2.94 (12.15)		
Week 24 Adjusted Mean Change (SE)	-7.14 (7.85)	-22.20 (9.91)		
Week 32 Adjusted Mean Change (SE)	-21.22 (8.45)	-9.25 (10.37)		
Week 40 Adjusted Mean Change (SE)	-12.35 (8.01)	-10.22 (10.17)		
Week 52 Adjusted Mean Change (SE)	-15.31 (8.52)	-8.50 (10.79)	-6.81 [-34.57; 20.96]	0.626
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.15 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.992</b>				
<b>Low score, N</b>	<b>17</b>	<b>15</b>		
N'	15	14		
Baseline Mean (SD)	50.70 (26.62)	39.27 (26.05)		
Week 52 Mean (SD)	34.42 (27.09)	29.55 (28.13)		
Week 4 Adjusted Mean Change (SE)	-15.22 (6.20)	-18.42 (6.64)		
Week 12 Adjusted Mean Change (SE)	-21.13 (6.81)	-19.64 (6.86)		
Week 16 Adjusted Mean Change (SE)	-16.63 (7.81)	-15.49 (7.72)		
Week 24 Adjusted Mean Change (SE)	-22.37 (6.73)	-30.27 (7.30)		
Week 32 Adjusted Mean Change (SE)	-19.91 (7.86)	-24.18 (7.89)		
Week 40 Adjusted Mean Change (SE)	-21.06 (7.19)	-13.08 (7.33)		
Week 52 Adjusted Mean Change (SE)	-14.27 (7.33)	-19.83 (8.38)	5.56 [-16.69; 27.80]	0.621
<b>High score, N</b>	<b>43</b>	<b>30</b>		
N'	40	26		
Baseline Mean (SD)	55.37 (24.69)	42.63 (28.23)		
Week 52 Mean (SD)	37.44 (28.13)	25.04 (21.56)		
Week 4 Adjusted Mean Change (SE)	-9.33 (3.83)	-14.57 (4.76)		
Week 12 Adjusted Mean Change (SE)	-15.85 (4.05)	-16.73 (5.03)		
Week 16 Adjusted Mean Change (SE)	-9.56 (4.56)	-14.82 (5.87)		
Week 24 Adjusted Mean Change (SE)	-17.55 (3.98)	-17.97 (5.14)		
Week 32 Adjusted Mean Change (SE)	-13.42 (4.47)	-15.44 (5.65)		
Week 40 Adjusted Mean Change (SE)	-18.54 (4.06)	-13.68 (5.17)		
Week 52 Adjusted Mean Change (SE)	-15.12 (4.36)	-15.86 (5.55)	0.74 [-13.54; 15.01]	0.918
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.16 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.591</b>				
<b>Non-carrier, N</b>	<b>40</b>	<b>24</b>		
N'	35	21		
Baseline Mean (SD)	50.73 (24.25)	44.76 (26.60)		
Week 52 Mean (SD)	37.60 (27.29)	27.88 (23.86)		
Week 4 Adjusted Mean Change (SE)	-10.11 (4.02)	-11.15 (5.26)		
Week 12 Adjusted Mean Change (SE)	-15.75 (4.25)	-20.49 (5.65)		
Week 16 Adjusted Mean Change (SE)	-10.68 (4.87)	-14.07 (6.36)		
Week 24 Adjusted Mean Change (SE)	-17.94 (4.28)	-21.26 (5.70)		
Week 32 Adjusted Mean Change (SE)	-17.20 (4.80)	-22.43 (6.31)		
Week 40 Adjusted Mean Change (SE)	-16.87 (4.38)	-13.38 (5.70)		
Week 52 Adjusted Mean Change (SE)	-11.13 (4.55)	-20.09 (6.29)	8.96 [-6.53; 24.46]	0.253
<b>Carrier, N</b>	<b>20</b>	<b>21</b>		
N'	20	19		
Baseline Mean (SD)	59.99 (26.12)	37.58 (28.23)		
Week 52 Mean (SD)	34.67 (29.18)	24.61 (22.94)		
Week 4 Adjusted Mean Change (SE)	-12.09 (5.50)	-21.09 (5.67)		
Week 12 Adjusted Mean Change (SE)	-20.23 (5.94)	-15.30 (5.73)		
Week 16 Adjusted Mean Change (SE)	-12.46 (6.64)	-16.25 (6.90)		
Week 24 Adjusted Mean Change (SE)	-20.58 (5.75)	-22.56 (6.28)		
Week 32 Adjusted Mean Change (SE)	-11.08 (6.64)	-13.74 (6.73)		
Week 40 Adjusted Mean Change (SE)	-23.86 (5.91)	-13.47 (6.18)		
Week 52 Adjusted Mean Change (SE)	-23.78 (6.51)	-12.35 (6.67)	-11.43 [-30.44; 7.58]	0.235
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.17 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.472</b>				
<b>Non-carrier, N</b>	<b>23</b>	<b>20</b>		
N'	21	19		
Baseline Mean (SD)	54.07 (22.69)	39.54 (25.55)		
Week 52 Mean (SD)	35.11 (28.39)	18.18 (23.16)		
Week 4 Adjusted Mean Change (SE)	-14.39 (5.19)	-13.87 (5.62)		
Week 12 Adjusted Mean Change (SE)	-15.43 (5.66)	-22.34 (5.94)		
Week 16 Adjusted Mean Change (SE)	-9.58 (6.34)	-16.88 (6.81)		
Week 24 Adjusted Mean Change (SE)	-16.37 (5.71)	-24.97 (6.34)		
Week 32 Adjusted Mean Change (SE)	-16.17 (6.34)	-25.43 (6.77)		
Week 40 Adjusted Mean Change (SE)	-17.08 (5.81)	-15.08 (6.15)		
Week 52 Adjusted Mean Change (SE)	-16.62 (6.12)	-23.35 (7.10)	6.72 [-12.09; 25.54]	0.479
<b>Carrier, N</b>	<b>37</b>	<b>25</b>		
N'	34	21		
Baseline Mean (SD)	54.01 (26.76)	43.15 (29.04)		
Week 52 Mean (SD)	37.55 (27.62)	30.91 (22.27)		
Week 4 Adjusted Mean Change (SE)	-8.72 (4.18)	-17.47 (5.33)		
Week 12 Adjusted Mean Change (SE)	-18.23 (4.35)	-14.00 (5.47)		
Week 16 Adjusted Mean Change (SE)	-12.37 (5.00)	-13.45 (6.43)		
Week 24 Adjusted Mean Change (SE)	-20.13 (4.25)	-19.49 (5.59)		
Week 32 Adjusted Mean Change (SE)	-14.38 (4.81)	-12.66 (6.08)		
Week 40 Adjusted Mean Change (SE)	-20.36 (4.41)	-12.48 (5.73)		
Week 52 Adjusted Mean Change (SE)	-13.92 (4.58)	-12.68 (5.87)	-1.24 [-16.20; 13.72]	0.869
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				



### 57.18 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.842</b>				
<b>Non-carrier, N</b>	<b>31</b>	<b>29</b>		
N'	29	26		
Baseline Mean (SD)	55.21 (24.46)	41.96 (26.85)		
Week 52 Mean (SD)	38.62 (26.76)	31.75 (25.16)		
Week 4 Adjusted Mean Change (SE)	-14.41 (4.46)	-17.64 (4.73)		
Week 12 Adjusted Mean Change (SE)	-15.51 (4.78)	-15.47 (5.02)		
Week 16 Adjusted Mean Change (SE)	-7.45 (5.47)	-12.93 (5.75)		
Week 24 Adjusted Mean Change (SE)	-15.52 (4.80)	-21.58 (5.17)		
Week 32 Adjusted Mean Change (SE)	-17.69 (5.59)	-18.41 (5.64)		
Week 40 Adjusted Mean Change (SE)	-20.34 (4.89)	-11.51 (5.11)		
Week 52 Adjusted Mean Change (SE)	-12.70 (5.15)	-15.12 (5.49)	2.41 [-12.70; 17.53]	0.751
<b>Carrier, N</b>	<b>29</b>	<b>16</b>		
N'	26	14		
Baseline Mean (SD)	52.77 (26.18)	40.70 (28.89)		
Week 52 Mean (SD)	34.39 (29.05)	15.23 (13.21)		
Week 4 Adjusted Mean Change (SE)	-6.79 (4.72)	-12.11 (6.58)		
Week 12 Adjusted Mean Change (SE)	-19.05 (5.03)	-22.13 (6.76)		
Week 16 Adjusted Mean Change (SE)	-15.15 (5.59)	-18.60 (7.88)		
Week 24 Adjusted Mean Change (SE)	-22.17 (4.89)	-22.50 (7.19)		
Week 32 Adjusted Mean Change (SE)	-13.09 (5.51)	-17.83 (8.11)		
Week 40 Adjusted Mean Change (SE)	-17.87 (5.00)	-18.04 (7.16)		
Week 52 Adjusted Mean Change (SE)	-17.33 (5.31)	-21.21 (8.08)	3.88 [-15.50; 23.26]	0.692
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 57.19 WPAI-GH Percent Overall Work Impairment due to Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=75)	ADA (N=63)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.073</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>33</b>		
N'	42	29		
Baseline Mean (SD)	54.30 (25.24)	38.88 (25.10)		
Week 52 Mean (SD)	35.11 (28.18)	32.03 (24.32)		
Week 4 Adjusted Mean Change (SE)	-11.41 (3.78)	-15.67 (4.60)		
Week 12 Adjusted Mean Change (SE)	-17.49 (4.03)	-14.51 (4.87)		
Week 16 Adjusted Mean Change (SE)	-12.20 (4.49)	-10.74 (5.40)		
Week 24 Adjusted Mean Change (SE)	-22.21 (3.85)	-18.36 (4.95)		
Week 32 Adjusted Mean Change (SE)	-17.22 (4.53)	-20.21 (5.50)		
Week 40 Adjusted Mean Change (SE)	-21.97 (3.96)	-7.99 (4.85)		
Week 52 Adjusted Mean Change (SE)	-17.04 (4.16)	-10.12 (5.43)	-6.92 [-20.78; 6.93]	0.323
<b>Carrier, N</b>	<b>14</b>	<b>12</b>		
N'	13	11		
Baseline Mean (SD)	53.16 (25.65)	48.10 (32.26)		
Week 52 Mean (SD)	38.55 (25.73)	14.66 (15.52)		
Week 4 Adjusted Mean Change (SE)	-9.79 (6.80)	-16.20 (7.33)		
Week 12 Adjusted Mean Change (SE)	-16.46 (7.00)	-25.28 (7.35)		
Week 16 Adjusted Mean Change (SE)	-8.61 (7.68)	-26.48 (8.78)		
Week 24 Adjusted Mean Change (SE)	-7.42 (7.11)	-30.27 (7.48)		
Week 32 Adjusted Mean Change (SE)	-8.44 (7.85)	-13.55 (8.46)		
Week 40 Adjusted Mean Change (SE)	-10.66 (7.02)	-26.95 (7.57)		
Week 52 Adjusted Mean Change (SE)	-8.33 (7.44)	-30.77 (7.79)	22.44 [0.86; 44.03]	0.042
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p> <p>Note: The table is based on all patients who were employed at baseline.</p>				

### 58.0 WPAI-GH Percent Activity Impairment due to Health - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 4 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	106 (96.4)	98 (97.0)	204 (96.7)
Week 16 Returns	109 (99.1)	96 (95.0)	205 (97.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	103 (93.6)	86 (85.1)	189 (89.6)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	82 (81.2)	187 (88.6)

### 58.1 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	99		
Baseline Mean (SD)	52.36 (25.41)	50.89 (27.24)		
Week 52 Mean (SD)	31.05 (23.65)	30.49 (24.24)		
Week 4 Adjusted Mean Change (SE)	-13.06 (2.11)	-10.06 (2.22)		
Week 12 Adjusted Mean Change (SE)	-18.77 (2.10)	-12.29 (2.20)		
Week 16 Adjusted Mean Change (SE)	-19.89 (2.22)	-12.17 (2.35)		
Week 24 Adjusted Mean Change (SE)	-21.23 (2.38)	-12.89 (2.56)		
Week 32 Adjusted Mean Change (SE)	-19.37 (2.22)	-18.11 (2.40)		
Week 40 Adjusted Mean Change (SE)	-20.10 (2.28)	-19.43 (2.48)		
Week 52 Adjusted Mean Change (SE)	-20.63 (2.24)	-19.33 (2.48)	-1.30 [-7.90; 5.30]	0.698
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				

## 58.2 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.652</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	92		
Baseline Mean (SD)	53.01 (24.85)	50.32 (27.26)		
Week 52 Mean (SD)	31.31 (23.46)	30.13 (24.36)		
Week 4 Adjusted Mean Change (SE)	-13.31 (2.19)	-10.13 (2.32)		
Week 12 Adjusted Mean Change (SE)	-18.88 (2.18)	-12.23 (2.29)		
Week 16 Adjusted Mean Change (SE)	-20.01 (2.30)	-11.88 (2.45)		
Week 24 Adjusted Mean Change (SE)	-22.17 (2.46)	-13.06 (2.66)		
Week 32 Adjusted Mean Change (SE)	-19.44 (2.31)	-18.00 (2.52)		
Week 40 Adjusted Mean Change (SE)	-20.75 (2.36)	-19.45 (2.59)		
Week 52 Adjusted Mean Change (SE)	-20.88 (2.33)	-19.79 (2.59)	-1.09 [-7.96; 5.78]	0.755
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	42.86 (33.52)	58.57 (27.95)		
Week 52 Mean (SD)	26.67 (28.75)	35.00 (24.29)		
Week 4 Adjusted Mean Change (SE)	-9.44 (8.42)	-9.10 (8.40)		
Week 12 Adjusted Mean Change (SE)	-17.11 (8.30)	-12.97 (8.29)		
Week 16 Adjusted Mean Change (SE)	-19.03 (9.21)	-15.75 (8.81)		
Week 24 Adjusted Mean Change (SE)	-7.90 (9.39)	-10.92 (9.38)		
Week 32 Adjusted Mean Change (SE)	-18.06 (8.72)	-19.37 (8.71)		
Week 40 Adjusted Mean Change (SE)	-10.94 (8.99)	-19.35 (8.97)		
Week 52 Adjusted Mean Change (SE)	-17.32 (9.21)	-13.59 (9.17)	-3.74 [-29.37; 21.90]	0.774
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.3 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.967</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	49.70 (25.90)	47.37 (29.06)		
Week 52 Mean (SD)	26.41 (22.70)	24.58 (23.15)		
Week 4 Adjusted Mean Change (SE)	-16.67 (2.73)	-12.71 (2.94)		
Week 12 Adjusted Mean Change (SE)	-23.52 (2.70)	-14.97 (2.87)		
Week 16 Adjusted Mean Change (SE)	-23.11 (2.89)	-14.82 (3.10)		
Week 24 Adjusted Mean Change (SE)	-25.63 (3.03)	-18.74 (3.31)		
Week 32 Adjusted Mean Change (SE)	-22.31 (2.87)	-22.14 (3.18)		
Week 40 Adjusted Mean Change (SE)	-23.11 (2.95)	-23.60 (3.26)		
Week 52 Adjusted Mean Change (SE)	-25.22 (2.83)	-24.94 (3.17)	-0.27 [-8.62; 8.08]	0.949
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	43		
Baseline Mean (SD)	56.36 (24.41)	55.45 (24.25)		
Week 52 Mean (SD)	38.29 (23.55)	38.82 (23.58)		
Week 4 Adjusted Mean Change (SE)	-7.71 (3.36)	-6.60 (3.35)		
Week 12 Adjusted Mean Change (SE)	-11.75 (3.30)	-8.78 (3.30)		
Week 16 Adjusted Mean Change (SE)	-15.11 (3.54)	-8.76 (3.61)		
Week 24 Adjusted Mean Change (SE)	-14.53 (3.80)	-4.83 (3.89)		
Week 32 Adjusted Mean Change (SE)	-15.00 (3.59)	-12.67 (3.66)		
Week 40 Adjusted Mean Change (SE)	-15.62 (3.65)	-13.81 (3.79)		
Week 52 Adjusted Mean Change (SE)	-13.68 (3.53)	-11.77 (3.72)	-1.91 [-11.96; 8.14]	0.708
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.4 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.274</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	35.83 (25.69)	31.43 (30.38)		
Week 52 Mean (SD)	21.30 (19.14)	20.00 (23.45)		
Week 4 Adjusted Mean Change (SE)	-17.91 (4.58)	-19.79 (4.95)		
Week 12 Adjusted Mean Change (SE)	-20.87 (4.63)	-22.77 (4.88)		
Week 16 Adjusted Mean Change (SE)	-25.71 (4.86)	-13.56 (5.25)		
Week 24 Adjusted Mean Change (SE)	-18.98 (5.31)	-15.35 (5.75)		
Week 32 Adjusted Mean Change (SE)	-20.39 (4.84)	-30.82 (5.39)		
Week 40 Adjusted Mean Change (SE)	-18.39 (5.03)	-29.63 (5.57)		
Week 52 Adjusted Mean Change (SE)	-26.88 (4.89)	-26.89 (5.53)	0.01 [-14.28; 14.30]	0.999
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	78		
Baseline Mean (SD)	56.98 (23.47)	56.00 (24.06)		
Week 52 Mean (SD)	33.78 (24.17)	33.23 (23.86)		
Week 4 Adjusted Mean Change (SE)	-11.66 (2.38)	-7.53 (2.49)		
Week 12 Adjusted Mean Change (SE)	-18.14 (2.36)	-9.52 (2.47)		
Week 16 Adjusted Mean Change (SE)	-18.22 (2.53)	-11.88 (2.67)		
Week 24 Adjusted Mean Change (SE)	-21.76 (2.72)	-12.26 (2.91)		
Week 32 Adjusted Mean Change (SE)	-19.04 (2.50)	-14.90 (2.67)		
Week 40 Adjusted Mean Change (SE)	-20.45 (2.58)	-16.78 (2.78)		
Week 52 Adjusted Mean Change (SE)	-18.82 (2.54)	-17.40 (2.77)	-1.42 [-8.81; 5.97]	0.706
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.5 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.631</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	50		
Baseline Mean (SD)	50.95 (25.45)	50.39 (27.35)		
Week 52 Mean (SD)	30.26 (21.94)	29.47 (24.27)		
Week 4 Adjusted Mean Change (SE)	-11.92 (3.43)	-11.27 (3.14)		
Week 12 Adjusted Mean Change (SE)	-13.60 (3.38)	-13.18 (3.07)		
Week 16 Adjusted Mean Change (SE)	-19.11 (3.60)	-12.77 (3.34)		
Week 24 Adjusted Mean Change (SE)	-16.47 (3.88)	-12.71 (3.62)		
Week 32 Adjusted Mean Change (SE)	-22.26 (3.62)	-16.91 (3.40)		
Week 40 Adjusted Mean Change (SE)	-17.28 (3.72)	-18.55 (3.58)		
Week 52 Adjusted Mean Change (SE)	-21.50 (3.69)	-18.53 (3.61)	-2.96 [-13.15; 7.23]	0.567
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	53.24 (25.54)	51.40 (27.41)		
Week 52 Mean (SD)	31.52 (24.76)	31.36 (24.46)		
Week 4 Adjusted Mean Change (SE)	-13.77 (2.70)	-8.83 (3.17)		
Week 12 Adjusted Mean Change (SE)	-22.01 (2.67)	-11.35 (3.12)		
Week 16 Adjusted Mean Change (SE)	-20.35 (2.85)	-11.56 (3.35)		
Week 24 Adjusted Mean Change (SE)	-24.10 (3.02)	-13.01 (3.63)		
Week 32 Adjusted Mean Change (SE)	-17.62 (2.83)	-19.21 (3.41)		
Week 40 Adjusted Mean Change (SE)	-21.86 (2.91)	-20.14 (3.48)		
Week 52 Adjusted Mean Change (SE)	-20.17 (2.86)	-20.01 (3.46)	-0.16 [-9.03; 8.72]	0.972
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 58.6 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.831</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	52.64 (23.97)	49.39 (28.68)		
Week 52 Mean (SD)	29.71 (23.59)	23.89 (22.33)		
Week 4 Adjusted Mean Change (SE)	-14.88 (2.61)	-9.55 (3.17)		
Week 12 Adjusted Mean Change (SE)	-20.84 (2.60)	-15.20 (3.10)		
Week 16 Adjusted Mean Change (SE)	-21.70 (2.73)	-16.51 (3.34)		
Week 24 Adjusted Mean Change (SE)	-24.44 (2.88)	-18.41 (3.63)		
Week 32 Adjusted Mean Change (SE)	-21.38 (2.74)	-17.72 (3.50)		
Week 40 Adjusted Mean Change (SE)	-22.42 (2.80)	-21.95 (3.61)		
Week 52 Adjusted Mean Change (SE)	-21.73 (2.75)	-22.41 (3.68)	0.68 [-8.39; 9.75]	0.883
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	50		
Baseline Mean (SD)	51.84 (28.27)	52.31 (26.02)		
Week 52 Mean (SD)	33.71 (23.90)	35.65 (24.64)		
Week 4 Adjusted Mean Change (SE)	-9.62 (3.59)	-10.56 (3.13)		
Week 12 Adjusted Mean Change (SE)	-14.87 (3.52)	-9.40 (3.09)		
Week 16 Adjusted Mean Change (SE)	-16.45 (3.74)	-7.98 (3.28)		
Week 24 Adjusted Mean Change (SE)	-14.91 (4.05)	-7.76 (3.51)		
Week 32 Adjusted Mean Change (SE)	-15.53 (3.81)	-18.17 (3.33)		
Week 40 Adjusted Mean Change (SE)	-15.66 (3.89)	-17.14 (3.41)		
Week 52 Adjusted Mean Change (SE)	-18.55 (3.86)	-16.68 (3.37)	-1.88 [-11.99; 8.23]	0.714
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.7 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.666</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	31		
Baseline Mean (SD)	50.98 (25.94)	47.19 (29.97)		
Week 52 Mean (SD)	30.00 (24.15)	25.20 (23.47)		
Week 4 Adjusted Mean Change (SE)	-15.97 (3.09)	-14.34 (3.97)		
Week 12 Adjusted Mean Change (SE)	-22.54 (3.09)	-14.99 (3.95)		
Week 16 Adjusted Mean Change (SE)	-23.08 (3.20)	-20.46 (4.16)		
Week 24 Adjusted Mean Change (SE)	-23.05 (3.50)	-15.11 (4.56)		
Week 32 Adjusted Mean Change (SE)	-21.72 (3.23)	-24.43 (4.22)		
Week 40 Adjusted Mean Change (SE)	-22.66 (3.34)	-24.51 (4.36)		
Week 52 Adjusted Mean Change (SE)	-21.66 (3.29)	-23.89 (4.46)	2.23 [-8.70; 13.15]	0.688
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	53.56 (25.10)	52.61 (25.93)		
Week 52 Mean (SD)	31.96 (23.39)	32.81 (24.40)		
Week 4 Adjusted Mean Change (SE)	-10.54 (2.87)	-8.13 (2.67)		
Week 12 Adjusted Mean Change (SE)	-15.56 (2.84)	-11.03 (2.64)		
Week 16 Adjusted Mean Change (SE)	-17.12 (3.00)	-8.42 (2.80)		
Week 24 Adjusted Mean Change (SE)	-19.68 (3.27)	-11.89 (3.11)		
Week 32 Adjusted Mean Change (SE)	-17.35 (3.02)	-15.19 (2.91)		
Week 40 Adjusted Mean Change (SE)	-17.90 (3.11)	-17.10 (3.01)		
Week 52 Adjusted Mean Change (SE)	-19.75 (3.08)	-17.22 (2.99)	-2.53 [-11.00; 5.94]	0.556
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.8 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.331</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	55.88 (24.83)	46.34 (26.34)		
Week 52 Mean (SD)	31.43 (24.15)	27.22 (22.50)		
Week 4 Adjusted Mean Change (SE)	-14.45 (2.93)	-17.66 (3.27)		
Week 12 Adjusted Mean Change (SE)	-18.02 (3.12)	-16.69 (3.50)		
Week 16 Adjusted Mean Change (SE)	-22.40 (3.21)	-15.85 (3.63)		
Week 24 Adjusted Mean Change (SE)	-25.59 (3.42)	-14.73 (3.89)		
Week 32 Adjusted Mean Change (SE)	-21.69 (3.22)	-19.63 (3.67)		
Week 40 Adjusted Mean Change (SE)	-23.94 (3.32)	-23.44 (3.76)		
Week 52 Adjusted Mean Change (SE)	-21.73 (3.23)	-22.80 (3.69)	1.07 [-8.66; 10.80]	0.828
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	25		
Baseline Mean (SD)	49.41 (22.82)	52.31 (29.44)		
Week 52 Mean (SD)	29.03 (22.56)	27.14 (25.13)		
Week 4 Adjusted Mean Change (SE)	-10.45 (3.58)	-10.67 (4.17)		
Week 12 Adjusted Mean Change (SE)	-17.20 (3.86)	-16.68 (4.44)		
Week 16 Adjusted Mean Change (SE)	-14.40 (3.94)	-18.67 (4.56)		
Week 24 Adjusted Mean Change (SE)	-16.28 (4.21)	-22.42 (4.94)		
Week 32 Adjusted Mean Change (SE)	-17.62 (4.03)	-23.31 (4.66)		
Week 40 Adjusted Mean Change (SE)	-18.63 (4.08)	-26.96 (4.86)		
Week 52 Adjusted Mean Change (SE)	-20.11 (4.00)	-21.86 (4.77)	1.75 [-10.54; 14.03]	0.779
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.9 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.697</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	26		
Baseline Mean (SD)	52.22 (25.49)	51.11 (26.65)		
Week 52 Mean (SD)	30.47 (24.68)	30.53 (21.98)		
Week 4 Adjusted Mean Change (SE)	-11.05 (3.20)	-10.26 (4.21)		
Week 12 Adjusted Mean Change (SE)	-19.46 (3.36)	-20.08 (4.42)		
Week 16 Adjusted Mean Change (SE)	-19.93 (3.48)	-15.04 (4.64)		
Week 24 Adjusted Mean Change (SE)	-22.49 (3.68)	-15.20 (4.97)		
Week 32 Adjusted Mean Change (SE)	-19.55 (3.46)	-17.10 (4.67)		
Week 40 Adjusted Mean Change (SE)	-22.51 (3.57)	-20.86 (4.83)		
Week 52 Adjusted Mean Change (SE)	-20.91 (3.54)	-20.74 (5.02)	-0.17 [-12.32; 11.97]	0.978
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	55.00 (21.78)	47.33 (28.76)		
Week 52 Mean (SD)	30.57 (22.35)	27.50 (26.05)		
Week 4 Adjusted Mean Change (SE)	-14.73 (3.48)	-17.75 (3.93)		
Week 12 Adjusted Mean Change (SE)	-15.86 (3.70)	-15.25 (4.15)		
Week 16 Adjusted Mean Change (SE)	-19.80 (3.82)	-16.38 (4.32)		
Week 24 Adjusted Mean Change (SE)	-21.66 (4.05)	-18.73 (4.61)		
Week 32 Adjusted Mean Change (SE)	-21.92 (3.81)	-22.67 (4.29)		
Week 40 Adjusted Mean Change (SE)	-21.90 (3.88)	-26.10 (4.47)		
Week 52 Adjusted Mean Change (SE)	-21.99 (3.89)	-22.47 (4.39)	0.48 [-11.15; 12.12]	0.935
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.10 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.451</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	32		
Baseline Mean (SD)	57.67 (25.55)	53.33 (30.17)		
Week 52 Mean (SD)	31.72 (23.46)	25.83 (26.69)		
Week 4 Adjusted Mean Change (SE)	-14.39 (3.86)	-19.72 (3.72)		
Week 12 Adjusted Mean Change (SE)	-19.02 (4.04)	-22.47 (3.92)		
Week 16 Adjusted Mean Change (SE)	-20.11 (4.26)	-18.44 (4.14)		
Week 24 Adjusted Mean Change (SE)	-21.05 (4.61)	-18.77 (4.57)		
Week 32 Adjusted Mean Change (SE)	-18.28 (4.21)	-24.10 (4.18)		
Week 40 Adjusted Mean Change (SE)	-22.50 (4.35)	-23.62 (4.32)		
Week 52 Adjusted Mean Change (SE)	-21.15 (4.23)	-24.17 (4.37)	3.03 [-8.98; 15.04]	0.619
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	52.94 (21.57)	44.12 (24.26)		
Week 52 Mean (SD)	30.41 (23.89)	28.18 (20.83)		
Week 4 Adjusted Mean Change (SE)	-12.55 (2.95)	-10.98 (3.66)		
Week 12 Adjusted Mean Change (SE)	-17.86 (3.11)	-11.78 (3.82)		
Week 16 Adjusted Mean Change (SE)	-19.36 (3.25)	-16.17 (4.06)		
Week 24 Adjusted Mean Change (SE)	-23.20 (3.45)	-17.09 (4.31)		
Week 32 Adjusted Mean Change (SE)	-22.62 (3.23)	-18.73 (4.01)		
Week 40 Adjusted Mean Change (SE)	-23.25 (3.31)	-26.12 (4.15)		
Week 52 Adjusted Mean Change (SE)	-22.23 (3.23)	-21.62 (4.00)	-0.60 [-10.78; 9.57]	0.907
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.11 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.444</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	54.65 (24.24)	46.98 (27.30)		
Week 52 Mean (SD)	31.28 (23.97)	28.72 (24.51)		
Week 4 Adjusted Mean Change (SE)	-10.82 (3.20)	-16.98 (3.20)		
Week 12 Adjusted Mean Change (SE)	-16.02 (3.40)	-15.25 (3.40)		
Week 16 Adjusted Mean Change (SE)	-17.59 (3.54)	-16.91 (3.54)		
Week 24 Adjusted Mean Change (SE)	-18.65 (3.77)	-16.58 (3.81)		
Week 32 Adjusted Mean Change (SE)	-17.30 (3.57)	-22.33 (3.57)		
Week 40 Adjusted Mean Change (SE)	-18.20 (3.63)	-25.39 (3.66)		
Week 52 Adjusted Mean Change (SE)	-20.30 (3.56)	-22.12 (3.56)	1.82 [-8.16; 11.80]	0.719
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	51.90 (24.22)	51.67 (28.23)		
Week 52 Mean (SD)	29.76 (23.18)	23.89 (20.62)		
Week 4 Adjusted Mean Change (SE)	-14.92 (3.23)	-11.39 (4.35)		
Week 12 Adjusted Mean Change (SE)	-19.27 (3.44)	-19.28 (4.61)		
Week 16 Adjusted Mean Change (SE)	-20.86 (3.55)	-17.11 (4.85)		
Week 24 Adjusted Mean Change (SE)	-25.13 (3.78)	-19.78 (5.20)		
Week 32 Adjusted Mean Change (SE)	-22.75 (3.54)	-18.72 (4.86)		
Week 40 Adjusted Mean Change (SE)	-25.45 (3.64)	-23.49 (5.08)		
Week 52 Adjusted Mean Change (SE)	-21.90 (3.53)	-23.41 (5.06)	1.51 [-10.68; 13.71]	0.807
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.12 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.411</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	46		
Baseline Mean (SD)	52.58 (23.60)	49.15 (28.88)		
Week 52 Mean (SD)	31.21 (23.85)	26.58 (21.34)		
Week 4 Adjusted Mean Change (SE)	-13.17 (2.55)	-15.90 (2.95)		
Week 12 Adjusted Mean Change (SE)	-18.07 (2.78)	-15.23 (3.19)		
Week 16 Adjusted Mean Change (SE)	-18.68 (2.78)	-14.26 (3.22)		
Week 24 Adjusted Mean Change (SE)	-23.51 (3.02)	-15.89 (3.57)		
Week 32 Adjusted Mean Change (SE)	-19.93 (2.95)	-22.64 (3.44)		
Week 40 Adjusted Mean Change (SE)	-21.98 (2.88)	-25.59 (3.40)		
Week 52 Adjusted Mean Change (SE)	-20.67 (2.86)	-22.64 (3.44)	1.96 [-6.90; 10.83]	0.662
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	55.50 (27.04)	46.67 (24.49)		
Week 52 Mean (SD)	26.84 (22.37)	22.35 (21.66)		
Week 4 Adjusted Mean Change (SE)	-15.21 (4.53)	-17.76 (4.72)		
Week 12 Adjusted Mean Change (SE)	-16.40 (4.89)	-25.24 (5.17)		
Week 16 Adjusted Mean Change (SE)	-24.05 (4.90)	-28.71 (5.21)		
Week 24 Adjusted Mean Change (SE)	-19.05 (5.48)	-27.97 (5.74)		
Week 32 Adjusted Mean Change (SE)	-19.51 (5.21)	-20.46 (5.54)		
Week 40 Adjusted Mean Change (SE)	-24.04 (5.12)	-29.00 (5.42)		
Week 52 Adjusted Mean Change (SE)	-23.17 (5.06)	-27.33 (5.30)	4.17 [-10.36; 18.69]	0.571
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.13 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.048</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	50		
Baseline Mean (SD)	51.75 (24.60)	48.63 (29.80)		
Week 52 Mean (SD)	31.03 (23.67)	25.00 (23.40)		
Week 4 Adjusted Mean Change (SE)	-11.10 (2.56)	-19.81 (2.88)		
Week 12 Adjusted Mean Change (SE)	-16.85 (2.81)	-18.92 (3.16)		
Week 16 Adjusted Mean Change (SE)	-17.18 (2.85)	-20.40 (3.23)		
Week 24 Adjusted Mean Change (SE)	-20.34 (3.08)	-21.55 (3.51)		
Week 32 Adjusted Mean Change (SE)	-19.18 (2.91)	-24.13 (3.29)		
Week 40 Adjusted Mean Change (SE)	-22.08 (2.96)	-27.13 (3.38)		
Week 52 Adjusted Mean Change (SE)	-19.93 (2.86)	-24.76 (3.30)	4.83 [-3.82; 13.47]	0.271
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	55.26 (23.42)	50.00 (21.32)		
Week 52 Mean (SD)	29.47 (21.72)	31.67 (22.50)		
Week 4 Adjusted Mean Change (SE)	-17.71 (4.66)	0.01 (5.89)		
Week 12 Adjusted Mean Change (SE)	-19.99 (5.10)	-11.74 (6.44)		
Week 16 Adjusted Mean Change (SE)	-23.89 (5.17)	-8.36 (6.53)		
Week 24 Adjusted Mean Change (SE)	-24.61 (5.53)	-7.61 (6.98)		
Week 32 Adjusted Mean Change (SE)	-19.58 (5.21)	-10.26 (6.70)		
Week 40 Adjusted Mean Change (SE)	-21.52 (5.33)	-18.98 (6.83)		
Week 52 Adjusted Mean Change (SE)	-22.47 (5.10)	-17.76 (6.44)	-4.71 [-20.95; 11.52]	0.567
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 58.14 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.818</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	52		
Baseline Mean (SD)	52.39 (24.64)	49.25 (28.14)		
Week 52 Mean (SD)	30.76 (22.82)	26.59 (24.58)		
Week 4 Adjusted Mean Change (SE)	-13.07 (2.49)	-13.33 (2.91)		
Week 12 Adjusted Mean Change (SE)	-17.83 (2.63)	-17.93 (3.08)		
Week 16 Adjusted Mean Change (SE)	-19.75 (2.71)	-16.35 (3.19)		
Week 24 Adjusted Mean Change (SE)	-21.69 (2.89)	-17.16 (3.43)		
Week 32 Adjusted Mean Change (SE)	-19.02 (2.74)	-19.84 (3.23)		
Week 40 Adjusted Mean Change (SE)	-21.52 (2.83)	-22.49 (3.37)		
Week 52 Adjusted Mean Change (SE)	-20.61 (2.76)	-22.96 (3.31)	2.35 [-6.18; 10.88]	0.587
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	59.23 (21.78)	43.00 (26.69)		
Week 52 Mean (SD)	30.77 (27.53)	33.00 (18.89)		
Week 4 Adjusted Mean Change (SE)	-13.20 (5.85)	-18.33 (6.66)		
Week 12 Adjusted Mean Change (SE)	-15.82 (6.27)	-4.98 (7.02)		
Week 16 Adjusted Mean Change (SE)	-16.82 (6.35)	-9.58 (7.22)		
Week 24 Adjusted Mean Change (SE)	-22.82 (6.73)	-19.56 (7.65)		
Week 32 Adjusted Mean Change (SE)	-24.91 (6.33)	-23.79 (7.20)		
Week 40 Adjusted Mean Change (SE)	-22.35 (6.58)	-28.06 (7.48)		
Week 52 Adjusted Mean Change (SE)	-22.05 (6.36)	-16.38 (7.23)	-5.67 [-24.82; 13.47]	0.559
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.15 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.681</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	25		
Baseline Mean (SD)	49.09 (28.93)	51.54 (31.46)		
Week 52 Mean (SD)	32.11 (25.07)	31.11 (26.32)		
Week 4 Adjusted Mean Change (SE)	-11.00 (4.48)	-15.48 (4.22)		
Week 12 Adjusted Mean Change (SE)	-18.46 (4.71)	-19.56 (4.44)		
Week 16 Adjusted Mean Change (SE)	-15.72 (4.96)	-19.24 (4.66)		
Week 24 Adjusted Mean Change (SE)	-19.70 (5.33)	-15.12 (5.07)		
Week 32 Adjusted Mean Change (SE)	-14.78 (4.97)	-19.88 (4.72)		
Week 40 Adjusted Mean Change (SE)	-19.57 (5.09)	-20.46 (4.87)		
Week 52 Adjusted Mean Change (SE)	-16.10 (5.03)	-20.53 (4.96)	4.43 [-9.54; 18.40]	0.532
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	54.76 (22.28)	46.83 (24.94)		
Week 52 Mean (SD)	30.00 (23.09)	25.38 (21.87)		
Week 4 Adjusted Mean Change (SE)	-13.51 (2.66)	-14.71 (3.30)		
Week 12 Adjusted Mean Change (SE)	-17.31 (2.81)	-14.85 (3.49)		
Week 16 Adjusted Mean Change (SE)	-20.39 (2.90)	-15.61 (3.63)		
Week 24 Adjusted Mean Change (SE)	-22.61 (3.10)	-19.10 (3.91)		
Week 32 Adjusted Mean Change (SE)	-21.79 (2.90)	-21.62 (3.64)		
Week 40 Adjusted Mean Change (SE)	-22.54 (2.96)	-27.12 (3.74)		
Week 52 Adjusted Mean Change (SE)	-22.65 (2.88)	-23.51 (3.61)	0.87 [-8.32; 10.05]	0.852
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.16 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.837</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	34		
Baseline Mean (SD)	52.16 (25.40)	50.57 (25.89)		
Week 52 Mean (SD)	30.20 (23.58)	27.41 (20.86)		
Week 4 Adjusted Mean Change (SE)	-12.16 (2.94)	-12.62 (3.60)		
Week 12 Adjusted Mean Change (SE)	-19.89 (3.11)	-18.93 (3.78)		
Week 16 Adjusted Mean Change (SE)	-19.19 (3.23)	-17.39 (3.98)		
Week 24 Adjusted Mean Change (SE)	-23.41 (3.45)	-18.97 (4.30)		
Week 32 Adjusted Mean Change (SE)	-19.53 (3.23)	-19.83 (4.01)		
Week 40 Adjusted Mean Change (SE)	-22.52 (3.33)	-23.97 (4.15)		
Week 52 Adjusted Mean Change (SE)	-21.13 (3.23)	-22.75 (4.15)	1.62 [-8.79; 12.03]	0.759
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	55.00 (22.33)	46.56 (29.47)		
Week 52 Mean (SD)	30.97 (23.57)	27.00 (25.62)		
Week 4 Adjusted Mean Change (SE)	-13.89 (3.61)	-17.57 (3.72)		
Week 12 Adjusted Mean Change (SE)	-14.20 (3.82)	-14.20 (3.93)		
Week 16 Adjusted Mean Change (SE)	-19.28 (3.99)	-16.56 (4.11)		
Week 24 Adjusted Mean Change (SE)	-19.47 (4.28)	-16.31 (4.44)		
Week 32 Adjusted Mean Change (SE)	-20.88 (4.01)	-22.38 (4.14)		
Week 40 Adjusted Mean Change (SE)	-20.74 (4.08)	-25.64 (4.28)		
Week 52 Adjusted Mean Change (SE)	-20.91 (4.01)	-22.33 (4.11)	1.43 [-9.99; 12.84]	0.805
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.17 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.398</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	30		
Baseline Mean (SD)	57.67 (25.55)	52.26 (30.84)		
Week 52 Mean (SD)	31.72 (23.46)	23.64 (26.82)		
Week 4 Adjusted Mean Change (SE)	-14.10 (3.84)	-18.72 (3.82)		
Week 12 Adjusted Mean Change (SE)	-18.66 (3.99)	-23.75 (4.00)		
Week 16 Adjusted Mean Change (SE)	-19.87 (4.21)	-20.41 (4.22)		
Week 24 Adjusted Mean Change (SE)	-20.76 (4.59)	-19.07 (4.70)		
Week 32 Adjusted Mean Change (SE)	-17.87 (4.22)	-23.33 (4.33)		
Week 40 Adjusted Mean Change (SE)	-22.08 (4.36)	-23.52 (4.48)		
Week 52 Adjusted Mean Change (SE)	-20.78 (4.20)	-25.20 (4.51)	4.43 [-7.76; 16.61]	0.474
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	50.91 (23.20)	45.56 (24.31)		
Week 52 Mean (SD)	29.80 (23.62)	29.43 (20.86)		
Week 4 Adjusted Mean Change (SE)	-12.21 (2.82)	-11.87 (3.51)		
Week 12 Adjusted Mean Change (SE)	-17.07 (2.95)	-10.88 (3.65)		
Week 16 Adjusted Mean Change (SE)	-18.86 (3.10)	-14.07 (3.87)		
Week 24 Adjusted Mean Change (SE)	-22.44 (3.32)	-16.25 (4.14)		
Week 32 Adjusted Mean Change (SE)	-21.26 (3.12)	-18.91 (3.88)		
Week 40 Adjusted Mean Change (SE)	-21.64 (3.20)	-25.23 (4.01)		
Week 52 Adjusted Mean Change (SE)	-21.17 (3.11)	-20.31 (3.83)	-0.86 [-10.63; 8.90]	0.861
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.18 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.444</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	54.65 (24.24)	46.98 (27.30)		
Week 52 Mean (SD)	31.28 (23.97)	28.72 (24.51)		
Week 4 Adjusted Mean Change (SE)	-10.82 (3.20)	-16.98 (3.20)		
Week 12 Adjusted Mean Change (SE)	-16.02 (3.40)	-15.25 (3.40)		
Week 16 Adjusted Mean Change (SE)	-17.59 (3.54)	-16.91 (3.54)		
Week 24 Adjusted Mean Change (SE)	-18.65 (3.77)	-16.58 (3.81)		
Week 32 Adjusted Mean Change (SE)	-17.30 (3.57)	-22.33 (3.57)		
Week 40 Adjusted Mean Change (SE)	-18.20 (3.63)	-25.39 (3.66)		
Week 52 Adjusted Mean Change (SE)	-20.30 (3.56)	-22.12 (3.56)	1.82 [-8.16; 11.80]	0.719
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	23		
Baseline Mean (SD)	51.90 (24.22)	51.67 (28.23)		
Week 52 Mean (SD)	29.76 (23.18)	23.89 (20.62)		
Week 4 Adjusted Mean Change (SE)	-14.92 (3.23)	-11.39 (4.35)		
Week 12 Adjusted Mean Change (SE)	-19.27 (3.44)	-19.28 (4.61)		
Week 16 Adjusted Mean Change (SE)	-20.86 (3.55)	-17.11 (4.85)		
Week 24 Adjusted Mean Change (SE)	-25.13 (3.78)	-19.78 (5.20)		
Week 32 Adjusted Mean Change (SE)	-22.75 (3.54)	-18.72 (4.86)		
Week 40 Adjusted Mean Change (SE)	-25.45 (3.64)	-23.49 (5.08)		
Week 52 Adjusted Mean Change (SE)	-21.90 (3.53)	-23.41 (5.06)	1.51 [-10.68; 13.71]	0.807
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 58.19 WPAI-GH Percent Activity Impairment due to Health - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.570</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	48		
Baseline Mean (SD)	52.00 (23.66)	49.18 (28.93)		
Week 52 Mean (SD)	30.66 (23.87)	28.75 (23.00)		
Week 4 Adjusted Mean Change (SE)	-12.48 (2.60)	-14.87 (3.02)		
Week 12 Adjusted Mean Change (SE)	-17.93 (2.78)	-14.30 (3.22)		
Week 16 Adjusted Mean Change (SE)	-18.34 (2.80)	-13.29 (3.26)		
Week 24 Adjusted Mean Change (SE)	-22.80 (3.03)	-14.46 (3.60)		
Week 32 Adjusted Mean Change (SE)	-20.06 (2.87)	-21.49 (3.36)		
Week 40 Adjusted Mean Change (SE)	-21.54 (2.95)	-23.76 (3.49)		
Week 52 Adjusted Mean Change (SE)	-20.79 (2.84)	-20.51 (3.41)	-0.27 [-9.07; 8.52]	0.951
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	55.00 (25.03)	47.22 (23.96)		
Week 52 Mean (SD)	25.88 (20.02)	23.53 (24.22)		
Week 4 Adjusted Mean Change (SE)	-14.76 (4.97)	-14.49 (4.93)		
Week 12 Adjusted Mean Change (SE)	-16.62 (5.27)	-22.05 (5.23)		
Week 16 Adjusted Mean Change (SE)	-22.41 (5.33)	-25.89 (5.38)		
Week 24 Adjusted Mean Change (SE)	-19.66 (5.94)	-25.09 (5.81)		
Week 32 Adjusted Mean Change (SE)	-20.20 (5.49)	-18.38 (5.52)		
Week 40 Adjusted Mean Change (SE)	-23.53 (5.67)	-26.04 (5.76)		
Week 52 Adjusted Mean Change (SE)	-23.71 (5.44)	-26.26 (5.40)	2.55 [-12.62; 17.72]	0.740
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.0 Tender Dactylitis Count - Return Rates (FAS)

	Treatment Groups		
	SEC (N=110)	ADA (N=101)	Total (N=211)
<b>Number of patients with valid data n (%)</b>			
Baseline Returns	110 (100.0)	101 (100.0)	211 (100.0)
Week 2 Returns	109 (99.1)	100 (99.0)	209 (99.1)
Week 4 Returns	110 (100.0)	98 (97.0)	208 (98.6)
Week 8 Returns	110 (100.0)	99 (98.0)	209 (99.1)
Week 12 Returns	107 (97.3)	98 (97.0)	205 (97.2)
Week 16 Returns	109 (99.1)	94 (93.1)	203 (96.2)
Week 24 Returns	107 (97.3)	90 (89.1)	197 (93.4)
Week 32 Returns	102 (92.7)	86 (85.1)	188 (89.1)
Week 40 Returns	106 (96.4)	84 (83.2)	190 (90.0)
Week 52 Returns	105 (95.5)	85 (84.2)	190 (90.0)

### 59.1 Tender Dactylitis Count - Change from Baseline (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
N'	110	100		
Baseline Mean (SD)	0.43 (0.73)	0.41 (0.71)		
Week 52 Mean (SD)	0.03 (0.26)	0.01 (0.08)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.02)	-0.42 (0.02)	0.02 [-0.04; 0.07]	0.582
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, treatment x visit, baseline value x visit            Covariance structure: unstructured (un)</p>				



## 59.2 Tender Dactylitis Count - Change from Baseline by Age (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.028</b>				
<b>&lt; 65 years, N</b>	<b>103</b>	<b>94</b>		
N'	103	93		
Baseline Mean (SD)	0.42 (0.71)	0.42 (0.72)		
Week 52 Mean (SD)	0.01 (0.07)	0.01 (0.08)		
Week 52 Adjusted Mean Change (SE)	-0.43 (0.02)	-0.42 (0.02)	-0.01 [-0.06; 0.04]	0.759
<b>≥ 65 years, N</b>	<b>7</b>	<b>7</b>		
N'	7	7		
Baseline Mean (SD)	0.53 (1.14)	0.30 (0.55)		
Week 52 Mean (SD)	0.43 (1.05)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.04 (0.07)	-0.42 (0.07)	0.38 [0.19; 0.57]	<.001
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.3 Tender Dactylitis Count - Change from Baseline by Gender (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.539</b>				
<b>Male, N</b>	<b>66</b>	<b>57</b>		
N'	66	56		
Baseline Mean (SD)	0.40 (0.66)	0.46 (0.73)		
Week 52 Mean (SD)	0.01 (0.09)	0.01 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.43 (0.02)	-0.42 (0.03)	-0.01 [-0.08; 0.06]	0.846
<b>Female, N</b>	<b>44</b>	<b>44</b>		
N'	44	44		
Baseline Mean (SD)	0.46 (0.84)	0.35 (0.69)		
Week 52 Mean (SD)	0.06 (0.40)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.36 (0.03)	-0.42 (0.03)	0.05 [-0.03; 0.13]	0.239
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.4 Tender Dactylitis Count - Change from Baseline by Disease Severity (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.582</b>				
<b>PASDAS &lt; 5.4, N</b>	<b>24</b>	<b>21</b>		
N'	24	21		
Baseline Mean (SD)	0.06 (0.20)	0.12 (0.31)		
Week 52 Mean (SD)	0.03 (0.14)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.38 (0.04)	-0.39 (0.05)	0.01 [-0.11; 0.13]	0.880
<b>PASDAS ≥ 5.4, N</b>	<b>86</b>	<b>80</b>		
N'	86	79		
Baseline Mean (SD)	0.53 (0.79)	0.49 (0.76)		
Week 52 Mean (SD)	0.03 (0.28)	0.01 (0.08)		
Week 52 Adjusted Mean Change (SE)	-0.41 (0.02)	-0.43 (0.02)	0.02 [-0.04; 0.08]	0.585
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.5 Tender Dactylitis Count - Change from Baseline by Moderate/Severe PSO D (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.535</b>				
<b>Moderate/Severe Psoriasis (Def D): No, N</b>	<b>42</b>	<b>51</b>		
N'	42	51		
Baseline Mean (SD)	0.27 (0.52)	0.47 (0.77)		
Week 52 Mean (SD)	0.02 (0.11)	0.02 (0.11)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.03)	-0.41 (0.03)	0.01 [-0.07; 0.10]	0.774
<b>Moderate/Severe Psoriasis (Def D): Yes, N</b>	<b>68</b>	<b>50</b>		
N'	68	49		
Baseline Mean (SD)	0.52 (0.83)	0.36 (0.64)		
Week 52 Mean (SD)	0.04 (0.32)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.02)	-0.42 (0.03)	0.02 [-0.05; 0.09]	0.598
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment            x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters,            subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.6 Tender Dactylitis Count - Change from Baseline by Lymphocyte Count at BL (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.142</b>				
<b>≤ Median, N</b>	<b>72</b>	<b>49</b>		
N'	72	49		
Baseline Mean (SD)	0.44 (0.71)	0.45 (0.67)		
Week 52 Mean (SD)	0.01 (0.08)	0.02 (0.11)		
Week 52 Adjusted Mean Change (SE)	-0.42 (0.02)	-0.41 (0.03)	-0.01 [-0.08; 0.06]	0.806
<b>&gt; Median, N</b>	<b>38</b>	<b>52</b>		
N'	38	51		
Baseline Mean (SD)	0.41 (0.78)	0.38 (0.75)		
Week 52 Mean (SD)	0.07 (0.43)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.36 (0.03)	-0.42 (0.03)	0.06 [-0.02; 0.15]	0.139
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.7 Tender Dactylitis Count - Change from Baseline by Enthesitis at BL According to LEI (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.421</b>				
<b>Enthesitis: No, N</b>	<b>51</b>	<b>32</b>		
N'	51	32		
Baseline Mean (SD)	0.29 (0.54)	0.31 (0.63)		
Week 52 Mean (SD)	0.01 (0.10)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.41 (0.03)	-0.42 (0.04)	0.01 [-0.07; 0.10]	0.740
<b>Enthesitis: Yes, N</b>	<b>59</b>	<b>69</b>		
N'	59	68		
Baseline Mean (SD)	0.55 (0.85)	0.46 (0.74)		
Week 52 Mean (SD)	0.05 (0.34)	0.01 (0.09)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.03)	-0.41 (0.02)	0.02 [-0.05; 0.09]	0.624
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.8 Tender Dactylitis Count - Change from Baseline by HLA-DQA1\*05 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.284</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>41</b>		
N'	51	41		
Baseline Mean (SD)	0.42 (0.70)	0.40 (0.76)		
Week 52 Mean (SD)	0.01 (0.10)	0.02 (0.11)		
Week 52 Adjusted Mean Change (SE)	-0.39 (0.01)	-0.38 (0.01)	-0.01 [-0.04; 0.03]	0.636
<b>Carrier, N</b>	<b>34</b>	<b>26</b>		
N'	34	26		
Baseline Mean (SD)	0.34 (0.67)	0.40 (0.54)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.01)	-0.40 (0.02)	-0.00 [-0.05; 0.04]	0.985
<p>N': Number of patients in the analysis  CI: Confidence interval  MMRM: Mixed effects repeated measures model  N.E.: Not estimable  SD: Standard deviation  SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:  treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit  Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.9 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs10555659 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.411</b>				
<b>Non-carrier, N</b>	<b>45</b>	<b>27</b>		
N'	45	27		
Baseline Mean (SD)	0.45 (0.71)	0.38 (0.69)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.41 (0.01)	-0.41 (0.01)	-0.00 [-0.04; 0.03]	0.756
<b>Carrier, N</b>	<b>38</b>	<b>30</b>		
N'	38	30		
Baseline Mean (SD)	0.34 (0.67)	0.44 (0.72)		
Week 52 Mean (SD)	0.02 (0.12)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.39 (0.01)	-0.41 (0.01)	0.02 [-0.01; 0.05]	0.196
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 59.10 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs111937633 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.135</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>33</b>		
N'	30	33		
Baseline Mean (SD)	0.44 (0.73)	0.32 (0.49)		
Week 52 Mean (SD)	0.02 (0.13)	0.03 (0.14)		
Week 52 Adjusted Mean Change (SE)	-0.37 (0.02)	-0.37 (0.02)	-0.01 [-0.05; 0.04]	0.762
<b>Carrier, N</b>	<b>51</b>	<b>34</b>		
N'	51	34		
Baseline Mean (SD)	0.35 (0.65)	0.48 (0.83)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.01)	-0.39 (0.01)	-0.00 [-0.04; 0.03]	0.916
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.11 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs11726476 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.112</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	0.36 (0.68)	0.26 (0.55)		
Week 52 Mean (SD)	0.02 (0.11)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.38 (0.01)	-0.40 (0.01)	0.02 [-0.02; 0.05]	0.379
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	0.41 (0.69)	0.65 (0.82)		
Week 52 Mean (SD)	0.00 (0.00)	0.03 (0.15)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.01)	-0.36 (0.02)	-0.04 [-0.08; 0.01]	0.086
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.12 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs10609046 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.209</b>				
<b>Non-carrier, N</b>	<b>62</b>	<b>47</b>		
N'	62	47		
Baseline Mean (SD)	0.39 (0.68)	0.41 (0.69)		
Week 52 Mean (SD)	0.01 (0.09)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.01)	-0.40 (0.01)	0.01 [-0.03; 0.04]	0.708
<b>Carrier, N</b>	<b>20</b>	<b>18</b>		
N'	20	18		
Baseline Mean (SD)	0.38 (0.73)	0.43 (0.70)		
Week 52 Mean (SD)	0.00 (0.00)	0.04 (0.17)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.02)	-0.36 (0.02)	-0.04 [-0.09; 0.02]	0.178
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.13 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs8007401 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.924</b>				
<b>Non-carrier, N</b>	<b>63</b>	<b>51</b>		
N'	63	51		
Baseline Mean (SD)	0.39 (0.67)	0.43 (0.68)		
Week 52 Mean (SD)	0.00 (0.00)	0.02 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.01)	-0.38 (0.01)	-0.02 [-0.05; 0.01]	0.262
<b>Carrier, N</b>	<b>19</b>	<b>12</b>		
N'	19	12		
Baseline Mean (SD)	0.33 (0.71)	0.32 (0.77)		
Week 52 Mean (SD)	0.04 (0.16)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.36 (0.02)	-0.40 (0.02)	0.04 [-0.03; 0.10]	0.248
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.14 Tender Dactylitis Count - Change from Baseline by Lead Candidate Variant rs7349145 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.824</b>				
<b>Non-carrier, N</b>	<b>71</b>	<b>53</b>		
N'	71	53		
Baseline Mean (SD)	0.34 (0.68)	0.36 (0.70)		
Week 52 Mean (SD)	0.01 (0.09)	0.02 (0.10)		
Week 52 Adjusted Mean Change (SE)	-0.39 (0.01)	-0.38 (0.01)	-0.01 [-0.04; 0.02]	0.574
<b>Carrier, N</b>	<b>13</b>	<b>10</b>		
N'	13	10		
Baseline Mean (SD)	0.67 (0.71)	0.48 (0.66)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.39 (0.02)	-0.40 (0.03)	0.00 [-0.07; 0.07]	0.896
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.15 Tender Dactylitis Count - Change from Baseline by Lead Candidate Allele Score (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.033</b>				
<b>Low score, N</b>	<b>22</b>	<b>26</b>		
N'	22	26		
Baseline Mean (SD)	0.42 (0.73)	0.34 (0.62)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.02)	-0.40 (0.02)	-0.00 [-0.06; 0.05]	0.849
<b>High score, N</b>	<b>63</b>	<b>41</b>		
N'	63	41		
Baseline Mean (SD)	0.38 (0.67)	0.44 (0.72)		
Week 52 Mean (SD)	0.01 (0.09)	0.02 (0.11)		
Week 52 Adjusted Mean Change (SE)	-0.39 (0.01)	-0.38 (0.01)	-0.01 [-0.04; 0.02]	0.601
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.16 Tender Dactylitis Count - Change from Baseline by Linkage Variant rs10891185 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.549</b>				
<b>Non-carrier, N</b>	<b>51</b>	<b>35</b>		
N'	51	35		
Baseline Mean (SD)	0.45 (0.72)	0.39 (0.67)		
Week 52 Mean (SD)	0.01 (0.10)	0.02 (0.13)		
Week 52 Adjusted Mean Change (SE)	-0.39 (0.01)	-0.37 (0.01)	-0.02 [-0.06; 0.02]	0.344
<b>Carrier, N</b>	<b>34</b>	<b>32</b>		
N'	34	32		
Baseline Mean (SD)	0.29 (0.62)	0.41 (0.70)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.01)	-0.40 (0.01)	0.00 [-0.04; 0.04]	0.879
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.17 Tender Dactylitis Count - Change from Baseline by Linkage Variant rs12065362 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.126</b>				
<b>Non-carrier, N</b>	<b>30</b>	<b>31</b>		
N'	30	31		
Baseline Mean (SD)	0.44 (0.73)	0.30 (0.46)		
Week 52 Mean (SD)	0.02 (0.13)	0.03 (0.14)		
Week 52 Adjusted Mean Change (SE)	-0.38 (0.02)	-0.37 (0.02)	-0.01 [-0.05; 0.04]	0.711
<b>Carrier, N</b>	<b>55</b>	<b>36</b>		
N'	55	36		
Baseline Mean (SD)	0.36 (0.67)	0.49 (0.82)		
Week 52 Mean (SD)	0.00 (0.00)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.01)	-0.40 (0.01)	-0.00 [-0.04; 0.03]	0.921
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				



### 59.18 Tender Dactylitis Count - Change from Baseline by Linkage Variant rs11721988 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.112</b>				
<b>Non-carrier, N</b>	<b>43</b>	<b>43</b>		
N'	43	43		
Baseline Mean (SD)	0.36 (0.68)	0.26 (0.55)		
Week 52 Mean (SD)	0.02 (0.11)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.38 (0.01)	-0.40 (0.01)	0.02 [-0.02; 0.05]	0.379
<b>Carrier, N</b>	<b>42</b>	<b>24</b>		
N'	42	24		
Baseline Mean (SD)	0.41 (0.69)	0.65 (0.82)		
Week 52 Mean (SD)	0.00 (0.00)	0.03 (0.15)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.01)	-0.36 (0.02)	-0.04 [-0.08; 0.01]	0.086
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

### 59.19 Tender Dactylitis Count - Change from Baseline by Linkage Variant rs7787032 (FAS)

	Treatment Groups		Comparison	
	SEC (N=110)	ADA (N=101)	Mean Difference [95% CI]	p-value
<b>Interaction test: p=0.154</b>				
<b>Non-carrier, N</b>	<b>65</b>	<b>49</b>		
N'	65	49		
Baseline Mean (SD)	0.41 (0.68)	0.39 (0.68)		
Week 52 Mean (SD)	0.01 (0.09)	0.00 (0.00)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.01)	-0.40 (0.01)	0.01 [-0.03; 0.04]	0.702
<b>Carrier, N</b>	<b>18</b>	<b>18</b>		
N'	18	18		
Baseline Mean (SD)	0.36 (0.74)	0.43 (0.70)		
Week 52 Mean (SD)	0.00 (0.00)	0.04 (0.17)		
Week 52 Adjusted Mean Change (SE)	-0.40 (0.02)	-0.36 (0.02)	-0.04 [-0.09; 0.02]	0.187
<p>N': Number of patients in the analysis            CI: Confidence interval            MMRM: Mixed effects repeated measures model            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Interaction test and adjusted mean change, mean difference and p-value from MMRM with fixed effects:            treatment, visit, weight, baseline value, subgroup, treatment x visit, baseline value x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit            Covariance structure: unstructured (un)</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients in the analysis is at least 10 in each subgroup.</p>				

## Safety Analysis

### S.1.1 Adverse Events, Binary Analysis (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
Any AE, n (%)	74 (67.3)	71 (70.3)	0.87 [0.48; 1.56] 0.636	0.96 [0.80; 1.15] 0.635	-0.030 [-0.155; 0.095] 0.635
Any AE, disease specific events excluded, n (%)	73 (66.4)	68 (67.3)	0.96 [0.54; 1.70] 0.882	0.99 [0.82; 1.19] 0.882	-0.010 [-0.137; 0.118] 0.882
Any SAE, n (%)	7 (6.4)	7 (6.9)	0.91 [0.31; 2.70] 0.869	0.92 [0.33; 2.53] 0.869	-0.006 [-0.073; 0.062] 0.869
Any SAE, disease specific events excluded, n (%)	7 (6.4)	6 (5.9)	1.08 [0.35; 3.32] 0.898	1.07 [0.37; 3.08] 0.898	0.004 [-0.061; 0.069] 0.898
Any severe AE, n (%)	3 (2.7)	2 (2.0)	1.39 [0.23; 8.48] 0.720	1.38 [0.23; 8.08] 0.723	0.007 [-0.033; 0.048] 0.720
Any severe AE, disease specific events excluded, n (%)	3 (2.7)	2 (2.0)	1.39 [0.23; 8.48] 0.720	1.38 [0.23; 8.08] 0.723	0.007 [-0.033; 0.048] 0.720
Any AE leading to study discontinuation, n (%)	0 (0.0)	3 (3.0)	N.E.	0.13 [0.01; 2.51] 0.177	-0.030 [-0.063; 0.003] 0.079
Any AE leading to study drug discontinuation, n (%)	1 (0.9)	3 (3.0)	0.30 [0.03; 2.93] 0.264	0.31 [0.03; 2.90] 0.302	-0.021 [-0.058; 0.017] 0.282
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>OR (with Wald CI) from logistic regression model with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value).</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

## List of Excluded Disease-Specific SOC/Preferred Terms

<b>Preferred Terms (grouped by disease-specific event category)</b>
<b>General disorders and administration site conditions</b>
Fatigue
Malaise
Pain
Peripheral swelling
<b>Investigations</b>
Antinuclear antibody positive
DNA antibody positive
Double stranded DNA antibody
Double stranded DNA antibody positive
<b>Musculoskeletal and connective tissue disorders</b>
Arthralgia
Arthritis
Arthropathy
Back pain
Bone lesion
Bone pain
Bursitis
Chondritis
Chondropathy
Dactylitis
Fibromyalgia
Foot deformity
Groin pain
Joint effusion
Joint swelling
Muscular weakness
Musculoskeletal discomfort
Musculoskeletal pain
Musculoskeletal stiffness
Myalgia
Neck pain
Pain in extremity
Patellofemoral pain syndrome
Periarthritis
Plantar fasciitis

<b>Preferred Terms (grouped by disease-specific event category)</b>
Polyarthritis
Psoriatic arthropathy
Soft tissue swelling
Spinal pain
Synovitis
Tendon disorder
Tendon pain
Tendonitis
Tenosynovitis
<b>Nervous system disorders</b>
Lethargy
<b>Psychiatric disorders</b>
Mood altered
Sleep disorder
Stress
<b>Skin and subcutaneous tissue disorders</b>
Dry skin
Erythema
Pruritus
Pruritus generalised
Psoriasis
Skin discolouration
Skin disorder
Skin exfoliation
Skin induration
Skin irritation
Skin lesion

### S.1.2 Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
<b>Any adverse event, n (%)</b>	<b>74 (67.3)</b>	<b>71 (70.3)</b>	<b>0.87</b> <b>[0.48; 1.56]</b> <b>0.636</b>	<b>0.96</b> <b>[0.80; 1.15]</b> <b>0.635</b>	<b>-0.030</b> <b>[-0.155; 0.095]</b> <b>0.635</b>
Mild, n (%)	71 (64.5)	64 (63.4)	1.05 [0.60; 1.85] 0.859	1.02 [0.83; 1.25] 0.859	0.012 [-0.118; 0.141] 0.859
Moderate, n (%)	23 (20.9)	35 (34.7)	0.50 [0.27; 0.92] 0.025	0.60 [0.38; 0.95] 0.028	-0.137 [-0.257; -0.017] 0.025
Severe, n (%)	3 (2.7)	2 (2.0)	1.39 [0.23; 8.48] 0.720	1.38 [0.23; 8.08] 0.723	0.007 [-0.033; 0.048] 0.720
<b>Infections and infestations, n (%)</b>	<b>62 (56.4)</b>	<b>48 (47.5)</b>	<b>1.43</b> <b>[0.83; 2.45]</b> <b>0.199</b>	<b>1.19</b> <b>[0.91; 1.54]</b> <b>0.203</b>	<b>0.088</b> <b>[-0.046; 0.223]</b> <b>0.198</b>
Mild, n (%)	57 (51.8)	38 (37.6)	1.78 [1.03; 3.09] 0.038	1.38 [1.01; 1.88] 0.042	0.142 [0.009; 0.275] 0.036
Moderate, n (%)	11 (10.0)	17 (16.8)	0.55 [0.24; 1.24] 0.143	0.59 [0.29; 1.21] 0.150	-0.068 [-0.160; 0.024] 0.146
Severe, n (%)	1 (0.9)	0 (0.0)	N.E.	2.76 [0.11; 66.91] 0.533	0.009 [-0.009; 0.027] 0.315
<b>Nasopharyngitis, n (%)</b>	<b>25 (22.7)</b>	<b>12 (11.9)</b>	<b>2.18</b> <b>[1.03; 4.62]</b> <b>0.036</b>	<b>1.91</b> <b>[1.02; 3.60]</b> <b>0.045</b>	<b>0.108</b> <b>[0.008; 0.209]</b> <b>0.035</b>
Mild, n (%)	25 (22.7)	9 (8.9)	3.01 [1.33; 6.81] 0.005	2.55 [1.25; 5.20] 0.010	0.138 [0.042; 0.234] 0.005
Moderate, n (%)	1 (0.9)	3 (3.0)	0.30 [0.03; 2.93] 0.264	0.31 [0.03; 2.90] 0.302	-0.021 [-0.058; 0.017] 0.282
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infection, n (%)</b>	<b>8 (7.3)</b>	<b>10 (9.9)</b>	<b>0.71</b> <b>[0.27; 1.89]</b> <b>0.495</b>	<b>0.73</b> <b>[0.30; 1.79]</b> <b>0.497</b>	<b>-0.026</b> <b>[-0.102; 0.050]</b> <b>0.497</b>
Mild, n (%)	6 (5.5)	9 (8.9)	0.59 [0.20; 1.72] 0.328	0.61 [0.23; 1.66] 0.335	-0.035 [-0.104; 0.035] 0.333
Moderate, n (%)	2 (1.8)	2 (2.0)	0.92 [0.13; 6.63] 0.931	0.92 [0.13; 6.40] 0.931	-0.002 [-0.039; 0.035] 0.931

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Musculoskeletal and connective tissue disorders, n (%)</b>	<b>16 (14.5)</b>	<b>23 (22.8)</b>	<b>0.58</b> <b>[0.29; 1.17]</b> <b>0.124</b>	<b>0.64</b> <b>[0.36; 1.14]</b> <b>0.129</b>	<b>-0.082</b> <b>[-0.187; 0.023]</b> <b>0.125</b>
Mild, n (%)	13 (11.8)	17 (16.8)	0.66 [0.30; 1.44] 0.297	0.70 [0.36; 1.37] 0.301	-0.050 [-0.145; 0.045] 0.299
Moderate, n (%)	5 (4.5)	7 (6.9)	0.64 [0.20; 2.08] 0.455	0.66 [0.21; 2.00] 0.459	-0.024 [-0.087; 0.039] 0.458
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Skin and subcutaneous tissue disorders, n (%)</b>	<b>16 (14.5)</b>	<b>18 (17.8)</b>	<b>0.78</b> <b>[0.38; 1.64]</b> <b>0.518</b>	<b>0.82</b> <b>[0.44; 1.51]</b> <b>0.519</b>	<b>-0.033</b> <b>[-0.132; 0.067]</b> <b>0.519</b>
Mild, n (%)	13 (11.8)	14 (13.9)	0.83 [0.37; 1.87] 0.657	0.85 [0.42; 1.73] 0.657	-0.020 [-0.111; 0.070] 0.658
Moderate, n (%)	2 (1.8)	7 (6.9)	0.25 [0.05; 1.23] 0.060	0.26 [0.06; 1.23] 0.090	-0.051 [-0.107; 0.004] 0.071
Severe, n (%)	2 (1.8)	1 (1.0)	1.85 [0.17; 20.74] 0.608	1.84 [0.17; 19.95] 0.617	0.008 [-0.023; 0.040] 0.607
<b>Nervous system disorders, n (%)</b>	<b>11 (10.0)</b>	<b>17 (16.8)</b>	<b>0.55</b> <b>[0.24; 1.24]</b> <b>0.143</b>	<b>0.59</b> <b>[0.29; 1.21]</b> <b>0.150</b>	<b>-0.068</b> <b>[-0.160; 0.024]</b> <b>0.146</b>
Mild, n (%)	11 (10.0)	13 (12.9)	0.75 [0.32; 1.76] 0.512	0.78 [0.36; 1.65] 0.513	-0.029 [-0.115; 0.057] 0.513
Moderate, n (%)	0 (0.0)	6 (5.9)	N.E.	0.07 [0.00; 1.24] 0.070	-0.059 [-0.106; -0.013] 0.012
Severe, n (%)	0 (0.0)	1 (1.0)	N.E.	0.31 [0.01; 7.43] 0.467	-0.010 [-0.029; 0.009] 0.315
<b>Gastrointestinal disorders, n (%)</b>	<b>14 (12.7)</b>	<b>16 (15.8)</b>	<b>0.77</b> <b>[0.36; 1.68]</b> <b>0.518</b>	<b>0.80</b> <b>[0.41; 1.56]</b> <b>0.519</b>	<b>-0.031</b> <b>[-0.126; 0.063]</b> <b>0.519</b>
Mild, n (%)	14 (12.7)	15 (14.9)	0.84 [0.38; 1.83] 0.655	0.86 [0.44; 1.69] 0.655	-0.021 [-0.114; 0.072] 0.655
Moderate, n (%)	0 (0.0)	1 (1.0)	N.E.	0.31 [0.01; 7.43] 0.467	-0.010 [-0.029; 0.009] 0.315
Severe, n (%)	1 (0.9)	0 (0.0)	N.E.	2.76 [0.11; 66.91] 0.533	0.009 [-0.009; 0.027] 0.315

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Respiratory, thoracic and mediastinal disorders, n (%)</b>	<b>13 (11.8)</b>	<b>7 (6.9)</b>	<b>1.80</b> [0.69; 4.71] <b>0.222</b>	<b>1.71</b> [0.71; 4.10] <b>0.234</b>	<b>0.049</b> [-0.029; 0.127] <b>0.220</b>
Mild, n (%)	11 (10.0)	7 (6.9)	1.49 [0.56; 4.01] 0.423	1.44 [0.58; 3.58] 0.429	0.031 [-0.044; 0.106] 0.421
Moderate, n (%)	4 (3.6)	1 (1.0)	3.77 [0.41; 34.34] 0.190	3.67 [0.42; 32.32] 0.241	0.026 [-0.013; 0.066] 0.194
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Investigations, n (%)</b>	<b>6 (5.5)</b>	<b>12 (11.9)</b>	<b>0.43</b> [0.15; 1.19] <b>0.093</b>	<b>0.46</b> [0.18; 1.18] <b>0.105</b>	<b>-0.064</b> [-0.140; 0.012] <b>0.098</b>
Mild, n (%)	6 (5.5)	11 (10.9)	0.47 [0.17; 1.33] 0.145	0.50 [0.19; 1.30] 0.157	-0.054 [-0.128; 0.020] 0.150
Moderate, n (%)	2 (1.8)	4 (4.0)	0.45 [0.08; 2.51] 0.347	0.46 [0.09; 2.45] 0.363	-0.021 [-0.067; 0.024] 0.356
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>General disorders and administration site conditions, n (%)</b>	<b>10 (9.1)</b>	<b>10 (9.9)</b>	<b>0.91</b> [0.36; 2.29] <b>0.841</b>	<b>0.92</b> [0.40; 2.11] <b>0.841</b>	<b>-0.008</b> [-0.087; 0.071] <b>0.841</b>
Mild, n (%)	8 (7.3)	8 (7.9)	0.91 [0.33; 2.53] 0.859	0.92 [0.36; 2.36] 0.859	-0.006 [-0.078; 0.065] 0.859
Moderate, n (%)	2 (1.8)	2 (2.0)	0.92 [0.13; 6.63] 0.931	0.92 [0.13; 6.40] 0.931	-0.002 [-0.039; 0.035] 0.931
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

N: Number of patients in the analysis  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

OR (with Wald CI) from logistic regression model with treatment as predictor, p-value from likelihood-ratio test.  
RR and RD calculated directly (with Wald CI and p-value).

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.



### S.1.3 Serious Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
<b>Any SAE, n (%)</b>	<b>7 (6.4)</b>	<b>7 (6.9)</b>	<b>0.91</b> [0.31; 2.70] <b>0.869</b>	<b>0.92</b> [0.33; 2.53] <b>0.869</b>	<b>-0.006</b> [-0.073; 0.062] <b>0.869</b>
Mild, n (%)	2 (1.8)	1 (1.0)	1.85 [0.17; 20.74] 0.608	1.84 [0.17; 19.95] 0.617	0.008 [-0.023; 0.040] 0.607
Moderate, n (%)	3 (2.7)	6 (5.9)	0.44 [0.11; 1.82] 0.246	0.46 [0.12; 1.79] 0.262	-0.032 [-0.087; 0.023] 0.254
Severe, n (%)	3 (2.7)	2 (2.0)	1.39 [0.23; 8.48] 0.720	1.38 [0.23; 8.08] 0.723	0.007 [-0.033; 0.048] 0.720
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR (with Wald CI) from logistic regression model with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value).</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.1.4 Any Adverse Event Leading to Study Discontinuation by SOC and PT, Frequencies (SAF)

	Treatment Groups	
	SEC (N=110)	ADA (N=101)
N'	110	101
Musculoskeletal and connective tissue disorders, n (%)	0 (0.0)	1 (1.0)
Intervertebral disc protrusion, n (%)	0 (0.0)	1 (1.0)
Nervous system disorders, n (%)	0 (0.0)	1 (1.0)
Paraesthesia, n (%)	0 (0.0)	1 (1.0)
Skin and subcutaneous tissue disorders, n (%)	0 (0.0)	1 (1.0)
Psoriasis, n (%)	0 (0.0)	1 (1.0)
N': Number of patients in the analysis		

### S.1.5 Any Adverse Event Leading to Study Drug Discontinuation by SOC and PT, Frequencies (SAF)

	Treatment Groups	
	SEC (N=110)	ADA (N=101)
N'	110	101
Musculoskeletal and connective tissue disorders, n (%)	0 (0.0)	1 (1.0)
Intervertebral disc protrusion, n (%)	0 (0.0)	1 (1.0)
Nervous system disorders, n (%)	0 (0.0)	1 (1.0)
Paraesthesia, n (%)	0 (0.0)	1 (1.0)
Skin and subcutaneous tissue disorders, n (%)	1 (0.9)	1 (1.0)
Palmoplantar pustulosis, n (%)	1 (0.9)	0 (0.0)
Psoriasis, n (%)	0 (0.0)	1 (1.0)
N': Number of patients in the analysis		

### S.1.6 Adverse Events of Special Interest by Severity, Binary Analysis (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
<b>Candida infections, n (%)</b>	<b>3 (2.7)</b>	<b>2 (2.0)</b>	<b>1.39</b> <b>[0.23; 8.48]</b> <b>0.720</b>	<b>1.38</b> <b>[0.23; 8.08]</b> <b>0.723</b>	<b>0.007</b> <b>[-0.033; 0.048]</b> <b>0.720</b>
Mild, n (%)	3 (2.7)	2 (2.0)	1.39 [0.23; 8.48] 0.720	1.38 [0.23; 8.08] 0.723	0.007 [-0.033; 0.048] 0.720
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Cardio-cerebrovascular-related events, n (%)</b>	<b>3 (2.7)</b>	<b>6 (5.9)</b>	<b>0.44</b> <b>[0.11; 1.82]</b> <b>0.246</b>	<b>0.46</b> <b>[0.12; 1.79]</b> <b>0.262</b>	<b>-0.032</b> <b>[-0.087; 0.023]</b> <b>0.254</b>
Mild, n (%)	2 (1.8)	4 (4.0)	0.45 [0.08; 2.51] 0.347	0.46 [0.09; 2.45] 0.363	-0.021 [-0.067; 0.024] 0.356
Moderate, n (%)	0 (0.0)	3 (3.0)	N.E.	0.13 [0.01; 2.51] 0.177	-0.030 [-0.063; 0.003] 0.079
Severe, n (%)	1 (0.9)	0 (0.0)	N.E.	2.76 [0.11; 66.91] 0.533	0.009 [-0.009; 0.027] 0.315
Serious, n (%)	1 (0.9)	2 (2.0)	0.45 [0.04; 5.09] 0.509	0.46 [0.04; 4.99] 0.522	-0.011 [-0.043; 0.022] 0.518
<b>Inflammatory bowel disease, n (%)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>N.E.</b>	<b>N.E.</b>	<b>N.E.</b>
Mild, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections, n (%)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>N.E.</b>	<b>N.E.</b>	<b>N.E.</b>
Mild, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections, n (%)</b>	<b>2 (1.8)</b>	<b>2 (2.0)</b>	<b>0.92</b> <b>[0.13; 6.63]</b> <b>0.931</b>	<b>0.92</b> <b>[0.13; 6.40]</b> <b>0.931</b>	<b>-0.002</b> <b>[-0.039; 0.035]</b> <b>0.931</b>

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Mild, n (%)	2 (1.8)	2 (2.0)	0.92 [0.13; 6.63] 0.931	0.92 [0.13; 6.40] 0.931	-0.002 [-0.039; 0.035] 0.931
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Staphylococcal infections, n (%)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>N.E.</b>	<b>N.E.</b>	<b>N.E.</b>
Mild, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death), n (%)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>N.E.</b>	<b>N.E.</b>	<b>N.E.</b>
Mild, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ), n (%)</b>	<b>1 (0.9)</b>	<b>1 (1.0)</b>	<b>0.92</b> [0.06; 14.86] <b>0.952</b>	<b>0.92</b> [0.06; 14.49] <b>0.952</b>	<b>-0.001</b> [-0.027; 0.025] <b>0.952</b>
Mild, n (%)	0 (0.0)	1 (1.0)	N.E.	0.31 [0.01; 7.43] 0.467	-0.010 [-0.029; 0.009] 0.315
Moderate, n (%)	1 (0.9)	0 (0.0)	N.E.	2.76 [0.11; 66.91] 0.533	0.009 [-0.009; 0.027] 0.315
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC), n (%)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>N.E.</b>	<b>N.E.</b>	<b>N.E.</b>
Mild, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections, n (%)</b>	<b>44 (40.0)</b>	<b>31 (30.7)</b>	<b>1.51</b> [0.85; 2.66] <b>0.157</b>	<b>1.30</b> [0.90; 1.89] <b>0.163</b>	<b>0.093</b> [-0.035; 0.221] <b>0.155</b>
Mild, n (%)	42 (38.2)	25 (24.8)	1.88 [1.04; 3.40] 0.035	1.54 [1.02; 2.34] 0.041	0.134 [0.010; 0.258] 0.033

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	6 (5.5)	7 (6.9)	0.77 [0.25; 2.39] 0.656	0.79 [0.27; 2.26] 0.657	-0.015 [-0.080; 0.050] 0.657
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

N: Number of patients in the analysis  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

OR (with Wald CI) from logistic regression model with treatment as predictor, p-value from likelihood-ratio test.  
RR and RD calculated directly (with Wald CI and p-value).

OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

### S.2.1 Adverse Events, Binary Analysis by Age (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' < 65 years	103	94			
N' ≥ 65 years	7	7			
<b>Any AE</b>					
Interaction test	p=0.903				
< 65 years, n (%)	69 (67.0)	66 (70.2)	0.86 [0.47; 1.57] 0.626	0.95 [0.79; 1.15] 0.626	-0.032 [-0.162; 0.097] 0.626
≥ 65 years, n (%)	5 (71.4)	5 (71.4)	1.00 [0.10; 10.17] 1.000	1.00 [0.52; 1.94] 1.000	0.000 [-0.473; 0.473] 1.000
<b>Any SAE</b>					
Interaction test	p=0.953				
< 65 years, n (%)	6 (5.8)	6 (6.4)	0.91 [0.28; 2.92] 0.870	0.91 [0.30; 2.73] 0.870	-0.006 [-0.073; 0.061] 0.870
≥ 65 years, n (%)	1 (14.3)	1 (14.3)	1.00 [0.05; 19.96] 1.000	1.00 [0.08; 13.02] 1.000	0.000 [-0.367; 0.367] 1.000
<b>Any severe AE</b>					
Interaction test	N.E.				
< 65 years, n (%)	2 (1.9)	2 (2.1)	0.91 [0.13; 6.60] 0.926	0.91 [0.13; 6.35] 0.926	-0.002 [-0.041; 0.038] 0.927
≥ 65 years, n (%)	1 (14.3)	0 (0.0)	N.E.	3.00 [0.14; 63.15] 0.480	0.143 [-0.116; 0.402] 0.280
<b>Any AE leading to study discontinuation</b>					
Interaction test	N.E.				
< 65 years, n (%)	0 (0.0)	3 (3.2)	N.E.	0.13 [0.01; 2.49] 0.176	-0.032 [-0.067; 0.004] 0.078
≥ 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Any AE leading to study drug discontinuation</b>					
Interaction test	N.E.				
< 65 years, n (%)	1 (1.0)	3 (3.2)	0.30 [0.03; 2.91] 0.261	0.30 [0.03; 2.87] 0.299	-0.022 [-0.062; 0.018] 0.280

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
≥ 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					



## S.2.2 Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' < 65 years	103	94			
N' ≥ 65 years	7	7			
<b>Nasopharyngitis</b>					
Interaction test	p=0.483				
< 65 years, n (%)	23 (22.3)	10 (10.6)	2.41 [1.08; 5.39] 0.026	2.10 [1.06; 4.18] 0.035	0.117 [0.015; 0.219] 0.024
≥ 65 years, n (%)	2 (28.6)	2 (28.6)	1.00 [0.10; 10.17] 1.000	1.00 [0.19; 5.24] 1.000	0.000 [-0.473; 0.473] 1.000
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.  Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (p &lt; 0.05 in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### **S.2.3 Serious Adverse Events by SOC and PT, Binary Analysis by Age (SAF)**

There are no data meeting the display criteria for this table.

## **S.2.4 Severe Adverse Events by SOC and PT, Binary Analysis by Age (SAF)**

There are no data meeting the display criteria for this table.

### S.2.5 Adverse Events of Special Interest, Binary Analysis by Age (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' < 65 years	103	94			
N' ≥ 65 years	7	7			
<b>Candida infections</b>					
Interaction test	N.E.				
< 65 years, n (%)	3 (2.9)	2 (2.1)	1.38 [0.23; 8.44] 0.725	1.37 [0.23; 8.01] 0.728	0.008 [-0.036; 0.052] 0.725
≥ 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	p=0.552				
< 65 years, n (%)	2 (1.9)	5 (5.3)	0.35 [0.07; 1.86] 0.196	0.37 [0.07; 1.84] 0.222	-0.034 [-0.086; 0.019] 0.208
≥ 65 years, n (%)	1 (14.3)	1 (14.3)	1.00 [0.05; 19.96] 1.000	1.00 [0.08; 13.02] 1.000	0.000 [-0.367; 0.367] 1.000
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
< 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
≥ 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
< 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
≥ 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
< 65 years, n (%)	2 (1.9)	2 (2.1)	0.91 [0.13; 6.60] 0.926	0.91 [0.13; 6.35] 0.926	-0.002 [-0.041; 0.038] 0.927
≥ 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Staphylococcal infections</b>					
Interaction test	N.E.				
< 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
≥ 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
< 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
≥ 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
< 65 years, n (%)	1 (1.0)	1 (1.1)	0.91 [0.06; 14.79] 0.948	0.91 [0.06; 14.39] 0.948	-0.001 [-0.029; 0.027] 0.948
≥ 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
< 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
≥ 65 years, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.723				
< 65 years, n (%)	42 (40.8)	29 (30.9)	1.54 [0.86; 2.78] 0.146	1.32 [0.90; 1.94] 0.152	0.099 [-0.034; 0.232] 0.144
≥ 65 years, n (%)	2 (28.6)	2 (28.6)	1.00 [0.10; 10.17] 1.000	1.00 [0.19; 5.24] 1.000	0.000 [-0.473; 0.473] 1.000
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.3.1 Adverse Events, Binary Analysis by Gender (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' Male	66	57			
N' Female	44	44			
Any AE					
Interaction test	p=0.504				
Male, n (%)	42 (63.6)	40 (70.2)	0.74 [0.35; 1.59] 0.442	0.91 [0.71; 1.16] 0.441	-0.065 [-0.231; 0.101] 0.440
Female, n (%)	32 (72.7)	31 (70.5)	1.12 [0.44; 2.83] 0.813	1.03 [0.79; 1.34] 0.813	0.023 [-0.166; 0.211] 0.813
Any SAE					
Interaction test	p=0.102				
Male, n (%)	6 (9.1)	3 (5.3)	1.80 [0.43; 7.55] 0.411	1.73 [0.45; 6.60] 0.424	0.038 [-0.052; 0.129] 0.407
Female, n (%)	1 (2.3)	4 (9.1)	0.23 [0.02; 2.17] 0.154	0.25 [0.03; 2.15] 0.207	-0.068 [-0.164; 0.027] 0.163
Any severe AE					
Interaction test	N.E.				
Male, n (%)	3 (4.5)	1 (1.8)	2.67 [0.27; 26.38] 0.371	2.59 [0.28; 24.22] 0.404	0.028 [-0.033; 0.089] 0.368
Female, n (%)	0 (0.0)	1 (2.3)	N.E.	0.33 [0.01; 7.97] 0.497	-0.023 [-0.067; 0.021] 0.312
Any AE leading to study discontinuation					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	2 (3.5)	N.E.	0.17 [0.01; 3.53] 0.254	-0.035 [-0.083; 0.013] 0.150
Female, n (%)	0 (0.0)	1 (2.3)	N.E.	0.33 [0.01; 7.97] 0.497	-0.023 [-0.067; 0.021] 0.312
Any AE leading to study drug discontinuation					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Male, n (%)	0 (0.0)	2 (3.5)	N.E.	0.17 [0.01; 3.53] 0.254	-0.035 [-0.083; 0.013] 0.150
Female, n (%)	1 (2.3)	1 (2.3)	1.00 [0.06; 16.51] 1.000	1.00 [0.06; 15.49] 1.000	0.000 [-0.062; 0.062] 1.000

N: Number of patients in the analysis  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup\*treatment groups.  
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

### S.3.2 Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' Male	66	57			
N' Female	44	44			
<b>Nasopharyngitis</b>					
Interaction test	p=0.343				
Male, n (%)	17 (25.8)	6 (10.5)	2.95 [1.07; 8.10] 0.027	2.45 [1.03; 5.79] 0.042	0.152 [0.020; 0.285] 0.024
Female, n (%)	8 (18.2)	6 (13.6)	1.41 [0.44; 4.46] 0.559	1.33 [0.50; 3.53] 0.562	0.045 [-0.107; 0.198] 0.559
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.  Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					



### **S.3.3 Serious Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)**

There are no data meeting the display criteria for this table.

### **S.3.4 Severe Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)**

There are no data meeting the display criteria for this table.

### S.3.5 Adverse Events of Special Interest, Binary Analysis by Gender (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' Male	66	57			
N' Female	44	44			
<b>Candida infections</b>					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	3 (6.8)	2 (4.5)	1.54 [0.24; 9.68] 0.644	1.50 [0.26; 8.54] 0.648	0.023 [-0.074; 0.119] 0.645
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	N.E.				
Male, n (%)	3 (4.5)	5 (8.8)	0.50 [0.11; 2.17] 0.343	0.52 [0.13; 2.07] 0.353	-0.042 [-0.131; 0.047] 0.352
Female, n (%)	0 (0.0)	1 (2.3)	N.E.	0.33 [0.01; 7.97] 0.497	-0.023 [-0.067; 0.021] 0.312
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	p=0.941				
Male, n (%)	1 (1.5)	1 (1.8)	0.86 [0.05; 14.09] 0.917	0.86 [0.06; 13.50] 0.917	-0.002 [-0.047; 0.043] 0.917
Female, n (%)	1 (2.3)	1 (2.3)	1.00 [0.06; 16.51] 1.000	1.00 [0.06; 15.49] 1.000	0.000 [-0.062; 0.062] 1.000
<b>Staphylococcal infections</b>					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Male, n (%)	1 (1.5)	1 (1.8)	0.86 [0.05; 14.09] 0.917	0.86 [0.06; 13.50] 0.917	-0.002 [-0.047; 0.043] 0.917
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Male, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.749				
Male, n (%)	27 (40.9)	17 (29.8)	1.63 [0.77; 3.45] 0.199	1.37 [0.84; 2.24] 0.209	0.111 [-0.057; 0.279] 0.196
Female, n (%)	17 (38.6)	14 (31.8)	1.35 [0.56; 3.25] 0.503	1.21 [0.69; 2.15] 0.505	0.068 [-0.131; 0.267] 0.502
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.4.1 Adverse Events, Binary Analysis by Disease Severity (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' PASDAS < 5.4	24	21			
N' PASDAS ≥ 5.4	86	80			
<b>Any AE</b>					
Interaction test	p=0.231				
PASDAS < 5.4, n (%)	14 (58.3)	16 (76.2)	0.44 [0.12; 1.59] 0.201	0.77 [0.51; 1.16] 0.206	-0.179 [-0.447; 0.090] 0.192
PASDAS ≥ 5.4, n (%)	60 (69.8)	55 (68.8)	1.05 [0.54; 2.03] 0.887	1.01 [0.83; 1.24] 0.887	0.010 [-0.130; 0.151] 0.887
<b>Any SAE</b>					
Interaction test	p=0.600				
PASDAS < 5.4, n (%)	3 (12.5)	2 (9.5)	1.36 [0.20; 9.02] 0.750	1.31 [0.24; 7.12] 0.753	0.030 [-0.153; 0.212] 0.749
PASDAS ≥ 5.4, n (%)	4 (4.7)	5 (6.3)	0.73 [0.19; 2.83] 0.649	0.74 [0.21; 2.67] 0.651	-0.016 [-0.085; 0.053] 0.651
<b>Any severe AE</b>					
Interaction test	p=0.684				
PASDAS < 5.4, n (%)	1 (4.2)	1 (4.8)	0.87 [0.05; 14.82] 0.923	0.88 [0.06; 13.14] 0.923	-0.006 [-0.127; 0.115] 0.923
PASDAS ≥ 5.4, n (%)	2 (2.3)	1 (1.3)	1.88 [0.17; 21.15] 0.599	1.86 [0.17; 20.12] 0.609	0.011 [-0.029; 0.051] 0.599
<b>Any AE leading to study discontinuation</b>					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	2 (9.5)	N.E.	0.18 [0.01; 3.47] 0.253	-0.095 [-0.221; 0.030] 0.137
PASDAS ≥ 5.4, n (%)	0 (0.0)	1 (1.3)	N.E.	0.31 [0.01; 7.51] 0.472	-0.013 [-0.037; 0.012] 0.314
<b>Any AE leading to study drug discontinuation</b>					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASDAS < 5.4, n (%)	1 (4.2)	2 (9.5)	0.41 [0.03; 4.91] 0.470	0.44 [0.04; 4.49] 0.486	-0.054 [-0.202; 0.095] 0.481
PASDAS ≥ 5.4, n (%)	0 (0.0)	1 (1.3)	N.E.	0.31 [0.01; 7.51] 0.472	-0.013 [-0.037; 0.012] 0.314

N: Number of patients in the analysis  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup\*treatment groups.  
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

### S.4.2 Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' PASDAS < 5.4	24	21			
N' PASDAS ≥ 5.4	86	80			
<b>Nasopharyngitis</b>					
Interaction test	p=0.085				
PASDAS < 5.4, n (%)	6 (25.0)	6 (28.6)	0.83 [0.22; 3.13] 0.787	0.88 [0.33; 2.30] 0.787	-0.036 [-0.295; 0.224] 0.787
PASDAS ≥ 5.4, n (%)	19 (22.1)	6 (7.5)	3.50 [1.32; 9.28] 0.007	2.95 [1.24; 7.00] 0.014	0.146 [0.041; 0.251] 0.006
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.  Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (p &lt; 0.05 in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### **S.4.3 Serious Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)**

There are no data meeting the display criteria for this table.



#### **S.4.4 Severe Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)**

There are no data meeting the display criteria for this table.

### S.4.5 Adverse Events of Special Interest, Binary Analysis by Disease Severity (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' PASDAS < 5.4	24	21			
N' PASDAS ≥ 5.4	86	80			
<b>Candida infections</b>					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	1 (4.2)	0 (0.0)	N.E.	2.64 [0.11; 61.54] 0.546	0.042 [-0.038; 0.122] 0.307
PASDAS ≥ 5.4, n (%)	2 (2.3)	2 (2.5)	0.93 [0.13; 6.75] 0.942	0.93 [0.13; 6.45] 0.942	-0.002 [-0.048; 0.045] 0.942
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	p=0.953				
PASDAS < 5.4, n (%)	1 (4.2)	2 (9.5)	0.41 [0.03; 4.91] 0.470	0.44 [0.04; 4.49] 0.486	-0.054 [-0.202; 0.095] 0.481
PASDAS ≥ 5.4, n (%)	2 (2.3)	4 (5.0)	0.45 [0.08; 2.54] 0.353	0.47 [0.09; 2.47] 0.369	-0.027 [-0.084; 0.031] 0.361
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
PASDAS ≥ 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
PASDAS ≥ 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	1 (4.8)	N.E.	0.29 [0.01; 6.84] 0.445	-0.048 [-0.139; 0.043] 0.306
PASDAS ≥ 5.4, n (%)	2 (2.3)	1 (1.3)	1.88 [0.17; 21.15] 0.599	1.86 [0.17; 20.12] 0.609	0.011 [-0.029; 0.051] 0.599
<b>Staphylococcal infections</b>					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASDAS < 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
PASDAS ≥ 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
PASDAS ≥ 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	1 (4.2)	0 (0.0)	N.E.	2.64 [0.11; 61.54] 0.546	0.042 [-0.038; 0.122] 0.307
PASDAS ≥ 5.4, n (%)	0 (0.0)	1 (1.3)	N.E.	0.31 [0.01; 7.51] 0.472	-0.013 [-0.037; 0.012] 0.314
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
PASDAS < 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
PASDAS ≥ 5.4, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.069				
PASDAS < 5.4, n (%)	7 (29.2)	9 (42.9)	0.55 [0.16; 1.89] 0.338	0.68 [0.31; 1.51] 0.343	-0.137 [-0.416; 0.142] 0.336
PASDAS ≥ 5.4, n (%)	37 (43.0)	22 (27.5)	1.99 [1.04; 3.81] 0.036	1.56 [1.02; 2.41] 0.042	0.155 [0.012; 0.298] 0.034
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					



### S.5.1 Adverse Events, Binary Analysis by Moderate/Severe PSO D (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' Moderate/Severe Psoriasis (Def D): No	42	51			
N' Moderate/Severe Psoriasis (Def D): Yes	68	50			
Any AE					
Interaction test p=0.926					
Moderate/Severe Psoriasis (Def D): No, n (%)	27 (64.3)	35 (68.6)	0.82 [0.35; 1.95] 0.659	0.94 [0.70; 1.25] 0.661	-0.043 [-0.236; 0.150] 0.659
Moderate/Severe Psoriasis (Def D): Yes, n (%)	47 (69.1)	36 (72.0)	0.87 [0.39; 1.94] 0.734	0.96 [0.76; 1.21] 0.733	-0.029 [-0.195; 0.137] 0.734
Any SAE					
Interaction test N.E.					
Moderate/Severe Psoriasis (Def D): No, n (%)	2 (4.8)	0 (0.0)	N.E.	6.05 [0.30; 122.60] 0.241	0.048 [-0.017; 0.112] 0.147
Moderate/Severe Psoriasis (Def D): Yes, n (%)	5 (7.4)	7 (14.0)	0.49 [0.15; 1.64] 0.241	0.53 [0.18; 1.56] 0.246	-0.066 [-0.181; 0.048] 0.255
Any severe AE					
Interaction test N.E.					
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate/Severe Psoriasis (Def D): Yes, n (%)	3 (4.4)	2 (4.0)	1.11 [0.18; 6.89] 0.912	1.10 [0.19; 6.36] 0.913	0.004 [-0.069; 0.077] 0.912
Any AE leading to study discontinuation					
Interaction test N.E.					
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	2 (3.9)	N.E.	0.24 [0.01; 4.90] 0.355	-0.039 [-0.092; 0.014] 0.149
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	1 (2.0)	N.E.	0.25 [0.01; 5.93] 0.388	-0.020 [-0.059; 0.019] 0.312
Any AE leading to study drug discontinuation					
Interaction test N.E.					

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate/Severe Psoriasis (Def D): No, n (%)	1 (2.4)	2 (3.9)	0.60 [0.05; 6.83] 0.672	0.61 [0.06; 6.47] 0.679	-0.015 [-0.086; 0.055] 0.668
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	1 (2.0)	N.E.	0.25 [0.01; 5.93] 0.388	-0.020 [-0.059; 0.019] 0.312

N: Number of patients in the analysis  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup\*treatment groups.  
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

### S.5.2 Adverse Events by SOC and PT, Binary Analysis by Moderate/Severe PSO D (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' Moderate/Severe Psoriasis (Def D): No	42	51			
N' Moderate/Severe Psoriasis (Def D): Yes	68	50			
<b>Nasopharyngitis</b>					
Interaction test	p=0.389				
Moderate/Severe Psoriasis (Def D): No, n (%)	9 (21.4)	4 (7.8)	3.20 [0.91; 11.29] 0.059	2.73 [0.91; 8.25] 0.075	0.136 [-0.009; 0.280] 0.065
Moderate/Severe Psoriasis (Def D): Yes, n (%)	16 (23.5)	8 (16.0)	1.62 [0.63; 4.14] 0.311	1.47 [0.68; 3.16] 0.324	0.075 [-0.068; 0.218] 0.303
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### **S.5.3 Serious Adverse Events by SOC and PT, Binary Analysis by Moderate/Severe PSD (SAF)**

There are no data meeting the display criteria for this table.



#### **S.5.4 Severe Adverse Events by SOC and PT, Binary Analysis by Moderate/Severe PSD (SAF)**

There are no data meeting the display criteria for this table.

### S.5.5 Adverse Events of Special Interest, Binary Analysis by Moderate/Severe PSO D (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' Moderate/Severe Psoriasis (Def D): No	42	51			
N' Moderate/Severe Psoriasis (Def D): Yes	68	50			
<b>Candida infections</b>					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	3 (7.1)	1 (2.0)	3.85 [0.39; 38.42] 0.215	3.64 [0.39; 33.74] 0.255	0.052 [-0.035; 0.139] 0.241
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	1 (2.0)	N.E.	0.25 [0.01; 5.93] 0.388	-0.020 [-0.059; 0.019] 0.312
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	p=0.896				
Moderate/Severe Psoriasis (Def D): No, n (%)	1 (2.4)	3 (5.9)	0.39 [0.04; 3.90] 0.394	0.40 [0.04; 3.75] 0.426	-0.035 [-0.114; 0.044] 0.387
Moderate/Severe Psoriasis (Def D): Yes, n (%)	2 (2.9)	3 (6.0)	0.47 [0.08; 2.95] 0.418	0.49 [0.09; 2.83] 0.425	-0.031 [-0.108; 0.047] 0.437
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	p=0.800				
Moderate/Severe Psoriasis (Def D): No, n (%)	1 (2.4)	1 (2.0)	1.22 [0.07; 20.10] 0.890	1.21 [0.08; 18.84] 0.890	0.004 [-0.056; 0.064] 0.890

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate/Severe Psoriasis (Def D): Yes, n (%)	1 (1.5)	1 (2.0)	0.73 [0.04; 11.98] 0.827	0.74 [0.05; 11.48] 0.826	-0.005 [-0.054; 0.043] 0.830
<b>Staphylococcal infections</b>					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	1 (2.4)	0 (0.0)	N.E.	3.63 [0.15; 86.81] 0.426	0.024 [-0.022; 0.070] 0.311
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	1 (2.0)	N.E.	0.25 [0.01; 5.93] 0.388	-0.020 [-0.059; 0.019] 0.312
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Moderate/Severe Psoriasis (Def D): No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Moderate/Severe Psoriasis (Def D): Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.596				
Moderate/Severe Psoriasis (Def D): No, n (%)	13 (31.0)	14 (27.5)	1.18 [0.48; 2.91] 0.711	1.13 [0.60; 2.13] 0.711	0.035 [-0.151; 0.221] 0.712
Moderate/Severe Psoriasis (Def D): Yes, n (%)	31 (45.6)	17 (34.0)	1.63 [0.76; 3.46] 0.204	1.34 [0.84; 2.14] 0.217	0.116 [-0.061; 0.293] 0.199

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>				

### S.6.1 Adverse Events, Binary Analysis by Lymphocyte Count at BL (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' ≤ Median	72	49			
N' > Median	38	52			
<b>Any AE</b>					
Interaction test	p=0.302				
≤ Median, n (%)	51 (70.8)	40 (81.6)	0.55 [0.23; 1.32] 0.171	0.87 [0.71; 1.06] 0.162	-0.108 [-0.259; 0.043] 0.161
> Median, n (%)	23 (60.5)	31 (59.6)	1.04 [0.44; 2.44] 0.931	1.02 [0.72; 1.43] 0.930	0.009 [-0.196; 0.214] 0.931
<b>Any SAE</b>					
Interaction test	p=0.947				
≤ Median, n (%)	5 (6.9)	4 (8.2)	0.84 [0.21; 3.30] 0.803	0.85 [0.24; 3.01] 0.802	-0.012 [-0.109; 0.084] 0.805
> Median, n (%)	2 (5.3)	3 (5.8)	0.91 [0.14; 5.71] 0.917	0.91 [0.16; 5.20] 0.918	-0.005 [-0.100; 0.090] 0.917
<b>Any severe AE</b>					
Interaction test	N.E.				
≤ Median, n (%)	3 (4.2)	2 (4.1)	1.02 [0.16; 6.35] 0.982	1.02 [0.18; 5.89] 0.982	0.001 [-0.071; 0.073] 0.982
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Any AE leading to study discontinuation</b>					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	1 (2.0)	N.E.	0.23 [0.01; 5.49] 0.363	-0.020 [-0.060; 0.019] 0.312
> Median, n (%)	0 (0.0)	2 (3.8)	N.E.	0.27 [0.01; 5.50] 0.396	-0.038 [-0.091; 0.014] 0.149
<b>Any AE leading to study drug discontinuation</b>					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	1 (2.0)	N.E.	0.23 [0.01; 5.49] 0.363	-0.020 [-0.060; 0.019] 0.312

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
> Median, n (%)	1 (2.6)	2 (3.8)	0.68 [0.06; 7.73] 0.748	0.68 [0.06; 7.27] 0.753	-0.012 [-0.085; 0.061] 0.744
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.6.2 Adverse Events by SOC and PT, Binary Analysis by Lymphocyte Count at BL (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' ≤ Median	72	49			
N' > Median	38	52			
<b>Nasopharyngitis</b>					
Interaction test	p=0.143				
≤ Median, n (%)	15 (20.8)	8 (16.3)	1.35 [0.52; 3.48] 0.532	1.28 [0.59; 2.78] 0.539	0.045 [-0.095; 0.185] 0.527
> Median, n (%)	10 (26.3)	4 (7.7)	4.29 [1.23; 14.95] 0.016	3.42 [1.16; 10.09] 0.026	0.186 [0.029; 0.344] 0.021
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (p &lt; 0.05 in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### **S.6.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lymphocyte Count at BL (SAF)**

There are no data meeting the display criteria for this table.



#### **S.6.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lymphocyte Count at BL (SAF)**

There are no data meeting the display criteria for this table.

### S.6.5 Adverse Events of Special Interest, Binary Analysis by Lymphocyte Count at BL (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' ≤ Median	72	49			
N' > Median	38	52			
<b>Candida infections</b>					
Interaction test	p=0.448				
≤ Median, n (%)	1 (1.4)	1 (2.0)	0.68 [0.04; 11.07] 0.784	0.68 [0.04; 10.62] 0.784	-0.007 [-0.054; 0.041] 0.790
> Median, n (%)	2 (5.3)	1 (1.9)	2.83 [0.25; 32.44] 0.386	2.74 [0.26; 29.10] 0.404	0.033 [-0.047; 0.114] 0.414
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	p=0.632				
≤ Median, n (%)	2 (2.8)	4 (8.2)	0.32 [0.06; 1.83] 0.185	0.34 [0.06; 1.79] 0.203	-0.054 [-0.139; 0.032] 0.217
> Median, n (%)	1 (2.6)	2 (3.8)	0.68 [0.06; 7.73] 0.748	0.68 [0.06; 7.27] 0.753	-0.012 [-0.085; 0.061] 0.744
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	p=0.725				
≤ Median, n (%)	1 (1.4)	1 (2.0)	0.68 [0.04; 11.07] 0.784	0.68 [0.04; 10.62] 0.784	-0.007 [-0.054; 0.041] 0.790
> Median, n (%)	1 (2.6)	1 (1.9)	1.38 [0.08; 22.76] 0.823	1.37 [0.09; 21.20] 0.822	0.007 [-0.056; 0.070] 0.826
<b>Staphylococcal infections</b>					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
≤ Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
≤ Median, n (%)	1 (1.4)	1 (2.0)	0.68 [0.04; 11.07] 0.784	0.68 [0.04; 10.62] 0.784	-0.007 [-0.054; 0.041] 0.790
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
≤ Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
> Median, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.222				
≤ Median, n (%)	30 (41.7)	20 (40.8)	1.04 [0.50; 2.17] 0.926	1.02 [0.66; 1.58] 0.926	0.009 [-0.170; 0.187] 0.926
> Median, n (%)	14 (36.8)	11 (21.2)	2.17 [0.85; 5.55] 0.102	1.74 [0.89; 3.40] 0.104	0.157 [-0.032; 0.346] 0.104
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.7.1 Adverse Events, Binary Analysis by Enthesitis at BL According to LEI (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' Enthesitis: No	51	32			
N' Enthesitis: Yes	59	69			
<b>Any AE</b>					
Interaction test	p=0.467				
Enthesitis: No, n (%)	35 (68.6)	25 (78.1)	0.61 [0.22; 1.71] 0.342	0.88 [0.68; 1.14] 0.330	-0.095 [-0.287; 0.097] 0.331
Enthesitis: Yes, n (%)	39 (66.1)	46 (66.7)	0.98 [0.47; 2.03] 0.946	0.99 [0.77; 1.27] 0.946	-0.006 [-0.170; 0.159] 0.946
<b>Any SAE</b>					
Interaction test	p=0.597				
Enthesitis: No, n (%)	5 (9.8)	3 (9.4)	1.05 [0.23; 4.73] 0.949	1.05 [0.27; 4.08] 0.949	0.004 [-0.126; 0.134] 0.948
Enthesitis: Yes, n (%)	2 (3.4)	4 (5.8)	0.57 [0.10; 3.23] 0.516	0.58 [0.11; 3.08] 0.527	-0.024 [-0.096; 0.048] 0.512
<b>Any severe AE</b>					
Interaction test	N.E.				
Enthesitis: No, n (%)	2 (3.9)	0 (0.0)	N.E.	3.17 [0.16; 64.05] 0.451	0.039 [-0.014; 0.092] 0.149
Enthesitis: Yes, n (%)	1 (1.7)	2 (2.9)	0.58 [0.05; 6.53] 0.650	0.58 [0.05; 6.29] 0.658	-0.012 [-0.064; 0.039] 0.647
<b>Any AE leading to study discontinuation</b>					
Interaction test	N.E.				
Enthesitis: No, n (%)	0 (0.0)	2 (6.3)	N.E.	0.13 [0.01; 2.56] 0.178	-0.063 [-0.146; 0.021] 0.144
Enthesitis: Yes, n (%)	0 (0.0)	1 (1.4)	N.E.	0.39 [0.02; 9.37] 0.561	-0.014 [-0.043; 0.014] 0.314
<b>Any AE leading to study drug discontinuation</b>					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Enthesitis: No, n (%)	0 (0.0)	2 (6.3)	N.E.	0.13 [0.01; 2.56] 0.178	-0.063 [-0.146; 0.021] 0.144
Enthesitis: Yes, n (%)	1 (1.7)	1 (1.4)	1.17 [0.07; 19.16] 0.911	1.17 [0.07; 18.29] 0.911	0.002 [-0.041; 0.046] 0.912

N: Number of patients in the analysis  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup\*treatment groups.  
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

### S.7.2 Adverse Events by SOC and PT, Binary Analysis by Enthesitis at BL According to LEI (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' Enthesitis: No	51	32			
N' Enthesitis: Yes	59	69			
<b>Nasopharyngitis</b>					
Interaction test	p=0.993				
Enthesitis: No, n (%)	14 (27.5)	5 (15.6)	2.04 [0.66; 6.36] 0.203	1.76 [0.70; 4.41] 0.230	0.118 [-0.057; 0.294] 0.187
Enthesitis: Yes, n (%)	11 (18.6)	7 (10.1)	2.03 [0.73; 5.63] 0.168	1.84 [0.76; 4.44] 0.176	0.085 [-0.037; 0.207] 0.173
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### **S.7.3 Serious Adverse Events by SOC and PT, Binary Analysis by Enthesitis at BL According to LEI (SAF)**

There are no data meeting the display criteria for this table.

#### **S.7.4 Severe Adverse Events by SOC and PT, Binary Analysis by Enthesitis at BL According to LEI (SAF)**

There are no data meeting the display criteria for this table.



### S.7.5 Adverse Events of Special Interest, Binary Analysis by Enthesitis at BL According to LEI (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	110	101			
N' Enthesitis: No	51	32			
N' Enthesitis: Yes	59	69			
<b>Candida infections</b>					
Interaction test	N.E.				
Enthesitis: No, n (%)	2 (3.9)	0 (0.0)	N.E.	3.17 [0.16; 64.05] 0.451	0.039 [-0.014; 0.092] 0.149
Enthesitis: Yes, n (%)	1 (1.7)	2 (2.9)	0.58 [0.05; 6.53] 0.650	0.58 [0.05; 6.29] 0.658	-0.012 [-0.064; 0.039] 0.647
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	p=0.150				
Enthesitis: No, n (%)	1 (2.0)	4 (12.5)	0.14 [0.01; 1.31] 0.050	0.16 [0.02; 1.34] 0.091	-0.105 [-0.226; 0.015] 0.087
Enthesitis: Yes, n (%)	2 (3.4)	2 (2.9)	1.18 [0.16; 8.61] 0.874	1.17 [0.17; 8.05] 0.874	0.005 [-0.056; 0.066] 0.874
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Enthesitis: No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Enthesitis: Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Enthesitis: No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Enthesitis: Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Enthesitis: No, n (%)	2 (3.9)	1 (3.1)	1.27 [0.11; 14.55] 0.849	1.25 [0.12; 13.28] 0.850	0.008 [-0.072; 0.088] 0.846
Enthesitis: Yes, n (%)	0 (0.0)	1 (1.4)	N.E.	0.39 [0.02; 9.37] 0.561	-0.014 [-0.043; 0.014] 0.314
<b>Staphylococcal infections</b>					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Enthesitis: No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Enthesitis: Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Enthesitis: No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Enthesitis: Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Enthesitis: No, n (%)	1 (2.0)	0 (0.0)	N.E.	1.90 [0.08; 45.36] 0.691	0.020 [-0.018; 0.058] 0.313
Enthesitis: Yes, n (%)	0 (0.0)	1 (1.4)	N.E.	0.39 [0.02; 9.37] 0.561	-0.014 [-0.043; 0.014] 0.314
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Enthesitis: No, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Enthesitis: Yes, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.553				
Enthesitis: No, n (%)	23 (45.1)	10 (31.3)	1.81 [0.71; 4.58] 0.206	1.44 [0.79; 2.62] 0.228	0.138 [-0.072; 0.349] 0.198
Enthesitis: Yes, n (%)	21 (35.6)	21 (30.4)	1.26 [0.60; 2.65] 0.536	1.17 [0.71; 1.92] 0.535	0.052 [-0.112; 0.215] 0.536
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.8.1 Adverse Events, Binary Analysis by HLA-DQA1\*05 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	51	41			
N' Carrier	34	26			
<b>Any AE</b>					
Interaction test	p=0.628				
Non-carrier, n (%)	34 (66.7)	32 (78.0)	0.56 [0.22; 1.44] 0.225	0.85 [0.66; 1.10] 0.222	-0.114 [-0.295; 0.067] 0.218
Carrier, n (%)	23 (67.6)	22 (84.6)	0.38 [0.11; 1.37] 0.125	0.80 [0.60; 1.06] 0.123	-0.170 [-0.379; 0.040] 0.113
<b>Any SAE</b>					
Interaction test	p=0.192				
Non-carrier, n (%)	1 (2.0)	4 (9.8)	0.19 [0.02; 1.72] 0.095	0.20 [0.02; 1.73] 0.144	-0.078 [-0.176; 0.021] 0.121
Carrier, n (%)	3 (8.8)	2 (7.7)	1.16 [0.18; 7.51] 0.875	1.15 [0.21; 6.37] 0.875	0.011 [-0.129; 0.151] 0.874
<b>Any severe AE</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (2.4)	N.E.	0.27 [0.01; 6.44] 0.418	-0.024 [-0.072; 0.023] 0.311
Carrier, n (%)	2 (5.9)	0 (0.0)	N.E.	3.86 [0.19; 77.06] 0.377	0.059 [-0.020; 0.138] 0.145
<b>Any AE leading to study discontinuation</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (2.4)	N.E.	0.27 [0.01; 6.44] 0.418	-0.024 [-0.072; 0.023] 0.311
Carrier, n (%)	0 (0.0)	1 (3.8)	N.E.	0.26 [0.01; 6.07] 0.400	-0.038 [-0.112; 0.035] 0.308
<b>Any AE leading to study drug discontinuation</b>					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Non-carrier, n (%)	1 (2.0)	1 (2.4)	0.80 [0.05; 13.19] 0.876	0.80 [0.05; 12.47] 0.876	-0.005 [-0.065; 0.056] 0.877
Carrier, n (%)	0 (0.0)	1 (3.8)	N.E.	0.26 [0.01; 6.07] 0.400	-0.038 [-0.112; 0.035] 0.308

N: Number of patients in the analysis  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup\*treatment groups.  
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

## S.8.2 Adverse Events by SOC and PT, Binary Analysis by HLA-DQA1\*05 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	51	41			
N' Carrier	34	26			
<b>Nasopharyngitis</b>					
Interaction test	p=0.344				
Non-carrier, n (%)	10 (19.6)	7 (17.1)	1.18 [0.41; 3.45] 0.755	1.15 [0.48; 2.75] 0.756	0.025 [-0.133; 0.184] 0.754
Carrier, n (%)	9 (26.5)	3 (11.5)	2.76 [0.66; 11.47] 0.142	2.29 [0.69; 7.64] 0.176	0.149 [-0.043; 0.342] 0.129
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.  Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (p &lt; 0.05 in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### **S.8.3 Serious Adverse Events by SOC and PT, Binary Analysis by HLA-DQA1\*05 (SAF)**

There are no data meeting the display criteria for this table.

#### **S.8.4 Severe Adverse Events by SOC and PT, Binary Analysis by HLA-DQA1\*05 (SAF)**

There are no data meeting the display criteria for this table.

### S.8.5 Adverse Events of Special Interest, Binary Analysis by HLA-DQA1\*05 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	51	41			
N' Carrier	34	26			
<b>Candida infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	2 (3.9)	2 (4.9)	0.80 [0.11; 5.91] 0.824	0.80 [0.12; 5.46] 0.823	-0.010 [-0.094; 0.075] 0.825
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	4 (9.8)	N.E.	0.09 [0.00; 1.62] 0.102	-0.098 [-0.188; -0.007] 0.035
Carrier, n (%)	2 (5.9)	1 (3.8)	1.56 [0.13; 18.23] 0.717	1.53 [0.15; 15.97] 0.723	0.020 [-0.088; 0.129] 0.712
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	2 (3.9)	0 (0.0)	N.E.	4.04 [0.20; 81.85] 0.363	0.039 [-0.014; 0.092] 0.149
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Staphylococcal infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.



	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.0)	1 (2.4)	0.80 [0.05; 13.19] 0.876	0.80 [0.05; 12.47] 0.876	-0.005 [-0.065; 0.056] 0.877
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.903				
Non-carrier, n (%)	20 (39.2)	17 (41.5)	0.91 [0.39; 2.11] 0.827	0.95 [0.57; 1.56] 0.827	-0.022 [-0.224; 0.179] 0.827
Carrier, n (%)	13 (38.2)	10 (38.5)	0.99 [0.35; 2.83] 0.986	0.99 [0.52; 1.90] 0.986	-0.002 [-0.251; 0.246] 0.986
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.9.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs10555659 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	83	57			
N' Non-carrier	45	27			
N' Carrier	38	30			
Any AE					
Interaction test	p=0.736				
Non-carrier, n (%)	30 (66.7)	21 (77.8)	0.57 [0.19; 1.71] 0.309	0.86 [0.64; 1.14] 0.295	-0.111 [-0.320; 0.098] 0.297
Carrier, n (%)	26 (68.4)	25 (83.3)	0.43 [0.13; 1.41] 0.153	0.82 [0.63; 1.07] 0.151	-0.149 [-0.348; 0.050] 0.142
Any SAE					
Interaction test	p=0.305				
Non-carrier, n (%)	1 (2.2)	3 (11.1)	0.18 [0.02; 1.84] 0.116	0.20 [0.02; 1.83] 0.154	-0.089 [-0.215; 0.037] 0.167
Carrier, n (%)	3 (7.9)	3 (10.0)	0.77 [0.14; 4.13] 0.762	0.79 [0.17; 3.64] 0.762	-0.021 [-0.158; 0.116] 0.764
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (3.7)	N.E.	0.20 [0.01; 4.81] 0.323	-0.037 [-0.108; 0.034] 0.308
Carrier, n (%)	2 (5.3)	0 (0.0)	N.E.	3.97 [0.20; 79.79] 0.367	0.053 [-0.018; 0.124] 0.146
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (7.4)	N.E.	0.12 [0.01; 2.44] 0.169	-0.074 [-0.173; 0.025] 0.142
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (7.4)	N.E.	0.12 [0.01; 2.44] 0.169	-0.074 [-0.173; 0.025] 0.142

	Treatment Groups			Comparison	
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	1 (2.6)	0 (0.0)	N.E.	2.38 [0.10; 56.53] 0.591	0.026 [-0.025; 0.077] 0.311
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.9.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10555659 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	83	57			
N' Non-carrier	45	27			
N' Carrier	38	30			
<b>Nasopharyngitis</b>					
Interaction test	p=0.380				
Non-carrier, n (%)	12 (26.7)	4 (14.8)	2.09 [0.60; 7.30] 0.231	1.80 [0.65; 5.02] 0.262	0.119 [-0.068; 0.305] 0.212
Carrier, n (%)	6 (15.8)	5 (16.7)	0.94 [0.26; 3.43] 0.922	0.95 [0.32; 2.81] 0.922	-0.009 [-0.185; 0.168] 0.922
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### **S.9.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10555659 (SAF)**

There are no data meeting the display criteria for this table.

**S.9.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate  
Variant rs10555659 (SAF)**

There are no data meeting the display criteria for this table.

### S.9.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs10555659 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	83	57			
N' Non-carrier	45	27			
N' Carrier	38	30			
<b>Candida infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (7.4)	N.E.	0.12 [0.01; 2.44] 0.169	-0.074 [-0.173; 0.025] 0.142
Carrier, n (%)	2 (5.3)	0 (0.0)	N.E.	3.97 [0.20; 79.79] 0.367	0.053 [-0.018; 0.124] 0.146
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (3.7)	N.E.	0.20 [0.01; 4.81] 0.323	-0.037 [-0.108; 0.034] 0.308
Carrier, n (%)	2 (5.3)	4 (13.3)	0.36 [0.06; 2.12] 0.244	0.39 [0.08; 2.01] 0.263	-0.081 [-0.222; 0.060] 0.261
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.2)	0 (0.0)	N.E.	1.83 [0.08; 43.30] 0.709	0.022 [-0.021; 0.065] 0.312
Carrier, n (%)	1 (2.6)	0 (0.0)	N.E.	2.38 [0.10; 56.53] 0.591	0.026 [-0.025; 0.077] 0.311
<b>Staphylococcal infections</b>					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (3.7)	N.E.	0.20 [0.01; 4.81] 0.323	-0.037 [-0.108; 0.034] 0.308
Carrier, n (%)	1 (2.6)	0 (0.0)	N.E.	2.38 [0.10; 56.53] 0.591	0.026 [-0.025; 0.077] 0.311
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.205				
Non-carrier, n (%)	19 (42.2)	9 (33.3)	1.46 [0.54; 3.95] 0.452	1.27 [0.67; 2.39] 0.465	0.089 [-0.140; 0.318] 0.447
Carrier, n (%)	13 (34.2)	14 (46.7)	0.59 [0.22; 1.59] 0.297	0.73 [0.41; 1.31] 0.297	-0.125 [-0.358; 0.109] 0.296
<p>N: Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					



### S.10.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs111937633 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	81	67			
N' Non-carrier	30	33			
N' Carrier	51	34			
<b>Any AE</b>					
Interaction test	p=0.029				
Non-carrier, n (%)	18 (60.0)	30 (90.9)	0.15 [0.04; 0.60] 0.003	0.66 [0.48; 0.90] 0.009	-0.309 [-0.510; -0.108] 0.003
Carrier, n (%)	35 (68.6)	24 (70.6)	0.91 [0.35; 2.35] 0.847	0.97 [0.73; 1.29] 0.847	-0.020 [-0.219; 0.180] 0.847
<b>Any SAE</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	3 (9.1)	N.E.	0.16 [0.01; 2.91] 0.214	-0.091 [-0.189; 0.007] 0.069
Carrier, n (%)	3 (5.9)	3 (8.8)	0.65 [0.12; 3.41] 0.607	0.67 [0.14; 3.11] 0.606	-0.029 [-0.145; 0.086] 0.617
<b>Any severe AE</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	1 (2.0)	1 (2.9)	0.66 [0.04; 10.92] 0.772	0.67 [0.04; 10.30] 0.772	-0.010 [-0.078; 0.059] 0.779
<b>Any AE leading to study discontinuation</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (3.0)	N.E.	0.37 [0.02; 8.65] 0.533	-0.030 [-0.089; 0.028] 0.310
Carrier, n (%)	0 (0.0)	1 (2.9)	N.E.	0.22 [0.01; 5.35] 0.356	-0.029 [-0.086; 0.027] 0.310
<b>Any AE leading to study drug discontinuation</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (3.0)	N.E.	0.37 [0.02; 8.65] 0.533	-0.030 [-0.089; 0.028] 0.310

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	1 (2.9)	N.E.	0.22 [0.01; 5.35] 0.356	-0.029 [-0.086; 0.027] 0.310
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.10.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs111937633 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	81	67			
N' Non-carrier	30	33			
N' Carrier	51	34			
<b>Nasopharyngitis</b>					
Interaction test	p=0.900				
Non-carrier, n (%)	8 (26.7)	6 (18.2)	1.64 [0.49; 5.43] 0.418	1.47 [0.58; 3.74] 0.423	0.085 [-0.121; 0.291] 0.419
Carrier, n (%)	10 (19.6)	4 (11.8)	1.83 [0.52; 6.39] 0.331	1.67 [0.57; 4.88] 0.352	0.078 [-0.075; 0.232] 0.317
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

**S.10.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate  
Variant rs111937633 (SAF)**

There are no data meeting the display criteria for this table.

**S.10.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate  
Variant rs111937633 (SAF)**

There are no data meeting the display criteria for this table.

### S.10.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs111937633 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	81	67			
N' Non-carrier	30	33			
N' Carrier	51	34			
<b>Candida infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (6.1)	N.E.	0.22 [0.01; 4.39] 0.321	-0.061 [-0.142; 0.021] 0.145
Carrier, n (%)	2 (3.9)	0 (0.0)	N.E.	3.37 [0.17; 68.00] 0.429	0.039 [-0.014; 0.092] 0.149
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (6.1)	N.E.	0.22 [0.01; 4.39] 0.321	-0.061 [-0.142; 0.021] 0.145
Carrier, n (%)	1 (2.0)	3 (8.8)	0.21 [0.02; 2.08] 0.145	0.22 [0.02; 2.05] 0.184	-0.069 [-0.171; 0.034] 0.190
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	2 (3.9)	0 (0.0)	N.E.	3.37 [0.17; 68.00] 0.429	0.039 [-0.014; 0.092] 0.149
<b>Staphylococcal infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (3.3)	1 (3.0)	1.10 [0.07; 18.46] 0.945	1.10 [0.07; 16.82] 0.945	0.003 [-0.084; 0.090] 0.945
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.416				
Non-carrier, n (%)	12 (40.0)	16 (48.5)	0.71 [0.26; 1.93] 0.498	0.83 [0.47; 1.45] 0.502	-0.085 [-0.329; 0.160] 0.496
Carrier, n (%)	19 (37.3)	11 (32.4)	1.24 [0.50; 3.10] 0.642	1.15 [0.63; 2.10] 0.646	0.049 [-0.157; 0.255] 0.641
<p>N: Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.11.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	43	43			
N' Carrier	42	24			
Any AE					
Interaction test	p=0.695				
Non-carrier, n (%)	29 (67.4)	34 (79.1)	0.55 [0.21; 1.45] 0.222	0.85 [0.66; 1.10] 0.228	-0.116 [-0.302; 0.069] 0.219
Carrier, n (%)	28 (66.7)	20 (83.3)	0.40 [0.11; 1.40] 0.133	0.80 [0.61; 1.06] 0.117	-0.167 [-0.373; 0.040] 0.113
Any SAE					
Interaction test	p=0.445				
Non-carrier, n (%)	2 (4.7)	5 (11.6)	0.37 [0.07; 2.03] 0.230	0.40 [0.08; 1.95] 0.257	-0.070 [-0.184; 0.045] 0.233
Carrier, n (%)	2 (4.8)	1 (4.2)	1.15 [0.10; 13.39] 0.911	1.14 [0.11; 11.95] 0.911	0.006 [-0.097; 0.109] 0.910
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.3)	1 (2.3)	1.00 [0.06; 16.52] 1.000	1.00 [0.06; 15.48] 1.000	0.000 [-0.064; 0.064] 1.000
Carrier, n (%)	1 (2.4)	0 (0.0)	N.E.	1.74 [0.07; 41.21] 0.730	0.024 [-0.022; 0.070] 0.311
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (2.3)	N.E.	0.33 [0.01; 7.96] 0.497	-0.023 [-0.068; 0.022] 0.312
Carrier, n (%)	0 (0.0)	1 (4.2)	N.E.	0.19 [0.01; 4.58] 0.309	-0.042 [-0.122; 0.038] 0.307
Any AE leading to study drug discontinuation					
Interaction test	N.E.				



	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Non-carrier, n (%)	1 (2.3)	1 (2.3)	1.00 [0.06; 16.52] 1.000	1.00 [0.06; 15.48] 1.000	0.000 [-0.064; 0.064] 1.000
Carrier, n (%)	0 (0.0)	1 (4.2)	N.E.	0.19 [0.01; 4.58] 0.309	-0.042 [-0.122; 0.038] 0.307

N: Number of patients in the analysis  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup\*treatment groups.  
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

### S.11.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	43	43			
N' Carrier	42	24			
<b>Nasopharyngitis</b>					
Interaction test	p=0.064				
Non-carrier, n (%)	9 (20.9)	9 (20.9)	1.00 [0.35; 2.83] 1.000	1.00 [0.44; 2.27] 1.000	0.000 [-0.172; 0.172] 1.000
Carrier, n (%)	10 (23.8)	1 (4.2)	7.19 [0.86; 60.14] 0.025	5.71 [0.78; 41.95] 0.087	0.196 [0.045; 0.348] 0.011
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

**S.11.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate  
Variant rs11726476 (SAF)**

There are no data meeting the display criteria for this table.

**S.11.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate  
Variant rs11726476 (SAF)**

There are no data meeting the display criteria for this table.

### S.11.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs11726476 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	43	43			
N' Carrier	42	24			
<b>Candida infections</b>					
Interaction test	p=0.776				
Non-carrier, n (%)	1 (2.3)	1 (2.3)	1.00 [0.06; 16.52] 1.000	1.00 [0.06; 15.48] 1.000	0.000 [-0.064; 0.064] 1.000
Carrier, n (%)	1 (2.4)	1 (4.2)	0.56 [0.03; 9.40] 0.690	0.57 [0.04; 8.73] 0.687	-0.018 [-0.110; 0.074] 0.705
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	p=0.543				
Non-carrier, n (%)	1 (2.3)	2 (4.7)	0.49 [0.04; 5.59] 0.553	0.50 [0.05; 5.31] 0.565	-0.023 [-0.101; 0.054] 0.556
Carrier, n (%)	1 (2.4)	3 (12.5)	0.17 [0.02; 1.74] 0.104	0.19 [0.02; 1.73] 0.141	-0.101 [-0.241; 0.039] 0.157
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.3)	0 (0.0)	N.E.	3.00 [0.13; 71.66] 0.497	0.023 [-0.022; 0.068] 0.312
Carrier, n (%)	1 (2.4)	0 (0.0)	N.E.	1.74 [0.07; 41.21] 0.730	0.024 [-0.022; 0.070] 0.311
<b>Staphylococcal infections</b>					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.3)	0 (0.0)	N.E.	3.00 [0.13; 71.66] 0.497	0.023 [-0.022; 0.068] 0.312
Carrier, n (%)	0 (0.0)	1 (4.2)	N.E.	0.19 [0.01; 4.58] 0.309	-0.042 [-0.122; 0.038] 0.307
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.564				
Non-carrier, n (%)	17 (39.5)	19 (44.2)	0.83 [0.35; 1.95] 0.662	0.89 [0.54; 1.47] 0.663	-0.047 [-0.255; 0.162] 0.662
Carrier, n (%)	16 (38.1)	8 (33.3)	1.23 [0.43; 3.53] 0.698	1.14 [0.58; 2.27] 0.702	0.048 [-0.191; 0.287] 0.696
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.12.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	82	65			
N' Non-carrier	62	47			
N' Carrier	20	18			
Any AE					
Interaction test	p=0.442				
Non-carrier, n (%)	40 (64.5)	38 (80.9)	0.43 [0.18; 1.05] 0.058	0.80 [0.63; 1.01] 0.056	-0.163 [-0.327; 0.000] 0.051
Carrier, n (%)	15 (75.0)	14 (77.8)	0.86 [0.19; 3.85] 0.840	0.96 [0.68; 1.37] 0.840	-0.028 [-0.298; 0.242] 0.840
Any SAE					
Interaction test	p=0.653				
Non-carrier, n (%)	3 (4.8)	5 (10.6)	0.43 [0.10; 1.89] 0.252	0.45 [0.11; 1.81] 0.263	-0.058 [-0.161; 0.045] 0.270
Carrier, n (%)	1 (5.0)	1 (5.6)	0.89 [0.05; 15.44] 0.939	0.90 [0.06; 13.36] 0.939	-0.006 [-0.148; 0.137] 0.939
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	2 (3.2)	1 (2.1)	1.53 [0.13; 17.43] 0.725	1.52 [0.14; 16.22] 0.731	0.011 [-0.049; 0.071] 0.721
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (4.3)	N.E.	0.15 [0.01; 3.10] 0.221	-0.043 [-0.100; 0.015] 0.148
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	1 (1.6)	2 (4.3)	0.37 [0.03; 4.19] 0.405	0.38 [0.04; 4.06] 0.422	-0.026 [-0.092; 0.039] 0.430
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>				



### S.12.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	82	65			
N' Non-carrier	62	47			
N' Carrier	20	18			
<b>Nasopharyngitis</b>					
Interaction test	p=0.864				
Non-carrier, n (%)	14 (22.6)	7 (14.9)	1.67 [0.61; 4.53] 0.309	1.52 [0.66; 3.46] 0.322	0.077 [-0.069; 0.222] 0.301
Carrier, n (%)	4 (20.0)	2 (11.1)	2.00 [0.32; 12.51] 0.449	1.80 [0.37; 8.68] 0.464	0.089 [-0.139; 0.317] 0.444
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### **S.12.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)**

There are no data meeting the display criteria for this table.

### **S.12.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)**

There are no data meeting the display criteria for this table.

### S.12.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs10609046 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	82	65			
N' Non-carrier	62	47			
N' Carrier	20	18			
<b>Candida infections</b>					
Interaction test	p=0.933				
Non-carrier, n (%)	1 (1.6)	1 (2.1)	0.75 [0.05; 12.38] 0.844	0.76 [0.05; 11.81] 0.843	-0.005 [-0.057; 0.047] 0.846
Carrier, n (%)	1 (5.0)	1 (5.6)	0.89 [0.05; 15.44] 0.939	0.90 [0.06; 13.36] 0.939	-0.006 [-0.148; 0.137] 0.939
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	N.E.				
Non-carrier, n (%)	2 (3.2)	3 (6.4)	0.49 [0.08; 3.05] 0.438	0.51 [0.09; 2.90] 0.444	-0.032 [-0.114; 0.051] 0.454
Carrier, n (%)	0 (0.0)	2 (11.1)	N.E.	0.18 [0.01; 3.54] 0.260	-0.111 [-0.256; 0.034] 0.134
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (1.6)	0 (0.0)	N.E.	2.29 [0.10; 54.89] 0.610	0.016 [-0.015; 0.047] 0.313
Carrier, n (%)	1 (5.0)	0 (0.0)	N.E.	2.71 [0.12; 62.71] 0.533	0.050 [-0.046; 0.146] 0.305
<b>Staphylococcal infections</b>					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (1.6)	1 (2.1)	0.75 [0.05; 12.38] 0.844	0.76 [0.05; 11.81] 0.843	-0.005 [-0.057; 0.047] 0.846
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.421				
Non-carrier, n (%)	21 (33.9)	18 (38.3)	0.83 [0.37; 1.82] 0.633	0.88 [0.54; 1.46] 0.632	-0.044 [-0.226; 0.138] 0.634
Carrier, n (%)	11 (55.0)	8 (44.4)	1.53 [0.42; 5.50] 0.515	1.24 [0.65; 2.37] 0.521	0.106 [-0.211; 0.422] 0.513
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.13.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	82	63			
N' Non-carrier	63	51			
N' Carrier	19	12			
<b>Any AE</b>					
Interaction test	p=0.033				
Non-carrier, n (%)	40 (63.5)	43 (84.3)	0.32 [0.13; 0.81] 0.011	0.75 [0.60; 0.94] 0.012	-0.208 [-0.363; -0.053] 0.009
Carrier, n (%)	16 (84.2)	8 (66.7)	2.67 [0.48; 14.90] 0.260	1.26 [0.81; 1.97] 0.303	0.175 [-0.138; 0.489] 0.272
<b>Any SAE</b>					
Interaction test	N.E.				
Non-carrier, n (%)	4 (6.3)	4 (7.8)	0.80 [0.19; 3.36] 0.757	0.81 [0.21; 3.08] 0.757	-0.015 [-0.110; 0.080] 0.759
Carrier, n (%)	0 (0.0)	1 (8.3)	N.E.	0.22 [0.01; 4.92] 0.337	-0.083 [-0.240; 0.073] 0.296
<b>Any severe AE</b>					
Interaction test	N.E.				
Non-carrier, n (%)	2 (3.2)	1 (2.0)	1.64 [0.14; 18.61] 0.684	1.62 [0.15; 17.35] 0.691	0.012 [-0.046; 0.070] 0.680
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Any AE leading to study discontinuation</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (3.9)	N.E.	0.16 [0.01; 3.31] 0.237	-0.039 [-0.092; 0.014] 0.149
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Any AE leading to study drug discontinuation</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (1.6)	2 (3.9)	0.40 [0.03; 4.49] 0.438	0.40 [0.04; 4.34] 0.455	-0.023 [-0.085; 0.038] 0.457
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>				

### S.13.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	82	63			
N' Non-carrier	63	51			
N' Carrier	19	12			
<b>Nasopharyngitis</b>					
Interaction test	p=0.252				
Non-carrier, n (%)	17 (27.0)	7 (13.7)	2.32 [0.88; 6.14] 0.079	1.97 [0.88; 4.37] 0.097	0.133 [-0.012; 0.277] 0.072
Carrier, n (%)	2 (10.5)	2 (16.7)	0.59 [0.07; 4.85] 0.623	0.63 [0.10; 3.91] 0.621	-0.061 [-0.313; 0.191] 0.633
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					



**S.13.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate  
Variant rs8007401 (SAF)**

There are no data meeting the display criteria for this table.
--

**S.13.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate  
Variant rs8007401 (SAF)**

There are no data meeting the display criteria for this table.

### S.13.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs8007401 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	82	63			
N' Non-carrier	63	51			
N' Carrier	19	12			
<b>Candida infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	2 (3.2)	1 (2.0)	1.64 [0.14; 18.61] 0.684	1.62 [0.15; 17.35] 0.691	0.012 [-0.046; 0.070] 0.680
Carrier, n (%)	0 (0.0)	1 (8.3)	N.E.	0.22 [0.01; 4.92] 0.337	-0.083 [-0.240; 0.073] 0.296
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	N.E.				
Non-carrier, n (%)	2 (3.2)	4 (7.8)	0.39 [0.07; 2.19] 0.267	0.40 [0.08; 2.12] 0.285	-0.047 [-0.132; 0.039] 0.285
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	2 (3.2)	0 (0.0)	N.E.	4.06 [0.20; 82.77] 0.362	0.032 [-0.012; 0.075] 0.151
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Staphylococcal infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (2.0)	N.E.	0.27 [0.01; 6.51] 0.421	-0.020 [-0.058; 0.018] 0.313
Carrier, n (%)	1 (5.3)	0 (0.0)	N.E.	1.95 [0.09; 44.32] 0.675	0.053 [-0.048; 0.153] 0.304
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.210				
Non-carrier, n (%)	28 (44.4)	21 (41.2)	1.14 [0.54; 2.41] 0.726	1.08 [0.70; 1.66] 0.727	0.033 [-0.150; 0.215] 0.726
Carrier, n (%)	4 (21.1)	5 (41.7)	0.37 [0.08; 1.83] 0.222	0.51 [0.17; 1.52] 0.223	-0.206 [-0.540; 0.128] 0.226
<p>N: Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.14.1 Adverse Events, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	84	63			
N' Non-carrier	71	53			
N' Carrier	13	10			
Any AE					
Interaction test	p=0.391				
Non-carrier, n (%)	47 (66.2)	44 (83.0)	0.40 [0.17; 0.96] 0.033	0.80 [0.65; 0.98] 0.031	-0.168 [-0.318; -0.019] 0.027
Carrier, n (%)	9 (69.2)	7 (70.0)	0.96 [0.16; 5.80] 0.968	0.99 [0.57; 1.70] 0.968	-0.008 [-0.387; 0.371] 0.968
Any SAE					
Interaction test	p=0.731				
Non-carrier, n (%)	3 (4.2)	5 (9.4)	0.42 [0.10; 1.86] 0.245	0.45 [0.11; 1.79] 0.256	-0.052 [-0.144; 0.039] 0.265
Carrier, n (%)	1 (7.7)	1 (10.0)	0.75 [0.04; 13.68] 0.846	0.77 [0.05; 10.85] 0.846	-0.023 [-0.259; 0.213] 0.848
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	1 (1.4)	1 (1.9)	0.74 [0.05; 12.15] 0.835	0.75 [0.05; 11.66] 0.835	-0.005 [-0.051; 0.041] 0.838
Carrier, n (%)	1 (7.7)	0 (0.0)	N.E.	2.36 [0.11; 52.41] 0.588	0.077 [-0.068; 0.222] 0.298
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (3.8)	N.E.	0.15 [0.01; 3.06] 0.218	-0.038 [-0.089; 0.014] 0.149
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	1 (1.4)	2 (3.8)	0.36 [0.03; 4.13] 0.398	0.37 [0.03; 4.01] 0.416	-0.024 [-0.082; 0.035] 0.425

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.14.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	84	63			
N' Non-carrier	71	53			
N' Carrier	13	10			
<b>Nasopharyngitis</b>					
Interaction test	p=0.613				
Non-carrier, n (%)	15 (21.1)	7 (13.2)	1.76 [0.66; 4.68] 0.248	1.60 [0.70; 3.64] 0.264	0.079 [-0.052; 0.211] 0.238
Carrier, n (%)	4 (30.8)	3 (30.0)	1.04 [0.17; 6.23] 0.968	1.03 [0.29; 3.58] 0.968	0.008 [-0.371; 0.387] 0.968
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

**S.14.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate  
Variant rs7349145 (SAF)**

There are no data meeting the display criteria for this table.



**S.14.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate  
Variant rs7349145 (SAF)**

There are no data meeting the display criteria for this table.

### S.14.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Variant rs7349145 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	84	63			
N' Non-carrier	71	53			
N' Carrier	13	10			
<b>Candida infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	2 (2.8)	2 (3.8)	0.74 [0.10; 5.42] 0.767	0.75 [0.11; 5.13] 0.766	-0.010 [-0.074; 0.055] 0.770
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	p=0.432				
Non-carrier, n (%)	1 (1.4)	4 (7.5)	0.18 [0.02; 1.61] 0.082	0.19 [0.02; 1.62] 0.128	-0.061 [-0.138; 0.015] 0.114
Carrier, n (%)	1 (7.7)	1 (10.0)	0.75 [0.04; 13.68] 0.846	0.77 [0.05; 10.85] 0.846	-0.023 [-0.259; 0.213] 0.848
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	2 (2.8)	0 (0.0)	N.E.	3.75 [0.18; 76.52] 0.390	0.028 [-0.010; 0.067] 0.151
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Staphylococcal infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (1.4)	1 (1.9)	0.74 [0.05; 12.15] 0.835	0.75 [0.05; 11.66] 0.835	-0.005 [-0.051; 0.041] 0.838
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.219				
Non-carrier, n (%)	25 (35.2)	22 (41.5)	0.77 [0.37; 1.59] 0.475	0.85 [0.54; 1.33] 0.473	-0.063 [-0.236; 0.110] 0.476
Carrier, n (%)	8 (61.5)	4 (40.0)	2.40 [0.44; 12.98] 0.304	1.54 [0.64; 3.68] 0.333	0.215 [-0.187; 0.618] 0.294
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.15.1 Adverse Events, Binary Analysis by Lead Candidate Allele Score (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Low score	22	26			
N' High score	63	41			
<b>Any AE</b>					
Interaction test	p=0.030				
Low score, n (%)	13 (59.1)	24 (92.3)	0.12 [0.02; 0.64] 0.005	0.64 [0.44; 0.92] 0.017	-0.332 [-0.562; -0.103] 0.005
High score, n (%)	44 (69.8)	30 (73.2)	0.85 [0.35; 2.04] 0.713	0.95 [0.75; 1.22] 0.711	-0.033 [-0.210; 0.143] 0.712
<b>Any SAE</b>					
Interaction test	p=0.702				
Low score, n (%)	1 (4.5)	3 (11.5)	0.37 [0.04; 3.79] 0.370	0.39 [0.04; 3.52] 0.405	-0.070 [-0.220; 0.081] 0.363
High score, n (%)	3 (4.8)	3 (7.3)	0.63 [0.12; 3.30] 0.589	0.65 [0.14; 3.07] 0.587	-0.026 [-0.121; 0.070] 0.600
<b>Any severe AE</b>					
Interaction test	N.E.				
Low score, n (%)	1 (4.5)	1 (3.8)	1.19 [0.07; 20.21] 0.904	1.18 [0.08; 17.82] 0.904	0.007 [-0.107; 0.121] 0.904
High score, n (%)	1 (1.6)	0 (0.0)	N.E.	1.97 [0.08; 47.20] 0.676	0.016 [-0.015; 0.047] 0.313
<b>Any AE leading to study discontinuation</b>					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	2 (7.7)	N.E.	0.23 [0.01; 4.65] 0.341	-0.077 [-0.179; 0.026] 0.141
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Any AE leading to study drug discontinuation</b>					
Interaction test	N.E.				
Low score, n (%)	1 (4.5)	2 (7.7)	0.57 [0.05; 6.76] 0.650	0.59 [0.06; 6.09] 0.658	-0.031 [-0.166; 0.103] 0.646

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.15.2 Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Allele Score (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Low score	22	26			
N' High score	63	41			
<b>Nasopharyngitis</b>					
Interaction test	p=0.670				
Low score, n (%)	4 (18.2)	4 (15.4)	1.22 [0.27; 5.59] 0.796	1.18 [0.33; 4.18] 0.796	0.028 [-0.185; 0.241] 0.797
High score, n (%)	15 (23.8)	6 (14.6)	1.82 [0.64; 5.17] 0.247	1.63 [0.69; 3.85] 0.268	0.092 [-0.059; 0.243] 0.233
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### **S.15.3 Serious Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Allele Score (SAF)**

There are no data meeting the display criteria for this table.

### **S.15.4 Severe Adverse Events by SOC and PT, Binary Analysis by Lead Candidate Allele Score (SAF)**

There are no data meeting the display criteria for this table.



### S.15.5 Adverse Events of Special Interest, Binary Analysis by Lead Candidate Allele Score (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Low score	22	26			
N' High score	63	41			
<b>Candida infections</b>					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	1 (3.8)	N.E.	0.39 [0.02; 9.15] 0.560	-0.038 [-0.112; 0.035] 0.308
High score, n (%)	2 (3.2)	1 (2.4)	1.31 [0.12; 14.95] 0.825	1.30 [0.12; 13.90] 0.827	0.007 [-0.057; 0.071] 0.822
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	p=0.259				
Low score, n (%)	1 (4.5)	1 (3.8)	1.19 [0.07; 20.21] 0.904	1.18 [0.08; 17.82] 0.904	0.007 [-0.107; 0.121] 0.904
High score, n (%)	1 (1.6)	4 (9.8)	0.15 [0.02; 1.39] 0.057	0.16 [0.02; 1.40] 0.099	-0.082 [-0.178; 0.014] 0.095
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
High score, n (%)	2 (3.2)	0 (0.0)	N.E.	3.28 [0.16; 66.66] 0.439	0.032 [-0.012; 0.075] 0.151
<b>Staphylococcal infections</b>					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	1 (3.8)	N.E.	0.39 [0.02; 9.15] 0.560	-0.038 [-0.112; 0.035] 0.308
High score, n (%)	1 (1.6)	0 (0.0)	N.E.	1.97 [0.08; 47.20] 0.676	0.016 [-0.015; 0.047] 0.313
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Low score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
High score, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.983				
Low score, n (%)	8 (36.4)	10 (38.5)	0.91 [0.28; 2.96] 0.881	0.95 [0.45; 1.97] 0.881	-0.021 [-0.296; 0.254] 0.881
High score, n (%)	25 (39.7)	17 (41.5)	0.93 [0.42; 2.07] 0.857	0.96 [0.60; 1.54] 0.856	-0.018 [-0.211; 0.175] 0.857
<p>N: Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.16.1 Adverse Events, Binary Analysis by Linkage Variant rs10891185 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	51	35			
N' Carrier	34	32			
Any AE					
Interaction test	p=0.588				
Non-carrier, n (%)	34 (66.7)	27 (77.1)	0.59 [0.22; 1.58] 0.289	0.86 [0.66; 1.13] 0.280	-0.105 [-0.295; 0.085] 0.280
Carrier, n (%)	23 (67.6)	27 (84.4)	0.39 [0.12; 1.28] 0.109	0.80 [0.61; 1.06] 0.117	-0.167 [-0.369; 0.034] 0.104
Any SAE					
Interaction test	p=0.806				
Non-carrier, n (%)	2 (3.9)	3 (8.6)	0.44 [0.07; 2.75] 0.371	0.46 [0.08; 2.60] 0.378	-0.046 [-0.153; 0.060] 0.394
Carrier, n (%)	2 (5.9)	3 (9.4)	0.60 [0.09; 3.87] 0.591	0.63 [0.11; 3.51] 0.596	-0.035 [-0.163; 0.093] 0.594
Any severe AE					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.0)	1 (2.9)	0.68 [0.04; 11.25] 0.788	0.69 [0.04; 10.61] 0.788	-0.009 [-0.076; 0.058] 0.793
Carrier, n (%)	1 (2.9)	0 (0.0)	N.E.	2.83 [0.12; 67.01] 0.520	0.029 [-0.027; 0.086] 0.310
Any AE leading to study discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (5.7)	N.E.	0.14 [0.01; 2.80] 0.197	-0.057 [-0.134; 0.020] 0.145
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (5.7)	N.E.	0.14 [0.01; 2.80] 0.197	-0.057 [-0.134; 0.020] 0.145

	Treatment Groups			Comparison	
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	1 (2.9)	0 (0.0)	N.E.	2.83 [0.12; 67.01] 0.520	0.029 [-0.027; 0.086] 0.310
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.16.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs10891185 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	51	35			
N' Carrier	34	32			
<b>Nasopharyngitis</b>					
Interaction test	p=0.318				
Non-carrier, n (%)	14 (27.5)	5 (14.3)	2.27 [0.73; 7.02] 0.140	1.92 [0.76; 4.85] 0.167	0.132 [-0.037; 0.300] 0.126
Carrier, n (%)	5 (14.7)	5 (15.6)	0.93 [0.24; 3.58] 0.917	0.94 [0.30; 2.95] 0.917	-0.009 [-0.182; 0.164] 0.917
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

**S.16.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant  
rs10891185 (SAF)**

There are no data meeting the display criteria for this table.

**S.16.4 Severe Adverse Events by SOC and PT, Binary Analysis by Linkage Variant  
rs10891185 (SAF)**

There are no data meeting the display criteria for this table.

### S.16.5 Adverse Events of Special Interest, Binary Analysis by Linkage Variant rs10891185 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	51	35			
N' Carrier	34	32			
<b>Candida infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (5.7)	N.E.	0.14 [0.01; 2.80] 0.197	-0.057 [-0.134; 0.020] 0.145
Carrier, n (%)	2 (5.9)	0 (0.0)	N.E.	4.71 [0.23; 94.59] 0.311	0.059 [-0.020; 0.138] 0.145
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	p=0.522				
Non-carrier, n (%)	1 (2.0)	1 (2.9)	0.68 [0.04; 11.25] 0.788	0.69 [0.04; 10.61] 0.788	-0.009 [-0.076; 0.058] 0.793
Carrier, n (%)	1 (2.9)	4 (12.5)	0.21 [0.02; 2.01] 0.131	0.24 [0.03; 1.99] 0.185	-0.096 [-0.223; 0.032] 0.143
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.0)	0 (0.0)	N.E.	2.08 [0.09; 49.56] 0.652	0.020 [-0.018; 0.058] 0.313
Carrier, n (%)	1 (2.9)	0 (0.0)	N.E.	2.83 [0.12; 67.01] 0.520	0.029 [-0.027; 0.086] 0.310
<b>Staphylococcal infections</b>					
Interaction test	N.E.				



	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.0)	1 (2.9)	0.68 [0.04; 11.25] 0.788	0.69 [0.04; 10.61] 0.788	-0.009 [-0.076; 0.058] 0.793
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.252				
Non-carrier, n (%)	21 (41.2)	12 (34.3)	1.34 [0.55; 3.28] 0.517	1.20 [0.68; 2.11] 0.524	0.069 [-0.138; 0.276] 0.515
Carrier, n (%)	12 (35.3)	15 (46.9)	0.62 [0.23; 1.66] 0.338	0.75 [0.42; 1.35] 0.342	-0.116 [-0.352; 0.120] 0.336
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.17.1 Adverse Events, Binary Analysis by Linkage Variant rs12065362 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	30	31			
N' Carrier	55	36			
<b>Any AE</b>					
Interaction test	p=0.032				
Non-carrier, n (%)	18 (60.0)	28 (90.3)	0.16 [0.04; 0.65] 0.005	0.66 [0.49; 0.91] 0.011	-0.303 [-0.507; -0.099] 0.004
Carrier, n (%)	39 (70.9)	26 (72.2)	0.94 [0.37; 2.38] 0.892	0.98 [0.75; 1.28] 0.892	-0.013 [-0.202; 0.176] 0.892
<b>Any SAE</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	3 (9.7)	N.E.	0.15 [0.01; 2.74] 0.199	-0.097 [-0.201; 0.007] 0.068
Carrier, n (%)	4 (7.3)	3 (8.3)	0.86 [0.18; 4.10] 0.853	0.87 [0.21; 3.67] 0.853	-0.011 [-0.124; 0.103] 0.855
<b>Any severe AE</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	2 (3.6)	1 (2.8)	1.32 [0.12; 15.12] 0.821	1.31 [0.12; 13.91] 0.823	0.009 [-0.064; 0.082] 0.818
<b>Any AE leading to study discontinuation</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (3.2)	N.E.	0.34 [0.01; 8.13] 0.508	-0.032 [-0.094; 0.030] 0.309
Carrier, n (%)	0 (0.0)	1 (2.8)	N.E.	0.22 [0.01; 5.26] 0.350	-0.028 [-0.081; 0.026] 0.310
<b>Any AE leading to study drug discontinuation</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (3.2)	N.E.	0.34 [0.01; 8.13] 0.508	-0.032 [-0.094; 0.030] 0.309

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	1 (1.8)	1 (2.8)	0.65 [0.04; 10.70] 0.763	0.65 [0.04; 10.14] 0.762	-0.010 [-0.074; 0.055] 0.770
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.17.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs12065362 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	30	31			
N' Carrier	55	36			
<b>Nasopharyngitis</b>					
Interaction test	p=0.751				
Non-carrier, n (%)	8 (26.7)	6 (19.4)	1.52 [0.45; 5.05] 0.497	1.38 [0.54; 3.50] 0.500	0.073 [-0.138; 0.284] 0.496
Carrier, n (%)	11 (20.0)	4 (11.1)	2.00 [0.58; 6.85] 0.254	1.80 [0.62; 5.22] 0.279	0.089 [-0.058; 0.236] 0.237
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### **S.17.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs12065362 (SAF)**

There are no data meeting the display criteria for this table.

**S.17.4 Severe Adverse Events by SOC and PT, Binary Analysis by Linkage Variant  
rs12065362 (SAF)**

There are no data meeting the display criteria for this table.

### S.17.5 Adverse Events of Special Interest, Binary Analysis by Linkage Variant rs12065362 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	30	31			
N' Carrier	55	36			
<b>Candida infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (6.5)	N.E.	0.21 [0.01; 4.13] 0.302	-0.065 [-0.151; 0.022] 0.144
Carrier, n (%)	2 (3.6)	0 (0.0)	N.E.	3.30 [0.16; 66.88] 0.436	0.036 [-0.013; 0.086] 0.150
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (6.5)	N.E.	0.21 [0.01; 4.13] 0.302	-0.065 [-0.151; 0.022] 0.144
Carrier, n (%)	2 (3.6)	3 (8.3)	0.42 [0.07; 2.62] 0.343	0.44 [0.08; 2.48] 0.350	-0.047 [-0.150; 0.056] 0.371
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	2 (3.6)	0 (0.0)	N.E.	3.30 [0.16; 66.88] 0.436	0.036 [-0.013; 0.086] 0.150
<b>Staphylococcal infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (3.3)	1 (3.2)	1.03 [0.06; 17.33] 0.981	1.03 [0.07; 15.78] 0.981	0.001 [-0.088; 0.090] 0.981
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.239				
Non-carrier, n (%)	12 (40.0)	16 (51.6)	0.63 [0.23; 1.72] 0.362	0.78 [0.44; 1.35] 0.368	-0.116 [-0.364; 0.132] 0.359
Carrier, n (%)	21 (38.2)	11 (30.6)	1.40 [0.57; 3.43] 0.454	1.25 [0.69; 2.27] 0.464	0.076 [-0.122; 0.274] 0.450
<p>N: Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					



### S.18.1 Adverse Events, Binary Analysis by Linkage Variant rs11721988 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	43	43			
N' Carrier	42	24			
<b>Any AE</b>					
Interaction test	p=0.695				
Non-carrier, n (%)	29 (67.4)	34 (79.1)	0.55 [0.21; 1.45] 0.222	0.85 [0.66; 1.10] 0.228	-0.116 [-0.302; 0.069] 0.219
Carrier, n (%)	28 (66.7)	20 (83.3)	0.40 [0.11; 1.40] 0.133	0.80 [0.61; 1.06] 0.117	-0.167 [-0.373; 0.040] 0.113
<b>Any SAE</b>					
Interaction test	p=0.445				
Non-carrier, n (%)	2 (4.7)	5 (11.6)	0.37 [0.07; 2.03] 0.230	0.40 [0.08; 1.95] 0.257	-0.070 [-0.184; 0.045] 0.233
Carrier, n (%)	2 (4.8)	1 (4.2)	1.15 [0.10; 13.39] 0.911	1.14 [0.11; 11.95] 0.911	0.006 [-0.097; 0.109] 0.910
<b>Any severe AE</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.3)	1 (2.3)	1.00 [0.06; 16.52] 1.000	1.00 [0.06; 15.48] 1.000	0.000 [-0.064; 0.064] 1.000
Carrier, n (%)	1 (2.4)	0 (0.0)	N.E.	1.74 [0.07; 41.21] 0.730	0.024 [-0.022; 0.070] 0.311
<b>Any AE leading to study discontinuation</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	1 (2.3)	N.E.	0.33 [0.01; 7.96] 0.497	-0.023 [-0.068; 0.022] 0.312
Carrier, n (%)	0 (0.0)	1 (4.2)	N.E.	0.19 [0.01; 4.58] 0.309	-0.042 [-0.122; 0.038] 0.307
<b>Any AE leading to study drug discontinuation</b>					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Non-carrier, n (%)	1 (2.3)	1 (2.3)	1.00 [0.06; 16.52] 1.000	1.00 [0.06; 15.48] 1.000	0.000 [-0.064; 0.064] 1.000
Carrier, n (%)	0 (0.0)	1 (4.2)	N.E.	0.19 [0.01; 4.58] 0.309	-0.042 [-0.122; 0.038] 0.307

N: Number of patients in the analysis  
n (%): Number and percentage of patients with event  
CI: Confidence Interval  
N.E.: Not estimable  
OR: Odds Ratio  
RR: Relative Risk  
RD: Risk Difference

Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  
If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  
RR and RD calculated directly (with Wald CI and p-value) within subgroups.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup\*treatment groups.  
OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  
RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.

### S.18.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs11721988 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	43	43			
N' Carrier	42	24			
<b>Nasopharyngitis</b>					
Interaction test	p=0.064				
Non-carrier, n (%)	9 (20.9)	9 (20.9)	1.00 [0.35; 2.83] 1.000	1.00 [0.44; 2.27] 1.000	0.000 [-0.172; 0.172] 1.000
Carrier, n (%)	10 (23.8)	1 (4.2)	7.19 [0.86; 60.14] 0.025	5.71 [0.78; 41.95] 0.087	0.196 [0.045; 0.348] 0.011
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

**S.18.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant  
rs11721988 (SAF)**

There are no data meeting the display criteria for this table.

**S.18.4 Severe Adverse Events by SOC and PT, Binary Analysis by Linkage Variant  
rs11721988 (SAF)**

There are no data meeting the display criteria for this table.

### S.18.5 Adverse Events of Special Interest, Binary Analysis by Linkage Variant rs11721988 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	85	67			
N' Non-carrier	43	43			
N' Carrier	42	24			
<b>Candida infections</b>					
Interaction test	p=0.776				
Non-carrier, n (%)	1 (2.3)	1 (2.3)	1.00 [0.06; 16.52] 1.000	1.00 [0.06; 15.48] 1.000	0.000 [-0.064; 0.064] 1.000
Carrier, n (%)	1 (2.4)	1 (4.2)	0.56 [0.03; 9.40] 0.690	0.57 [0.04; 8.73] 0.687	-0.018 [-0.110; 0.074] 0.705
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	p=0.543				
Non-carrier, n (%)	1 (2.3)	2 (4.7)	0.49 [0.04; 5.59] 0.553	0.50 [0.05; 5.31] 0.565	-0.023 [-0.101; 0.054] 0.556
Carrier, n (%)	1 (2.4)	3 (12.5)	0.17 [0.02; 1.74] 0.104	0.19 [0.02; 1.73] 0.141	-0.101 [-0.241; 0.039] 0.157
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.3)	0 (0.0)	N.E.	3.00 [0.13; 71.66] 0.497	0.023 [-0.022; 0.068] 0.312
Carrier, n (%)	1 (2.4)	0 (0.0)	N.E.	1.74 [0.07; 41.21] 0.730	0.024 [-0.022; 0.070] 0.311
<b>Staphylococcal infections</b>					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (2.3)	0 (0.0)	N.E.	3.00 [0.13; 71.66] 0.497	0.023 [-0.022; 0.068] 0.312
Carrier, n (%)	0 (0.0)	1 (4.2)	N.E.	0.19 [0.01; 4.58] 0.309	-0.042 [-0.122; 0.038] 0.307
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.564				
Non-carrier, n (%)	17 (39.5)	19 (44.2)	0.83 [0.35; 1.95] 0.662	0.89 [0.54; 1.47] 0.663	-0.047 [-0.255; 0.162] 0.662
Carrier, n (%)	16 (38.1)	8 (33.3)	1.23 [0.43; 3.53] 0.698	1.14 [0.58; 2.27] 0.702	0.048 [-0.191; 0.287] 0.696
<p>N: Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

### S.19.1 Adverse Events, Binary Analysis by Linkage Variant rs7787032 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	83	67			
N' Non-carrier	65	49			
N' Carrier	18	18			
<b>Any AE</b>					
Interaction test	p=0.510				
Non-carrier, n (%)	42 (64.6)	40 (81.6)	0.41 [0.17; 0.99] 0.042	0.79 [0.63; 0.99] 0.040	-0.170 [-0.329; -0.011] 0.036
Carrier, n (%)	13 (72.2)	14 (77.8)	0.74 [0.16; 3.38] 0.700	0.93 [0.64; 1.36] 0.701	-0.056 [-0.338; 0.227] 0.700
<b>Any SAE</b>					
Interaction test	N.E.				
Non-carrier, n (%)	3 (4.6)	6 (12.2)	0.35 [0.08; 1.46] 0.136	0.38 [0.10; 1.43] 0.152	-0.076 [-0.181; 0.029] 0.154
Carrier, n (%)	1 (5.6)	0 (0.0)	N.E.	3.00 [0.13; 69.09] 0.492	0.056 [-0.050; 0.161] 0.303
<b>Any severe AE</b>					
Interaction test	N.E.				
Non-carrier, n (%)	2 (3.1)	1 (2.0)	1.52 [0.13; 17.30] 0.729	1.51 [0.14; 16.16] 0.734	0.010 [-0.047; 0.068] 0.725
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Any AE leading to study discontinuation</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	2 (4.1)	N.E.	0.15 [0.01; 3.09] 0.220	-0.041 [-0.096; 0.015] 0.149
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Any AE leading to study drug discontinuation</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (1.5)	2 (4.1)	0.37 [0.03; 4.17] 0.403	0.38 [0.04; 4.04] 0.420	-0.025 [-0.088; 0.038] 0.429
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.



Treatment Groups		Comparison		
SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>				

### S.19.2 Adverse Events by SOC and PT, Binary Analysis by Linkage Variant rs7787032 (SAF)

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	83	67			
N' Non-carrier	65	49			
N' Carrier	18	18			
<b>Nasopharyngitis</b>					
Interaction test	p=0.815				
Non-carrier, n (%)	15 (23.1)	7 (14.3)	1.80 [0.67; 4.83] 0.233	1.62 [0.71; 3.66] 0.250	0.088 [-0.054; 0.230] 0.224
Carrier, n (%)	4 (22.2)	3 (16.7)	1.43 [0.27; 7.55] 0.673	1.33 [0.35; 5.13] 0.675	0.056 [-0.202; 0.313] 0.673
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test. If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test. RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant (<math>p &lt; 0.05</math> in Wald test of RR).</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups. OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					

**S.19.3 Serious Adverse Events by SOC and PT, Binary Analysis by Linkage Variant  
rs7787032 (SAF)**

There are no data meeting the display criteria for this table.

**S.19.4 Severe Adverse Events by SOC and PT, Binary Analysis by Linkage Variant  
rs7787032 (SAF)**

There are no data meeting the display criteria for this table.

### S.19.5 Adverse Events of Special Interest, Binary Analysis by Linkage Variant rs7787032 (SAF)


	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	83	67			
N' Non-carrier	65	49			
N' Carrier	18	18			
<b>Candida infections</b>					
Interaction test	p=0.888				
Non-carrier, n (%)	1 (1.5)	1 (2.0)	0.75 [0.05; 12.30] 0.840	0.75 [0.05; 11.76] 0.840	-0.005 [-0.055; 0.045] 0.843
Carrier, n (%)	1 (5.6)	1 (5.6)	1.00 [0.06; 17.33] 1.000	1.00 [0.07; 14.79] 1.000	0.000 [-0.150; 0.150] 1.000
<b>Cardio-cerebrovascular-related events</b>					
Interaction test	N.E.				
Non-carrier, n (%)	2 (3.1)	3 (6.1)	0.49 [0.08; 3.03] 0.435	0.50 [0.09; 2.89] 0.441	-0.030 [-0.110; 0.049] 0.451
Carrier, n (%)	0 (0.0)	2 (11.1)	N.E.	0.20 [0.01; 3.89] 0.288	-0.111 [-0.256; 0.034] 0.134
<b>Inflammatory bowel disease</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Opportunistic infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Herpes viral infections</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (1.5)	0 (0.0)	N.E.	2.27 [0.09; 54.62] 0.613	0.015 [-0.015; 0.045] 0.314
Carrier, n (%)	1 (5.6)	0 (0.0)	N.E.	3.00 [0.13; 69.09] 0.492	0.056 [-0.050; 0.161] 0.303
<b>Staphylococcal infections</b>					
Interaction test	N.E.				

	Treatment Groups		Comparison		
	SEC (N=110)	ADA (N=101)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>MACE (MI, Stroke, Cardiovascular death)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	1 (1.5)	1 (2.0)	0.75 [0.05; 12.30] 0.840	0.75 [0.05; 11.76] 0.840	-0.005 [-0.055; 0.045] 0.843
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Malignant or unspecified tumours (SMQ excl BCC and SCC)</b>					
Interaction test	N.E.				
Non-carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Carrier, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Upper respiratory tract infections</b>					
Interaction test	p=0.940				
Non-carrier, n (%)	23 (35.4)	18 (36.7)	0.94 [0.44; 2.04] 0.882	0.96 [0.59; 1.58] 0.882	-0.014 [-0.192; 0.165] 0.882
Carrier, n (%)	9 (50.0)	9 (50.0)	1.00 [0.27; 3.69] 1.000	1.00 [0.52; 1.92] 1.000	0.000 [-0.327; 0.327] 1.000
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR (with Wald CI) from logistic regression model with predictors treatment, subgroup and treatment x subgroup, p-value from likelihood-ratio test.  If the interaction test is N.E.: OR (with Wald CI) from separate logistic regression models for each subgroup with treatment as predictor, p-value from likelihood-ratio test.  RR and RD calculated directly (with Wald CI and p-value) within subgroups.</p> <p>Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups.</p>					


## Figures

### Efficacy Analysis

#### 6.1 HAQ-DI - Boxplot (FAS)




### 15.1 Patient's Assessment of PsA Pain (VAS) - Boxplot (FAS)







### 16.1 Patient's Global Assessment of PsA Disease Activity (VAS) - Boxplot (FAS)




### 17.1 Patient's Global Assessment of Disease Activity for PASDAS (VAS) - Boxplot (FAS)




### 38.1 DLQI - Boxplot (FAS)



### 40.1 EQ-5D VAS Score - Boxplot (FAS)




### 41.1 FACIT Fatigue - Boxplot (FAS)




### 41.13 FACIT Fatigue - Boxplot by Lead Candidate Variant rs8007401 (FAS)

Non-carrier




Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

### Carrier



Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.


### 43.1 SF-36 Bodily Pain - Boxplot (FAS)






### 43.19 SF-36 Bodily Pain - Boxplot by Linkage Variant rs7787032 (FAS)

#### Non-carrier




Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

### Carrier




Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.


### 44.1 SF-36 General Health - Boxplot (FAS)




### 45.1 SF-36 Mental Health - Boxplot (FAS)



### 46.1 SF-36 Physical Functioning - Boxplot (FAS)




### 47.1 SF-36 Role Emotional - Boxplot (FAS)




### 47.13 SF-36 Role Emotional - Boxplot by Lead Candidate Variant rs8007401 (FAS)

Non-carrier



Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.


### Carrier




Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.



### 48.1 SF-36 Role Physical - Boxplot (FAS)




### 49.1 SF-36 Social Functioning - Boxplot (FAS)




### 49.7 SF-36 Social Functioning - Boxplot by Enthesitis at BL According to LEI (FAS)

Enthesitis: No




Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

**Enthesitis: Yes**




**Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.**

### 50.1 SF-36 Vitality - Boxplot (FAS)




### 50.13 SF-36 Vitality - Boxplot by Lead Candidate Variant rs8007401 (FAS)

Non-carrier




Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

### Carrier



**Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.**


### 51.1 SF-36 MCS - Boxplot (FAS)






### 51.13 SF-36 MCS - Boxplot by Lead Candidate Variant rs8007401 (FAS)

#### Non-carrier




Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

### Carrier




Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.


### 53.1 SF-36 PCS - Boxplot (FAS)




### 55.1 WPAI-GH Percent Work Time Missed due to Health - Boxplot (FAS)




### 56.1 WPAI-GH Percent Impairment while Working - Boxplot (FAS)



### 57.1 WPAI-GH Percent Overall Work Impairment due to Health - Boxplot (FAS)




### 58.1 WPAI-GH Percent Activity Impairment due to Health - Boxplot (FAS)



### 58.13 WPAI-GH Percent Activity Impairment due to Health - Boxplot by Lead Candidate Variant rs8007401 (FAS)


#### Non-carrier



Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.



### Carrier



Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.